sentence	label
To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of BC6OTHER greatly attenuated expression of both BC6ENTG and its receptor while increasing BC6ENTC secretion and expression of BC6OTHER and BC6OTHER .	False
To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of BC6OTHER greatly attenuated expression of both BC6OTHER and its receptor while increasing BC6ENTC secretion and expression of BC6ENTG and BC6OTHER .	False
To corroborate the above findings, we showed that in vitro exposure of TIC to a luteinizing concentration of BC6OTHER greatly attenuated expression of both BC6OTHER and its receptor while increasing BC6ENTC secretion and expression of BC6OTHER and BC6ENTG .	False
BC6ENTG and BC6ENTC followed a similar pattern, both increasing after luteolysis, before falling sharply after the BC6OTHER surge.	False
BC6OTHER and BC6ENTC followed a similar pattern, both increasing after luteolysis, before falling sharply after the BC6ENTG surge.	False
BC6ENTG and BC6OTHER mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with BC6OTHER peaking in large (11 - 18 mm) BC6ENTC - active follicles and BC6OTHER peaking in 9 - to 10 - mm follicles before declining in larger (11 - 18 mm) follicles.	False
BC6OTHER and BC6ENTG mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with BC6OTHER peaking in large (11 - 18 mm) BC6ENTC - active follicles and BC6OTHER peaking in 9 - to 10 - mm follicles before declining in larger (11 - 18 mm) follicles.	False
BC6OTHER and BC6OTHER mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with BC6ENTG peaking in large (11 - 18 mm) BC6ENTC - active follicles and BC6OTHER peaking in 9 - to 10 - mm follicles before declining in larger (11 - 18 mm) follicles.	False
BC6OTHER and BC6OTHER mRNA levels were much higher in TIC than granulosa cell and increased progressively during follicle maturation with BC6OTHER peaking in large (11 - 18 mm) BC6ENTC - active follicles and BC6ENTG peaking in 9 - to 10 - mm follicles before declining in larger (11 - 18 mm) follicles.	False
Sixty one compounds, grouped as the 6H, BC6ENTC , BC6OTHER and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6ENTG ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6ENTC , BC6OTHER and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6ENTG ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6ENTC , BC6OTHER and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6ENTG ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6ENTC , BC6OTHER and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6ENTG ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6ENTC and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6ENTG ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6ENTC and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6ENTG ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6ENTC and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6ENTG ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6ENTC and BC6OTHER derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6ENTG ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6OTHER and BC6ENTC derivatives, were tested for cytotoxicity, their effects on BC6ENTG ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6OTHER and BC6ENTC derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6ENTG ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6OTHER and BC6ENTC derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6ENTG ( BC6OTHER ) production by these cells.	False
Sixty one compounds, grouped as the 6H, BC6OTHER , BC6OTHER and BC6ENTC derivatives, were tested for cytotoxicity, their effects on BC6OTHER ( BC6OTHER ) - induced proliferative response of human peripheral blood mononuclear cells (PBMC) and lipopolysaccharide (LPS) - induced BC6OTHER ( BC6ENTG ) production by these cells.	False
Inhibition of MCF - 7 cell growth by the selective BC6ENTG antagonists BC6ENTC and BC6OTHER is consistent with a role for BC6OTHER antagonism in the broad growth - inhibitory properties of BC6OTHER .	CPR:6
Inhibition of MCF - 7 cell growth by the selective BC6OTHER antagonists BC6ENTC and BC6OTHER is consistent with a role for BC6ENTG antagonism in the broad growth - inhibitory properties of BC6OTHER .	False
Inhibition of MCF - 7 cell growth by the selective BC6ENTG antagonists BC6OTHER and BC6ENTC is consistent with a role for BC6OTHER antagonism in the broad growth - inhibitory properties of BC6OTHER .	CPR:6
Inhibition of MCF - 7 cell growth by the selective BC6OTHER antagonists BC6OTHER and BC6ENTC is consistent with a role for BC6ENTG antagonism in the broad growth - inhibitory properties of BC6OTHER .	False
Inhibition of MCF - 7 cell growth by the selective BC6ENTG antagonists BC6OTHER and BC6OTHER is consistent with a role for BC6OTHER antagonism in the broad growth - inhibitory properties of BC6ENTC .	False
Inhibition of MCF - 7 cell growth by the selective BC6OTHER antagonists BC6OTHER and BC6OTHER is consistent with a role for BC6ENTG antagonism in the broad growth - inhibitory properties of BC6ENTC .	CPR:4
We conclude that BC6ENTC and BC6OTHER may be useful in the control of BC6OTHER - and BC6ENTG - induced growth of BC6OTHER - positive and BC6OTHER - negative human breast tumors.	False
We conclude that BC6ENTC and BC6OTHER may be useful in the control of BC6OTHER - and BC6OTHER - induced growth of BC6ENTG - positive and BC6OTHER - negative human breast tumors.	False
We conclude that BC6ENTC and BC6OTHER may be useful in the control of BC6OTHER - and BC6OTHER - induced growth of BC6OTHER - positive and BC6ENTG - negative human breast tumors.	False
We conclude that BC6OTHER and BC6ENTC may be useful in the control of BC6OTHER - and BC6ENTG - induced growth of BC6OTHER - positive and BC6OTHER - negative human breast tumors.	False
We conclude that BC6OTHER and BC6ENTC may be useful in the control of BC6OTHER - and BC6OTHER - induced growth of BC6ENTG - positive and BC6OTHER - negative human breast tumors.	False
We conclude that BC6OTHER and BC6ENTC may be useful in the control of BC6OTHER - and BC6OTHER - induced growth of BC6OTHER - positive and BC6ENTG - negative human breast tumors.	False
We conclude that BC6OTHER and BC6OTHER may be useful in the control of BC6ENTC - and BC6ENTG - induced growth of BC6OTHER - positive and BC6OTHER - negative human breast tumors.	False
We conclude that BC6OTHER and BC6OTHER may be useful in the control of BC6ENTC - and BC6OTHER - induced growth of BC6ENTG - positive and BC6OTHER - negative human breast tumors.	False
We conclude that BC6OTHER and BC6OTHER may be useful in the control of BC6ENTC - and BC6OTHER - induced growth of BC6OTHER - positive and BC6ENTG - negative human breast tumors.	False
BC6OTHER and BC6OTHER had no effect on the BC6OTHER binding properties of the MCF - 7 BC6ENTG , nor did BC6OTHER interfere with the induction of BC6OTHER by BC6ENTC .	False
BC6OTHER and BC6OTHER had no effect on the BC6OTHER binding properties of the MCF - 7 BC6OTHER , nor did BC6OTHER interfere with the induction of BC6ENTG by BC6ENTC .	False
Similar concentrations of these compounds blocked BC6ENTC - induced growth of MCF - 7 cells, but BC6ENTG ( BC6OTHER ) interactions do not seem to be involved.	False
Similar concentrations of these compounds blocked BC6ENTC - induced growth of MCF - 7 cells, but BC6OTHER ( BC6ENTG ) interactions do not seem to be involved.	False
Similar concentrations of these compounds blocked BC6OTHER - induced growth of MCF - 7 cells, but BC6ENTC receptor ( BC6ENTG ) interactions do not seem to be involved.	False
BC6ENTC and BC6OTHER had no effect on the BC6OTHER binding properties of the MCF - 7 BC6ENTG , nor did BC6OTHER interfere with the induction of BC6OTHER by BC6OTHER .	False
BC6ENTC and BC6OTHER had no effect on the BC6OTHER binding properties of the MCF - 7 BC6OTHER , nor did BC6OTHER interfere with the induction of BC6ENTG by BC6OTHER .	False
BC6OTHER and BC6ENTC had no effect on the BC6OTHER binding properties of the MCF - 7 BC6ENTG , nor did BC6OTHER interfere with the induction of BC6OTHER by BC6OTHER .	False
BC6OTHER and BC6ENTC had no effect on the BC6OTHER binding properties of the MCF - 7 BC6OTHER , nor did BC6OTHER interfere with the induction of BC6ENTG by BC6OTHER .	False
BC6OTHER and BC6OTHER had no effect on the BC6ENTC binding properties of the MCF - 7 BC6ENTG , nor did BC6OTHER interfere with the induction of BC6OTHER by BC6OTHER .	False
BC6OTHER and BC6OTHER had no effect on the BC6ENTC binding properties of the MCF - 7 BC6OTHER , nor did BC6OTHER interfere with the induction of BC6ENTG by BC6OTHER .	False
Furthermore, BC6ENTC also inhibited incorporation of BC6OTHER into MCF - 7 cells stimulated by BC6ENTG in serum - free medium.	False
BC6OTHER and BC6OTHER had no effect on the BC6OTHER binding properties of the MCF - 7 BC6ENTG , nor did BC6ENTC interfere with the induction of BC6OTHER by BC6OTHER .	False
BC6OTHER and BC6OTHER had no effect on the BC6OTHER binding properties of the MCF - 7 BC6OTHER , nor did BC6ENTC interfere with the induction of BC6ENTG by BC6OTHER .	False
BC6OTHER and BC6OTHER had no effect on the BC6OTHER binding properties of the MCF - 7 BC6ENTG , nor did BC6OTHER interfere with the induction of BC6ENTC receptors by BC6OTHER .	False
Furthermore, BC6OTHER also inhibited incorporation of BC6ENTC into MCF - 7 cells stimulated by BC6ENTG in serum - free medium.	False
The Ki for BC6ENTC in serum - free medium alone, 0.46 microM, was similar to that determined in the presence of BC6ENTG (0.42 microM), BC6OTHER (0.54 microM), and BC6OTHER (0.43 microM).	False
The Ki for BC6ENTC in serum - free medium alone, 0.46 microM, was similar to that determined in the presence of BC6OTHER (0.42 microM), BC6ENTG (0.54 microM), and BC6OTHER (0.43 microM).	False
The Ki for BC6ENTC in serum - free medium alone, 0.46 microM, was similar to that determined in the presence of BC6OTHER (0.42 microM), BC6OTHER (0.54 microM), and BC6ENTG (0.43 microM).	False
BC6ENTC also blocked cell growth and BC6OTHER incorporation into the BC6ENTG - positive T47D and ZR75 - 1B human breast cancer cell lines and the BC6OTHER - negative human breast cancer cell line, CHEM - MB - 231.	False
BC6ENTC also blocked cell growth and BC6OTHER incorporation into the BC6OTHER - positive T47D and ZR75 - 1B human breast cancer cell lines and the BC6ENTG - negative human breast cancer cell line, CHEM - MB - 231.	False
BC6OTHER also blocked cell growth and BC6ENTC incorporation into the BC6ENTG - positive T47D and ZR75 - 1B human breast cancer cell lines and the BC6OTHER - negative human breast cancer cell line, CHEM - MB - 231.	False
BC6OTHER also blocked cell growth and BC6ENTC incorporation into the BC6OTHER - positive T47D and ZR75 - 1B human breast cancer cell lines and the BC6ENTG - negative human breast cancer cell line, CHEM - MB - 231.	False
Although numerous mechanisms of action of BC6ENTC and BC6OTHER have been identified, both drugs are BC6ENTG antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.	CPR:6
Although numerous mechanisms of action of BC6OTHER and BC6ENTC have been identified, both drugs are BC6ENTG antagonists at drug concentrations that inhibit breast cancer cell growth in vitro.	CPR:6
In an attempt to further improve overall profiles of the BC6OTHER series of GSMs, in particular the BC6ENTG activity, conformational modifications of the core structure resulted in the identification of fused BC6ENTC such as 7i which had an improved BC6OTHER inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	False
In an attempt to further improve overall profiles of the BC6OTHER series of GSMs, in particular the BC6OTHER activity, conformational modifications of the core structure resulted in the identification of fused BC6ENTC such as 7i which had an improved BC6ENTG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	CPR:4
In an attempt to further improve overall profiles of the BC6ENTC series of GSMs, in particular the BC6ENTG activity, conformational modifications of the core structure resulted in the identification of fused BC6OTHER such as 7i which had an improved BC6OTHER inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	False
In an attempt to further improve overall profiles of the BC6ENTC series of GSMs, in particular the BC6OTHER activity, conformational modifications of the core structure resulted in the identification of fused BC6OTHER such as 7i which had an improved BC6ENTG inhibition profile and was a highly efficacious GSM in vitro and in vivo in rats.	False
The discovery of fused BC6ENTC as BC6ENTG modulators for treatment of Alzheimer's disease.	False
These studies show that BC6ENTG and BC6OTHER metabolize BC6ENTC to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and / or liver could influence BC6OTHER disposition in humans.	CPR:9
These studies show that BC6OTHER and BC6ENTG metabolize BC6ENTC to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and / or liver could influence BC6OTHER disposition in humans.	CPR:9
These studies show that BC6ENTG and BC6OTHER metabolize BC6OTHER to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and / or liver could influence BC6ENTC disposition in humans.	False
These studies show that BC6OTHER and BC6ENTG metabolize BC6OTHER to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and / or liver could influence BC6ENTC disposition in humans.	False
It is possible that variations in BC6ENTG enzyme - mediated metabolism of BC6ENTC may contribute to this phenomenon.	CPR:9
This hypothesis was explored by evaluating the contributions of BC6ENTG , and BC6OTHER enzymes in the metabolism of BC6ENTC in vitro and relating metabolism to changes in BC6OTHER enzyme mRNA expression via the BC6OTHER in lung and liver cells.	False
This hypothesis was explored by evaluating the contributions of BC6OTHER , and BC6ENTG enzymes in the metabolism of BC6ENTC in vitro and relating metabolism to changes in BC6OTHER enzyme mRNA expression via the BC6OTHER in lung and liver cells.	CPR:9
This hypothesis was explored by evaluating the contributions of BC6OTHER , and BC6OTHER enzymes in the metabolism of BC6ENTC in vitro and relating metabolism to changes in BC6ENTG enzyme mRNA expression via the BC6OTHER in lung and liver cells.	False
This hypothesis was explored by evaluating the contributions of BC6OTHER , and BC6OTHER enzymes in the metabolism of BC6ENTC in vitro and relating metabolism to changes in BC6OTHER enzyme mRNA expression via the BC6ENTG in lung and liver cells.	False
BC6ENTG and BC6OTHER metabolized BC6ENTC via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; BC6OTHER did not metabolize BC6OTHER .	CPR:9
BC6OTHER and BC6ENTG metabolized BC6ENTC via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; BC6OTHER did not metabolize BC6OTHER .	CPR:9
BC6OTHER and BC6OTHER metabolized BC6ENTC via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; BC6ENTG did not metabolize BC6OTHER .	False
BC6ENTG and BC6OTHER metabolized BC6OTHER via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; BC6OTHER did not metabolize BC6ENTC .	False
BC6OTHER and BC6ENTG metabolized BC6OTHER via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; BC6OTHER did not metabolize BC6ENTC .	False
BC6OTHER and BC6OTHER metabolized BC6OTHER via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; BC6ENTG did not metabolize BC6ENTC .	False
Metabolism of BC6ENTC by BC6ENTG Enzymes.	CPR:9
BC6OTHER targets and activates the BC6ENTC - dependent protein deacetylase SIRT1; in turn, BC6ENTG induces an intracellular antioxidative mechanism by inducing mitochondrial BC6OTHER dismutase ( BC6OTHER ).	False
BC6OTHER targets and activates the BC6ENTC - dependent protein deacetylase SIRT1; in turn, BC6OTHER induces an intracellular antioxidative mechanism by inducing BC6ENTG ( BC6OTHER ).	False
BC6OTHER targets and activates the BC6ENTC - dependent protein deacetylase SIRT1; in turn, BC6OTHER induces an intracellular antioxidative mechanism by inducing mitochondrial BC6OTHER dismutase ( BC6ENTG ).	False
BC6OTHER targets and activates the BC6ENTG ; in turn, BC6OTHER induces an intracellular antioxidative mechanism by inducing mitochondrial BC6ENTC dismutase ( BC6OTHER ).	False
BC6OTHER targets and activates the BC6OTHER ; in turn, BC6ENTG induces an intracellular antioxidative mechanism by inducing mitochondrial BC6ENTC dismutase ( BC6OTHER ).	False
BC6OTHER targets and activates the BC6OTHER ; in turn, BC6OTHER induces an intracellular antioxidative mechanism by inducing mitochondrial BC6ENTC dismutase ( BC6ENTG ).	False
However, BC6OTHER , but not BC6OTHER , induced BC6OTHER - dependent BC6OTHER deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6ENTC , BC6ENTG knockdown blunted these effects.	False
However, BC6OTHER , but not BC6OTHER , induced BC6ENTG - dependent BC6OTHER deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6ENTC , BC6OTHER knockdown blunted these effects.	False
However, BC6OTHER , but not BC6OTHER , induced BC6OTHER - dependent BC6ENTG deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6ENTC , BC6OTHER knockdown blunted these effects.	False
However, BC6OTHER , but not BC6OTHER , induced BC6OTHER - dependent BC6OTHER deacetylation and BC6ENTG expression in mouse C2C12 skeletal myoblasts; as with BC6ENTC , BC6OTHER knockdown blunted these effects.	False
However, BC6ENTC , but not BC6OTHER , induced BC6OTHER - dependent BC6OTHER deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6ENTG knockdown blunted these effects.	False
However, BC6ENTC , but not BC6OTHER , induced BC6ENTG - dependent BC6OTHER deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6OTHER knockdown blunted these effects.	CPR:3
However, BC6ENTC , but not BC6OTHER , induced BC6OTHER - dependent BC6ENTG deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6OTHER knockdown blunted these effects.	False
However, BC6ENTC , but not BC6OTHER , induced BC6OTHER - dependent BC6OTHER deacetylation and BC6ENTG expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6OTHER knockdown blunted these effects.	CPR:3
However, BC6OTHER , but not BC6ENTC , induced BC6OTHER - dependent BC6OTHER deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6ENTG knockdown blunted these effects.	False
However, BC6OTHER , but not BC6ENTC , induced BC6ENTG - dependent BC6OTHER deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6OTHER knockdown blunted these effects.	False
However, BC6OTHER , but not BC6ENTC , induced BC6OTHER - dependent BC6ENTG deacetylation and BC6OTHER expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6OTHER knockdown blunted these effects.	False
However, BC6OTHER , but not BC6ENTC , induced BC6OTHER - dependent BC6OTHER deacetylation and BC6ENTG expression in mouse C2C12 skeletal myoblasts; as with BC6OTHER , BC6OTHER knockdown blunted these effects.	False
BC6ENTC targets and activates the BC6ENTG ; in turn, BC6OTHER induces an intracellular antioxidative mechanism by inducing mitochondrial BC6OTHER dismutase ( BC6OTHER ).	CPR:3
BC6ENTC targets and activates the BC6OTHER ; in turn, BC6ENTG induces an intracellular antioxidative mechanism by inducing mitochondrial BC6OTHER dismutase ( BC6OTHER ).	CPR:3
BC6ENTC targets and activates the BC6OTHER ; in turn, BC6OTHER induces an intracellular antioxidative mechanism by inducing BC6ENTG ( BC6OTHER ).	CPR:3
BC6ENTC targets and activates the BC6OTHER ; in turn, BC6OTHER induces an intracellular antioxidative mechanism by inducing mitochondrial BC6OTHER dismutase ( BC6ENTG ).	CPR:3
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6ENTC antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6ENTC antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6ENTC antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6ENTC antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6OTHER .	False
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6ENTC and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6ENTC and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6ENTC and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6ENTC and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6OTHER .	False
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6ENTC are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6ENTC are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6ENTC are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6ENTC are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6OTHER .	False
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6ENTC - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6ENTC - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6ENTC - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6ENTC - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6OTHER .	False
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6ENTC .	False
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6ENTC .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6ENTC .	CPR:6
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6ENTC .	CPR:6
 Additional neuroendocrine experiments in a parallel group of rats revealed a dose - related increase in BC6ENTG and BC6OTHER levels after i.v. BC6ENTC , pointing to a general state of arousal in these BC6OTHER - treated animals.	CPR:3
 Additional neuroendocrine experiments in a parallel group of rats revealed a dose - related increase in BC6OTHER and BC6ENTG levels after i.v. BC6ENTC , pointing to a general state of arousal in these BC6OTHER - treated animals.	CPR:3
 Additional neuroendocrine experiments in a parallel group of rats revealed a dose - related increase in BC6ENTG and BC6OTHER levels after i.v. BC6OTHER , pointing to a general state of arousal in these BC6ENTC - treated animals.	False
 Additional neuroendocrine experiments in a parallel group of rats revealed a dose - related increase in BC6OTHER and BC6ENTG levels after i.v. BC6OTHER , pointing to a general state of arousal in these BC6ENTC - treated animals.	False
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6ENTC and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	CPR:6
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6ENTC and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	CPR:6
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6ENTC and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6ENTC and BC6OTHER , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6OTHER .	False
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6OTHER and BC6ENTC , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	CPR:6
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6OTHER and BC6ENTC , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	CPR:6
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6ENTC , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6ENTC , and mixed BC6OTHER and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6OTHER .	False
These data indicate that mixed BC6ENTG / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6ENTC and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6ENTG receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6ENTC and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6ENTC and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6ENTG / BC6OTHER antagonist BC6OTHER .	False
These data indicate that mixed BC6OTHER / BC6OTHER receptor antagonists such as BC6OTHER and BC6OTHER , and mixed BC6ENTC and BC6OTHER antagonists such as BC6OTHER and BC6OTHER are more potent antagonists of BC6OTHER - induced behavioural inhibition in rats than the more selective BC6OTHER / BC6ENTG antagonist BC6OTHER .	False
There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of BC6ENTC stain or reduced immunolabeling of BC6ENTG - positive ( BC6OTHER (+)) neurons.	False
There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of BC6ENTC stain or reduced immunolabeling of BC6OTHER - positive ( BC6ENTG (+)) neurons.	False
There was no evidence that PQ induced neuronal degeneration in the SNpc or degenerating neuronal processes in the striatum, as indicated by the absence of uptake of BC6OTHER stain or reduced immunolabeling of BC6ENTC - hydroxylase - positive ( BC6ENTG (+)) neurons.	False
This study also suggests that even if the reduction in BC6ENTG (+) neurons reported by others occurs in PQ - treated mice, this apparent phenotypic change is unaccompanied by neuronal cell death or by modification of BC6ENTC levels in the striatum.	False
Interestingly, BC6ENTG treatment of α BC6OTHER KD cells reduced BC6ENTC phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6OTHER phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6ENTG KD cells reduced BC6ENTC phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6OTHER phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6OTHER KD cells reduced BC6ENTC phosphorylation of BC6ENTG (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6OTHER phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6OTHER KD cells reduced BC6ENTC phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6ENTG , while enhancing BC6OTHER phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6OTHER KD cells reduced BC6ENTC phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6OTHER phosphorylation (pS(307)) of BC6ENTG .	False
Interestingly, BC6ENTG treatment of α BC6OTHER KD cells reduced BC6OTHER phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6ENTC phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6ENTG KD cells reduced BC6OTHER phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6ENTC phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6OTHER KD cells reduced BC6OTHER phosphorylation of BC6ENTG (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6ENTC phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6OTHER KD cells reduced BC6OTHER phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6ENTG , while enhancing BC6ENTC phosphorylation (pS(307)) of BC6OTHER .	False
Interestingly, BC6OTHER treatment of α BC6OTHER KD cells reduced BC6OTHER phosphorylation of BC6OTHER (pY(896)), and phosphorylation of BC6OTHER , while enhancing BC6ENTC phosphorylation (pS(307)) of BC6ENTG .	False
Consequently the α BC6ENTG KD cells exhibited blunted suppression of BC6OTHER secretion following BC6OTHER treatment in the presence of high BC6ENTC .	False
Consequently the α BC6OTHER KD cells exhibited blunted suppression of BC6ENTG secretion following BC6OTHER treatment in the presence of high BC6ENTC .	False
Consequently the α BC6OTHER KD cells exhibited blunted suppression of BC6OTHER secretion following BC6ENTG treatment in the presence of high BC6ENTC .	False
BC6ENTG ( BC6OTHER ) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in β - cells has been reported to impair BC6OTHER secretion leading to BC6ENTC intolerance.	False
BC6OTHER ( BC6ENTG ) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in β - cells has been reported to impair BC6OTHER secretion leading to BC6ENTC intolerance.	False
BC6OTHER ( BC6OTHER ) is a transcription factor that plays a crucial role in the unfolded protein response (UPR) and its deficiency in β - cells has been reported to impair BC6ENTG secretion leading to BC6ENTC intolerance.	False
α BC6ENTG KO mice exhibited BC6ENTC intolerance, mild BC6OTHER resistance and an inability to suppress BC6OTHER secretion following BC6OTHER stimulation.	False
α BC6OTHER KO mice exhibited BC6ENTC intolerance, mild BC6ENTG resistance and an inability to suppress BC6OTHER secretion following BC6OTHER stimulation.	False
α BC6OTHER KO mice exhibited BC6ENTC intolerance, mild BC6OTHER resistance and an inability to suppress BC6ENTG secretion following BC6OTHER stimulation.	False
α BC6ENTG KO mice exhibited BC6OTHER intolerance, mild BC6OTHER resistance and an inability to suppress BC6OTHER secretion following BC6ENTC stimulation.	False
α BC6OTHER KO mice exhibited BC6OTHER intolerance, mild BC6ENTG resistance and an inability to suppress BC6OTHER secretion following BC6ENTC stimulation.	False
α BC6OTHER KO mice exhibited BC6OTHER intolerance, mild BC6OTHER resistance and an inability to suppress BC6ENTG secretion following BC6ENTC stimulation.	False
Pretreatment with the BC6ENTG antagonist, BC6OTHER , and the BC6OTHER receptor antagonist, BC6OTHER , blocked BC6ENTC induction of BC6OTHER in the striatum.	False
Pretreatment with the BC6OTHER D1 receptor antagonist, BC6OTHER , and the BC6ENTG antagonist, BC6OTHER , blocked BC6ENTC induction of BC6OTHER in the striatum.	False
Pretreatment with the BC6OTHER D1 receptor antagonist, BC6OTHER , and the BC6OTHER receptor antagonist, BC6OTHER , blocked BC6ENTC induction of BC6ENTG in the striatum.	CPR:3
However, BC6ENTC induction of BC6ENTG in the striatum was unaffected by the BC6OTHER antagonist, BC6OTHER .	CPR:3
However, BC6ENTC induction of BC6OTHER in the striatum was unaffected by the BC6ENTG antagonist, BC6OTHER .	False
However, BC6OTHER induction of BC6ENTG in the striatum was unaffected by the BC6ENTC D2 receptor antagonist, BC6OTHER .	False
However, BC6OTHER induction of BC6ENTG in the striatum was unaffected by the BC6OTHER antagonist, BC6ENTC .	False
However, BC6OTHER induction of BC6OTHER in the striatum was unaffected by the BC6ENTG antagonist, BC6ENTC .	CPR:6
These results suggest that BC6ENTC induction of BC6ENTG in the rat striatum is related to BC6OTHER and BC6OTHER .	CPR:3
These results suggest that BC6ENTC induction of BC6OTHER in the rat striatum is related to BC6ENTG and BC6OTHER .	False
These results suggest that BC6ENTC induction of BC6OTHER in the rat striatum is related to BC6OTHER and BC6ENTG .	False
These results suggest that BC6OTHER induction of BC6ENTG in the rat striatum is related to BC6ENTC D1 and BC6OTHER .	False
These results suggest that BC6OTHER induction of BC6OTHER in the rat striatum is related to BC6ENTC D1 and BC6ENTG .	False
These results suggest that BC6OTHER induction of BC6ENTG in the rat striatum is related to BC6OTHER and BC6ENTC receptors.	False
These results suggest that BC6OTHER induction of BC6OTHER in the rat striatum is related to BC6ENTG and BC6ENTC receptors.	False
 BC6ENTC induces BC6ENTG in rat striatum: reversal with BC6OTHER and BC6OTHER antagonists.	CPR:3
 BC6ENTC induces BC6OTHER in rat striatum: reversal with BC6ENTG and BC6OTHER antagonists.	False
 BC6ENTC induces BC6OTHER in rat striatum: reversal with BC6OTHER and BC6ENTG antagonists.	False
 BC6OTHER induces BC6ENTG in rat striatum: reversal with BC6ENTC D1 and BC6OTHER antagonists.	False
 BC6OTHER induces BC6OTHER in rat striatum: reversal with BC6ENTC D1 and BC6ENTG antagonists.	False
 BC6OTHER induces BC6ENTG in rat striatum: reversal with BC6OTHER and BC6ENTC receptor antagonists.	False
 BC6OTHER induces BC6OTHER in rat striatum: reversal with BC6ENTG and BC6ENTC receptor antagonists.	False
BC6ENTC ( BC6OTHER ) induced BC6ENTG expression in the central, dorsal - medial and ventral - medial part of the striatum.	CPR:3
BC6OTHER ( BC6ENTC ) induced BC6ENTG expression in the central, dorsal - medial and ventral - medial part of the striatum.	CPR:3
The distribution pattern of BC6ENTG induced by BC6ENTC was more similar to those seen with dopaminomimetics than with BC6OTHER ( BC6OTHER ) receptor antagonists.	CPR:3
The distribution pattern of BC6OTHER induced by BC6ENTC was more similar to those seen with dopaminomimetics than with BC6ENTG antagonists.	False
The distribution pattern of BC6ENTG induced by BC6OTHER was more similar to those seen with dopaminomimetics than with BC6ENTC ( BC6OTHER ) receptor antagonists.	False
The distribution pattern of BC6ENTG induced by BC6OTHER was more similar to those seen with dopaminomimetics than with BC6OTHER ( BC6ENTC ) receptor antagonists.	False
Pretreatment with the BC6ENTC D1 receptor antagonist, BC6OTHER , and the BC6ENTG antagonist, BC6OTHER , blocked BC6OTHER induction of BC6OTHER in the striatum.	False
Pretreatment with the BC6ENTC D1 receptor antagonist, BC6OTHER , and the BC6OTHER receptor antagonist, BC6OTHER , blocked BC6OTHER induction of BC6ENTG in the striatum.	False
Pretreatment with the BC6ENTG antagonist, BC6ENTC , and the BC6OTHER receptor antagonist, BC6OTHER , blocked BC6OTHER induction of BC6OTHER in the striatum.	CPR:6
Pretreatment with the BC6OTHER D1 receptor antagonist, BC6ENTC , and the BC6ENTG antagonist, BC6OTHER , blocked BC6OTHER induction of BC6OTHER in the striatum.	False
Pretreatment with the BC6OTHER D1 receptor antagonist, BC6ENTC , and the BC6OTHER receptor antagonist, BC6OTHER , blocked BC6OTHER induction of BC6ENTG in the striatum.	CPR:4
Pretreatment with the BC6ENTG antagonist, BC6OTHER , and the BC6ENTC receptor antagonist, BC6OTHER , blocked BC6OTHER induction of BC6OTHER in the striatum.	False
Pretreatment with the BC6OTHER D1 receptor antagonist, BC6OTHER , and the BC6ENTC receptor antagonist, BC6OTHER , blocked BC6OTHER induction of BC6ENTG in the striatum.	False
Pretreatment with the BC6ENTG antagonist, BC6OTHER , and the BC6OTHER receptor antagonist, BC6ENTC , blocked BC6OTHER induction of BC6OTHER in the striatum.	False
Pretreatment with the BC6OTHER D1 receptor antagonist, BC6OTHER , and the BC6ENTG antagonist, BC6ENTC , blocked BC6OTHER induction of BC6OTHER in the striatum.	CPR:6
Pretreatment with the BC6OTHER D1 receptor antagonist, BC6OTHER , and the BC6OTHER receptor antagonist, BC6ENTC , blocked BC6OTHER induction of BC6ENTG in the striatum.	CPR:4
BC6OTHER ( BC6OTHER ) is an important vasorelaxant produced along with BC6OTHER from BC6OTHER in a reaction catalyzed by endothelial BC6ENTC synthase ( BC6ENTG ).	False
BC6OTHER ( BC6ENTC ) is an important vasorelaxant produced along with BC6OTHER from BC6OTHER in a reaction catalyzed by BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6ENTC ) is an important vasorelaxant produced along with BC6OTHER from BC6OTHER in a reaction catalyzed by endothelial BC6OTHER synthase ( BC6ENTG ).	CPR:9
BC6ENTC ( BC6OTHER ) is an important vasorelaxant produced along with BC6OTHER from BC6OTHER in a reaction catalyzed by BC6ENTG ( BC6OTHER ).	CPR:9
BC6ENTC ( BC6OTHER ) is an important vasorelaxant produced along with BC6OTHER from BC6OTHER in a reaction catalyzed by endothelial BC6OTHER synthase ( BC6ENTG ).	CPR:9
BC6OTHER ( BC6OTHER ) is an important vasorelaxant produced along with BC6ENTC from BC6OTHER in a reaction catalyzed by BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6OTHER ) is an important vasorelaxant produced along with BC6ENTC from BC6OTHER in a reaction catalyzed by endothelial BC6OTHER synthase ( BC6ENTG ).	CPR:9
BC6OTHER ( BC6OTHER ) is an important vasorelaxant produced along with BC6OTHER from BC6ENTC in a reaction catalyzed by BC6ENTG ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6OTHER ) is an important vasorelaxant produced along with BC6OTHER from BC6ENTC in a reaction catalyzed by endothelial BC6OTHER synthase ( BC6ENTG ).	CPR:9
As further support, BC6OTHER , an inhibitor of BC6ENTC synthase ( BC6ENTG ), a component of the BC6OTHER - BC6OTHER cycle, inhibited BC6OTHER production in a dose - dependent manner.	False
As further support, BC6ENTC , an inhibitor of BC6ENTG ( BC6OTHER ), a component of the BC6OTHER - BC6OTHER cycle, inhibited BC6OTHER production in a dose - dependent manner.	CPR:4
As further support, BC6ENTC , an inhibitor of BC6OTHER ( BC6ENTG ), a component of the BC6OTHER - BC6OTHER cycle, inhibited BC6OTHER production in a dose - dependent manner.	CPR:4
As further support, BC6OTHER , an inhibitor of BC6ENTG ( BC6OTHER ), a component of the BC6ENTC - BC6OTHER cycle, inhibited BC6OTHER production in a dose - dependent manner.	False
As further support, BC6OTHER , an inhibitor of BC6OTHER ( BC6ENTG ), a component of the BC6ENTC - BC6OTHER cycle, inhibited BC6OTHER production in a dose - dependent manner.	False
As further support, BC6OTHER , an inhibitor of BC6ENTG ( BC6OTHER ), a component of the BC6OTHER - BC6ENTC cycle, inhibited BC6OTHER production in a dose - dependent manner.	False
As further support, BC6OTHER , an inhibitor of BC6OTHER ( BC6ENTG ), a component of the BC6OTHER - BC6ENTC cycle, inhibited BC6OTHER production in a dose - dependent manner.	False
As further support, BC6OTHER , an inhibitor of BC6ENTG ( BC6OTHER ), a component of the BC6OTHER - BC6OTHER cycle, inhibited BC6ENTC production in a dose - dependent manner.	False
As further support, BC6OTHER , an inhibitor of BC6OTHER ( BC6ENTG ), a component of the BC6OTHER - BC6OTHER cycle, inhibited BC6ENTC production in a dose - dependent manner.	False
By binding to both the BC6ENTG and neuronal BC6OTHER synthase ( BC6OTHER ), BC6OTHER mediates a specific coupling between BC6OTHER activation and BC6ENTC production.	False
By binding to both the BC6OTHER and BC6ENTG ( BC6OTHER ), BC6OTHER mediates a specific coupling between BC6OTHER activation and BC6ENTC production.	False
By binding to both the BC6OTHER and neuronal BC6OTHER synthase ( BC6ENTG ), BC6OTHER mediates a specific coupling between BC6OTHER activation and BC6ENTC production.	False
By binding to both the BC6OTHER and neuronal BC6OTHER synthase ( BC6OTHER ), BC6ENTG mediates a specific coupling between BC6OTHER activation and BC6ENTC production.	False
By binding to both the BC6OTHER and neuronal BC6OTHER synthase ( BC6OTHER ), BC6OTHER mediates a specific coupling between BC6ENTG activation and BC6ENTC production.	False
An alternative approach to modulate the BC6ENTG - related activity is to perturb the BC6OTHER / BC6OTHER / BC6OTHER complex by targeting BC6OTHER , thereby decreasing BC6ENTC production without interfering with the BC6OTHER BC6OTHER function.	False
An alternative approach to modulate the BC6OTHER - related activity is to perturb the BC6ENTG / BC6OTHER / BC6OTHER complex by targeting BC6OTHER , thereby decreasing BC6ENTC production without interfering with the BC6OTHER BC6OTHER function.	False
An alternative approach to modulate the BC6OTHER - related activity is to perturb the BC6OTHER / BC6ENTG / BC6OTHER complex by targeting BC6OTHER , thereby decreasing BC6ENTC production without interfering with the BC6OTHER BC6OTHER function.	False
An alternative approach to modulate the BC6OTHER - related activity is to perturb the BC6OTHER / BC6OTHER / BC6ENTG complex by targeting BC6OTHER , thereby decreasing BC6ENTC production without interfering with the BC6OTHER BC6OTHER function.	False
An alternative approach to modulate the BC6OTHER - related activity is to perturb the BC6OTHER / BC6OTHER / BC6OTHER complex by targeting BC6ENTG , thereby decreasing BC6ENTC production without interfering with the BC6OTHER BC6OTHER function.	False
An alternative approach to modulate the BC6OTHER - related activity is to perturb the BC6OTHER / BC6OTHER / BC6OTHER complex by targeting BC6OTHER , thereby decreasing BC6ENTC production without interfering with the BC6ENTG BC6OTHER function.	False
An alternative approach to modulate the BC6OTHER - related activity is to perturb the BC6OTHER / BC6OTHER / BC6OTHER complex by targeting BC6OTHER , thereby decreasing BC6ENTC production without interfering with the BC6OTHER BC6ENTG function.	False
Excessive BC6ENTG ( BC6OTHER ) - dependent production of BC6ENTC ( BC6OTHER ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6OTHER ).	False
Excessive BC6OTHER receptor ( BC6OTHER ) - dependent production of BC6ENTC ( BC6OTHER ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6ENTG ( BC6OTHER ).	False
Excessive BC6OTHER receptor ( BC6OTHER ) - dependent production of BC6ENTC ( BC6OTHER ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6ENTG ).	False
Excessive BC6OTHER receptor ( BC6ENTG ) - dependent production of BC6ENTC ( BC6OTHER ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6OTHER ).	False
Here, we compared the effects of a dimeric BC6ENTG inhibitor, BC6ENTC , and the BC6OTHER antagonist, BC6OTHER , on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	CPR:4
Here, we compared the effects of a dimeric BC6OTHER inhibitor, BC6ENTC , and the BC6ENTG antagonist, BC6OTHER , on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	False
Here, we compared the effects of a dimeric BC6ENTG inhibitor, BC6OTHER , and the BC6OTHER antagonist, BC6ENTC , on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	False
Here, we compared the effects of a dimeric BC6OTHER inhibitor, BC6OTHER , and the BC6ENTG antagonist, BC6ENTC , on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.	CPR:6
Excessive BC6ENTG ( BC6OTHER ) - dependent production of BC6OTHER ( BC6ENTC ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6OTHER ).	False
Excessive BC6OTHER receptor ( BC6OTHER ) - dependent production of BC6OTHER ( BC6ENTC ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6ENTG ( BC6OTHER ).	False
Excessive BC6OTHER receptor ( BC6OTHER ) - dependent production of BC6OTHER ( BC6ENTC ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6ENTG ).	False
Excessive BC6OTHER receptor ( BC6ENTG ) - dependent production of BC6OTHER ( BC6ENTC ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6OTHER ).	False
 BC6ENTC , a dimeric inhibitor of PSD - 95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the BC6ENTG antagonist BC6OTHER .	False
 BC6OTHER , a dimeric inhibitor of PSD - 95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the BC6ENTG antagonist BC6ENTC .	CPR:6
Excessive BC6ENTC receptor ( BC6OTHER ) - dependent production of BC6OTHER ( BC6OTHER ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6ENTG ( BC6OTHER ).	False
Excessive BC6ENTC receptor ( BC6OTHER ) - dependent production of BC6OTHER ( BC6OTHER ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6ENTG ).	False
Excessive BC6ENTC receptor ( BC6ENTG ) - dependent production of BC6OTHER ( BC6OTHER ) is involved in the development and maintenance of chronic pain states, and is mediated by BC6OTHER ( BC6OTHER ).	False
By binding to both the BC6ENTG and neuronal BC6ENTC synthase ( BC6OTHER ), BC6OTHER mediates a specific coupling between BC6OTHER activation and BC6OTHER production.	False
By binding to both the BC6OTHER and neuronal BC6ENTC synthase ( BC6ENTG ), BC6OTHER mediates a specific coupling between BC6OTHER activation and BC6OTHER production.	False
By binding to both the BC6OTHER and neuronal BC6ENTC synthase ( BC6OTHER ), BC6ENTG mediates a specific coupling between BC6OTHER activation and BC6OTHER production.	False
By binding to both the BC6OTHER and neuronal BC6ENTC synthase ( BC6OTHER ), BC6OTHER mediates a specific coupling between BC6ENTG activation and BC6OTHER production.	False
Neuroparalysis and BC6OTHER efficacy in BC6ENTC poisoning: a study of BC6ENTG .	False
Patients who received BC6ENTC prior to hospitalization had a higher rate of intermediate syndrome and lower levels of BC6ENTG at admission than those who had not.	CPR:4
The temporal profile of BC6ENTG ( BC6OTHER ) and in vitro BC6OTHER - reactivated BC6OTHER was studied in a cohort of 25 BC6ENTC - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6OTHER treatment.	False
The temporal profile of BC6OTHER ( BC6ENTG ) and in vitro BC6OTHER - reactivated BC6OTHER was studied in a cohort of 25 BC6ENTC - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6OTHER treatment.	False
The temporal profile of BC6OTHER ( BC6OTHER ) and in vitro BC6OTHER - reactivated BC6ENTG was studied in a cohort of 25 BC6ENTC - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6OTHER treatment.	False
The study suggests that (i) BC6ENTG reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BC6OTHER ; and (iii) the lack of BC6ENTC efficacy in our patients maybe due to their severity of poisoning and the timing of BC6OTHER treatment.	False
The study suggests that (i) BC6OTHER reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BC6ENTG ; and (iii) the lack of BC6ENTC efficacy in our patients maybe due to their severity of poisoning and the timing of BC6OTHER treatment.	False
The study suggests that (i) BC6ENTG reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BC6OTHER ; and (iii) the lack of BC6OTHER efficacy in our patients maybe due to their severity of poisoning and the timing of BC6ENTC treatment.	False
The study suggests that (i) BC6OTHER reflects the clinical course of poisoning, confirming earlier studies; (ii) intermediate syndrome may be associated with a persistent inhibition of BC6ENTG ; and (iii) the lack of BC6OTHER efficacy in our patients maybe due to their severity of poisoning and the timing of BC6ENTC treatment.	False
The temporal profile of BC6ENTG ( BC6OTHER ) and in vitro BC6OTHER - reactivated BC6OTHER was studied in a cohort of 25 BC6OTHER - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6ENTC treatment.	False
The temporal profile of BC6OTHER ( BC6ENTG ) and in vitro BC6OTHER - reactivated BC6OTHER was studied in a cohort of 25 BC6OTHER - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6ENTC treatment.	False
The temporal profile of BC6OTHER ( BC6OTHER ) and in vitro BC6OTHER - reactivated BC6ENTG was studied in a cohort of 25 BC6OTHER - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6ENTC treatment.	False
The temporal profile of BC6ENTG ( BC6OTHER ) and in vitro BC6ENTC - reactivated BC6OTHER was studied in a cohort of 25 BC6OTHER - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6OTHER treatment.	False
The temporal profile of BC6OTHER ( BC6ENTG ) and in vitro BC6ENTC - reactivated BC6OTHER was studied in a cohort of 25 BC6OTHER - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6OTHER treatment.	False
The temporal profile of BC6OTHER ( BC6OTHER ) and in vitro BC6ENTC - reactivated BC6ENTG was studied in a cohort of 25 BC6OTHER - poisoned patients to examine their relationship to the development of intermediate syndrome and to understand reasons for lack of efficacy of BC6OTHER treatment.	CPR:3
Reactivation potentials of BC6ENTG (the difference between BC6ENTC - reactivated and - unreactivated enzyme activity) declined significantly with time after BC6OTHER ingestion.	CPR:3
Reactivation potentials of BC6ENTG (the difference between BC6OTHER - reactivated and - unreactivated enzyme activity) declined significantly with time after BC6ENTC ingestion.	CPR:4
Neuroparalysis and BC6ENTC efficacy in BC6OTHER poisoning: a study of BC6ENTG .	False
CONCLUSION: BC6ENTC is a well tolerated BC6ENTG inhibitor.	CPR:4
UNLABELLED: BC6ENTC is an inhibitor of the BC6ENTG .	CPR:4
They do so by actions on BC6ENTG , and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating BC6OTHER release through BC6ENTC release or BC6OTHER synthesis.	False
They do so by actions on BC6ENTG , and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating BC6OTHER release through BC6OTHER release or BC6ENTC synthesis.	False
BACKGROUND: Neuronal nicotinic BC6ENTC receptor ( BC6ENTG ) agonists produce antinociception in animals.	False
This study tested whether BC6ENTG agonists stimulate spinal release of the neurotransmitter BC6ENTC either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce BC6OTHER release.	False
This study tested whether BC6ENTG agonists stimulate spinal release of the neurotransmitter BC6OTHER either by direct actions on noradrenergic terminals or indirectly by stimulating release of other neurotransmitters to induce BC6ENTC release.	False
Probes were perfused with artificial cerebrospinal fluid containing CHEM, the specific BC6ENTG agonist BC6ENTC , or BC6OTHER plus BC6OTHER antagonists and BC6OTHER measured in the microdialysates.	CPR:5
Probes were perfused with artificial cerebrospinal fluid containing CHEM, the specific BC6OTHER agonist BC6ENTC , or BC6OTHER plus BC6ENTG antagonists and BC6OTHER measured in the microdialysates.	False
Probes were perfused with artificial cerebrospinal fluid containing CHEM, the specific BC6ENTG agonist BC6OTHER , or BC6ENTC plus BC6OTHER antagonists and BC6OTHER measured in the microdialysates.	CPR:5
Probes were perfused with artificial cerebrospinal fluid containing CHEM, the specific BC6OTHER agonist BC6OTHER , or BC6ENTC plus BC6ENTG antagonists and BC6OTHER measured in the microdialysates.	False
Probes were perfused with artificial cerebrospinal fluid containing CHEM, the specific BC6ENTG agonist BC6OTHER , or BC6OTHER plus BC6OTHER antagonists and BC6ENTC measured in the microdialysates.	False
Probes were perfused with artificial cerebrospinal fluid containing CHEM, the specific BC6OTHER agonist BC6OTHER , or BC6OTHER plus BC6ENTG antagonists and BC6ENTC measured in the microdialysates.	False
The effects of specific BC6ENTC receptor antagonists and BC6ENTG inhibitors were also examined.	False
The effects of specific BC6ENTG antagonists and BC6ENTC synthase inhibitors were also examined.	False
RESULTS: Both BC6ENTC and BC6OTHER induced BC6OTHER release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not BC6OTHER antagonists or BC6ENTG inhibitors.	False
 BC6ENTG regulation of spinal BC6ENTC release.	False
RESULTS: Both BC6OTHER and BC6ENTC induced BC6OTHER release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not BC6OTHER antagonists or BC6ENTG inhibitors.	False
RESULTS: Both BC6OTHER and BC6OTHER induced BC6ENTC release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not BC6OTHER antagonists or BC6ENTG inhibitors.	False
RESULTS: Both BC6OTHER and BC6OTHER induced BC6OTHER release in spinal microdialsyates, an effect reduced by nicotinic antagonists but not BC6ENTC antagonists or BC6ENTG inhibitors.	False
Both of the nicotinic agonists stimulated BC6ENTC release in synaptosomes, and the effect of BC6OTHER was blocked at lower concentrations of BC6ENTG - than BC6OTHER - preferring BC6OTHER antagonists.	False
Both of the nicotinic agonists stimulated BC6ENTC release in synaptosomes, and the effect of BC6OTHER was blocked at lower concentrations of BC6OTHER - than BC6ENTG - preferring BC6OTHER antagonists.	False
Both of the nicotinic agonists stimulated BC6ENTC release in synaptosomes, and the effect of BC6OTHER was blocked at lower concentrations of BC6OTHER - than BC6OTHER - preferring BC6ENTG antagonists.	False
Both of the nicotinic agonists stimulated BC6OTHER release in synaptosomes, and the effect of BC6ENTC was blocked at lower concentrations of BC6ENTG - than BC6OTHER - preferring BC6OTHER antagonists.	False
Both of the nicotinic agonists stimulated BC6OTHER release in synaptosomes, and the effect of BC6ENTC was blocked at lower concentrations of BC6OTHER - than BC6ENTG - preferring BC6OTHER antagonists.	False
Both of the nicotinic agonists stimulated BC6OTHER release in synaptosomes, and the effect of BC6ENTC was blocked at lower concentrations of BC6OTHER - than BC6OTHER - preferring BC6ENTG antagonists.	False
CONCLUSION: These results suggest that one mechanism by which BC6ENTG agonists act for analgesia is to stimulate spinal BC6ENTC release.	False
They do so by actions on BC6ENTG , and perhaps other subtypes, most likely located on noradrenergic terminals, rather than by indirectly stimulating BC6ENTC release through BC6OTHER release or BC6OTHER synthesis.	False
CONCLUSIONS AND IMPLICATIONS: BC6ENTC analogues with better BC6ENTG channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and BC6OTHER channel interaction are mechanistically distinct and separable properties of the compounds.	CPR:4
CONCLUSIONS AND IMPLICATIONS: BC6ENTC analogues with better BC6OTHER channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and BC6ENTG channel interaction are mechanistically distinct and separable properties of the compounds.	False
The principal aim of the study was to find BC6ENTC analogues that retained BC6ENTG inhibition but with reduced cytotoxicity.	CPR:4
Interaction with the BC6ENTG channel and cytotoxicity of BC6ENTC and BC6OTHER analogues.	False
Interaction with the BC6ENTG channel and cytotoxicity of BC6OTHER and BC6ENTC analogues.	False
Pharmacological and in silico investigations concerning the interactions of these compounds with the BC6ENTG channel revealed that compounds carrying a basic BC6ENTC in the side chain display a much higher affinity than those lacking such a group.	False
Specifically, BC6ENTC and BC6OTHER revealed a higher affinity towards BC6ENTG channels than BC6OTHER .	False
Specifically, BC6OTHER and BC6ENTC revealed a higher affinity towards BC6ENTG channels than BC6OTHER .	False
Specifically, BC6OTHER and BC6OTHER revealed a higher affinity towards BC6ENTG channels than BC6ENTC .	False
Here, we report that the antifibrotic drug BC6ENTC ( BC6OTHER , BC6OTHER ) elicits growth - inhibitory effects and reduces BC6ENTG protein levels in human glioma cell lines.	CPR:4
Here, we report that the antifibrotic drug BC6OTHER ( BC6ENTC , BC6OTHER ) elicits growth - inhibitory effects and reduces BC6ENTG protein levels in human glioma cell lines.	CPR:4
Here, we report that the antifibrotic drug BC6OTHER ( BC6OTHER , BC6ENTC ) elicits growth - inhibitory effects and reduces BC6ENTG protein levels in human glioma cell lines.	CPR:4
This reduction in BC6ENTG is biologically relevant since BC6ENTC treatment reduces the growth inhibition of BC6OTHER - sensitive CCL - 64 cells mediated by conditioned media of glioma cells.	CPR:4
This reduction in BC6OTHER is biologically relevant since BC6ENTC treatment reduces the growth inhibition of BC6ENTG - sensitive CCL - 64 cells mediated by conditioned media of glioma cells.	CPR:4
BC6ENTC leads to a reduction of BC6ENTG mRNA levels and of the mature BC6OTHER protein due to decreased expression and direct inhibition of the BC6OTHER BC6OTHER BC6OTHER .	CPR:4
BC6ENTC leads to a reduction of BC6OTHER mRNA levels and of the mature BC6ENTG protein due to decreased expression and direct inhibition of the BC6OTHER BC6OTHER BC6OTHER .	CPR:4
BC6ENTC leads to a reduction of BC6OTHER mRNA levels and of the mature BC6OTHER protein due to decreased expression and direct inhibition of the BC6ENTG BC6OTHER BC6OTHER .	CPR:4
BC6ENTC leads to a reduction of BC6OTHER mRNA levels and of the mature BC6OTHER protein due to decreased expression and direct inhibition of the BC6OTHER BC6ENTG BC6OTHER .	CPR:4
BC6ENTC leads to a reduction of BC6OTHER mRNA levels and of the mature BC6OTHER protein due to decreased expression and direct inhibition of the BC6OTHER BC6OTHER BC6ENTG .	CPR:4
In addition, BC6ENTC reduces the protein levels of the BC6ENTG , a BC6OTHER target gene and BC6OTHER substrate involved in carcinogenesis.	CPR:4
In addition, BC6ENTC reduces the protein levels of the BC6OTHER , a BC6ENTG target gene and BC6OTHER substrate involved in carcinogenesis.	CPR:4
In addition, BC6ENTC reduces the protein levels of the BC6OTHER , a BC6OTHER target gene and BC6ENTG substrate involved in carcinogenesis.	False
These data define BC6ENTC or BC6OTHER - related agents as promising agents for human cancers associated with enhanced BC6ENTG activity.	False
These data define BC6OTHER or BC6ENTC - related agents as promising agents for human cancers associated with enhanced BC6ENTG activity.	False
 BC6ENTC inhibits BC6ENTG expression in malignant glioma cells.	CPR:4
We used immunofluorescence microscopy and BC6ENTC permeabilization assays to determine the subcellular location of endogenous BC6ENTG in primary human and rat hepatocytes.	False
Human and rat BC6ENTG BC6OTHER BC6OTHER - acyltransferase are liver - specific peroxisomal enzymes: implications for intracellular BC6ENTC transport.	False
Human and rat BC6ENTG BC6ENTC BC6OTHER - acyltransferase are liver - specific peroxisomal enzymes: implications for intracellular BC6OTHER transport.	False
Human and rat BC6ENTG BC6OTHER BC6ENTC - acyltransferase are liver - specific peroxisomal enzymes: implications for intracellular BC6OTHER transport.	False
UNLABELLED: BC6ENTC - BC6OTHER : BC6OTHER BC6OTHER - acyltransferase ( BC6ENTG ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6OTHER .	False
UNLABELLED: BC6ENTG BC6OTHER BC6OTHER - acyltransferase ( BC6OTHER ) is the sole enzyme responsible for conjugation of primary and secondary BC6ENTC to BC6OTHER and BC6OTHER .	CPR:9
UNLABELLED: CHEM - BC6OTHER : BC6OTHER BC6OTHER - acyltransferase ( BC6ENTG ) is the sole enzyme responsible for conjugation of primary and secondary BC6ENTC to BC6OTHER and BC6OTHER .	CPR:9
UNLABELLED: BC6ENTG BC6OTHER BC6OTHER - acyltransferase ( BC6OTHER ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6ENTC and BC6OTHER .	CPR:9
UNLABELLED: CHEM - BC6OTHER : BC6OTHER BC6OTHER - acyltransferase ( BC6ENTG ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6ENTC and BC6OTHER .	CPR:9
UNLABELLED: BC6ENTG BC6OTHER BC6OTHER - acyltransferase ( BC6OTHER ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6ENTC .	CPR:9
UNLABELLED: CHEM - BC6OTHER : BC6OTHER BC6OTHER - acyltransferase ( BC6ENTG ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6ENTC .	CPR:9
UNLABELLED: CHEM - BC6ENTC : BC6OTHER BC6OTHER - acyltransferase ( BC6ENTG ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6OTHER .	False
UNLABELLED: BC6ENTG BC6ENTC BC6OTHER - acyltransferase ( BC6OTHER ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6OTHER .	False
UNLABELLED: CHEM - BC6OTHER : BC6ENTC BC6OTHER - acyltransferase ( BC6ENTG ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6OTHER .	False
UNLABELLED: BC6ENTG BC6OTHER BC6ENTC - acyltransferase ( BC6OTHER ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6OTHER .	False
UNLABELLED: CHEM - BC6OTHER : BC6OTHER BC6ENTC - acyltransferase ( BC6ENTG ) is the sole enzyme responsible for conjugation of primary and secondary BC6OTHER to BC6OTHER and BC6OTHER .	False
The absence or presence of a cytosolic pool of BC6ENTG has important implications for the intracellular transport of unconjugated / deconjugated BC6ENTC .	CPR:9
Key findings suggest that BC6ENTG attenuates a broad number of BC6ENTC and BC6OTHER induced behaviors and associated neuronal activity in rodents.	False
Key findings suggest that BC6ENTG attenuates a broad number of BC6OTHER and BC6ENTC induced behaviors and associated neuronal activity in rodents.	False
Evidence also outlines a role for BC6ENTG in the prosocial effects of BC6ENTC ( BC6OTHER , BC6OTHER ) in both rodents and humans.	False
Evidence also outlines a role for BC6ENTG in the prosocial effects of BC6OTHER ( BC6ENTC , BC6OTHER ) in both rodents and humans.	False
Evidence also outlines a role for BC6ENTG in the prosocial effects of BC6OTHER ( BC6OTHER , BC6ENTC ) in both rodents and humans.	False
Clinical trials should now investigate the effectiveness of BC6ENTG as a novel intervention for psychostimulant addiction and should aim to determine its specific role in the therapeutic properties of BC6ENTC that are currently being investigated.	False
BMMs are the major source of inflammatory factors and BC6ENTG , including BC6ENTC protease BC6OTHER ( BC6OTHER ).	False
BMMs are the major source of inflammatory factors and BC6OTHER , including BC6ENTC protease BC6ENTG ( BC6OTHER ).	False
BMMs are the major source of inflammatory factors and BC6OTHER , including BC6ENTC protease BC6OTHER ( BC6ENTG ).	False
CONCLUSION: Loss of BC6ENTC BC6ENTG function may predispose to BC6OTHER - associated PPH in man.	False
CONCLUSION: Loss of BC6OTHER BC6ENTG function may predispose to BC6ENTC - associated PPH in man.	False
A mouse model incriminates the BC6ENTG but contrasts with other models where this receptor has been shown to mediate pulmonary arterial relaxation via BC6ENTC production.	False
 BC6ENTG loss of function mutation in a patient with BC6ENTC - associated primary pulmonary hypertension.	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6ENTG ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6ENTG ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6ENTG ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6ENTG ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6ENTG ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6ENTC receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6ENTG ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6ENTG ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6ENTG ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6ENTG ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6ENTG ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6ENTG ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6ENTG ).	False
This analysis revealed significant differences in the expression level of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6ENTC binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6ENTG ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6ENTG ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6ENTG ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6ENTG ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTC receptor gamma ( BC6ENTG ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6ENTG ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6ENTG ).	False
This analysis revealed significant differences in the expression level of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTC receptor gamma ( BC6OTHER ), and BC6OTHER response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6ENTG ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6ENTG ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6ENTG ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6ENTG ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6ENTG ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
This analysis revealed significant differences in the expression level of the nicotinic BC6OTHER receptor subunit alpha ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6ENTG ).	False
This analysis revealed significant differences in the expression level of the BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), type 1 cellular BC6OTHER binding protein ( BC6OTHER ), BC6OTHER receptor gamma ( BC6OTHER ), and BC6ENTC response element binding protein ( BC6OTHER ).	False
Although BC6ENTC greatly attenuates BC6ENTG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of BC6OTHER inactivation without altering its voltage dependence.	CPR:3
Although BC6ENTC greatly attenuates BC6OTHER inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of BC6ENTG inactivation without altering its voltage dependence.	CPR:4
Here, we investigate whether the inverse functional response to BC6ENTC in BC6ENTG and BC6OTHER channels is related to differences in BC6OTHER binding site or to intrinsic mechanisms of inactivation.	False
Here, we investigate whether the inverse functional response to BC6ENTC in BC6OTHER and BC6ENTG channels is related to differences in BC6OTHER binding site or to intrinsic mechanisms of inactivation.	False
Here, we investigate whether the inverse functional response to BC6OTHER in BC6ENTG and BC6OTHER channels is related to differences in BC6ENTC binding site or to intrinsic mechanisms of inactivation.	False
Here, we investigate whether the inverse functional response to BC6OTHER in BC6OTHER and BC6ENTG channels is related to differences in BC6ENTC binding site or to intrinsic mechanisms of inactivation.	False
Rapid and voltage - dependent inactivation greatly attenuates outward currents in BC6ENTC - a - go - go - related gene ( BC6ENTG ) BC6OTHER .	False
Rapid and voltage - dependent inactivation greatly attenuates outward currents in BC6ENTC - a - go - go - related gene ( BC6OTHER ) BC6ENTG .	False
BC6ENTC is a mixed agonist of mutant BC6ENTG and BC6OTHER / BC6OTHER chimera channels that inactivate by a combination of slow and fast mechanisms.	CPR:5
BC6ENTC is a mixed agonist of mutant BC6OTHER and BC6ENTG / BC6OTHER chimera channels that inactivate by a combination of slow and fast mechanisms.	CPR:5
BC6ENTC is a mixed agonist of mutant BC6OTHER and BC6OTHER / BC6ENTG chimera channels that inactivate by a combination of slow and fast mechanisms.	CPR:5
 BC6ENTC interacts with a common binding site to elicit opposite effects on inactivation gating of BC6ENTG and BC6OTHER BC6OTHER .	CPR:3
 BC6ENTC interacts with a common binding site to elicit opposite effects on inactivation gating of BC6OTHER and BC6ENTG BC6OTHER .	CPR:3
 BC6ENTC interacts with a common binding site to elicit opposite effects on inactivation gating of BC6OTHER and BC6OTHER BC6ENTG .	CPR:3
 BC6OTHER interacts with a common binding site to elicit opposite effects on inactivation gating of BC6ENTG and BC6OTHER BC6ENTC channels.	False
 BC6OTHER interacts with a common binding site to elicit opposite effects on inactivation gating of BC6OTHER and BC6ENTG BC6ENTC channels.	False
Rapid and voltage - dependent inactivation greatly attenuates outward currents in BC6OTHER ( BC6ENTG ) BC6ENTC channels.	False
Rapid and voltage - dependent inactivation greatly attenuates outward currents in BC6ENTG ( BC6OTHER ) BC6ENTC channels.	False
With the exception of three residues, the specific BC6ENTC that form the putative binding pocket for BC6OTHER in BC6ENTG are conserved in BC6OTHER .	False
With the exception of three residues, the specific BC6ENTC that form the putative binding pocket for BC6OTHER in BC6OTHER are conserved in BC6ENTG .	False
With the exception of three residues, the specific BC6OTHER that form the putative binding pocket for BC6ENTC in BC6ENTG are conserved in BC6OTHER .	False
With the exception of three residues, the specific BC6OTHER that form the putative binding pocket for BC6ENTC in BC6OTHER are conserved in BC6ENTG .	False
Mutations introduced into BC6ENTG to replicate the BC6ENTC binding site in BC6OTHER did not alter the functional response to BC6OTHER .	False
Mutations introduced into BC6OTHER to replicate the BC6ENTC binding site in BC6ENTG did not alter the functional response to BC6OTHER .	False
Mutations introduced into BC6ENTG to replicate the BC6OTHER binding site in BC6OTHER did not alter the functional response to BC6ENTC .	False
Mutations introduced into BC6OTHER to replicate the BC6OTHER binding site in BC6ENTG did not alter the functional response to BC6ENTC .	False
Together these findings suggest that BC6ENTC binds to the same site in BC6ENTG and BC6OTHER channels to elicit opposite functional effects.	False
Together these findings suggest that BC6ENTC binds to the same site in BC6OTHER and BC6ENTG channels to elicit opposite functional effects.	False
In contrast, inactivation of related BC6ENTC - a - go - go ( BC6ENTG ) BC6OTHER channels is very slow and minimally reduces outward currents.	False
In contrast, inactivation of related BC6ENTC - a - go - go ( BC6OTHER ) BC6ENTG is very slow and minimally reduces outward currents.	False
In contrast, inactivation of related BC6ENTG ( BC6OTHER ) BC6ENTC channels is very slow and minimally reduces outward currents.	False
In contrast, inactivation of related BC6OTHER - a - go - go ( BC6ENTG ) BC6ENTC channels is very slow and minimally reduces outward currents.	False
In this study we explored the toxicity of BC6ENTC toward NSCs focusing on apoptosis and status of BC6ENTG survival signaling.	False
 BC6ENTC induced apoptotic changes in neural stem cells: amelioration by BC6ENTG support.	False
BC6ENTC toxicity coincided with reduced BC6ENTG level and its downstream effectors: BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER , BC6OTHER suggesting repressed BC6OTHER / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER , BC6OTHER suggesting repressed BC6OTHER / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER BC6OTHER , BC6OTHER suggesting repressed BC6OTHER / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER BC6OTHER , BC6OTHER suggesting repressed BC6OTHER / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG BC6OTHER , BC6OTHER suggesting repressed BC6OTHER / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER BC6ENTG , BC6OTHER suggesting repressed BC6OTHER / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER , BC6ENTG suggesting repressed BC6OTHER / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER , BC6OTHER suggesting repressed BC6ENTG / BC6OTHER signaling.	CPR:4
BC6ENTC toxicity coincided with reduced BC6OTHER level and its downstream effectors: BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER , BC6OTHER suggesting repressed BC6OTHER / BC6ENTG signaling.	CPR:4
Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against BC6ENTC through activating BC6ENTG / BC6OTHER pathway.	False
Multiple neurotrophic factor support in the form of Olfactory Ensheathing Cell's Conditioned Media (OEC CM) potentially protected NSCs against BC6ENTC through activating BC6OTHER / BC6ENTG pathway.	False
This was confirmed on adding BC6ENTC the BC6ENTG inhibitor which abolished the protection.	CPR:4
The endogenous BC6OTHER BC6ENTC ( BC6OTHER ) dilates cerebral arteries via BC6ENTG activation, which requires recognition by a BC6OTHER site that includes BC6OTHER 169.	False
The endogenous BC6OTHER BC6ENTC ( BC6OTHER ) dilates cerebral arteries via BC6OTHER activation, which requires recognition by a BC6ENTG site that includes BC6OTHER 169.	False
The endogenous BC6OTHER BC6OTHER ( BC6ENTC ) dilates cerebral arteries via BC6ENTG activation, which requires recognition by a BC6OTHER site that includes BC6OTHER 169.	False
The endogenous BC6OTHER BC6OTHER ( BC6ENTC ) dilates cerebral arteries via BC6OTHER activation, which requires recognition by a BC6ENTG site that includes BC6OTHER 169.	False
The endogenous BC6OTHER BC6OTHER ( BC6OTHER ) dilates cerebral arteries via BC6ENTG activation, which requires recognition by a BC6OTHER site that includes BC6ENTC 169.	False
The endogenous BC6OTHER BC6OTHER ( BC6OTHER ) dilates cerebral arteries via BC6OTHER activation, which requires recognition by a BC6ENTG site that includes BC6ENTC 169.	False
BC6ENTC activated the BC6ENTG cloned from rat cerebral artery myocytes with a potency (EC50 = 53 μM) similar to and an efficacy (×2.5 potentiation) significantly greater than that of BC6OTHER .	CPR:3
BC6OTHER activated the BC6ENTG cloned from rat cerebral artery myocytes with a potency (EC50 = 53 μM) similar to and an efficacy (×2.5 potentiation) significantly greater than that of BC6ENTC .	CPR:3
BC6ENTC failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets BC6ENTG via the BC6OTHER BC6OTHER - sensing site.	CPR:3
BC6ENTC failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets BC6OTHER via the BC6ENTG BC6OTHER - sensing site.	False
Cerebrovascular Dilation via Selective Targeting of the BC6ENTC BC6OTHER - Recognition Site in the BC6ENTG by a Novel Nonsteroidal Agent.	False
Cerebrovascular Dilation via Selective Targeting of the BC6OTHER BC6ENTC - Recognition Site in the BC6ENTG by a Novel Nonsteroidal Agent.	False
BC6OTHER failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets BC6ENTG via the BC6OTHER BC6ENTC - sensing site.	False
BC6OTHER failed to activate the channels made of cbv1 + β2, β3, β4, or β1T169A, indicating that this drug selectively targets BC6OTHER via the BC6ENTG BC6ENTC - sensing site.	False
BC6ENTC failed to dilate the arteries from the BC6ENTG knockout mouse, underscoring BC6OTHER 's role in BC6OTHER action.	False
BC6ENTC failed to dilate the arteries from the BC6OTHER knockout mouse, underscoring BC6ENTG 's role in BC6OTHER action.	False
BC6OTHER failed to dilate the arteries from the BC6ENTG knockout mouse, underscoring BC6OTHER 's role in BC6ENTC action.	False
BC6OTHER failed to dilate the arteries from the BC6OTHER knockout mouse, underscoring BC6ENTG 's role in BC6ENTC action.	False
Finally, carotid artery - infusion of BC6ENTC (45 μM) dilated the pial cerebral arterioles via selective BC6ENTG targeting.	False
In conclusion, we have identified for the first time a nonsteroidal agent that selectively activates BC6ENTG by targeting the BC6ENTC - sensing site in BC6OTHER , rendering vasodilation.	False
In conclusion, we have identified for the first time a nonsteroidal agent that selectively activates BC6OTHER by targeting the BC6ENTC - sensing site in BC6ENTG , rendering vasodilation.	False
The endogenous BC6ENTC BC6OTHER ( BC6OTHER ) dilates cerebral arteries via BC6ENTG activation, which requires recognition by a BC6OTHER site that includes BC6OTHER 169.	False
The endogenous BC6ENTC BC6OTHER ( BC6OTHER ) dilates cerebral arteries via BC6OTHER activation, which requires recognition by a BC6ENTG site that includes BC6OTHER 169.	False
Thus, BC6OTHER and other BC6ENTG BC6OTHER inhibitors provide an intriguing new way to halt BC6ENTC - induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038 / cdd.2013.31.	False
Thus, BC6OTHER and other BC6OTHER BC6ENTG inhibitors provide an intriguing new way to halt BC6ENTC - induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038 / cdd.2013.31.	False
Recently, the BC6ENTG BC6OTHER inhibitor BC6ENTC ( BC6OTHER ) has become the focus of research as a fertoprotective drug against BC6OTHER .	CPR:4
Recently, the BC6OTHER BC6ENTG inhibitor BC6ENTC ( BC6OTHER ) has become the focus of research as a fertoprotective drug against BC6OTHER .	CPR:4
Recently, the BC6ENTG BC6OTHER inhibitor BC6OTHER ( BC6ENTC ) has become the focus of research as a fertoprotective drug against BC6OTHER .	CPR:4
Recently, the BC6OTHER BC6ENTG inhibitor BC6OTHER ( BC6ENTC ) has become the focus of research as a fertoprotective drug against BC6OTHER .	CPR:4
Recently, the BC6ENTG BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) has become the focus of research as a fertoprotective drug against BC6ENTC .	False
Recently, the BC6OTHER BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) has become the focus of research as a fertoprotective drug against BC6ENTC .	False
We found that, before apoptosis, BC6ENTC induces BC6ENTG and BC6OTHER expression in the oocyte.	CPR:3
We found that, before apoptosis, BC6ENTC induces BC6OTHER and BC6ENTG expression in the oocyte.	CPR:3
While BC6ENTC was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6ENTG , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6ENTC was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6ENTG / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6ENTC was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6ENTG and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6ENTC was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6ENTG and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6ENTC was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6ENTG , thereby abrogating oocyte cell death.	False
While BC6OTHER was unable to block BC6ENTC - induced DNA damage and damage response, such as the upregulation of BC6ENTG , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	CPR:3
While BC6OTHER was unable to block BC6ENTC - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6ENTG / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6OTHER was unable to block BC6ENTC - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6ENTG and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6OTHER was unable to block BC6ENTC - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6ENTG and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6OTHER was unable to block BC6ENTC - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6ENTG , thereby abrogating oocyte cell death.	False
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6ENTG , BC6ENTC inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6ENTC inhibited the BC6OTHER - induced nuclear accumulation of BC6ENTG / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	CPR:4
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6ENTC inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6ENTG and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	CPR:4
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6ENTC inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6ENTG and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	CPR:3
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6ENTC inhibited the BC6OTHER - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6ENTG , thereby abrogating oocyte cell death.	CPR:4
Rescue of BC6ENTC - damaged oocytes from programmed cell death through inactivation of the BC6ENTG family signaling network.	False
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6ENTG , BC6OTHER inhibited the BC6ENTC - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	False
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6ENTC - induced nuclear accumulation of BC6ENTG / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	CPR:3
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6ENTC - induced nuclear accumulation of BC6OTHER / BC6ENTG and the subsequent downregulation of BC6OTHER and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	CPR:3
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6ENTC - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6ENTG and upregulation of BC6OTHER , thereby abrogating oocyte cell death.	CPR:4
While BC6OTHER was unable to block BC6OTHER - induced DNA damage and damage response, such as the upregulation of BC6OTHER , BC6OTHER inhibited the BC6ENTC - induced nuclear accumulation of BC6OTHER / BC6OTHER and the subsequent downregulation of BC6OTHER and upregulation of BC6ENTG , thereby abrogating oocyte cell death.	CPR:3
Surprisingly, the conditional deletion of BC6ENTC 63, but not BC6ENTG , in oocytes inhibited apoptosis, as well as the accumulation of BC6OTHER and BC6OTHER caused by BC6OTHER .	False
Surprisingly, the conditional deletion of BC6ENTC 63, but not BC6OTHER , in oocytes inhibited apoptosis, as well as the accumulation of BC6ENTG and BC6OTHER caused by BC6OTHER .	False
Surprisingly, the conditional deletion of BC6ENTC 63, but not BC6OTHER , in oocytes inhibited apoptosis, as well as the accumulation of BC6OTHER and BC6ENTG caused by BC6OTHER .	False
Surprisingly, the conditional deletion of BC6ENTG , but not BC6OTHER , in oocytes inhibited apoptosis, as well as the accumulation of BC6OTHER and BC6OTHER caused by BC6ENTC .	False
Surprisingly, the conditional deletion of BC6OTHER 63, but not BC6ENTG , in oocytes inhibited apoptosis, as well as the accumulation of BC6OTHER and BC6OTHER caused by BC6ENTC .	False
Surprisingly, the conditional deletion of BC6OTHER 63, but not BC6OTHER , in oocytes inhibited apoptosis, as well as the accumulation of BC6ENTG and BC6OTHER caused by BC6ENTC .	CPR:3
Surprisingly, the conditional deletion of BC6OTHER 63, but not BC6OTHER , in oocytes inhibited apoptosis, as well as the accumulation of BC6OTHER and BC6ENTG caused by BC6ENTC .	CPR:3
These data suggest that BC6ENTG is the master regulator of BC6ENTC - induced oocyte death.	False
The expression kinetics of BC6ENTG , BC6OTHER and BC6OTHER suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6OTHER and BC6OTHER and, in turn, the activation of BC6OTHER by BC6OTHER - induced BC6OTHER expression.	False
The expression kinetics of BC6OTHER , BC6ENTG and BC6OTHER suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6OTHER and BC6OTHER and, in turn, the activation of BC6OTHER by BC6OTHER - induced BC6OTHER expression.	False
The expression kinetics of BC6OTHER , BC6OTHER and BC6ENTG suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6OTHER and BC6OTHER and, in turn, the activation of BC6OTHER by BC6OTHER - induced BC6OTHER expression.	False
The expression kinetics of BC6OTHER , BC6OTHER and BC6OTHER suggest that BC6ENTC activates BC6ENTG - dependent expression of BC6OTHER and BC6OTHER and, in turn, the activation of BC6OTHER by BC6OTHER - induced BC6OTHER expression.	CPR:3
The expression kinetics of BC6OTHER , BC6OTHER and BC6OTHER suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6ENTG and BC6OTHER and, in turn, the activation of BC6OTHER by BC6OTHER - induced BC6OTHER expression.	CPR:3
The expression kinetics of BC6OTHER , BC6OTHER and BC6OTHER suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6OTHER and BC6ENTG and, in turn, the activation of BC6OTHER by BC6OTHER - induced BC6OTHER expression.	CPR:3
The expression kinetics of BC6OTHER , BC6OTHER and BC6OTHER suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6OTHER and BC6OTHER and, in turn, the activation of BC6ENTG by BC6OTHER - induced BC6OTHER expression.	CPR:3
The expression kinetics of BC6OTHER , BC6OTHER and BC6OTHER suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6OTHER and BC6OTHER and, in turn, the activation of BC6OTHER by BC6ENTG - induced BC6OTHER expression.	CPR:3
The expression kinetics of BC6OTHER , BC6OTHER and BC6OTHER suggest that BC6ENTC activates BC6OTHER - dependent expression of BC6OTHER and BC6OTHER and, in turn, the activation of BC6OTHER by BC6OTHER - induced BC6ENTG expression.	CPR:3
Our findings indicate that BC6ENTC protects oocytes from BC6OTHER - induced cell death by inhibiting BC6ENTG BC6OTHER , which would otherwise activate BC6OTHER - BC6OTHER - mediated apoptosis.	CPR:4
Our findings indicate that BC6ENTC protects oocytes from BC6OTHER - induced cell death by inhibiting BC6OTHER BC6ENTG , which would otherwise activate BC6OTHER - BC6OTHER - mediated apoptosis.	CPR:3
Our findings indicate that BC6ENTC protects oocytes from BC6OTHER - induced cell death by inhibiting BC6OTHER BC6OTHER , which would otherwise activate BC6ENTG - BC6OTHER - mediated apoptosis.	CPR:4
Our findings indicate that BC6ENTC protects oocytes from BC6OTHER - induced cell death by inhibiting BC6OTHER BC6OTHER , which would otherwise activate BC6OTHER - BC6ENTG - mediated apoptosis.	CPR:4
Our findings indicate that BC6OTHER protects oocytes from BC6ENTC - induced cell death by inhibiting BC6ENTG BC6OTHER , which would otherwise activate BC6OTHER - BC6OTHER - mediated apoptosis.	CPR:3
Our findings indicate that BC6OTHER protects oocytes from BC6ENTC - induced cell death by inhibiting BC6OTHER BC6ENTG , which would otherwise activate BC6OTHER - BC6OTHER - mediated apoptosis.	CPR:3
Our findings indicate that BC6OTHER protects oocytes from BC6ENTC - induced cell death by inhibiting BC6OTHER BC6OTHER , which would otherwise activate BC6ENTG - BC6OTHER - mediated apoptosis.	CPR:3
Our findings indicate that BC6OTHER protects oocytes from BC6ENTC - induced cell death by inhibiting BC6OTHER BC6OTHER , which would otherwise activate BC6OTHER - BC6ENTG - mediated apoptosis.	CPR:3
Thus, BC6ENTC and other BC6ENTG BC6OTHER inhibitors provide an intriguing new way to halt BC6OTHER - induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038 / cdd.2013.31.	CPR:4
Thus, BC6ENTC and other BC6OTHER BC6ENTG inhibitors provide an intriguing new way to halt BC6OTHER - induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038 / cdd.2013.31.	CPR:4
Furthermore, the BC6ENTC (11) selectively induced apoptosis in A549 cells without affecting the BC6ENTG activity level.	False
OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as BC6ENTC and BC6OTHER agonist, exert direct regulatory action on BC6ENTG ( BC6OTHER ) expression by endometrial epithelial cells.	False
OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as BC6ENTC and BC6OTHER agonist, exert direct regulatory action on BC6OTHER ( BC6ENTG ) expression by endometrial epithelial cells.	False
OBJECTIVE: To assess whether hormonal agents used in the medical treatment of endometriosis, such as BC6ENTC and BC6ENTG agonist, exert direct regulatory action on BC6OTHER ( BC6OTHER ) expression by endometrial epithelial cells.	False
RESULT(S): BC6OTHER , a BC6ENTG agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6ENTC (10CHEM( - 5) M), a BC6OTHER analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	False
RESULT(S): BC6OTHER , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6ENTG expression, whereas BC6ENTC (10CHEM( - 5) M), a BC6OTHER analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	False
RESULT(S): BC6OTHER , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6ENTC (10CHEM( - 5) M), a BC6OTHER analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6ENTG expression.	CPR:4
RESULT(S): BC6OTHER , a BC6ENTG agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6ENTC analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	False
RESULT(S): BC6OTHER , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6ENTG expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6ENTC analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	False
RESULT(S): BC6OTHER , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6ENTC analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6ENTG expression.	CPR:4
RESULT(S): BC6OTHER , a BC6ENTG agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6OTHER analog, and BC6ENTC , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	False
RESULT(S): BC6OTHER , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6ENTG expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6OTHER analog, and BC6ENTC , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	False
RESULT(S): BC6OTHER , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6OTHER analog, and BC6ENTC , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6ENTG expression.	CPR:4
DESIGN: Primary cultures of epithelial cells isolated from human endometrium were exposed to different concentrations of BC6ENTG and BC6ENTC hormone analogs.	False
RESULT(S): BC6ENTC , a BC6ENTG agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6OTHER analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	CPR:5
RESULT(S): BC6ENTC , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6ENTG expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6OTHER analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6OTHER expression.	False
RESULT(S): BC6ENTC , a BC6OTHER agonist (0.1 - 10 ng / mL), had no significant effect on BC6OTHER expression, whereas BC6OTHER (10CHEM( - 5) M), a BC6OTHER analog, and BC6OTHER , an anti - inflammatory glucocorticoid hormone (10CHEM), showed a direct and a dose - dependent inhibitory effect on BC6ENTG expression.	False
Experimentation using isoforms of BC6ENTG engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6OTHER binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6OTHER and BC6OTHER to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6ENTG that impact BC6OTHER binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6OTHER and BC6OTHER to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6ENTG binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6OTHER and BC6OTHER to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6OTHER binding indicate that BC6ENTG mediates cognate interactions between cells expressing BC6OTHER and BC6OTHER to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6OTHER binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6ENTG and BC6OTHER to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6OTHER binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6OTHER and BC6ENTG to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6OTHER binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6OTHER and BC6OTHER to activate cells, e.g., increase BC6ENTG phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6OTHER binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6OTHER and BC6OTHER to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6ENTG , and induce release of BC6OTHER .	False
Experimentation using isoforms of BC6OTHER engineered to have BC6ENTC substitutions in the BC6OTHER that impact BC6OTHER binding indicate that BC6OTHER mediates cognate interactions between cells expressing BC6OTHER and BC6OTHER to activate cells, e.g., increase BC6OTHER phosphorylation, up - regulate cell surface expression of the activation marker BC6OTHER , and induce release of BC6ENTG .	False
High throughput screening led to the identification of a novel series of BC6ENTC α7 nicotinic BC6OTHER receptor ( BC6ENTG ) agonists.	CPR:5
High throughput screening led to the identification of a novel series of BC6ENTC BC6ENTG ( BC6OTHER ) agonists.	CPR:5
High throughput screening led to the identification of a novel series of BC6OTHER α7 nicotinic BC6ENTC receptor ( BC6ENTG ) agonists.	False
Discovery of a novel series of BC6ENTC BC6ENTG agonists.	CPR:5
However, BC6OTHER BC6OTHER was significantly associated with BC6ENTC levels (AA genotype: 290 + / - 122 pmol / l; AG: 381 + / - 151 pmol / l and GG: 415 + / - 100 pmol / l), as was BC6ENTG BC6OTHER (AA: 478 + / - 219 pmol / l, AG: 306 + / - 124 pmol / l and GG: 306 + / - 123 pmol / l).	False
However, BC6OTHER BC6OTHER was significantly associated with BC6ENTC levels (AA genotype: 290 + / - 122 pmol / l; AG: 381 + / - 151 pmol / l and GG: 415 + / - 100 pmol / l), as was BC6OTHER BC6ENTG (AA: 478 + / - 219 pmol / l, AG: 306 + / - 124 pmol / l and GG: 306 + / - 123 pmol / l).	False
However, BC6ENTG BC6OTHER was significantly associated with BC6ENTC levels (AA genotype: 290 + / - 122 pmol / l; AG: 381 + / - 151 pmol / l and GG: 415 + / - 100 pmol / l), as was BC6OTHER BC6OTHER (AA: 478 + / - 219 pmol / l, AG: 306 + / - 124 pmol / l and GG: 306 + / - 123 pmol / l).	False
However, BC6OTHER BC6ENTG was significantly associated with BC6ENTC levels (AA genotype: 290 + / - 122 pmol / l; AG: 381 + / - 151 pmol / l and GG: 415 + / - 100 pmol / l), as was BC6OTHER BC6OTHER (AA: 478 + / - 219 pmol / l, AG: 306 + / - 124 pmol / l and GG: 306 + / - 123 pmol / l).	False
Differences in BC6ENTC and CHEM levels with the BC6ENTG BC6OTHER and BC6OTHER BC6OTHER polymorphisms were noted.	False
Differences in BC6ENTC and CHEM levels with the BC6OTHER BC6ENTG and BC6OTHER BC6OTHER polymorphisms were noted.	False
Differences in BC6ENTC and CHEM levels with the BC6OTHER BC6OTHER and BC6ENTG BC6OTHER polymorphisms were noted.	False
Differences in BC6ENTC and CHEM levels with the BC6OTHER BC6OTHER and BC6OTHER BC6ENTG polymorphisms were noted.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6ENTG ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6ENTG ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6ENTG and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6ENTG ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6ENTG ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6ENTG ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6ENTG ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6ENTC - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6ENTG ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6ENTG ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6ENTG and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6OTHER and BC6ENTG ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6ENTG ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6ENTG ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6ENTG ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTC reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6ENTG ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTG ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTC synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6ENTG ) BC6OTHER and BC6OTHER ; BC6ENTC synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6ENTG and BC6OTHER ; BC6ENTC synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6ENTG ; BC6ENTC synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTC synthase ( BC6ENTG ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTC synthase ( BC6OTHER ) BC6ENTG ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTC synthase ( BC6OTHER ) BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTC synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6ENTG ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTC synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6ENTG ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTG ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTC synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6ENTG ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTC synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6ENTG and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTC synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6ENTG ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTC synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ; BC6ENTC synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6ENTG ) BC6OTHER ; BC6ENTC synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6ENTG ; BC6ENTC synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTC synthase reductase ( BC6ENTG ) BC6OTHER ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTC synthase reductase ( BC6OTHER ) BC6ENTG ] in relation to total plasma BC6OTHER levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6ENTG ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6ENTG ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6ENTG and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6ENTG ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6ENTG ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6ENTG ; BC6OTHER synthase reductase ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6ENTG ( BC6OTHER ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6ENTG ) BC6OTHER ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
We studied several single nucleotide polymorphisms (SNP) in BC6OTHER - regulating genes [ BC6OTHER reductase ( BC6OTHER ) BC6OTHER and BC6OTHER ; BC6OTHER synthase ( BC6OTHER ) BC6OTHER ; BC6OTHER synthase reductase ( BC6OTHER ) BC6ENTG ] in relation to total plasma BC6ENTC levels, transplant coronary artery disease and thromboembolic episodes in 84 heart transplant patients, and we compared the incidence of these polymorphisms with those in a healthy adult controls.	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6ENTC , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6ENTC , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6ENTC and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6ENTC and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6ENTC .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6ENTC .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6ENTG antagonists, BC6OTHER inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
To assess the safety and efficacy of combination therapies for LUTS associated with BPH, a search of the MEDLINE and CHEM databases (1976 - 2008) was conducted for relevant trials and reviews using the terms benign prostatic hyperplasia, lower urinary tract symptoms, BC6OTHER antagonists, BC6ENTG inhibitors, anti - muscarinics, anticholinergics, combination therapy, BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , erectile dysfunction, BC6OTHER , BC6OTHER and BC6OTHER .	False
Decreased BC6ENTG activity with unchanged mRNA stability suggested that BC6ENTC suppressed BC6OTHER gene expression at the transcriptional level.	False
Decreased BC6OTHER activity with unchanged mRNA stability suggested that BC6ENTC suppressed BC6ENTG gene expression at the transcriptional level.	CPR:4
 BC6ENTC downregulates BC6ENTG through activation of BC6OTHER .	CPR:4
 BC6ENTC downregulates BC6OTHER through activation of BC6ENTG .	CPR:3
However, the expression of BC6ENTG was not suppressed by other BC6OTHER antagonists such as BC6ENTC or BC6OTHER .	False
However, the expression of BC6OTHER was not suppressed by other BC6ENTG antagonists such as BC6ENTC or BC6OTHER .	CPR:6
However, the expression of BC6ENTG was not suppressed by other BC6OTHER antagonists such as BC6OTHER or BC6ENTC .	False
However, the expression of BC6OTHER was not suppressed by other BC6ENTG antagonists such as BC6OTHER or BC6ENTC .	CPR:6
OBJECTIVE: BC6ENTC , an BC6OTHER ( BC6OTHER ) antagonist, was found to have a unique property: it is a partial agonist of BC6ENTG ( BC6OTHER ).	CPR:5
OBJECTIVE: BC6ENTC , an BC6OTHER ( BC6OTHER ) antagonist, was found to have a unique property: it is a partial agonist of BC6OTHER ( BC6ENTG ).	CPR:5
OBJECTIVE: BC6ENTC , an BC6ENTG ( BC6OTHER ) antagonist, was found to have a unique property: it is a partial agonist of BC6OTHER ( BC6OTHER ).	CPR:6
OBJECTIVE: BC6ENTC , an BC6OTHER ( BC6ENTG ) antagonist, was found to have a unique property: it is a partial agonist of BC6OTHER ( BC6OTHER ).	CPR:6
Since the suppression of BC6ENTG expression was prevented by pretreatment with BC6ENTC , a BC6OTHER antagonist, BC6OTHER should have participated in the process.	CPR:3
Since the suppression of BC6OTHER expression was prevented by pretreatment with BC6ENTC , a BC6ENTG antagonist, BC6OTHER should have participated in the process.	CPR:6
Since the suppression of BC6OTHER expression was prevented by pretreatment with BC6ENTC , a BC6OTHER antagonist, BC6ENTG should have participated in the process.	False
The deletion and mutation analysis of the BC6ENTG gene promoter indicated that a BC6OTHER located in the proximal promoter region is responsible for the BC6ENTC - induced downregulation.	CPR:4
The deletion and mutation analysis of the BC6OTHER gene promoter indicated that a BC6ENTG located in the proximal promoter region is responsible for the BC6ENTC - induced downregulation.	CPR:4
CONCLUSION: Our data provides a novel insight into an effect of BC6ENTC : BC6OTHER inhibits BC6ENTG gene expression through BC6OTHER activation.	False
CONCLUSION: Our data provides a novel insight into an effect of BC6ENTC : BC6OTHER inhibits BC6OTHER gene expression through BC6ENTG activation.	False
CONCLUSION: Our data provides a novel insight into an effect of BC6OTHER : BC6ENTC inhibits BC6ENTG gene expression through BC6OTHER activation.	CPR:4
CONCLUSION: Our data provides a novel insight into an effect of BC6OTHER : BC6ENTC inhibits BC6OTHER gene expression through BC6ENTG activation.	CPR:3
Since previous studies have demonstrated that BC6ENTG activators suppressed BC6OTHER expression, we examined whether BC6ENTC affects BC6OTHER expression in vascular smooth muscle cells.	False
Since previous studies have demonstrated that BC6OTHER activators suppressed BC6ENTG expression, we examined whether BC6ENTC affects BC6OTHER expression in vascular smooth muscle cells.	False
Since previous studies have demonstrated that BC6OTHER activators suppressed BC6OTHER expression, we examined whether BC6ENTC affects BC6ENTG expression in vascular smooth muscle cells.	False
RESULTS: BC6ENTC decreased the expression of BC6ENTG at the mRNA and protein levels in a dose - and time - dependent manner.	CPR:4
RATIONALE: BC6ENTG antagonists, such as BC6ENTC , have been shown to possess cognitive - enhancing and wakefulness - promoting effects.	CPR:6
Assessment of the abuse liability of BC6ENTC , a novel BC6ENTG antagonist.	CPR:6
CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to BC6ENTG antagonists, indicates that BC6ENTC is unlikely to possess a high potential for abuse in the human population and suggests that BC6OTHER antagonists, as a class, are similar in this regard.	False
CONCLUSIONS: The sum of these preclinical data, the first of their kind applied to BC6OTHER antagonists, indicates that BC6ENTC is unlikely to possess a high potential for abuse in the human population and suggests that BC6ENTG antagonists, as a class, are similar in this regard.	CPR:6
To explore the relationship between BC6ENTC transport and ion permeation through the BC6ENTG , we established a human BC6OTHER transporter ( BC6OTHER ) cell line suitable for biochemical analysis and patch - clamp recording.	False
To explore the relationship between BC6ENTC transport and ion permeation through the BC6OTHER , we established a BC6ENTG ( BC6OTHER ) cell line suitable for biochemical analysis and patch - clamp recording.	False
To explore the relationship between BC6ENTC transport and ion permeation through the BC6OTHER , we established a human BC6OTHER transporter ( BC6ENTG ) cell line suitable for biochemical analysis and patch - clamp recording.	False
To explore the relationship between BC6OTHER transport and ion permeation through the BC6ENTC transporter, we established a BC6ENTG ( BC6OTHER ) cell line suitable for biochemical analysis and patch - clamp recording.	False
To explore the relationship between BC6OTHER transport and ion permeation through the BC6ENTC transporter, we established a human BC6OTHER transporter ( BC6ENTG ) cell line suitable for biochemical analysis and patch - clamp recording.	False
To explore the relationship between BC6OTHER transport and ion permeation through the BC6ENTG , we established a human BC6ENTC transporter ( BC6OTHER ) cell line suitable for biochemical analysis and patch - clamp recording.	False
To explore the relationship between BC6OTHER transport and ion permeation through the BC6OTHER , we established a human BC6ENTC transporter ( BC6ENTG ) cell line suitable for biochemical analysis and patch - clamp recording.	False
Stable transfection of BC6ENTG cDNA into HEK - 293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and BC6OTHER - specific antibodies, (2) high - affinity, BC6ENTC - dependent transport of BC6OTHER , and (3) inhibitor sensitivities similar to those of native membranes.	False
Stable transfection of BC6OTHER cDNA into HEK - 293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and BC6ENTG - specific antibodies, (2) high - affinity, BC6ENTC - dependent transport of BC6OTHER , and (3) inhibitor sensitivities similar to those of native membranes.	False
Stable transfection of BC6ENTG cDNA into HEK - 293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and BC6OTHER - specific antibodies, (2) high - affinity, BC6OTHER - dependent transport of BC6ENTC , and (3) inhibitor sensitivities similar to those of native membranes.	False
Stable transfection of BC6OTHER cDNA into HEK - 293 (human embryonic kidney) cells results in lines exhibiting (1) a high number of transporter copies per cell (10(6)), as detected by radioligand binding and BC6ENTG - specific antibodies, (2) high - affinity, BC6OTHER - dependent transport of BC6ENTC , and (3) inhibitor sensitivities similar to those of native membranes.	False
In addition to BC6OTHER - dependent currents, transfected cells posses an BC6ENTC - independent mode of charge movement mediated by BC6ENTG .	False
Whole - cell voltage - clamp of BC6ENTG - 293 cells reveals BC6ENTC - induced, BC6OTHER - dependent currents blocked by antidepressants and BC6OTHER that are absent in parental cells.	CPR:3
Whole - cell voltage - clamp of BC6ENTG - 293 cells reveals BC6OTHER - induced, BC6ENTC - dependent currents blocked by antidepressants and BC6OTHER that are absent in parental cells.	False
Whole - cell voltage - clamp of BC6ENTG - 293 cells reveals BC6OTHER - induced, BC6OTHER - dependent currents blocked by antidepressants and BC6ENTC that are absent in parental cells.	CPR:4
In addition to BC6ENTC - dependent currents, transfected cells posses an BC6OTHER - independent mode of charge movement mediated by BC6ENTG .	False
 BC6ENTC - dependent BC6OTHER - induced currents in BC6ENTG - transfected HEK - 293 cells blocked by BC6OTHER and antidepressants.	False
 BC6OTHER - dependent BC6OTHER - induced currents in BC6ENTG - transfected HEK - 293 cells blocked by BC6ENTC and antidepressants.	CPR:4
 BC6OTHER - dependent BC6ENTC - induced currents in BC6ENTG - transfected HEK - 293 cells blocked by BC6OTHER and antidepressants.	CPR:3
BC6ENTG antagonists without effect in non - transfected cells abolish both BC6ENTC - dependent and BC6OTHER - independent modes of charge movement in transfected cells.	False
BC6ENTG antagonists without effect in non - transfected cells abolish both BC6OTHER - dependent and BC6ENTC - independent modes of charge movement in transfected cells.	False
To explain our observations, we propose that BC6ENTG function as BC6OTHER with an indefinite stoichiometry relating ion flux to BC6ENTC transport.	CPR:9
To explain our observations, we propose that BC6OTHER function as BC6ENTG with an indefinite stoichiometry relating ion flux to BC6ENTC transport.	False
BC6ENTG is characterized by a late S(N)1 transition state with significant participation of the BC6ENTC nucleophile.	False
KIEs were measured on the arsenolysis of BC6ENTC ( BC6OTHER ) catalyzed by BC6ENTG and were corrected for the forward commitment to catalysis.	CPR:9
KIEs were measured on the arsenolysis of BC6OTHER ( BC6ENTC ) catalyzed by BC6ENTG and were corrected for the forward commitment to catalysis.	CPR:9
The primary intrinsic KIEs ( BC6ENTC and BC6OTHER ) suggest that BC6ENTG has a dissociative S(N)1 transition state with its cationic center at the anomeric BC6OTHER and insignificant bond order to the leaving group.	False
The primary intrinsic KIEs ( BC6OTHER and BC6ENTC ) suggest that BC6ENTG has a dissociative S(N)1 transition state with its cationic center at the anomeric BC6OTHER and insignificant bond order to the leaving group.	False
The primary intrinsic KIEs ( BC6OTHER and BC6OTHER ) suggest that BC6ENTG has a dissociative S(N)1 transition state with its cationic center at the anomeric BC6ENTC and insignificant bond order to the leaving group.	False
Kinetic isotope effects (KIEs) and computer modeling using density functional theory were used to approximate the transition state of human BC6ENTC phosphorylase ( BC6ENTG ).	False
The rationale for using BC6ENTG inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of BC6ENTC in the inflamed mucosa, BC6OTHER being the most potent chemotactic and chemokinetic metabolite of BC6OTHER .	False
The rationale for using BC6ENTG inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of BC6OTHER in the inflamed mucosa, BC6ENTC being the most potent chemotactic and chemokinetic metabolite of BC6OTHER .	False
The rationale for using BC6ENTG inhibitors for the treatment of inflammatory bowel disease (IBD) is based on the increased generation of BC6OTHER in the inflamed mucosa, BC6OTHER being the most potent chemotactic and chemokinetic metabolite of BC6ENTC .	False
Furthermore, conventional drugs, such as CHEM, BC6ENTC , and BC6OTHER , inhibit BC6OTHER production and specific BC6ENTG inhibition accelerates healing in animal models of acute colitis.	False
Furthermore, conventional drugs, such as CHEM, BC6OTHER , and BC6ENTC , inhibit BC6OTHER production and specific BC6ENTG inhibition accelerates healing in animal models of acute colitis.	False
Furthermore, conventional drugs, such as CHEM, BC6OTHER , and BC6OTHER , inhibit BC6ENTC production and specific BC6ENTG inhibition accelerates healing in animal models of acute colitis.	False
The unique role of the enzyme BC6ENTG ( BC6OTHER ) in the production of BC6ENTC ( BC6OTHER ) makes it a likely target for biochemical manipulation.	CPR:9
The unique role of the enzyme BC6OTHER ( BC6ENTG ) in the production of BC6ENTC ( BC6OTHER ) makes it a likely target for biochemical manipulation.	CPR:9
The compounds identified as BC6ENTG inhibitors can be divided into antioxidants, substrate - analogous, and a large miscellaneous group of inhibitors, where BC6ENTC are potent and more selective inhibitors of BC6OTHER .	False
The compounds identified as BC6OTHER inhibitors can be divided into antioxidants, substrate - analogous, and a large miscellaneous group of inhibitors, where BC6ENTC are potent and more selective inhibitors of BC6ENTG .	CPR:4
The BC6ENTC , BC6OTHER , is the first selective BC6ENTG inhibitor evaluated for the treatment of patients with IBD.	CPR:4
The BC6OTHER , BC6ENTC , is the first selective BC6ENTG inhibitor evaluated for the treatment of patients with IBD.	CPR:4
The unique role of the enzyme BC6ENTG ( BC6OTHER ) in the production of BC6OTHER ( BC6ENTC ) makes it a likely target for biochemical manipulation.	CPR:9
The unique role of the enzyme BC6OTHER ( BC6ENTG ) in the production of BC6OTHER ( BC6ENTC ) makes it a likely target for biochemical manipulation.	CPR:9
The proof that any putative BC6ENTG inhibitor is blocking BC6ENTC production is an important stage in assessing any such drug.	False
OBJECTIVE: BC6ENTC is the first in a new class of synthetic BC6OTHER inhibitors that binds reversibly with high affinity to BC6ENTG .	False
OBJECTIVE: BC6ENTC is the first in a new class of synthetic BC6ENTG inhibitors that binds reversibly with high affinity to BC6OTHER .	CPR:4
Because BC6ENTG requires BC6ENTC for its function, this links the microarray and biochemical data and identifies BC6OTHER as a potential mediator of the anticancer properties of BC6OTHER .	False
Because BC6OTHER requires BC6ENTC for its function, this links the microarray and biochemical data and identifies BC6ENTG as a potential mediator of the anticancer properties of BC6OTHER .	False
Because BC6ENTG requires BC6OTHER for its function, this links the microarray and biochemical data and identifies BC6OTHER as a potential mediator of the anticancer properties of BC6ENTC .	False
Because BC6OTHER requires BC6OTHER for its function, this links the microarray and biochemical data and identifies BC6ENTG as a potential mediator of the anticancer properties of BC6ENTC .	False
BC6ENTC , a specific inhibitor of BC6ENTG , induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.	CPR:4
These included BC6ENTC - binding inhibitor / BC6ENTG the BC6OTHER and BC6OTHER .	False
These included BC6ENTC - binding inhibitor / BC6OTHER - binding protein, the BC6ENTG and BC6OTHER .	False
These included BC6ENTC - binding inhibitor / BC6OTHER - binding protein, the BC6OTHER and BC6ENTG .	False
These included BC6ENTG / BC6ENTC - binding protein, the BC6OTHER and BC6OTHER .	False
These included BC6OTHER - binding inhibitor / BC6ENTC - binding protein, the BC6ENTG and BC6OTHER .	False
These included BC6OTHER - binding inhibitor / BC6ENTC - binding protein, the BC6OTHER and BC6ENTG .	False
BC6ENTC decarboxylase ( BC6ENTG ) catalyses the first step in the synthesis of the CHEM BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER ( BC6ENTG ) catalyses the first step in the synthesis of the CHEM BC6OTHER , BC6ENTC and BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) catalyses the first step in the synthesis of the CHEM BC6OTHER , BC6ENTC and BC6OTHER .	CPR:9
BC6OTHER ( BC6ENTG ) catalyses the first step in the synthesis of the CHEM BC6OTHER , BC6OTHER and BC6ENTC .	CPR:9
BC6ENTG ( BC6OTHER ) catalyses the first step in the synthesis of the CHEM BC6OTHER , BC6OTHER and BC6ENTC .	CPR:9
BC6OTHER ( BC6ENTG ) catalyses the first step in the synthesis of the CHEM BC6ENTC , BC6OTHER and BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) catalyses the first step in the synthesis of the CHEM BC6ENTC , BC6OTHER and BC6OTHER .	CPR:9
 BC6ENTG is rapidly induced in growth - stimulated mouse fibroblasts and releases BC6ENTC decarboxylase from BC6OTHER suppression.	False
 BC6OTHER is rapidly induced in growth - stimulated mouse fibroblasts and releases BC6ENTC decarboxylase from BC6ENTG suppression.	False
BC6ENTG BC6OTHER N - acyltransferase ( BC6OTHER ) is responsible for the amidation of BC6ENTC with the BC6OTHER BC6OTHER and BC6OTHER .	CPR:9
BC6OTHER BC6OTHER : BC6OTHER N - acyltransferase ( BC6ENTG ) is responsible for the amidation of BC6ENTC with the BC6OTHER BC6OTHER and BC6OTHER .	CPR:9
Quantification and regulation of the subcellular distribution of BC6ENTG BC6ENTC N - acyltransferase activity in rat liver.	False
BC6ENTC BC6OTHER : BC6OTHER N - acyltransferase ( BC6ENTG ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6OTHER and BC6OTHER .	False
BC6OTHER BC6ENTC : BC6OTHER N - acyltransferase ( BC6ENTG ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6OTHER and BC6OTHER .	False
These data support the novel finding that BC6ENTC treatment does not directly regulate BC6ENTG activity but does alter the subcellular localization of BC6OTHER .	False
These data support the novel finding that BC6ENTC treatment does not directly regulate BC6OTHER activity but does alter the subcellular localization of BC6ENTG .	False
BC6ENTG BC6OTHER N - acyltransferase ( BC6OTHER ) is responsible for the amidation of BC6OTHER with the BC6ENTC BC6OTHER and BC6OTHER .	False
BC6OTHER BC6OTHER : BC6OTHER N - acyltransferase ( BC6ENTG ) is responsible for the amidation of BC6OTHER with the BC6ENTC BC6OTHER and BC6OTHER .	False
BC6ENTG BC6OTHER N - acyltransferase ( BC6OTHER ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6ENTC and BC6OTHER .	False
BC6OTHER BC6OTHER : BC6OTHER N - acyltransferase ( BC6ENTG ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6ENTC and BC6OTHER .	False
BC6ENTG BC6OTHER N - acyltransferase ( BC6OTHER ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6OTHER and BC6ENTC .	False
BC6OTHER BC6OTHER : BC6OTHER N - acyltransferase ( BC6ENTG ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6OTHER and BC6ENTC .	False
BC6ENTG BC6ENTC N - acyltransferase ( BC6OTHER ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6OTHER and BC6OTHER .	False
BC6OTHER BC6OTHER : BC6ENTC N - acyltransferase ( BC6ENTG ) is responsible for the amidation of BC6OTHER with the BC6OTHER BC6OTHER and BC6OTHER .	False
Treatment with BC6ENTC or BC6OTHER had no effect on BC6ENTG activity in any subcellular compartment.	False
Treatment with BC6OTHER or BC6ENTC had no effect on BC6ENTG activity in any subcellular compartment.	False
Regulation of multiple BC6ENTC cyclases ( BC6ENTG ) provides unique inputs to mediate the synthesis of BC6OTHER , a ubiquitous second messenger that controls many aspects of cellular function.	False
On stimulation by BC6ENTG , the activities of BC6OTHER can be further selectively modulated by other pathways to ensure precise control of intracellular BC6ENTC responses to specific stimuli.	False
On stimulation by BC6OTHER , the activities of BC6ENTG can be further selectively modulated by other pathways to ensure precise control of intracellular BC6ENTC responses to specific stimuli.	CPR:9
Although both enzymes could fully restore regulation of BC6ENTC by BC6ENTG , activation of the BC6OTHER pathway preferentially synergized with BC6OTHER .	False
Although both enzymes could fully restore regulation of BC6ENTC by BC6OTHER , activation of the BC6ENTG pathway preferentially synergized with BC6OTHER .	False
Although both enzymes could fully restore regulation of BC6ENTC by BC6OTHER , activation of the BC6OTHER pathway preferentially synergized with BC6ENTG .	False
Exchange of domains between the two isoforms indicates that the BC6ENTG and the BC6ENTC - terminus of the BC6OTHER are important for directing selective regulation of BC6OTHER by the BC6OTHER pathway.	False
Exchange of domains between the two isoforms indicates that the BC6OTHER and the BC6ENTC - terminus of the BC6ENTG are important for directing selective regulation of BC6OTHER by the BC6OTHER pathway.	False
Exchange of domains between the two isoforms indicates that the BC6OTHER and the BC6ENTC - terminus of the BC6OTHER are important for directing selective regulation of BC6ENTG by the BC6OTHER pathway.	False
Exchange of domains between the two isoforms indicates that the BC6OTHER and the BC6ENTC - terminus of the BC6OTHER are important for directing selective regulation of BC6OTHER by the BC6ENTG pathway.	False
Regulation of multiple BC6ENTG ( BC6OTHER ) provides unique inputs to mediate the synthesis of BC6ENTC , a ubiquitous second messenger that controls many aspects of cellular function.	CPR:9
Regulation of multiple BC6OTHER cyclases ( BC6ENTG ) provides unique inputs to mediate the synthesis of BC6ENTC , a ubiquitous second messenger that controls many aspects of cellular function.	CPR:9
Regions on BC6ENTC cyclase VII required for selective regulation by the BC6ENTG pathway.	False
In a Phase III trial comparing BC6OTHER and BC6ENTC with BC6OTHER alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6OTHER , a BC6OTHER , and trastuzumab, the combination of BC6OTHER and BC6OTHER was associated with a numeric improvement in response rate compared with BC6OTHER alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
In a Phase III trial comparing BC6OTHER and BC6OTHER with BC6ENTC alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6OTHER , a BC6OTHER , and trastuzumab, the combination of BC6OTHER and BC6OTHER was associated with a numeric improvement in response rate compared with BC6OTHER alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
In a Phase III trial comparing BC6OTHER and BC6OTHER with BC6OTHER alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6ENTC , a BC6OTHER , and trastuzumab, the combination of BC6OTHER and BC6OTHER was associated with a numeric improvement in response rate compared with BC6OTHER alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
In a Phase III trial comparing BC6OTHER and BC6OTHER with BC6OTHER alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6OTHER , a BC6ENTC , and trastuzumab, the combination of BC6OTHER and BC6OTHER was associated with a numeric improvement in response rate compared with BC6OTHER alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
In a Phase III trial comparing BC6OTHER and BC6OTHER with BC6OTHER alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6OTHER , a BC6OTHER , and trastuzumab, the combination of BC6ENTC and BC6OTHER was associated with a numeric improvement in response rate compared with BC6OTHER alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
In a Phase III trial comparing BC6OTHER and BC6OTHER with BC6OTHER alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6OTHER , a BC6OTHER , and trastuzumab, the combination of BC6OTHER and BC6ENTC was associated with a numeric improvement in response rate compared with BC6OTHER alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
In a Phase III trial comparing BC6OTHER and BC6OTHER with BC6OTHER alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6OTHER , a BC6OTHER , and trastuzumab, the combination of BC6OTHER and BC6OTHER was associated with a numeric improvement in response rate compared with BC6ENTC alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
Search terms included BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , receptor BC6OTHER kinase, dual - receptor blockade, adverse events, and clinical trials.	False
Search terms included BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , receptor BC6OTHER kinase, dual - receptor blockade, adverse events, and clinical trials.	False
Search terms included BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , dual - receptor blockade, adverse events, and clinical trials.	False
It is indicated for use in combination with BC6ENTC for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress BC6ENTG ( BC6OTHER ) and who have received previous treatment that included an BC6OTHER , a BC6OTHER , and trastuzumab.	False
It is indicated for use in combination with BC6ENTC for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress BC6OTHER ( BC6ENTG ) and who have received previous treatment that included an BC6OTHER , a BC6OTHER , and trastuzumab.	False
CONCLUSIONS: BC6ENTC is a dual inhibitor of the BC6ENTG and BC6OTHER BC6OTHER .	CPR:4
CONCLUSIONS: BC6ENTC is a dual inhibitor of the BC6OTHER and BC6ENTG BC6OTHER .	CPR:4
CONCLUSIONS: BC6ENTC is a dual inhibitor of the BC6OTHER and BC6OTHER BC6ENTG .	CPR:4
CONCLUSIONS: BC6OTHER is a dual inhibitor of the BC6ENTG and BC6OTHER BC6ENTC kinases.	False
CONCLUSIONS: BC6OTHER is a dual inhibitor of the BC6OTHER and BC6ENTG BC6ENTC kinases.	False
It is approved by the FDA for use in combination with BC6ENTC for the treatment of BC6ENTG - positive MBC that has progressed with standard treatment.	False
It is indicated for use in combination with BC6OTHER for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress BC6ENTG ( BC6OTHER ) and who have received previous treatment that included an BC6ENTC , a BC6OTHER , and trastuzumab.	False
It is indicated for use in combination with BC6OTHER for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress BC6OTHER ( BC6ENTG ) and who have received previous treatment that included an BC6ENTC , a BC6OTHER , and trastuzumab.	False
It is indicated for use in combination with BC6OTHER for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress BC6ENTG ( BC6OTHER ) and who have received previous treatment that included an BC6OTHER , a BC6ENTC , and trastuzumab.	False
It is indicated for use in combination with BC6OTHER for the treatment of patients with advanced breast cancer or metastatic breast cancer (MBC) whose tumors overexpress BC6OTHER ( BC6ENTG ) and who have received previous treatment that included an BC6OTHER , a BC6ENTC , and trastuzumab.	False
Search terms included BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , receptor BC6OTHER kinase, dual - receptor blockade, adverse events, and clinical trials.	False
Search terms included BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , receptor BC6OTHER kinase, dual - receptor blockade, adverse events, and clinical trials.	False
Search terms included BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , dual - receptor blockade, adverse events, and clinical trials.	False
 BC6ENTC : a dual inhibitor of BC6ENTG BC6OTHER .	CPR:4
 BC6ENTC : a dual inhibitor of BC6OTHER BC6ENTG .	CPR:4
 BC6OTHER : a dual inhibitor of BC6ENTG BC6ENTC kinases.	False
Search terms included BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , receptor BC6ENTC kinase, dual - receptor blockade, adverse events, and clinical trials.	False
Search terms included BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , receptor BC6ENTC kinase, dual - receptor blockade, adverse events, and clinical trials.	False
BACKGROUND: BC6ENTC , the first dual inhibitor of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) BC6OTHER kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
BACKGROUND: BC6ENTC , the first dual inhibitor of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) BC6ENTG , was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
BACKGROUND: BC6ENTC , the first dual inhibitor of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) BC6OTHER kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
BACKGROUND: BC6ENTC , the first dual inhibitor of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) BC6OTHER kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
BACKGROUND: BC6ENTC , the first dual inhibitor of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) BC6OTHER kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	CPR:4
BC6ENTC is metabolized primarily by the BC6ENTG isozyme, with 1 metabolite remaining active against BC6OTHER but not BC6OTHER .	CPR:9
BC6ENTC is metabolized primarily by the BC6OTHER isozyme, with 1 metabolite remaining active against BC6ENTG but not BC6OTHER .	False
BC6ENTC is metabolized primarily by the BC6OTHER isozyme, with 1 metabolite remaining active against BC6OTHER but not BC6ENTG .	False
BACKGROUND: BC6OTHER , the first dual inhibitor of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) BC6ENTC kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	False
BACKGROUND: BC6OTHER , the first dual inhibitor of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) BC6ENTC kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	False
BACKGROUND: BC6OTHER , the first dual inhibitor of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) BC6ENTC kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	False
BACKGROUND: BC6OTHER , the first dual inhibitor of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) BC6ENTC kinases, was approved by the US Food and Drug Administration (FDA) in 2007.	False
In a Phase III trial comparing BC6ENTC and BC6OTHER with BC6OTHER alone in women with BC6ENTG - positive, locally advanced breast cancer or MBC that had progressed after treatment with an BC6OTHER , a BC6OTHER , and trastuzumab, the combination of BC6OTHER and BC6OTHER was associated with a numeric improvement in response rate compared with BC6OTHER alone (22% vs 14%, respectively; P = NS) and a significant increase in time to progression (6.2 vs 4.3 months; hazard ratio = 0.57; 95% CI, 0.43 - 0.77; P < 0.001).	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6ENTC - dependent enzymes, BC6ENTG , BC6OTHER reductase, and BC6OTHER formyltransferase.	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6ENTC - dependent enzymes, BC6OTHER synthase, BC6ENTG , and BC6OTHER formyltransferase.	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6ENTC - dependent enzymes, BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	False
 BC6ENTC and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTG , BC6OTHER reductase, and BC6OTHER formyltransferase.	False
 BC6ENTC and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6ENTG , and BC6OTHER formyltransferase.	False
 BC6ENTC and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	False
 BC6OTHER and BC6ENTC combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTG , BC6OTHER reductase, and BC6OTHER formyltransferase.	False
 BC6OTHER and BC6ENTC combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6ENTG , and BC6OTHER formyltransferase.	False
 BC6OTHER and BC6ENTC combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6ENTC ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTG , BC6OTHER reductase, and BC6OTHER formyltransferase.	CPR:4
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6ENTC ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6ENTG , and BC6OTHER formyltransferase.	CPR:4
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6ENTC ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	CPR:4
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTC synthase, BC6ENTG , and BC6OTHER formyltransferase.	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTC synthase, BC6OTHER reductase, and BC6ENTG .	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTG , BC6ENTC reductase, and BC6OTHER formyltransferase.	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6ENTC reductase, and BC6ENTG .	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTG , BC6OTHER reductase, and BC6ENTC formyltransferase.	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6OTHER ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6ENTG , and BC6ENTC formyltransferase.	False
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6ENTC ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6ENTG , BC6OTHER reductase, and BC6OTHER formyltransferase.	CPR:4
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6ENTC ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6ENTG , and BC6OTHER formyltransferase.	CPR:4
 BC6OTHER and BC6OTHER combinations in vitro and in vivo. BC6OTHER ( BC6ENTC ) is a novel antimetabolite that inhibits at least three BC6OTHER - dependent enzymes, BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	CPR:4
We found that BC6ENTC markedly induced endoplasmic reticulum (ER) stress - related genes, such as BC6ENTG , BC6OTHER ( BC6OTHER ) and / or the BC6OTHER ( BC6OTHER ).	CPR:3
We found that BC6ENTC markedly induced endoplasmic reticulum (ER) stress - related genes, such as BC6OTHER , BC6ENTG ( BC6OTHER ) and / or the BC6OTHER ( BC6OTHER ).	CPR:3
We found that BC6ENTC markedly induced endoplasmic reticulum (ER) stress - related genes, such as BC6OTHER , BC6OTHER ( BC6ENTG ) and / or the BC6OTHER ( BC6OTHER ).	CPR:3
We found that BC6ENTC markedly induced endoplasmic reticulum (ER) stress - related genes, such as BC6OTHER , BC6OTHER ( BC6OTHER ) and / or the BC6ENTG ( BC6OTHER ).	CPR:3
We found that BC6ENTC markedly induced endoplasmic reticulum (ER) stress - related genes, such as BC6OTHER , BC6OTHER ( BC6OTHER ) and / or the BC6OTHER ( BC6ENTG ).	CPR:3
However, down - regulation of BC6ENTG and / or BC6OTHER expression by siRNA had no effect on BC6ENTC - induced apoptosis in Caki and HCT116 cells.	False
However, down - regulation of BC6OTHER and / or BC6ENTG expression by siRNA had no effect on BC6ENTC - induced apoptosis in Caki and HCT116 cells.	False
This leads to decreased expression of BC6ENTG , which in turn reduces BC6ENTC transport.	CPR:9
BC6ENTC and BC6ENTG treatment reversed these altered parameters to near control.	False
 BC6ENTG mediated excitotoxicity in cerebral cortex of BC6OTHER induced diabetic rat: ameliorating effects of BC6ENTC .	False
 BC6ENTG mediated excitotoxicity in cerebral cortex of BC6ENTC induced diabetic rat: ameliorating effects of BC6OTHER .	False
Gene expression studies in diabetic rats showed a down regulation of BC6ENTG mRNA leading to accumulation of BC6ENTC .	False
BACKGROUND: The novel antiepileptic drug BC6OTHER is the first selective M - current BC6ENTC channel opener for BC6ENTG and BC6OTHER channels.	False
BACKGROUND: The novel antiepileptic drug BC6OTHER is the first selective M - current BC6ENTC channel opener for BC6OTHER and BC6ENTG channels.	False
BACKGROUND: The novel antiepileptic drug BC6ENTC is the first selective M - current BC6OTHER channel opener for BC6ENTG and BC6OTHER channels.	CPR:3
BACKGROUND: The novel antiepileptic drug BC6ENTC is the first selective M - current BC6OTHER channel opener for BC6OTHER and BC6ENTG channels.	CPR:3
BACKGROUND: The novel antiepileptic drug BC6ENTC is the first selective BC6ENTG opener for BC6OTHER and BC6OTHER channels.	CPR:3
The concentration of BC6ENTC required to inhibit the assembly or to induce the disassembly of BC6ENTG : BC6OTHER microtubules is markedly dependent upon the microtubule protein concentration.	CPR:4
The concentration of BC6ENTC required to inhibit the assembly or to induce the disassembly of BC6OTHER : BC6ENTG microtubules is markedly dependent upon the microtubule protein concentration.	CPR:4
Analysis of this relationship shows that BC6ENTC and BC6OTHER compete for common BC6ENTG sites, that BC6OTHER can bind 5 - 6 moles.mole - 1 BC6OTHER , and that the Kd of these sites is congruent to 20 microM BC6OTHER .	False
Analysis of this relationship shows that BC6ENTC and BC6OTHER compete for common BC6OTHER sites, that BC6ENTG can bind 5 - 6 moles.mole - 1 BC6OTHER , and that the Kd of these sites is congruent to 20 microM BC6OTHER .	False
Analysis of this relationship shows that BC6ENTC and BC6ENTG compete for common BC6OTHER sites, that BC6OTHER can bind 5 - 6 moles.mole - 1 BC6OTHER , and that the Kd of these sites is congruent to 20 microM BC6OTHER .	False
Analysis of this relationship shows that BC6OTHER and BC6OTHER compete for common BC6ENTG sites, that BC6OTHER can bind 5 - 6 moles.mole - 1 BC6ENTC , and that the Kd of these sites is congruent to 20 microM BC6OTHER .	False
Analysis of this relationship shows that BC6OTHER and BC6OTHER compete for common BC6OTHER sites, that BC6ENTG can bind 5 - 6 moles.mole - 1 BC6ENTC , and that the Kd of these sites is congruent to 20 microM BC6OTHER .	False
Analysis of this relationship shows that BC6OTHER and BC6ENTG compete for common BC6OTHER sites, that BC6OTHER can bind 5 - 6 moles.mole - 1 BC6ENTC , and that the Kd of these sites is congruent to 20 microM BC6OTHER .	False
Analysis of this relationship shows that BC6OTHER and BC6OTHER compete for common BC6ENTG sites, that BC6OTHER can bind 5 - 6 moles.mole - 1 BC6OTHER , and that the Kd of these sites is congruent to 20 microM BC6ENTC .	False
Analysis of this relationship shows that BC6OTHER and BC6OTHER compete for common BC6OTHER sites, that BC6ENTG can bind 5 - 6 moles.mole - 1 BC6OTHER , and that the Kd of these sites is congruent to 20 microM BC6ENTC .	False
Analysis of this relationship shows that BC6OTHER and BC6ENTG compete for common BC6OTHER sites, that BC6OTHER can bind 5 - 6 moles.mole - 1 BC6OTHER , and that the Kd of these sites is congruent to 20 microM BC6ENTC .	False
It is proposed that two molecules of BC6ENTC interact with each of the three tubulin - binding sites of BC6ENTG and inhibit the BC6OTHER : BC6OTHER interaction by neutralising two highly conserved basic residues.	False
It is proposed that two molecules of BC6ENTC interact with each of the three tubulin - binding sites of BC6OTHER and inhibit the BC6ENTG : BC6OTHER interaction by neutralising two highly conserved basic residues.	CPR:4
It is proposed that two molecules of BC6ENTC interact with each of the three tubulin - binding sites of BC6OTHER and inhibit the BC6OTHER : BC6ENTG interaction by neutralising two highly conserved basic residues.	CPR:4
Stoichiometry of BC6ENTC binding to BC6OTHER measured by the disassembly of BC6OTHER : BC6ENTG microtubules.	False
Stoichiometry of BC6ENTC binding to BC6ENTG measured by the disassembly of BC6OTHER : BC6OTHER microtubules.	False
Stoichiometry of BC6ENTC binding to BC6OTHER measured by the disassembly of BC6ENTG : BC6OTHER microtubules.	False
Structure - activity relationship analysis of highly potent subtype - selective ligands ( BC6OTHER EC(50) 10 - 90 pM) revealed that a BC6ENTC substituent incorporated at C6 position of the BC6OTHER ring dramatically enhanced the BC6ENTG potency and at the same time decreased BC6OTHER potency.	False
Structure - activity relationship analysis of highly potent subtype - selective ligands ( BC6OTHER EC(50) 10 - 90 pM) revealed that a BC6ENTC substituent incorporated at C6 position of the BC6OTHER ring dramatically enhanced the BC6OTHER potency and at the same time decreased BC6ENTG potency.	False
Structure - activity relationship analysis of highly potent subtype - selective ligands ( BC6ENTG EC(50) 10 - 90 pM) revealed that a BC6ENTC substituent incorporated at C6 position of the BC6OTHER ring dramatically enhanced the BC6OTHER potency and at the same time decreased BC6OTHER potency.	False
Structure - activity relationship analysis of highly potent subtype - selective ligands ( BC6OTHER EC(50) 10 - 90 pM) revealed that a BC6OTHER substituent incorporated at C6 position of the BC6ENTC ring dramatically enhanced the BC6ENTG potency and at the same time decreased BC6OTHER potency.	False
Structure - activity relationship analysis of highly potent subtype - selective ligands ( BC6OTHER EC(50) 10 - 90 pM) revealed that a BC6OTHER substituent incorporated at C6 position of the BC6ENTC ring dramatically enhanced the BC6OTHER potency and at the same time decreased BC6ENTG potency.	False
Structure - activity relationship analysis of highly potent subtype - selective ligands ( BC6ENTG EC(50) 10 - 90 pM) revealed that a BC6OTHER substituent incorporated at C6 position of the BC6ENTC ring dramatically enhanced the BC6OTHER potency and at the same time decreased BC6OTHER potency.	False
Characterization of substituted BC6ENTC as highly selective agonists at the BC6ENTG .	CPR:5
The most potent subtype - selective ligand, 2q had a substantially higher potency for BC6ENTG than BC6ENTC for elevation of [ BC6OTHER ]i and inhibition of CHEM - elevated CHEM.	False
The most potent subtype - selective ligand, 2q had a substantially higher potency for BC6ENTG than BC6OTHER for elevation of [ BC6ENTC ]i and inhibition of CHEM - elevated CHEM.	False
The two subtypes of BC6ENTG are primarily responsible for mediating the actions of BC6ENTC .	False
The pharmacological potencies of a series of substituted BC6ENTC towards BC6ENTG and BC6OTHER were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6OTHER phosphorylation and BC6OTHER assays.	False
The pharmacological potencies of a series of substituted BC6ENTC towards human BC6OTHER MT(1) and BC6ENTG were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6OTHER phosphorylation and BC6OTHER assays.	False
The pharmacological potencies of a series of substituted BC6ENTC towards human BC6OTHER MT(1) and BC6OTHER were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6ENTG phosphorylation and BC6OTHER assays.	False
The pharmacological potencies of a series of substituted BC6OTHER towards human BC6ENTC MT(1) and BC6ENTG were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6OTHER phosphorylation and BC6OTHER assays.	False
The pharmacological potencies of a series of substituted BC6OTHER towards human BC6ENTC MT(1) and BC6OTHER were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6ENTG phosphorylation and BC6OTHER assays.	False
The pharmacological potencies of a series of substituted BC6OTHER towards BC6ENTG and BC6OTHER were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6OTHER phosphorylation and BC6ENTC assays.	False
The pharmacological potencies of a series of substituted BC6OTHER towards human BC6OTHER MT(1) and BC6ENTG were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6OTHER phosphorylation and BC6ENTC assays.	False
The pharmacological potencies of a series of substituted BC6OTHER towards human BC6OTHER MT(1) and BC6OTHER were evaluated by the FLIPR high - throughput screening assay, whilst their subtype - selectivity was subsequently verified with BC6ENTG phosphorylation and BC6ENTC assays.	False
By substituting BC6OTHER for BC6ENTC in CHEM - CHEM at positions 9 and 15, the inhibitory effect on BC6OTHER binding to BBM was reduced, which may be related to a decrease in the BC6ENTG content in the peptide.	False
By substituting BC6OTHER for BC6OTHER in CHEM - CHEM at positions 9 and 15, the inhibitory effect on BC6ENTC binding to BBM was reduced, which may be related to a decrease in the BC6ENTG content in the peptide.	False
BC6ENTC binding to BBM treated with BC6ENTG , in which BC6OTHER completely disappeared, was significantly but not completely decreased compared with the native BBM.	False
BC6ENTC binding to BBM treated with BC6OTHER , in which BC6ENTG completely disappeared, was significantly but not completely decreased compared with the native BBM.	False
Inhibition of BC6ENTC binding to rat renal brush - border membrane by BC6ENTG ligands and basic peptides.	False
In addition, treatment of BBM with BC6ENTG led to a decrease in the inhibitory effect of CHEM on BC6ENTC binding.	False
These observations support that BC6ENTG ligands and basic peptides including CHEM - CHEM decrease renal accumulation of BC6ENTC by inhibiting its binding to BBM of proximal tubule cells, partly interacting with BC6OTHER .	False
These observations support that BC6OTHER ligands and basic peptides including CHEM - CHEM decrease renal accumulation of BC6ENTC by inhibiting its binding to BBM of proximal tubule cells, partly interacting with BC6ENTG .	False
In addition, the BC6ENTG conformation may play an important role in the inhibitory effect of CHEM on the binding of BC6ENTC to BBM.	False
Our previous studies showed that coadministration of BC6OTHER and a 20 - residue basic peptide, CHEM ( BC6ENTG , pI=10.87) inhibits renal accumulation of BC6ENTC .	False
Our previous studies showed that coadministration of BC6ENTG and a 20 - residue basic peptide, CHEM ( BC6OTHER , pI=10.87) inhibits renal accumulation of BC6ENTC .	False
In this study, we examined effects of ligands of BC6ENTG , an endocytic receptor involved in renal uptake of BC6ENTC , and basic peptides including CHEM - CHEM and its mutant peptides on BC6OTHER binding to isolated rat renal brush - border membrane (BBM).	False
In this study, we examined effects of ligands of BC6ENTG , an endocytic receptor involved in renal uptake of BC6OTHER , and basic peptides including CHEM - CHEM and its mutant peptides on BC6ENTC binding to isolated rat renal brush - border membrane (BBM).	False
BC6ENTC binding to BBM was inhibited by BC6ENTG ligands, basic peptide fragments of BC6OTHER , and CHEM in a concentration - dependent manner.	False
BC6ENTC binding to BBM was inhibited by BC6OTHER ligands, basic peptide fragments of BC6ENTG , and CHEM in a concentration - dependent manner.	False
By substituting BC6ENTC for BC6OTHER in CHEM - CHEM at positions 9 and 15, the inhibitory effect on BC6OTHER binding to BBM was reduced, which may be related to a decrease in the BC6ENTG content in the peptide.	False
In this randomized double - blind placebo - controlled cross - over trial, the effects of a BC6ENTC supplement on serum pro - oxidant - antioxidant balance (PAB) and antibody titres to BC6OTHER (anti - BC6OTHER ) and BC6OTHER (anti - BC6ENTG ) were investigated.	False
In this randomized double - blind placebo - controlled cross - over trial, the effects of a BC6ENTC supplement on serum pro - oxidant - antioxidant balance (PAB) and antibody titres to BC6ENTG (anti - BC6OTHER ) and BC6OTHER (anti - BC6OTHER ) were investigated.	False
In this randomized double - blind placebo - controlled cross - over trial, the effects of a BC6ENTC supplement on serum pro - oxidant - antioxidant balance (PAB) and antibody titres to BC6OTHER (anti - BC6ENTG ) and BC6OTHER (anti - BC6OTHER ) were investigated.	False
In this randomized double - blind placebo - controlled cross - over trial, the effects of a BC6ENTC supplement on serum pro - oxidant - antioxidant balance (PAB) and antibody titres to BC6OTHER (anti - BC6OTHER ) and BC6ENTG (anti - BC6OTHER ) were investigated.	False
 BC6ENTC Modulate CHEM - Oxidant - Antioxidant Balance but not the Immune Response to BC6OTHER and BC6ENTG in Obese Individuals.	False
 BC6ENTC Modulate CHEM - Oxidant - Antioxidant Balance but not the Immune Response to BC6ENTG and BC6OTHER in Obese Individuals.	False
Modulation of BC6ENTG expression was observed at or above a BC6ENTC dose of 150 mg / day.	False
Our results demonstrate that the combination of CHEM and BC6ENTC is well tolerated and that even low doses (150 mg / day) of BC6OTHER are capable of in vivo upregulation of BC6ENTG expression on circulating leukemia cells.	False
Our results demonstrate that the combination of CHEM and BC6OTHER is well tolerated and that even low doses (150 mg / day) of BC6ENTC are capable of in vivo upregulation of BC6ENTG expression on circulating leukemia cells.	CPR:3
In vitro studies demonstrated that the BC6ENTG ( BC6OTHER ) CHEM, BC6ENTC , at biologically relevant concentrations of 10( - 6) M to 10( - 8) M, upregulated both the BC6OTHER and BC6OTHER subunits of the BC6OTHER and enhanced 5 - to 10 - fold the susceptibility of T - cell leukemia cells to CHEM.	False
In vitro studies demonstrated that the BC6OTHER ( BC6ENTG ) CHEM, BC6ENTC , at biologically relevant concentrations of 10( - 6) M to 10( - 8) M, upregulated both the BC6OTHER and BC6OTHER subunits of the BC6OTHER and enhanced 5 - to 10 - fold the susceptibility of T - cell leukemia cells to CHEM.	False
In vitro studies demonstrated that the BC6OTHER ( BC6OTHER ) CHEM, BC6ENTC , at biologically relevant concentrations of 10( - 6) M to 10( - 8) M, upregulated both the BC6ENTG and BC6OTHER subunits of the BC6OTHER and enhanced 5 - to 10 - fold the susceptibility of T - cell leukemia cells to CHEM.	CPR:3
In vitro studies demonstrated that the BC6OTHER ( BC6OTHER ) CHEM, BC6ENTC , at biologically relevant concentrations of 10( - 6) M to 10( - 8) M, upregulated both the BC6OTHER and BC6ENTG subunits of the BC6OTHER and enhanced 5 - to 10 - fold the susceptibility of T - cell leukemia cells to CHEM.	CPR:3
In vitro studies demonstrated that the BC6OTHER ( BC6OTHER ) CHEM, BC6ENTC , at biologically relevant concentrations of 10( - 6) M to 10( - 8) M, upregulated both the BC6OTHER and BC6OTHER subunits of the BC6ENTG and enhanced 5 - to 10 - fold the susceptibility of T - cell leukemia cells to CHEM.	CPR:3
We found that intracellular BC6OTHER depletion by BC6ENTC as well as other BC6ENTG ( BC6OTHER ) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6OTHER expression.	False
We found that intracellular BC6OTHER depletion by BC6ENTC as well as other BC6OTHER ( BC6ENTG ) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6OTHER expression.	False
We found that intracellular BC6OTHER depletion by BC6ENTC as well as other BC6OTHER ( BC6OTHER ) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6ENTG expression.	False
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6ENTG ( BC6ENTC dehydrogenase) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6OTHER expression.	False
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6OTHER ( BC6ENTC dehydrogenase) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6ENTG expression.	False
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6ENTG ( BC6OTHER ) inhibitors, such as BC6ENTC and BC6OTHER , up - regulated BC6OTHER expression.	False
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6OTHER ( BC6ENTG ) inhibitors, such as BC6ENTC and BC6OTHER , up - regulated BC6OTHER expression.	False
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6OTHER ( BC6OTHER ) inhibitors, such as BC6ENTC and BC6OTHER , up - regulated BC6ENTG expression.	CPR:3
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6ENTG ( BC6OTHER ) inhibitors, such as BC6OTHER and BC6ENTC , up - regulated BC6OTHER expression.	False
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6OTHER ( BC6ENTG ) inhibitors, such as BC6OTHER and BC6ENTC , up - regulated BC6OTHER expression.	False
We found that intracellular BC6OTHER depletion by BC6OTHER as well as other BC6OTHER ( BC6OTHER ) inhibitors, such as BC6OTHER and BC6ENTC , up - regulated BC6ENTG expression.	CPR:3
BC6ENTC unregulated BC6ENTG (eleven - nineteen BC6OTHER - rich leukaemia) 3 mRNA expression before BC6OTHER up - regulation.	CPR:3
BC6ENTC unregulated BC6OTHER ( BC6ENTG mRNA expression before BC6OTHER up - regulation.	CPR:3
BC6ENTC unregulated BC6OTHER (eleven - nineteen BC6OTHER - rich leukaemia) 3 mRNA expression before BC6ENTG up - regulation.	CPR:3
BC6OTHER unregulated BC6ENTG (eleven - nineteen BC6ENTC - rich leukaemia) 3 mRNA expression before BC6OTHER up - regulation.	False
BC6OTHER unregulated BC6OTHER (eleven - nineteen BC6ENTC - rich leukaemia) 3 mRNA expression before BC6ENTG up - regulation.	False
We observed that BC6ENTC enhanced BC6ENTG recruitment to BC6OTHER , whereas knockdown of BC6OTHER diminished BC6OTHER - induced BC6OTHER mRNA up - regulation.	CPR:3
We observed that BC6ENTC enhanced BC6OTHER recruitment to BC6ENTG , whereas knockdown of BC6OTHER diminished BC6OTHER - induced BC6OTHER mRNA up - regulation.	CPR:3
We observed that BC6ENTC enhanced BC6OTHER recruitment to BC6OTHER , whereas knockdown of BC6ENTG diminished BC6OTHER - induced BC6OTHER mRNA up - regulation.	False
We observed that BC6ENTC enhanced BC6OTHER recruitment to BC6OTHER , whereas knockdown of BC6OTHER diminished BC6OTHER - induced BC6ENTG mRNA up - regulation.	False
 BC6ENTC - induced intracellular BC6OTHER depletion activates transcription elongation in BC6ENTG gene expression.	CPR:3
 BC6OTHER - induced intracellular BC6ENTC depletion activates transcription elongation in BC6ENTG gene expression.	False
We observed that BC6OTHER enhanced BC6ENTG recruitment to BC6OTHER , whereas knockdown of BC6OTHER diminished BC6ENTC - induced BC6OTHER mRNA up - regulation.	False
We observed that BC6OTHER enhanced BC6OTHER recruitment to BC6ENTG , whereas knockdown of BC6OTHER diminished BC6ENTC - induced BC6OTHER mRNA up - regulation.	False
We observed that BC6OTHER enhanced BC6OTHER recruitment to BC6OTHER , whereas knockdown of BC6ENTG diminished BC6ENTC - induced BC6OTHER mRNA up - regulation.	False
We observed that BC6OTHER enhanced BC6OTHER recruitment to BC6OTHER , whereas knockdown of BC6OTHER diminished BC6ENTC - induced BC6ENTG mRNA up - regulation.	CPR:3
BC6ENTC also enhanced recruitment of BC6ENTG ( BC6OTHER ) and BC6OTHER to BC6OTHER .	CPR:3
BC6ENTC also enhanced recruitment of BC6OTHER ( BC6ENTG ) and BC6OTHER to BC6OTHER .	CPR:3
BC6ENTC also enhanced recruitment of BC6OTHER ( BC6OTHER ) and BC6ENTG to BC6OTHER .	CPR:3
BC6ENTC also enhanced recruitment of BC6OTHER ( BC6OTHER ) and BC6OTHER to BC6ENTG .	CPR:3
These data suggest that BC6ENTC - induced intracellular BC6OTHER depletion recruits a super elongation complex containing BC6ENTG , BC6OTHER and BC6OTHER , to BC6OTHER , and modulates BC6OTHER mRNA transcription elongation.	CPR:3
These data suggest that BC6ENTC - induced intracellular BC6OTHER depletion recruits a super elongation complex containing BC6OTHER , BC6ENTG and BC6OTHER , to BC6OTHER , and modulates BC6OTHER mRNA transcription elongation.	CPR:3
These data suggest that BC6ENTC - induced intracellular BC6OTHER depletion recruits a super elongation complex containing BC6OTHER , BC6OTHER and BC6ENTG , to BC6OTHER , and modulates BC6OTHER mRNA transcription elongation.	CPR:3
These data suggest that BC6ENTC - induced intracellular BC6OTHER depletion recruits a super elongation complex containing BC6OTHER , BC6OTHER and BC6OTHER , to BC6ENTG , and modulates BC6OTHER mRNA transcription elongation.	CPR:3
These data suggest that BC6ENTC - induced intracellular BC6OTHER depletion recruits a super elongation complex containing BC6OTHER , BC6OTHER and BC6OTHER , to BC6OTHER , and modulates BC6ENTG mRNA transcription elongation.	False
These data suggest that BC6OTHER - induced intracellular BC6ENTC depletion recruits a super elongation complex containing BC6ENTG , BC6OTHER and BC6OTHER , to BC6OTHER , and modulates BC6OTHER mRNA transcription elongation.	False
These data suggest that BC6OTHER - induced intracellular BC6ENTC depletion recruits a super elongation complex containing BC6OTHER , BC6ENTG and BC6OTHER , to BC6OTHER , and modulates BC6OTHER mRNA transcription elongation.	False
These data suggest that BC6OTHER - induced intracellular BC6ENTC depletion recruits a super elongation complex containing BC6OTHER , BC6OTHER and BC6ENTG , to BC6OTHER , and modulates BC6OTHER mRNA transcription elongation.	False
These data suggest that BC6OTHER - induced intracellular BC6ENTC depletion recruits a super elongation complex containing BC6OTHER , BC6OTHER and BC6OTHER , to BC6ENTG , and modulates BC6OTHER mRNA transcription elongation.	False
These data suggest that BC6OTHER - induced intracellular BC6ENTC depletion recruits a super elongation complex containing BC6OTHER , BC6OTHER and BC6OTHER , to BC6OTHER , and modulates BC6ENTG mRNA transcription elongation.	False
 Collectively, we have elucidated a basal mechanism for BC6ENTC - induced BC6ENTG mRNA up - regulation by acceleration of transcription elongation, which may be crucial in understanding its pleiotropic functions in vivo.	CPR:3
It was reported previously that BC6ENTG gene ( BC6OTHER ) expression was up - regulated by BC6ENTC treatment in hepatitis C virus - infected haemophilia patients; however, its precise mechanism is still unknown.	CPR:3
It was reported previously that BC6OTHER gene ( BC6ENTG ) expression was up - regulated by BC6ENTC treatment in hepatitis C virus - infected haemophilia patients; however, its precise mechanism is still unknown.	CPR:3
BC6ENTG ( BC6OTHER ) is a BC6ENTC - dependent glycoprotein synthesized in hepatocytes.	False
BC6OTHER ( BC6ENTG ) is a BC6ENTC - dependent glycoprotein synthesized in hepatocytes.	False
In the present study, we investigated the molecular mechanism of BC6ENTC - induced up - regulation of BC6ENTG expression in HepG2 (human hepatoma cell line).	CPR:3
We found that intracellular BC6ENTC depletion by BC6OTHER as well as other BC6ENTG ( BC6OTHER ) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6OTHER expression.	False
We found that intracellular BC6ENTC depletion by BC6OTHER as well as other BC6OTHER ( BC6ENTG ) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6OTHER expression.	False
We found that intracellular BC6ENTC depletion by BC6OTHER as well as other BC6OTHER ( BC6OTHER ) inhibitors, such as BC6OTHER and BC6OTHER , up - regulated BC6ENTG expression.	False
Both types of granules contain BC6ENTG that catalyzes oxidative cross - linking of BC6ENTC .	CPR:9
Multipart Copolyelectrolyte Adhesive of the Sandcastle Worm, Phragmatopoma californica (Fewkes): BC6ENTG Catalyzed Curing through Peptidyl - BC6ENTC .	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6ENTC phosphoribosyltransferase ( BC6ENTG ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6ENTC phosphoribosyltransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6ENTC phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6ENTG ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6ENTG enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6ENTC phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTG ( BC6OTHER ), BC6ENTC phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6ENTG ), BC6ENTC phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6ENTC phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6ENTG ), and BC6ENTC phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6ENTC phosphoribosyltransferase ( BC6ENTG ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6ENTG enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6ENTC phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTG ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6ENTC phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6ENTG ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6ENTC phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6ENTC nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6ENTG ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6ENTC nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), which enable this genus to acquire BC6ENTC nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6ENTG ), which enable this genus to acquire BC6ENTC nutrients from their hosts.	False
Leishmania species express three BC6ENTG enzymes, BC6OTHER phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6ENTC nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTG ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6ENTC nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6OTHER phosphoribosyltransferase ( BC6ENTG ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6ENTC nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTC phosphoribosyltransferase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTC phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6ENTG ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTC phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6ENTG ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTC phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6ENTG ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6ENTG enzymes, BC6ENTC phosphoribosyltransferase ( BC6OTHER ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
Leishmania species express three BC6OTHER enzymes, BC6ENTC phosphoribosyltransferase ( BC6ENTG ), BC6OTHER phosphoribosyltransferase ( BC6OTHER ), and BC6OTHER phosphoribosyltransferase ( BC6OTHER ), which enable this genus to acquire BC6OTHER nutrients from their hosts.	False
These data support the hypothesis that none of the three BC6ENTG is essential for BC6ENTC salvage or viability by itself and that BC6OTHER salvage occurs through multiple anabolic routes in both parasite life cycle stages.	False
These data support the hypothesis that none of the three BC6ENTG is essential for BC6OTHER salvage or viability by itself and that BC6ENTC salvage occurs through multiple anabolic routes in both parasite life cycle stages.	False
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6ENTC , and BC6ENTG / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6OTHER , respectively.	False
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6ENTC , and BC6OTHER / BC6ENTG and BC6OTHER also metabolized BC6OTHER and BC6OTHER , respectively.	False
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6ENTC , and BC6OTHER / BC6OTHER and BC6ENTG also metabolized BC6OTHER and BC6OTHER , respectively.	False
BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6ENTC , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6OTHER , respectively.	CPR:9
BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER metabolized BC6ENTC , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6OTHER , respectively.	CPR:9
BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER metabolized BC6ENTC , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6OTHER , respectively.	CPR:9
BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG metabolized BC6ENTC , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6OTHER , respectively.	CPR:9
BC6ENTC - containing monooxygenases ( BC6OTHER ), drug - metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including BC6ENTG and BC6OTHER ), but remain to be investigated in cynomolgus macaque.	False
BC6ENTC - containing monooxygenases ( BC6OTHER ), drug - metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including BC6OTHER and BC6ENTG ), but remain to be investigated in cynomolgus macaque.	False
BC6ENTC - containing monooxygenases ( BC6ENTG ), drug - metabolizing enzymes essential for the metabolism of endogenous biochemicals and foreign compounds, have been characterized in human (including BC6OTHER and BC6OTHER ), but remain to be investigated in cynomolgus macaque.	False
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6ENTG / BC6OTHER and BC6OTHER also metabolized BC6ENTC and BC6OTHER , respectively.	CPR:9
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6ENTG and BC6OTHER also metabolized BC6ENTC and BC6OTHER , respectively.	CPR:9
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6ENTG also metabolized BC6ENTC and BC6OTHER , respectively.	CPR:9
BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6ENTC and BC6OTHER , respectively.	False
BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6ENTC and BC6OTHER , respectively.	False
BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6ENTC and BC6OTHER , respectively.	False
BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6ENTC and BC6OTHER , respectively.	False
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6ENTG / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6ENTC , respectively.	CPR:9
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6ENTG and BC6OTHER also metabolized BC6OTHER and BC6ENTC , respectively.	CPR:9
BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6ENTG also metabolized BC6OTHER and BC6ENTC , respectively.	CPR:9
BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6ENTC , respectively.	False
BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6ENTC , respectively.	False
BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6ENTC , respectively.	False
BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG metabolized BC6OTHER , and BC6OTHER / BC6OTHER and BC6OTHER also metabolized BC6OTHER and BC6ENTC , respectively.	False
Rates of BC6ENTC BC6OTHER - oxygenation (catalyzed by BC6ENTG ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6OTHER BC6OTHER - oxygenation might be partly accounted for by the variable BC6OTHER expression.	CPR:9
Rates of BC6ENTC BC6OTHER - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6ENTG protein expression, indicating that the inter - animal variations in BC6OTHER BC6OTHER - oxygenation might be partly accounted for by the variable BC6OTHER expression.	False
Rates of BC6ENTC BC6OTHER - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6OTHER BC6OTHER - oxygenation might be partly accounted for by the variable BC6ENTG expression.	False
Rates of BC6OTHER BC6ENTC - oxygenation (catalyzed by BC6ENTG ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6OTHER BC6OTHER - oxygenation might be partly accounted for by the variable BC6OTHER expression.	CPR:9
Rates of BC6OTHER BC6ENTC - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6ENTG protein expression, indicating that the inter - animal variations in BC6OTHER BC6OTHER - oxygenation might be partly accounted for by the variable BC6OTHER expression.	False
Rates of BC6OTHER BC6ENTC - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6OTHER BC6OTHER - oxygenation might be partly accounted for by the variable BC6ENTG expression.	False
Rates of BC6OTHER BC6OTHER - oxygenation (catalyzed by BC6ENTG ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6ENTC BC6OTHER - oxygenation might be partly accounted for by the variable BC6OTHER expression.	False
Rates of BC6OTHER BC6OTHER - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6ENTG protein expression, indicating that the inter - animal variations in BC6ENTC BC6OTHER - oxygenation might be partly accounted for by the variable BC6OTHER expression.	False
Rates of BC6OTHER BC6OTHER - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6ENTC BC6OTHER - oxygenation might be partly accounted for by the variable BC6ENTG expression.	CPR:9
Rates of BC6OTHER BC6OTHER - oxygenation (catalyzed by BC6ENTG ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6OTHER BC6ENTC - oxygenation might be partly accounted for by the variable BC6OTHER expression.	False
Rates of BC6OTHER BC6OTHER - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6ENTG protein expression, indicating that the inter - animal variations in BC6OTHER BC6ENTC - oxygenation might be partly accounted for by the variable BC6OTHER expression.	False
Rates of BC6OTHER BC6OTHER - oxygenation (catalyzed by BC6OTHER ) varied (approximately 20 - fold) among the 28 cynomolgus livers and were significantly correlated with BC6OTHER protein expression, indicating that the inter - animal variations in BC6OTHER BC6ENTC - oxygenation might be partly accounted for by the variable BC6ENTG expression.	CPR:9
BC6ENTG metabolized BC6ENTC only slightly, but minimal expression of BC6OTHER in all tissue precludes the importance of BC6OTHER in drug metabolism, unlike cynomolgus BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER which were all functional.	CPR:9
BC6OTHER metabolized BC6ENTC only slightly, but minimal expression of BC6ENTG in all tissue precludes the importance of BC6OTHER in drug metabolism, unlike cynomolgus BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER which were all functional.	False
BC6OTHER metabolized BC6ENTC only slightly, but minimal expression of BC6OTHER in all tissue precludes the importance of BC6ENTG in drug metabolism, unlike cynomolgus BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER which were all functional.	False
BC6OTHER metabolized BC6ENTC only slightly, but minimal expression of BC6OTHER in all tissue precludes the importance of BC6OTHER in drug metabolism, unlike cynomolgus BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER which were all functional.	CPR:9
BC6OTHER metabolized BC6ENTC only slightly, but minimal expression of BC6OTHER in all tissue precludes the importance of BC6OTHER in drug metabolism, unlike cynomolgus BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER which were all functional.	CPR:9
BC6OTHER metabolized BC6ENTC only slightly, but minimal expression of BC6OTHER in all tissue precludes the importance of BC6OTHER in drug metabolism, unlike cynomolgus BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER which were all functional.	CPR:9
BC6OTHER metabolized BC6ENTC only slightly, but minimal expression of BC6OTHER in all tissue precludes the importance of BC6OTHER in drug metabolism, unlike cynomolgus BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG which were all functional.	CPR:9
BC6ENTC sequences of cynomolgus BC6ENTG , respectively, shared high sequence identities (94 - 98%) and were closely clustered in a phylogenetic tree, with BC6OTHER .	False
BC6ENTC sequences of cynomolgus BC6OTHER , respectively, shared high sequence identities (94 - 98%) and were closely clustered in a phylogenetic tree, with BC6ENTG .	False
As examples, BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER have increased BC6ENTG selectivity when compared with BC6OTHER and BC6OTHER .	False
As examples, BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER have increased BC6ENTG selectivity when compared with BC6OTHER and BC6OTHER .	False
As examples, BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER have increased BC6ENTG selectivity when compared with BC6OTHER and BC6OTHER .	False
As examples, BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC have increased BC6ENTG selectivity when compared with BC6OTHER and BC6OTHER .	False
As examples, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER have increased BC6ENTG selectivity when compared with BC6ENTC and BC6OTHER .	False
As examples, BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER have increased BC6ENTG selectivity when compared with BC6OTHER and BC6ENTC .	False
BC6ENTC secretion by MSCs was directly related to their BC6ENTG expression levels, suggesting a mechanism - increased concentrations of BC6OTHER in the leukemic cell microenvironment - for the protective effects we observed.	CPR:9
BC6OTHER secretion by MSCs was directly related to their BC6ENTG expression levels, suggesting a mechanism - increased concentrations of BC6ENTC in the leukemic cell microenvironment - for the protective effects we observed.	False
Because of their low BC6OTHER ( BC6ENTG ) expression and BC6OTHER biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to BC6ENTC depletion.	False
Because of their low BC6ENTG ( BC6OTHER ) expression and BC6OTHER biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to BC6ENTC depletion.	False
Because of their low BC6ENTC synthetase ( BC6ENTG ) expression and BC6OTHER biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to BC6OTHER depletion.	False
Because of their low BC6OTHER ( BC6ENTG ) expression and BC6ENTC biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to BC6OTHER depletion.	CPR:9
Because of their low BC6ENTG ( BC6OTHER ) expression and BC6ENTC biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to BC6OTHER depletion.	CPR:9
The BC6ENTG gene, which encodes the lysosomal BC6ENTC transporter LYAAT1 / BC6OTHER , generates multiple alternative mRNAs, some of which encode truncated proteins.	False
The BC6OTHER gene, which encodes the lysosomal BC6ENTC transporter LYAAT1 / BC6ENTG , generates multiple alternative mRNAs, some of which encode truncated proteins.	False
BC6OTHER is expressed in numerous tissues, whereas expression of BC6OTHER , which encodes the BC6ENTC transporter BC6ENTG / BC6OTHER , is most abundant in kidney and muscle.	False
BC6OTHER is expressed in numerous tissues, whereas expression of BC6OTHER , which encodes the BC6ENTC transporter BC6OTHER / BC6ENTG , is most abundant in kidney and muscle.	False
BC6ENTG is expressed in numerous tissues, whereas expression of BC6OTHER , which encodes the BC6ENTC transporter BC6OTHER / BC6OTHER , is most abundant in kidney and muscle.	False
BC6OTHER is expressed in numerous tissues, whereas expression of BC6ENTG , which encodes the BC6ENTC transporter BC6OTHER / BC6OTHER , is most abundant in kidney and muscle.	False
UNLABELLED: BC6ENTG overexpressed in human tumors, such as BC6ENTC receptors, can be used for in vivo targeting for diagnostic and therapeutic purposes.	False
Four proteins, namely BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	False
Four proteins, namely BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	False
Four proteins, namely BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC binding protein were increased in the urine in temporal association with the appearance of chronic predisposition.	False
Increased urinary excretion of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER correlates with chronic sensitization to BC6ENTC nephrotoxicity in rats.	CPR:3
Increased urinary excretion of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER correlates with chronic sensitization to BC6ENTC nephrotoxicity in rats.	CPR:3
Increased urinary excretion of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER correlates with chronic sensitization to BC6ENTC nephrotoxicity in rats.	CPR:3
Increased urinary excretion of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG correlates with chronic sensitization to BC6ENTC nephrotoxicity in rats.	CPR:3
However, in certain situations such as high dose BC6OTHER therapy, or in poor metabolizers of BC6ENTG substrates, clinically significant interactions might occur, particularly when BC6ENTC is coadministered with drugs with a narrow therapeutic index.	False
The inhibitory effects of BC6ENTC , a nonselective irreversible inhibitor of BC6OTHER oxidase ( BC6OTHER ), on three BC6ENTG ( BC6OTHER ) enzymes, namely BC6OTHER , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6ENTC , a nonselective irreversible inhibitor of BC6OTHER oxidase ( BC6OTHER ), on three BC6OTHER ( BC6ENTG ) enzymes, namely BC6OTHER , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6ENTC , a nonselective irreversible inhibitor of BC6OTHER oxidase ( BC6OTHER ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6ENTG , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6ENTC , a nonselective irreversible inhibitor of BC6OTHER oxidase ( BC6OTHER ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6OTHER , BC6ENTG , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6ENTC , a nonselective irreversible inhibitor of BC6OTHER oxidase ( BC6OTHER ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6OTHER , BC6OTHER , and BC6ENTG , have been evaluated in vitro.	False
The inhibitory effects of BC6ENTC , a nonselective irreversible inhibitor of BC6ENTG ( BC6OTHER ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6OTHER , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	CPR:4
The inhibitory effects of BC6ENTC , a nonselective irreversible inhibitor of BC6OTHER oxidase ( BC6ENTG ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6OTHER , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	CPR:4
A range of substrate concentrations was coincubated with a range of BC6ENTC concentrations in the presence of each of the BC6ENTG enzymes at 37 degrees C for a predetermined period of time.	False
The results demonstrated that BC6ENTC is a competitive inhibitor of BC6ENTG (Ki = 32 microM) and BC6OTHER (Ki = 367 microM) and a noncompetitive inhibitor of BC6OTHER (Ki = 56 microM).	CPR:4
The results demonstrated that BC6ENTC is a competitive inhibitor of BC6OTHER (Ki = 32 microM) and BC6ENTG (Ki = 367 microM) and a noncompetitive inhibitor of BC6OTHER (Ki = 56 microM).	CPR:4
The results demonstrated that BC6ENTC is a competitive inhibitor of BC6OTHER (Ki = 32 microM) and BC6OTHER (Ki = 367 microM) and a noncompetitive inhibitor of BC6ENTG (Ki = 56 microM).	CPR:4
The inhibitory effects of BC6OTHER , a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6OTHER ), on three BC6ENTG ( BC6OTHER ) enzymes, namely BC6OTHER , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6OTHER , a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6OTHER ), on three BC6OTHER ( BC6ENTG ) enzymes, namely BC6OTHER , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6OTHER , a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6OTHER ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6ENTG , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6OTHER , a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6OTHER ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6OTHER , BC6ENTG , and BC6OTHER , have been evaluated in vitro.	False
The inhibitory effects of BC6OTHER , a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6OTHER ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6OTHER , BC6OTHER , and BC6ENTG , have been evaluated in vitro.	False
The inhibitory effects of BC6OTHER , a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6ENTG ), on three BC6OTHER ( BC6OTHER ) enzymes, namely BC6OTHER , BC6OTHER , and BC6OTHER , have been evaluated in vitro.	False
However, in certain situations such as high dose BC6ENTC therapy, or in poor metabolizers of BC6ENTG substrates, clinically significant interactions might occur, particularly when BC6OTHER is coadministered with drugs with a narrow therapeutic index.	False
Inhibitory effects of the BC6ENTC oxidase inhibitor BC6OTHER on the BC6OTHER enzymes BC6ENTG , BC6OTHER , and BC6OTHER .	False
Inhibitory effects of the BC6ENTC oxidase inhibitor BC6OTHER on the BC6OTHER enzymes BC6OTHER , BC6ENTG , and BC6OTHER .	False
Inhibitory effects of the BC6ENTC oxidase inhibitor BC6OTHER on the BC6OTHER enzymes BC6OTHER , BC6OTHER , and BC6ENTG .	False
Inhibitory effects of the BC6ENTC oxidase inhibitor BC6OTHER on the BC6ENTG enzymes BC6OTHER , BC6OTHER , and BC6OTHER .	False
Inhibitory effects of the BC6OTHER oxidase inhibitor BC6ENTC on the BC6OTHER enzymes BC6ENTG , BC6OTHER , and BC6OTHER .	False
Inhibitory effects of the BC6OTHER oxidase inhibitor BC6ENTC on the BC6OTHER enzymes BC6OTHER , BC6ENTG , and BC6OTHER .	False
Inhibitory effects of the BC6OTHER oxidase inhibitor BC6ENTC on the BC6OTHER enzymes BC6OTHER , BC6OTHER , and BC6ENTG .	False
Inhibitory effects of the BC6ENTG inhibitor BC6ENTC on the BC6OTHER enzymes BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Inhibitory effects of the BC6OTHER oxidase inhibitor BC6ENTC on the BC6ENTG enzymes BC6OTHER , BC6OTHER , and BC6OTHER .	False
Patients stable on BC6ENTC therapy and concurrently taking a BC6ENTG ( BC6OTHER ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6OTHER ) randomly received BC6OTHER 200 mg / day or BC6OTHER 25 mg / day for three weeks.	False
Patients stable on BC6ENTC therapy and concurrently taking a BC6OTHER ( BC6ENTG ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6OTHER ) randomly received BC6OTHER 200 mg / day or BC6OTHER 25 mg / day for three weeks.	False
Adverse drug reactions were similar for each BC6ENTG inhibitor, but the rate of edema requiring medical intervention was higher in the BC6ENTC group.	False
Patients stable on BC6OTHER therapy and concurrently taking a BC6ENTG ( BC6OTHER ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6ENTC , or BC6OTHER ) randomly received BC6OTHER 200 mg / day or BC6OTHER 25 mg / day for three weeks.	CPR:4
Patients stable on BC6OTHER therapy and concurrently taking a BC6OTHER ( BC6ENTG ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6ENTC , or BC6OTHER ) randomly received BC6OTHER 200 mg / day or BC6OTHER 25 mg / day for three weeks.	CPR:4
Patients stable on BC6OTHER therapy and concurrently taking a BC6ENTG ( BC6OTHER ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6ENTC ) randomly received BC6OTHER 200 mg / day or BC6OTHER 25 mg / day for three weeks.	CPR:4
Patients stable on BC6OTHER therapy and concurrently taking a BC6OTHER ( BC6ENTG ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6ENTC ) randomly received BC6OTHER 200 mg / day or BC6OTHER 25 mg / day for three weeks.	CPR:4
Patients stable on BC6OTHER therapy and concurrently taking a BC6ENTG ( BC6OTHER ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6OTHER ) randomly received BC6ENTC 200 mg / day or BC6OTHER 25 mg / day for three weeks.	CPR:4
Patients stable on BC6OTHER therapy and concurrently taking a BC6OTHER ( BC6ENTG ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6OTHER ) randomly received BC6ENTC 200 mg / day or BC6OTHER 25 mg / day for three weeks.	CPR:4
Patients stable on BC6OTHER therapy and concurrently taking a BC6ENTG ( BC6OTHER ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6OTHER ) randomly received BC6OTHER 200 mg / day or BC6ENTC 25 mg / day for three weeks.	CPR:4
Patients stable on BC6OTHER therapy and concurrently taking a BC6OTHER ( BC6ENTG ) inhibitor comparator (traditional nonsteroidal antiinflammatory medications, BC6OTHER , or BC6OTHER ) randomly received BC6OTHER 200 mg / day or BC6ENTC 25 mg / day for three weeks.	CPR:4
BC6ENTC , popularly known for its cooling effect, activates BC6ENTG - - a cold - activated BC6OTHER .	CPR:3
BC6ENTC , popularly known for its cooling effect, activates BC6OTHER - - a cold - activated BC6ENTG .	CPR:3
However, human physiological studies demonstrate a paradoxical role of BC6ENTC in modulation of warm sensation, and here, we show that BC6OTHER also activates heat - activated BC6ENTG .	False
However, human physiological studies demonstrate a paradoxical role of BC6OTHER in modulation of warm sensation, and here, we show that BC6ENTC also activates heat - activated BC6ENTG .	CPR:3
We further show that BC6ENTC inhibits BC6ENTG , potentially explaining the use of BC6OTHER as an analgesic.	CPR:4
We further show that BC6OTHER inhibits BC6ENTG , potentially explaining the use of BC6ENTC as an analgesic.	False
Similar to BC6ENTC , both BC6OTHER and BC6OTHER (initially reported to be specific activators of BC6ENTG and BC6OTHER , respectively) also modulate other BC6OTHER .	CPR:3
Similar to BC6ENTC , both BC6OTHER and BC6OTHER (initially reported to be specific activators of BC6OTHER and BC6ENTG , respectively) also modulate other BC6OTHER .	CPR:3
Similar to BC6ENTC , both BC6OTHER and BC6OTHER (initially reported to be specific activators of BC6OTHER and BC6OTHER , respectively) also modulate other BC6ENTG .	False
Similar to BC6OTHER , both BC6ENTC and BC6OTHER (initially reported to be specific activators of BC6ENTG and BC6OTHER , respectively) also modulate other BC6OTHER .	CPR:3
Similar to BC6OTHER , both BC6ENTC and BC6OTHER (initially reported to be specific activators of BC6OTHER and BC6ENTG , respectively) also modulate other BC6OTHER .	CPR:3
Similar to BC6OTHER , both BC6ENTC and BC6OTHER (initially reported to be specific activators of BC6OTHER and BC6OTHER , respectively) also modulate other BC6ENTG .	False
Similar to BC6OTHER , both BC6OTHER and BC6ENTC (initially reported to be specific activators of BC6ENTG and BC6OTHER , respectively) also modulate other BC6OTHER .	CPR:3
Similar to BC6OTHER , both BC6OTHER and BC6ENTC (initially reported to be specific activators of BC6OTHER and BC6ENTG , respectively) also modulate other BC6OTHER .	CPR:3
Similar to BC6OTHER , both BC6OTHER and BC6ENTC (initially reported to be specific activators of BC6OTHER and BC6OTHER , respectively) also modulate other BC6ENTG .	False
BC6ENTG / BC6OTHER channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6OTHER drugs, such as BC6OTHER , BC6ENTC , and BC6OTHER , at submicromolar concentrations.	CPR:4
BC6OTHER / BC6ENTG channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6OTHER drugs, such as BC6OTHER , BC6ENTC , and BC6OTHER , at submicromolar concentrations.	CPR:4
BC6ENTG / BC6OTHER channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6OTHER drugs, such as BC6OTHER , BC6OTHER , and BC6ENTC , at submicromolar concentrations.	CPR:4
BC6OTHER / BC6ENTG channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6OTHER drugs, such as BC6OTHER , BC6OTHER , and BC6ENTC , at submicromolar concentrations.	CPR:4
By contrast, the closely related BC6ENTG ( BC6OTHER ) is 100 - fold less sensitive to BC6ENTC .	False
By contrast, the closely related BC6OTHER ( BC6ENTG ) is 100 - fold less sensitive to BC6ENTC .	False
The BC6OTHER ( BC6OTHER ) encodes a BC6ENTC channel with biophysical properties nearly identical to the BC6ENTG ( BC6OTHER ).	False
The BC6OTHER ( BC6OTHER ) encodes a BC6ENTC channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier BC6OTHER current ( BC6ENTG ).	False
The BC6OTHER ( BC6ENTG ) encodes a BC6ENTC channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier BC6OTHER current ( BC6OTHER ).	False
The BC6ENTG ( BC6OTHER ) encodes a BC6ENTC channel with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier BC6OTHER current ( BC6OTHER ).	False
To identify the molecular determinants for BC6ENTC block, we first engineered chimeras between BC6ENTG and BC6OTHER and then used site - directed mutagenesis to localize single BC6OTHER residues responsible for block.	False
To identify the molecular determinants for BC6ENTC block, we first engineered chimeras between BC6OTHER and BC6ENTG and then used site - directed mutagenesis to localize single BC6OTHER residues responsible for block.	False
To identify the molecular determinants for BC6OTHER block, we first engineered chimeras between BC6ENTG and BC6OTHER and then used site - directed mutagenesis to localize single BC6ENTC residues responsible for block.	False
To identify the molecular determinants for BC6OTHER block, we first engineered chimeras between BC6OTHER and BC6ENTG and then used site - directed mutagenesis to localize single BC6ENTC residues responsible for block.	False
Molecular determinants of BC6ENTC block of BC6ENTG BC6OTHER .	CPR:4
Molecular determinants of BC6ENTC block of BC6OTHER BC6ENTG .	CPR:4
Molecular determinants of BC6OTHER block of BC6ENTG BC6ENTC channels.	False
Thus, our results indicate that important determinants of BC6ENTC binding are localized to the pore region of BC6ENTG .	False
The BC6OTHER ( BC6OTHER ) encodes a BC6OTHER with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier BC6ENTC current ( BC6ENTG ).	False
The BC6OTHER ( BC6ENTG ) encodes a BC6OTHER with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier BC6ENTC current ( BC6OTHER ).	False
The BC6ENTG ( BC6OTHER ) encodes a BC6OTHER with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier BC6ENTC current ( BC6OTHER ).	False
The BC6OTHER ( BC6OTHER ) encodes a BC6ENTG with biophysical properties nearly identical to the rapid component of the cardiac delayed rectifier BC6ENTC current ( BC6OTHER ).	False
Moreover, the reverse mutation BC6ENTG BC6OTHER increased the affinity of BC6OTHER BC6ENTC channels for BC6OTHER , whereas C - type inactivation could not be recovered.	False
Moreover, the reverse mutation BC6OTHER BC6ENTG increased the affinity of BC6OTHER BC6ENTC channels for BC6OTHER , whereas C - type inactivation could not be recovered.	False
Moreover, the reverse mutation BC6OTHER BC6OTHER increased the affinity of BC6ENTG BC6ENTC channels for BC6OTHER , whereas C - type inactivation could not be recovered.	False
Moreover, the reverse mutation BC6ENTG BC6OTHER increased the affinity of BC6OTHER BC6OTHER channels for BC6ENTC , whereas C - type inactivation could not be recovered.	False
Moreover, the reverse mutation BC6OTHER BC6ENTG increased the affinity of BC6OTHER BC6OTHER channels for BC6ENTC , whereas C - type inactivation could not be recovered.	False
Moreover, the reverse mutation BC6OTHER BC6OTHER increased the affinity of BC6ENTG BC6OTHER channels for BC6ENTC , whereas C - type inactivation could not be recovered.	False
Moreover, the reverse mutation BC6OTHER BC6OTHER increased the affinity of BC6OTHER BC6ENTG for BC6ENTC , whereas C - type inactivation could not be recovered.	False
Thus, the BC6ENTC in position BC6ENTG 620 may participate directly in BC6OTHER binding; however, an intact C - type inactivation process seems to be crucial for high - affinity drug binding.	False
Thus, the BC6OTHER in position BC6ENTG 620 may participate directly in BC6ENTC binding; however, an intact C - type inactivation process seems to be crucial for high - affinity drug binding.	False
BC6ENTG / BC6OTHER channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6ENTC drugs, such as BC6OTHER , BC6OTHER , and BC6OTHER , at submicromolar concentrations.	CPR:4
BC6OTHER / BC6ENTG channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6ENTC drugs, such as BC6OTHER , BC6OTHER , and BC6OTHER , at submicromolar concentrations.	CPR:4
BC6ENTG / BC6OTHER channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6OTHER drugs, such as BC6ENTC , BC6OTHER , and BC6OTHER , at submicromolar concentrations.	CPR:4
BC6OTHER / BC6ENTG channels are a prime target for the pharmacological management of arrhythmias and are selectively blocked by class III antiarrhythmic BC6OTHER drugs, such as BC6ENTC , BC6OTHER , and BC6OTHER , at submicromolar concentrations.	CPR:4
By synthesizing and testing a series of BC6OTHER point - mutated BC6ENTG , we identified which BC6ENTC was important for the inhibition of the BC6OTHER function.	False
By synthesizing and testing a series of BC6OTHER point - mutated BC6OTHER , we identified which BC6ENTC was important for the inhibition of the BC6ENTG function.	False
The structures of active and inactive BC6ENTC - mutated BC6ENTG , and of BC6OTHER , were determined by NMR.	False
The structures of active and inactive BC6ENTC - mutated BC6OTHER , and of BC6ENTG , were determined by NMR.	False
In heart failure, aberrations in the inhibition of sarcoplasmic BC6ENTC ATPase by BC6ENTG are associated with anomalies in cardiac functions.	False
The interplay between cardiac sarcoplasmic BC6ENTC ATPase and BC6ENTG is a key regulating factor of contraction and relaxation in the cardiac muscle.	False
The aim of our research was to find molecules able to interfere with the inhibitory activity of BC6ENTG on sarcoplasmic BC6ENTC ATPase.	False
By synthesizing and testing a series of BC6ENTC point - mutated BC6ENTG , we identified which BC6OTHER was important for the inhibition of the BC6OTHER function.	False
By synthesizing and testing a series of BC6ENTC point - mutated BC6OTHER , we identified which BC6OTHER was important for the inhibition of the BC6ENTG function.	False
These results link BC6ENTG to the regulation of BC6ENTC dynamics and identify enzymatic activity of BC6OTHER as a critical factor for modulating cross - striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in BC6OTHER ( - / - ) mice.	False
These results link BC6OTHER to the regulation of BC6ENTC dynamics and identify enzymatic activity of BC6ENTG as a critical factor for modulating cross - striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in BC6OTHER ( - / - ) mice.	False
These results link BC6OTHER to the regulation of BC6ENTC dynamics and identify enzymatic activity of BC6OTHER as a critical factor for modulating cross - striated muscle function by generating a unique muscle phenotype exhibiting both, reduced fatigability and enhanced force in BC6ENTG ( - / - ) mice.	False
Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that BC6ENTG catalytic activity directly regulated the promoters of the fast fiber - specific BC6OTHER and the slow fiber - specific sarco / endoplasmic reticulum BC6ENTC - ATPase (SERCA) 2 gene.	False
Using reporter gene and electrophoretic gel mobility shift assays we demonstrated that BC6OTHER catalytic activity directly regulated the promoters of the fast fiber - specific BC6ENTG and the slow fiber - specific sarco / endoplasmic reticulum BC6ENTC - ATPase (SERCA) 2 gene.	False
BC6ENTC , a well known BC6ENTG inhibitor, is also a potent inhibitor of BC6OTHER with a Ki value of 56 nM.	CPR:4
BC6ENTC , a well known BC6OTHER inhibitor, is also a potent inhibitor of BC6ENTG with a Ki value of 56 nM.	CPR:4
BC6ENTC , a BC6OTHER used in the treatment of hirsutism, acne and prostate cancer as well as BC6OTHER and BC6OTHER that are widely used as oral contraceptives also inhibit BC6ENTG activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
BC6OTHER , a BC6ENTC used in the treatment of hirsutism, acne and prostate cancer as well as BC6OTHER and BC6OTHER that are widely used as oral contraceptives also inhibit BC6ENTG activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
BC6OTHER , a BC6OTHER used in the treatment of hirsutism, acne and prostate cancer as well as BC6ENTC and BC6OTHER that are widely used as oral contraceptives also inhibit BC6ENTG activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
BC6OTHER , a BC6OTHER used in the treatment of hirsutism, acne and prostate cancer as well as BC6OTHER and BC6ENTC that are widely used as oral contraceptives also inhibit BC6ENTG activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.	CPR:4
Inhibitory effect of synthetic BC6ENTC , BC6OTHER and BC6OTHER on BC6ENTG activity.	CPR:4
Inhibitory effect of synthetic BC6OTHER , BC6ENTC and BC6OTHER on BC6ENTG activity.	CPR:4
BC6ENTG ( BC6OTHER ) purified from human placenta transforms C - 21 ( BC6ENTC and BC6OTHER ) as well as C - 19 ( BC6OTHER and BC6OTHER ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
Human placental BC6OTHER dehydrogenase / 5 CHEM isomerase ( BC6ENTG ) purified from human placenta transforms C - 21 ( BC6ENTC and BC6OTHER ) as well as C - 19 ( BC6OTHER and BC6OTHER ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
Inhibitory effect of synthetic BC6OTHER , BC6OTHER and BC6ENTC on BC6ENTG activity.	CPR:4
BC6ENTG ( BC6OTHER ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6ENTC ) as well as C - 19 ( BC6OTHER and BC6OTHER ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
Human placental BC6OTHER dehydrogenase / 5 CHEM isomerase ( BC6ENTG ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6ENTC ) as well as C - 19 ( BC6OTHER and BC6OTHER ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
Human placental BC6ENTC dehydrogenase / 5 CHEM isomerase ( BC6ENTG ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6OTHER ) as well as C - 19 ( BC6OTHER and BC6OTHER ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	False
BC6ENTG ( BC6OTHER ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6OTHER ) as well as C - 19 ( BC6ENTC and BC6OTHER ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
Human placental BC6OTHER dehydrogenase / 5 CHEM isomerase ( BC6ENTG ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6OTHER ) as well as C - 19 ( BC6ENTC and BC6OTHER ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
BC6ENTG ( BC6OTHER ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6OTHER ) as well as C - 19 ( BC6OTHER and BC6ENTC ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
Human placental BC6OTHER dehydrogenase / 5 CHEM isomerase ( BC6ENTG ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6OTHER ) as well as C - 19 ( BC6OTHER and BC6ENTC ) CHEM into the corresponding BC6OTHER and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
BC6ENTG ( BC6OTHER ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6OTHER ) as well as C - 19 ( BC6OTHER and BC6OTHER ) CHEM into the corresponding BC6ENTC and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
Human placental BC6OTHER dehydrogenase / 5 CHEM isomerase ( BC6ENTG ) purified from human placenta transforms C - 21 ( BC6OTHER and BC6OTHER ) as well as C - 19 ( BC6OTHER and BC6OTHER ) CHEM into the corresponding BC6ENTC and is thus involved in the biosynthesis of all classes of hormonal CHEM.	CPR:9
BC6ENTC , BC6OTHER and BC6OTHER are potent inhibitors of BC6ENTG with Ki values of approximately 50 nM.	CPR:4
BC6OTHER , BC6ENTC and BC6OTHER are potent inhibitors of BC6ENTG with Ki values of approximately 50 nM.	CPR:4
BC6OTHER , BC6OTHER and BC6ENTC are potent inhibitors of BC6ENTG with Ki values of approximately 50 nM.	CPR:4
A preliminary clinical investigation with the BC6ENTG substrate probe BC6ENTC established that BC6OTHER did not inhibit intestinal or hepatic BC6OTHER .	False
A preliminary clinical investigation with the BC6OTHER substrate probe BC6ENTC established that BC6OTHER did not inhibit intestinal or hepatic BC6ENTG .	False
A preliminary clinical investigation with the BC6ENTG substrate probe BC6OTHER established that BC6ENTC did not inhibit intestinal or hepatic BC6OTHER .	False
A preliminary clinical investigation with the BC6OTHER substrate probe BC6OTHER established that BC6ENTC did not inhibit intestinal or hepatic BC6ENTG .	False
BC6ENTC BC6OTHER - demethylation in vitro is catalyzed by hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER , but clinical disposition is often attributed to BC6ENTG .	CPR:9
BC6ENTC BC6OTHER - demethylation in vitro is catalyzed by hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER , but clinical disposition is often attributed to BC6OTHER .	CPR:9
BC6ENTC BC6OTHER - demethylation in vitro is catalyzed by hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER , but clinical disposition is often attributed to BC6OTHER .	CPR:9
BC6ENTC BC6OTHER - demethylation in vitro is catalyzed by hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG , but clinical disposition is often attributed to BC6OTHER .	CPR:9
Role of BC6ENTG in BC6ENTC metabolism and clearance.	False
BC6OTHER BC6ENTC - demethylation in vitro is catalyzed by hepatic BC6OTHER ( BC6OTHER ) and BC6OTHER , but clinical disposition is often attributed to BC6ENTG .	CPR:9
BC6OTHER BC6ENTC - demethylation in vitro is catalyzed by hepatic BC6ENTG ( BC6OTHER ) and BC6OTHER , but clinical disposition is often attributed to BC6OTHER .	CPR:9
BC6OTHER BC6ENTC - demethylation in vitro is catalyzed by hepatic BC6OTHER ( BC6ENTG ) and BC6OTHER , but clinical disposition is often attributed to BC6OTHER .	CPR:9
BC6OTHER BC6ENTC - demethylation in vitro is catalyzed by hepatic BC6OTHER ( BC6OTHER ) and BC6ENTG , but clinical disposition is often attributed to BC6OTHER .	CPR:9
BC6ENTG inhibition reduces BC6ENTC BC6OTHER - demethylation and clearance, and alters BC6OTHER concentrations, demonstrating an important role for BC6OTHER in clinical BC6OTHER disposition.	False
BC6OTHER inhibition reduces BC6ENTC BC6OTHER - demethylation and clearance, and alters BC6OTHER concentrations, demonstrating an important role for BC6ENTG in clinical BC6OTHER disposition.	False
BC6ENTG inhibition reduces BC6OTHER BC6ENTC - demethylation and clearance, and alters BC6OTHER concentrations, demonstrating an important role for BC6OTHER in clinical BC6OTHER disposition.	False
BC6OTHER inhibition reduces BC6OTHER BC6ENTC - demethylation and clearance, and alters BC6OTHER concentrations, demonstrating an important role for BC6ENTG in clinical BC6OTHER disposition.	False
BC6ENTG inhibition reduces BC6OTHER BC6OTHER - demethylation and clearance, and alters BC6ENTC concentrations, demonstrating an important role for BC6OTHER in clinical BC6OTHER disposition.	False
BC6OTHER inhibition reduces BC6OTHER BC6OTHER - demethylation and clearance, and alters BC6ENTC concentrations, demonstrating an important role for BC6ENTG in clinical BC6OTHER disposition.	False
BC6ENTG inhibition reduces BC6OTHER BC6OTHER - demethylation and clearance, and alters BC6OTHER concentrations, demonstrating an important role for BC6OTHER in clinical BC6ENTC disposition.	False
BC6OTHER inhibition reduces BC6OTHER BC6OTHER - demethylation and clearance, and alters BC6OTHER concentrations, demonstrating an important role for BC6ENTG in clinical BC6ENTC disposition.	CPR:9
This investigation tested the hypothesis that BC6ENTG is a prominent BC6OTHER isoform responsible for clinical BC6ENTC BC6OTHER - demethylation and clearance, using the in vivo mechanism - based BC6OTHER inhibitor BC6OTHER , given orally for 4 days.	CPR:9
This investigation tested the hypothesis that BC6OTHER is a prominent BC6ENTG isoform responsible for clinical BC6ENTC BC6OTHER - demethylation and clearance, using the in vivo mechanism - based BC6OTHER inhibitor BC6OTHER , given orally for 4 days.	CPR:9
This investigation tested the hypothesis that BC6OTHER is a prominent BC6OTHER isoform responsible for clinical BC6ENTC BC6OTHER - demethylation and clearance, using the in vivo mechanism - based BC6ENTG inhibitor BC6OTHER , given orally for 4 days.	False
This investigation tested the hypothesis that BC6ENTG is a prominent BC6OTHER isoform responsible for clinical BC6OTHER BC6ENTC - demethylation and clearance, using the in vivo mechanism - based BC6OTHER inhibitor BC6OTHER , given orally for 4 days.	CPR:9
This investigation tested the hypothesis that BC6OTHER is a prominent BC6ENTG isoform responsible for clinical BC6OTHER BC6ENTC - demethylation and clearance, using the in vivo mechanism - based BC6OTHER inhibitor BC6OTHER , given orally for 4 days.	CPR:9
This investigation tested the hypothesis that BC6OTHER is a prominent BC6OTHER isoform responsible for clinical BC6OTHER BC6ENTC - demethylation and clearance, using the in vivo mechanism - based BC6ENTG inhibitor BC6OTHER , given orally for 4 days.	False
This investigation tested the hypothesis that BC6ENTG is a prominent BC6OTHER isoform responsible for clinical BC6OTHER BC6OTHER - demethylation and clearance, using the in vivo mechanism - based BC6OTHER inhibitor BC6ENTC , given orally for 4 days.	False
This investigation tested the hypothesis that BC6OTHER is a prominent BC6ENTG isoform responsible for clinical BC6OTHER BC6OTHER - demethylation and clearance, using the in vivo mechanism - based BC6OTHER inhibitor BC6ENTC , given orally for 4 days.	False
This investigation tested the hypothesis that BC6OTHER is a prominent BC6OTHER isoform responsible for clinical BC6OTHER BC6OTHER - demethylation and clearance, using the in vivo mechanism - based BC6ENTG inhibitor BC6ENTC , given orally for 4 days.	CPR:4
They also increased BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6ENTC peroxidase ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) and BC6ENTC peroxidase ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6ENTC peroxidase ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) and BC6ENTC peroxidase ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6ENTC peroxidase ( BC6ENTG ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6ENTC - Px) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6ENTC - Px) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC - Px) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) and BC6OTHER ( BC6ENTC - Px) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6ENTG ( BC6ENTC - Px) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6ENTC ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6ENTC ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6ENTC ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6ENTC ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activity, while decreasing BC6ENTC ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activity, while decreasing BC6ENTC ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6ENTG ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6ENTC ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6ENTG ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6ENTC ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6ENTC ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6ENTC ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6ENTC ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6OTHER dismutase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activity, while decreasing BC6OTHER ( BC6ENTC ) levels in serum and in the livers of mice.	False
They also increased BC6ENTG ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6ENTG ), BC6ENTC dismutase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
They also increased BC6OTHER ( BC6OTHER ), BC6ENTC dismutase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) activity, while decreasing BC6OTHER ( BC6OTHER ) levels in serum and in the livers of mice.	False
Finally, chronic administration of BC6ENTC in diabetic mice restored cardiac autophagy by activating BC6OTHER - BC6OTHER pathways and dissociating BC6OTHER and BC6ENTG .	False
Finally, chronic administration of BC6ENTC in diabetic mice restored cardiac autophagy by activating BC6ENTG - BC6OTHER pathways and dissociating BC6OTHER and BC6OTHER .	CPR:3
Finally, chronic administration of BC6ENTC in diabetic mice restored cardiac autophagy by activating BC6OTHER - BC6ENTG pathways and dissociating BC6OTHER and BC6OTHER .	CPR:3
Finally, chronic administration of BC6ENTC in diabetic mice restored cardiac autophagy by activating BC6OTHER - BC6OTHER pathways and dissociating BC6ENTG and BC6OTHER .	False
We hypothesized that BC6ENTG - induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of BC6OTHER on the interaction between BC6OTHER and BC6OTHER , a switch between autophagy and apoptosis, in diabetic mice and high BC6ENTC - treated H9c2 cardiac myoblast cells.	False
We hypothesized that BC6OTHER - induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of BC6ENTG on the interaction between BC6OTHER and BC6OTHER , a switch between autophagy and apoptosis, in diabetic mice and high BC6ENTC - treated H9c2 cardiac myoblast cells.	False
We hypothesized that BC6OTHER - induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of BC6OTHER on the interaction between BC6ENTG and BC6OTHER , a switch between autophagy and apoptosis, in diabetic mice and high BC6ENTC - treated H9c2 cardiac myoblast cells.	False
We hypothesized that BC6OTHER - induced autophagy ameliorates diabetic cardiomyopathy by inhibiting cardiomyocyte apoptosis and examined the effects of BC6OTHER on the interaction between BC6OTHER and BC6ENTG , a switch between autophagy and apoptosis, in diabetic mice and high BC6ENTC - treated H9c2 cardiac myoblast cells.	False
Exposure of H9c2 cells to high BC6ENTC reduced BC6ENTG activity, inhibited Jun BC6OTHER - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6OTHER .	CPR:4
Exposure of H9c2 cells to high BC6ENTC reduced BC6OTHER activity, inhibited BC6ENTG ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6OTHER .	CPR:4
Exposure of H9c2 cells to high BC6ENTC reduced BC6OTHER activity, inhibited Jun BC6OTHER - terminal kinase 1 ( BC6ENTG ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6OTHER .	CPR:4
Exposure of H9c2 cells to high BC6ENTC reduced BC6OTHER activity, inhibited Jun BC6OTHER - terminal kinase 1 ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6OTHER .	CPR:4
Exposure of H9c2 cells to high BC6ENTC reduced BC6OTHER activity, inhibited Jun BC6OTHER - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) signaling, and promoted BC6OTHER binding to BC6OTHER .	CPR:4
Exposure of H9c2 cells to high BC6ENTC reduced BC6OTHER activity, inhibited Jun BC6OTHER - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6ENTG binding to BC6OTHER .	False
Exposure of H9c2 cells to high BC6ENTC reduced BC6OTHER activity, inhibited Jun BC6OTHER - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6ENTG .	False
Exposure of H9c2 cells to high BC6OTHER reduced BC6ENTG activity, inhibited Jun BC6ENTC - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6OTHER .	False
Exposure of H9c2 cells to high BC6OTHER reduced BC6OTHER activity, inhibited Jun BC6ENTC - terminal kinase 1 ( BC6ENTG ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6OTHER .	False
Exposure of H9c2 cells to high BC6OTHER reduced BC6OTHER activity, inhibited Jun BC6ENTC - terminal kinase 1 ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6OTHER .	False
Exposure of H9c2 cells to high BC6OTHER reduced BC6OTHER activity, inhibited Jun BC6ENTC - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) signaling, and promoted BC6OTHER binding to BC6OTHER .	False
Exposure of H9c2 cells to high BC6OTHER reduced BC6OTHER activity, inhibited Jun BC6ENTC - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6ENTG binding to BC6OTHER .	False
Exposure of H9c2 cells to high BC6OTHER reduced BC6OTHER activity, inhibited Jun BC6ENTC - terminal kinase 1 ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) signaling, and promoted BC6OTHER binding to BC6ENTG .	False
Activation of BC6ENTG , which normalized cardiac autophagy, attenuated high BC6ENTC - induced apoptosis in cultured H9c2 cells.	False
Diabetic cardiomyopathy is associated with suppression of cardiac autophagy, and activation of BC6ENTC - activated protein kinase ( BC6ENTG ) restores cardiac autophagy and prevents cardiomyopathy in diabetic mice, albeit by an unknown mechanism.	False
 BC6ENTC sequence of the gene for BC6ENTG ( BC6OTHER ).	False
 BC6ENTC sequence of the gene for BC6OTHER ( BC6ENTG ).	False
The two active sites of dimeric BC6ENTG ( BC6OTHER ), a BC6OTHER ( BC6ENTC ) - dependent enzyme, are located on the subunit interface with contribution of essential BC6OTHER from each subunit.	False
The two active sites of dimeric BC6OTHER synthase ( BC6ENTG ), a BC6OTHER ( BC6ENTC ) - dependent enzyme, are located on the subunit interface with contribution of essential BC6OTHER from each subunit.	False
Transient kinetic analysis of the formation and decay of the BC6ENTC intermediate EQ(2) indicated that, although their rates were similar in BC6ENTG and BC6OTHER , accumulation of this intermediate was greater in the BC6OTHER - catalyzed reaction.	False
Transient kinetic analysis of the formation and decay of the BC6ENTC intermediate EQ(2) indicated that, although their rates were similar in BC6OTHER and BC6ENTG , accumulation of this intermediate was greater in the BC6OTHER - catalyzed reaction.	False
Transient kinetic analysis of the formation and decay of the BC6ENTC intermediate EQ(2) indicated that, although their rates were similar in BC6OTHER and BC6OTHER , accumulation of this intermediate was greater in the BC6ENTG - catalyzed reaction.	False
Collectively, these results suggest that BC6ENTC is the active form of the coenzyme and forms a more prominent coenzyme structure in BC6ENTG than in BC6OTHER at pH approximately 7.5.	False
Collectively, these results suggest that BC6ENTC is the active form of the coenzyme and forms a more prominent coenzyme structure in BC6OTHER than in BC6ENTG at pH approximately 7.5.	False
The two active sites of dimeric BC6ENTG ( BC6OTHER ), a BC6OTHER ( BC6OTHER ) - dependent enzyme, are located on the subunit interface with contribution of essential BC6ENTC from each subunit.	False
The two active sites of dimeric BC6OTHER synthase ( BC6ENTG ), a BC6OTHER ( BC6OTHER ) - dependent enzyme, are located on the subunit interface with contribution of essential BC6ENTC from each subunit.	False
The two active sites of dimeric BC6ENTC synthase ( BC6ENTG ), a BC6OTHER ( BC6OTHER ) - dependent enzyme, are located on the subunit interface with contribution of essential BC6OTHER from each subunit.	False
The two active sites of dimeric BC6ENTG ( BC6OTHER ), a BC6ENTC ( BC6OTHER ) - dependent enzyme, are located on the subunit interface with contribution of essential BC6OTHER from each subunit.	False
The two active sites of dimeric BC6OTHER synthase ( BC6ENTG ), a BC6ENTC ( BC6OTHER ) - dependent enzyme, are located on the subunit interface with contribution of essential BC6OTHER from each subunit.	False
 BC6ENTG mediated hemodynamic profile of BC6ENTC .	False
We show that the expression of BC6ENTG is induced in response to BC6ENTC in MCF - 7 cells and that the induction is mediated by BC6OTHER - regulated enhancers located distally upstream from the gene.	CPR:3
We show that the expression of BC6OTHER is induced in response to BC6ENTC in MCF - 7 cells and that the induction is mediated by BC6ENTG - regulated enhancers located distally upstream from the gene.	CPR:3
In sum, identification of BC6ENTG as an BC6OTHER target gene adds a novel potential mechanism by which BC6ENTC can contribute to breast cancer cell proliferation and carcinogenesis.	False
In sum, identification of BC6OTHER as an BC6ENTG target gene adds a novel potential mechanism by which BC6ENTC can contribute to breast cancer cell proliferation and carcinogenesis.	False
 BC6ENTG BC6OTHER is a novel BC6ENTC receptor target associating with high grade breast tumors.	False
 BC6OTHER BC6ENTG is a novel BC6ENTC receptor target associating with high grade breast tumors.	False
We present our studies to demonstrate that BC6OTHER , but not BC6OTHER , binds BC6ENTC at high affinities and effectively mediates BC6ENTG signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing BC6OTHER .	CPR:3
We present our studies to demonstrate that BC6OTHER , but not BC6OTHER , binds BC6ENTC at high affinities and effectively mediates BC6OTHER signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing BC6ENTG .	False
We present our studies to demonstrate that BC6ENTG , but not BC6OTHER , binds BC6ENTC at high affinities and effectively mediates BC6OTHER signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing BC6OTHER .	False
We present our studies to demonstrate that BC6OTHER , but not BC6ENTG , binds BC6ENTC at high affinities and effectively mediates BC6OTHER signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing BC6OTHER .	False
A BC6ENTG to BC6ENTC ( BC6OTHER ) was identified recently but the physiological / pharmacological role of the receptor remains poorly defined.	False
A BC6ENTG to BC6OTHER ( BC6ENTC ) was identified recently but the physiological / pharmacological role of the receptor remains poorly defined.	False
Furthermore, BC6ENTG , but not BC6OTHER , expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by BC6ENTC .	False
Furthermore, BC6OTHER , but not BC6ENTG , expressed in differentiated 3T3L1 adipocytes effectively mediated inhibition of lipolysis by BC6ENTC .	False
Our results provided direct evidence indicating that BC6ENTG , but not BC6OTHER , was sufficient to mediate anti - lipolytic effect of BC6ENTC in adipose tissue.	False
Our results provided direct evidence indicating that BC6OTHER , but not BC6ENTG , was sufficient to mediate anti - lipolytic effect of BC6ENTC in adipose tissue.	False
 BC6ENTC mediates lipolysis in adipose tissue through its BC6ENTG .	False
BC6ENTG phosphorylates BC6OTHER at BC6ENTC - 26 ( BC6OTHER 26) and primes it for inactivation.	False
BC6OTHER phosphorylates BC6ENTG at BC6ENTC - 26 ( BC6OTHER 26) and primes it for inactivation.	False
BC6ENTG phosphorylates BC6OTHER at BC6OTHER - 26 ( BC6ENTC 26) and primes it for inactivation.	False
BC6OTHER phosphorylates BC6ENTG at BC6OTHER - 26 ( BC6ENTC 26) and primes it for inactivation.	False
Elimination of BC6ENTC 26 phosphorylation promotes BC6ENTG proapoptotic activity, thereby accelerating BC6OTHER - induced apoptosis in cultured cells and increasing mortality in animals.	False
Elimination of BC6ENTC 26 phosphorylation promotes BC6OTHER proapoptotic activity, thereby accelerating BC6ENTG - induced apoptosis in cultured cells and increasing mortality in animals.	False
The use of a combination of a BC6ENTC BC6ENTG receptor antagonist, BC6OTHER and a BC6OTHER antagonist has significantly improved the control of acute and delayed emesis in single - day chemotherapy.	False
The use of a combination of a BC6ENTC BC6OTHER receptor antagonist, BC6OTHER and a BC6ENTG antagonist has significantly improved the control of acute and delayed emesis in single - day chemotherapy.	False
The use of a combination of a BC6OTHER BC6ENTG receptor antagonist, BC6ENTC and a BC6OTHER antagonist has significantly improved the control of acute and delayed emesis in single - day chemotherapy.	False
The use of a combination of a BC6OTHER BC6OTHER receptor antagonist, BC6ENTC and a BC6ENTG antagonist has significantly improved the control of acute and delayed emesis in single - day chemotherapy.	False
BC6ENTC , a second - generation BC6ENTG receptor antagonist with a different half - life, a different binding capacity and a different mechanism of action than the first - generation BC6OTHER receptor antagonists appears to be the most effective agent in its class.	CPR:6
BC6ENTC , a second - generation BC6OTHER receptor antagonist with a different half - life, a different binding capacity and a different mechanism of action than the first - generation BC6ENTG receptor antagonists appears to be the most effective agent in its class.	False
BC6ENTC , the first and only agent clinically available in the BC6ENTG antagonist drug class has been used effectively as an additive agent to the BC6OTHER receptor antagonists and BC6OTHER to control CINV.	CPR:6
BC6ENTC , the first and only agent clinically available in the BC6OTHER antagonist drug class has been used effectively as an additive agent to the BC6ENTG receptor antagonists and BC6OTHER to control CINV.	False
BC6OTHER , the first and only agent clinically available in the BC6ENTG antagonist drug class has been used effectively as an additive agent to the BC6OTHER receptor antagonists and BC6ENTC to control CINV.	False
BC6OTHER , the first and only agent clinically available in the BC6OTHER antagonist drug class has been used effectively as an additive agent to the BC6ENTG receptor antagonists and BC6ENTC to control CINV.	False
BC6ENTC and BC6OTHER are other BC6ENTG antagonists that are currently in phase III clinical trials.	CPR:6
BC6OTHER and BC6ENTC are other BC6ENTG antagonists that are currently in phase III clinical trials.	CPR:6
To further investigate this positive correlation and its possible therapeutic implications, a selective BC6ENTG inhibitor, BC6ENTC , was tested on three variants of HT - 29 colon cancer cell lines, HT - 29 / Inv1, HT - 29 / Inv2 and HT - 29 / Inv3, with graded increases of in vitro Matrigel invasive potential and BC6OTHER expression levels.	CPR:4
To further investigate this positive correlation and its possible therapeutic implications, a selective BC6OTHER inhibitor, BC6ENTC , was tested on three variants of HT - 29 colon cancer cell lines, HT - 29 / Inv1, HT - 29 / Inv2 and HT - 29 / Inv3, with graded increases of in vitro Matrigel invasive potential and BC6ENTG expression levels.	False
These data indicate that BC6ENTC could improve glycemic control without its use resulting in BC6ENTG secretion, hypoglycemia, and body weight gain, and may provide a unique approach to the treatment of diabetes.	False
The low - affinity BC6ENTC BC6OTHER cotransporter ( BC6ENTG ) is responsible for most of the BC6OTHER reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	False
We discovered BC6ENTC , a novel selective BC6ENTG inhibitor, and found that selective inhibition of BC6OTHER increased urinary BC6OTHER excretion and consequently decreased plasma BC6OTHER levels.	CPR:4
We discovered BC6ENTC , a novel selective BC6OTHER inhibitor, and found that selective inhibition of BC6ENTG increased urinary BC6OTHER excretion and consequently decreased plasma BC6OTHER levels.	CPR:4
The low - affinity CHEM BC6ENTC cotransporter ( BC6ENTG ) is responsible for most of the BC6OTHER reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	False
We discovered BC6OTHER , a novel selective BC6ENTG inhibitor, and found that selective inhibition of BC6OTHER increased urinary BC6ENTC excretion and consequently decreased plasma BC6OTHER levels.	False
We discovered BC6OTHER , a novel selective BC6OTHER inhibitor, and found that selective inhibition of BC6ENTG increased urinary BC6ENTC excretion and consequently decreased plasma BC6OTHER levels.	False
We discovered BC6OTHER , a novel selective BC6ENTG inhibitor, and found that selective inhibition of BC6OTHER increased urinary BC6OTHER excretion and consequently decreased plasma BC6ENTC levels.	False
We discovered BC6OTHER , a novel selective BC6OTHER inhibitor, and found that selective inhibition of BC6ENTG increased urinary BC6OTHER excretion and consequently decreased plasma BC6ENTC levels.	False
In this report, we examined the antihyperglycemic effects of BC6ENTC in normal and diabetic rats in comparison with those of a BC6OTHER ( BC6OTHER ) and an BC6ENTG inhibitor ( BC6OTHER ).	False
In this report, we examined the antihyperglycemic effects of BC6OTHER in normal and diabetic rats in comparison with those of a BC6ENTC ( BC6OTHER ) and an BC6ENTG inhibitor ( BC6OTHER ).	False
In this report, we examined the antihyperglycemic effects of BC6OTHER in normal and diabetic rats in comparison with those of a BC6OTHER ( BC6ENTC ) and an BC6ENTG inhibitor ( BC6OTHER ).	False
In this report, we examined the antihyperglycemic effects of BC6OTHER in normal and diabetic rats in comparison with those of a BC6OTHER ( BC6OTHER ) and an BC6ENTG inhibitor ( BC6ENTC ).	CPR:4
BC6ENTC increased urinary BC6OTHER excretion in a dose - dependent manner, and inhibited the increase in plasma BC6OTHER after BC6OTHER loading independently of BC6ENTG secretion in normal rats.	False
BC6OTHER increased urinary BC6ENTC excretion in a dose - dependent manner, and inhibited the increase in plasma BC6OTHER after BC6OTHER loading independently of BC6ENTG secretion in normal rats.	False
BC6OTHER increased urinary BC6OTHER excretion in a dose - dependent manner, and inhibited the increase in plasma BC6ENTC after BC6OTHER loading independently of BC6ENTG secretion in normal rats.	False
BC6OTHER increased urinary BC6OTHER excretion in a dose - dependent manner, and inhibited the increase in plasma BC6OTHER after BC6ENTC loading independently of BC6ENTG secretion in normal rats.	False
The low - affinity BC6ENTG ( BC6OTHER ) is responsible for most of the BC6ENTC reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	CPR:9
The low - affinity CHEM BC6OTHER cotransporter ( BC6ENTG ) is responsible for most of the BC6ENTC reabsorption in the kidney and has been highlighted as a novel therapeutic target for the treatment of diabetes.	CPR:9
 BC6ENTC , a selective BC6ENTG inhibitor, improves glycemic control in BC6OTHER - induced diabetic rats and Zucker CHEM.	CPR:4
 BC6OTHER , a selective BC6ENTG inhibitor, improves glycemic control in BC6ENTC - induced diabetic rats and Zucker CHEM.	False
Chronic treatment with BC6ENTC reduced the levels of BC6ENTG and fasting plasma BC6OTHER , and improved the glycemic response after BC6OTHER loading in Zucker CHEM.	CPR:4
Chronic treatment with BC6OTHER reduced the levels of BC6ENTG and fasting plasma BC6ENTC , and improved the glycemic response after BC6OTHER loading in Zucker CHEM.	False
Chronic treatment with BC6OTHER reduced the levels of BC6ENTG and fasting plasma BC6OTHER , and improved the glycemic response after BC6ENTC loading in Zucker CHEM.	False
Several variables associated to BC6ENTG ( BC6OTHER ), the biological target of BC6OTHER ( BC6ENTC ) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	False
Several variables associated to BC6OTHER synthase ( BC6ENTG ), the biological target of BC6OTHER ( BC6ENTC ) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	False
Low BC6ENTG expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression - free survival (PFS) in patients treated with BC6ENTC .	CPR:4
Several variables associated to BC6ENTC synthase ( BC6ENTG ), the biological target of BC6OTHER ( BC6OTHER ) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	False
Several variables associated to BC6ENTG ( BC6OTHER ), the biological target of BC6ENTC ( BC6OTHER ) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	False
Several variables associated to BC6OTHER synthase ( BC6ENTG ), the biological target of BC6ENTC ( BC6OTHER ) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients.	False
 BC6ENTG expression pattern, expression level and single BC6OTHER polymorphism are predictors for disease - free survival in patients of colorectal cancer treated with BC6ENTC .	False
 BC6ENTG expression pattern, expression level and single BC6ENTC polymorphism are predictors for disease - free survival in patients of colorectal cancer treated with BC6OTHER .	False
The high fat diet significantly increased hepatic mRNA expressions of BC6ENTG , BC6OTHER and BC6OTHER genes in comparison to the control diet, which was subsequently reversed by supplementation with BC6ENTC .	CPR:4
The high fat diet significantly increased hepatic mRNA expressions of BC6OTHER , BC6ENTG and BC6OTHER genes in comparison to the control diet, which was subsequently reversed by supplementation with BC6ENTC .	CPR:4
The high fat diet significantly increased hepatic mRNA expressions of BC6OTHER , BC6OTHER and BC6ENTG genes in comparison to the control diet, which was subsequently reversed by supplementation with BC6ENTC .	CPR:4
In addition, BC6ENTC supplementation significantly reduced hepatic mRNA abundance of BC6ENTG , BC6OTHER and BC6OTHER compared to the control group.	CPR:4
In addition, BC6ENTC supplementation significantly reduced hepatic mRNA abundance of BC6OTHER , BC6ENTG and BC6OTHER compared to the control group.	CPR:4
In addition, BC6ENTC supplementation significantly reduced hepatic mRNA abundance of BC6OTHER , BC6OTHER and BC6ENTG compared to the control group.	CPR:4
Finally, epididymal mRNA abundance of BC6ENTG was significantly increased by BC6ENTC supplementation, compared to levels in the control and HF groups.	CPR:3
Enhancement of BC6ENTG expression by BC6ENTC was further confirmed in differentiated 3T3 - L1 adipocytes.	CPR:3
Here, we show that oral administration of BC6ENTC , which leads to activation of an BC6ENTG , suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in BC6OTHER - deficient mdx mice.	CPR:3
Here, we show that oral administration of BC6ENTC , which leads to activation of an BC6OTHER - dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in BC6ENTG - deficient mdx mice.	False
Here, we show that oral administration of BC6OTHER , which leads to activation of an BC6ENTC - dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in BC6ENTG - deficient mdx mice.	False
The pro - hypertrophic co - activator BC6ENTG protein but not BC6OTHER mRNA was up - regulated in the mdx heart, and BC6ENTC administration down - regulated the BC6OTHER protein level.	False
The pro - hypertrophic co - activator BC6OTHER protein but not BC6ENTG mRNA was up - regulated in the mdx heart, and BC6ENTC administration down - regulated the BC6OTHER protein level.	False
The pro - hypertrophic co - activator BC6OTHER protein but not BC6OTHER mRNA was up - regulated in the mdx heart, and BC6ENTC administration down - regulated the BC6ENTG protein level.	CPR:4
In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1) - agonist BC6ENTC was inhibited by the overexpression of BC6ENTG as well as BC6OTHER , both of which down - regulated BC6OTHER protein levels but not BC6OTHER mRNA levels.	False
In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1) - agonist BC6ENTC was inhibited by the overexpression of BC6OTHER as well as BC6OTHER , both of which down - regulated BC6ENTG protein levels but not BC6OTHER mRNA levels.	False
In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1) - agonist BC6ENTC was inhibited by the overexpression of BC6OTHER as well as BC6OTHER , both of which down - regulated BC6OTHER protein levels but not BC6ENTG mRNA levels.	False
In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1) - agonist BC6OTHER was inhibited by the overexpression of BC6ENTG as well as BC6ENTC , both of which down - regulated BC6OTHER protein levels but not BC6OTHER mRNA levels.	False
In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1) - agonist BC6OTHER was inhibited by the overexpression of BC6OTHER as well as BC6ENTC , both of which down - regulated BC6ENTG protein levels but not BC6OTHER mRNA levels.	CPR:4
In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1) - agonist BC6OTHER was inhibited by the overexpression of BC6OTHER as well as BC6ENTC , both of which down - regulated BC6OTHER protein levels but not BC6ENTG mRNA levels.	False
We found that BC6ENTG induced BC6OTHER down - regulation via the BC6OTHER - BC6OTHER pathway by deacetylation of BC6ENTC residues for ubiquitination.	False
We found that BC6OTHER induced BC6ENTG down - regulation via the BC6OTHER - BC6OTHER pathway by deacetylation of BC6ENTC residues for ubiquitination.	False
We found that BC6OTHER induced BC6OTHER down - regulation via the BC6ENTG - BC6OTHER pathway by deacetylation of BC6ENTC residues for ubiquitination.	False
We found that BC6OTHER induced BC6OTHER down - regulation via the BC6OTHER - BC6ENTG pathway by deacetylation of BC6ENTC residues for ubiquitination.	False
 BC6ENTC improves cardiomyopathy in BC6OTHER - deficient mice through BC6OTHER protein - mediated modulation of BC6ENTG protein.	False
 BC6ENTC improves cardiomyopathy in BC6ENTG - deficient mice through BC6OTHER protein - mediated modulation of BC6OTHER protein.	False
 BC6ENTC improves cardiomyopathy in BC6OTHER - deficient mice through BC6ENTG protein - mediated modulation of BC6OTHER protein.	False
Despite the importance of BC6ENTG *28 in BC6ENTC pharmacogenetics, our capability to predict drug - induced severe toxicity remains limited.	False
Refining the BC6ENTG haplotype associated with BC6OTHER - induced hematological toxicity in metastatic colorectal cancer patients treated with BC6ENTC / BC6OTHER - based regimens.	False
Refining the BC6ENTG haplotype associated with BC6OTHER - induced hematological toxicity in metastatic colorectal cancer patients treated with BC6OTHER / BC6ENTC - based regimens.	False
Refining the BC6ENTG haplotype associated with BC6ENTC - induced hematological toxicity in metastatic colorectal cancer patients treated with BC6OTHER / BC6OTHER - based regimens.	False
Our results suggest that specific SNPs in BC6ENTG , other than BC6OTHER *28, may influence BC6ENTC toxicity and should be considered to refine pharmacogenetic testing.	False
Our results suggest that specific SNPs in BC6OTHER , other than BC6ENTG *28, may influence BC6ENTC toxicity and should be considered to refine pharmacogenetic testing.	False
A catheterized rat model was used to define the intestinal and hepatic components of oral bioavailability for an BC6ENTG inhibitor, BC6ENTC .	CPR:4
Intestinal and hepatic first - pass extraction of the BC6ENTG inhibitor BC6ENTC in rats with chronic vascular catheters.	CPR:4
The obtained results showed that BC6ENTC increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	CPR:4
The obtained results showed that BC6ENTC increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	CPR:4
The obtained results showed that BC6ENTC increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	CPR:4
The obtained results showed that BC6ENTC increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	CPR:4
The obtained results showed that BC6ENTC increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTG ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	CPR:4
The obtained results showed that BC6ENTC increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6ENTG ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	CPR:4
The obtained results showed that BC6ENTC increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6ENTG activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	CPR:4
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTG ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6ENTG ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6ENTG activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTC dehydrogenase, BC6ENTG , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTC dehydrogenase, BC6OTHER , BC6ENTG and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTC dehydrogenase, BC6OTHER , BC6OTHER and BC6ENTG : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTC dehydrogenase, BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTG ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTC dehydrogenase, BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6ENTG ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTC dehydrogenase, BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6ENTG activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTC dehydrogenase ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER : BC6ENTC dehydrogenase ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER : BC6ENTC dehydrogenase ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG : BC6ENTC dehydrogenase ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTC dehydrogenase ( BC6ENTG ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTC dehydrogenase ( BC6OTHER ), BC6ENTG activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6ENTC and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6ENTC and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6ENTC and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6ENTC and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTG ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6ENTC and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6ENTG ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6ENTC and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6ENTG activities as well as epididymal sperm counts and motility, while BC6ENTC and BC6OTHER treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6ENTC treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6ENTC treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6ENTC treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG : BC6OTHER ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6ENTC treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6ENTG ( BC6OTHER ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6ENTC treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6ENTG ), BC6OTHER activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6ENTC treatment reversed this change to control values.	False
The obtained results showed that BC6OTHER increased lipid peroxidation and abnormal sperm count and decreased plasma BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : BC6OTHER ( BC6OTHER ), BC6ENTG activities as well as epididymal sperm counts and motility, while BC6OTHER and BC6ENTC treatment reversed this change to control values.	False
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6ENTG )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	CPR:4
Acute intoxication with BC6ENTC was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER )).	CPR:4
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC - Px), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC - Px), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC - Px), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC - Px), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6ENTC - Px), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6ENTC - Px), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC - Px), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC - Px), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC - Px), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC reductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC ( BC6OTHER ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), and BC6ENTG ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6ENTC ), and CHEM - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6ENTG ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6ENTC - BC6OTHER - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6ENTG )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Acute intoxication with BC6OTHER was also followed by significantly decreased activity of the antioxidant defence system ( BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and CHEM - BC6ENTC - transferase ( BC6OTHER )).	False
Stenesen and colleagues (2012) activate BC6ENTG both directly and indirectly by altering BC6ENTC biosynthesis to slow aging in Drosophila, highlighting BC6OTHER as a conserved life span modulator that links energy sensing to longevity.	False
Stenesen and colleagues (2012) activate BC6OTHER both directly and indirectly by altering BC6ENTC biosynthesis to slow aging in Drosophila, highlighting BC6ENTG as a conserved life span modulator that links energy sensing to longevity.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTC analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	CPR:5
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6ENTC ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTC agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	CPR:5
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6ENTC , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	CPR:5
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	CPR:5
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6ENTC ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6ENTC ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	CPR:6
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6ENTC BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6ENTC BC6ENTG antagonist) are also in clinical use.	CPR:6
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6ENTC antagonist) are also in clinical use.	False
 While a number of orally active non - peptide BC6ENTG antagonists (Vaptans); notably, BC6ENTC , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6OTHER , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6ENTC , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6ENTG / BC6OTHER , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6ENTC , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6ENTG , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
BC6ENTC ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTG (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTG BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6ENTG (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6ENTG (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6ENTG (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTG BC6OTHER ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6ENTG ?	False
BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
 While a number of orally active non - peptide BC6ENTG antagonists (Vaptans); notably, BC6OTHER , BC6ENTC and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6OTHER , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6ENTC and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6ENTG / BC6OTHER , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6ENTC and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6ENTG , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
 While a number of orally active non - peptide BC6ENTG antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6ENTC , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6OTHER , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6ENTC , are currently in Phase III clinical trials; to date, only the mixed BC6ENTG / BC6OTHER , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6ENTC , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6ENTG , antagonist BC6OTHER ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
BC6ENTG ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTG ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTG (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTG BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6ENTG (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6ENTG (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6ENTG (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTG BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6ENTG ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6ENTG ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
 While a number of orally active non - peptide BC6ENTG antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6OTHER , antagonist BC6ENTC ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6ENTG / BC6OTHER , antagonist BC6ENTC ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6ENTG , antagonist BC6ENTC ( BC6OTHER ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
 While a number of orally active non - peptide BC6ENTG antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6OTHER , antagonist BC6OTHER ( BC6ENTC ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	False
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6ENTG / BC6OTHER , antagonist BC6OTHER ( BC6ENTC ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
 While a number of orally active non - peptide BC6OTHER antagonists (Vaptans); notably, BC6OTHER , BC6OTHER and BC6OTHER , are currently in Phase III clinical trials; to date, only the mixed BC6OTHER / BC6ENTG , antagonist BC6OTHER ( BC6ENTC ), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.	CPR:6
Promising new non - peptide BC6ENTG and BC6ENTC antagonists, as well as non - peptide BC6OTHER and BC6OTHER agonists are now in pre - clinical development.	False
Promising new non - peptide BC6OTHER and BC6ENTC antagonists, as well as non - peptide BC6ENTG and BC6OTHER agonists are now in pre - clinical development.	False
Promising new non - peptide BC6OTHER and BC6ENTC antagonists, as well as non - peptide BC6OTHER and BC6ENTG agonists are now in pre - clinical development.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTG (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTG BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6ENTG (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6ENTG (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6ENTG (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6ENTG ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTC BC6OTHER ?	False
Promising new non - peptide BC6ENTG and BC6OTHER antagonists, as well as non - peptide BC6OTHER and BC6ENTC agonists are now in pre - clinical development.	False
Promising new non - peptide BC6OTHER and BC6ENTG antagonists, as well as non - peptide BC6OTHER and BC6ENTC agonists are now in pre - clinical development.	False
Promising new non - peptide BC6OTHER and BC6OTHER antagonists, as well as non - peptide BC6ENTG and BC6ENTC agonists are now in pre - clinical development.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6ENTG (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTG BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6ENTG (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6ENTG (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6ENTG (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTG BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6ENTG ?	False
The pharmacological properties of promising new selective BC6ENTC antagonists and BC6ENTG agonists are also presented.	False
BC6ENTG ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTG (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTG BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6ENTG (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6ENTG (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6ENTG (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6ENTG ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTG BC6OTHER ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6ENTG ?	False
BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6ENTG ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
The current status of non - peptide BC6ENTC and BC6ENTG antagonists and agonists is also summarized.	False
The current status of non - peptide BC6ENTG and BC6ENTC antagonists and agonists is also summarized.	False
The relative merits of peptide and non - peptide BC6ENTC and BC6ENTG agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	False
The relative merits of peptide and non - peptide BC6ENTG and BC6ENTC agonists and antagonists as: (1) research tools and (2) therapeutic agents will be evaluated.	False
Peptide and non - peptide agonists and antagonists for the BC6ENTC and BC6ENTG BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6ENTC and BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6ENTC and BC6OTHER BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6ENTC and BC6OTHER BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6ENTC and BC6OTHER BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6ENTG and BC6ENTC BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6ENTC BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6ENTC BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6ENTC BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6ENTC BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG : research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6ENTG and BC6OTHER BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC receptors: research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6ENTG BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC receptors: research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6OTHER BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC receptors: research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6OTHER BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC receptors: research tools and potential therapeutic agents.	False
Peptide and non - peptide agonists and antagonists for the BC6OTHER and BC6OTHER BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC receptors: research tools and potential therapeutic agents.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6ENTG BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6ENTG (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6ENTG (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6ENTG (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTG BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6ENTG ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) mediate their biological actions by acting on four known receptors: The BC6ENTC (uterine) and the BC6OTHER BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of BC6ENTC and BC6ENTG than their non - peptide counterparts.	False
Many of the receptor selective peptide agonists and antagonists from this and other laboratories are far more widely used as pharmacological tools for studies on the peripheral and central effects of BC6ENTG and BC6ENTC than their non - peptide counterparts.	False
BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6ENTG (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6ENTG (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6ENTG (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6ENTG (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6ENTG BC6OTHER ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6ENTG ?	False
BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) mediate their biological actions by acting on four known receptors: The BC6OTHER (uterine) and the BC6ENTC BC6OTHER (vasopressor), BC6OTHER (pituitary), BC6OTHER (renal) receptors and a fifth putative BC6OTHER BC6OTHER ?	False
In addition to BC6ENTC and to a lesser extent BC6ENTG (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6ENTC and to a lesser extent BC6OTHER (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6ENTG and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTC (CHEM), a number of BC6OTHER and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
In addition to BC6ENTG and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6ENTG (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6ENTG analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6ENTG agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6ENTG ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist) and BC6OTHER ( BC6OTHER BC6OTHER antagonist) are also in clinical use.	False
In addition to BC6OTHER and to a lesser extent BC6OTHER (CHEM), a number of BC6ENTC and BC6OTHER analogues; such as BC6OTHER ( BC6OTHER agonist) dD BC6OTHER ( BC6OTHER , BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist) and BC6OTHER ( BC6OTHER BC6ENTG antagonist) are also in clinical use.	False
Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of BC6ENTG BC6OTHER and BC6OTHER in rat kidney in response to BC6ENTC treatment.	False
Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of BC6OTHER BC6ENTG and BC6OTHER in rat kidney in response to BC6ENTC treatment.	False
Quantitative polymerase chain reaction, western blotting, immunohistochemical analysis and immunofluorescence were used to determine the changes in the expression of BC6OTHER BC6OTHER and BC6ENTG in rat kidney in response to BC6ENTC treatment.	False
Inhibitory effect of BC6ENTC on excretion of BC6OTHER via BC6ENTG in rats.	False
Inhibitory effect of BC6OTHER on excretion of BC6ENTC via BC6ENTG in rats.	False
Moreover, BC6ENTC decreased expression of BC6ENTG and BC6OTHER in rat kidney.	CPR:4
Moreover, BC6ENTC decreased expression of BC6OTHER and BC6ENTG in rat kidney.	CPR:4
The mechanism of interaction between BC6ENTC and BC6OTHER could be explained at least in part by inhibitory effect of BC6OTHER on expression of BC6ENTG in rat kidney.	False
The mechanism of interaction between BC6OTHER and BC6ENTC could be explained at least in part by inhibitory effect of BC6OTHER on expression of BC6ENTG in rat kidney.	False
The mechanism of interaction between BC6OTHER and BC6OTHER could be explained at least in part by inhibitory effect of BC6ENTC on expression of BC6ENTG in rat kidney.	CPR:4
Cell culture studies demonstrated that BC6ENTC is capable of delivering anti - BC6OTHER BC6OTHER siRNA to lipopolysaccharide (LPS) - stimulated macrophages and significantly inhibits the expression of BC6ENTG .	CPR:4
Cell culture studies demonstrated that BC6ENTC is capable of delivering anti - BC6ENTG BC6OTHER siRNA to lipopolysaccharide (LPS) - stimulated macrophages and significantly inhibits the expression of BC6OTHER .	False
Cell culture studies demonstrated that BC6ENTC is capable of delivering anti - BC6OTHER BC6ENTG siRNA to lipopolysaccharide (LPS) - stimulated macrophages and significantly inhibits the expression of BC6OTHER .	False
BC6ENTC / anti - BC6ENTG siRNA nanocomplexes significantly reduced the BC6OTHER ( BC6OTHER transaminase) and the hepatic cellular damages in BC6OTHER - intoxicated mice.	False
BC6ENTC / anti - BC6OTHER siRNA nanocomplexes significantly reduced the BC6ENTG ( BC6OTHER transaminase) and the hepatic cellular damages in BC6OTHER - intoxicated mice.	CPR:4
BC6ENTC / anti - BC6OTHER siRNA nanocomplexes significantly reduced the BC6OTHER ( BC6ENTG ) and the hepatic cellular damages in BC6OTHER - intoxicated mice.	CPR:4
BC6OTHER / anti - BC6ENTG siRNA nanocomplexes significantly reduced the BC6OTHER ( BC6ENTC transaminase) and the hepatic cellular damages in BC6OTHER - intoxicated mice.	False
BC6OTHER / anti - BC6OTHER siRNA nanocomplexes significantly reduced the BC6ENTG ( BC6ENTC transaminase) and the hepatic cellular damages in BC6OTHER - intoxicated mice.	False
BC6OTHER / anti - BC6ENTG siRNA nanocomplexes significantly reduced the BC6OTHER ( BC6OTHER transaminase) and the hepatic cellular damages in BC6ENTC - intoxicated mice.	False
BC6OTHER / anti - BC6OTHER siRNA nanocomplexes significantly reduced the BC6ENTG ( BC6OTHER transaminase) and the hepatic cellular damages in BC6ENTC - intoxicated mice.	False
BC6OTHER / anti - BC6OTHER siRNA nanocomplexes significantly reduced the BC6OTHER ( BC6ENTG ) and the hepatic cellular damages in BC6ENTC - intoxicated mice.	False
A model of the BC6ENTG was used to study the receptor interactions of BC6OTHER , the typical antipsychotics BC6ENTC and BC6OTHER , and the atypical antipsychotics BC6OTHER and BC6OTHER .	False
A model of the BC6ENTG was used to study the receptor interactions of BC6OTHER , the typical antipsychotics BC6OTHER and BC6ENTC , and the atypical antipsychotics BC6OTHER and BC6OTHER .	False
A model of the BC6ENTG was used to study the receptor interactions of BC6OTHER , the typical antipsychotics BC6OTHER and BC6OTHER , and the atypical antipsychotics BC6ENTC and BC6OTHER .	False
A model of the BC6ENTG was used to study the receptor interactions of BC6OTHER , the typical antipsychotics BC6OTHER and BC6OTHER , and the atypical antipsychotics BC6OTHER and BC6ENTC .	False
A model of the BC6ENTG was used to study the receptor interactions of BC6ENTC , the typical antipsychotics BC6OTHER and BC6OTHER , and the atypical antipsychotics BC6OTHER and BC6OTHER .	False
The BC6ENTC - dependent drug efflux pump BC6OTHER ( BC6ENTG ) affects the absorption and disposition of many compounds.	False
The BC6ENTC - dependent drug efflux pump BC6ENTG ( BC6OTHER ) affects the absorption and disposition of many compounds.	False
The assays included in BC6ENTC predictions, inhibition assays (based on cellular uptake of BC6OTHER or BC6OTHER ), and functional assays ( BC6ENTG activity assay and transcellular transport assay, the latter for a subset of compounds).	False
The assays included in BC6OTHER predictions, inhibition assays (based on cellular uptake of BC6ENTC or BC6OTHER ), and functional assays ( BC6ENTG activity assay and transcellular transport assay, the latter for a subset of compounds).	False
The assays included in BC6OTHER predictions, inhibition assays (based on cellular uptake of BC6OTHER or BC6ENTC ), and functional assays ( BC6ENTG activity assay and transcellular transport assay, the latter for a subset of compounds).	False
Herein we report novel BC6OTHER - and BC6OTHER - based BC6OTHER (8, 10) and BC6OTHER (9, 11) bearing the BC6ENTC group at the CAP moiety as BC6ENTG ( BC6OTHER ) inhibitors.	CPR:4
Herein we report novel BC6OTHER - and BC6OTHER - based BC6OTHER (8, 10) and BC6OTHER (9, 11) bearing the BC6ENTC group at the CAP moiety as BC6OTHER ( BC6ENTG ) inhibitors.	CPR:4
Herein we report novel BC6ENTC - and BC6OTHER - based BC6OTHER (8, 10) and BC6OTHER (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6ENTG ( BC6OTHER ) inhibitors.	CPR:4
Herein we report novel BC6ENTC - and BC6OTHER - based BC6OTHER (8, 10) and BC6OTHER (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6OTHER ( BC6ENTG ) inhibitors.	CPR:4
Compounds 8 b and 10 c selectively inhibited BC6ENTG at the nanomolar level, whereas the other BC6ENTC effected an increase in BC6OTHER levels in human acute myeloid leukemia U937 cells.	False
Compounds 8 b and 10 c selectively inhibited BC6OTHER at the nanomolar level, whereas the other BC6ENTC effected an increase in BC6ENTG levels in human acute myeloid leukemia U937 cells.	CPR:3
Herein we report novel BC6OTHER - and BC6ENTC - based BC6OTHER (8, 10) and BC6OTHER (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6ENTG ( BC6OTHER ) inhibitors.	CPR:4
Herein we report novel BC6OTHER - and BC6ENTC - based BC6OTHER (8, 10) and BC6OTHER (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6OTHER ( BC6ENTG ) inhibitors.	CPR:4
Herein we report novel BC6OTHER - and BC6OTHER - based BC6ENTC (8, 10) and BC6OTHER (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6ENTG ( BC6OTHER ) inhibitors.	CPR:4
Herein we report novel BC6OTHER - and BC6OTHER - based BC6ENTC (8, 10) and BC6OTHER (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6OTHER ( BC6ENTG ) inhibitors.	CPR:4
Herein we report novel BC6OTHER - and BC6OTHER - based BC6OTHER (8, 10) and BC6ENTC (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6ENTG ( BC6OTHER ) inhibitors.	CPR:4
Herein we report novel BC6OTHER - and BC6OTHER - based BC6OTHER (8, 10) and BC6ENTC (9, 11) bearing the BC6OTHER group at the CAP moiety as BC6OTHER ( BC6ENTG ) inhibitors.	CPR:4
 BC6ENTC - Containing BC6ENTG Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.	CPR:4
BC6ENTG binding was unchanged by presence of BC6ENTC .	False
Both BC6ENTG isoforms bound BC6ENTC , but the rate of BC6OTHER hydrolysis was very slow (<0.002 s( - 1)) and not significantly enhanced by BC6OTHER .	False
Both BC6OTHER isoforms bound BC6ENTC , but the rate of BC6OTHER hydrolysis was very slow (<0.002 s( - 1)) and not significantly enhanced by BC6ENTG .	False
Both BC6ENTG isoforms bound BC6OTHER , but the rate of BC6ENTC hydrolysis was very slow (<0.002 s( - 1)) and not significantly enhanced by BC6OTHER .	False
Both BC6OTHER isoforms bound BC6OTHER , but the rate of BC6ENTC hydrolysis was very slow (<0.002 s( - 1)) and not significantly enhanced by BC6ENTG .	False
Phosphorylation of the regulatory light chain had no effect on BC6ENTC hydrolysis, and neither did the addition of tropomyosin or of GOLPH3, a BC6ENTG binding partner.	False
Electron microscopy of BC6ENTG - S1 showed that the lever is strongly angled with respect to the long axis of the motor domain, suggesting a pre - power stroke conformation regardless of the presence of BC6ENTC .	False
The BC6ENTG isoform, additionally, has an BC6ENTC - terminal BC6OTHER .	False
The BC6OTHER isoform, additionally, has an BC6ENTC - terminal BC6ENTG .	False
BC6ENTC was a less potent antagonist of tissue responses to BC6OTHER , and the underestimation in the pKB (as compared to that obtained with BC6OTHER ) could be eliminated by prior treatment of tissues with the BC6ENTG inhibitor BC6OTHER .	False
BC6OTHER was a less potent antagonist of tissue responses to BC6ENTC , and the underestimation in the pKB (as compared to that obtained with BC6OTHER ) could be eliminated by prior treatment of tissues with the BC6ENTG inhibitor BC6OTHER .	False
BC6OTHER was a less potent antagonist of tissue responses to BC6OTHER , and the underestimation in the pKB (as compared to that obtained with BC6ENTC ) could be eliminated by prior treatment of tissues with the BC6ENTG inhibitor BC6OTHER .	False
BC6OTHER was a less potent antagonist of tissue responses to BC6OTHER , and the underestimation in the pKB (as compared to that obtained with BC6OTHER ) could be eliminated by prior treatment of tissues with the BC6ENTG inhibitor BC6ENTC .	CPR:4
These data suggested that BC6ENTC had a dual effect on tissue responses to BC6OTHER - producing potentiation by blockade of BC6ENTG and concomitant antagonism by blockade of BC6OTHER .	CPR:4
These data suggested that BC6ENTC had a dual effect on tissue responses to BC6OTHER - producing potentiation by blockade of BC6OTHER and concomitant antagonism by blockade of BC6ENTG .	CPR:6
BC6ENTC is known to be an inhibitor of BC6OTHER , and recent data have shown this drug to antagonize BC6ENTG as well.	CPR:6
BC6ENTC is known to be an inhibitor of BC6ENTG , and recent data have shown this drug to antagonize BC6OTHER as well.	CPR:4
These data suggested that BC6OTHER had a dual effect on tissue responses to BC6ENTC - producing potentiation by blockade of BC6ENTG and concomitant antagonism by blockade of BC6OTHER .	CPR:5
These data suggested that BC6OTHER had a dual effect on tissue responses to BC6ENTC - producing potentiation by blockade of BC6OTHER and concomitant antagonism by blockade of BC6ENTG .	False
Inactivation of BC6ENTG in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of BC6ENTC BC6OTHER into lipids, and biomass accumulation.	False
Inactivation of BC6ENTG in both transformed and nontransformed cells promotes a metabolic shift to aerobic glycolysis, increased allocation of BC6OTHER BC6ENTC into lipids, and biomass accumulation.	False
It has been shown to improve the clinical benefits of BC6OTHER plus an BC6ENTG inhibitor ( BC6OTHER ) when given to patients with Parkinson's disease and end - of - dose deterioration in the response to BC6ENTC (the 'wearing off' phenomenon).	False
It has been shown to improve the clinical benefits of BC6OTHER plus an BC6OTHER decarboxylase inhibitor ( BC6ENTG ) when given to patients with Parkinson's disease and end - of - dose deterioration in the response to BC6ENTC (the 'wearing off' phenomenon).	False
In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with BC6ENTC (200 mg with each dose of BC6OTHER / BC6ENTG inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.	False
UNLABELLED: BC6OTHER is a potent and specific peripheral BC6ENTC - BC6OTHER - methyltransferase ( BC6ENTG ) inhibitor.	False
In 2 well conducted trials of 6 months' duration and smaller short term studies, treatment with BC6OTHER (200 mg with each dose of BC6ENTC / BC6ENTG inhibitor) was associated with significant increases in daily 'on' time and decreases in 'off' time.	False
UNLABELLED: BC6OTHER is a potent and specific peripheral CHEM - BC6ENTC - methyltransferase ( BC6ENTG ) inhibitor.	False
BC6ENTC also provided benefits when given with controlled release BC6OTHER / BC6ENTG inhibitor or with standard BC6OTHER / BC6OTHER inhibitor and BC6OTHER in small trials.	False
BC6ENTC also provided benefits when given with controlled release BC6OTHER / BC6OTHER inhibitor or with standard BC6OTHER / BC6ENTG inhibitor and BC6OTHER in small trials.	False
BC6OTHER also provided benefits when given with controlled release BC6ENTC / BC6ENTG inhibitor or with standard BC6OTHER / BC6OTHER inhibitor and BC6OTHER in small trials.	False
BC6OTHER also provided benefits when given with controlled release BC6ENTC / BC6OTHER inhibitor or with standard BC6OTHER / BC6ENTG inhibitor and BC6OTHER in small trials.	False
BC6OTHER also provided benefits when given with controlled release BC6OTHER / BC6ENTG inhibitor or with standard BC6ENTC / BC6OTHER inhibitor and BC6OTHER in small trials.	False
BC6OTHER also provided benefits when given with controlled release BC6OTHER / BC6OTHER inhibitor or with standard BC6ENTC / BC6ENTG inhibitor and BC6OTHER in small trials.	False
BC6OTHER also provided benefits when given with controlled release BC6OTHER / BC6ENTG inhibitor or with standard BC6OTHER / BC6OTHER inhibitor and BC6ENTC in small trials.	False
BC6OTHER also provided benefits when given with controlled release BC6OTHER / BC6OTHER inhibitor or with standard BC6OTHER / BC6ENTG inhibitor and BC6ENTC in small trials.	False
UNLABELLED: BC6ENTC is a potent and specific peripheral BC6ENTG ( BC6OTHER ) inhibitor.	CPR:4
UNLABELLED: BC6ENTC is a potent and specific peripheral CHEM - BC6OTHER - methyltransferase ( BC6ENTG ) inhibitor.	CPR:4
It has been shown to improve the clinical benefits of BC6ENTC plus an BC6ENTG inhibitor ( BC6OTHER ) when given to patients with Parkinson's disease and end - of - dose deterioration in the response to BC6OTHER (the 'wearing off' phenomenon).	False
It has been shown to improve the clinical benefits of BC6ENTC plus an BC6OTHER decarboxylase inhibitor ( BC6ENTG ) when given to patients with Parkinson's disease and end - of - dose deterioration in the response to BC6OTHER (the 'wearing off' phenomenon).	False
CONCLUSIONS: The efficacy and tolerability of CHEM administered with BC6ENTC / BC6ENTG inhibitor have not yet been compared with those of other strategies for the treatment of Parkinson's disease.	False
It has been shown to improve the clinical benefits of BC6OTHER plus an BC6ENTC decarboxylase inhibitor ( BC6ENTG ) when given to patients with Parkinson's disease and end - of - dose deterioration in the response to BC6OTHER (the 'wearing off' phenomenon).	False
With no BC6ENTC kinases ( BC6ENTG ) play important roles in plant growth and development.	False
Disruption of BC6OTHER Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating BC6ENTC Content and Activities of BC6ENTG and BC6OTHER .	False
Disruption of BC6ENTG Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating BC6ENTC Content and Activities of BC6OTHER and BC6OTHER .	False
Disruption of BC6OTHER Enhances Tolerance of Arabidopsis to Salt and Osmotic Stresses via Modulating BC6ENTC Content and Activities of BC6OTHER and BC6ENTG .	False
Taken together, we revealed that maintaining higher BC6OTHER and BC6OTHER activities might be one of the reasons that the disruption of BC6ENTG enhances the tolerance to salt stress, and accumulating more BC6ENTC and higher activities of BC6OTHER and BC6OTHER might result in the higher tolerance of BC6OTHER to osmotic stress.	False
Taken together, we revealed that maintaining higher BC6OTHER and BC6OTHER activities might be one of the reasons that the disruption of BC6OTHER enhances the tolerance to salt stress, and accumulating more BC6ENTC and higher activities of BC6ENTG and BC6OTHER might result in the higher tolerance of BC6OTHER to osmotic stress.	False
Taken together, we revealed that maintaining higher BC6OTHER and BC6OTHER activities might be one of the reasons that the disruption of BC6OTHER enhances the tolerance to salt stress, and accumulating more BC6ENTC and higher activities of BC6OTHER and BC6ENTG might result in the higher tolerance of BC6OTHER to osmotic stress.	False
Taken together, we revealed that maintaining higher BC6OTHER and BC6OTHER activities might be one of the reasons that the disruption of BC6OTHER enhances the tolerance to salt stress, and accumulating more BC6ENTC and higher activities of BC6OTHER and BC6OTHER might result in the higher tolerance of BC6ENTG to osmotic stress.	False
Taken together, we revealed that maintaining higher BC6ENTG and BC6OTHER activities might be one of the reasons that the disruption of BC6OTHER enhances the tolerance to salt stress, and accumulating more BC6ENTC and higher activities of BC6OTHER and BC6OTHER might result in the higher tolerance of BC6OTHER to osmotic stress.	False
Taken together, we revealed that maintaining higher BC6OTHER and BC6ENTG activities might be one of the reasons that the disruption of BC6OTHER enhances the tolerance to salt stress, and accumulating more BC6ENTC and higher activities of BC6OTHER and BC6OTHER might result in the higher tolerance of BC6OTHER to osmotic stress.	False
Here, we report that BC6ENTG is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by BC6ENTC and BC6OTHER treatment.	False
Here, we report that BC6ENTG is mainly expressed in primary root, hypocotyl, stamen and pistil and is induced by BC6OTHER and BC6ENTC treatment.	False
Compared to the wild - type, the T - DNA knock - out BC6ENTG mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the BC6ENTC and BC6OTHER treatment, respectively.	False
Compared to the wild - type, the T - DNA knock - out BC6ENTG mutant was more tolerant to severe salinity and osmotic stresses, as indicated by 27% and 198% more fresh weight in the BC6OTHER and BC6ENTC treatment, respectively.	False
The BC6ENTG mutant also accumulated 1.43 - fold more BC6ENTC than the wild - type in the BC6OTHER treatment.	False
The BC6ENTG mutant also accumulated 1.43 - fold more BC6OTHER than the wild - type in the BC6ENTC treatment.	False
Under BC6ENTC and BC6OTHER stresses, BC6ENTG ( BC6OTHER ) activity in BC6OTHER mutant was 1.92 - and 3.7 - times of that in CHEM- 0, respectively.	CPR:3
Under BC6ENTC and BC6OTHER stresses, BC6OTHER ( BC6ENTG ) activity in BC6OTHER mutant was 1.92 - and 3.7 - times of that in CHEM- 0, respectively.	CPR:3
Under BC6ENTC and BC6OTHER stresses, BC6OTHER ( BC6OTHER ) activity in BC6ENTG mutant was 1.92 - and 3.7 - times of that in CHEM- 0, respectively.	False
Under BC6OTHER and BC6ENTC stresses, BC6ENTG ( BC6OTHER ) activity in BC6OTHER mutant was 1.92 - and 3.7 - times of that in CHEM- 0, respectively.	CPR:3
Under BC6OTHER and BC6ENTC stresses, BC6OTHER ( BC6ENTG ) activity in BC6OTHER mutant was 1.92 - and 3.7 - times of that in CHEM- 0, respectively.	CPR:3
Under BC6OTHER and BC6ENTC stresses, BC6OTHER ( BC6OTHER ) activity in BC6ENTG mutant was 1.92 - and 3.7 - times of that in CHEM- 0, respectively.	False
Western blot assay demonstrated that BC6ENTC decreased BC6ENTG level and induced BC6OTHER translocation to cause BC6OTHER release.	CPR:4
Western blot assay demonstrated that BC6ENTC decreased BC6OTHER level and induced BC6ENTG translocation to cause BC6OTHER release.	CPR:3
Western blot assay demonstrated that BC6ENTC decreased BC6OTHER level and induced BC6OTHER translocation to cause BC6ENTG release.	CPR:3
Meanwhile, the alterations of BC6ENTG , BC6OTHER and BC6OTHER levels were also observed in response to BC6ENTC treatment.	False
Meanwhile, the alterations of BC6OTHER , BC6ENTG and BC6OTHER levels were also observed in response to BC6ENTC treatment.	False
Meanwhile, the alterations of BC6OTHER , BC6OTHER and BC6ENTG levels were also observed in response to BC6ENTC treatment.	False
BC6ENTC binds selectively and with high affinity to a BC6ENTG known as BC6OTHER , thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.	False
BC6ENTC binds selectively and with high affinity to a BC6OTHER known as BC6ENTG , thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.	False
Psychopharmacology of anticonvulsants: BC6ENTC as a BC6ENTG modulator.	False
When cultured in YPD medium containing 15% BC6ENTC under aerobic conditions, the BC6ENTG ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6ENTC under aerobic conditions, the BC6OTHER ( BC6ENTG ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6ENTC under aerobic conditions, the BC6OTHER ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6ENTG ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6ENTC under aerobic conditions, the BC6OTHER ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6ENTG ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6ENTG ( BC6ENTC dehydrogenase) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6ENTC dehydrogenase) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6ENTG ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6ENTC dehydrogenase) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6ENTG ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6ENTG ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6ENTC than the wild - type strain, while the BC6OTHER ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	CPR:9
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6ENTG ) gene disrupted mutant produced a lower level of BC6ENTC than the wild - type strain, while the BC6OTHER ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	CPR:9
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6ENTC than the wild - type strain, while the BC6ENTG ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6ENTC than the wild - type strain, while the BC6OTHER ( BC6ENTG ) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6ENTG ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6ENTC dehydrogenase) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6ENTG ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6ENTC dehydrogenase) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6ENTG ( BC6ENTC dehydrogenase) gene - disrupted mutant produced an increased level of BC6OTHER .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6ENTG ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6ENTC .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6ENTG ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6ENTC .	False
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6ENTG ( BC6OTHER ) gene - disrupted mutant produced an increased level of BC6ENTC .	CPR:9
When cultured in YPD medium containing 15% BC6OTHER under aerobic conditions, the BC6OTHER ( BC6OTHER ) gene disrupted mutant produced a lower level of BC6OTHER than the wild - type strain, while the BC6OTHER ( BC6ENTG ) gene - disrupted mutant produced an increased level of BC6ENTC .	CPR:9
On the other hand, the BC6ENTG ( BC6OTHER ) gene disrupted mutant produced significantly higher levels of BC6ENTC but did not form BC6OTHER at all.	CPR:9
On the other hand, the BC6OTHER ( BC6ENTG ) gene disrupted mutant produced significantly higher levels of BC6ENTC but did not form BC6OTHER at all.	CPR:9
On the other hand, the BC6ENTG ( BC6OTHER ) gene disrupted mutant produced significantly higher levels of BC6OTHER but did not form BC6ENTC at all.	False
On the other hand, the BC6OTHER ( BC6ENTG ) gene disrupted mutant produced significantly higher levels of BC6OTHER but did not form BC6ENTC at all.	False
When the growth condition was shifted from aerobic to anaerobic, the increased level of BC6ENTC in BC6ENTG disruptants was no longer observed, whereas the decreased level of BC6OTHER in the BC6OTHER diruptant was still observed.	CPR:9
When the growth condition was shifted from aerobic to anaerobic, the increased level of BC6ENTC in BC6OTHER disruptants was no longer observed, whereas the decreased level of BC6OTHER in the BC6ENTG diruptant was still observed.	False
When the growth condition was shifted from aerobic to anaerobic, the increased level of BC6OTHER in BC6ENTG disruptants was no longer observed, whereas the decreased level of BC6ENTC in the BC6OTHER diruptant was still observed.	False
When the growth condition was shifted from aerobic to anaerobic, the increased level of BC6OTHER in BC6OTHER disruptants was no longer observed, whereas the decreased level of BC6ENTC in the BC6ENTG diruptant was still observed.	CPR:9
A double mutant of the two BC6ENTC reductase isozyme genes ( BC6ENTG and BC6OTHER ) showed a BC6OTHER productivity of 50% as compared to the parent when cells were incubated in BC6OTHER - buffered solution.	False
A double mutant of the two BC6ENTC reductase isozyme genes ( BC6OTHER and BC6ENTG ) showed a BC6OTHER productivity of 50% as compared to the parent when cells were incubated in BC6OTHER - buffered solution.	False
A double mutant of the two BC6ENTG isozyme genes ( BC6OTHER and BC6OTHER ) showed a BC6ENTC productivity of 50% as compared to the parent when cells were incubated in BC6OTHER - buffered solution.	CPR:9
A double mutant of the two BC6OTHER reductase isozyme genes ( BC6ENTG and BC6OTHER ) showed a BC6ENTC productivity of 50% as compared to the parent when cells were incubated in BC6OTHER - buffered solution.	CPR:9
A double mutant of the two BC6OTHER reductase isozyme genes ( BC6OTHER and BC6ENTG ) showed a BC6ENTC productivity of 50% as compared to the parent when cells were incubated in BC6OTHER - buffered solution.	CPR:9
A double mutant of the two BC6ENTG isozyme genes ( BC6OTHER and BC6OTHER ) showed a BC6OTHER productivity of 50% as compared to the parent when cells were incubated in BC6ENTC - buffered solution.	False
A double mutant of the two BC6OTHER reductase isozyme genes ( BC6ENTG and BC6OTHER ) showed a BC6OTHER productivity of 50% as compared to the parent when cells were incubated in BC6ENTC - buffered solution.	False
A double mutant of the two BC6OTHER reductase isozyme genes ( BC6OTHER and BC6ENTG ) showed a BC6OTHER productivity of 50% as compared to the parent when cells were incubated in BC6ENTC - buffered solution.	False
Insights into dynamical behaviors of BC6ENTG and their interaction modes with BC6OTHER are crucial in understanding the structural and functional characteristics of BC6ENTC receptors.	False
In this study a computational approach, integrating protein structure prediction, automated molecular docking, and molecular dynamics simulations were employed to investigate the dual action mechanism of BC6ENTC on the BC6ENTG , with the eventual aim to develop new drugs for treating diseases affecting the central nervous system such as schizophrenia.	False
Potential binding conformations of BC6OTHER were obtained, and the BC6OTHER - BC6ENTC and BC6ENTG - BC6OTHER complexes were generated, which are in good agreement with most of experimental data.	False
Potential binding conformations of BC6ENTG were obtained, and the BC6OTHER - BC6ENTC and BC6OTHER - BC6OTHER complexes were generated, which are in good agreement with most of experimental data.	False
Potential binding conformations of BC6OTHER were obtained, and the BC6ENTG - BC6ENTC and BC6OTHER - BC6OTHER complexes were generated, which are in good agreement with most of experimental data.	False
 BC6ENTC D1 receptor agonist and BC6ENTG antagonist effects of the natural product BC6OTHER : molecular modeling and dynamics simulations.	False
 BC6ENTG agonist and BC6OTHER antagonist effects of the natural product BC6ENTC : molecular modeling and dynamics simulations.	CPR:5
 BC6OTHER agonist and BC6ENTG antagonist effects of the natural product BC6ENTC : molecular modeling and dynamics simulations.	CPR:6
BC6ENTC ( BC6OTHER ), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a BC6ENTG agonist and BC6OTHER antagonist.	CPR:5
BC6ENTC ( BC6OTHER ), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a BC6OTHER receptor D1 agonist and BC6ENTG antagonist.	CPR:6
Potential binding conformations of BC6OTHER were obtained, and the BC6OTHER - BC6OTHER and BC6ENTG - BC6ENTC complexes were generated, which are in good agreement with most of experimental data.	False
Potential binding conformations of BC6ENTG were obtained, and the BC6OTHER - BC6OTHER and BC6OTHER - BC6ENTC complexes were generated, which are in good agreement with most of experimental data.	False
Potential binding conformations of BC6OTHER were obtained, and the BC6ENTG - BC6OTHER and BC6OTHER - BC6ENTC complexes were generated, which are in good agreement with most of experimental data.	False
The BC6ENTG - BC6ENTC structure shows that the CHEM - 3 (EL - 2: extracellular loop 2; EL - 3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of BC6OTHER .	False
BC6OTHER ( BC6OTHER ), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a BC6ENTC receptor D1 agonist and BC6ENTG antagonist.	False
The BC6ENTG - BC6OTHER structure shows that the CHEM - 3 (EL - 2: extracellular loop 2; EL - 3: extracellular loop 3) salt bridge plays an important role for both the conformational change of the extracellular domain and the binding of BC6ENTC .	False
BC6OTHER ( BC6ENTC ), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a BC6ENTG agonist and BC6OTHER antagonist.	CPR:5
BC6OTHER ( BC6ENTC ), an active ingredient of the Chinese herb Stephania, is the first compound found to have dual function as a BC6OTHER receptor D1 agonist and BC6ENTG antagonist.	CPR:6
Insights into dynamical behaviors of BC6ENTG and their interaction modes with BC6ENTC are crucial in understanding the structural and functional characteristics of BC6OTHER .	False
Insights into dynamical behaviors of BC6OTHER and their interaction modes with BC6ENTC are crucial in understanding the structural and functional characteristics of BC6ENTG .	False
However, BC6ENTC produces less systemic beta 2 - and possibly BC6ENTG blockade than either BC6OTHER or BC6OTHER .	CPR:4
However, BC6OTHER produces less systemic beta 2 - and possibly BC6ENTG blockade than either BC6ENTC or BC6OTHER .	CPR:4
However, BC6OTHER produces less systemic beta 2 - and possibly BC6ENTG blockade than either BC6OTHER or BC6ENTC .	CPR:4
These currents were produced by BC6ENTC - BC6OTHER transporters ( BC6ENTG ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by BC6ENTC - BC6OTHER transporters ( BC6OTHER ) ( BC6ENTG ) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by BC6ENTC - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTG (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by BC6ENTC - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER ( BC6ENTG ) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by BC6ENTC - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6ENTG - / - cochleas.	False
These currents were produced by CHEM - BC6ENTC transporters ( BC6ENTG ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6ENTC transporters ( BC6OTHER ) ( BC6ENTG ) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6ENTC transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTG (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6ENTC transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER ( BC6ENTG ) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6ENTC transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6ENTG - / - cochleas.	False
These currents were produced by BC6ENTG ( BC6OTHER ) (excitatory BC6ENTC transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6ENTG ) (excitatory BC6ENTC transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6ENTC transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTG (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6ENTC transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER ( BC6ENTG ) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6ENTC transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6ENTG - / - cochleas.	False
These currents were produced by BC6ENTG ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6ENTC , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	CPR:4
These currents were produced by CHEM - BC6OTHER transporters ( BC6ENTG ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6ENTC , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	CPR:4
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) ( BC6ENTG ) because they were weakly inhibited by BC6ENTC , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	CPR:4
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6ENTC , an antagonist of BC6ENTG (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	CPR:6
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6ENTC , an antagonist of BC6OTHER ( BC6ENTG ) and were absent from IPCs in BC6OTHER - / - cochleas.	CPR:6
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6ENTC , an antagonist of BC6OTHER (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6ENTG - / - cochleas.	False
These currents were produced by BC6ENTG ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTC transporter - 1 (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6ENTG ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTC transporter - 1 (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) ( BC6ENTG ) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTC transporter - 1 (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTC transporter - 1 ( BC6ENTG ) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTC transporter - 1 (excitatory BC6OTHER transporter 2) and were absent from IPCs in BC6ENTG - / - cochleas.	False
These currents were produced by BC6ENTG ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6ENTC transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6ENTG ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6ENTC transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) ( BC6ENTG ) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6ENTC transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6ENTG (excitatory BC6ENTC transporter 2) and were absent from IPCs in BC6OTHER - / - cochleas.	False
These currents were produced by CHEM - BC6OTHER transporters ( BC6OTHER ) (excitatory BC6OTHER transporter 1) because they were weakly inhibited by BC6OTHER , an antagonist of BC6OTHER (excitatory BC6ENTC transporter 2) and were absent from IPCs in BC6ENTG - / - cochleas.	False
The BC6OTHER BC6ENTG mediates BC6ENTC uptake at inner hair cell afferent synapses in the mammalian cochlea.	CPR:9
The BC6ENTG BC6OTHER mediates BC6ENTC uptake at inner hair cell afferent synapses in the mammalian cochlea.	CPR:9
Furthermore, BC6ENTC - induced currents in outside - out patches from IPCs exhibited larger steady - state currents than responses elicited by BC6OTHER , a prominent feature of BC6ENTG , and examination of cochlea from BC6OTHER - Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	False
Furthermore, BC6ENTC - induced currents in outside - out patches from IPCs exhibited larger steady - state currents than responses elicited by BC6OTHER , a prominent feature of BC6OTHER , and examination of cochlea from BC6ENTG - Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	False
Furthermore, BC6OTHER - induced currents in outside - out patches from IPCs exhibited larger steady - state currents than responses elicited by BC6ENTC , a prominent feature of BC6ENTG , and examination of cochlea from BC6OTHER - Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	CPR:9
Furthermore, BC6OTHER - induced currents in outside - out patches from IPCs exhibited larger steady - state currents than responses elicited by BC6ENTC , a prominent feature of BC6OTHER , and examination of cochlea from BC6ENTG - Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.	False
Focal application of the transporter substrate BC6ENTC elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter - associated BC6ENTG and blocked by the transporter antagonist BC6OTHER .	False
Focal application of the transporter substrate BC6OTHER elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter - associated BC6ENTG and blocked by the transporter antagonist BC6ENTC .	CPR:6
BC6OTHER (50 to 100 nmol / L) was used to mimic an increase in beta - adrenergic tone, BC6ENTC (100 micromol / L) to block BC6ENTG (LQT2 model), and BC6OTHER (20 nmol / L) to augment late I( BC6OTHER ) (LQT3 model).	CPR:4
BC6OTHER (50 to 100 nmol / L) was used to mimic an increase in beta - adrenergic tone, BC6ENTC (100 micromol / L) to block BC6OTHER (LQT2 model), and BC6ENTG (20 nmol / L) to augment late I( BC6OTHER ) (LQT3 model).	CPR:4
BC6OTHER (50 to 100 nmol / L) was used to mimic an increase in beta - adrenergic tone, BC6OTHER (100 micromol / L) to block BC6ENTG (LQT2 model), and BC6OTHER (20 nmol / L) to augment late I( BC6ENTC ) (LQT3 model).	False
BC6OTHER (50 to 100 nmol / L) was used to mimic an increase in beta - adrenergic tone, BC6OTHER (100 micromol / L) to block BC6OTHER (LQT2 model), and BC6ENTG (20 nmol / L) to augment late I( BC6ENTC ) (LQT3 model).	False
BC6ENTC + BC6OTHER , BC6OTHER , and BC6ENTG produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation - induced CHEM (LQT1, 3 / 6; LQT2, 3 / 6; LQT3, 5 / 6).	False
BC6OTHER + BC6ENTC , BC6OTHER , and BC6ENTG produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation - induced CHEM (LQT1, 3 / 6; LQT2, 3 / 6; LQT3, 5 / 6).	False
BC6OTHER + BC6OTHER , BC6ENTC , and BC6ENTG produced preferential prolongation of the action potential duration at 90% repolarization (APD(90)) of the M cell, an increase of TDR, and spontaneous as well as stimulation - induced CHEM (LQT1, 3 / 6; LQT2, 3 / 6; LQT3, 5 / 6).	False
BC6ENTC 20 micromol / L reversed only 50% of the effect of BC6ENTG and failed to completely suppress CHEM in the LQT3 model (5 / 6 to 3 / 6).	False
CONCLUSIONS: Our data suggest that BC6ENTC channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation - induced CHEM when congenital or acquired LQTS is secondary to reduced BC6ENTG or BC6OTHER but less so when it is due to augmented late I( BC6OTHER ).	False
CONCLUSIONS: Our data suggest that BC6ENTC channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation - induced CHEM when congenital or acquired LQTS is secondary to reduced BC6OTHER or BC6ENTG but less so when it is due to augmented late I( BC6OTHER ).	False
CONCLUSIONS: Our data suggest that BC6ENTG openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation - induced CHEM when congenital or acquired LQTS is secondary to reduced BC6OTHER or BC6OTHER but less so when it is due to augmented late I( BC6ENTC ).	False
CONCLUSIONS: Our data suggest that BC6OTHER channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation - induced CHEM when congenital or acquired LQTS is secondary to reduced BC6ENTG or BC6OTHER but less so when it is due to augmented late I( BC6ENTC ).	False
CONCLUSIONS: Our data suggest that BC6OTHER channel openers may be capable of abbreviating the long QT interval, reducing TDR, and preventing spontaneous and stimulation - induced CHEM when congenital or acquired LQTS is secondary to reduced BC6OTHER or BC6ENTG but less so when it is due to augmented late I( BC6ENTC ).	False
BACKGROUND: This study examines the effects of BC6ENTC , a BC6ENTG opener, on transmural dispersion of repolarization (TDR) and induction of torsade de pointes (TdP) under conditions mimicking the LQT1, LQT2, and LQT3 forms of the congenital long - QT syndrome (LQTS).	CPR:3
BC6ENTC (50 to 100 nmol / L) was used to mimic an increase in beta - adrenergic tone, BC6OTHER (100 micromol / L) to block BC6ENTG (LQT2 model), and BC6OTHER (20 nmol / L) to augment late I( BC6OTHER ) (LQT3 model).	CPR:4
BC6ENTC (50 to 100 nmol / L) was used to mimic an increase in beta - adrenergic tone, BC6OTHER (100 micromol / L) to block BC6OTHER (LQT2 model), and BC6ENTG (20 nmol / L) to augment late I( BC6OTHER ) (LQT3 model).	CPR:4
Drug dependent changes in the NMR heteronuclear single - quantum coherence spectra of [ BC6ENTC ]Met - labeled BC6ENTG indicate that BC6OTHER and BC6OTHER bind to similar sites but only in the presence of BC6OTHER .	False
Drug dependent changes in the NMR heteronuclear single - quantum coherence spectra of [ BC6OTHER ]Met - labeled BC6ENTG indicate that BC6ENTC and BC6OTHER bind to similar sites but only in the presence of BC6OTHER .	False
Drug dependent changes in the NMR heteronuclear single - quantum coherence spectra of [ BC6OTHER ]Met - labeled BC6ENTG indicate that BC6OTHER and BC6ENTC bind to similar sites but only in the presence of BC6OTHER .	False
Drug dependent changes in the NMR heteronuclear single - quantum coherence spectra of [ BC6OTHER ]Met - labeled BC6ENTG indicate that BC6OTHER and BC6OTHER bind to similar sites but only in the presence of BC6ENTC .	False
There are 3 - 4 drug binding sites in the BC6ENTC - and BC6OTHER - terminal domains of intact BC6ENTG that exhibit fast exchange on the NMR time scale.	False
There are 3 - 4 drug binding sites in the BC6OTHER - and BC6ENTC - terminal domains of intact BC6ENTG that exhibit fast exchange on the NMR time scale.	False
Identification of binding sites for BC6ENTC and BC6OTHER on BC6ENTG .	False
Identification of binding sites for BC6OTHER and BC6ENTC on BC6ENTG .	False
This subregion in BC6ENTG makes a likely target against which to design new and selective BC6ENTC - sensitizing compounds.	False
For example, it is clear that the closed conformation of the regulatory BC6ENTC - terminal domain in BC6OTHER - bound BC6ENTG ( BC6OTHER ) presents a much different binding surface for BC6OTHER - sensitizing compounds than previously thought.	False
For example, it is clear that the closed conformation of the regulatory BC6ENTC - terminal domain in BC6OTHER - bound BC6OTHER ( BC6ENTG ) presents a much different binding surface for BC6OTHER - sensitizing compounds than previously thought.	False
For example, it is clear that the closed conformation of the regulatory BC6OTHER - terminal domain in BC6ENTC - bound BC6ENTG ( BC6OTHER ) presents a much different binding surface for BC6OTHER - sensitizing compounds than previously thought.	False
For example, it is clear that the closed conformation of the regulatory BC6OTHER - terminal domain in BC6ENTC - bound BC6OTHER ( BC6ENTG ) presents a much different binding surface for BC6OTHER - sensitizing compounds than previously thought.	False
For example, it is clear that the closed conformation of the regulatory BC6OTHER - terminal domain in BC6OTHER - bound BC6ENTG ( BC6OTHER ) presents a much different binding surface for BC6ENTC - sensitizing compounds than previously thought.	False
For example, it is clear that the closed conformation of the regulatory BC6OTHER - terminal domain in BC6OTHER - bound BC6OTHER ( BC6ENTG ) presents a much different binding surface for BC6ENTC - sensitizing compounds than previously thought.	False
We report here the use of CHEM groups as site - specific structural markers to identify drug binding sites for BC6ENTC and BC6OTHER on BC6ENTG .	False
We report here the use of CHEM groups as site - specific structural markers to identify drug binding sites for BC6OTHER and BC6ENTC on BC6ENTG .	False
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hemolytic anemia caused by somatic mutations in the BC6ENTC glycan - complementation class A gene and the resulting absence of a key complement regulatory protein, BC6ENTG .	False
BC6ENTC synthetase 4 ( BC6ENTG ) is involved in several cellular functions including steroidogenesis, synaptic development and cancer metastasis.	False
Functional characterization revealed that the BC6ENTG / BC6OTHER BC6OTHER binding site in the proximal promoter is involved in basal activity and that the BC6OTHER response element - binding site is involved in BC6ENTC stimulation of BC6OTHER transcription.	False
Functional characterization revealed that the BC6OTHER / BC6ENTG BC6OTHER binding site in the proximal promoter is involved in basal activity and that the BC6OTHER response element - binding site is involved in BC6ENTC stimulation of BC6OTHER transcription.	False
Functional characterization revealed that the BC6OTHER / BC6OTHER BC6ENTG binding site in the proximal promoter is involved in basal activity and that the BC6OTHER response element - binding site is involved in BC6ENTC stimulation of BC6OTHER transcription.	False
Functional characterization revealed that the BC6OTHER / BC6OTHER BC6OTHER binding site in the proximal promoter is involved in basal activity and that the BC6ENTG - binding site is involved in BC6ENTC stimulation of BC6OTHER transcription.	False
Functional characterization revealed that the BC6OTHER / BC6OTHER BC6OTHER binding site in the proximal promoter is involved in basal activity and that the BC6OTHER response element - binding site is involved in BC6ENTC stimulation of BC6ENTG transcription.	False
We demonstrated BC6ENTG and BC6ENTC regulation of BC6OTHER mRNA in mouse steroidogenic MA - 10 Leydig cells.	False
We demonstrated BC6OTHER and BC6ENTC regulation of BC6ENTG mRNA in mouse steroidogenic MA - 10 Leydig cells.	False
Functional characterization revealed that the BC6ENTG / BC6OTHER BC6OTHER binding site in the proximal promoter is involved in basal activity and that the BC6ENTC response element - binding site is involved in BC6OTHER stimulation of BC6OTHER transcription.	False
Functional characterization revealed that the BC6OTHER / BC6ENTG BC6OTHER binding site in the proximal promoter is involved in basal activity and that the BC6ENTC response element - binding site is involved in BC6OTHER stimulation of BC6OTHER transcription.	False
Functional characterization revealed that the BC6OTHER / BC6OTHER BC6ENTG binding site in the proximal promoter is involved in basal activity and that the BC6ENTC response element - binding site is involved in BC6OTHER stimulation of BC6OTHER transcription.	False
Functional characterization revealed that the BC6OTHER / BC6OTHER BC6OTHER binding site in the proximal promoter is involved in basal activity and that the BC6ENTC response element - binding site is involved in BC6OTHER stimulation of BC6ENTG transcription.	False
Characterization of the mouse promoter region of the BC6ENTC synthetase 4 gene: role of BC6ENTG and BC6OTHER .	False
Characterization of the mouse promoter region of the BC6ENTC synthetase 4 gene: role of BC6OTHER and BC6ENTG .	False
Melanoma targeting property of a BC6ENTC - labeled BC6OTHER bridge - cyclized BC6ENTG peptide.	False
Melanoma targeting property of a BC6OTHER - labeled BC6ENTC bridge - cyclized BC6ENTG peptide.	False
In order to produce potent new leads for anticancer drugs, a new series of BC6OTHER analogs was designed to resemble BC6ENTC ( BC6OTHER , 1) structure features and fitted with functional groups believed to enhance inhibition of BC6ENTG activity.	CPR:4
In order to produce potent new leads for anticancer drugs, a new series of BC6OTHER analogs was designed to resemble BC6OTHER ( BC6ENTC , 1) structure features and fitted with functional groups believed to enhance inhibition of BC6ENTG activity.	CPR:4
In order to produce potent new leads for anticancer drugs, a new series of BC6ENTC analogs was designed to resemble BC6OTHER ( BC6OTHER , 1) structure features and fitted with functional groups believed to enhance inhibition of BC6ENTG activity.	CPR:4
Synthesis, BC6ENTG inhibition, antitumor testing, and molecular modeling study of some new BC6ENTC analogs.	CPR:4
 BC6ENTC - mediated changes in adipose BC6OTHER metabolism are exaggerated, not diminished, in the absence of a functional BC6ENTG .	False
 BC6OTHER - mediated changes in adipose BC6ENTC metabolism are exaggerated, not diminished, in the absence of a functional BC6ENTG .	False
BC6ENTG (dim / dim) mice showed an exaggerated response to BC6ENTC in both depots.	False
De novo lipogenesis was also greatly increased in both depots in response to BC6ENTC in BC6ENTG (dim / dim), but not wild - type mice.	False
In contrast, the inhibitory effect of BC6ENTC on bone and skin collagen synthesis rates was greater in wild - type compared with BC6ENTG (dim / dim) mice.	False
Wild - type mice were more sensitive to BC6ENTC - dependent decreases in BC6ENTG sensitivity than BC6OTHER (dim / dim) mice.	False
Wild - type mice were more sensitive to BC6ENTC - dependent decreases in BC6OTHER sensitivity than BC6ENTG (dim / dim) mice.	False
Wild - type and BC6ENTG (dim / dim) mice were equally sensitive to BC6ENTC - dependent decreases in muscle protein synthesis.	False
To understand the role of BC6ENTG dimerization - dependent targets in multiple tissues, we measured metabolic fluxes through several disease - relevant GC target pathways using CHEM labeling and mass spectrometry in wild - type and BC6OTHER (dim / dim) mice administered the potent GC BC6ENTC ( BC6OTHER ).	False
To understand the role of BC6OTHER dimerization - dependent targets in multiple tissues, we measured metabolic fluxes through several disease - relevant GC target pathways using CHEM labeling and mass spectrometry in wild - type and BC6ENTG (dim / dim) mice administered the potent GC BC6ENTC ( BC6OTHER ).	False
To understand the role of BC6ENTG dimerization - dependent targets in multiple tissues, we measured metabolic fluxes through several disease - relevant GC target pathways using CHEM labeling and mass spectrometry in wild - type and BC6OTHER (dim / dim) mice administered the potent GC BC6OTHER ( BC6ENTC ).	False
To understand the role of BC6OTHER dimerization - dependent targets in multiple tissues, we measured metabolic fluxes through several disease - relevant GC target pathways using CHEM labeling and mass spectrometry in wild - type and BC6ENTG (dim / dim) mice administered the potent GC BC6OTHER ( BC6ENTC ).	False
Absolute BC6ENTC synthesis was increased in both wild - type and BC6ENTG (dim / dim) mice by BC6OTHER in the inguinal and epididymal fat depots.	False
Absolute BC6OTHER synthesis was increased in both wild - type and BC6ENTG (dim / dim) mice by BC6ENTC in the inguinal and epididymal fat depots.	False
The decrease and recovery of BC6ENTC uptake correlated highly (r = 0.93) with the recovery of BC6ENTG binding.	CPR:9
The turnover of BC6ENTG was determined from the rate of recovery of binding after administration of BC6ENTC , an irreversible inhibitor of ligand binding.	CPR:4
In preliminary studies, in vitro incubation of rat cerebral cortex with BC6ENTC produced a wash and temperature resistant inhibition of BC6ENTG binding densities (Bmax).	CPR:4
BC6ENTC protected against the BC6OTHER - induced inhibition of BC6ENTG binding.	False
BC6OTHER protected against the BC6ENTC - induced inhibition of BC6ENTG binding.	CPR:4
The objective of this study was to examine the turnover of the BC6ENTC transporter ( BC6ENTG ) by determining its production rate (r), degradation rate constant (k) and half - life of recovery (t1 / 2).	False
Following 6 h of in vivo intracerebroventricular injections of 100 nmol of BC6ENTC , there was a dose - and time - dependent reduction ( - 60%) of BC6ENTG binding in hippocampus and striatum, without a change in the Kd.	False
 BC6ENTG production and degradation rates: studies with BC6ENTC .	False
The solubility - driven structural modification of BC6OTHER is described, which resulted in the development of a new series of BC6ENTC analogues with high antibacterial activity against Gram - positive pathogens, including that against BC6OTHER - resistant strains and low BC6ENTG inhibition.	CPR:4
The solubility - driven structural modification of BC6OTHER is described, which resulted in the development of a new series of BC6OTHER analogues with high antibacterial activity against Gram - positive pathogens, including that against BC6ENTC - resistant strains and low BC6ENTG inhibition.	False
The solubility - driven structural modification of BC6ENTC is described, which resulted in the development of a new series of BC6OTHER analogues with high antibacterial activity against Gram - positive pathogens, including that against BC6OTHER - resistant strains and low BC6ENTG inhibition.	False
In conclusion, the BC6ENTG inhibitor BC6ENTC dose - dependently decreases BC6OTHER levels in humans following oral administration.	CPR:4
In conclusion, the BC6OTHER inhibitor BC6ENTC dose - dependently decreases BC6ENTG levels in humans following oral administration.	CPR:4
In conclusion, the BC6ENTG inhibitor BC6OTHER dose - dependently decreases BC6ENTC levels in humans following oral administration.	False
BC6ENTC has the potential to become the first orally active BC6ENTG inhibitor that provides a true alternative to BC6OTHER - inhibitors and BC6OTHER antagonists in therapy for hypertension and other cardiovascular and renal diseases.	CPR:4
BC6ENTC has the potential to become the first orally active BC6OTHER inhibitor that provides a true alternative to BC6ENTG - inhibitors and BC6OTHER antagonists in therapy for hypertension and other cardiovascular and renal diseases.	CPR:4
BC6ENTC has the potential to become the first orally active BC6OTHER inhibitor that provides a true alternative to BC6OTHER - inhibitors and BC6ENTG antagonists in therapy for hypertension and other cardiovascular and renal diseases.	CPR:6
BC6OTHER has the potential to become the first orally active BC6ENTG inhibitor that provides a true alternative to BC6OTHER - inhibitors and BC6ENTC receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	False
BC6OTHER has the potential to become the first orally active BC6OTHER inhibitor that provides a true alternative to BC6ENTG - inhibitors and BC6ENTC receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.	False
We tested the new orally active nonpeptidic BC6ENTG inhibitor BC6ENTC ( BC6OTHER , an BC6OTHER with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol / d BC6OTHER diet using a double - blind, 3 - way crossover protocol.	CPR:4
We tested the new orally active nonpeptidic BC6ENTG inhibitor BC6OTHER ( BC6ENTC , an BC6OTHER with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol / d BC6OTHER diet using a double - blind, 3 - way crossover protocol.	CPR:4
We tested the new orally active nonpeptidic BC6ENTG inhibitor BC6OTHER ( BC6OTHER , an BC6ENTC with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol / d BC6OTHER diet using a double - blind, 3 - way crossover protocol.	CPR:4
BC6ENTG is the main determinant of BC6ENTC levels.	False
There was a dose - dependent decrease in plasma BC6ENTG activity, BC6OTHER , and BC6OTHER following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6ENTC levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6ENTG , and BC6OTHER following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6ENTC levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6OTHER , and BC6ENTG following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6ENTC levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
We tested the new orally active nonpeptidic BC6ENTG inhibitor BC6OTHER ( BC6OTHER , an BC6OTHER with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol / d BC6ENTC diet using a double - blind, 3 - way crossover protocol.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6ENTC , and BC6OTHER following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6ENTG levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6ENTG activity, BC6ENTC , and BC6OTHER following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6ENTC , and BC6ENTG following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6OTHER , and BC6ENTC following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6ENTG levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6ENTG activity, BC6OTHER , and BC6ENTC following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6ENTG , and BC6ENTC following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6OTHER , and BC6OTHER following single doses of BC6ENTC starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6ENTG levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6ENTG activity, BC6OTHER , and BC6OTHER following single doses of BC6ENTC starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	CPR:4
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6ENTG , and BC6OTHER following single doses of BC6ENTC starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	CPR:4
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6OTHER , and BC6ENTG following single doses of BC6ENTC starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6OTHER was compared with placebo.	CPR:4
 BC6ENTC suppression in humans by the orally active BC6ENTG inhibitor BC6OTHER ( BC6OTHER ): comparison with BC6OTHER .	False
 BC6ENTG suppression in humans by the orally active BC6OTHER inhibitor BC6OTHER ( BC6OTHER ): comparison with BC6ENTC .	False
 BC6OTHER suppression in humans by the orally active BC6ENTG inhibitor BC6OTHER ( BC6OTHER ): comparison with BC6ENTC .	False
 BC6ENTG suppression in humans by the orally active BC6OTHER inhibitor BC6ENTC ( BC6OTHER ): comparison with BC6OTHER .	CPR:4
 BC6OTHER suppression in humans by the orally active BC6ENTG inhibitor BC6ENTC ( BC6OTHER ): comparison with BC6OTHER .	CPR:4
It, therefore, always appeared desirable to reduce BC6ENTC levels by direct inhibition of BC6ENTG .	False
 BC6ENTG suppression in humans by the orally active BC6OTHER inhibitor BC6OTHER ( BC6ENTC ): comparison with BC6OTHER .	CPR:4
 BC6OTHER suppression in humans by the orally active BC6ENTG inhibitor BC6OTHER ( BC6ENTC ): comparison with BC6OTHER .	CPR:4
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6OTHER , and BC6OTHER following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6ENTG levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6ENTC was compared with placebo.	CPR:4
There was a dose - dependent decrease in plasma BC6ENTG activity, BC6OTHER , and BC6OTHER following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6ENTC was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6ENTG , and BC6OTHER following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6ENTC was compared with placebo.	False
There was a dose - dependent decrease in plasma BC6OTHER activity, BC6OTHER , and BC6ENTG following single doses of BC6OTHER starting with 40 mg. Inhibition was still marked and significant after repeated dosing with maximal decreases in BC6OTHER levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of BC6ENTC was compared with placebo.	False
At the same time, mean plasma active BC6ENTG was increased 16 - and 34 - fold at the highest dose of BC6ENTC .	CPR:3
A low BC6ENTC diet is recommended if BC6OTHER is used together with nonselective BC6ENTG inhibitors or the selective, reversible BC6OTHER inhibitor, BC6OTHER .	False
A low BC6ENTC diet is recommended if BC6OTHER is used together with nonselective BC6OTHER inhibitors or the selective, reversible BC6ENTG inhibitor, BC6OTHER .	False
A low BC6OTHER diet is recommended if BC6ENTC is used together with nonselective BC6ENTG inhibitors or the selective, reversible BC6OTHER inhibitor, BC6OTHER .	CPR:4
A low BC6OTHER diet is recommended if BC6ENTC is used together with nonselective BC6OTHER inhibitors or the selective, reversible BC6ENTG inhibitor, BC6OTHER .	False
A low BC6OTHER diet is recommended if BC6OTHER is used together with nonselective BC6ENTG inhibitors or the selective, reversible BC6OTHER inhibitor, BC6ENTC .	False
A low BC6OTHER diet is recommended if BC6OTHER is used together with nonselective BC6OTHER inhibitors or the selective, reversible BC6ENTG inhibitor, BC6ENTC .	CPR:4
BC6ENTC ( BC6OTHER ), a selective, irreversible inhibitor of BC6ENTG ( BC6OTHER ) is widely used in the treatment of Parkinson's disease.	CPR:4
BC6ENTC ( BC6OTHER ), a selective, irreversible inhibitor of BC6OTHER ( BC6ENTG ) is widely used in the treatment of Parkinson's disease.	CPR:4
Unlike the nonselective BC6ENTG inhibitors, BC6ENTC does not significantly potentiate BC6OTHER - induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.	CPR:4
Unlike the nonselective BC6ENTG inhibitors, BC6OTHER does not significantly potentiate BC6ENTC - induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.	False
BC6OTHER ( BC6OTHER ), a selective, irreversible inhibitor of BC6ENTC oxidase type B ( BC6ENTG ) is widely used in the treatment of Parkinson's disease.	False
BC6OTHER ( BC6ENTC ), a selective, irreversible inhibitor of BC6ENTG ( BC6OTHER ) is widely used in the treatment of Parkinson's disease.	CPR:4
BC6OTHER ( BC6ENTC ), a selective, irreversible inhibitor of BC6OTHER ( BC6ENTG ) is widely used in the treatment of Parkinson's disease.	CPR:4
To determine if BC6ENTG could antagonize CHEM effects in normal tissue, we examined the effect of BC6ENTC on rat ventral prostate organ cultures and demonstrated that BC6OTHER can functionally antagonize the actions of BC6OTHER on prostate cell proliferation and tissue growth.	False
To determine if BC6OTHER could antagonize CHEM effects in normal tissue, we examined the effect of BC6ENTC on rat ventral prostate organ cultures and demonstrated that BC6ENTG can functionally antagonize the actions of BC6OTHER on prostate cell proliferation and tissue growth.	False
To determine if BC6ENTG could antagonize CHEM effects in normal tissue, we examined the effect of BC6OTHER on rat ventral prostate organ cultures and demonstrated that BC6ENTC can functionally antagonize the actions of BC6OTHER on prostate cell proliferation and tissue growth.	False
To determine if BC6OTHER could antagonize CHEM effects in normal tissue, we examined the effect of BC6ENTG on rat ventral prostate organ cultures and demonstrated that BC6ENTC can functionally antagonize the actions of BC6OTHER on prostate cell proliferation and tissue growth.	False
To determine if BC6ENTG could antagonize CHEM effects in normal tissue, we examined the effect of BC6OTHER on rat ventral prostate organ cultures and demonstrated that BC6OTHER can functionally antagonize the actions of BC6ENTC on prostate cell proliferation and tissue growth.	False
To determine if BC6OTHER could antagonize CHEM effects in normal tissue, we examined the effect of BC6ENTG on rat ventral prostate organ cultures and demonstrated that BC6OTHER can functionally antagonize the actions of BC6ENTC on prostate cell proliferation and tissue growth.	False
To determine if BC6OTHER could antagonize CHEM effects in normal tissue, we examined the effect of BC6OTHER on rat ventral prostate organ cultures and demonstrated that BC6ENTG can functionally antagonize the actions of BC6ENTC on prostate cell proliferation and tissue growth.	False
This antagonism of BC6ENTC action by BC6ENTG may underlie in part the capacity of BC6OTHER activation to inhibit prostate tumor growth.	False
This antagonism of BC6ENTC action by BC6OTHER may underlie in part the capacity of BC6ENTG activation to inhibit prostate tumor growth.	False
This antagonism of BC6OTHER action by BC6ENTC may underlie in part the capacity of BC6ENTG activation to inhibit prostate tumor growth.	False
This antagonism of BC6OTHER action by BC6ENTG may underlie in part the capacity of BC6ENTC receptor activation to inhibit prostate tumor growth.	False
BC6ENTG ( BC6ENTC ) analogs constitute the most widely employed medical treatment for prostatic cancer.	False
Since the BC6ENTC receptor has been shown to affect BC6ENTG function, we considered that part of BC6OTHER analog actions on prostate cells may be mediated through modulation of the BC6OTHER .	False
Since the BC6ENTC receptor has been shown to affect BC6OTHER function, we considered that part of BC6ENTG analog actions on prostate cells may be mediated through modulation of the BC6OTHER .	False
Since the BC6ENTC receptor has been shown to affect BC6OTHER function, we considered that part of BC6OTHER analog actions on prostate cells may be mediated through modulation of the BC6ENTG .	False
Since the BC6ENTG has been shown to affect BC6OTHER function, we considered that part of BC6ENTC analog actions on prostate cells may be mediated through modulation of the BC6OTHER .	False
Since the BC6OTHER has been shown to affect BC6ENTG function, we considered that part of BC6ENTC analog actions on prostate cells may be mediated through modulation of the BC6OTHER .	False
Since the BC6OTHER has been shown to affect BC6OTHER function, we considered that part of BC6ENTC analog actions on prostate cells may be mediated through modulation of the BC6ENTG .	False
BC6ENTC ( BC6ENTG ) analogs constitute the most widely employed medical treatment for prostatic cancer.	False
Using a model HEK293 cell line expressing the BC6ENTC receptor, we demonstrated a novel signalling pathway of the BC6ENTG that induces nuclear translocation of the BC6OTHER that renders it transcriptionally inactive.	False
Using a model HEK293 cell line expressing the BC6ENTC receptor, we demonstrated a novel signalling pathway of the BC6OTHER that induces nuclear translocation of the BC6ENTG that renders it transcriptionally inactive.	False
Using a model HEK293 cell line expressing the BC6ENTG , we demonstrated a novel signalling pathway of the BC6ENTC receptor that induces nuclear translocation of the BC6OTHER that renders it transcriptionally inactive.	False
Using a model HEK293 cell line expressing the BC6OTHER , we demonstrated a novel signalling pathway of the BC6ENTC receptor that induces nuclear translocation of the BC6ENTG that renders it transcriptionally inactive.	False
This mechanism involves the BC6ENTC - dependent BC6OTHER BC6OTHER , the non - receptor BC6OTHER kinase BC6OTHER and the BC6OTHER / BC6ENTG , BC6OTHER .	False
This mechanism involves the BC6ENTC - dependent BC6OTHER BC6OTHER , the non - receptor BC6OTHER kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6ENTG .	False
This mechanism involves the BC6ENTC - dependent BC6ENTG BC6OTHER , the non - receptor BC6OTHER kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6ENTC - dependent BC6OTHER BC6ENTG , the non - receptor BC6OTHER kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6ENTC - dependent BC6OTHER BC6OTHER , the BC6ENTG BC6OTHER and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6ENTC - dependent BC6OTHER BC6OTHER , the non - receptor BC6OTHER kinase BC6ENTG and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6ENTC - dependent BC6OTHER BC6OTHER , the non - receptor BC6OTHER kinase BC6OTHER and the BC6ENTG / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6ENTC kinase BC6OTHER , the non - receptor BC6OTHER kinase BC6OTHER and the BC6OTHER / BC6ENTG , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6ENTC kinase BC6OTHER , the non - receptor BC6OTHER kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6ENTG .	False
This mechanism involves the BC6OTHER - dependent BC6ENTC kinase BC6ENTG , the non - receptor BC6OTHER kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6ENTC kinase BC6OTHER , the BC6ENTG BC6OTHER and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6ENTC kinase BC6OTHER , the non - receptor BC6OTHER kinase BC6ENTG and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6ENTC kinase BC6OTHER , the non - receptor BC6OTHER kinase BC6OTHER and the BC6ENTG / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6OTHER BC6OTHER , the non - receptor BC6ENTC kinase BC6OTHER and the BC6OTHER / BC6ENTG , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6OTHER BC6OTHER , the non - receptor BC6ENTC kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6ENTG .	False
This mechanism involves the BC6OTHER - dependent BC6ENTG BC6OTHER , the non - receptor BC6ENTC kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6OTHER BC6ENTG , the non - receptor BC6ENTC kinase BC6OTHER and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6OTHER BC6OTHER , the non - receptor BC6ENTC kinase BC6ENTG and the BC6OTHER / BC6OTHER , BC6OTHER .	False
This mechanism involves the BC6OTHER - dependent BC6OTHER BC6OTHER , the non - receptor BC6ENTC kinase BC6OTHER and the BC6ENTG / BC6OTHER , BC6OTHER .	False
 BC6ENTC functionally antagonizes BC6OTHER activation of the BC6OTHER in prostate cells through focal adhesion complexes involving BC6ENTG .	False
 BC6ENTC functionally antagonizes BC6OTHER activation of the BC6ENTG in prostate cells through focal adhesion complexes involving BC6OTHER .	CPR:6
 BC6ENTG functionally antagonizes BC6ENTC activation of the BC6OTHER in prostate cells through focal adhesion complexes involving BC6OTHER .	False
 BC6OTHER functionally antagonizes BC6ENTC activation of the BC6OTHER in prostate cells through focal adhesion complexes involving BC6ENTG .	False
 BC6OTHER functionally antagonizes BC6ENTC activation of the BC6ENTG in prostate cells through focal adhesion complexes involving BC6OTHER .	CPR:3
In this setting there is a BC6ENTC - induced association and nuclear translocation of the BC6ENTG with BC6OTHER .	False
In this setting there is a BC6ENTC - induced association and nuclear translocation of the BC6OTHER with BC6ENTG .	False
BC6ENTC - induced BC6ENTG activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6OTHER - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	CPR:3
BC6ENTC - induced BC6OTHER activation opposed the association of BC6ENTG with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6OTHER - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	CPR:4
BC6ENTC - induced BC6OTHER activation opposed the association of BC6OTHER with BC6ENTG as overexpression of a dominant negative BC6OTHER enhanced the BC6OTHER - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	CPR:4
BC6ENTC - induced BC6OTHER activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6ENTG enhanced the BC6OTHER - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	False
BC6ENTC - induced BC6OTHER activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6ENTG - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	False
BC6ENTC - induced BC6OTHER activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6OTHER - induced nuclear translocation of a green fluorescent protein - tagged BC6ENTG .	False
BC6ENTG - induced BC6OTHER activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6ENTC - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	False
BC6OTHER - induced BC6ENTG activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6ENTC - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	False
BC6OTHER - induced BC6OTHER activation opposed the association of BC6ENTG with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6ENTC - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	False
BC6OTHER - induced BC6OTHER activation opposed the association of BC6OTHER with BC6ENTG as overexpression of a dominant negative BC6OTHER enhanced the BC6ENTC - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	False
BC6OTHER - induced BC6OTHER activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6ENTG enhanced the BC6ENTC - induced nuclear translocation of a green fluorescent protein - tagged BC6OTHER .	False
BC6OTHER - induced BC6OTHER activation opposed the association of BC6OTHER with BC6OTHER as overexpression of a dominant negative BC6OTHER enhanced the BC6ENTC - induced nuclear translocation of a green fluorescent protein - tagged BC6ENTG .	False
BC6ENTC - induced BC6ENTG activation resulted in the phosphorylation of expressed BC6OTHER and promoted its association with the BC6OTHER .	CPR:3
BC6ENTC - induced BC6OTHER activation resulted in the phosphorylation of expressed BC6ENTG and promoted its association with the BC6OTHER .	False
BC6ENTC - induced BC6OTHER activation resulted in the phosphorylation of expressed BC6OTHER and promoted its association with the BC6ENTG .	False
In contrast to BC6ENTC , BC6ENTG - induced nuclear translocation did not transcriptionally activate the BC6OTHER .	False
In contrast to BC6ENTC , BC6OTHER - induced nuclear translocation did not transcriptionally activate the BC6ENTG .	CPR:3
In contrast to BC6OTHER , BC6ENTC - induced nuclear translocation did not transcriptionally activate the BC6ENTG .	False
We then demonstrated that BC6ENTC can also stimulate BC6ENTG mobilization in human prostate PC3, BPH - 1 and LNCaP cells, and in cultured rat ventral prostate cells through the same mechanism.	False
To determine if BC6ENTC could antagonize CHEM effects in normal tissue, we examined the effect of BC6ENTG on rat ventral prostate organ cultures and demonstrated that BC6OTHER can functionally antagonize the actions of BC6OTHER on prostate cell proliferation and tissue growth.	False
To determine if BC6ENTC could antagonize CHEM effects in normal tissue, we examined the effect of BC6OTHER on rat ventral prostate organ cultures and demonstrated that BC6ENTG can functionally antagonize the actions of BC6OTHER on prostate cell proliferation and tissue growth.	False
BC6ENTC is a small - molecule inhibitor of BC6ENTG and BC6OTHER and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate - or high - risk myelofibrosis.	CPR:4
BC6ENTC is a small - molecule inhibitor of BC6OTHER and BC6ENTG and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate - or high - risk myelofibrosis.	CPR:4
BC6ENTC abolished these anti - BC6ENTG mAb - induced increases in lymphocytic cholinergic activity in a manner independent of its BC6OTHER - lowering activity.	CPR:4
 BC6ENTC regulates non - neuronal cholinergic activity in T lymphocytes via BC6ENTG - mediated pathways.	False
BC6OTHER abolished these anti - BC6ENTG mAb - induced increases in lymphocytic cholinergic activity in a manner independent of its BC6ENTC - lowering activity.	False
These results indicate that BC6ENTG contributes to the regulation of lymphocytic cholinergic activity via BC6OTHER - mediated pathways, and suggest that BC6ENTC exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	False
These results indicate that BC6OTHER contributes to the regulation of lymphocytic cholinergic activity via BC6ENTG - mediated pathways, and suggest that BC6ENTC exerts its immunosuppressive effects in part via modification of lymphocytic cholinergic activity.	False
We previously showed that BC6ENTG stimulates an independent, non - neuronal cholinergic system in T cells via BC6OTHER - mediated pathways, as evidenced by increases in BC6ENTC ( BC6OTHER ) synthesis and BC6OTHER ( BC6OTHER ) mRNA expression.	False
We previously showed that BC6OTHER stimulates an independent, non - neuronal cholinergic system in T cells via BC6ENTG - mediated pathways, as evidenced by increases in BC6ENTC ( BC6OTHER ) synthesis and BC6OTHER ( BC6OTHER ) mRNA expression.	False
We previously showed that BC6OTHER stimulates an independent, non - neuronal cholinergic system in T cells via BC6OTHER - mediated pathways, as evidenced by increases in BC6ENTC ( BC6OTHER ) synthesis and BC6ENTG ( BC6OTHER ) mRNA expression.	False
We previously showed that BC6OTHER stimulates an independent, non - neuronal cholinergic system in T cells via BC6OTHER - mediated pathways, as evidenced by increases in BC6ENTC ( BC6OTHER ) synthesis and BC6OTHER ( BC6ENTG ) mRNA expression.	False
We previously showed that BC6ENTG stimulates an independent, non - neuronal cholinergic system in T cells via BC6OTHER - mediated pathways, as evidenced by increases in BC6OTHER ( BC6ENTC ) synthesis and BC6OTHER ( BC6OTHER ) mRNA expression.	False
We previously showed that BC6OTHER stimulates an independent, non - neuronal cholinergic system in T cells via BC6ENTG - mediated pathways, as evidenced by increases in BC6OTHER ( BC6ENTC ) synthesis and BC6OTHER ( BC6OTHER ) mRNA expression.	False
We previously showed that BC6OTHER stimulates an independent, non - neuronal cholinergic system in T cells via BC6OTHER - mediated pathways, as evidenced by increases in BC6OTHER ( BC6ENTC ) synthesis and BC6ENTG ( BC6OTHER ) mRNA expression.	False
We previously showed that BC6OTHER stimulates an independent, non - neuronal cholinergic system in T cells via BC6OTHER - mediated pathways, as evidenced by increases in BC6OTHER ( BC6ENTC ) synthesis and BC6OTHER ( BC6ENTG ) mRNA expression.	False
The BC6ENTC - lowering drug BC6OTHER inhibits BC6ENTG signaling by binding to an allosteric site on BC6OTHER ( BC6OTHER ), which leads to immunomodulation.	False
The BC6ENTC - lowering drug BC6OTHER inhibits BC6OTHER signaling by binding to an allosteric site on BC6ENTG ( BC6OTHER ), which leads to immunomodulation.	False
The BC6ENTC - lowering drug BC6OTHER inhibits BC6OTHER signaling by binding to an allosteric site on BC6OTHER ( BC6ENTG ), which leads to immunomodulation.	False
The BC6OTHER - lowering drug BC6ENTC inhibits BC6ENTG signaling by binding to an allosteric site on BC6OTHER ( BC6OTHER ), which leads to immunomodulation.	CPR:4
The BC6OTHER - lowering drug BC6ENTC inhibits BC6OTHER signaling by binding to an allosteric site on BC6ENTG ( BC6OTHER ), which leads to immunomodulation.	False
The BC6OTHER - lowering drug BC6ENTC inhibits BC6OTHER signaling by binding to an allosteric site on BC6OTHER ( BC6ENTG ), which leads to immunomodulation.	False
We found that anti - BC6ENTG monoclonal antibody (mAb) increased BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and M5 muscarinic BC6OTHER receptor mRNA in MOLT - 3 cells, a human leukemic T cell line.	False
We found that anti - BC6OTHER monoclonal antibody (mAb) increased BC6ENTG activity, BC6ENTC synthesis and release, and expression of BC6OTHER and M5 muscarinic BC6OTHER receptor mRNA in MOLT - 3 cells, a human leukemic T cell line.	False
We found that anti - BC6OTHER monoclonal antibody (mAb) increased BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6ENTG and M5 muscarinic BC6OTHER receptor mRNA in MOLT - 3 cells, a human leukemic T cell line.	False
We found that anti - BC6OTHER monoclonal antibody (mAb) increased BC6OTHER activity, BC6ENTC synthesis and release, and expression of BC6OTHER and BC6ENTG mRNA in MOLT - 3 cells, a human leukemic T cell line.	False
We found that anti - BC6ENTG monoclonal antibody (mAb) increased BC6OTHER activity, BC6OTHER synthesis and release, and expression of BC6OTHER and M5 muscarinic BC6ENTC receptor mRNA in MOLT - 3 cells, a human leukemic T cell line.	False
We found that anti - BC6OTHER monoclonal antibody (mAb) increased BC6ENTG activity, BC6OTHER synthesis and release, and expression of BC6OTHER and M5 muscarinic BC6ENTC receptor mRNA in MOLT - 3 cells, a human leukemic T cell line.	False
We found that anti - BC6OTHER monoclonal antibody (mAb) increased BC6OTHER activity, BC6OTHER synthesis and release, and expression of BC6ENTG and M5 muscarinic BC6ENTC receptor mRNA in MOLT - 3 cells, a human leukemic T cell line.	False
In contrast, BC6ENTG knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6ENTC per se.	False
In contrast, BC6OTHER knockout ( BC6ENTG - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6ENTC per se.	False
In contrast, BC6OTHER knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6OTHER ) have reduced levels of BC6ENTG , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6ENTC per se.	False
Chronic treatment with the BC6ENTG inhibitor, BC6ENTC (DMI), reduced BC6OTHER levels in both control and BC6OTHER - / - mice, demonstrating that BC6OTHER is not required for the regulation of BC6OTHER by antidepressant drugs.	CPR:4
Chronic treatment with the BC6OTHER inhibitor, BC6ENTC (DMI), reduced BC6ENTG levels in both control and BC6OTHER - / - mice, demonstrating that BC6OTHER is not required for the regulation of BC6OTHER by antidepressant drugs.	CPR:4
Chronic treatment with the BC6OTHER inhibitor, BC6ENTC (DMI), reduced BC6OTHER levels in both control and BC6ENTG - / - mice, demonstrating that BC6OTHER is not required for the regulation of BC6OTHER by antidepressant drugs.	False
Chronic treatment with the BC6OTHER inhibitor, BC6ENTC (DMI), reduced BC6OTHER levels in both control and BC6OTHER - / - mice, demonstrating that BC6OTHER is not required for the regulation of BC6ENTG by antidepressant drugs.	False
Chronic treatment with the BC6ENTG inhibitor, BC6OTHER (DMI), reduced BC6OTHER levels in both control and BC6OTHER - / - mice, demonstrating that BC6ENTC is not required for the regulation of BC6OTHER by antidepressant drugs.	False
Chronic treatment with the BC6OTHER inhibitor, BC6OTHER (DMI), reduced BC6ENTG levels in both control and BC6OTHER - / - mice, demonstrating that BC6ENTC is not required for the regulation of BC6OTHER by antidepressant drugs.	False
Chronic treatment with the BC6OTHER inhibitor, BC6OTHER (DMI), reduced BC6OTHER levels in both control and BC6ENTG - / - mice, demonstrating that BC6ENTC is not required for the regulation of BC6OTHER by antidepressant drugs.	False
Chronic treatment with the BC6OTHER inhibitor, BC6OTHER (DMI), reduced BC6OTHER levels in both control and BC6OTHER - / - mice, demonstrating that BC6ENTC is not required for the regulation of BC6ENTG by antidepressant drugs.	False
 Regulation of BC6ENTC transporter abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6ENTG ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6ENTC transporter abundance by BC6OTHER and BC6OTHER in vivo. The BC6ENTG ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6ENTC transporter abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6ENTG signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6ENTC and BC6OTHER in vivo. The BC6OTHER transporter ( BC6ENTG ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6ENTC and BC6OTHER in vivo. The BC6ENTG ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6ENTC and BC6OTHER in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6ENTG signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6ENTG abundance by BC6ENTC and BC6OTHER in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6ENTC in vivo. The BC6OTHER transporter ( BC6ENTG ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6ENTC in vivo. The BC6ENTG ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6ENTC in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6ENTG signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6ENTG abundance by BC6OTHER and BC6ENTC in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6ENTG ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6ENTC ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6ENTG ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6ENTC ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6ENTG signaling by controlling the availability of synaptic BC6ENTC ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6ENTG abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6ENTC ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6ENTG ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6ENTC ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6ENTG ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6ENTC ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6ENTG signaling by controlling the availability of synaptic BC6OTHER ( BC6ENTC ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6ENTG abundance by BC6OTHER and BC6OTHER in vivo. The BC6OTHER transporter ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6ENTC ), and it is a direct target for some classes of antidepressant drugs.	False
BC6ENTG levels are normal in BC6OTHER knockout ( BC6OTHER - / - ) mice that lack BC6ENTC , demonstrating that the BC6OTHER does not require endogenous BC6OTHER for appropriate regulation under physiological conditions.	False
BC6OTHER levels are normal in BC6ENTG knockout ( BC6OTHER - / - ) mice that lack BC6ENTC , demonstrating that the BC6OTHER does not require endogenous BC6OTHER for appropriate regulation under physiological conditions.	False
BC6OTHER levels are normal in BC6OTHER knockout ( BC6ENTG - / - ) mice that lack BC6ENTC , demonstrating that the BC6OTHER does not require endogenous BC6OTHER for appropriate regulation under physiological conditions.	False
BC6OTHER levels are normal in BC6OTHER knockout ( BC6OTHER - / - ) mice that lack BC6ENTC , demonstrating that the BC6ENTG does not require endogenous BC6OTHER for appropriate regulation under physiological conditions.	False
BC6ENTG levels are normal in BC6OTHER knockout ( BC6OTHER - / - ) mice that lack BC6OTHER , demonstrating that the BC6OTHER does not require endogenous BC6ENTC for appropriate regulation under physiological conditions.	False
BC6OTHER levels are normal in BC6ENTG knockout ( BC6OTHER - / - ) mice that lack BC6OTHER , demonstrating that the BC6OTHER does not require endogenous BC6ENTC for appropriate regulation under physiological conditions.	False
BC6OTHER levels are normal in BC6OTHER knockout ( BC6ENTG - / - ) mice that lack BC6OTHER , demonstrating that the BC6OTHER does not require endogenous BC6ENTC for appropriate regulation under physiological conditions.	False
BC6OTHER levels are normal in BC6OTHER knockout ( BC6OTHER - / - ) mice that lack BC6OTHER , demonstrating that the BC6ENTG does not require endogenous BC6ENTC for appropriate regulation under physiological conditions.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6ENTC transporter ( BC6ENTG ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6OTHER abundance by BC6OTHER and BC6OTHER in vivo. The BC6ENTC transporter ( BC6OTHER ) regulates BC6ENTG signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
 Regulation of BC6ENTG abundance by BC6OTHER and BC6OTHER in vivo. The BC6ENTC transporter ( BC6OTHER ) regulates BC6OTHER signaling by controlling the availability of synaptic BC6OTHER ( BC6OTHER ), and it is a direct target for some classes of antidepressant drugs.	False
In contrast, BC6ENTG knockout ( BC6OTHER - / - ) mice that lack both BC6ENTC and BC6OTHER ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6ENTG - / - ) mice that lack both BC6ENTC and BC6OTHER ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6OTHER - / - ) mice that lack both BC6ENTC and BC6OTHER ( BC6OTHER ) have reduced levels of BC6ENTG , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6ENTG knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6ENTC ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6ENTG - / - ) mice that lack both BC6OTHER and BC6ENTC ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6ENTC ( BC6OTHER ) have reduced levels of BC6ENTG , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6ENTG knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6ENTC ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6ENTG - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6ENTC ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6ENTC ) have reduced levels of BC6ENTG , suggesting that it is down - regulated by a complete absence of BC6OTHER and not BC6OTHER per se.	False
In contrast, BC6ENTG knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6ENTC and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6ENTG - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6OTHER ) have reduced levels of BC6OTHER , suggesting that it is down - regulated by a complete absence of BC6ENTC and not BC6OTHER per se.	False
In contrast, BC6OTHER knockout ( BC6OTHER - / - ) mice that lack both BC6OTHER and BC6OTHER ( BC6OTHER ) have reduced levels of BC6ENTG , suggesting that it is down - regulated by a complete absence of BC6ENTC and not BC6OTHER per se.	False
Results of early clinical trials with both topically ( BC6ENTC , BC6OTHER ) and systemically (CC - 10004) active BC6ENTG inhibitors demonstrated efficacy in atopic dermatitis and in the case of CHEM, also in psoriasis.	CPR:4
Results of early clinical trials with both topically ( BC6OTHER , BC6ENTC ) and systemically (CC - 10004) active BC6ENTG inhibitors demonstrated efficacy in atopic dermatitis and in the case of CHEM, also in psoriasis.	CPR:4
The BC6ENTG is the predominant BC6ENTC degrading enzyme in a variety of inflammatory cells including eosinophils, neutrophils, macrophages, T cells and monocytes.	CPR:9
Consequently, BC6ENTG inhibitors including BC6ENTC and BC6OTHER have been tested in several models of allergic and irritant skin inflammation.	CPR:4
Consequently, BC6ENTG inhibitors including BC6OTHER and BC6ENTC have been tested in several models of allergic and irritant skin inflammation.	CPR:4
These BC6ENTG inhibitors displayed strong anti - inflammatory action in models of allergic contact dermatitis in mice, in the BC6ENTC induced skin inflammation in mice and in BC6OTHER sensitised guinea pigs.	False
These BC6OTHER inhibitors displayed strong anti - inflammatory action in models of allergic contact dermatitis in mice, in the BC6ENTC induced skin inflammation in mice and in BC6ENTG sensitised guinea pigs.	False
 BC6ENTC / BC6OTHER dipole couples agonist binding to BC6ENTG activation.	CPR:3
 BC6OTHER / BC6ENTC dipole couples agonist binding to BC6ENTG activation.	CPR:3
BC6ENTC - selective ionotropic BC6OTHER receptors ( BC6ENTG ) require external BC6OTHER and BC6OTHER as well as the neurotransmitter BC6OTHER for activation.	False
BC6ENTG ( BC6OTHER ) require external BC6OTHER and BC6OTHER as well as the neurotransmitter BC6ENTC for activation.	CPR:3
BC6OTHER - selective ionotropic BC6OTHER receptors ( BC6ENTG ) require external BC6OTHER and BC6OTHER as well as the neurotransmitter BC6ENTC for activation.	CPR:3
Although, external anions and cations apparently coactivate BC6ENTC receptors ( BC6ENTG ) in an identical manner, it has yet to be established how ions of opposite charge achieve this.	False
BC6OTHER - selective ionotropic BC6ENTC receptors ( BC6ENTG ) require external BC6OTHER and BC6OTHER as well as the neurotransmitter BC6OTHER for activation.	False
Consequently, other cation species may compete with BC6ENTC to regulate the time BC6ENTG remain in the open state.	False
BC6ENTG ( BC6OTHER ) require external BC6ENTC and BC6OTHER as well as the neurotransmitter BC6OTHER for activation.	CPR:3
BC6OTHER - selective ionotropic BC6OTHER receptors ( BC6ENTG ) require external BC6ENTC and BC6OTHER as well as the neurotransmitter BC6OTHER for activation.	CPR:3
BC6ENTG ( BC6OTHER ) require external BC6OTHER and BC6ENTC as well as the neurotransmitter BC6OTHER for activation.	CPR:3
BC6OTHER - selective ionotropic BC6OTHER receptors ( BC6ENTG ) require external BC6OTHER and BC6ENTC as well as the neurotransmitter BC6OTHER for activation.	CPR:3
Additionally, BC6ENTC and BC6OTHER ions coactivate BC6ENTG receptors by establishing a dipole, accounting for their common effect on BC6OTHER .	CPR:3
Additionally, BC6ENTC and BC6OTHER ions coactivate BC6OTHER receptors by establishing a dipole, accounting for their common effect on BC6ENTG .	False
Additionally, BC6OTHER and BC6ENTC ions coactivate BC6ENTG receptors by establishing a dipole, accounting for their common effect on BC6OTHER .	CPR:3
Additionally, BC6OTHER and BC6ENTC ions coactivate BC6OTHER receptors by establishing a dipole, accounting for their common effect on BC6ENTG .	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6ENTC / BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6ENTC / BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6ENTC / BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6ENTC / BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG - complex, hematocrit, blood BC6OTHER and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - BC6OTHER - complex, hematocrit, blood BC6ENTC and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - BC6OTHER - complex, hematocrit, blood BC6ENTC and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG - BC6OTHER - complex, hematocrit, blood BC6ENTC and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Twenty - nine taxi drivers (41 - 67 years old) were examined for urine BC6OTHER / BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - BC6ENTG - complex, hematocrit, blood BC6ENTC and blood pressure in the morning and at midnight during a duty day and in the following morning.	False
Here, in expressing BC6ENTC - hydrolyzing mutants of BC6ENTG in Nicotiana benthamiana using the MagnICON virus - assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof - of - principle that plants can express engineered BC6OTHER proteins with desired properties.	CPR:9
Here, in expressing BC6ENTC - hydrolyzing mutants of BC6OTHER in Nicotiana benthamiana using the MagnICON virus - assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof - of - principle that plants can express engineered BC6ENTG proteins with desired properties.	False
Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme BC6ENTG ( BC6OTHER ), which is capable of breaking down naturally occurring BC6ENTC before the drug can influence the reward centers of the brain or affect other areas of the body.	CPR:9
Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme BC6OTHER ( BC6ENTG ), which is capable of breaking down naturally occurring BC6ENTC before the drug can influence the reward centers of the brain or affect other areas of the body.	CPR:9
This prompted the design of variants of BC6ENTG which exhibit significantly improved catalytic activity against BC6ENTC .	CPR:9
Plants are a promising means to produce large amounts of these BC6ENTC hydrolase variants of BC6ENTG , cheaply, safely with no concerns regarding human pathogens and functionally equivalent to enzymes derived from other sources.	False
Plants as a source of BC6ENTG variants designed for enhanced BC6ENTC hydrolase activity.	False
and BC6ENTC 1 and 5 mg kg - 1 body wt., were given intravenously for comparison studies of potency at BC6ENTG , respectively.	False
We compared the BC6ENTG blocking potencies of BC6ENTC with those of its two stereoisomers (RR and SR) in pithed rats and in homogenized rat cerebral cortex and heart.	False
The BC6ENTG blocking activities of BC6ENTC and its RR - SR (50:50) stereoisomers.	False
Following both oral and intravenous dosing, the RR - SR combination was twice potent as BC6ENTC in terms of BC6ENTG antagonism at equivalent doses.	False
BC6ENTC and the enantiomers lacked affinity at BC6ENTG while at BC6OTHER the order of potency was BC6OTHER much greater than RR - SR greater than BC6OTHER .	False
BC6ENTC and the enantiomers lacked affinity at BC6OTHER while at BC6ENTG the order of potency was BC6OTHER much greater than RR - SR greater than BC6OTHER .	False
BC6OTHER and the enantiomers lacked affinity at BC6ENTG while at BC6OTHER the order of potency was BC6ENTC much greater than RR - SR greater than BC6OTHER .	False
BC6OTHER and the enantiomers lacked affinity at BC6OTHER while at BC6ENTG the order of potency was BC6ENTC much greater than RR - SR greater than BC6OTHER .	False
BC6OTHER and the enantiomers lacked affinity at BC6ENTG while at BC6OTHER the order of potency was BC6OTHER much greater than RR - SR greater than BC6ENTC .	False
BC6OTHER and the enantiomers lacked affinity at BC6OTHER while at BC6ENTG the order of potency was BC6OTHER much greater than RR - SR greater than BC6ENTC .	False
At BC6ENTG , the affinity of the compound RR - SR was about 3 times that of BC6ENTC .5.	False
As BC6ENTC is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of BC6ENTG actions), the combination of RR and SR may be a valuable substitute for BC6OTHER in the treatment of systemic hypertension.	False
As BC6OTHER is a mixture of active (RR and SR) and inactive (SS and SR) enantiomers (in terms of BC6ENTG actions), the combination of RR and SR may be a valuable substitute for BC6ENTC in the treatment of systemic hypertension.	False
Treatment with BC6ENTC and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6ENTG and BC6OTHER , and BC6OTHER or BC6OTHER inhibited production of BC6OTHER and BC6OTHER in HUVECs.	CPR:4
Treatment with BC6ENTC and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6ENTG , and BC6OTHER or BC6OTHER inhibited production of BC6OTHER and BC6OTHER in HUVECs.	CPR:4
Treatment with BC6ENTC and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6OTHER or BC6OTHER inhibited production of BC6ENTG and BC6OTHER in HUVECs.	False
Treatment with BC6ENTC and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6OTHER or BC6OTHER inhibited production of BC6OTHER and BC6ENTG in HUVECs.	False
Treatment with BC6OTHER and BC6ENTC resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6ENTG and BC6OTHER , and BC6OTHER or BC6OTHER inhibited production of BC6OTHER and BC6OTHER in HUVECs.	CPR:4
Treatment with BC6OTHER and BC6ENTC resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6ENTG , and BC6OTHER or BC6OTHER inhibited production of BC6OTHER and BC6OTHER in HUVECs.	CPR:4
Treatment with BC6OTHER and BC6ENTC resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6OTHER or BC6OTHER inhibited production of BC6ENTG and BC6OTHER in HUVECs.	False
Treatment with BC6OTHER and BC6ENTC resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6OTHER or BC6OTHER inhibited production of BC6OTHER and BC6ENTG in HUVECs.	False
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6ENTG and BC6OTHER , and BC6ENTC or BC6OTHER inhibited production of BC6OTHER and BC6OTHER in HUVECs.	False
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6ENTG , and BC6ENTC or BC6OTHER inhibited production of BC6OTHER and BC6OTHER in HUVECs.	False
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6ENTC or BC6OTHER inhibited production of BC6ENTG and BC6OTHER in HUVECs.	CPR:3
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6ENTC or BC6OTHER inhibited production of BC6OTHER and BC6ENTG in HUVECs.	CPR:4
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6ENTG and BC6OTHER , and BC6OTHER or BC6ENTC inhibited production of BC6OTHER and BC6OTHER in HUVECs.	False
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6ENTG , and BC6OTHER or BC6ENTC inhibited production of BC6OTHER and BC6OTHER in HUVECs.	False
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6OTHER or BC6ENTC inhibited production of BC6ENTG and BC6OTHER in HUVECs.	CPR:4
Treatment with BC6OTHER and BC6OTHER resulted in significantly prolonged aPTT and PT and inhibition of the activities of BC6OTHER and BC6OTHER , and BC6OTHER or BC6ENTC inhibited production of BC6OTHER and BC6ENTG in HUVECs.	CPR:4
In addition, treatment with BC6ENTC and BC6OTHER resulted in inhibition of BC6ENTG - induced production of BC6OTHER , and treatment with BC6OTHER resulted in significant reduction of the BC6OTHER to BC6OTHER ratio.	CPR:4
In addition, treatment with BC6ENTC and BC6OTHER resulted in inhibition of BC6OTHER - induced production of BC6ENTG , and treatment with BC6OTHER resulted in significant reduction of the BC6OTHER to BC6OTHER ratio.	CPR:4
In addition, treatment with BC6ENTC and BC6OTHER resulted in inhibition of BC6OTHER - induced production of BC6OTHER , and treatment with BC6OTHER resulted in significant reduction of the BC6ENTG to BC6OTHER ratio.	False
In addition, treatment with BC6ENTC and BC6OTHER resulted in inhibition of BC6OTHER - induced production of BC6OTHER , and treatment with BC6OTHER resulted in significant reduction of the BC6OTHER to BC6ENTG ratio.	False
In addition, treatment with BC6OTHER and BC6ENTC resulted in inhibition of BC6ENTG - induced production of BC6OTHER , and treatment with BC6OTHER resulted in significant reduction of the BC6OTHER to BC6OTHER ratio.	CPR:4
In addition, treatment with BC6OTHER and BC6ENTC resulted in inhibition of BC6OTHER - induced production of BC6ENTG , and treatment with BC6OTHER resulted in significant reduction of the BC6OTHER to BC6OTHER ratio.	CPR:4
In addition, treatment with BC6OTHER and BC6ENTC resulted in inhibition of BC6OTHER - induced production of BC6OTHER , and treatment with BC6OTHER resulted in significant reduction of the BC6ENTG to BC6OTHER ratio.	False
In addition, treatment with BC6OTHER and BC6ENTC resulted in inhibition of BC6OTHER - induced production of BC6OTHER , and treatment with BC6OTHER resulted in significant reduction of the BC6OTHER to BC6ENTG ratio.	False
In addition, treatment with BC6OTHER and BC6OTHER resulted in inhibition of BC6ENTG - induced production of BC6OTHER , and treatment with BC6ENTC resulted in significant reduction of the BC6OTHER to BC6OTHER ratio.	False
In addition, treatment with BC6OTHER and BC6OTHER resulted in inhibition of BC6OTHER - induced production of BC6ENTG , and treatment with BC6ENTC resulted in significant reduction of the BC6OTHER to BC6OTHER ratio.	False
In addition, treatment with BC6OTHER and BC6OTHER resulted in inhibition of BC6OTHER - induced production of BC6OTHER , and treatment with BC6ENTC resulted in significant reduction of the BC6ENTG to BC6OTHER ratio.	CPR:4
In addition, treatment with BC6OTHER and BC6OTHER resulted in inhibition of BC6OTHER - induced production of BC6OTHER , and treatment with BC6ENTC resulted in significant reduction of the BC6OTHER to BC6ENTG ratio.	CPR:4
Enzyme activities such as BC6ENTC dismutase, BC6OTHER , BC6ENTG and lipid peroxidation were also determined in the stomach tissues.	False
Enzyme activities such as BC6ENTG , BC6ENTC , BC6OTHER and lipid peroxidation were also determined in the stomach tissues.	False
Enzyme activities such as BC6OTHER , BC6ENTC , BC6ENTG and lipid peroxidation were also determined in the stomach tissues.	False
Consequently significant changes were observed in enzyme activities such as BC6ENTG , BC6OTHER , BC6ENTC and LPO in the stomach tissues when compared with BC6OTHER control group.	False
Consequently significant changes were observed in enzyme activities such as BC6OTHER , BC6ENTG , BC6ENTC and LPO in the stomach tissues when compared with BC6OTHER control group.	False
Consequently significant changes were observed in enzyme activities such as BC6ENTG , BC6OTHER , BC6OTHER and LPO in the stomach tissues when compared with BC6ENTC control group.	False
Consequently significant changes were observed in enzyme activities such as BC6OTHER , BC6ENTG , BC6OTHER and LPO in the stomach tissues when compared with BC6ENTC control group.	False
BC6ENTC ( BC6OTHER ), a novel drug approved for the treatment of relapsing - remitting multiple sclerosis, activates different BC6ENTG ( BC6OTHER ) subtypes.	CPR:3
BC6ENTC ( BC6OTHER ), a novel drug approved for the treatment of relapsing - remitting multiple sclerosis, activates different BC6OTHER receptor ( BC6ENTG ) subtypes.	CPR:3
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6ENTG ( BC6OTHER ) antagonist, BC6ENTC , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6OTHER - 3 - kinase ( BC6OTHER ) pathways.	CPR:6
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6ENTG ) antagonist, BC6ENTC , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6OTHER - 3 - kinase ( BC6OTHER ) pathways.	CPR:6
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6ENTC , and by inhibitors of the BC6ENTG ( BC6OTHER ) and the BC6OTHER - 3 - kinase ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6ENTC , and by inhibitors of the BC6OTHER ( BC6ENTG ) and the BC6OTHER - 3 - kinase ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6ENTC , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6ENTG ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6ENTC , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6OTHER - 3 - kinase ( BC6ENTG ) pathways.	False
Neuroprotection was attenuated by BC6ENTG , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6ENTC , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6OTHER - 3 - kinase ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6ENTG ( BC6OTHER ) antagonist, BC6OTHER , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6ENTC - 3 - kinase ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6ENTG ) antagonist, BC6OTHER , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6ENTC - 3 - kinase ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6OTHER , and by inhibitors of the BC6ENTG ( BC6OTHER ) and the BC6ENTC - 3 - kinase ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6OTHER , and by inhibitors of the BC6OTHER ( BC6ENTG ) and the BC6ENTC - 3 - kinase ( BC6OTHER ) pathways.	False
Neuroprotection was attenuated by BC6OTHER , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6OTHER , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6ENTC - 3 - kinase ( BC6ENTG ) pathways.	False
Neuroprotection was attenuated by BC6ENTG , and inhibited by the selective BC6OTHER ( BC6OTHER ) antagonist, BC6OTHER , and by inhibitors of the BC6OTHER ( BC6OTHER ) and the BC6ENTC - 3 - kinase ( BC6OTHER ) pathways.	False
BC6OTHER ( BC6ENTC ), a novel drug approved for the treatment of relapsing - remitting multiple sclerosis, activates different BC6ENTG ( BC6OTHER ) subtypes.	CPR:3
BC6OTHER ( BC6ENTC ), a novel drug approved for the treatment of relapsing - remitting multiple sclerosis, activates different BC6OTHER receptor ( BC6ENTG ) subtypes.	CPR:3
BC6OTHER ( BC6OTHER ), a novel drug approved for the treatment of relapsing - remitting multiple sclerosis, activates different BC6ENTC receptor ( BC6ENTG ) subtypes.	False
However, recent evidence suggests that the action of BC6ENTC involves BC6ENTG expressed by cells resident in the CNS, including neurons.	False
CHEM - induced activation of BC6OTHER in liver tissues was inhibited by BC6ENTC pretreatment, and yet the direct addition of BC6OTHER to liver extracts from CHEM - challenged mice failed to block BC6ENTG activation in vitro.	False
CHEM - induced activation of BC6ENTG in liver tissues was inhibited by BC6ENTC pretreatment, and yet the direct addition of BC6OTHER to liver extracts from CHEM - challenged mice failed to block BC6OTHER activation in vitro.	False
Effects of BC6ENTC on BC6ENTG - mediated fulminant hepatitis in mice.	False
CHEM - induced activation of BC6OTHER in liver tissues was inhibited by BC6OTHER pretreatment, and yet the direct addition of BC6ENTC to liver extracts from CHEM - challenged mice failed to block BC6ENTG activation in vitro.	False
CHEM - induced activation of BC6ENTG in liver tissues was inhibited by BC6OTHER pretreatment, and yet the direct addition of BC6ENTC to liver extracts from CHEM - challenged mice failed to block BC6OTHER activation in vitro.	False
Moreover, BC6ENTC efficiently suppressed the release of BC6ENTG from mitochondria of the liver tissues from CHEM - challenged mice.	CPR:4
In contrast, BC6ENTG activation and BC6OTHER truncation triggered by CHEM were not diminished by BC6ENTC pretreatment in mouse livers.	False
In contrast, BC6OTHER activation and BC6ENTG truncation triggered by CHEM were not diminished by BC6ENTC pretreatment in mouse livers.	False
Our results suggest that easing of BC6ENTG - triggered fulminant hepatitis by BC6ENTC may involve a mitochondrial apoptotic pathway, probably through preventing BC6OTHER release and thereby blocking downstream BC6OTHER activation.	False
Our results suggest that easing of BC6OTHER - triggered fulminant hepatitis by BC6ENTC may involve a mitochondrial apoptotic pathway, probably through preventing BC6ENTG release and thereby blocking downstream BC6OTHER activation.	CPR:4
Our results suggest that easing of BC6OTHER - triggered fulminant hepatitis by BC6ENTC may involve a mitochondrial apoptotic pathway, probably through preventing BC6OTHER release and thereby blocking downstream BC6ENTG activation.	CPR:4
We investigated the effects of BC6ENTC on fulminant hepatitis in C57BL / 6J mice induced by lethal challenge of the activating anti - BC6ENTG antibody, CHEM.	False
Intraperitoneal injection of CHEM (0.6 microg g( - 1)) to mice resulted in fulminant hepatitis, as evidenced by increase of BC6ENTG BC6ENTC transaminase activities and histopathological alterations in liver sections, as well as animal death.	False
CONCLUSIONS: The most interesting findings were the high mRNA expression of BC6ENTG receptors in lymphocytes potentially explaining the anti - inflammatory effects of BC6ENTC , BC6OTHER receptors in monocytes and a previously unrecognised expression of BC6OTHER in lymphocytes and monocytes.	False
CONCLUSIONS: The most interesting findings were the high mRNA expression of BC6OTHER receptors in lymphocytes potentially explaining the anti - inflammatory effects of BC6ENTC , BC6ENTG receptors in monocytes and a previously unrecognised expression of BC6OTHER in lymphocytes and monocytes.	False
CONCLUSIONS: The most interesting findings were the high mRNA expression of BC6OTHER receptors in lymphocytes potentially explaining the anti - inflammatory effects of BC6ENTC , BC6OTHER receptors in monocytes and a previously unrecognised expression of BC6ENTG in lymphocytes and monocytes.	False
BACKGROUND: Extracellular BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6ENTG receptors and BC6OTHER .	False
BACKGROUND: Extracellular BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6OTHER receptors and BC6ENTG .	False
BACKGROUND: Extracellular BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6ENTG receptors and BC6OTHER .	False
BACKGROUND: Extracellular BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6OTHER receptors and BC6ENTG .	False
BACKGROUND: Extracellular BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6ENTG receptors and BC6OTHER .	False
BACKGROUND: Extracellular BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6OTHER receptors and BC6ENTG .	False
BACKGROUND: Extracellular BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6ENTG receptors and BC6OTHER .	False
BACKGROUND: Extracellular BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6OTHER receptors and BC6ENTG .	False
BACKGROUND: Extracellular BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6ENTG receptors and BC6OTHER .	False
BACKGROUND: Extracellular BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) exert a wide range of biological effects in blood cells mediated by multiple ionotropic BC6OTHER receptors and BC6ENTG .	False
Additionally, a structural model of the BC6ENTG obtained by molecular dynamics simulation and energy minimization suggests that the BC6ENTC moiety of BC6OTHER - S16 could compete with the BC6OTHER - substrate.	False
Additionally, a structural model of the BC6ENTG obtained by molecular dynamics simulation and energy minimization suggests that the BC6OTHER moiety of BC6ENTC - S16 could compete with the BC6OTHER - substrate.	False
Additionally, a structural model of the BC6ENTG obtained by molecular dynamics simulation and energy minimization suggests that the BC6OTHER moiety of BC6OTHER - S16 could compete with the BC6ENTC - substrate.	False
In support of this observation, elongation can be reversed by the BC6OTHER inhibitor BC6ENTC , mRNA for the BC6ENTG antagonist BC6OTHER , or BC6OTHER CHEM.	False
In support of this observation, elongation can be reversed by the BC6OTHER inhibitor BC6ENTC , mRNA for the BC6OTHER antagonist BC6ENTG , or BC6OTHER CHEM.	False
In support of this observation, elongation can be reversed by the BC6OTHER inhibitor BC6ENTC , mRNA for the BC6OTHER antagonist BC6OTHER , or BC6ENTG CHEM.	False
In support of this observation, elongation can be reversed by the BC6ENTG inhibitor BC6ENTC , mRNA for the BC6OTHER antagonist BC6OTHER , or BC6OTHER CHEM.	CPR:4
Furthermore, expression of a multivalent but not a monovalent GAG containing BC6ENTG proteoglycan recapitulates the elongation phenotype observed with the bivalent BC6ENTC .	False
In this report, we utilized a library of BC6ENTC that produce two and three GAG chains on the same scaffold, respectively, thus mimicking CHEM, to examine the importance of GAG valency and chain type in regulating BC6ENTG / BC6OTHER interactions in vivo in zebrafish.	False
In this report, we utilized a library of BC6ENTC that produce two and three GAG chains on the same scaffold, respectively, thus mimicking CHEM, to examine the importance of GAG valency and chain type in regulating BC6OTHER / BC6ENTG interactions in vivo in zebrafish.	False
BC6ENTC competition binding assays showed that BC6OTHER potently bound to membrane from cells expressing recombinant BC6ENTG (Ki=1.5 nM), which was 20 - fold higher than that of BC6OTHER (Ki=30.4 nM).	False
BC6OTHER competition binding assays showed that BC6ENTC potently bound to membrane from cells expressing recombinant BC6ENTG (Ki=1.5 nM), which was 20 - fold higher than that of BC6OTHER (Ki=30.4 nM).	False
BC6OTHER competition binding assays showed that BC6OTHER potently bound to membrane from cells expressing recombinant BC6ENTG (Ki=1.5 nM), which was 20 - fold higher than that of BC6ENTC (Ki=30.4 nM).	False
BC6ENTC exhibited highly selective binding for the BC6ENTG (>2700 - fold) when compared to D1, D2, D3 and D5 BC6OTHER receptors.	False
BC6ENTC exhibited highly selective binding for the BC6OTHER (>2700 - fold) when compared to BC6ENTG .	False
BC6OTHER exhibited highly selective binding for the BC6ENTC D4.4 receptor (>2700 - fold) when compared to BC6ENTG .	False
BC6OTHER exhibited highly selective binding for the BC6ENTG (>2700 - fold) when compared to D1, D2, D3 and D5 BC6ENTC receptors.	False
Furthermore, in comparison to BC6ENTC and BC6OTHER , BC6OTHER exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for BC6ENTG (Ki=370 nM).	False
Furthermore, in comparison to BC6OTHER and BC6ENTC , BC6OTHER exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for BC6ENTG (Ki=370 nM).	False
BC6ENTC ( BC6OTHER ) was identified as a potent BC6ENTG antagonist with excellent receptor selectivity.	False
Furthermore, in comparison to BC6OTHER and BC6OTHER , BC6ENTC exhibits better receptor selectivity, showing no affinity up to 10 microM for a panel of more than 70 receptors and channels, with the exception of moderate affinity for BC6ENTG (Ki=370 nM).	False
BC6OTHER ( BC6ENTC ) was identified as a potent BC6ENTG antagonist with excellent receptor selectivity.	False
BC6ENTC potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6OTHER induced - BC6OTHER flux in BC6ENTG expressing cells, but not in human BC6OTHER D2L or D3 receptor cells.	False
BC6ENTC potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6OTHER induced - BC6OTHER flux in human BC6OTHER D4.4 receptor expressing cells, but not in BC6ENTG cells.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6ENTC - gamma - S binding assay and 1 microM BC6OTHER induced - BC6OTHER flux in BC6ENTG expressing cells, but not in human BC6OTHER D2L or D3 receptor cells.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6ENTC - gamma - S binding assay and 1 microM BC6OTHER induced - BC6OTHER flux in human BC6OTHER D4.4 receptor expressing cells, but not in BC6ENTG cells.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6ENTC induced - BC6OTHER flux in BC6ENTG expressing cells, but not in human BC6OTHER D2L or D3 receptor cells.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6ENTC induced - BC6OTHER flux in human BC6OTHER D4.4 receptor expressing cells, but not in BC6ENTG cells.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6OTHER induced - BC6ENTC flux in BC6ENTG expressing cells, but not in human BC6OTHER D2L or D3 receptor cells.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6OTHER induced - BC6ENTC flux in human BC6OTHER D4.4 receptor expressing cells, but not in BC6ENTG cells.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6OTHER induced - BC6OTHER flux in human BC6ENTC D4.4 receptor expressing cells, but not in BC6ENTG cells.	False
 BC6ENTC ( BC6OTHER ), a selective BC6ENTG antagonist.	False
 BC6OTHER ( BC6ENTC ), a selective BC6ENTG antagonist.	False
BC6OTHER potently inhibited the functional activity of agonist - induced BC6OTHER - gamma - S binding assay and 1 microM BC6OTHER induced - BC6OTHER flux in BC6ENTG expressing cells, but not in human BC6ENTC D2L or D3 receptor cells.	False
In contrast to BC6ENTC , BC6OTHER did not exhibit any significant intrinsic activity in a BC6ENTG .	False
In contrast to BC6OTHER , BC6ENTC did not exhibit any significant intrinsic activity in a BC6ENTG .	False
 Thus, BC6ENTC is a novel selective D4 antagonist that will enhance the ability to study BC6ENTG both in vitro and in vivo.	False
The increase in BC6ENTG activity was associated with the enhanced rate of BC6ENTC elimination in the hepatocyte culture.	False
The ensemble of results suggests that the ability of BC6ENTC pretreatment to enhance hepatocellular BC6ENTG activity may at least in part be attributed to the protection against BC6OTHER hepatotoxicity.	CPR:3
 BC6ENTC protects against BC6OTHER - induced hepatotoxicity by enhancing BC6ENTG activity.	CPR:3
 BC6OTHER protects against BC6ENTC - induced hepatotoxicity by enhancing BC6ENTG activity.	False
The ensemble of results suggests that the ability of BC6OTHER pretreatment to enhance hepatocellular BC6ENTG activity may at least in part be attributed to the protection against BC6ENTC hepatotoxicity.	False
Pretreating mice with BC6OTHER ( BC6OTHER ), a CHEM derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol / kg for 3 days protected against BC6ENTC - induced hepatic oxidative damage in mice, as evidenced by decreases in plasma BC6ENTG activity (78%) and hepatic BC6OTHER level (70%), when compared with the BC6OTHER intoxicated control.	CPR:4
Pretreating mice with BC6ENTC ( BC6OTHER ), a CHEM derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol / kg for 3 days protected against BC6OTHER - induced hepatic oxidative damage in mice, as evidenced by decreases in plasma BC6ENTG activity (78%) and hepatic BC6OTHER level (70%), when compared with the BC6OTHER intoxicated control.	False
Pretreating mice with BC6OTHER ( BC6OTHER ), a CHEM derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol / kg for 3 days protected against BC6OTHER - induced hepatic oxidative damage in mice, as evidenced by decreases in plasma BC6ENTG activity (78%) and hepatic BC6ENTC level (70%), when compared with the BC6OTHER intoxicated control.	False
Pretreating mice with BC6OTHER ( BC6ENTC ), a CHEM derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol / kg for 3 days protected against BC6OTHER - induced hepatic oxidative damage in mice, as evidenced by decreases in plasma BC6ENTG activity (78%) and hepatic BC6OTHER level (70%), when compared with the BC6OTHER intoxicated control.	False
Pretreating mice with BC6OTHER ( BC6OTHER ), a CHEM derivative isolated from the fruit of Schisandra chinensis, at a daily dose of 1 mmol / kg for 3 days protected against BC6OTHER - induced hepatic oxidative damage in mice, as evidenced by decreases in plasma BC6ENTG activity (78%) and hepatic BC6OTHER level (70%), when compared with the BC6ENTC intoxicated control.	False
In order to define the biochemical mechanism involved in the hepatoprotection afforded by BC6ENTC pretreatment, we examined the activity of BC6ENTG ( BC6OTHER ) in hepatocytes isolated from BC6OTHER pretreated rats.	False
In order to define the biochemical mechanism involved in the hepatoprotection afforded by BC6ENTC pretreatment, we examined the activity of BC6OTHER ( BC6ENTG ) in hepatocytes isolated from BC6OTHER pretreated rats.	False
In order to define the biochemical mechanism involved in the hepatoprotection afforded by BC6OTHER pretreatment, we examined the activity of BC6ENTG ( BC6OTHER ) in hepatocytes isolated from BC6ENTC pretreated rats.	False
In order to define the biochemical mechanism involved in the hepatoprotection afforded by BC6OTHER pretreatment, we examined the activity of BC6OTHER ( BC6ENTG ) in hepatocytes isolated from BC6ENTC pretreated rats.	False
Hepatocytes isolated from BC6ENTC pretreated (a daily dose of 1 mmol / kg for 3 days) rats showed a significant increase (25%) in BC6ENTG activity.	CPR:3
Preferentially expressed on presynaptic nerve terminals, the BC6ENTG negatively modulates BC6ENTC and BC6OTHER release and is widely distributed in the brain.	False
Preferentially expressed on presynaptic nerve terminals, the BC6ENTG negatively modulates BC6OTHER and BC6ENTC release and is widely distributed in the brain.	False
High levels of BC6ENTG are seen in brain areas such as prefrontal cortex, hippocampus and amygdala where BC6ENTC hyperfunction may be implicated in disorders and diseases such as anxiety and schizophrenia.	False
Introduction: The BC6OTHER , which belongs to the group II subfamily of metabotropic BC6ENTC receptors (mGlu) along with the BC6ENTG , has proven to be of particular importance in neuropharmacology.	False
Introduction: The BC6ENTG , which belongs to the group II subfamily of metabotropic BC6ENTC receptors (mGlu) along with the BC6OTHER , has proven to be of particular importance in neuropharmacology.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6ENTG ( BC6OTHER ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6ENTC - G2.0 - BC6OTHER or BC6OTHER - G3.0 - BC6OTHER dendrons.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6OTHER ( BC6ENTG ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6ENTC - G2.0 - BC6OTHER or BC6OTHER - G3.0 - BC6OTHER dendrons.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6ENTG ( BC6OTHER ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6OTHER - G2.0 - BC6ENTC or BC6OTHER - G3.0 - BC6OTHER dendrons.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6OTHER ( BC6ENTG ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6OTHER - G2.0 - BC6ENTC or BC6OTHER - G3.0 - BC6OTHER dendrons.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6ENTG ( BC6OTHER ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6OTHER - G2.0 - BC6OTHER or BC6ENTC - G3.0 - BC6OTHER dendrons.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6OTHER ( BC6ENTG ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6OTHER - G2.0 - BC6OTHER or BC6ENTC - G3.0 - BC6OTHER dendrons.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6ENTG ( BC6OTHER ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6OTHER - G2.0 - BC6OTHER or BC6OTHER - G3.0 - BC6ENTC dendrons.	False
We describe the synthesis of a core - shell biohybrid consisting of a BC6OTHER ( BC6ENTG ) core that serves as a reservoir for lipophilic molecules and a cationized shell region consisting of BC6OTHER - G2.0 - BC6OTHER or BC6OTHER - G3.0 - BC6ENTC dendrons.	False
The attachment of BC6ENTC - G2.0 - BC6OTHER dendrons to BC6ENTG yielded a nontoxic core - shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic BC6OTHER shell.	False
The attachment of BC6OTHER - G2.0 - BC6ENTC dendrons to BC6ENTG yielded a nontoxic core - shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic BC6OTHER shell.	False
The attachment of BC6OTHER - G2.0 - BC6OTHER dendrons to BC6ENTG yielded a nontoxic core - shell macromolecule that was clearly uptaken by A549 human epithelial cells due to the presence of the dendritic BC6ENTC shell.	False
Significantly higher loading of BC6ENTC was observed for dendronized G2 - DHSA compared with the native protein due to the availability of binding pockets of the BC6ENTG core, and interaction with the dendritic shell.	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6ENTC level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6ENTG ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6OTHER synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6ENTC level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6ENTG activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6ENTC level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6OTHER synthetase activity (5.5% of control), lack of hepatic BC6ENTG protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6ENTC level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6OTHER synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6ENTG gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6ENTC level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6OTHER synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6ENTG and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6ENTC level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6OTHER synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6ENTG ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6ENTC level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6ENTG ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6OTHER synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6OTHER level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6ENTG ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6ENTC synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6OTHER level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6ENTC synthetase activity (5.5% of control), lack of hepatic BC6ENTG protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6OTHER level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6ENTC synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6ENTG gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6OTHER level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6ENTC synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6ENTG and BC6OTHER ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6OTHER level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6OTHER ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6ENTC synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6ENTG ).	False
The diagnosis of CTLN2 was confirmed by elevations of plasma BC6OTHER level (384.3 nmol / mL; normal 17 - 43 nmol / mL) and serum BC6ENTG ( BC6OTHER ) (110 ng / mL; normal 4.6 - 12.2 ng / mL), decrease in hepatic BC6ENTC synthetase activity (5.5% of control), lack of hepatic BC6OTHER protein expression and mutations in BC6OTHER gene (compound heterozygote with BC6OTHER and BC6OTHER ).	False
To clarify the roles of BC6ENTG in hyperaccumulation of BC6OTHER and BC6OTHER in RBL - 2H3 cells, BC6OTHER - resistant and BC6OTHER - resistant cells were developed from RBL - 2H3 cells by continuous exposure to BC6OTHER and BC6ENTC , respectively.	False
RBL - Cdr cells also showed cross - resistance to BC6ENTC and BC6OTHER probably due to enhanced expression of BC6ENTG .	False
RBL - Cdr cells also showed cross - resistance to BC6OTHER and BC6ENTC probably due to enhanced expression of BC6ENTG .	False
These results suggest that BC6ENTG plays a pivotal role in the transport and toxicity of BC6ENTC and BC6OTHER in RBL - 2H3 cells.	CPR:9
Among the possible transporters involved in the uptake of BC6ENTC and BC6OTHER , the expression of BC6OTHER ( BC6OTHER ), encoded by BC6ENTG , showed a marked suppression in both RBL - Cdr and RBL - Mnr cells.	CPR:9
Among the possible transporters involved in the uptake of BC6ENTC and BC6OTHER , the expression of BC6ENTG ( BC6OTHER ), encoded by BC6OTHER , showed a marked suppression in both RBL - Cdr and RBL - Mnr cells.	CPR:9
Among the possible transporters involved in the uptake of BC6ENTC and BC6OTHER , the expression of BC6OTHER ( BC6ENTG ), encoded by BC6OTHER , showed a marked suppression in both RBL - Cdr and RBL - Mnr cells.	CPR:9
Among the possible transporters involved in the uptake of BC6OTHER and BC6ENTC , the expression of BC6OTHER ( BC6OTHER ), encoded by BC6ENTG , showed a marked suppression in both RBL - Cdr and RBL - Mnr cells.	CPR:9
Among the possible transporters involved in the uptake of BC6OTHER and BC6ENTC , the expression of BC6ENTG ( BC6OTHER ), encoded by BC6OTHER , showed a marked suppression in both RBL - Cdr and RBL - Mnr cells.	CPR:9
Among the possible transporters involved in the uptake of BC6OTHER and BC6ENTC , the expression of BC6OTHER ( BC6ENTG ), encoded by BC6OTHER , showed a marked suppression in both RBL - Cdr and RBL - Mnr cells.	CPR:9
Suppression of BC6ENTG expression is a common feature of BC6ENTC - resistant and BC6OTHER - resistant RBL - 2H3 cells.	False
Suppression of BC6ENTG expression is a common feature of BC6OTHER - resistant and BC6ENTC - resistant RBL - 2H3 cells.	False
These results suggest that BC6ENTG plays a pivotal role in the transport and toxicity of BC6OTHER and BC6ENTC in RBL - 2H3 cells.	CPR:9
To clarify the roles of BC6ENTG in hyperaccumulation of BC6ENTC and BC6OTHER in RBL - 2H3 cells, BC6OTHER - resistant and BC6OTHER - resistant cells were developed from RBL - 2H3 cells by continuous exposure to BC6OTHER and BC6OTHER , respectively.	False
To clarify the roles of BC6ENTG in hyperaccumulation of BC6OTHER and BC6ENTC in RBL - 2H3 cells, BC6OTHER - resistant and BC6OTHER - resistant cells were developed from RBL - 2H3 cells by continuous exposure to BC6OTHER and BC6OTHER , respectively.	False
To clarify the roles of BC6ENTG in hyperaccumulation of BC6OTHER and BC6OTHER in RBL - 2H3 cells, BC6ENTC - resistant and BC6OTHER - resistant cells were developed from RBL - 2H3 cells by continuous exposure to BC6OTHER and BC6OTHER , respectively.	False
To clarify the roles of BC6ENTG in hyperaccumulation of BC6OTHER and BC6OTHER in RBL - 2H3 cells, BC6OTHER - resistant and BC6ENTC - resistant cells were developed from RBL - 2H3 cells by continuous exposure to BC6OTHER and BC6OTHER , respectively.	False
To clarify the roles of BC6ENTG in hyperaccumulation of BC6OTHER and BC6OTHER in RBL - 2H3 cells, BC6OTHER - resistant and BC6OTHER - resistant cells were developed from RBL - 2H3 cells by continuous exposure to BC6ENTC and BC6OTHER , respectively.	False
The attachment of a BC6ENTC chain to LysB29 provided BC6ENTG detemir with reduced receptor affinities and metabolic and mitogenic potencies but did not change the balance between mitogenic and metabolic potencies.	False
In this study, we compared the BC6ENTG and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6ENTG binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6ENTG aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6ENTG ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6ENTG CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6ENTG ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6ENTG glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6ENTG ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6ENTG detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6ENTG ], and reference BC6OTHER analogs.	False
In this study, we compared the BC6OTHER and BC6OTHER binding properties and metabolic and mitogenic potencies of BC6OTHER aspart (B28Asp BC6OTHER ), BC6OTHER CHEM (B28Lys,B29Pro BC6OTHER ), BC6OTHER glargine (A21Gly,B31Arg,B32Arg BC6OTHER ), BC6OTHER detemir (CHEM) [B29Lys( BC6ENTC ), desB30 human BC6OTHER ], and reference BC6ENTG analogs.	False
Taken together these results indicate that in vivo or ex vivo exposure of intestinal tissue to BC6ENTC lead to similar intestinal lesions and activation of BC6ENTG .	CPR:3
Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of BC6ENTC to induce histological changes in the intestine and to activate the BC6ENTG BC6OTHER , BC6OTHER and BC6OTHER .	False
Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of BC6ENTC to induce histological changes in the intestine and to activate the BC6OTHER BC6ENTG , BC6OTHER and BC6OTHER .	False
Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of BC6ENTC to induce histological changes in the intestine and to activate the BC6OTHER BC6OTHER , BC6ENTG and BC6OTHER .	False
Using ex vivo and in vivo approaches, the purpose of this study was to investigate the ability of low doses of BC6ENTC to induce histological changes in the intestine and to activate the BC6OTHER BC6OTHER , BC6OTHER and BC6ENTG .	False
The food contaminant BC6ENTC activates the BC6ENTG in the intestine: interest of ex vivo models as an alternative to in vivo experiments.	CPR:3
Study of the additional subjects revealed that BC6ENTC does give rise to transiently high (58% - 64%) BC6ENTG occupancy 2 to 3 hours after a single dose that then decreases to minimal levels in 12 hours.	False
CONCLUSIONS: BC6ENTC shows a transiently high BC6ENTG occupancy, which decreases to very low levels by the end of the dosing interval.	False
As such, relatively little has been published regarding its in vivo effects at the BC6ENTC type 2 ( BC6ENTG ) and BC6OTHER type 2a (5 - HT2a) receptor systems.	False
As such, relatively little has been published regarding its in vivo effects at the BC6ENTC type 2 ( BC6OTHER ) and BC6ENTG systems.	False
As such, relatively little has been published regarding its in vivo effects at the BC6ENTG ( BC6OTHER ) and BC6ENTC type 2a (5 - HT2a) receptor systems.	False
As such, relatively little has been published regarding its in vivo effects at the BC6OTHER type 2 ( BC6ENTG ) and BC6ENTC type 2a (5 - HT2a) receptor systems.	False
RESULTS: BC6ENTC was an effective antipsychotic and improved the extrapyramidal symptoms and BC6ENTG level elevation noted at baseline.	CPR:3
A positron emission tomography study of BC6ENTC in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high BC6ENTG occupancy.	False
BC6ENTC is a potent non - competitive inhibitor of BC6ENTG from Candida (Ki = 30 nM).	CPR:4
 BC6ENTC : mode of action and properties of the BC6ENTG inhibition.	CPR:4
BC6ENTC ( BC6OTHER ) has primarily fungicidal action against many fungi as a result of its specific mechanism of BC6ENTG inhibition.	CPR:4
In contrast, inhibition of BC6ENTG only occurs at higher drug concentrations (Ki = 77 microM), and is competitive with BC6ENTC .	CPR:4
 Thus, BC6ENTC has no effect on BC6OTHER biosynthesis in vivo. BC6ENTG is not an enzyme of the BC6OTHER type, thereby avoiding potential inhibition of this class of enzymes.	False
 Thus, BC6ENTC has no effect on BC6OTHER biosynthesis in vivo. BC6OTHER epoxidase is not an enzyme of the BC6ENTG type, thereby avoiding potential inhibition of this class of enzymes.	False
 Thus, BC6OTHER has no effect on BC6ENTC biosynthesis in vivo. BC6ENTG is not an enzyme of the BC6OTHER type, thereby avoiding potential inhibition of this class of enzymes.	False
 Thus, BC6OTHER has no effect on BC6ENTC biosynthesis in vivo. BC6OTHER epoxidase is not an enzyme of the BC6ENTG type, thereby avoiding potential inhibition of this class of enzymes.	False
 Thus, BC6OTHER has no effect on BC6OTHER biosynthesis in vivo. BC6ENTC epoxidase is not an enzyme of the BC6ENTG type, thereby avoiding potential inhibition of this class of enzymes.	False
BC6OTHER ( BC6ENTC ) has primarily fungicidal action against many fungi as a result of its specific mechanism of BC6ENTG inhibition.	CPR:4
BC6ENTC rapidly increased BC6ENTG , BC6OTHER and BC6OTHER expression.	CPR:3
BC6ENTC rapidly increased BC6OTHER , BC6ENTG and BC6OTHER expression.	CPR:3
BC6ENTC rapidly increased BC6OTHER , BC6OTHER and BC6ENTG expression.	CPR:3
Cells were also co - incubated with the BC6ENTC and specific BC6ENTG inhibitors, which blocked the BC6OTHER - stimulated proliferation.	False
Cells were also co - incubated with the BC6OTHER and specific BC6ENTG inhibitors, which blocked the BC6ENTC - stimulated proliferation.	False
 BC6ENTC induces mitogenic signaling in breast cancer cell by an BC6ENTG - dependent mechanism.	False
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6ENTG , BC6OTHER and BC6OTHER BC6OTHER activity likely by activating BC6OTHER , BC6OTHER and BC6OTHER by an BC6OTHER - dependent mechanism.	CPR:3
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6OTHER , BC6ENTG and BC6OTHER BC6OTHER activity likely by activating BC6OTHER , BC6OTHER and BC6OTHER by an BC6OTHER - dependent mechanism.	False
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6OTHER , BC6OTHER and BC6ENTG BC6OTHER activity likely by activating BC6OTHER , BC6OTHER and BC6OTHER by an BC6OTHER - dependent mechanism.	CPR:3
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6OTHER , BC6OTHER and BC6OTHER BC6ENTG activity likely by activating BC6OTHER , BC6OTHER and BC6OTHER by an BC6OTHER - dependent mechanism.	CPR:3
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER activity likely by activating BC6ENTG , BC6OTHER and BC6OTHER by an BC6OTHER - dependent mechanism.	CPR:3
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER activity likely by activating BC6OTHER , BC6ENTG and BC6OTHER by an BC6OTHER - dependent mechanism.	CPR:3
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER activity likely by activating BC6OTHER , BC6OTHER and BC6ENTG by an BC6OTHER - dependent mechanism.	CPR:3
In conclusion, our results indicate that BC6ENTC increases BC cell proliferation in vitro by stimulating BC6OTHER , BC6OTHER and BC6OTHER BC6OTHER activity likely by activating BC6OTHER , BC6OTHER and BC6OTHER by an BC6ENTG - dependent mechanism.	False
Purpose of our study was to evaluate whether BC6ENTC regulates MCF - 7 cell proliferation by activating BC6ENTG , BC6OTHER and BC6OTHER BC6OTHER .	False
Purpose of our study was to evaluate whether BC6ENTC regulates MCF - 7 cell proliferation by activating BC6OTHER , BC6ENTG and BC6OTHER BC6OTHER .	False
Purpose of our study was to evaluate whether BC6ENTC regulates MCF - 7 cell proliferation by activating BC6OTHER , BC6OTHER and BC6ENTG BC6OTHER .	False
Purpose of our study was to evaluate whether BC6ENTC regulates MCF - 7 cell proliferation by activating BC6OTHER , BC6OTHER and BC6OTHER BC6ENTG .	False
BC6ENTC increased cell proliferation and the BC6ENTG - antagonist CHEM blunted it.	False
BC6ENTC ( BC6OTHER ) stimulates BC cells proliferation by binding the BC6ENTG ( BC6OTHER ).	False
BC6ENTC ( BC6OTHER ) stimulates BC cells proliferation by binding the BC6OTHER ( BC6ENTG ).	False
BC6ENTC decreased BC6ENTG expression, but not BC6OTHER .	CPR:4
BC6ENTC decreased BC6OTHER expression, but not BC6ENTG .	False
BC6OTHER ( BC6ENTC ) stimulates BC cells proliferation by binding the BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6ENTC ) stimulates BC cells proliferation by binding the BC6OTHER ( BC6ENTG ).	False
BC6ENTC also increased BC6ENTG , BC6OTHER and BC6OTHER phosphorylation while CHEM blocked it.	False
BC6ENTC also increased BC6OTHER , BC6ENTG and BC6OTHER phosphorylation while CHEM blocked it.	CPR:3
BC6ENTC also increased BC6OTHER , BC6OTHER and BC6ENTG phosphorylation while CHEM blocked it.	CPR:3
At baseline, week 12 and week 24, serum levels of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ( BC6ENTG ), BC6OTHER , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTG were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6ENTG Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ), BC6ENTC , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ), BC6ENTC , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6ENTG were measured and Free BC6OTHER Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC , and BC6OTHER were measured and Free BC6OTHER Index (FAI) and BC6ENTG Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6ENTC Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6ENTC Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6ENTC Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6ENTC Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6ENTC Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER , and BC6OTHER were measured and Free BC6ENTC Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTG were measured and Free BC6ENTC Index (FAI) and BC6OTHER Resistance (IR) indices were calculated.	False
At baseline, week 12 and week 24, serum levels of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER were measured and Free BC6ENTC Index (FAI) and BC6ENTG Resistance (IR) indices were calculated.	False
After 12 weeks BC6ENTG and BC6OTHER were increased, while BC6ENTC decreased.	False
After 12 weeks BC6OTHER and BC6ENTG were increased, while BC6ENTC decreased.	False
The present study investigates the combined effect of diet, physical exercise and BC6ENTC for 24 weeks, on serum BC6OTHER e ( BC6ENTG ) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.	False
The present study investigates the combined effect of diet, physical exercise and BC6ENTC for 24 weeks, on serum BC6ENTG e ( BC6OTHER ) levels in overweight and obese women with polycystic ovary syndrome (PCOS) and in overweight and obese controls.	False
We concluded that in overweight and obese women with PCOS BC6ENTC administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and BC6ENTG sensitivity, and increased serum BC6OTHER levels.	False
We concluded that in overweight and obese women with PCOS BC6ENTC administration, combined with diet and physical exercise, for 24 weeks, resulted in significant weight loss, improvement of hyperandrogenism and BC6OTHER sensitivity, and increased serum BC6ENTG levels.	CPR:3
Diet, physical exercise and BC6ENTC administration increase serum BC6ENTG ( BC6OTHER ) levels in women with polycystic ovary syndrome (PCOS).	CPR:3
Diet, physical exercise and BC6ENTC administration increase serum BC6OTHER ( BC6ENTG ) levels in women with polycystic ovary syndrome (PCOS).	CPR:3
Differential activation of BC6ENTG in discrete nucleus accumbens subregions during early and late BC6ENTC sensitization.	CPR:3
The present study examined the differential BC6OTHER - induced activation of the BC6OTHER ( BC6ENTC ) response element binding protein ( BC6ENTG ) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	False
The temporal and anatomical determinants of BC6ENTC - induced BC6ENTG activity may indicate functional differences among NAc shell subregions and suggest the involvement of BC6OTHER in early and late BC6OTHER effects.	CPR:3
The temporal and anatomical determinants of BC6ENTC - induced BC6OTHER activity may indicate functional differences among NAc shell subregions and suggest the involvement of BC6ENTG in early and late BC6OTHER effects.	False
The temporal and anatomical determinants of BC6OTHER - induced BC6ENTG activity may indicate functional differences among NAc shell subregions and suggest the involvement of BC6OTHER in early and late BC6ENTC effects.	False
The temporal and anatomical determinants of BC6OTHER - induced BC6OTHER activity may indicate functional differences among NAc shell subregions and suggest the involvement of BC6ENTG in early and late BC6ENTC effects.	False
BC6ENTG - dependent gene transcription, which may underlie long - lasting drug - induced changes in behavior and the subjective effects of BC6ENTC , varies depending on the stage of drug exposure or withdrawal and the cell population involved.	False
The present study examined the differential BC6ENTC - induced activation of the BC6OTHER ( BC6OTHER ) response element binding protein ( BC6ENTG ) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	CPR:3
The present study examined the differential BC6ENTC - induced activation of the BC6ENTG ( BC6OTHER ) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	CPR:3
Using immunohistochemistry, the authors analyzed changes in BC6ENTG phosphorylation in the NAc after 5 days of BC6ENTC , a short or long drug - free period, and a subsequent challenge injection.	CPR:3
Repeated BC6ENTC resulted in BC6OTHER phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated BC6OTHER , but rats challenged after 2 drug - free days yielded a more localized activation of BC6ENTG in the 3 most dorsomedial zones of the shell.	False
Repeated BC6ENTC resulted in BC6ENTG phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated BC6OTHER , but rats challenged after 2 drug - free days yielded a more localized activation of BC6OTHER in the 3 most dorsomedial zones of the shell.	CPR:3
The present study examined the differential BC6OTHER - induced activation of the BC6ENTC ( BC6OTHER ) response element binding protein ( BC6ENTG ) throughout discrete zones of analysis of the nucleus accumbens (NAc) in rats.	False
Repeated BC6OTHER resulted in BC6OTHER phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated BC6ENTC , but rats challenged after 2 drug - free days yielded a more localized activation of BC6ENTG in the 3 most dorsomedial zones of the shell.	CPR:3
Repeated BC6OTHER resulted in BC6ENTG phosphorylation in all analyzed subregions of the NAc excluding the most ventrolateral region of the shell 2 weeks after cessation of repeated BC6ENTC , but rats challenged after 2 drug - free days yielded a more localized activation of BC6OTHER in the 3 most dorsomedial zones of the shell.	False
Synovitis in horses is frequently treated by administration of non - BC6ENTC anti - inflammatory drugs (NSAIDs), which inhibit BC6ENTG isoforms ( BC6OTHER and BC6OTHER ).	False
Synovitis in horses is frequently treated by administration of non - BC6ENTC anti - inflammatory drugs (NSAIDs), which inhibit BC6OTHER isoforms ( BC6ENTG and BC6OTHER ).	False
Synovitis in horses is frequently treated by administration of non - BC6ENTC anti - inflammatory drugs (NSAIDs), which inhibit BC6OTHER isoforms ( BC6OTHER and BC6ENTG ).	False
In addition, both drugs significantly reduced BC6ENTC levels (P<0.05) 6 - h following LPS injection, whereas the probable BC6ENTG BC6OTHER BC6OTHER was significantly reduced by BC6OTHER (P<0.05), but not BC6OTHER .	False
In addition, both drugs significantly reduced BC6OTHER levels (P<0.05) 6 - h following LPS injection, whereas the probable BC6ENTG BC6ENTC BC6OTHER was significantly reduced by BC6OTHER (P<0.05), but not BC6OTHER .	False
In addition, both drugs significantly reduced BC6OTHER levels (P<0.05) 6 - h following LPS injection, whereas the probable BC6ENTG BC6OTHER BC6ENTC was significantly reduced by BC6OTHER (P<0.05), but not BC6OTHER .	False
In addition, both drugs significantly reduced BC6OTHER levels (P<0.05) 6 - h following LPS injection, whereas the probable BC6ENTG BC6OTHER BC6OTHER was significantly reduced by BC6ENTC (P<0.05), but not BC6OTHER .	CPR:4
In addition, both drugs significantly reduced BC6OTHER levels (P<0.05) 6 - h following LPS injection, whereas the probable BC6ENTG BC6OTHER BC6OTHER was significantly reduced by BC6OTHER (P<0.05), but not BC6ENTC .	False
The objective of the present study was to compare the anti - inflammatory effects of the preferential BC6ENTG inhibitor CHEM with the non - selective BC6OTHER inhibitor BC6ENTC in horses with lipopolysaccharide (LPS) - induced synovitis.	False
The objective of the present study was to compare the anti - inflammatory effects of the preferential BC6OTHER inhibitor CHEM with the non - selective BC6ENTG inhibitor BC6ENTC in horses with lipopolysaccharide (LPS) - induced synovitis.	CPR:4
Aqueous BC6ENTC (80%) extract of lentil hulls exhibited high antioxidant and anti - inflammatory activities preferentially inhibiting BC6ENTG (IC(50), 55 μg / ml), with moderate BC6OTHER (IC(50), 66 μg / ml) and BC6OTHER (IC(50), 119 μg / ml) inhibitory effects on the BC6OTHER pathway, whereas faba bean hull extracts exerted relatively mild BC6OTHER inhibitory activity.	CPR:4
Aqueous BC6ENTC (80%) extract of lentil hulls exhibited high antioxidant and anti - inflammatory activities preferentially inhibiting BC6OTHER (IC(50), 55 μg / ml), with moderate BC6ENTG (IC(50), 66 μg / ml) and BC6OTHER (IC(50), 119 μg / ml) inhibitory effects on the BC6OTHER pathway, whereas faba bean hull extracts exerted relatively mild BC6OTHER inhibitory activity.	CPR:4
Aqueous BC6ENTC (80%) extract of lentil hulls exhibited high antioxidant and anti - inflammatory activities preferentially inhibiting BC6OTHER (IC(50), 55 μg / ml), with moderate BC6OTHER (IC(50), 66 μg / ml) and BC6ENTG (IC(50), 119 μg / ml) inhibitory effects on the BC6OTHER pathway, whereas faba bean hull extracts exerted relatively mild BC6OTHER inhibitory activity.	CPR:4
Aqueous BC6ENTC (80%) extract of lentil hulls exhibited high antioxidant and anti - inflammatory activities preferentially inhibiting BC6OTHER (IC(50), 55 μg / ml), with moderate BC6OTHER (IC(50), 66 μg / ml) and BC6OTHER (IC(50), 119 μg / ml) inhibitory effects on the BC6ENTG pathway, whereas faba bean hull extracts exerted relatively mild BC6OTHER inhibitory activity.	CPR:4
Aqueous BC6ENTC (80%) extract of lentil hulls exhibited high antioxidant and anti - inflammatory activities preferentially inhibiting BC6OTHER (IC(50), 55 μg / ml), with moderate BC6OTHER (IC(50), 66 μg / ml) and BC6OTHER (IC(50), 119 μg / ml) inhibitory effects on the BC6OTHER pathway, whereas faba bean hull extracts exerted relatively mild BC6ENTG inhibitory activity.	CPR:4
Known BC6ENTG antagonists ( BC6ENTC , BC6OTHER and BC6OTHER ) were also able to block the response of BC6OTHER to BC6OTHER (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	CPR:6
Known BC6OTHER antagonists ( BC6ENTC , BC6OTHER and BC6OTHER ) were also able to block the response of BC6ENTG to BC6OTHER (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	CPR:4
Known BC6ENTG antagonists ( BC6OTHER , BC6ENTC and BC6OTHER ) were also able to block the response of BC6OTHER to BC6OTHER (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	CPR:6
Known BC6OTHER antagonists ( BC6OTHER , BC6ENTC and BC6OTHER ) were also able to block the response of BC6ENTG to BC6OTHER (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	CPR:4
Known BC6ENTG antagonists ( BC6OTHER , BC6OTHER and BC6ENTC ) were also able to block the response of BC6OTHER to BC6OTHER (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	CPR:6
Known BC6OTHER antagonists ( BC6OTHER , BC6OTHER and BC6ENTC ) were also able to block the response of BC6ENTG to BC6OTHER (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	CPR:4
Known BC6ENTG antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) were also able to block the response of BC6OTHER to BC6ENTC (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	False
Known BC6OTHER antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) were also able to block the response of BC6ENTG to BC6ENTC (IC(50): 0.8+ / - 1.0, 3.5+ / - 1.1 and 18+ / - 1.1 microM, respectively).	CPR:3
The BC6ENTC response of BC6ENTG - transfected HEK293 cells to the endogenous BC6OTHER agonist BC6OTHER was potentiated by low pH.	False
The BC6ENTC response of BC6OTHER - transfected HEK293 cells to the endogenous BC6ENTG agonist BC6OTHER was potentiated by low pH.	False
The BC6OTHER response of BC6ENTG - transfected HEK293 cells to the endogenous BC6OTHER agonist BC6ENTC was potentiated by low pH.	CPR:3
The BC6OTHER response of BC6OTHER - transfected HEK293 cells to the endogenous BC6ENTG agonist BC6ENTC was potentiated by low pH.	CPR:5
In contrast, BC6ENTC - and BC6OTHER - activated BC6ENTG currents were suppressed by low pH.	CPR:3
In contrast, BC6OTHER - and BC6ENTC - activated BC6ENTG currents were suppressed by low pH.	CPR:3
BC6OTHER ( BC6ENTG ) is a BC6ENTC - permeable channel, which can be activated by low temperatures, BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6ENTG ( BC6OTHER ) is a BC6ENTC - permeable channel, which can be activated by low temperatures, BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER ( BC6ENTG ) is a BC6OTHER , which can be activated by low temperatures, BC6OTHER , BC6ENTC and BC6OTHER .	CPR:3
BC6OTHER ( BC6OTHER ) is a BC6ENTG , which can be activated by low temperatures, BC6OTHER , BC6ENTC and BC6OTHER .	CPR:3
BC6ENTG ( BC6OTHER ) is a BC6OTHER , which can be activated by low temperatures, BC6OTHER , BC6ENTC and BC6OTHER .	CPR:3
We tested whether substances which are structurally related to BC6ENTC , or which produce a cooling sensation, could activate BC6ENTG , and compared the responses of BC6OTHER and BC6OTHER to these ligands.	False
We tested whether substances which are structurally related to BC6ENTC , or which produce a cooling sensation, could activate BC6OTHER , and compared the responses of BC6ENTG and BC6OTHER to these ligands.	False
We tested whether substances which are structurally related to BC6ENTC , or which produce a cooling sensation, could activate BC6OTHER , and compared the responses of BC6OTHER and BC6ENTG to these ligands.	False
The effects of 70 odorants and BC6ENTC - related substances on recombinant BC6ENTG ( BC6OTHER ), expressed in HEK293 cells, were examined using a FLIPR assay.	False
The effects of 70 odorants and BC6ENTC - related substances on recombinant BC6OTHER ( BC6ENTG ), expressed in HEK293 cells, were examined using a FLIPR assay.	False
BC6OTHER ( BC6ENTG ) is a BC6OTHER , which can be activated by low temperatures, BC6ENTC , BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER ( BC6OTHER ) is a BC6ENTG , which can be activated by low temperatures, BC6ENTC , BC6OTHER and BC6OTHER .	CPR:3
BC6ENTG ( BC6OTHER ) is a BC6OTHER , which can be activated by low temperatures, BC6ENTC , BC6OTHER and BC6OTHER .	CPR:3
Characterization of the mouse cold - BC6ENTC receptor BC6ENTG and BC6OTHER BC6OTHER using a fluorometric imaging plate reader (FLIPR) assay.	False
Characterization of the mouse cold - BC6ENTC receptor BC6OTHER and BC6ENTG BC6OTHER using a fluorometric imaging plate reader (FLIPR) assay.	False
Characterization of the mouse cold - BC6ENTC receptor BC6OTHER and BC6OTHER BC6ENTG using a fluorometric imaging plate reader (FLIPR) assay.	False
BC6OTHER ( BC6ENTG ) is a BC6OTHER , which can be activated by low temperatures, BC6OTHER , BC6OTHER and BC6ENTC .	CPR:3
BC6OTHER ( BC6OTHER ) is a BC6ENTG , which can be activated by low temperatures, BC6OTHER , BC6OTHER and BC6ENTC .	CPR:3
BC6ENTG ( BC6OTHER ) is a BC6OTHER , which can be activated by low temperatures, BC6OTHER , BC6OTHER and BC6ENTC .	CPR:3
The present study aimed to determine the protective effects and the underlying mechanisms of BC6ENTC on BC6ENTG ( BC6OTHER ) - induced allergic inflammation in a mouse model of allergic asthma.	False
The present study aimed to determine the protective effects and the underlying mechanisms of BC6ENTC on BC6OTHER ( BC6ENTG ) - induced allergic inflammation in a mouse model of allergic asthma.	False
 BC6ENTC attenuates allergic airway inflammation by regulation of CD4(+)CD25(+) regulatory T cells (Tregs) / Th17 balance in BC6ENTG - sensitized mice.	False
Histological studies demonstrated that BC6ENTC substantially inhibited BC6ENTG - induced eosinophilia in lung tissue.	CPR:4
The results in vivo show BC6ENTG - induced significantly broke Treg / Th17 balance; BC6ENTC treatments markedly attenuated the inflammatory in asthma model by regulating Treg / Th17 balance.	CPR:4
Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright - Giemsa staining, histological assessment was measured by BC6ENTC and BC6OTHER (HE) staining, BALF levels of Treg / Th17 BC6ENTG were measured by enzyme - linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	False
Airway resistance (Raw) was measured by the forced oscillation technique, differential cell count in BAL fluid (BALF) was measured by Wright - Giemsa staining, histological assessment was measured by BC6OTHER and BC6ENTC (HE) staining, BALF levels of Treg / Th17 BC6ENTG were measured by enzyme - linked immunosorbent assay, Treg cells and Th17 cells were evaluated by flow cytometry (FCM).	False
Our study demonstrated that BC6ENTC inhibited BC6ENTG - induced increases in eosinophil count; BC6OTHER level were recovered in bronchoalveolar lavage fluid increased BC6OTHER level in bronchoalveolar lavage fluid.	CPR:4
Our study demonstrated that BC6ENTC inhibited BC6OTHER - induced increases in eosinophil count; BC6ENTG level were recovered in bronchoalveolar lavage fluid increased BC6OTHER level in bronchoalveolar lavage fluid.	CPR:4
Our study demonstrated that BC6ENTC inhibited BC6OTHER - induced increases in eosinophil count; BC6OTHER level were recovered in bronchoalveolar lavage fluid increased BC6ENTG level in bronchoalveolar lavage fluid.	CPR:3
Moderate inhibitory effect of BC6ENTG - C oxidation by BC6ENTC was observed.	CPR:4
As part of a comprehensive study of the physiochemical and biological properties of BC6ENTC , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6OTHER - BC6OTHER model system and BC6ENTG BC6OTHER ( BC6OTHER - C) oxidation assay.	False
As part of a comprehensive study of the physiochemical and biological properties of BC6ENTC , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6OTHER - BC6OTHER model system and BC6OTHER BC6OTHER ( BC6ENTG - C) oxidation assay.	False
As part of a comprehensive study of the physiochemical and biological properties of BC6OTHER , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6ENTC - BC6OTHER model system and BC6ENTG BC6OTHER ( BC6OTHER - C) oxidation assay.	False
As part of a comprehensive study of the physiochemical and biological properties of BC6OTHER , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6ENTC - BC6OTHER model system and BC6OTHER BC6OTHER ( BC6ENTG - C) oxidation assay.	False
As part of a comprehensive study of the physiochemical and biological properties of BC6OTHER , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6OTHER - BC6ENTC model system and BC6ENTG BC6OTHER ( BC6OTHER - C) oxidation assay.	False
As part of a comprehensive study of the physiochemical and biological properties of BC6OTHER , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6OTHER - BC6ENTC model system and BC6OTHER BC6OTHER ( BC6ENTG - C) oxidation assay.	False
As part of a comprehensive study of the physiochemical and biological properties of BC6OTHER , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6OTHER - BC6OTHER model system and BC6ENTG BC6ENTC ( BC6OTHER - C) oxidation assay.	False
As part of a comprehensive study of the physiochemical and biological properties of BC6OTHER , successfully synthesized chemoenzymatically in our lab, their antioxidant activity was evaluated using three different in vitro model systems, namely bulk oil model system, BC6OTHER - BC6OTHER model system and BC6OTHER BC6ENTC ( BC6ENTG - C) oxidation assay.	False
However, the involvement of the BC6ENTG - dependent pathway in the process of cell death induced by either BC6OTHER 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan BC6OTHER inhibitor BC6ENTC .	False
However, the involvement of the BC6OTHER - dependent pathway in the process of cell death induced by either BC6OTHER 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan BC6ENTG inhibitor BC6ENTC .	CPR:4
 BC6ENTC Cause G2 / M Arrest Associated with the Modulation of BC6ENTG and BC6OTHER in Human Breast Cancer MCF - 7 Cells.	False
 BC6ENTC Cause G2 / M Arrest Associated with the Modulation of BC6OTHER and BC6ENTG in Human Breast Cancer MCF - 7 Cells.	False
Moreover, since reduced levels of BC6OTHER and BC6OTHER proteins but no change in BC6ENTG levels could be detected in MCF - 7 cells after BC6ENTC 3g or 3n treatment our results suggest that BC6OTHER treated cells die from lethal mitosis.	False
Moreover, since reduced levels of BC6ENTG and BC6OTHER proteins but no change in BC6OTHER levels could be detected in MCF - 7 cells after BC6ENTC 3g or 3n treatment our results suggest that BC6OTHER treated cells die from lethal mitosis.	CPR:4
Moreover, since reduced levels of BC6OTHER and BC6ENTG proteins but no change in BC6OTHER levels could be detected in MCF - 7 cells after BC6ENTC 3g or 3n treatment our results suggest that BC6OTHER treated cells die from lethal mitosis.	CPR:4
Moreover, since reduced levels of BC6OTHER and BC6OTHER proteins but no change in BC6ENTG levels could be detected in MCF - 7 cells after BC6OTHER 3g or 3n treatment our results suggest that BC6ENTC treated cells die from lethal mitosis.	False
Moreover, since reduced levels of BC6ENTG and BC6OTHER proteins but no change in BC6OTHER levels could be detected in MCF - 7 cells after BC6OTHER 3g or 3n treatment our results suggest that BC6ENTC treated cells die from lethal mitosis.	False
Moreover, since reduced levels of BC6OTHER and BC6ENTG proteins but no change in BC6OTHER levels could be detected in MCF - 7 cells after BC6OTHER 3g or 3n treatment our results suggest that BC6ENTC treated cells die from lethal mitosis.	False
However, the involvement of the BC6ENTG - dependent pathway in the process of cell death induced by either BC6ENTC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan BC6OTHER inhibitor BC6OTHER .	False
However, the involvement of the BC6OTHER - dependent pathway in the process of cell death induced by either BC6ENTC 3g or 3n is discarded since cell death could not be prevented by pretreatment with the pan BC6ENTG inhibitor BC6OTHER .	False
BC6ENTC is a BC6ENTG secretagogue that also enhances tissue viability in different organs.	CPR:3
Pharmacokinetic study of BC6ENTG - Releasing Peptide 6 ( BC6ENTC ) in nine male healthy volunteers.	False
In macrophages, levels of BC6ENTG , BC6OTHER , CHEM, BC6OTHER and BC6OTHER were increased by BC6ENTC used alone or in combination with HSV - 2.	CPR:3
In macrophages, levels of BC6OTHER , BC6ENTG , CHEM, BC6OTHER and BC6OTHER were increased by BC6ENTC used alone or in combination with HSV - 2.	CPR:3
In macrophages, levels of BC6OTHER , BC6OTHER , CHEM, BC6ENTG and BC6OTHER were increased by BC6ENTC used alone or in combination with HSV - 2.	CPR:3
In macrophages, levels of BC6OTHER , BC6OTHER , CHEM, BC6OTHER and BC6ENTG were increased by BC6ENTC used alone or in combination with HSV - 2.	CPR:3
Effect of the Potent Antiviral BC6ENTC on BC6ENTG Production by Murine Macrophages Stimulated with HSV - 2.	False
Besides, BC6ENTC not only synergized BC6ENTG production combined with BC6OTHER , but also prolonged its expression in time.	CPR:3
Besides, BC6ENTC not only synergized BC6OTHER production combined with BC6ENTG , but also prolonged its expression in time.	CPR:3
Results indicate that BC6ENTC inhibits HSV - 2 multiplication in epithelial cells and also increases BC6ENTG production in macrophages, both important actions to the clearance of infecting virus in the mouse vagina.	CPR:3
The antiherpetic action of BC6ENTC was measured by plaque reduction assay, and the immunomodulatory effect was determined by measuring the BC6ENTG production using a bioassay and ELISA method.	False
Beneficial metabolic effects were observed similarly in ob / ob mice treated twice daily with BC6OTHER for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating BC6ENTC (p < 0.05 to p < 0.01) and BC6ENTG (p < 0.05 to p < 0.001) and improved BC6OTHER tolerance (p < 0.05) and BC6OTHER sensitivity (p < 0.001).	False
Beneficial metabolic effects were observed similarly in ob / ob mice treated twice daily with BC6OTHER for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating BC6ENTC (p < 0.05 to p < 0.01) and BC6OTHER (p < 0.05 to p < 0.001) and improved BC6OTHER tolerance (p < 0.05) and BC6ENTG sensitivity (p < 0.001).	False
Beneficial metabolic effects were observed similarly in ob / ob mice treated twice daily with BC6ENTG for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating BC6ENTC (p < 0.05 to p < 0.01) and BC6OTHER (p < 0.05 to p < 0.001) and improved BC6OTHER tolerance (p < 0.05) and BC6OTHER sensitivity (p < 0.001).	False
Beneficial metabolic effects were observed similarly in ob / ob mice treated twice daily with BC6OTHER for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating BC6OTHER (p < 0.05 to p < 0.01) and BC6ENTG (p < 0.05 to p < 0.001) and improved BC6ENTC tolerance (p < 0.05) and BC6OTHER sensitivity (p < 0.001).	False
Beneficial metabolic effects were observed similarly in ob / ob mice treated twice daily with BC6OTHER for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating BC6OTHER (p < 0.05 to p < 0.01) and BC6OTHER (p < 0.05 to p < 0.001) and improved BC6ENTC tolerance (p < 0.05) and BC6ENTG sensitivity (p < 0.001).	False
Beneficial metabolic effects were observed similarly in ob / ob mice treated twice daily with BC6ENTG for 18 days, including significantly reduced energy intake (p < 0.05), body weight (p < 0.05 to p < 0.01), circulating BC6OTHER (p < 0.05 to p < 0.01) and BC6OTHER (p < 0.05 to p < 0.001) and improved BC6ENTC tolerance (p < 0.05) and BC6OTHER sensitivity (p < 0.001).	False
Twice daily injection of BC6ENTG in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6OTHER and BC6OTHER - BC6ENTC (p < 0.001) and improved BC6OTHER sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6OTHER tolerance.	False
Twice daily injection of BC6OTHER in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6ENTG and BC6OTHER - BC6ENTC (p < 0.001) and improved BC6OTHER sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6OTHER tolerance.	False
Twice daily injection of BC6OTHER in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6OTHER and BC6ENTG - BC6ENTC (p < 0.001) and improved BC6OTHER sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6OTHER tolerance.	False
Twice daily injection of BC6OTHER in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6OTHER and BC6OTHER - BC6ENTC (p < 0.001) and improved BC6ENTG sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6OTHER tolerance.	False
Twice daily injection of BC6ENTG in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6OTHER and BC6OTHER - BC6OTHER (p < 0.001) and improved BC6OTHER sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6ENTC tolerance.	False
Twice daily injection of BC6OTHER in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6ENTG and BC6OTHER - BC6OTHER (p < 0.001) and improved BC6OTHER sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6ENTC tolerance.	False
Twice daily injection of BC6OTHER in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6OTHER and BC6ENTG - BC6OTHER (p < 0.001) and improved BC6OTHER sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6ENTC tolerance.	False
Twice daily injection of BC6OTHER in normal mice transferred to a high fat diet reduced energy intake (p < 0.001), body weight (p < 0.01), circulating BC6OTHER and BC6OTHER - BC6OTHER (p < 0.001) and improved BC6ENTG sensitivity (p < 0.001) as well as oral and intraperitoneal (p < 0.001) BC6ENTC tolerance.	False
Energy intake, body weight, circulating BC6ENTG and BC6ENTC tolerance of BC6OTHER mice were similar to lean controls.	False
Energy intake, body weight, circulating BC6OTHER and BC6ENTC tolerance of BC6ENTG mice were similar to lean controls.	False
In addition, BC6ENTG prevented the effect of high fat feeding on BC6ENTC accumulation in liver and muscle.	False
The relatively large CHEM substrates can diffuse quickly into the BC6ENTG / BC6ENTC crystals and the enzymatic reaction can occur without significant crystal damage.	False
The bacterial enzyme BC6ENTG ( BC6OTHER ) catalyses the phosphorolysis of an CHEM bond in maltodextrins, removing the non - reducing BC6OTHER residues of linear CHEM as BC6ENTC ( BC6OTHER ).	CPR:9
The bacterial enzyme BC6OTHER ( BC6ENTG ) catalyses the phosphorolysis of an CHEM bond in maltodextrins, removing the non - reducing BC6OTHER residues of linear CHEM as BC6ENTC ( BC6OTHER ).	CPR:9
The bacterial enzyme BC6ENTG ( BC6OTHER ) catalyses the phosphorolysis of an CHEM bond in maltodextrins, removing the non - reducing BC6OTHER residues of linear CHEM as BC6OTHER ( BC6ENTC ).	CPR:9
The bacterial enzyme BC6OTHER ( BC6ENTG ) catalyses the phosphorolysis of an CHEM bond in maltodextrins, removing the non - reducing BC6OTHER residues of linear CHEM as BC6OTHER ( BC6ENTC ).	CPR:9
The 2.0A crystal structure of the BC6ENTG / BC6ENTC binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6OTHER , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6OTHER / BC6ENTC binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6ENTG , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6ENTG / BC6OTHER binary complex shows that the BC6ENTC substrate adopts a conformation seen previously with both inactive and active forms of BC6OTHER , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6OTHER / BC6OTHER binary complex shows that the BC6ENTC substrate adopts a conformation seen previously with both inactive and active forms of BC6ENTG , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6ENTG / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6OTHER , with the BC6ENTC group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6OTHER / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6ENTG , with the BC6ENTC group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6ENTG / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6OTHER , with the BC6OTHER group not in close contact with the BC6ENTC group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6OTHER / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6ENTG , with the BC6OTHER group not in close contact with the BC6ENTC group of the essential BC6OTHER ( BC6OTHER ) cofactor.	False
The comparison between BC6ENTG structures shows that CHEM377, through a CHEM bond with the BC6ENTC group of BC6OTHER substrate, triggers a conformational change of the 380s loop.	False
The 2.0A crystal structure of the BC6ENTG / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6OTHER , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6ENTC ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6OTHER / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6ENTG , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6ENTC ( BC6OTHER ) cofactor.	False
The 2.0A crystal structure of the BC6ENTG / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6OTHER , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6ENTC ) cofactor.	False
The 2.0A crystal structure of the BC6OTHER / BC6OTHER binary complex shows that the BC6OTHER substrate adopts a conformation seen previously with both inactive and active forms of BC6ENTG , with the BC6OTHER group not in close contact with the BC6OTHER group of the essential BC6OTHER ( BC6ENTC ) cofactor.	False
In the active BC6ENTG enzyme, the residue CHEM569 stabilizes the negative - charged BC6ENTC , whereas in the inactive form of BC6OTHER this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.	False
In the active BC6OTHER enzyme, the residue CHEM569 stabilizes the negative - charged BC6ENTC , whereas in the inactive form of BC6ENTG this key residue is held away from the catalytic site by loop 280s and an allosteric transition of the mammalian enzyme is required for activation.	False
The comparison between BC6ENTG structures shows that CHEM377, through a CHEM bond with the BC6OTHER group of BC6ENTC substrate, triggers a conformational change of the 380s loop.	False
The structures solved after the diffusion of CHEM (either BC6ENTC , G4 or BC6OTHER , G5) into BC6ENTG / BC6OTHER crystals show the formation of BC6OTHER and elongation of the CHEM chain.	False
The structures solved after the diffusion of CHEM (either BC6OTHER , G4 or BC6ENTC , G5) into BC6ENTG / BC6OTHER crystals show the formation of BC6OTHER and elongation of the CHEM chain.	False
The bacterial enzyme BC6ENTG ( BC6OTHER ) catalyses the phosphorolysis of an CHEM bond in maltodextrins, removing the non - reducing BC6ENTC residues of linear CHEM as BC6OTHER ( BC6OTHER ).	False
The bacterial enzyme BC6OTHER ( BC6ENTG ) catalyses the phosphorolysis of an CHEM bond in maltodextrins, removing the non - reducing BC6ENTC residues of linear CHEM as BC6OTHER ( BC6OTHER ).	False
The structures solved after the diffusion of CHEM (either BC6OTHER , G4 or BC6OTHER , G5) into BC6ENTG / BC6ENTC crystals show the formation of BC6OTHER and elongation of the CHEM chain.	False
The structures solved after the diffusion of CHEM (either BC6OTHER , G4 or BC6OTHER , G5) into BC6ENTG / BC6OTHER crystals show the formation of BC6ENTC and elongation of the CHEM chain.	False
Compounds of several other structural families, including the BC6ENTC BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6ENTC BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6ENTC , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6ENTC , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6ENTC BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6ENTC BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6ENTC , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6ENTC , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6ENTC BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6ENTC BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6ENTC and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6ENTC and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6ENTC , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6ENTC , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6ENTC BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6ENTC BC6OTHER and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6ENTC and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6ENTC and BC6OTHER , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6ENTC , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6ENTC , and the BC6OTHER BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Although highly homologous to other BC6ENTG , BC6OTHER is resistant to the BC6ENTC BC6OTHER ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6ENTG is resistant to the BC6ENTC BC6OTHER ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6ENTC BC6OTHER ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6ENTG in the family, such as the BC6OTHER or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6ENTC BC6OTHER ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6ENTG or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6ENTC BC6OTHER ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6ENTC BC6OTHER , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6ENTC BC6OTHER , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6ENTC , are potent inhibitors of BC6ENTG BC6OTHER .	CPR:4
Compounds of several other structural families, including the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , the BC6OTHER BC6OTHER and BC6OTHER , and the BC6OTHER BC6ENTC , are potent inhibitors of BC6OTHER BC6ENTG .	CPR:4
The hematopoietic class III receptor BC6ENTC kinase (RTK) Flt3 ( BC6ENTG , BC6OTHER ) has recently received much attention as a potential drug target.	False
The hematopoietic class III receptor BC6ENTC kinase (RTK) Flt3 ( BC6OTHER , BC6ENTG ) has recently received much attention as a potential drug target.	False
Signal transduction of BC6ENTG involves activation of several conserved pathways, including the BC6OTHER / BC6OTHER and the BC6ENTC - 3 - kinase / BC6OTHER signaling cascades.	False
Signal transduction of BC6OTHER involves activation of several conserved pathways, including the BC6ENTG / BC6OTHER and the BC6ENTC - 3 - kinase / BC6OTHER signaling cascades.	False
Signal transduction of BC6OTHER involves activation of several conserved pathways, including the BC6OTHER / BC6ENTG and the BC6ENTC - 3 - kinase / BC6OTHER signaling cascades.	False
Signal transduction of BC6OTHER involves activation of several conserved pathways, including the BC6OTHER / BC6OTHER and the BC6ENTC - 3 - kinase / BC6ENTG signaling cascades.	False
Selective inhibitors of BC6ENTG BC6ENTC kinase activity have the potential to suppress aberrant BC6OTHER signaling.	False
Selective inhibitors of BC6OTHER BC6ENTC kinase activity have the potential to suppress aberrant BC6ENTG signaling.	False
Although highly homologous to other BC6ENTG , BC6OTHER is resistant to the BC6OTHER BC6ENTC ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6ENTG is resistant to the BC6OTHER BC6ENTC ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6ENTC ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6ENTG in the family, such as the BC6OTHER or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6ENTC ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6ENTG or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6ENTC ( BC6OTHER , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6ENTG .	CPR:4
Although highly homologous to other BC6ENTG , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6ENTC , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6ENTG is resistant to the BC6OTHER BC6OTHER ( BC6ENTC , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6ENTC , BC6OTHER ), a potent inhibitor of other BC6ENTG in the family, such as the BC6OTHER or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6ENTC , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6ENTG or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6ENTC , BC6OTHER ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6ENTG .	CPR:4
Although highly homologous to other BC6ENTG , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTC ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6ENTG is resistant to the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTC ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6OTHER .	False
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTC ), a potent inhibitor of other BC6ENTG in the family, such as the BC6OTHER or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTC ), a potent inhibitor of other BC6OTHER in the family, such as the BC6ENTG or BC6OTHER .	CPR:4
Although highly homologous to other BC6OTHER , BC6OTHER is resistant to the BC6OTHER BC6OTHER ( BC6OTHER , BC6ENTC ), a potent inhibitor of other BC6OTHER in the family, such as the BC6OTHER or BC6ENTG .	CPR:4
BC6ENTC binding to BC6ENTG is prevented by the BC6OTHER 691 side - chain in the BC6OTHER binding center and mutating this site to BC6OTHER renders the corresponding BC6OTHER mutant sensitive to BC6OTHER .	False
BC6ENTC binding to BC6OTHER is prevented by the BC6OTHER 691 side - chain in the BC6OTHER binding center and mutating this site to BC6OTHER renders the corresponding BC6ENTG mutant sensitive to BC6OTHER .	False
BC6OTHER binding to BC6ENTG is prevented by the BC6ENTC 691 side - chain in the BC6OTHER binding center and mutating this site to BC6OTHER renders the corresponding BC6OTHER mutant sensitive to BC6OTHER .	False
BC6OTHER binding to BC6OTHER is prevented by the BC6ENTC 691 side - chain in the BC6OTHER binding center and mutating this site to BC6OTHER renders the corresponding BC6ENTG mutant sensitive to BC6OTHER .	False
BC6OTHER binding to BC6ENTG is prevented by the BC6OTHER 691 side - chain in the BC6ENTC binding center and mutating this site to BC6OTHER renders the corresponding BC6OTHER mutant sensitive to BC6OTHER .	False
BC6OTHER binding to BC6OTHER is prevented by the BC6OTHER 691 side - chain in the BC6ENTC binding center and mutating this site to BC6OTHER renders the corresponding BC6ENTG mutant sensitive to BC6OTHER .	False
BC6OTHER binding to BC6ENTG is prevented by the BC6OTHER 691 side - chain in the BC6OTHER binding center and mutating this site to BC6ENTC renders the corresponding BC6OTHER mutant sensitive to BC6OTHER .	False
BC6OTHER binding to BC6OTHER is prevented by the BC6OTHER 691 side - chain in the BC6OTHER binding center and mutating this site to BC6ENTC renders the corresponding BC6ENTG mutant sensitive to BC6OTHER .	False
BC6OTHER binding to BC6ENTG is prevented by the BC6OTHER 691 side - chain in the BC6OTHER binding center and mutating this site to BC6OTHER renders the corresponding BC6OTHER mutant sensitive to BC6ENTC .	False
BC6OTHER binding to BC6OTHER is prevented by the BC6OTHER 691 side - chain in the BC6OTHER binding center and mutating this site to BC6OTHER renders the corresponding BC6ENTG mutant sensitive to BC6ENTC .	CPR:4
The access of BC6ENTC to the mitochondria is regulated by the BC6ENTG , BC6OTHER , serving as the acute regulator of steroidogenesis.	False
The access of BC6ENTC to the mitochondria is regulated by the BC6OTHER , BC6ENTG , serving as the acute regulator of steroidogenesis.	False
The precise fashion in which these proteins interact and move BC6ENTC from the OMM to BC6ENTG , and the means by which BC6OTHER is loaded into the OMM, remain unclear.	CPR:9
The precise fashion in which these proteins interact and move BC6OTHER from the OMM to BC6ENTG , and the means by which BC6ENTC is loaded into the OMM, remain unclear.	False
Human deficiency diseases have been described for BC6ENTG and for all the mitochondrial steroidogenic enzymes, but not for the electron transfer proteins or for the components of the BC6ENTC import machine.	False
Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the BC6ENTC side - chain cleavage enzyme, BC6ENTG , and its two electron - transfer partners, BC6OTHER and BC6OTHER .	CPR:9
Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the BC6ENTC side - chain cleavage enzyme, BC6OTHER , and its two electron - transfer partners, BC6ENTG and BC6OTHER .	False
Mitochondria in the steroidogenic cells of the adrenal, gonad, placenta and brain contain the BC6ENTC side - chain cleavage enzyme, BC6OTHER , and its two electron - transfer partners, BC6OTHER and BC6ENTG .	False
Several other steroidogenic enzymes, including BC6ENTC dehydrogenase, BC6ENTG and BC6OTHER synthase also reside in mitochondria.	False
Several other steroidogenic enzymes, including BC6ENTC dehydrogenase, BC6OTHER and BC6ENTG also reside in mitochondria.	False
Several other steroidogenic enzymes, including BC6ENTG , BC6OTHER and BC6ENTC synthase also reside in mitochondria.	False
Several other steroidogenic enzymes, including BC6OTHER dehydrogenase, BC6ENTG and BC6ENTC synthase also reside in mitochondria.	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6ENTG antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6ENTC H1 receptor antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6ENTG antagonist, and BC6OTHER BC6OTHER , a BC6ENTC H1 receptor antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6ENTC BC6OTHER , a BC6ENTG antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	CPR:6
We have investigated the effects of BC6ENTC BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6ENTG antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6ENTC BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6ENTC , a BC6ENTG antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	CPR:6
We have investigated the effects of BC6OTHER BC6ENTC , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6ENTG antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6ENTC , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6ENTG antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6ENTC .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6ENTG antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6ENTC .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6ENTC .	False
Role of BC6ENTG and mast cells in gaseous BC6ENTC - induced airway microvascular leakage in rats.	False
The increase in vascular permeability induced by BC6ENTC in the rat airway was mediated predominantly by BC6ENTG stimulation.	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6ENTG antagonist, BC6ENTC BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6ENTC BC6OTHER , a BC6ENTG antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	CPR:6
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6ENTC BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6ENTG antagonist, BC6OTHER BC6ENTC , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6ENTC , a BC6ENTG antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	CPR:6
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6ENTC , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6ENTG antagonist, BC6OTHER BC6OTHER , a BC6ENTC B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6ENTC B2 receptor antagonist, and BC6OTHER BC6OTHER , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6ENTG antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6ENTC BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6ENTG antagonist, and BC6ENTC BC6OTHER , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6ENTC BC6OTHER , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	CPR:6
We have investigated the effects of BC6OTHER BC6OTHER , a BC6ENTG antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6ENTC , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6ENTG antagonist, and BC6OTHER BC6ENTC , a BC6OTHER antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	False
We have investigated the effects of BC6OTHER BC6OTHER , a BC6OTHER antagonist, BC6OTHER BC6OTHER , a BC6OTHER B2 receptor antagonist, and BC6OTHER BC6ENTC , a BC6ENTG antagonist with mast cell - stabilizing properties, on microvascular leakage induced by gaseous BC6OTHER .	CPR:6
BC6ENTC decreases levels of serum CHEM and causes some increase in BC6ENTG - BC6OTHER levels.	CPR:3
BC6OTHER decreases levels of serum CHEM and causes some increase in BC6ENTG - BC6ENTC levels.	False
BC6ENTC undergoes intensive and finally complete hepatic metabolism via the BC6ENTG systems.	CPR:9
In addition, there is inhibition of BC6ENTC uptake, eventually resulting in changes in BC6OTHER levels, dependent on the type of BC6ENTG .	False
In addition, there is inhibition of BC6OTHER uptake, eventually resulting in changes in BC6ENTC levels, dependent on the type of BC6ENTG .	False
As BC6ENTG exerts their effects by coupling to BC6OTHER proteins reducing BC6ENTC ( BC6OTHER ) levels (a key player in the modulation of cholangiocyte hyperplasia / damage), we evaluated the role of BC6OTHER in the regulation of biliary growth.	False
As BC6OTHER exerts their effects by coupling to BC6ENTG proteins reducing BC6ENTC ( BC6OTHER ) levels (a key player in the modulation of cholangiocyte hyperplasia / damage), we evaluated the role of BC6OTHER in the regulation of biliary growth.	False
As BC6OTHER exerts their effects by coupling to BC6OTHER proteins reducing BC6ENTC ( BC6OTHER ) levels (a key player in the modulation of cholangiocyte hyperplasia / damage), we evaluated the role of BC6ENTG in the regulation of biliary growth.	False
BC6ENTC inhibition of cholangiocyte growth was associated with decreased BC6OTHER levels and BC6ENTG / BC6OTHER / BC6OTHER phosphorylation.	CPR:4
BC6ENTC inhibition of cholangiocyte growth was associated with decreased BC6OTHER levels and BC6OTHER / BC6ENTG / BC6OTHER phosphorylation.	CPR:4
BC6ENTC inhibition of cholangiocyte growth was associated with decreased BC6OTHER levels and BC6OTHER / BC6OTHER / BC6ENTG phosphorylation.	CPR:4
BC6OTHER inhibition of cholangiocyte growth was associated with decreased BC6ENTC levels and BC6ENTG / BC6OTHER / BC6OTHER phosphorylation.	False
BC6OTHER inhibition of cholangiocyte growth was associated with decreased BC6ENTC levels and BC6OTHER / BC6ENTG / BC6OTHER phosphorylation.	False
BC6OTHER inhibition of cholangiocyte growth was associated with decreased BC6ENTC levels and BC6OTHER / BC6OTHER / BC6ENTG phosphorylation.	False
Downregulation of BC6ENTC - dependent BC6ENTG / BC6OTHER / BC6OTHER phosphorylation (by activation of BC6OTHER ) is important in the inhibition of cholangiocyte growth in liver diseases.	False
Downregulation of BC6ENTC - dependent BC6OTHER / BC6ENTG / BC6OTHER phosphorylation (by activation of BC6OTHER ) is important in the inhibition of cholangiocyte growth in liver diseases.	False
Downregulation of BC6ENTC - dependent BC6OTHER / BC6OTHER / BC6ENTG phosphorylation (by activation of BC6OTHER ) is important in the inhibition of cholangiocyte growth in liver diseases.	False
Downregulation of BC6ENTC - dependent BC6OTHER / BC6OTHER / BC6OTHER phosphorylation (by activation of BC6ENTG ) is important in the inhibition of cholangiocyte growth in liver diseases.	False
As BC6ENTG exerts their effects by coupling to BC6OTHER proteins reducing BC6OTHER ( BC6ENTC ) levels (a key player in the modulation of cholangiocyte hyperplasia / damage), we evaluated the role of BC6OTHER in the regulation of biliary growth.	False
As BC6OTHER exerts their effects by coupling to BC6ENTG proteins reducing BC6OTHER ( BC6ENTC ) levels (a key player in the modulation of cholangiocyte hyperplasia / damage), we evaluated the role of BC6OTHER in the regulation of biliary growth.	False
As BC6OTHER exerts their effects by coupling to BC6OTHER proteins reducing BC6OTHER ( BC6ENTC ) levels (a key player in the modulation of cholangiocyte hyperplasia / damage), we evaluated the role of BC6ENTG in the regulation of biliary growth.	False
BC6ENTC regulates many functions by binding to four BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ).	False
BC6ENTC regulates many functions by binding to four BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ).	False
BC6ENTC regulates many functions by binding to four BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ).	False
BC6ENTC regulates many functions by binding to four BC6OTHER ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ).	False
BC6ENTC regulates many functions by binding to four BC6OTHER ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ).	False
(2) Does in vivo administration of BC6ENTC ( BC6OTHER ) ( BC6ENTG agonist), BC6OTHER ( BC6OTHER antagonist) or BC6OTHER , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	CPR:5
(2) Does in vivo administration of BC6ENTC ( BC6OTHER ) ( BC6OTHER agonist), BC6OTHER ( BC6ENTG antagonist) or BC6OTHER , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	False
(2) Does in vivo administration of BC6OTHER ( BC6ENTC ) ( BC6ENTG agonist), BC6OTHER ( BC6OTHER antagonist) or BC6OTHER , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	CPR:5
(2) Does in vivo administration of BC6OTHER ( BC6ENTC ) ( BC6OTHER agonist), BC6OTHER ( BC6ENTG antagonist) or BC6OTHER , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	False
(2) Does in vivo administration of BC6OTHER ( BC6OTHER ) ( BC6ENTG agonist), BC6ENTC ( BC6OTHER antagonist) or BC6OTHER , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	False
(2) Does in vivo administration of BC6OTHER ( BC6OTHER ) ( BC6OTHER agonist), BC6ENTC ( BC6ENTG antagonist) or BC6OTHER , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	CPR:6
BC6OTHER regulates many functions by binding to four BC6ENTC G - coupled receptor proteins ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ).	False
BC6OTHER regulates many functions by binding to four BC6ENTC G - coupled receptor proteins ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG ).	False
BC6OTHER regulates many functions by binding to four BC6ENTC G - coupled receptor proteins ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ).	False
BC6OTHER regulates many functions by binding to four BC6ENTC G - coupled receptor proteins ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ).	False
(2) Does in vivo administration of BC6OTHER ( BC6OTHER ) ( BC6ENTG agonist), BC6OTHER ( BC6OTHER antagonist) or BC6ENTC , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	False
(2) Does in vivo administration of BC6OTHER ( BC6OTHER ) ( BC6OTHER agonist), BC6OTHER ( BC6ENTG antagonist) or BC6ENTC , in the absence / presence of BC6OTHER , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	False
(2) Does in vivo administration of BC6OTHER ( BC6OTHER ) ( BC6ENTG agonist), BC6OTHER ( BC6OTHER antagonist) or BC6OTHER , in the absence / presence of BC6ENTC , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	False
(2) Does in vivo administration of BC6OTHER ( BC6OTHER ) ( BC6OTHER agonist), BC6OTHER ( BC6ENTG antagonist) or BC6OTHER , in the absence / presence of BC6ENTC , to bile duct ligated (BDL) rats regulate cholangiocyte proliferation?	False
and (3) Does BC6ENTC inhibit cholangiocyte proliferation by downregulation of BC6OTHER - dependent phosphorylation of BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6ENTC inhibit cholangiocyte proliferation by downregulation of BC6OTHER - dependent phosphorylation of BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6ENTC inhibit cholangiocyte proliferation by downregulation of BC6OTHER - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6ENTC inhibit cholangiocyte proliferation by downregulation of BC6OTHER - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6ENTC inhibit cholangiocyte proliferation by downregulation of BC6OTHER - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) / BC6ENTG ( BC6OTHER )?	False
and (3) Does BC6ENTC inhibit cholangiocyte proliferation by downregulation of BC6OTHER - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6ENTG )?	False
and (3) Does BC6OTHER inhibit cholangiocyte proliferation by downregulation of BC6ENTC - dependent phosphorylation of BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6OTHER inhibit cholangiocyte proliferation by downregulation of BC6ENTC - dependent phosphorylation of BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6OTHER inhibit cholangiocyte proliferation by downregulation of BC6ENTC - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6OTHER inhibit cholangiocyte proliferation by downregulation of BC6ENTC - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6OTHER )?	False
and (3) Does BC6OTHER inhibit cholangiocyte proliferation by downregulation of BC6ENTC - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) / BC6ENTG ( BC6OTHER )?	False
and (3) Does BC6OTHER inhibit cholangiocyte proliferation by downregulation of BC6ENTC - dependent phosphorylation of BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) / BC6OTHER ( BC6ENTG )?	False
H3 BC6ENTC receptor agonist inhibits biliary growth of BDL rats by downregulation of the BC6OTHER / BC6ENTG / BC6OTHER pathway.	False
H3 BC6ENTC receptor agonist inhibits biliary growth of BDL rats by downregulation of the BC6OTHER / BC6OTHER / BC6ENTG pathway.	False
H3 BC6ENTC receptor agonist inhibits biliary growth of BDL rats by downregulation of the BC6ENTG / BC6OTHER / BC6OTHER pathway.	False
 BC6ENTG agonist inhibits biliary growth of BDL rats by downregulation of the BC6ENTC - dependent PKA / BC6OTHER / BC6OTHER pathway.	False
H3 BC6OTHER receptor agonist inhibits biliary growth of BDL rats by downregulation of the BC6ENTC - dependent PKA / BC6ENTG / BC6OTHER pathway.	False
H3 BC6OTHER receptor agonist inhibits biliary growth of BDL rats by downregulation of the BC6ENTC - dependent PKA / BC6OTHER / BC6ENTG pathway.	False
Following in vivo treatment of BDL rats with BC6ENTC for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6OTHER , we evaluated cholangiocyte proliferation, BC6OTHER levels and BC6ENTG , BC6OTHER and BC6OTHER phosphorylation.	False
Following in vivo treatment of BDL rats with BC6ENTC for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6OTHER , we evaluated cholangiocyte proliferation, BC6OTHER levels and BC6OTHER , BC6ENTG and BC6OTHER phosphorylation.	False
Following in vivo treatment of BDL rats with BC6ENTC for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6OTHER , we evaluated cholangiocyte proliferation, BC6OTHER levels and BC6OTHER , BC6OTHER and BC6ENTG phosphorylation.	False
Following in vivo treatment of BDL rats with BC6OTHER for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6ENTC , we evaluated cholangiocyte proliferation, BC6OTHER levels and BC6ENTG , BC6OTHER and BC6OTHER phosphorylation.	False
Following in vivo treatment of BDL rats with BC6OTHER for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6ENTC , we evaluated cholangiocyte proliferation, BC6OTHER levels and BC6OTHER , BC6ENTG and BC6OTHER phosphorylation.	False
Following in vivo treatment of BDL rats with BC6OTHER for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6ENTC , we evaluated cholangiocyte proliferation, BC6OTHER levels and BC6OTHER , BC6OTHER and BC6ENTG phosphorylation.	False
Following in vivo treatment of BDL rats with BC6OTHER for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6OTHER , we evaluated cholangiocyte proliferation, BC6ENTC levels and BC6ENTG , BC6OTHER and BC6OTHER phosphorylation.	False
Following in vivo treatment of BDL rats with BC6OTHER for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6OTHER , we evaluated cholangiocyte proliferation, BC6ENTC levels and BC6OTHER , BC6ENTG and BC6OTHER phosphorylation.	False
Following in vivo treatment of BDL rats with BC6OTHER for 1 week, and in vitro stimulation of BDL cholangiocytes with BC6OTHER , we evaluated cholangiocyte proliferation, BC6ENTC levels and BC6OTHER , BC6OTHER and BC6ENTG phosphorylation.	False
Endocrine therapy that targets the BC6ENTC receptor ( BC6OTHER ) is a standard of care for the treatment of postmenopausal women with BC6ENTG - positive breast cancer.	False
Endocrine therapy that targets the BC6ENTC receptor ( BC6ENTG ) is a standard of care for the treatment of postmenopausal women with BC6OTHER - positive breast cancer.	False
BC6ENTC blocks the action of BC6OTHER by binding to the BC6ENTG , and possesses both BC6OTHER - agonist and antagonist properties.	False
BC6ENTC blocks the action of BC6OTHER by binding to the BC6OTHER , and possesses both BC6ENTG - agonist and antagonist properties.	CPR:6
BC6OTHER blocks the action of BC6ENTC by binding to the BC6ENTG , and possesses both BC6OTHER - agonist and antagonist properties.	False
BC6OTHER blocks the action of BC6ENTC by binding to the BC6OTHER , and possesses both BC6ENTG - agonist and antagonist properties.	False
"The subsequent development of the BC6ENTG inhibitors (AIs) is an important therapeutic advance by creating a ""no BC6ENTC "" environment."	False
BC6ENTC is a novel BC6ENTG antagonist that destroys the BC6OTHER and its signaling pathway and is not associated with BC6OTHER - like agonist effects.	CPR:6
BC6ENTC is a novel BC6OTHER antagonist that destroys the BC6ENTG and its signaling pathway and is not associated with BC6OTHER - like agonist effects.	CPR:4
BC6OTHER is a novel BC6ENTG antagonist that destroys the BC6OTHER and its signaling pathway and is not associated with BC6ENTC - like agonist effects.	False
BC6OTHER is a novel BC6OTHER antagonist that destroys the BC6ENTG and its signaling pathway and is not associated with BC6ENTC - like agonist effects.	False
It produces high response rates compared with other SERMs and is not cross - resistant to BC6ENTC or BC6ENTG inhibitors and is equally as effective as the AI BC6OTHER in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant BC6OTHER therapy.	False
It produces high response rates compared with other SERMs and is not cross - resistant to BC6OTHER or BC6ENTG inhibitors and is equally as effective as the AI BC6ENTC in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant BC6OTHER therapy.	False
It produces high response rates compared with other SERMs and is not cross - resistant to BC6OTHER or BC6ENTG inhibitors and is equally as effective as the AI BC6OTHER in the treatment of postmenopausal women with advanced breast cancer who have progressed on prior adjuvant BC6ENTC therapy.	False
The selective BC6ENTG modulator (SERM) BC6ENTC has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of BC6OTHER - positive disease.	False
The selective BC6OTHER modulator (SERM) BC6ENTC has been in use for the treatment of advanced breast cancer for more than 30 years and is currently a treatment option for all stages of BC6ENTG - positive disease.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6ENTG PAM, BC6OTHER ( BC6ENTC ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6ENTC ), (human and rat BC6ENTG EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6ENTC ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6ENTG selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6ENTG PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6ENTC CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6ENTG EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6ENTC CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6ENTG selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6ENTC CRC.	False
This Letter describes the further chemical optimization of the BC6ENTG PAM MLPCN probes BC6ENTC and BC6OTHER .	False
This Letter describes the further chemical optimization of the BC6ENTG PAM MLPCN probes BC6OTHER and BC6ENTC .	False
Discovery of BC6ENTC : The first sub - micromolar, selective BC6ENTG PAM.	False
An HTS campaign identified several weak BC6ENTG CHEM ( BC6OTHER EC50 >10μM) with a structurally related BC6ENTC core that possessed a southern BC6OTHER linkage.	False
An HTS campaign identified several weak BC6OTHER CHEM ( BC6ENTG EC50 >10μM) with a structurally related BC6ENTC core that possessed a southern BC6OTHER linkage.	False
An HTS campaign identified several weak BC6ENTG CHEM ( BC6OTHER EC50 >10μM) with a structurally related BC6OTHER core that possessed a southern BC6ENTC linkage.	False
An HTS campaign identified several weak BC6OTHER CHEM ( BC6ENTG EC50 >10μM) with a structurally related BC6OTHER core that possessed a southern BC6ENTC linkage.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6ENTC linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6ENTG PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6ENTC linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6ENTG EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6ENTC linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6ENTG selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6ENTC / BC6OTHER cores led to the first sub - micromolar BC6ENTG PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6ENTC / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6ENTG EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6ENTC / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6ENTG selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6ENTC cores led to the first sub - micromolar BC6ENTG PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6ENTC cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6ENTG EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6ENTC cores led to the first sub - micromolar BC6OTHER PAM, BC6OTHER ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6ENTG selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6ENTG PAM, BC6ENTC ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6ENTC ( BC6OTHER ), (human and rat BC6ENTG EC50s of 409nM and 500nM, respectively) with excellent BC6OTHER selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
While SAR within the HTS series was very shallow and unable to be optimized, grafting the BC6OTHER linkage onto the BC6OTHER / BC6OTHER cores led to the first sub - micromolar BC6OTHER PAM, BC6ENTC ( BC6OTHER ), (human and rat BC6OTHER EC50s of 409nM and 500nM, respectively) with excellent BC6ENTG selectivity (M1 - M4 EC50s >30μM) and a robust 20 - fold leftward shift of the BC6OTHER CRC.	False
BC6ENTC suppressed BC6ENTG gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6OTHER - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	CPR:4
BC6ENTC suppressed BC6OTHER gene transcription enhanced by BC6ENTG without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6OTHER - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	False
BC6ENTC suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6ENTG expression or Smad1 phosphorylation, and BC6OTHER - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	False
BC6ENTC suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6OTHER - BC6ENTG complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	False
BC6ENTC suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6OTHER - BC6OTHER complex was bound to BC6ENTG , which forms heterodimers with BC6OTHER .	False
BC6ENTC suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6OTHER - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6ENTG .	False
BC6OTHER suppressed BC6ENTG gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6ENTC - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	False
BC6OTHER suppressed BC6OTHER gene transcription enhanced by BC6ENTG without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6ENTC - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	False
BC6OTHER suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6ENTG expression or Smad1 phosphorylation, and BC6ENTC - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	False
BC6OTHER suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6ENTC - BC6ENTG complex was bound to BC6OTHER , which forms heterodimers with BC6OTHER .	False
BC6OTHER suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6ENTC - BC6OTHER complex was bound to BC6ENTG , which forms heterodimers with BC6OTHER .	False
BC6OTHER suppressed BC6OTHER gene transcription enhanced by BC6OTHER without affecting BC6OTHER expression or Smad1 phosphorylation, and BC6ENTC - BC6OTHER complex was bound to BC6OTHER , which forms heterodimers with BC6ENTG .	False
High doses of BC6ENTG counteracted the effect of BC6ENTC on apoptosis of mPOBs, which was blunted by neutralizing anti - BC6OTHER antibody or BC6OTHER small interfering RNA.	False
High doses of BC6OTHER counteracted the effect of BC6ENTC on apoptosis of mPOBs, which was blunted by neutralizing anti - BC6ENTG antibody or BC6OTHER small interfering RNA.	False
High doses of BC6OTHER counteracted the effect of BC6ENTC on apoptosis of mPOBs, which was blunted by neutralizing anti - BC6OTHER antibody or BC6ENTG small interfering RNA.	False
These results demonstrate that BC6ENTG and GCs interact to regulate BC6OTHER expression in parallel with osteoblast differentiation and apoptosis and suggest that BC6OTHER and BC6ENTC may regulate osteoblast differentiation and apoptosis via their effect on BC6OTHER expression.	False
These results demonstrate that BC6OTHER and GCs interact to regulate BC6ENTG expression in parallel with osteoblast differentiation and apoptosis and suggest that BC6OTHER and BC6ENTC may regulate osteoblast differentiation and apoptosis via their effect on BC6OTHER expression.	False
These results demonstrate that BC6OTHER and GCs interact to regulate BC6OTHER expression in parallel with osteoblast differentiation and apoptosis and suggest that BC6ENTG and BC6ENTC may regulate osteoblast differentiation and apoptosis via their effect on BC6OTHER expression.	False
These results demonstrate that BC6OTHER and GCs interact to regulate BC6OTHER expression in parallel with osteoblast differentiation and apoptosis and suggest that BC6OTHER and BC6ENTC may regulate osteoblast differentiation and apoptosis via their effect on BC6ENTG expression.	False
In addition, putative osteogenic actions of BC6ENTG might be ascribed not only to its BC6ENTC - terminal domain but also to its BC6OTHER - unrelated BC6OTHER - terminal region.	False
In addition, putative osteogenic actions of BC6OTHER might be ascribed not only to its BC6ENTC - terminal domain but also to its BC6ENTG - unrelated BC6OTHER - terminal region.	False
In addition, putative osteogenic actions of BC6ENTG might be ascribed not only to its BC6OTHER - terminal domain but also to its BC6OTHER - unrelated BC6ENTC - terminal region.	False
In addition, putative osteogenic actions of BC6OTHER might be ascribed not only to its BC6OTHER - terminal domain but also to its BC6ENTG - unrelated BC6ENTC - terminal region.	False
Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that BC6ENTC - terminal BC6ENTG peptides might be considered a promising bone anabolic therapy.	False
Studies demonstrated that these BC6ENTC derived BC6OTHER were mainly pan - BC6ENTG inhibitors.	False
Studies demonstrated that these BC6OTHER derived BC6ENTC were mainly pan - BC6ENTG inhibitors.	False
This is distinct from BC6ENTG inhibitors based on non - BC6ENTC derived BC6OTHER , where high selectivity against BC6OTHER could be obtained.	CPR:4
This is distinct from BC6OTHER inhibitors based on non - BC6ENTC derived BC6OTHER , where high selectivity against BC6ENTG could be obtained.	CPR:4
This is distinct from BC6ENTG inhibitors based on non - BC6OTHER derived BC6ENTC , where high selectivity against BC6OTHER could be obtained.	CPR:4
This is distinct from BC6OTHER inhibitors based on non - BC6OTHER derived BC6ENTC , where high selectivity against BC6ENTG could be obtained.	CPR:4
SAR and lead optimization studies for BC6ENTG inhibitors based on BC6ENTC - derived BC6OTHER are described.	CPR:4
SAR and lead optimization studies for BC6ENTG inhibitors based on BC6OTHER - derived BC6ENTC are described.	CPR:4
 BC6ENTC derived BC6OTHER as BC6ENTG / BC6OTHER inhibitors.	CPR:4
 BC6ENTC derived BC6OTHER as BC6OTHER / BC6ENTG inhibitors.	CPR:4
 BC6OTHER derived BC6ENTC as BC6ENTG / BC6OTHER inhibitors.	CPR:4
 BC6OTHER derived BC6ENTC as BC6OTHER / BC6ENTG inhibitors.	CPR:4
The group treated with BC6ENTC alone showed decreased plasma BC6ENTG ( BC6OTHER ) activity (87% of control), whereas BC6OTHER plus exercise significantly decreased the BC6OTHER activity (79% of control), indicating an interactive effect of the combination.	CPR:4
The group treated with BC6ENTC alone showed decreased plasma BC6OTHER ( BC6ENTG ) activity (87% of control), whereas BC6OTHER plus exercise significantly decreased the BC6OTHER activity (79% of control), indicating an interactive effect of the combination.	CPR:4
The group treated with BC6ENTC alone showed decreased plasma BC6OTHER ( BC6OTHER ) activity (87% of control), whereas BC6OTHER plus exercise significantly decreased the BC6ENTG activity (79% of control), indicating an interactive effect of the combination.	False
The group treated with BC6OTHER alone showed decreased plasma BC6ENTG ( BC6OTHER ) activity (87% of control), whereas BC6ENTC plus exercise significantly decreased the BC6OTHER activity (79% of control), indicating an interactive effect of the combination.	False
The group treated with BC6OTHER alone showed decreased plasma BC6OTHER ( BC6ENTG ) activity (87% of control), whereas BC6ENTC plus exercise significantly decreased the BC6OTHER activity (79% of control), indicating an interactive effect of the combination.	False
The group treated with BC6OTHER alone showed decreased plasma BC6OTHER ( BC6OTHER ) activity (87% of control), whereas BC6ENTC plus exercise significantly decreased the BC6ENTG activity (79% of control), indicating an interactive effect of the combination.	CPR:4
However, BC6ENTG activity in triceps muscle decreased significantly (78% of control) in the group treated with BC6ENTC plus exercise.	CPR:4
BC6ENTG activity in plasma increased slightly (compared to control, BC6ENTC or exercise group) in mice treated with BC6OTHER plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.	CPR:3
BC6ENTG activity in plasma increased slightly (compared to control, BC6OTHER or exercise group) in mice treated with BC6ENTC plus exercise, which may be indicative of perturbation in the integrity of the skeletal muscle due to combination.	CPR:3
This study was designed to investigate the delayed effects of BC6ENTC and treadmill exercise on BC6ENTG activity, lipid peroxidation and histology of peripheral tissues of mice.	False
In the present study, BC6ENTC (1 and 2μM) inhibited the BC6ENTG - induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
In the present study, BC6ENTC (1 and 2μM) inhibited the BC6OTHER - induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including BC6ENTG , BC6OTHER , and BC6OTHER .	False
In the present study, BC6OTHER (1 and 2μM) inhibited the BC6ENTG - induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including BC6OTHER , BC6ENTC , and BC6OTHER .	False
In the present study, BC6OTHER (1 and 2μM) inhibited the BC6OTHER - induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including BC6ENTG , BC6ENTC , and BC6OTHER .	False
In the present study, BC6OTHER (1 and 2μM) inhibited the BC6ENTG - induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including BC6OTHER , BC6OTHER , and BC6ENTC .	False
In the present study, BC6OTHER (1 and 2μM) inhibited the BC6OTHER - induced aggregation of human platelets, but did not inhibit the activation of platelets by other agonists, including BC6ENTG , BC6OTHER , and BC6ENTC .	False
BC6ENTC inhibited the phosphorylation of BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6OTHER ) formation.	CPR:4
BC6ENTC inhibited the phosphorylation of BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6OTHER ) formation.	CPR:4
BC6ENTC inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6OTHER ) formation.	CPR:4
BC6ENTC inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6OTHER ) formation.	CPR:4
BC6ENTC inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6OTHER ) formation.	CPR:4
BC6ENTC inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6OTHER ) formation.	CPR:4
BC6ENTC inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6ENTG - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6OTHER ) formation.	CPR:4
BC6OTHER inhibited the phosphorylation of BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6ENTC mobilization and BC6OTHER radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6ENTC mobilization and BC6OTHER radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6ENTC mobilization and BC6OTHER radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6ENTC mobilization and BC6OTHER radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6ENTC mobilization and BC6OTHER radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6ENTC mobilization and BC6OTHER radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6ENTG - activated human platelets, and significantly reduced intracellular BC6ENTC mobilization and BC6OTHER radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6ENTC radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6ENTC radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6ENTC radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6ENTC radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6ENTC radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6ENTC radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6ENTG - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6ENTC radical ( BC6OTHER ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6ENTC ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6ENTC ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6ENTC ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6ENTC ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and BC6OTHER in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6ENTC ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG in BC6OTHER - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6ENTC ) formation.	False
BC6OTHER inhibited the phosphorylation of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER in BC6ENTG - activated human platelets, and significantly reduced intracellular BC6OTHER mobilization and BC6OTHER radical ( BC6ENTC ) formation.	False
BC6ENTC also reduced the BC6ENTG activation and platelet aggregation stimulated by CHEM.	CPR:4
BC6ENTC did not influence the binding of a fluorescent triflavin probe to the BC6ENTG on platelet membrane, and neither BC6OTHER nor BC6OTHER significantly reversed the BC6OTHER - mediated inhibition of platelet aggregation.	False
BC6OTHER did not influence the binding of a fluorescent triflavin probe to the BC6ENTG on platelet membrane, and neither BC6ENTC nor BC6OTHER significantly reversed the BC6OTHER - mediated inhibition of platelet aggregation.	False
BC6OTHER did not influence the binding of a fluorescent triflavin probe to the BC6ENTG on platelet membrane, and neither BC6OTHER nor BC6ENTC significantly reversed the BC6OTHER - mediated inhibition of platelet aggregation.	False
BC6OTHER did not influence the binding of a fluorescent triflavin probe to the BC6ENTG on platelet membrane, and neither BC6OTHER nor BC6OTHER significantly reversed the BC6ENTC - mediated inhibition of platelet aggregation.	False
In conclusion, BC6ENTC may inhibit platelet activation by inhibiting the BC6ENTG - BC6OTHER cascade and BC6OTHER radical formation, followed by suppressing the activation of BC6OTHER and BC6OTHER .	CPR:4
In conclusion, BC6ENTC may inhibit platelet activation by inhibiting the BC6OTHER - BC6ENTG cascade and BC6OTHER radical formation, followed by suppressing the activation of BC6OTHER and BC6OTHER .	CPR:4
In conclusion, BC6ENTC may inhibit platelet activation by inhibiting the BC6OTHER - BC6OTHER cascade and BC6OTHER radical formation, followed by suppressing the activation of BC6ENTG and BC6OTHER .	CPR:4
In conclusion, BC6ENTC may inhibit platelet activation by inhibiting the BC6OTHER - BC6OTHER cascade and BC6OTHER radical formation, followed by suppressing the activation of BC6OTHER and BC6ENTG .	CPR:4
In conclusion, BC6OTHER may inhibit platelet activation by inhibiting the BC6ENTG - BC6OTHER cascade and BC6ENTC radical formation, followed by suppressing the activation of BC6OTHER and BC6OTHER .	False
In conclusion, BC6OTHER may inhibit platelet activation by inhibiting the BC6OTHER - BC6ENTG cascade and BC6ENTC radical formation, followed by suppressing the activation of BC6OTHER and BC6OTHER .	False
In conclusion, BC6OTHER may inhibit platelet activation by inhibiting the BC6OTHER - BC6OTHER cascade and BC6ENTC radical formation, followed by suppressing the activation of BC6ENTG and BC6OTHER .	False
In conclusion, BC6OTHER may inhibit platelet activation by inhibiting the BC6OTHER - BC6OTHER cascade and BC6ENTC radical formation, followed by suppressing the activation of BC6OTHER and BC6ENTG .	False
BC6OTHER ( BC6ENTG ) and BC6OTHER - beta - synthase ( BC6OTHER ) utilize BC6ENTC as substrate to form BC6OTHER .	CPR:9
BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) utilize BC6ENTC as substrate to form BC6OTHER .	CPR:9
BC6OTHER ( BC6OTHER ) and BC6OTHER - beta - synthase ( BC6ENTG ) utilize BC6ENTC as substrate to form BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) and BC6OTHER - beta - synthase ( BC6OTHER ) utilize BC6ENTC as substrate to form BC6OTHER .	CPR:9
These effects of BC6ENTG blockade suggest an important proinflammatory role of BC6ENTC in regulating the severity of pancreatitis and associated lung injury and raise the possibility that BC6OTHER may exert similar activity in other forms of inflammation.	False
These effects of BC6ENTG blockade suggest an important proinflammatory role of BC6OTHER in regulating the severity of pancreatitis and associated lung injury and raise the possibility that BC6ENTC may exert similar activity in other forms of inflammation.	False
BC6OTHER ( BC6ENTG ) and BC6OTHER - beta - synthase ( BC6OTHER ) utilize BC6OTHER as substrate to form BC6ENTC .	CPR:9
BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) utilize BC6OTHER as substrate to form BC6ENTC .	CPR:9
BC6OTHER ( BC6OTHER ) and BC6OTHER - beta - synthase ( BC6ENTG ) utilize BC6OTHER as substrate to form BC6ENTC .	CPR:9
BC6ENTG ( BC6OTHER ) and BC6OTHER - beta - synthase ( BC6OTHER ) utilize BC6OTHER as substrate to form BC6ENTC .	CPR:9
Of these two enzymes, BC6ENTC - gamma - lyase ( BC6ENTG ) is believed to be the key enzyme that forms BC6OTHER in the cardiovascular system.	False
Of these two enzymes, BC6ENTG ( BC6OTHER ) is believed to be the key enzyme that forms BC6ENTC in the cardiovascular system.	CPR:9
Of these two enzymes, BC6OTHER ( BC6ENTG ) is believed to be the key enzyme that forms BC6ENTC in the cardiovascular system.	CPR:9
In this paper, we report the presence of BC6ENTC synthesizing enzyme activity and BC6ENTG (as determined by mRNA signal) in the pancreas.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6ENTG inhibitor, BC6ENTC ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6OTHER (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	CPR:4
Also, prophylactic, as well as therapeutic, treatment with the BC6OTHER inhibitor, BC6ENTC ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6ENTG (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6ENTG inhibitor, BC6OTHER ( BC6ENTC ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6OTHER (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	CPR:4
Also, prophylactic, as well as therapeutic, treatment with the BC6OTHER inhibitor, BC6OTHER ( BC6ENTC ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6ENTG (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6ENTG inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6ENTC - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6OTHER (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6OTHER inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6ENTC - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6ENTG (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
BC6ENTC - gamma - lyase ( BC6ENTG ) and BC6OTHER - beta - synthase ( BC6OTHER ) utilize BC6OTHER as substrate to form BC6OTHER .	False
BC6ENTC - gamma - lyase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) utilize BC6OTHER as substrate to form BC6OTHER .	False
BC6ENTC - gamma - lyase ( BC6OTHER ) and BC6OTHER - beta - synthase ( BC6ENTG ) utilize BC6OTHER as substrate to form BC6OTHER .	False
Also, prophylactic, as well as therapeutic, treatment with the BC6ENTG inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6OTHER (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6ENTC , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6OTHER inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6ENTG (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6ENTC , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6ENTG inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6OTHER (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6ENTC , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6OTHER inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6ENTG (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6ENTC , 7811+ / - 428; P<0.05 BC6OTHER c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6ENTG inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6OTHER (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6ENTC c.f.	False
Also, prophylactic, as well as therapeutic, treatment with the BC6OTHER inhibitor, BC6OTHER ( BC6OTHER ), significantly reduced the severity of BC6OTHER - induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma BC6ENTG (U / L) (control, 1204+ / - 59); prophylactic treatment: placebo, 10635+ / - 305; BC6OTHER , 7904+ / - 495; therapeutic treatment: placebo, 10427+ / - 470; BC6OTHER , 7811+ / - 428; P<0.05 BC6ENTC c.f.	False
BC6OTHER ( BC6ENTG ) and BC6ENTC - beta - synthase ( BC6OTHER ) utilize BC6OTHER as substrate to form BC6OTHER .	False
BC6OTHER ( BC6OTHER ) and BC6ENTC - beta - synthase ( BC6ENTG ) utilize BC6OTHER as substrate to form BC6OTHER .	False
BC6ENTG ( BC6OTHER ) and BC6ENTC - beta - synthase ( BC6OTHER ) utilize BC6OTHER as substrate to form BC6OTHER .	False
placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic BC6ENTG ( BC6OTHER ) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+ / - 0.63; BC6ENTC , 2.97+ / - 0.39; therapeutic treatment: placebo, 5.48+ / - 0.52; BC6OTHER , 3.03+ / - 0.47; P<0.05 BC6OTHER c.f.	CPR:3
placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic BC6OTHER ( BC6ENTG ) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+ / - 0.63; BC6ENTC , 2.97+ / - 0.39; therapeutic treatment: placebo, 5.48+ / - 0.52; BC6OTHER , 3.03+ / - 0.47; P<0.05 BC6OTHER c.f.	CPR:3
placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic BC6ENTG ( BC6OTHER ) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+ / - 0.63; BC6OTHER , 2.97+ / - 0.39; therapeutic treatment: placebo, 5.48+ / - 0.52; BC6ENTC , 3.03+ / - 0.47; P<0.05 BC6OTHER c.f.	False
placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic BC6OTHER ( BC6ENTG ) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+ / - 0.63; BC6OTHER , 2.97+ / - 0.39; therapeutic treatment: placebo, 5.48+ / - 0.52; BC6ENTC , 3.03+ / - 0.47; P<0.05 BC6OTHER c.f.	False
placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic BC6ENTG ( BC6OTHER ) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+ / - 0.63; BC6OTHER , 2.97+ / - 0.39; therapeutic treatment: placebo, 5.48+ / - 0.52; BC6OTHER , 3.03+ / - 0.47; P<0.05 BC6ENTC c.f.	False
placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic BC6OTHER ( BC6ENTG ) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+ / - 0.63; BC6OTHER , 2.97+ / - 0.39; therapeutic treatment: placebo, 5.48+ / - 0.52; BC6OTHER , 3.03+ / - 0.47; P<0.05 BC6ENTC c.f.	False
BC6OTHER , like BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER had highest affinity for the BC6ENTG , BC6OTHER and putative BC6OTHER receptor.	False
BC6OTHER , like BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER had highest affinity for the BC6OTHER , BC6ENTG and putative BC6OTHER receptor.	False
BC6OTHER , like BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER had highest affinity for the BC6OTHER , BC6OTHER and putative BC6ENTG receptor.	False
BC6OTHER , like BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC had highest affinity for the BC6ENTG , BC6OTHER and putative BC6OTHER receptor.	False
BC6OTHER , like BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC had highest affinity for the BC6OTHER , BC6ENTG and putative BC6OTHER receptor.	False
BC6OTHER , like BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC had highest affinity for the BC6OTHER , BC6OTHER and putative BC6ENTG receptor.	False
Kinetic studies comparing the binding of BC6ENTC and BC6OTHER to the BC6ENTG and BC6OTHER receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10 - 15 min.	False
Kinetic studies comparing the binding of BC6ENTC and BC6OTHER to the BC6OTHER and BC6ENTG receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10 - 15 min.	False
Kinetic studies comparing the binding of BC6OTHER and BC6ENTC to the BC6ENTG and BC6OTHER receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10 - 15 min.	False
Kinetic studies comparing the binding of BC6OTHER and BC6ENTC to the BC6OTHER and BC6ENTG receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10 - 15 min.	False
However, BC6ENTC had over 6 - fold higher affinity than BC6OTHER at the BC6ENTG receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3 - fold higher affinity than BC6OTHER at the BC6OTHER receptor (K(D): 3.14 and 11.07 nM, respectively).	False
However, BC6ENTC had over 6 - fold higher affinity than BC6OTHER at the BC6OTHER receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3 - fold higher affinity than BC6OTHER at the BC6ENTG receptor (K(D): 3.14 and 11.07 nM, respectively).	False
However, BC6OTHER had over 6 - fold higher affinity than BC6ENTC at the BC6ENTG receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3 - fold higher affinity than BC6OTHER at the BC6OTHER receptor (K(D): 3.14 and 11.07 nM, respectively).	False
However, BC6OTHER had over 6 - fold higher affinity than BC6ENTC at the BC6OTHER receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3 - fold higher affinity than BC6OTHER at the BC6ENTG receptor (K(D): 3.14 and 11.07 nM, respectively).	False
However, BC6OTHER had over 6 - fold higher affinity than BC6OTHER at the BC6ENTG receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3 - fold higher affinity than BC6ENTC at the BC6OTHER receptor (K(D): 3.14 and 11.07 nM, respectively).	False
However, BC6OTHER had over 6 - fold higher affinity than BC6OTHER at the BC6OTHER receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3 - fold higher affinity than BC6ENTC at the BC6ENTG receptor (K(D): 3.14 and 11.07 nM, respectively).	False
Characterisation of the BC6ENTC receptor binding profile of BC6OTHER and kinetics of BC6OTHER binding at BC6ENTG and BC6OTHER receptors.	False
Characterisation of the BC6ENTC receptor binding profile of BC6OTHER and kinetics of BC6OTHER binding at BC6OTHER and BC6ENTG receptors.	False
Characterisation of the BC6OTHER binding profile of BC6ENTC and kinetics of BC6OTHER binding at BC6ENTG and BC6OTHER receptors.	False
Characterisation of the BC6OTHER binding profile of BC6ENTC and kinetics of BC6OTHER binding at BC6OTHER and BC6ENTG receptors.	False
Characterisation of the BC6ENTG binding profile of BC6ENTC and kinetics of BC6OTHER binding at BC6OTHER and BC6OTHER receptors.	False
Characterisation of the BC6OTHER binding profile of BC6OTHER and kinetics of BC6ENTC binding at BC6ENTG and BC6OTHER receptors.	False
Characterisation of the BC6OTHER binding profile of BC6OTHER and kinetics of BC6ENTC binding at BC6OTHER and BC6ENTG receptors.	False
Characterisation of the BC6ENTG binding profile of BC6OTHER and kinetics of BC6ENTC binding at BC6OTHER and BC6OTHER receptors.	False
Association and dissociation rates for both radioligands could only be accurately determined at the BC6ENTG receptor and then only at 4 degrees C. At this temperature, BC6ENTC had a significantly (P<0.05) faster association rate (K(on) 0.249 min( - 1) nM( - 1)) than BC6OTHER (K(on) 0.024 min( - 1) nM( - 1)) and a significantly (P<0.05) slower off - rate (K(off) 0.027 min( - 1) compared to 0.037 min( - 1) for BC6OTHER ).	False
Association and dissociation rates for both radioligands could only be accurately determined at the BC6ENTG receptor and then only at 4 degrees C. At this temperature, BC6OTHER had a significantly (P<0.05) faster association rate (K(on) 0.249 min( - 1) nM( - 1)) than BC6ENTC (K(on) 0.024 min( - 1) nM( - 1)) and a significantly (P<0.05) slower off - rate (K(off) 0.027 min( - 1) compared to 0.037 min( - 1) for BC6OTHER ).	False
The affinity of BC6OTHER ( BC6OTHER ) for a range of BC6ENTC receptors was compared to values obtained for other BC6ENTG receptor agonists known to be effective in the treatment of migraine.	False
Association and dissociation rates for both radioligands could only be accurately determined at the BC6ENTG receptor and then only at 4 degrees C. At this temperature, BC6OTHER had a significantly (P<0.05) faster association rate (K(on) 0.249 min( - 1) nM( - 1)) than BC6OTHER (K(on) 0.024 min( - 1) nM( - 1)) and a significantly (P<0.05) slower off - rate (K(off) 0.027 min( - 1) compared to 0.037 min( - 1) for BC6ENTC ).	False
The affinity of BC6ENTC ( BC6OTHER ) for a range of BC6ENTG was compared to values obtained for other BC6OTHER receptor agonists known to be effective in the treatment of migraine.	False
The affinity of BC6ENTC ( BC6OTHER ) for a range of BC6OTHER receptors was compared to values obtained for other BC6ENTG receptor agonists known to be effective in the treatment of migraine.	False
BC6ENTC , like BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER had highest affinity for the BC6ENTG , BC6OTHER and putative BC6OTHER receptor.	False
BC6ENTC , like BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER had highest affinity for the BC6OTHER , BC6ENTG and putative BC6OTHER receptor.	False
BC6ENTC , like BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER had highest affinity for the BC6OTHER , BC6OTHER and putative BC6ENTG receptor.	False
BC6OTHER , like BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER had highest affinity for the BC6ENTG , BC6OTHER and putative BC6OTHER receptor.	False
BC6OTHER , like BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER had highest affinity for the BC6OTHER , BC6ENTG and putative BC6OTHER receptor.	False
BC6OTHER , like BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER had highest affinity for the BC6OTHER , BC6OTHER and putative BC6ENTG receptor.	False
The affinity of BC6OTHER ( BC6ENTC ) for a range of BC6ENTG was compared to values obtained for other BC6OTHER receptor agonists known to be effective in the treatment of migraine.	False
The affinity of BC6OTHER ( BC6ENTC ) for a range of BC6OTHER receptors was compared to values obtained for other BC6ENTG receptor agonists known to be effective in the treatment of migraine.	False
BC6OTHER , like BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER had highest affinity for the BC6ENTG , BC6OTHER and putative BC6OTHER receptor.	False
BC6OTHER , like BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER had highest affinity for the BC6OTHER , BC6ENTG and putative BC6OTHER receptor.	False
BC6OTHER , like BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER had highest affinity for the BC6OTHER , BC6OTHER and putative BC6ENTG receptor.	False
OBJECTIVES: This study examined the effect of a small - molecule, direct BC6OTHER inhibitor, BC6ENTC , on reperfusion induced by BC6ENTG ( BC6OTHER ) in patients with acute myocardial infarction (AMI).	False
OBJECTIVES: This study examined the effect of a small - molecule, direct BC6OTHER inhibitor, BC6ENTC , on reperfusion induced by BC6OTHER ( BC6ENTG ) in patients with acute myocardial infarction (AMI).	False
OBJECTIVES: This study examined the effect of a small - molecule, direct BC6ENTG inhibitor, BC6ENTC , on reperfusion induced by BC6OTHER ( BC6OTHER ) in patients with acute myocardial infarction (AMI).	CPR:4
A multicenter, randomized study of BC6OTHER versus heparin as adjunct to BC6OTHER ( BC6ENTG ) in acute myocardial infarction: myocardial infarction with BC6ENTC and BC6OTHER (MINT) study.	False
A multicenter, randomized study of BC6OTHER versus heparin as adjunct to BC6OTHER ( BC6OTHER ) in acute myocardial infarction: myocardial infarction with BC6ENTC and BC6ENTG (MINT) study.	False
A multicenter, randomized study of BC6OTHER versus heparin as adjunct to BC6ENTG ( BC6OTHER ) in acute myocardial infarction: myocardial infarction with BC6ENTC and BC6OTHER (MINT) study.	False
A multicenter, randomized study of BC6ENTC versus heparin as adjunct to BC6OTHER ( BC6ENTG ) in acute myocardial infarction: myocardial infarction with BC6OTHER and BC6OTHER (MINT) study.	False
A multicenter, randomized study of BC6ENTC versus heparin as adjunct to BC6OTHER ( BC6OTHER ) in acute myocardial infarction: myocardial infarction with BC6OTHER and BC6ENTG (MINT) study.	False
A multicenter, randomized study of BC6ENTC versus heparin as adjunct to BC6ENTG ( BC6OTHER ) in acute myocardial infarction: myocardial infarction with BC6OTHER and BC6OTHER (MINT) study.	False
CONCLUSIONS: BC6ENTC , as compared with heparin, appears to enhance reperfusion with BC6ENTG in patients with AMI, particularly in those patients with delayed presentation.	False
In vitro and in vivo studies have shown that BC6ENTC has advantages over heparin for the inhibition of clot - bound BC6ENTG and for the enhancement of thrombolysis with BC6OTHER .	CPR:4
In vitro and in vivo studies have shown that BC6ENTC has advantages over heparin for the inhibition of clot - bound BC6OTHER and for the enhancement of thrombolysis with BC6ENTG .	False
METHODS: One hundred and twenty - five patients with AMI within 6 h were randomized to heparin, low - dose BC6ENTC or high - dose BC6OTHER in addition to BC6ENTG .	False
METHODS: One hundred and twenty - five patients with AMI within 6 h were randomized to heparin, low - dose BC6OTHER or high - dose BC6ENTC in addition to BC6ENTG .	False
On the contrary, BC6ENTG could be concentration - dependently modulated by BC6ENTC .	False
Whereas the addition of BC6ENTC in the low micromolar range produced an irreversible activation of the channel, application of higher concentrations caused a reversible voltage - dependent inhibition of heterologously expressed BC6ENTG channels, resulting from a reduction of single - channel open times.	CPR:4
 BC6ENTC is a bimodal modulator of BC6ENTG channels.	False
In addition, we provide evidence that BC6ENTC also acts on endogenous BC6ENTG in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP - 1, from which BC6OTHER is released upon activation of BC6OTHER .	False
In addition, we provide evidence that BC6ENTC also acts on endogenous BC6OTHER in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP - 1, from which BC6OTHER is released upon activation of BC6ENTG .	CPR:3
In addition, we provide evidence that BC6OTHER also acts on endogenous BC6ENTG in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP - 1, from which BC6ENTC is released upon activation of BC6OTHER .	False
In addition, we provide evidence that BC6OTHER also acts on endogenous BC6OTHER in cultured dorsal root ganglion neurons from rats and in the enterochromaffin model cell line QGP - 1, from which BC6ENTC is released upon activation of BC6ENTG .	False
Our study shows that BC6ENTG is a target for BC6ENTC , suggesting that an activation of BC6OTHER might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with BC6OTHER .	False
Our study shows that BC6OTHER is a target for BC6ENTC , suggesting that an activation of BC6ENTG might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with BC6OTHER .	CPR:3
Our study shows that BC6ENTG is a target for BC6OTHER , suggesting that an activation of BC6OTHER might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with BC6ENTC .	False
Our study shows that BC6OTHER is a target for BC6OTHER , suggesting that an activation of BC6ENTG might contribute to adverse side effects such as nausea and painful injections, which can occur during treatment with BC6ENTC .	CPR:3
We wanted to test whether sensory BC6ENTG are a molecular target for BC6ENTC .	False
Here, we show that BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , as well as BC6OTHER , and BC6OTHER , which are expressed in dorsal root ganglion neurons, are insensitive toward BC6ENTC treatment.	False
Here, we show that BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , as well as BC6OTHER , and BC6OTHER , which are expressed in dorsal root ganglion neurons, are insensitive toward BC6ENTC treatment.	False
Here, we show that BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , as well as BC6OTHER , and BC6OTHER , which are expressed in dorsal root ganglion neurons, are insensitive toward BC6ENTC treatment.	False
Here, we show that BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , as well as BC6OTHER , and BC6OTHER , which are expressed in dorsal root ganglion neurons, are insensitive toward BC6ENTC treatment.	False
Here, we show that BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as BC6ENTG , and BC6OTHER , which are expressed in dorsal root ganglion neurons, are insensitive toward BC6ENTC treatment.	False
Here, we show that BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , as well as BC6OTHER , and BC6ENTG , which are expressed in dorsal root ganglion neurons, are insensitive toward BC6ENTC treatment.	False
Neither selective BC6ENTG , nor nonselective BC6OTHER inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas BC6ENTC treatment resulted in epidermal and granulation tissue atrophy.	False
Neither selective BC6OTHER , nor nonselective BC6ENTG inhibition had a significant effect on the macroscopic or microscopic morphology of the wounds, whereas BC6ENTC treatment resulted in epidermal and granulation tissue atrophy.	False
In addition, neither selective BC6ENTG , nor nonselective BC6OTHER inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas BC6ENTC reduced the tensile strength of the wounds by 30 - 38% throughout the healing period.	False
In addition, neither selective BC6OTHER , nor nonselective BC6ENTG inhibition altered keratinocyte proliferation and differentiation, dermal angiogenesis or the recovery of wound tensile strength, whereas BC6ENTC reduced the tensile strength of the wounds by 30 - 38% throughout the healing period.	False
OBJECTIVE: Because of these physiological effects and the widespread use of the selective BC6ENTG inhibitor, BC6ENTC , we wanted to determine if inhibition of BC6OTHER would affect incisional skin wound healing.	CPR:4
OBJECTIVE: Because of these physiological effects and the widespread use of the selective BC6OTHER inhibitor, BC6ENTC , we wanted to determine if inhibition of BC6ENTG would affect incisional skin wound healing.	False
METHODS: Using a cutaneous full - thickness, sutured, incisional wound model in hairless SKH - 1 mice, we evaluated the role of BC6ENTG in the wound healing process by comparing the effects of a nonselective BC6OTHER inhibitor, BC6ENTC , with a selective BC6OTHER inhibitor, SC - 791.	False
METHODS: Using a cutaneous full - thickness, sutured, incisional wound model in hairless SKH - 1 mice, we evaluated the role of BC6OTHER in the wound healing process by comparing the effects of a nonselective BC6ENTG inhibitor, BC6ENTC , with a selective BC6OTHER inhibitor, SC - 791.	CPR:4
METHODS: Using a cutaneous full - thickness, sutured, incisional wound model in hairless SKH - 1 mice, we evaluated the role of BC6OTHER in the wound healing process by comparing the effects of a nonselective BC6OTHER inhibitor, BC6ENTC , with a selective BC6ENTG inhibitor, SC - 791.	False
BC6ENTC decreased the stability of BC6ENTG - mRNA and BC6OTHER mRNA.	False
BC6ENTC decreased the stability of BC6OTHER - mRNA and BC6ENTG mRNA.	False
Although BC6ENTC inhibits PG biosynthesis, most do not affect the BC6ENTG activity of BC6OTHER , which can generate proximate carcinogens.	False
Although BC6ENTC inhibits PG biosynthesis, most do not affect the BC6OTHER activity of BC6ENTG , which can generate proximate carcinogens.	False
Because BC6ENTC does not completely inhibit BC6ENTG expression or PG biosynthesis, a therapeutic strategy combining BC6OTHER with BC6OTHER might be more effective than using either agent alone.	False
Because BC6OTHER does not completely inhibit BC6ENTG expression or PG biosynthesis, a therapeutic strategy combining BC6ENTC with BC6OTHER might be more effective than using either agent alone.	False
Because BC6OTHER does not completely inhibit BC6ENTG expression or PG biosynthesis, a therapeutic strategy combining BC6OTHER with BC6ENTC might be more effective than using either agent alone.	False
Present studies demonstrate that BC6ENTG will also catalyze BC6OTHER production with the same active site CHEM if a suitable substrate such as BC6ENTC is provided.	CPR:9
BC6ENTG usually catalyzes the conversion of BC6ENTC to CHEM and oxidation of BC6OTHER to the corresponding CHEM.	CPR:9
None of the following enzymes tested catalyzed the new reaction: BC6ENTC oxidase, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6ENTC oxidase, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6ENTC oxidase, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6ENTC oxidase, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6ENTC oxidase, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG .	False
None of the following enzymes tested catalyzed the new reaction: BC6ENTG , BC6OTHER , BC6ENTC dismutase, BC6OTHER , BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6ENTG , BC6ENTC dismutase, BC6OTHER , BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6ENTC dismutase, BC6ENTG , BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6ENTC dismutase, BC6OTHER , BC6ENTG , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6ENTC dismutase, BC6OTHER , BC6OTHER , and BC6ENTG .	False
None of the following enzymes tested catalyzed the new reaction: BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC oxidase, BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC oxidase, BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC oxidase, BC6OTHER , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC oxidase, BC6ENTG , and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC oxidase, BC6OTHER , and BC6ENTG .	False
None of the following enzymes tested catalyzed the new reaction: BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC beta - hydroxylase, and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC beta - hydroxylase, and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC beta - hydroxylase, and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC beta - hydroxylase, and BC6OTHER .	False
None of the following enzymes tested catalyzed the new reaction: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC beta - hydroxylase, and BC6ENTG .	False
BC6ENTG inhibitors such as BC6ENTC , BC6OTHER , and BC6OTHER inhibited the reaction drastically, suggesting the participation of the active site BC6OTHER of the enzyme in the catalysis.	CPR:4
BC6ENTG inhibitors such as BC6OTHER , BC6ENTC , and BC6OTHER inhibited the reaction drastically, suggesting the participation of the active site BC6OTHER of the enzyme in the catalysis.	CPR:4
BC6ENTG inhibitors such as BC6OTHER , BC6OTHER , and BC6ENTC inhibited the reaction drastically, suggesting the participation of the active site BC6OTHER of the enzyme in the catalysis.	CPR:4
BC6ENTG inhibitors such as BC6OTHER , BC6OTHER , and BC6OTHER inhibited the reaction drastically, suggesting the participation of the active site BC6ENTC of the enzyme in the catalysis.	False
BC6ENTC , a well - known competitive inhibitor of BC6ENTG , competitively inhibited the new reaction also.	CPR:4
BC6ENTG usually catalyzes the conversion of BC6OTHER to CHEM and oxidation of BC6ENTC to the corresponding CHEM.	CPR:9
 BC6ENTG catalyzes an unusual oxidative decarboxylation of BC6ENTC .	CPR:9
Present studies demonstrate that BC6ENTG will also catalyze BC6ENTC production with the same active site CHEM if a suitable substrate such as BC6OTHER is provided.	CPR:9
In particular, we showed that BC6ENTC significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	CPR:4
In particular, we showed that BC6ENTC significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	CPR:4
In particular, we showed that BC6ENTC significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in EA.hy926 cells.	CPR:3
In particular, we showed that BC6ENTC significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in EA.hy926 cells.	CPR:3
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6ENTC species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6ENTC species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6ENTC species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6ENTC species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6ENTC ) and BC6ENTG ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6ENTC ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6ENTC ) and BC6ENTG ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6ENTG ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTC dismutase ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTC dismutase ( BC6OTHER ) in EA.hy926 cells.	False
In particular, we showed that BC6OTHER significantly reduced the formation of intracellular reactive BC6OTHER species (ROS), the level of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) leakage, and enhanced production of the endogenous antioxidants, BC6OTHER ( BC6OTHER ) and BC6ENTC dismutase ( BC6ENTG ) in EA.hy926 cells.	False
Treatment of these cells with BC6ENTC significantly induced BC6ENTG expression.	CPR:3
 BC6ENTC protects human EA.hy926 endothelial cells against gamma - radiation induced oxidative injury by activating the BC6ENTG / BC6OTHER pathway.	CPR:3
 BC6ENTC protects human EA.hy926 endothelial cells against gamma - radiation induced oxidative injury by activating the BC6OTHER / BC6ENTG pathway.	CPR:3
Moreover, BC6ENTC promoted the nuclear translocation of BC6ENTG ( BC6OTHER ).	False
Moreover, BC6ENTC promoted the nuclear translocation of BC6OTHER ( BC6ENTG ).	False
 BC6OTHER protects human EA.hy926 endothelial cells against gamma - radiation induced oxidative injury by activating the BC6ENTG / BC6ENTC oxygenase - 1 pathway.	False
The BC6ENTC - induced BC6ENTG expression was abrogated by BC6OTHER siRNA.	CPR:3
The BC6ENTC - induced BC6OTHER expression was abrogated by BC6ENTG siRNA.	False
Furthermore, inhibition of BC6ENTG with BC6ENTC ( BC6OTHER ) significantly reversed the protective effect of BC6OTHER against radiation - induced damage in EA.hy926 cells.	CPR:4
Furthermore, inhibition of BC6ENTG with BC6OTHER ( BC6ENTC ) significantly reversed the protective effect of BC6OTHER against radiation - induced damage in EA.hy926 cells.	CPR:4
Furthermore, inhibition of BC6ENTG with BC6OTHER ( BC6OTHER ) significantly reversed the protective effect of BC6ENTC against radiation - induced damage in EA.hy926 cells.	CPR:3
Our findings confirmed that BC6ENTC protected EA.hy926 cells against radiation - induced injury through the BC6ENTG / BC6OTHER pathway.	CPR:3
Our findings confirmed that BC6ENTC protected EA.hy926 cells against radiation - induced injury through the BC6OTHER / BC6ENTG pathway.	CPR:3
However, the presence of BC6ENTG inhibited the formation of the BC6ENTC - soluble heteromer, but not the BC6OTHER - stable reduction sensitive heteromer.	False
However, the presence of BC6ENTG inhibited the formation of the BC6OTHER - soluble heteromer, but not the BC6ENTC - stable reduction sensitive heteromer.	False
In the present work we show that reduction sensitive and BC6ENTC - stable heteromers can be reconstituted in vitro by mixing BC6ENTG with either CHEM, versican or BC6OTHER isolated from various monocytic cell lines.	False
In the present work we show that reduction sensitive and BC6ENTC - stable heteromers can be reconstituted in vitro by mixing BC6OTHER with either CHEM, versican or BC6ENTG isolated from various monocytic cell lines.	False
In addition, a strong but BC6ENTC - soluble BC6ENTG · BC6OTHER heteromer was formed.	False
In addition, a strong but BC6ENTC - soluble BC6OTHER · BC6ENTG heteromer was formed.	False
As for the heteromer isolated from THP - 1 cells, the in vitro reconstituted BC6ENTC - stable and BC6OTHER - soluble heteromers had a weaker binding to gelatin than the BC6ENTG monomer.	False
As for the heteromer isolated from THP - 1 cells, the in vitro reconstituted BC6OTHER - stable and BC6ENTC - soluble heteromers had a weaker binding to gelatin than the BC6ENTG monomer.	False
Aim: In this study we explored the association between genetic variations in BC6OTHER and BC6ENTG genes, residing on chromosome 6q23, and disease severity in β - hemoglobinopathy patients, as well as the association between these variants with response to BC6ENTC (HU) treatment.	False
Aim: In this study we explored the association between genetic variations in BC6ENTG and BC6OTHER genes, residing on chromosome 6q23, and disease severity in β - hemoglobinopathy patients, as well as the association between these variants with response to BC6ENTC (HU) treatment.	False
Genomic variation in the BC6ENTG gene is associated with β - thalassemia disease severity and BC6ENTC treatment efficacy.	False
In this work, the metabolism of four frequently prescribed inhaled GCs, BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , by the BC6ENTG family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
In this work, the metabolism of four frequently prescribed inhaled GCs, BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , by the BC6ENTG family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
In this work, the metabolism of four frequently prescribed inhaled GCs, BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , by the BC6ENTG family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
In this work, the metabolism of four frequently prescribed inhaled GCs, BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , by the BC6ENTG family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites.	CPR:9
BC6ENTG , which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:9
BC6ENTG , which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:9
BC6ENTG , which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:9
In contrast, BC6ENTC was only metabolized via BC6ENTG , with no significant turnover by BC6OTHER or BC6OTHER .	CPR:9
In contrast, BC6ENTC was only metabolized via BC6OTHER , with no significant turnover by BC6ENTG or BC6OTHER .	False
In contrast, BC6ENTC was only metabolized via BC6OTHER , with no significant turnover by BC6OTHER or BC6ENTG .	False
Whether an adaptation of the BC6OTHER starting dose to the results of two BC6ENTG activity tests before BC6OTHER administration a priori, and the adaptation of doses to BC6ENTC exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	False
The reasons why doses are not individualised routinely are difficulties in defining, predicting and achieving an optimal BC6ENTC exposure or dose because of a narrow therapeutic index, nonlinear pharmacokinetics, variabilities in administration rates and metabolism, and in targets like BC6ENTG .	False
To individualise BC6ENTC administration before the first dose, assessment of the individual BC6ENTG ( BC6OTHER ) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of BC6OTHER elimination.	False
To individualise BC6ENTC administration before the first dose, assessment of the individual BC6OTHER ( BC6ENTG ) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of BC6OTHER elimination.	False
To individualise BC6OTHER administration before the first dose, assessment of the individual BC6ENTC dehydrogenase ( BC6ENTG ) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of BC6OTHER elimination.	False
To individualise BC6OTHER administration before the first dose, assessment of the individual BC6ENTG ( BC6OTHER ) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of BC6ENTC elimination.	False
To individualise BC6OTHER administration before the first dose, assessment of the individual BC6OTHER ( BC6ENTG ) activity may be useful, because this genetically highly polymorphic enzyme controls approximately 80% of BC6ENTC elimination.	False
A complete or partial loss of BC6ENTG activity in 0.1 and 3 - 5% of Caucasians, respectively, leads to increased BC6ENTC exposure and toxicity.	False
Several methods to assess BC6ENTG activity in patients have been proposed (genotyping, various phenotyping methods), but each of them has limitations, as has the BC6ENTC test dose approach.	False
Whether an adaptation of the BC6ENTC starting dose to the results of two BC6ENTG activity tests before BC6OTHER administration a priori, and the adaptation of doses to BC6OTHER exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	False
Whether an adaptation of the BC6OTHER starting dose to the results of two BC6ENTG activity tests before BC6ENTC administration a priori, and the adaptation of doses to BC6OTHER exposure a posteriori is a reasonable approach to better prevent toxicity and increase efficacy, remains to be evaluated in randomised clinical studies comparing these strategies to routine clinical safety monitoring.	False
Isovaleric acidemia is an autosomal recessive disease of BC6ENTC metabolism due to deficiency of BC6ENTG .	False
We examined in cats the 1) ulcerogenic effects of selective BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6ENTC ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6ENTC ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6ENTG isoforms and BC6ENTC ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6ENTC ( BC6OTHER ) level in the duodenum, and 3) localization of BC6ENTG isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6ENTC ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6ENTC ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6ENTG isoforms and BC6OTHER ( BC6ENTC ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6ENTC ) level in the duodenum, and 3) localization of BC6ENTG isoforms in the duodenum.	False
Localization and expression of BC6ENTG isoforms (by immunohistochemistry, Western blot) and BC6ENTC level (by enzyme immunoassay) were examined.	False
Second, feeding increased both the expression of BC6ENTG isoforms and BC6ENTC level in the duodenum, and the effects were markedly inhibited by pretreatment with BC6OTHER .	False
Second, feeding increased both the expression of BC6ENTG isoforms and BC6OTHER level in the duodenum, and the effects were markedly inhibited by pretreatment with BC6ENTC .	CPR:4
We examined in cats the 1) ulcerogenic effects of selective BC6ENTG ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	CPR:4
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6ENTG isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6ENTC , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6ENTG isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6ENTG ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	CPR:4
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6ENTG ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6ENTG isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6ENTC ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6ENTG isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6ENTC , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	CPR:4
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6ENTG isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6ENTC , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6ENTG isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6ENTC ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	CPR:4
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6ENTG isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6ENTC ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6OTHER on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6ENTG isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6ENTG ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6ENTC on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6ENTG ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6ENTC on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6ENTC on the expression of BC6ENTG isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6OTHER isoforms in the duodenum.	False
We examined in cats the 1) ulcerogenic effects of selective BC6OTHER ( BC6OTHER , BC6OTHER ) and BC6OTHER ( BC6OTHER , BC6OTHER ) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and BC6ENTC on the expression of BC6OTHER isoforms and BC6OTHER ( BC6OTHER ) level in the duodenum, and 3) localization of BC6ENTG isoforms in the duodenum.	False
Neither BC6OTHER nor BC6ENTC inhibited down - regulation of BC6ENTG mRNA by BC6OTHER .	CPR:3
Neither BC6OTHER nor BC6OTHER inhibited down - regulation of BC6ENTG mRNA by BC6ENTC .	CPR:4
BC6ENTC caused BC6ENTG mRNA level to decrease with a half - life of 3.2 + / - 0.4 h and blocked the effect of BC6OTHER to decrease basal BC6OTHER mRNA level.	CPR:4
BC6ENTC caused BC6OTHER mRNA level to decrease with a half - life of 3.2 + / - 0.4 h and blocked the effect of BC6OTHER to decrease basal BC6ENTG mRNA level.	CPR:4
BC6OTHER caused BC6ENTG mRNA level to decrease with a half - life of 3.2 + / - 0.4 h and blocked the effect of BC6ENTC to decrease basal BC6OTHER mRNA level.	False
BC6OTHER caused BC6OTHER mRNA level to decrease with a half - life of 3.2 + / - 0.4 h and blocked the effect of BC6ENTC to decrease basal BC6ENTG mRNA level.	False
Both BC6ENTC and BC6OTHER increased the rate of BC6ENTG mRNA degradation.	CPR:4
Both BC6OTHER and BC6ENTC increased the rate of BC6ENTG mRNA degradation.	CPR:4
In BC6ENTC - desensitized cells, BC6OTHER and BC6ENTG each caused the expected down - regulation of BC6OTHER mRNA.	False
In BC6ENTC - desensitized cells, BC6OTHER and BC6OTHER each caused the expected down - regulation of BC6ENTG mRNA.	CPR:4
In BC6OTHER - desensitized cells, BC6ENTC and BC6ENTG each caused the expected down - regulation of BC6OTHER mRNA.	False
In BC6OTHER - desensitized cells, BC6ENTC and BC6OTHER each caused the expected down - regulation of BC6ENTG mRNA.	CPR:4
The BC6OTHER inhibitor BC6ENTC prolonged the normally transient effect of BC6OTHER for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6ENTG mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6OTHER gene transcription.	False
The BC6OTHER inhibitor BC6ENTC prolonged the normally transient effect of BC6OTHER for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6ENTG substrate and 2) a permissive effect on BC6OTHER gene transcription.	False
The BC6OTHER inhibitor BC6ENTC prolonged the normally transient effect of BC6OTHER for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6ENTG gene transcription.	False
The BC6ENTG inhibitor BC6ENTC prolonged the normally transient effect of BC6OTHER for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6OTHER gene transcription.	CPR:4
The BC6OTHER inhibitor BC6ENTC prolonged the normally transient effect of BC6OTHER for at least 24 h. We conclude that BC6ENTG exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6OTHER gene transcription.	False
The BC6OTHER inhibitor BC6OTHER prolonged the normally transient effect of BC6ENTC for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6ENTG mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6OTHER gene transcription.	False
The BC6OTHER inhibitor BC6OTHER prolonged the normally transient effect of BC6ENTC for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6ENTG substrate and 2) a permissive effect on BC6OTHER gene transcription.	False
The BC6OTHER inhibitor BC6OTHER prolonged the normally transient effect of BC6ENTC for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6ENTG gene transcription.	False
The BC6ENTG inhibitor BC6OTHER prolonged the normally transient effect of BC6ENTC for at least 24 h. We conclude that BC6OTHER exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6OTHER gene transcription.	False
The BC6OTHER inhibitor BC6OTHER prolonged the normally transient effect of BC6ENTC for at least 24 h. We conclude that BC6ENTG exerts two opposing effects on BC6OTHER mRNA levels, 1) a decrease in the stability of the mRNA that requires the sustained phosphorylation of a BC6OTHER substrate and 2) a permissive effect on BC6OTHER gene transcription.	False
BC6ENTC , BC6OTHER , and BC6ENTG each decreased BC6OTHER mRNA levels by 70 - 80%.	False
BC6ENTC , BC6OTHER , and BC6OTHER each decreased BC6ENTG mRNA levels by 70 - 80%.	CPR:4
CHEM and BC6ENTC destabilize BC6ENTG mRNA in vascular smooth muscle cells.	CPR:4
BC6OTHER , BC6ENTC , and BC6ENTG each decreased BC6OTHER mRNA levels by 70 - 80%.	False
BC6OTHER , BC6ENTC , and BC6OTHER each decreased BC6ENTG mRNA levels by 70 - 80%.	CPR:4
The mechanism by which BC6ENTC ( BC6OTHER ) down - regulates BC6ENTG ( BC6OTHER ) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
The mechanism by which BC6ENTC ( BC6OTHER ) down - regulates BC6OTHER ( BC6ENTG ) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
The BC6ENTG inhibitor BC6ENTC ( BC6OTHER ) abolished the effects of BC6OTHER and BC6OTHER and decreased basal mRNA levels by 52 + / - 3%.	CPR:4
The BC6ENTG inhibitor BC6OTHER ( BC6ENTC ) abolished the effects of BC6OTHER and BC6OTHER and decreased basal mRNA levels by 52 + / - 3%.	CPR:4
The BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) abolished the effects of BC6ENTC and BC6OTHER and decreased basal mRNA levels by 52 + / - 3%.	False
The BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) abolished the effects of BC6OTHER and BC6ENTC and decreased basal mRNA levels by 52 + / - 3%.	False
The mechanism by which BC6OTHER ( BC6ENTC ) down - regulates BC6ENTG ( BC6OTHER ) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
The mechanism by which BC6OTHER ( BC6ENTC ) down - regulates BC6OTHER ( BC6ENTG ) mRNA was studied in rabbit aortic smooth muscle cells.	CPR:4
Neither BC6ENTC nor BC6OTHER inhibited down - regulation of BC6ENTG mRNA by BC6OTHER .	CPR:3
Besides this direct activity, an excess of BC6OTHER compounds detectable in red wine, may exert an additional indirect action by blocking BC6OTHER - related BC6ENTG induction, thus totally preventing the pro - oxidant and pro - inflammatory events triggered by dietary BC6ENTC .	False
This report concerns the marked up - regulation in differentiated CHEM - 2 colonic epithelial cells of two key inflammatory BC6ENTG , BC6OTHER and BC6OTHER , caused by a mixture of BC6ENTC representative of a high BC6OTHER diet.	CPR:3
This report concerns the marked up - regulation in differentiated CHEM - 2 colonic epithelial cells of two key inflammatory BC6OTHER , BC6ENTG and BC6OTHER , caused by a mixture of BC6ENTC representative of a high BC6OTHER diet.	CPR:3
This report concerns the marked up - regulation in differentiated CHEM - 2 colonic epithelial cells of two key inflammatory BC6OTHER , BC6OTHER and BC6ENTG , caused by a mixture of BC6ENTC representative of a high BC6OTHER diet.	CPR:3
This report concerns the marked up - regulation in differentiated CHEM - 2 colonic epithelial cells of two key inflammatory BC6ENTG , BC6OTHER and BC6OTHER , caused by a mixture of BC6OTHER representative of a high BC6ENTC diet.	CPR:3
This report concerns the marked up - regulation in differentiated CHEM - 2 colonic epithelial cells of two key inflammatory BC6OTHER , BC6ENTG and BC6OTHER , caused by a mixture of BC6OTHER representative of a high BC6ENTC diet.	CPR:3
This report concerns the marked up - regulation in differentiated CHEM - 2 colonic epithelial cells of two key inflammatory BC6OTHER , BC6OTHER and BC6ENTG , caused by a mixture of BC6OTHER representative of a high BC6ENTC diet.	CPR:3
This strong pro - inflammatory effect appeared to be dependent on the net imbalance of red - ox equilibrium with the production of excessive levels of reactive BC6ENTC species through the colonic BC6ENTG BC6OTHER activation.	False
This strong pro - inflammatory effect appeared to be dependent on the net imbalance of red - ox equilibrium with the production of excessive levels of reactive BC6ENTC species through the colonic BC6OTHER BC6ENTG activation.	False
This strong pro - inflammatory effect appeared to be dependent on the net imbalance of red - ox equilibrium with the production of excessive levels of reactive BC6OTHER species through the colonic BC6ENTC - oxidase BC6ENTG activation.	False
BC6ENTC - dependent BC6ENTG activation, as well as BC6OTHER synthesis, were completely prevented by CHEM extract that contains an abundant CHEM fraction, in particular BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC - dependent BC6OTHER activation, as well as BC6ENTG synthesis, were completely prevented by CHEM extract that contains an abundant CHEM fraction, in particular BC6OTHER and BC6OTHER .	CPR:3
BC6OTHER - dependent BC6ENTG activation, as well as BC6OTHER synthesis, were completely prevented by CHEM extract that contains an abundant CHEM fraction, in particular BC6ENTC and BC6OTHER .	CPR:4
BC6OTHER - dependent BC6OTHER activation, as well as BC6ENTG synthesis, were completely prevented by CHEM extract that contains an abundant CHEM fraction, in particular BC6ENTC and BC6OTHER .	CPR:4
BC6OTHER - dependent BC6ENTG activation, as well as BC6OTHER synthesis, were completely prevented by CHEM extract that contains an abundant CHEM fraction, in particular BC6OTHER and BC6ENTC .	CPR:4
BC6OTHER - dependent BC6OTHER activation, as well as BC6ENTG synthesis, were completely prevented by CHEM extract that contains an abundant CHEM fraction, in particular BC6OTHER and BC6ENTC .	CPR:4
Conversely, cell pre - treatment with Vermentino white wine extract with smaller CHEM fraction showed only a partial BC6ENTG down - regulation and was ineffective in BC6OTHER synthesis induced by dietary BC6ENTC .	CPR:3
Conversely, cell pre - treatment with Vermentino white wine extract with smaller CHEM fraction showed only a partial BC6OTHER down - regulation and was ineffective in BC6ENTG synthesis induced by dietary BC6ENTC .	CPR:3
Besides this direct activity, an excess of BC6ENTC compounds detectable in red wine, may exert an additional indirect action by blocking BC6OTHER - related BC6ENTG induction, thus totally preventing the pro - oxidant and pro - inflammatory events triggered by dietary BC6OTHER .	CPR:4
Besides this direct activity, an excess of BC6OTHER compounds detectable in red wine, may exert an additional indirect action by blocking BC6ENTC - related BC6ENTG induction, thus totally preventing the pro - oxidant and pro - inflammatory events triggered by dietary BC6OTHER .	CPR:3
However, the favorable metabolic phenotype observed in BC6OTHER - deficient hosts was lost in BC6ENTG ( - / - ) mice also lacking adaptive immunity ( BC6OTHER ( - / - )x BC6OTHER ( - / - )), demonstrating that BC6OTHER expression in the adaptive rather than the innate immune system impacts host BC6ENTC homeostasis.	False
However, the favorable metabolic phenotype observed in BC6OTHER - deficient hosts was lost in BC6OTHER ( - / - ) mice also lacking adaptive immunity ( BC6ENTG ( - / - )x BC6OTHER ( - / - )), demonstrating that BC6OTHER expression in the adaptive rather than the innate immune system impacts host BC6ENTC homeostasis.	False
However, the favorable metabolic phenotype observed in BC6OTHER - deficient hosts was lost in BC6OTHER ( - / - ) mice also lacking adaptive immunity ( BC6OTHER ( - / - )x BC6ENTG ( - / - )), demonstrating that BC6OTHER expression in the adaptive rather than the innate immune system impacts host BC6ENTC homeostasis.	False
However, the favorable metabolic phenotype observed in BC6OTHER - deficient hosts was lost in BC6OTHER ( - / - ) mice also lacking adaptive immunity ( BC6OTHER ( - / - )x BC6OTHER ( - / - )), demonstrating that BC6ENTG expression in the adaptive rather than the innate immune system impacts host BC6ENTC homeostasis.	False
However, the favorable metabolic phenotype observed in BC6ENTG - deficient hosts was lost in BC6OTHER ( - / - ) mice also lacking adaptive immunity ( BC6OTHER ( - / - )x BC6OTHER ( - / - )), demonstrating that BC6OTHER expression in the adaptive rather than the innate immune system impacts host BC6ENTC homeostasis.	False
In summary, high levels of BC6ENTG expression, which may be required for several BC6ENTC - dependent processes in cancer, including the production of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , is regulated by BC6OTHER and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6OTHER expression, which may be required for several BC6ENTC - dependent processes in cancer, including the production of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , is regulated by BC6ENTG and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6ENTG expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , is regulated by BC6OTHER and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6OTHER expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , is regulated by BC6ENTG and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6ENTG expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , is regulated by BC6OTHER and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6OTHER expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , is regulated by BC6ENTG and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6ENTG expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , is regulated by BC6OTHER and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6OTHER expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , is regulated by BC6ENTG and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6ENTG expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , is regulated by BC6OTHER and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
In summary, high levels of BC6OTHER expression, which may be required for several BC6OTHER - dependent processes in cancer, including the production of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , is regulated by BC6ENTG and may provide an important molecular pathway linking inflammation and metabolism to ovarian tumorigenesis.	False
Here, we show that BC6ENTG also induces expression of arate - limiting enzyme in BC6ENTC synthesis, BC6OTHER synthetase ( BC6OTHER ), thereby linking inflammation with several BC6OTHER - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Here, we show that BC6OTHER also induces expression of arate - limiting enzyme in BC6ENTC synthesis, BC6ENTG ( BC6OTHER ), thereby linking inflammation with several BC6OTHER - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Here, we show that BC6OTHER also induces expression of arate - limiting enzyme in BC6ENTC synthesis, BC6OTHER synthetase ( BC6ENTG ), thereby linking inflammation with several BC6OTHER - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Here, we show that BC6ENTG also induces expression of arate - limiting enzyme in BC6OTHER synthesis, BC6ENTC synthetase ( BC6OTHER ), thereby linking inflammation with several BC6OTHER - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Here, we show that BC6OTHER also induces expression of arate - limiting enzyme in BC6OTHER synthesis, BC6ENTC synthetase ( BC6ENTG ), thereby linking inflammation with several BC6OTHER - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Here, we show that BC6ENTG also induces expression of arate - limiting enzyme in BC6OTHER synthesis, BC6OTHER synthetase ( BC6OTHER ), thereby linking inflammation with several BC6ENTC - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Here, we show that BC6OTHER also induces expression of arate - limiting enzyme in BC6OTHER synthesis, BC6ENTG ( BC6OTHER ), thereby linking inflammation with several BC6ENTC - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Here, we show that BC6OTHER also induces expression of arate - limiting enzyme in BC6OTHER synthesis, BC6OTHER synthetase ( BC6ENTG ), thereby linking inflammation with several BC6ENTC - dependent metabolic pathways, implicated in accelerated carcinogenesis and tumour progression.	False
Aberrant regulation of BC6ENTC synthetase by BC6ENTG in human epithelial ovarian cancer.	False
Blood complete counts, high - sensitive BC6ENTG , BC6ENTC and routine biochemical tests were carried out by routine procedures.	False
CONCLUSIONS: Our data suggest that BC6ENTG polymorphisms are important determinants of antihypertensive response to BC6ENTC .	False
In the future, codon 49 and 389 genotypes or BC6ENTG haplotypes might be used to predict the diastolic blood pressure response to BC6ENTC in patients with hypertension.	False
We tested the hypothesis that 2 common polymorphisms in the gene for BC6ENTG are associated with antihypertensive response to BC6ENTC in patients with uncomplicated hypertension.	False
 BC6ENTG polymorphisms and antihypertensive response to BC6ENTC .	False
Studies in rats, mice and monkeys show that GC - 1 lowers BC6ENTC with 600 - to 1400 - fold more potency and approximately two - to threefold more efficacy than BC6OTHER , a compound that blocks BC6ENTG .	False
Studies in rats, mice and monkeys show that GC - 1 lowers BC6OTHER with 600 - to 1400 - fold more potency and approximately two - to threefold more efficacy than BC6ENTC , a compound that blocks BC6ENTG .	CPR:4
GC - 1 also decreases plasma levels of BC6ENTC and BC6ENTG , and induces loss of fat.	False
Anorexia induced by BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC seems to be the result of their ability to increase the release of BC6OTHER and / or BC6OTHER from nerve terminals and inhibit their reuptake or, in the case of BC6OTHER , to stimulate directly BC6ENTG .	False
Anorexia induced by BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER seems to be the result of their ability to increase the release of BC6ENTC and / or BC6OTHER from nerve terminals and inhibit their reuptake or, in the case of BC6OTHER , to stimulate directly BC6ENTG .	False
Anorexia induced by BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER seems to be the result of their ability to increase the release of BC6OTHER and / or BC6ENTC from nerve terminals and inhibit their reuptake or, in the case of BC6OTHER , to stimulate directly BC6ENTG .	False
Anorexia induced by BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER seems to be the result of their ability to increase the release of BC6OTHER and / or BC6OTHER from nerve terminals and inhibit their reuptake or, in the case of BC6ENTC , to stimulate directly BC6ENTG .	CPR:3
It has been suggested that BC6ENTG and D1 BC6ENTC receptors are involved in their effect on food intake.	False
BC6ENTG receptors mediate the satiating effect of BC6ENTC , whereas the mechanism by which BC6OTHER uptake inhibitors such as BC6OTHER and BC6OTHER cause anorexia is not clear.	False
BC6ENTG receptors mediate the satiating effect of BC6OTHER , whereas the mechanism by which BC6ENTC uptake inhibitors such as BC6OTHER and BC6OTHER cause anorexia is not clear.	False
BC6ENTG receptors mediate the satiating effect of BC6OTHER , whereas the mechanism by which BC6OTHER uptake inhibitors such as BC6ENTC and BC6OTHER cause anorexia is not clear.	False
BC6ENTG receptors mediate the satiating effect of BC6OTHER , whereas the mechanism by which BC6OTHER uptake inhibitors such as BC6OTHER and BC6ENTC cause anorexia is not clear.	False
Anorexia induced by BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER seems to be the result of their ability to increase the release of BC6OTHER and / or BC6OTHER from nerve terminals and inhibit their reuptake or, in the case of BC6OTHER , to stimulate directly BC6ENTG .	False
Anorexia induced by BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER seems to be the result of their ability to increase the release of BC6OTHER and / or BC6OTHER from nerve terminals and inhibit their reuptake or, in the case of BC6OTHER , to stimulate directly BC6ENTG .	False
Anorexia induced by BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER seems to be the result of their ability to increase the release of BC6OTHER and / or BC6OTHER from nerve terminals and inhibit their reuptake or, in the case of BC6OTHER , to stimulate directly BC6ENTG .	False
We have expressed BC6ENTG and the BC6OTHER for BC6OTHER and BC6ENTC in a neuroendocrine cell line and measured the quantal release of BC6OTHER and BC6OTHER using a novel double - sniffer patch - clamp technique.	CPR:9
We have expressed BC6OTHER and the BC6ENTG for BC6OTHER and BC6ENTC in a neuroendocrine cell line and measured the quantal release of BC6OTHER and BC6OTHER using a novel double - sniffer patch - clamp technique.	CPR:9
We have expressed BC6ENTG and the BC6OTHER for BC6OTHER and BC6OTHER in a neuroendocrine cell line and measured the quantal release of BC6ENTC and BC6OTHER using a novel double - sniffer patch - clamp technique.	False
We have expressed BC6OTHER and the BC6ENTG for BC6OTHER and BC6OTHER in a neuroendocrine cell line and measured the quantal release of BC6ENTC and BC6OTHER using a novel double - sniffer patch - clamp technique.	False
We have expressed BC6ENTG and the BC6OTHER for BC6OTHER and BC6OTHER in a neuroendocrine cell line and measured the quantal release of BC6OTHER and BC6ENTC using a novel double - sniffer patch - clamp technique.	False
We have expressed BC6OTHER and the BC6ENTG for BC6OTHER and BC6OTHER in a neuroendocrine cell line and measured the quantal release of BC6OTHER and BC6ENTC using a novel double - sniffer patch - clamp technique.	False
We found that BC6ENTC is released from vesicles when BC6ENTG is coexpressed with either the BC6OTHER BC6OTHER or the BC6OTHER BC6OTHER .	CPR:9
We found that BC6ENTC is released from vesicles when BC6OTHER is coexpressed with either the BC6ENTG BC6OTHER or the BC6OTHER BC6OTHER .	False
We found that BC6ENTC is released from vesicles when BC6OTHER is coexpressed with either the BC6OTHER BC6ENTG or the BC6OTHER BC6OTHER .	False
We found that BC6ENTC is released from vesicles when BC6OTHER is coexpressed with either the BC6OTHER BC6OTHER or the BC6ENTG BC6OTHER .	False
We found that BC6ENTC is released from vesicles when BC6OTHER is coexpressed with either the BC6OTHER BC6OTHER or the BC6OTHER BC6ENTG .	False
However, BC6ENTG was more effective than BC6OTHER , probably because BC6OTHER is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic BC6ENTC concentration required for efficient vesicular loading by BC6OTHER .	False
However, BC6OTHER was more effective than BC6ENTG , probably because BC6OTHER is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic BC6ENTC concentration required for efficient vesicular loading by BC6OTHER .	False
However, BC6OTHER was more effective than BC6OTHER , probably because BC6ENTG is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic BC6ENTC concentration required for efficient vesicular loading by BC6OTHER .	False
However, BC6OTHER was more effective than BC6OTHER , probably because BC6OTHER is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic BC6ENTC concentration required for efficient vesicular loading by BC6ENTG .	CPR:9
The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when BC6ENTC is introduced into the secretory cell and competes for uptake by BC6ENTG .	CPR:9
Interestingly, the BC6ENTG ortholog from Caenorhabditis elegans (UNC - 47), a species lacking BC6ENTC transmission, also supports BC6OTHER exocytosis in the presence of BC6OTHER , and a point mutation of UNC - 47 that abolishes BC6OTHER transmission in the worm confers CHEM specificity.	False
Interestingly, the BC6OTHER ortholog from Caenorhabditis elegans (UNC - 47), a species lacking BC6ENTC transmission, also supports BC6OTHER exocytosis in the presence of BC6ENTG , and a point mutation of UNC - 47 that abolishes BC6OTHER transmission in the worm confers CHEM specificity.	False
Interestingly, the BC6ENTG ortholog from Caenorhabditis elegans (UNC - 47), a species lacking BC6OTHER transmission, also supports BC6ENTC exocytosis in the presence of BC6OTHER , and a point mutation of UNC - 47 that abolishes BC6OTHER transmission in the worm confers CHEM specificity.	False
Interestingly, the BC6OTHER ortholog from Caenorhabditis elegans (UNC - 47), a species lacking BC6OTHER transmission, also supports BC6ENTC exocytosis in the presence of BC6ENTG , and a point mutation of UNC - 47 that abolishes BC6OTHER transmission in the worm confers CHEM specificity.	CPR:9
Interestingly, the BC6ENTG ortholog from Caenorhabditis elegans (UNC - 47), a species lacking BC6OTHER transmission, also supports BC6OTHER exocytosis in the presence of BC6OTHER , and a point mutation of UNC - 47 that abolishes BC6ENTC transmission in the worm confers CHEM specificity.	False
Interestingly, the BC6OTHER ortholog from Caenorhabditis elegans (UNC - 47), a species lacking BC6OTHER transmission, also supports BC6OTHER exocytosis in the presence of BC6ENTG , and a point mutation of UNC - 47 that abolishes BC6ENTC transmission in the worm confers CHEM specificity.	False
Together, these results suggest that an increased cytosolic availability of BC6ENTC in BC6ENTG - containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.	CPR:9
The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, BC6ENTC and BC6OTHER , share the same BC6ENTG ( BC6OTHER ) and are both present in neurons during postnatal development.	CPR:9
The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, BC6ENTC and BC6OTHER , share the same vesicular inhibitory BC6OTHER transporter ( BC6ENTG ) and are both present in neurons during postnatal development.	CPR:9
The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, BC6OTHER and BC6ENTC , share the same BC6ENTG ( BC6OTHER ) and are both present in neurons during postnatal development.	CPR:9
The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, BC6OTHER and BC6ENTC , share the same vesicular inhibitory BC6OTHER transporter ( BC6ENTG ) and are both present in neurons during postnatal development.	CPR:9
The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, BC6OTHER and BC6OTHER , share the same vesicular inhibitory BC6ENTC transporter ( BC6ENTG ) and are both present in neurons during postnatal development.	False
We have expressed BC6ENTG and the BC6OTHER for BC6ENTC and BC6OTHER in a neuroendocrine cell line and measured the quantal release of BC6OTHER and BC6OTHER using a novel double - sniffer patch - clamp technique.	CPR:9
We have expressed BC6OTHER and the BC6ENTG for BC6ENTC and BC6OTHER in a neuroendocrine cell line and measured the quantal release of BC6OTHER and BC6OTHER using a novel double - sniffer patch - clamp technique.	CPR:9
CONCLUSIONS: After the initial bleach, BC6ENTC impeded photon absorption by BC6OTHER by inhibiting metabolic BC6ENTG regeneration.	CPR:4
CONCLUSIONS: After the initial bleach, BC6ENTC impeded photon absorption by BC6ENTG by inhibiting metabolic BC6OTHER regeneration.	False
PURPOSE: To determine whether the volatile anesthetic BC6ENTC protects against light - induced BC6ENTG degeneration in the rodent retina.	False
RESULTS: BC6ENTC anesthesia reversibly inhibited metabolic BC6ENTG regeneration and thus prevented BC6OTHER from absorbing high numbers of photons during light exposure.	CPR:4
RESULTS: BC6ENTC anesthesia reversibly inhibited metabolic BC6OTHER regeneration and thus prevented BC6ENTG from absorbing high numbers of photons during light exposure.	CPR:4
Consequently, BC6ENTG of mice and rats anesthetized with BC6ENTC were completely protected against degeneration induced by white light.	False
Protective effect of BC6ENTC anesthesia on CHEM light damage: inhibition of metabolic BC6ENTG regeneration.	CPR:4
Blocking BC6ENTC formation by a targeted knock down of BC6ENTG results in significantly increased BC6OTHER levels, which lead to severe embryonic patterning defects.	CPR:9
Blocking BC6OTHER formation by a targeted knock down of BC6ENTG results in significantly increased BC6ENTC levels, which lead to severe embryonic patterning defects.	False
Thus, we provide evidence that a balanced competition between BC6ENTG and BC6OTHER for yolk BC6ENTC defines embryonic compartments either for BC6OTHER or BC6OTHER synthesis.	False
Thus, we provide evidence that a balanced competition between BC6OTHER and BC6ENTG for yolk BC6ENTC defines embryonic compartments either for BC6OTHER or BC6OTHER synthesis.	False
Thus, we provide evidence that a balanced competition between BC6ENTG and BC6OTHER for yolk BC6OTHER defines embryonic compartments either for BC6ENTC or BC6OTHER synthesis.	False
Thus, we provide evidence that a balanced competition between BC6OTHER and BC6ENTG for yolk BC6OTHER defines embryonic compartments either for BC6ENTC or BC6OTHER synthesis.	False
Thus, we provide evidence that a balanced competition between BC6ENTG and BC6OTHER for yolk BC6OTHER defines embryonic compartments either for BC6OTHER or BC6ENTC synthesis.	False
Thus, we provide evidence that a balanced competition between BC6OTHER and BC6ENTG for yolk BC6OTHER defines embryonic compartments either for BC6OTHER or BC6ENTC synthesis.	False
We show here for zebrafish that embryonic CHEM homeostasis essentially depends on the activity of a BC6ENTC : BC6OTHER acyltransferase ( BC6ENTG ).	False
We show here for zebrafish that embryonic CHEM homeostasis essentially depends on the activity of a BC6OTHER : BC6ENTC acyltransferase ( BC6ENTG ).	False
During embryogenesis, BC6ENTG is expressed in mostly non - overlapping domains opposite to BC6ENTC dehydrogenase 2 ( BC6OTHER ), the key enzyme for BC6OTHER synthesis.	False
During embryogenesis, BC6OTHER is expressed in mostly non - overlapping domains opposite to BC6ENTC dehydrogenase 2 ( BC6ENTG ), the key enzyme for BC6OTHER synthesis.	False
During embryogenesis, BC6ENTG is expressed in mostly non - overlapping domains opposite to BC6OTHER dehydrogenase 2 ( BC6OTHER ), the key enzyme for BC6ENTC synthesis.	False
During embryogenesis, BC6OTHER is expressed in mostly non - overlapping domains opposite to BC6ENTG ( BC6OTHER ), the key enzyme for BC6ENTC synthesis.	CPR:9
During embryogenesis, BC6OTHER is expressed in mostly non - overlapping domains opposite to BC6OTHER dehydrogenase 2 ( BC6ENTG ), the key enzyme for BC6ENTC synthesis.	CPR:9
The goal of this study was to identify compounds that block the BC6ENTG BC6OTHER with high affinity, focusing on two classes of compounds: BC6OTHER (e.g., BC6ENTC ) and BC6OTHER (e.g., BC6OTHER ).	False
The goal of this study was to identify compounds that block the BC6OTHER BC6ENTG with high affinity, focusing on two classes of compounds: BC6OTHER (e.g., BC6ENTC ) and BC6OTHER (e.g., BC6OTHER ).	False
The goal of this study was to identify compounds that block the BC6ENTG BC6OTHER with high affinity, focusing on two classes of compounds: BC6OTHER (e.g., BC6OTHER ) and BC6ENTC (e.g., BC6OTHER ).	False
The goal of this study was to identify compounds that block the BC6OTHER BC6ENTG with high affinity, focusing on two classes of compounds: BC6OTHER (e.g., BC6OTHER ) and BC6ENTC (e.g., BC6OTHER ).	False
The goal of this study was to identify compounds that block the BC6ENTG BC6OTHER with high affinity, focusing on two classes of compounds: BC6OTHER (e.g., BC6OTHER ) and BC6OTHER (e.g., BC6ENTC ).	False
The goal of this study was to identify compounds that block the BC6OTHER BC6ENTG with high affinity, focusing on two classes of compounds: BC6OTHER (e.g., BC6OTHER ) and BC6OTHER (e.g., BC6ENTC ).	False
Compounds were tested using a validated BC6ENTC influx assay into a cell line expressing recombinant BC6ENTG channels.	False
This study identified four clinically approved antihypertensive drugs ( BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ) as potent BC6ENTG blockers (IC(50) < 3 microM).	CPR:4
This study identified four clinically approved antihypertensive drugs ( BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ) as potent BC6ENTG blockers (IC(50) < 3 microM).	CPR:4
This study identified four clinically approved antihypertensive drugs ( BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ) as potent BC6ENTG blockers (IC(50) < 3 microM).	CPR:4
This study identified four clinically approved antihypertensive drugs ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ) as potent BC6ENTG blockers (IC(50) < 3 microM).	CPR:4
Molecular pharmacology of BC6ENTG T - type BC6ENTC channels: block by antihypertensives, antiarrhythmics, and their analogs.	False
"Antihypertensive drugs of the "" BC6ENTG blocker"" or "" BC6OTHER antagonist"" class have been used to establish the physiological role of L - type BC6ENTC channels in vascular smooth muscle."	False
"Antihypertensive drugs of the "" BC6ENTC channel blocker"" or "" BC6OTHER antagonist"" class have been used to establish the physiological role of BC6ENTG in vascular smooth muscle."	False
BC6ENTG play a role in cardiac pacemaking, BC6ENTC secretion, and renal hemodynamics, leading to the hypothesis that mixed T - and L - type blockers may have therapeutic advantages over selective L - type blockers.	False
"Antihypertensive drugs of the "" BC6OTHER channel blocker"" or "" BC6ENTC antagonist"" class have been used to establish the physiological role of BC6ENTG in vascular smooth muscle."	False
"Antihypertensive drugs of the "" BC6ENTG blocker"" or "" BC6ENTC antagonist"" class have been used to establish the physiological role of L - type BC6OTHER channels in vascular smooth muscle."	False
The goal of this study was to identify compounds that block the BC6ENTG BC6OTHER with high affinity, focusing on two classes of compounds: BC6ENTC (e.g., BC6OTHER ) and BC6OTHER (e.g., BC6OTHER ).	False
The goal of this study was to identify compounds that block the BC6OTHER BC6ENTG with high affinity, focusing on two classes of compounds: BC6ENTC (e.g., BC6OTHER ) and BC6OTHER (e.g., BC6OTHER ).	False
BC6ENTC served as inhibitor of an interfering BC6ENTG present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.	CPR:4
BC6ENTG ( BC6OTHER ) are inner mitochondrial membrane transporters which act as pores for BC6ENTC ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of CHEM synthesis.	CPR:9
BC6OTHER ( BC6ENTG ) are inner mitochondrial membrane transporters which act as pores for BC6ENTC ions, dissipating the electrochemical gradient that develops during mitochondrial respiration at the expense of CHEM synthesis.	CPR:9
In contrast to BC6ENTG , BC6OTHER mRNA levels were only slightly modified by BC6ENTC in adipocytes.	False
In contrast to BC6OTHER , BC6ENTG mRNA levels were only slightly modified by BC6ENTC in adipocytes.	False
 BC6ENTG ( BC6OTHER ) activators, BC6ENTC and BC6OTHER , increase BC6OTHER mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.	CPR:3
 BC6OTHER ( BC6OTHER ) activators, BC6ENTC and BC6OTHER , increase BC6ENTG mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.	CPR:3
 BC6OTHER ( BC6ENTG ) activators, BC6ENTC and BC6OTHER , increase BC6OTHER mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.	CPR:3
 BC6ENTG ( BC6OTHER ) activators, BC6OTHER and BC6ENTC , increase BC6OTHER mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.	CPR:3
 BC6OTHER ( BC6OTHER ) activators, BC6OTHER and BC6ENTC , increase BC6ENTG mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.	CPR:3
 BC6OTHER ( BC6ENTG ) activators, BC6OTHER and BC6ENTC , increase BC6OTHER mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes.	CPR:3
The induction in BC6ENTG expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after BC6ENTC or BC6OTHER treatment.	CPR:3
The induction in BC6ENTG expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after BC6OTHER or BC6ENTC treatment.	CPR:3
Since it has been proposed that BC6ENTG could be involved in the regulation of the use of CHEM as fuel substrates, the BC6OTHER induction achieved after BC6ENTC and BC6OTHER treatment may indicate a higher oxidation of BC6OTHER , limiting their availability to be stored as BC6OTHER .	False
Since it has been proposed that BC6OTHER could be involved in the regulation of the use of CHEM as fuel substrates, the BC6ENTG induction achieved after BC6ENTC and BC6OTHER treatment may indicate a higher oxidation of BC6OTHER , limiting their availability to be stored as BC6OTHER .	CPR:3
Since it has been proposed that BC6ENTG could be involved in the regulation of the use of CHEM as fuel substrates, the BC6OTHER induction achieved after BC6OTHER and BC6ENTC treatment may indicate a higher oxidation of BC6OTHER , limiting their availability to be stored as BC6OTHER .	False
Since it has been proposed that BC6OTHER could be involved in the regulation of the use of CHEM as fuel substrates, the BC6ENTG induction achieved after BC6OTHER and BC6ENTC treatment may indicate a higher oxidation of BC6OTHER , limiting their availability to be stored as BC6OTHER .	CPR:3
Since it has been proposed that BC6ENTG could be involved in the regulation of the use of CHEM as fuel substrates, the BC6OTHER induction achieved after BC6OTHER and BC6OTHER treatment may indicate a higher oxidation of BC6ENTC , limiting their availability to be stored as BC6OTHER .	False
Since it has been proposed that BC6OTHER could be involved in the regulation of the use of CHEM as fuel substrates, the BC6ENTG induction achieved after BC6OTHER and BC6OTHER treatment may indicate a higher oxidation of BC6ENTC , limiting their availability to be stored as BC6OTHER .	False
Since it has been proposed that BC6ENTG could be involved in the regulation of the use of CHEM as fuel substrates, the BC6OTHER induction achieved after BC6OTHER and BC6OTHER treatment may indicate a higher oxidation of BC6OTHER , limiting their availability to be stored as BC6ENTC .	False
Since it has been proposed that BC6OTHER could be involved in the regulation of the use of CHEM as fuel substrates, the BC6ENTG induction achieved after BC6OTHER and BC6OTHER treatment may indicate a higher oxidation of BC6OTHER , limiting their availability to be stored as BC6ENTC .	False
We have studied the effects of two CHEM, BC6ENTC and BC6OTHER , on BC6ENTG and BC6OTHER mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	False
We have studied the effects of two CHEM, BC6ENTC and BC6OTHER , on BC6OTHER and BC6ENTG mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	False
We have studied the effects of two CHEM, BC6OTHER and BC6ENTC , on BC6ENTG and BC6OTHER mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	False
We have studied the effects of two CHEM, BC6OTHER and BC6ENTC , on BC6OTHER and BC6ENTG mRNA levels in primary monolayer cultures of rat adipocytes and undifferentiated preadipocytes.	False
Thus, BC6ENTC treatment resulted in an 8 - fold induction in BC6ENTG mRNA levels in preadipocytes compared with the 3.5 - fold induction observed in adipocytes.	CPR:3
Caution is necessary only when it is coadministered with drugs metabolised by BC6ENTG , such as BC6ENTC , or administered to the elderly or patients with severe hepatic or renal impairment.	CPR:9
It is more potent and selective than BC6ENTC in inhibiting BC6OTHER re - uptake in the CNS, and less potent than various other selective BC6OTHER re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6OTHER in binding to the BC6ENTG and BC6OTHER .	False
It is more potent and selective than BC6ENTC in inhibiting BC6OTHER re - uptake in the CNS, and less potent than various other selective BC6OTHER re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6OTHER in binding to the BC6OTHER H1 and BC6ENTG .	False
It is more potent and selective than BC6OTHER in inhibiting BC6ENTC re - uptake in the CNS, and less potent than various other selective BC6OTHER re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6OTHER in binding to the BC6ENTG and BC6OTHER .	False
It is more potent and selective than BC6OTHER in inhibiting BC6ENTC re - uptake in the CNS, and less potent than various other selective BC6OTHER re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6OTHER in binding to the BC6OTHER H1 and BC6ENTG .	False
It is more potent and selective than BC6OTHER in inhibiting BC6OTHER re - uptake in the CNS, and less potent than various other selective BC6ENTC re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6OTHER in binding to the BC6ENTG and BC6OTHER .	False
It is more potent and selective than BC6OTHER in inhibiting BC6OTHER re - uptake in the CNS, and less potent than various other selective BC6ENTC re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6OTHER in binding to the BC6OTHER H1 and BC6ENTG .	False
It is more potent and selective than BC6OTHER in inhibiting BC6OTHER re - uptake in the CNS, and less potent than various other selective BC6OTHER re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6ENTC in binding to the BC6ENTG and BC6OTHER .	False
It is more potent and selective than BC6OTHER in inhibiting BC6OTHER re - uptake in the CNS, and less potent than various other selective BC6OTHER re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6ENTC in binding to the BC6OTHER H1 and BC6ENTG .	False
It is more potent and selective than BC6OTHER in inhibiting BC6OTHER re - uptake in the CNS, and less potent than various other selective BC6OTHER re - uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than BC6OTHER in binding to the BC6ENTC H1 and BC6ENTG .	False
These hormones induce metamorphosis by controlling gene expression through binding to BC6ENTC receptors ( BC6ENTG ).	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6ENTC , we aimed to determine BC6ENTG gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6ENTC , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: BC6ENTG ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6ENTC , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6ENTG ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6ENTC , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - BC6ENTG , a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6ENTC , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a BC6ENTG and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6ENTC , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6ENTG , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6ENTG gene expression patterns in Necturus maculosus as well as the expression of two BC6ENTC - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6ENTC - related genes: BC6ENTG ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6ENTC - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6ENTG ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6ENTC - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - BC6ENTG , a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6ENTC - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a BC6ENTG and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6ENTC - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6ENTG , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6ENTG gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6ENTC - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6ENTC - Binding Protein ( BC6ENTG ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6ENTC - Binding Protein ( BC6OTHER ) - BC6ENTG , a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6ENTC - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a BC6ENTG and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6ENTC - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6ENTG , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6ENTG gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6ENTC kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: BC6ENTG ( BC6OTHER ) - M2 - BC6ENTC kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6ENTG ) - M2 - BC6ENTC kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6ENTC kinase, a gene encoding a BC6ENTG and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6ENTC kinase, a gene encoding a cytosolic BC6OTHER binding protein and BC6ENTG , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6ENTG gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6ENTC binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: BC6ENTG ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6ENTC binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6ENTG ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6ENTC binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - BC6ENTG , a gene encoding a cytosolic BC6ENTC binding protein and BC6OTHER , a direct TH target gene in Xenopus laevis.	False
Since metamorphosis depends on the acquisition of response of tadpole tissues to BC6OTHER , we aimed to determine BC6OTHER gene expression patterns in Necturus maculosus as well as the expression of two BC6OTHER - related genes: Cytosolic BC6OTHER - Binding Protein ( BC6OTHER ) - M2 - BC6OTHER kinase, a gene encoding a cytosolic BC6ENTC binding protein and BC6ENTG , a direct TH target gene in Xenopus laevis.	False
We showed that dietary supplement of BC6OTHER enhanced the expression of BC6ENTG genes and the cellular BC6ENTC content in vital organs such as brain, kidney, liver and heart.	False
Consistently, the BC6ENTC - lowering agent ( BC6OTHER ) downregulated the expression of BC6ENTG genes in several organs especially the liver and in cultured liver cells.	False
Consistently, the BC6OTHER - lowering agent ( BC6ENTC ) downregulated the expression of BC6ENTG genes in several organs especially the liver and in cultured liver cells.	False
Further, BC6ENTC metabolites, predominantly the BC6OTHER , the natural ligands for BC6ENTG ( BC6OTHER ), induced these genes via upregulation of BC6OTHER ( BC6OTHER ) that bound to the regulatory regions of these genes.	False
Further, BC6ENTC metabolites, predominantly the BC6OTHER , the natural ligands for BC6OTHER ( BC6ENTG ), induced these genes via upregulation of BC6OTHER ( BC6OTHER ) that bound to the regulatory regions of these genes.	False
Further, BC6ENTC metabolites, predominantly the BC6OTHER , the natural ligands for BC6OTHER ( BC6OTHER ), induced these genes via upregulation of BC6ENTG ( BC6OTHER ) that bound to the regulatory regions of these genes.	CPR:3
Further, BC6ENTC metabolites, predominantly the BC6OTHER , the natural ligands for BC6OTHER ( BC6OTHER ), induced these genes via upregulation of BC6OTHER ( BC6ENTG ) that bound to the regulatory regions of these genes.	CPR:3
Further, BC6OTHER metabolites, predominantly the BC6ENTC , the natural ligands for BC6ENTG ( BC6OTHER ), induced these genes via upregulation of BC6OTHER ( BC6OTHER ) that bound to the regulatory regions of these genes.	False
Further, BC6OTHER metabolites, predominantly the BC6ENTC , the natural ligands for BC6OTHER ( BC6ENTG ), induced these genes via upregulation of BC6OTHER ( BC6OTHER ) that bound to the regulatory regions of these genes.	False
Further, BC6OTHER metabolites, predominantly the BC6ENTC , the natural ligands for BC6OTHER ( BC6OTHER ), induced these genes via upregulation of BC6ENTG ( BC6OTHER ) that bound to the regulatory regions of these genes.	CPR:3
Further, BC6OTHER metabolites, predominantly the BC6ENTC , the natural ligands for BC6OTHER ( BC6OTHER ), induced these genes via upregulation of BC6OTHER ( BC6ENTG ) that bound to the regulatory regions of these genes.	CPR:3
Further, BC6OTHER metabolites, predominantly the BC6OTHER , the natural ligands for BC6ENTG ( BC6OTHER ), induced these genes via upregulation of BC6ENTC regulatory element binding protein - 1c ( BC6OTHER ) that bound to the regulatory regions of these genes.	False
Further, BC6OTHER metabolites, predominantly the BC6OTHER , the natural ligands for BC6OTHER ( BC6ENTG ), induced these genes via upregulation of BC6ENTC regulatory element binding protein - 1c ( BC6OTHER ) that bound to the regulatory regions of these genes.	False
Further, BC6OTHER metabolites, predominantly the BC6OTHER , the natural ligands for BC6OTHER ( BC6OTHER ), induced these genes via upregulation of BC6ENTC regulatory element binding protein - 1c ( BC6ENTG ) that bound to the regulatory regions of these genes.	False
The tissue BC6ENTC level is maintained through a cascade of metabolic reactions where BC6ENTG ( BC6OTHER ) catalyze the terminal reaction of BC6OTHER biosynthesis from BC6OTHER , a rate - limiting step.	False
The tissue BC6ENTC level is maintained through a cascade of metabolic reactions where BC6OTHER dehydrogenases ( BC6ENTG ) catalyze the terminal reaction of BC6OTHER biosynthesis from BC6OTHER , a rate - limiting step.	False
The tissue BC6OTHER level is maintained through a cascade of metabolic reactions where BC6ENTC dehydrogenases ( BC6ENTG ) catalyze the terminal reaction of BC6OTHER biosynthesis from BC6OTHER , a rate - limiting step.	False
The tissue BC6OTHER level is maintained through a cascade of metabolic reactions where BC6ENTG ( BC6OTHER ) catalyze the terminal reaction of BC6ENTC biosynthesis from BC6OTHER , a rate - limiting step.	CPR:9
The tissue BC6OTHER level is maintained through a cascade of metabolic reactions where BC6OTHER dehydrogenases ( BC6ENTG ) catalyze the terminal reaction of BC6ENTC biosynthesis from BC6OTHER , a rate - limiting step.	CPR:9
The tissue BC6OTHER level is maintained through a cascade of metabolic reactions where BC6ENTG ( BC6OTHER ) catalyze the terminal reaction of BC6OTHER biosynthesis from BC6ENTC , a rate - limiting step.	CPR:9
The tissue BC6OTHER level is maintained through a cascade of metabolic reactions where BC6OTHER dehydrogenases ( BC6ENTG ) catalyze the terminal reaction of BC6OTHER biosynthesis from BC6ENTC , a rate - limiting step.	CPR:9
We showed that dietary supplement of BC6ENTC enhanced the expression of BC6ENTG genes and the cellular BC6OTHER content in vital organs such as brain, kidney, liver and heart.	False
Immunoblot analysis further confirmed increased cellular BC6ENTC - binding protein I ( BC6ENTG ) and BC6OTHER protein levels and decreased level of BC6OTHER protein with increasing BC6OTHER protein expression.	False
Immunoblot analysis further confirmed increased cellular BC6ENTC - binding protein I ( BC6OTHER ) and BC6ENTG protein levels and decreased level of BC6OTHER protein with increasing BC6OTHER protein expression.	False
Immunoblot analysis further confirmed increased cellular BC6ENTC - binding protein I ( BC6OTHER ) and BC6OTHER protein levels and decreased level of BC6ENTG protein with increasing BC6OTHER protein expression.	False
Immunoblot analysis further confirmed increased cellular BC6ENTC - binding protein I ( BC6OTHER ) and BC6OTHER protein levels and decreased level of BC6OTHER protein with increasing BC6ENTG protein expression.	False
As BC6ENTG was elevated far more than any other genes, we observed that the BC6ENTC , BC6OTHER and BC6OTHER , that bind BC6OTHER , promoted BC6OTHER - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6ENTC , BC6OTHER and BC6OTHER , that bind BC6ENTG , promoted BC6OTHER - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6ENTC , BC6OTHER and BC6OTHER , that bind BC6OTHER , promoted BC6OTHER - associated functional cell differentiation in BC6ENTG PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6ENTG was elevated far more than any other genes, we observed that the BC6OTHER , BC6ENTC and BC6OTHER , that bind BC6OTHER , promoted BC6OTHER - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6OTHER , BC6ENTC and BC6OTHER , that bind BC6ENTG , promoted BC6OTHER - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6OTHER , BC6ENTC and BC6OTHER , that bind BC6OTHER , promoted BC6OTHER - associated functional cell differentiation in BC6ENTG PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6ENTG was elevated far more than any other genes, we observed that the BC6OTHER , BC6OTHER and BC6ENTC , that bind BC6OTHER , promoted BC6OTHER - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6OTHER , BC6OTHER and BC6ENTC , that bind BC6ENTG , promoted BC6OTHER - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6OTHER , BC6OTHER and BC6ENTC , that bind BC6OTHER , promoted BC6OTHER - associated functional cell differentiation in BC6ENTG PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6ENTG was elevated far more than any other genes, we observed that the BC6OTHER , BC6OTHER and BC6OTHER , that bind BC6OTHER , promoted BC6ENTC - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6OTHER , BC6OTHER and BC6OTHER , that bind BC6ENTG , promoted BC6ENTC - associated functional cell differentiation in BC6OTHER PC - 3 cells, but not in neo control PC - 3 cells.	False
As BC6OTHER was elevated far more than any other genes, we observed that the BC6OTHER , BC6OTHER and BC6OTHER , that bind BC6OTHER , promoted BC6ENTC - associated functional cell differentiation in BC6ENTG PC - 3 cells, but not in neo control PC - 3 cells.	False
Subsequent examination of the BC6ENTC receptors BC6ENTG ) expression levels demonstrated an absence of BC6OTHER in the neo control cells and re - expression in the BC6OTHER expressing cells, consistent with previous findings where BC6OTHER is believed to play a critical role as a tumor suppressor gene that is lost during de - differentiation of prostate epithelial cells.	False
Subsequent examination of the BC6ENTC receptors BC6OTHER ) expression levels demonstrated an absence of BC6ENTG in the neo control cells and re - expression in the BC6OTHER expressing cells, consistent with previous findings where BC6OTHER is believed to play a critical role as a tumor suppressor gene that is lost during de - differentiation of prostate epithelial cells.	False
Subsequent examination of the BC6ENTC receptors BC6OTHER ) expression levels demonstrated an absence of BC6OTHER in the neo control cells and re - expression in the BC6ENTG expressing cells, consistent with previous findings where BC6OTHER is believed to play a critical role as a tumor suppressor gene that is lost during de - differentiation of prostate epithelial cells.	False
Subsequent examination of the BC6ENTC receptors BC6OTHER ) expression levels demonstrated an absence of BC6OTHER in the neo control cells and re - expression in the BC6OTHER expressing cells, consistent with previous findings where BC6ENTG is believed to play a critical role as a tumor suppressor gene that is lost during de - differentiation of prostate epithelial cells.	False
Hence, re - expression of the BC6ENTG appears to partially reverse de - differentiation of prostate cancer cells by up - regulating the expression of BC6OTHER for localized sequestration of BC6ENTC that are available to newly up - regulated BC6OTHER , BC6OTHER , and BC6OTHER .	False
Hence, re - expression of the BC6OTHER appears to partially reverse de - differentiation of prostate cancer cells by up - regulating the expression of BC6ENTG for localized sequestration of BC6ENTC that are available to newly up - regulated BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:3
Hence, re - expression of the BC6OTHER appears to partially reverse de - differentiation of prostate cancer cells by up - regulating the expression of BC6OTHER for localized sequestration of BC6ENTC that are available to newly up - regulated BC6ENTG , BC6OTHER , and BC6OTHER .	False
Hence, re - expression of the BC6OTHER appears to partially reverse de - differentiation of prostate cancer cells by up - regulating the expression of BC6OTHER for localized sequestration of BC6ENTC that are available to newly up - regulated BC6OTHER , BC6ENTG , and BC6OTHER .	False
Hence, re - expression of the BC6OTHER appears to partially reverse de - differentiation of prostate cancer cells by up - regulating the expression of BC6OTHER for localized sequestration of BC6ENTC that are available to newly up - regulated BC6OTHER , BC6OTHER , and BC6ENTG .	False
To better understand the molecular mechanism of BC6ENTG on tumor suppression, we utilized a complementary BC6ENTC microarray composed of approximately 6,000 human cancer - related genes to determine the gene expression pattern altered by re - introduction of BC6OTHER into PC - 3 prostate tumor cells.	False
To better understand the molecular mechanism of BC6OTHER on tumor suppression, we utilized a complementary BC6ENTC microarray composed of approximately 6,000 human cancer - related genes to determine the gene expression pattern altered by re - introduction of BC6ENTG into PC - 3 prostate tumor cells.	False
The BC6ENTG inhibitor BC6ENTC (300µM, 24h) completely abolished BC6OTHER - induced DA release.	CPR:4
The BC6ENTG inhibitor BC6OTHER (300µM, 24h) completely abolished BC6ENTC - induced DA release.	False
BC6ENTC significantly increased DA precursor accumulation in cells treated with BC6OTHER (10µM), revealing that BC6OTHER increases BC6ENTG activity.	False
BC6OTHER significantly increased DA precursor accumulation in cells treated with BC6ENTC (10µM), revealing that BC6OTHER increases BC6ENTG activity.	False
BC6OTHER significantly increased DA precursor accumulation in cells treated with BC6OTHER (10µM), revealing that BC6ENTC increases BC6ENTG activity.	CPR:3
PURPOSE: BC6ENTG inhibitors and BC6ENTC are the mainstay of pharmacological intervention for the cognitive symptoms of Alzheimer's disease (AD).	False
These results suggest that BC6OTHER signaling through BC6OTHER in the gill regulates the expression of BC6ENTG , thereby linking this BC6OTHER with an effector of BC6ENTC uptake in zebrafish for the first time.	False
These results suggest that BC6OTHER signaling through BC6OTHER in the gill regulates the expression of BC6OTHER , thereby linking this BC6ENTG with an effector of BC6ENTC uptake in zebrafish for the first time.	False
These results suggest that BC6ENTG signaling through BC6OTHER in the gill regulates the expression of BC6OTHER , thereby linking this BC6OTHER with an effector of BC6ENTC uptake in zebrafish for the first time.	False
These results suggest that BC6OTHER signaling through BC6ENTG in the gill regulates the expression of BC6OTHER , thereby linking this BC6OTHER with an effector of BC6ENTC uptake in zebrafish for the first time.	False
Ion - poor conditions led to increases in the expression of BC6ENTG ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6ENTG ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6ENTG ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6ENTG ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTG ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6ENTG ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6ENTG ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and BC6ENTG ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6ENTG ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6ENTG ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6ENTG ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6ENTG ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6ENTG ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6ENTG ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTG ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6ENTG ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6ENTG ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and BC6ENTG ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6ENTG ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6ENTG ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6ENTG ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6ENTG ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6ENTG ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6ENTG ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6ENTG ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and BC6ENTG ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6ENTG ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTC / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6ENTG ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6ENTG ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6ENTG ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6ENTG ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6ENTG ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6ENTG ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and BC6ENTG ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6ENTG ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6ENTC exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6OTHER channel ( BC6OTHER ; BC6ENTG ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6ENTG ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6ENTG ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6ENTG ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6ENTG ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6ENTG ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6ENTG ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6ENTG ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6ENTG ; BC6OTHER ) transcripts within the gill.	False
Ion - poor conditions led to increases in the expression of BC6OTHER ( BC6OTHER ), BC6OTHER / BC6OTHER cotransporter ( BC6OTHER ; BC6OTHER ), BC6OTHER / BC6OTHER exchanger ( BC6OTHER ; BC6OTHER ), and epithelial BC6ENTC channel ( BC6OTHER ; BC6ENTG ) transcripts within the gill.	False
 BC6ENTG regulates transcription of the ion uptake BC6ENTC / BC6OTHER cotransporter ( BC6OTHER ) gene in zebrafish gill.	False
 BC6OTHER regulates transcription of the ion uptake BC6ENTC / BC6OTHER cotransporter ( BC6ENTG ) gene in zebrafish gill.	False
 BC6ENTG regulates transcription of the ion uptake BC6OTHER / BC6ENTC cotransporter ( BC6OTHER ) gene in zebrafish gill.	False
 BC6OTHER regulates transcription of the ion uptake BC6OTHER / BC6ENTC cotransporter ( BC6ENTG ) gene in zebrafish gill.	False
Distinct roles of BC6ENTC in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of BC6ENTG and BC6OTHER activation in hippocampus and prefrontal cortex.	CPR:3
Distinct roles of BC6ENTC in modulating spatial memory consolidation, retrieval, reconsolidation and the accompanying changes of BC6OTHER and BC6ENTG activation in hippocampus and prefrontal cortex.	CPR:3
Activation of both BC6ENTG and BC6OTHER in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in BC6ENTC - treated mouse groups.	False
Activation of both BC6OTHER and BC6ENTG in the hippocampus was found following memory consolidation but not after retrieval or reconsolidation in BC6ENTC - treated mouse groups.	False
In contrast, activation of both BC6ENTG and BC6OTHER in the PFC was found following memory retrieval but not other processes in BC6ENTC - treated mouse groups.	CPR:3
In contrast, activation of both BC6OTHER and BC6ENTG in the PFC was found following memory retrieval but not other processes in BC6ENTC - treated mouse groups.	CPR:3
Moreover, activation of the BC6ENTG and BC6OTHER signaling pathway in the hippocampus might be involved in BC6ENTC - induced spatial memory changes.	CPR:3
Moreover, activation of the BC6OTHER and BC6ENTG signaling pathway in the hippocampus might be involved in BC6ENTC - induced spatial memory changes.	CPR:3
The BC6ENTG ( BC6OTHER ) and the transcription factor BC6ENTC response element - binding protein ( BC6OTHER ) were involved in neuroplastic changes associated with learning and memory.	False
The BC6OTHER ( BC6ENTG ) and the transcription factor BC6ENTC response element - binding protein ( BC6OTHER ) were involved in neuroplastic changes associated with learning and memory.	False
The BC6OTHER ( BC6OTHER ) and the transcription factor BC6ENTC response element - binding protein ( BC6ENTG ) were involved in neuroplastic changes associated with learning and memory.	False
On the other hand, BC6ENTC did not modify the eosinophil spontaneous adhesion to the resting or BC6ENTG plus BC6OTHER - stimulated pulmonary endothelial cells.	False
On the other hand, BC6ENTC did not modify the eosinophil spontaneous adhesion to the resting or BC6OTHER plus BC6ENTG - stimulated pulmonary endothelial cells.	False
Similarly, BC6ENTC did not modulate BC6ENTG - or CHEM - activated eosinophil adhesion to the resting endothelial cells.	False
BC6ENTC (SB) is an BC6ENTG ( BC6OTHER ) antagonist that has previously been shown to inhibit BC6OTHER - based cancer cell invasion, and to possess in vivo anti - inflammatory and anti - nociceptive effects.	CPR:6
BC6ENTC (SB) is an BC6OTHER ( BC6ENTG ) antagonist that has previously been shown to inhibit BC6OTHER - based cancer cell invasion, and to possess in vivo anti - inflammatory and anti - nociceptive effects.	CPR:6
BC6ENTC (SB) is an BC6OTHER ( BC6OTHER ) antagonist that has previously been shown to inhibit BC6ENTG - based cancer cell invasion, and to possess in vivo anti - inflammatory and anti - nociceptive effects.	CPR:4
Molecular docking studies suggested that SB has a good affinity towards BC6ENTC - binding site on BC6ENTG subunit.	False
Of note, BC6ENTC which is a close structural analogue of BC6OTHER with a potent BC6ENTG antagonistic activity did not exhibit a similar antimitotic activity.	CPR:6
Of note, BC6OTHER which is a close structural analogue of BC6ENTC with a potent BC6ENTG antagonistic activity did not exhibit a similar antimitotic activity.	CPR:6
The crystal structure of BC6ENTG complexed with BC6OTHER and BC6OTHER revealed that BC6OTHER binds to the BC6OTHER and that upon binding, it acetylates BC6ENTC 199.	False
The crystal structure of BC6OTHER complexed with BC6OTHER and BC6OTHER revealed that BC6OTHER binds to the BC6ENTG and that upon binding, it acetylates BC6ENTC 199.	False
The BC6ENTG had twofold weaker binding affinity for BC6ENTC as demonstrated by fluorescence quenching.	False
Reduced binding affinity means that BC6ENTC is more easily released from BC6ENTG into the circulation.	False
 BC6ENTG - based design of a BC6ENTC prodrug.	False
Taken together, our results not only provide a template for design of BC6ENTG - based prodrugs, but also pave the way toward more effective use of BC6ENTC in the clinic.	False
About 99% of a dose of BC6ENTC is unavailable for reaction with the target enzyme, because BC6OTHER strongly binds to BC6ENTG ( BC6OTHER ).	False
About 99% of a dose of BC6ENTC is unavailable for reaction with the target enzyme, because BC6OTHER strongly binds to BC6OTHER ( BC6ENTG ).	False
About 99% of a dose of BC6OTHER is unavailable for reaction with the target enzyme, because BC6ENTC strongly binds to BC6ENTG ( BC6OTHER ).	False
About 99% of a dose of BC6OTHER is unavailable for reaction with the target enzyme, because BC6ENTC strongly binds to BC6OTHER ( BC6ENTG ).	False
To reduce the binding affinity of BC6ENTC to BC6ENTG , we designed and synthesized the prodrug BC6OTHER .	False
The BC6ENTG inhibitor, BC6ENTC , is used in the clinic for its anti - inflammatory activity.	CPR:4
To reduce the binding affinity of BC6OTHER to BC6ENTG , we designed and synthesized the prodrug BC6ENTC .	False
The crystal structure of BC6ENTG complexed with BC6ENTC and BC6OTHER revealed that BC6OTHER binds to the BC6OTHER and that upon binding, it acetylates BC6OTHER 199.	False
The crystal structure of BC6OTHER complexed with BC6ENTC and BC6OTHER revealed that BC6OTHER binds to the BC6ENTG and that upon binding, it acetylates BC6OTHER 199.	False
The crystal structure of BC6ENTG complexed with BC6OTHER and BC6ENTC revealed that BC6OTHER binds to the BC6OTHER and that upon binding, it acetylates BC6OTHER 199.	False
The crystal structure of BC6OTHER complexed with BC6OTHER and BC6ENTC revealed that BC6OTHER binds to the BC6ENTG and that upon binding, it acetylates BC6OTHER 199.	False
The crystal structure of BC6ENTG complexed with BC6OTHER and BC6OTHER revealed that BC6ENTC binds to the BC6OTHER and that upon binding, it acetylates BC6OTHER 199.	False
The crystal structure of BC6OTHER complexed with BC6OTHER and BC6OTHER revealed that BC6ENTC binds to the BC6ENTG and that upon binding, it acetylates BC6OTHER 199.	False
Design and synthesis of novel BC6ENTC derivatives as BC6ENTG inhibitors.	CPR:4
The BC6OTHER constitutive BC6ENTC receptor ( BC6ENTG ), BC6OTHER X receptor ( BC6OTHER ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6ENTC receptor ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6ENTC receptor ( BC6OTHER ), BC6OTHER X receptor ( BC6ENTG ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6ENTC receptor ( BC6OTHER ), BC6OTHER X receptor ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6ENTC receptor ( BC6OTHER ), BC6OTHER X receptor ( BC6OTHER ) and BC6OTHER receptor ( BC6ENTG ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6ENTG constitutive BC6ENTC receptor ( BC6OTHER ), BC6OTHER X receptor ( BC6OTHER ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6ENTG ), BC6ENTC X receptor ( BC6OTHER ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6OTHER ), BC6ENTC X receptor ( BC6ENTG ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6OTHER ), BC6ENTC X receptor ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6OTHER ), BC6ENTC X receptor ( BC6OTHER ) and BC6OTHER receptor ( BC6ENTG ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER BC6ENTG ( BC6OTHER ), BC6ENTC X receptor ( BC6OTHER ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6ENTG constitutive BC6OTHER receptor ( BC6OTHER ), BC6ENTC X receptor ( BC6OTHER ) and BC6OTHER receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6ENTG ), BC6OTHER X receptor ( BC6OTHER ) and BC6ENTC receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6ENTC receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6OTHER ), BC6OTHER X receptor ( BC6ENTG ) and BC6ENTC receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER constitutive BC6OTHER receptor ( BC6OTHER ), BC6OTHER X receptor ( BC6OTHER ) and BC6ENTC receptor ( BC6ENTG ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6OTHER BC6ENTG ( BC6OTHER ), BC6OTHER X receptor ( BC6OTHER ) and BC6ENTC receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
The BC6ENTG constitutive BC6OTHER receptor ( BC6OTHER ), BC6OTHER X receptor ( BC6OTHER ) and BC6ENTC receptor ( BC6OTHER ) control a large array of genes that code for important proteins in humans including metabolic enzymes and transporters.	False
To mechanistically evaluate this regional selectivity, we assessed BC6ENTG ( BC6OTHER ) expression in the uninvolved mucosa and demonstrated a 3 - to 4 - fold excess in the distal relative to the proximal bowel in both MIN mice and BC6ENTC - treated rats.	CPR:3
To mechanistically evaluate this regional selectivity, we assessed BC6OTHER ( BC6ENTG ) expression in the uninvolved mucosa and demonstrated a 3 - to 4 - fold excess in the distal relative to the proximal bowel in both MIN mice and BC6ENTC - treated rats.	CPR:3
The striking distal predilection of BC6ENTC may be, at least partially, explained by distal bowel over - expression of BC6ENTG and BC6OTHER .	False
The striking distal predilection of BC6ENTC may be, at least partially, explained by distal bowel over - expression of BC6OTHER and BC6ENTG .	False
The related BC6OTHER BC6OTHER and BC6ENTC and the nonselective BC6ENTG agonist BC6OTHER were less potent BC6OTHER agonists.	False
The related BC6OTHER BC6OTHER and BC6ENTC and the nonselective BC6OTHER agonist BC6OTHER were less potent BC6ENTG agonists.	CPR:5
The related BC6OTHER BC6OTHER and BC6OTHER and the nonselective BC6ENTG agonist BC6ENTC were less potent BC6OTHER agonists.	CPR:5
The related BC6OTHER BC6OTHER and BC6OTHER and the nonselective BC6OTHER agonist BC6ENTC were less potent BC6ENTG agonists.	CPR:5
The CHEM - opioid receptor agonist / BC6OTHER antagonist BC6ENTC was a pure antagonist at both rat brain and human BC6ENTG receptors.	CPR:6
The CHEM - opioid receptor agonist / BC6ENTG antagonist BC6ENTC was a pure antagonist at both rat brain and human BC6OTHER receptors.	CPR:6
The nonselective BC6ENTG partial agonist BC6ENTC and the nonselective BC6OTHER antagonist BC6OTHER exhibited pure antagonism at rat brain receptors, but displayed partial agonism at BC6OTHER receptors.	CPR:5
The nonselective BC6OTHER partial agonist BC6ENTC and the nonselective BC6ENTG antagonist BC6OTHER exhibited pure antagonism at rat brain receptors, but displayed partial agonism at BC6OTHER receptors.	False
The nonselective BC6OTHER partial agonist BC6ENTC and the nonselective BC6OTHER antagonist BC6OTHER exhibited pure antagonism at rat brain receptors, but displayed partial agonism at BC6ENTG receptors.	False
The nonselective BC6ENTG partial agonist BC6OTHER and the nonselective BC6OTHER antagonist BC6ENTC exhibited pure antagonism at rat brain receptors, but displayed partial agonism at BC6OTHER receptors.	False
The nonselective BC6OTHER partial agonist BC6OTHER and the nonselective BC6ENTG antagonist BC6ENTC exhibited pure antagonism at rat brain receptors, but displayed partial agonism at BC6OTHER receptors.	CPR:6
The nonselective BC6OTHER partial agonist BC6OTHER and the nonselective BC6OTHER antagonist BC6ENTC exhibited pure antagonism at rat brain receptors, but displayed partial agonism at BC6ENTG receptors.	CPR:5
In addition, the stereospecificity required at BC6ENTG appears to be retained at the BC6OTHER , since BC6ENTC is inactive at both receptors.	False
In addition, the stereospecificity required at BC6OTHER appears to be retained at the BC6ENTG , since BC6ENTC is inactive at both receptors.	False
The affinity and functional profile of opioids possessing activity at the BC6ENTG was determined using CHEM and nociceptin - stimulated BC6ENTC binding.	False
The BC6ENTG - selective agonist BC6ENTC potently and competitively displaced CHEM at rat brain receptors (IC(50) 62 nM).	CPR:5
BC6ENTC exhibited full agonism for enhancement of BC6OTHER binding to human recombinant BC6ENTG receptors (EC(50) 50 nM).	CPR:5
BC6OTHER exhibited full agonism for enhancement of BC6ENTC binding to human recombinant BC6ENTG receptors (EC(50) 50 nM).	False
The related BC6ENTC BC6OTHER and BC6OTHER and the nonselective BC6ENTG agonist BC6OTHER were less potent BC6OTHER agonists.	False
The related BC6ENTC BC6OTHER and BC6OTHER and the nonselective BC6OTHER agonist BC6OTHER were less potent BC6ENTG agonists.	CPR:5
The related BC6OTHER BC6ENTC and BC6OTHER and the nonselective BC6ENTG agonist BC6OTHER were less potent BC6OTHER agonists.	False
The related BC6OTHER BC6ENTC and BC6OTHER and the nonselective BC6OTHER agonist BC6OTHER were less potent BC6ENTG agonists.	CPR:5
These strains, defective in BC6ENTG and BC6ENTC kinase, respectively, are characterized by both disturbances of BC6OTHER pools and a mutator phenotype.	False
These strains, defective in BC6ENTG and BC6OTHER , respectively, are characterized by both disturbances of BC6ENTC pools and a mutator phenotype.	False
These strains, defective in BC6OTHER deaminase and BC6ENTG , respectively, are characterized by both disturbances of BC6ENTC pools and a mutator phenotype.	False
We show that BC6OTHER strains suffer from increased intracellular levels of BC6ENTC (4 - fold) and reduced levels of BC6OTHER (2 - fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch - repair defective (mutL) background, a strong mutator effect for BC6ENTG and BC6OTHER transversions (27 - and 42 - fold enhancement, respectively).	False
We show that BC6OTHER strains suffer from increased intracellular levels of BC6ENTC (4 - fold) and reduced levels of BC6OTHER (2 - fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch - repair defective (mutL) background, a strong mutator effect for BC6OTHER and BC6ENTG transversions (27 - and 42 - fold enhancement, respectively).	False
We show that BC6ENTG strains suffer from increased intracellular levels of BC6ENTC (4 - fold) and reduced levels of BC6OTHER (2 - fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch - repair defective (mutL) background, a strong mutator effect for BC6OTHER and BC6OTHER transversions (27 - and 42 - fold enhancement, respectively).	False
We show that BC6OTHER strains suffer from increased intracellular levels of BC6OTHER (4 - fold) and reduced levels of BC6ENTC (2 - fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch - repair defective (mutL) background, a strong mutator effect for BC6ENTG and BC6OTHER transversions (27 - and 42 - fold enhancement, respectively).	False
We show that BC6OTHER strains suffer from increased intracellular levels of BC6OTHER (4 - fold) and reduced levels of BC6ENTC (2 - fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch - repair defective (mutL) background, a strong mutator effect for BC6OTHER and BC6ENTG transversions (27 - and 42 - fold enhancement, respectively).	False
We show that BC6ENTG strains suffer from increased intracellular levels of BC6OTHER (4 - fold) and reduced levels of BC6ENTC (2 - fold), while displaying, as measured using a set of lacZ reversion markers in a mismatch - repair defective (mutL) background, a strong mutator effect for BC6OTHER and BC6OTHER transversions (27 - and 42 - fold enhancement, respectively).	False
In contrast, BC6ENTG strains possess a lowered BC6ENTC level (4 - fold) and modestly enhanced BC6OTHER level (2 - fold), while its mutator effect is specific for just the BC6OTHER transversions.	False
In contrast, BC6OTHER strains possess a lowered BC6ENTC level (4 - fold) and modestly enhanced BC6OTHER level (2 - fold), while its mutator effect is specific for just the BC6ENTG transversions.	False
In contrast, BC6ENTG strains possess a lowered BC6OTHER level (4 - fold) and modestly enhanced BC6ENTC level (2 - fold), while its mutator effect is specific for just the BC6OTHER transversions.	False
In contrast, BC6OTHER strains possess a lowered BC6OTHER level (4 - fold) and modestly enhanced BC6ENTC level (2 - fold), while its mutator effect is specific for just the BC6ENTG transversions.	False
The accuracy of DNA synthesis depends on the accuracy of the BC6ENTG as well as the quality and concentration(s) of the available BC6ENTC DNA precursors ( BC6OTHER ).	False
Overall, our analysis reveals for both strains a satisfactory correlation between BC6ENTC pool alterations and the replication error rates, and also suggests that a minimal explanation for the BC6ENTG mutator does not require assumptions beyond the predicted effect of the BC6OTHER pools.	False
Overall, our analysis reveals for both strains a satisfactory correlation between BC6OTHER pool alterations and the replication error rates, and also suggests that a minimal explanation for the BC6ENTG mutator does not require assumptions beyond the predicted effect of the BC6ENTC pools.	False
The accuracy of DNA synthesis depends on the accuracy of the BC6ENTG as well as the quality and concentration(s) of the available BC6OTHER DNA precursors ( BC6ENTC ).	False
These strains, defective in BC6ENTC deaminase and BC6ENTG , respectively, are characterized by both disturbances of BC6OTHER pools and a mutator phenotype.	False
BC6ENTC is a collective term for compounds which bind to and activate BC6OTHER ( BC6OTHER and BC6ENTG ), members of BC6OTHER superfamily.	False
BC6ENTC is a collective term for compounds which bind to and activate BC6OTHER ( BC6OTHER and BC6OTHER ), members of BC6ENTG superfamily.	CPR:3
BC6ENTC is a collective term for compounds which bind to and activate BC6ENTG ( BC6OTHER and BC6OTHER ), members of BC6OTHER superfamily.	CPR:3
BC6ENTC is a collective term for compounds which bind to and activate BC6OTHER ( BC6ENTG and BC6OTHER ), members of BC6OTHER superfamily.	False
The most important endogeneous BC6ENTC is BC6OTHER ( BC6OTHER ) which is an BC6ENTG ligand.	False
The most important endogeneous BC6OTHER is BC6ENTC ( BC6OTHER ) which is an BC6ENTG ligand.	False
The most important endogeneous BC6OTHER is BC6OTHER ( BC6ENTC ) which is an BC6ENTG ligand.	False
Among them, BC6ENTC ( BC6OTHER ) is an BC6ENTG - and BC6OTHER - specific (but BC6OTHER - and BC6OTHER - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6ENTC ( BC6OTHER ) is an BC6OTHER - and BC6ENTG - specific (but BC6OTHER - and BC6OTHER - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6ENTC ( BC6OTHER ) is an BC6OTHER - and BC6OTHER - specific (but BC6ENTG - and BC6OTHER - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6ENTC ( BC6OTHER ) is an BC6OTHER - and BC6OTHER - specific (but BC6OTHER - and BC6ENTG - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6ENTC ) is an BC6ENTG - and BC6OTHER - specific (but BC6OTHER - and BC6OTHER - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6ENTC ) is an BC6OTHER - and BC6ENTG - specific (but BC6OTHER - and BC6OTHER - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6ENTC ) is an BC6OTHER - and BC6OTHER - specific (but BC6ENTG - and BC6OTHER - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6ENTC ) is an BC6OTHER - and BC6OTHER - specific (but BC6OTHER - and BC6ENTG - nonbinding) synthetic BC6OTHER that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6OTHER ) is an BC6ENTG - and BC6OTHER - specific (but BC6OTHER - and BC6OTHER - nonbinding) synthetic BC6ENTC that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6OTHER ) is an BC6OTHER - and BC6ENTG - specific (but BC6OTHER - and BC6OTHER - nonbinding) synthetic BC6ENTC that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6OTHER ) is an BC6OTHER - and BC6OTHER - specific (but BC6ENTG - and BC6OTHER - nonbinding) synthetic BC6ENTC that is effective in the treatment of psoriasis patients and relapsed APL.	False
Among them, BC6OTHER ( BC6OTHER ) is an BC6OTHER - and BC6OTHER - specific (but BC6OTHER - and BC6ENTG - nonbinding) synthetic BC6ENTC that is effective in the treatment of psoriasis patients and relapsed APL.	False
The aim of the present study was to analyse the role of BC6ENTG in the BC6ENTC - induced myocardial remodeling, especially the interstitial fibrosis.	False
Blockade of BC6ENTG - and desensitization of BC6OTHER reduce BC6ENTC - induced cardiac fibrosis.	False
Blockade of BC6OTHER - and desensitization of BC6ENTG reduce BC6ENTC - induced cardiac fibrosis.	False
BC6OTHER blockade and BC6ENTG down - regulation provided similar protection against BC6ENTC - induced cardiac interstitial fibrosis suggesting that both BC6OTHER are involved in such cardiac remodeling process.	False
BC6OTHER blockade and BC6OTHER down - regulation provided similar protection against BC6ENTC - induced cardiac interstitial fibrosis suggesting that both BC6ENTG are involved in such cardiac remodeling process.	False
BC6ENTG blockade and BC6OTHER down - regulation provided similar protection against BC6ENTC - induced cardiac interstitial fibrosis suggesting that both BC6OTHER are involved in such cardiac remodeling process.	False
Rats received a concomitant treatment with the selective BC6ENTG antagonist, BC6ENTC (50 mg / kg / day p.o.)	CPR:6
or were chronically pretreated with the selective BC6ENTG agonist BC6ENTC (40 microg / kg / h) for 1 week to induce BC6OTHER desensitization.	CPR:5
or were chronically pretreated with the selective BC6OTHER agonist BC6ENTC (40 microg / kg / h) for 1 week to induce BC6ENTG desensitization.	False
The pretreatment with BC6ENTC induced a 59% down - regulation of left ventricular BC6ENTG compared to control.	CPR:4
BC6ENTC induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	CPR:4
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6ENTC , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6ENTC , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6ENTC , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6ENTC , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTC peroxidase, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTC peroxidase, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTC peroxidase, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6ENTC reductase, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTC reductase, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTC reductase, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6ENTG , BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - dehydrogenases, BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - dehydrogenases, BC6OTHER and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC - dehydrogenases, BC6ENTG and BC6OTHER .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6ENTC .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER and BC6ENTC .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER and BC6ENTC .	False
BC6OTHER induced myocardial infarcted rats showed a significant increase in the levels of cardiac diagnostic markers, heart mitochondrial lipid peroxidation, BC6OTHER , and a significant decrease in the activities / levels of heart mitochondrial BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG and BC6ENTC .	False
BC6OTHER increased the number and area of BC6OTHER BC6ENTC - transferase placental form ( BC6ENTG )(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	False
BC6ENTC also increased the numbers of CHEM, BC6ENTG (+), and BC6OTHER (+) liver cells, as well as the number of BC6OTHER (+) lymphocytes.	CPR:4
BC6ENTC also increased the numbers of CHEM, BC6OTHER (+), and BC6ENTG (+) liver cells, as well as the number of BC6OTHER (+) lymphocytes.	CPR:4
BC6ENTC also increased the numbers of CHEM, BC6OTHER (+), and BC6OTHER (+) liver cells, as well as the number of BC6ENTG (+) lymphocytes.	CPR:4
BC6OTHER also increased the numbers of CHEM, BC6ENTG (+), and BC6ENTC oxygenase - 1(+) liver cells, as well as the number of BC6OTHER (+) lymphocytes.	False
BC6OTHER also increased the numbers of CHEM, BC6OTHER (+), and BC6ENTC oxygenase - 1(+) liver cells, as well as the number of BC6ENTG (+) lymphocytes.	False
EMIQ increased liver levels of BC6ENTC - reactive substance and BC6OTHER , and TUNEL(+) apoptotic cells, BC6ENTG ( BC6OTHER )(+) cells and BC6OTHER (+) cells within BC6OTHER (+) foci.	False
EMIQ increased liver levels of BC6ENTC - reactive substance and BC6OTHER , and TUNEL(+) apoptotic cells, BC6OTHER ( BC6ENTG )(+) cells and BC6OTHER (+) cells within BC6OTHER (+) foci.	False
EMIQ increased liver levels of BC6ENTC - reactive substance and BC6OTHER , and TUNEL(+) apoptotic cells, BC6OTHER ( BC6OTHER )(+) cells and BC6OTHER (+) cells within BC6ENTG (+) foci.	False
EMIQ increased liver levels of BC6OTHER - reactive substance and BC6ENTC , and TUNEL(+) apoptotic cells, BC6ENTG ( BC6OTHER )(+) cells and BC6OTHER (+) cells within BC6OTHER (+) foci.	False
EMIQ increased liver levels of BC6OTHER - reactive substance and BC6ENTC , and TUNEL(+) apoptotic cells, BC6OTHER ( BC6ENTG )(+) cells and BC6OTHER (+) cells within BC6OTHER (+) foci.	False
EMIQ increased liver levels of BC6OTHER - reactive substance and BC6ENTC , and TUNEL(+) apoptotic cells, BC6OTHER ( BC6OTHER )(+) cells and BC6OTHER (+) cells within BC6ENTG (+) foci.	False
EMIQ increased liver levels of BC6OTHER - reactive substance and BC6OTHER , and TUNEL(+) apoptotic cells, BC6ENTG ( BC6OTHER )(+) cells and BC6ENTC (+) cells within BC6OTHER (+) foci.	False
EMIQ increased liver levels of BC6OTHER - reactive substance and BC6OTHER , and TUNEL(+) apoptotic cells, BC6OTHER ( BC6ENTG )(+) cells and BC6ENTC (+) cells within BC6OTHER (+) foci.	False
EMIQ increased liver levels of BC6OTHER - reactive substance and BC6OTHER , and TUNEL(+) apoptotic cells, BC6OTHER ( BC6OTHER )(+) cells and BC6ENTC (+) cells within BC6ENTG (+) foci.	False
BC6ENTC increased the number and area of BC6ENTG ( BC6OTHER )(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	CPR:3
BC6ENTC increased the number and area of BC6OTHER BC6OTHER - transferase placental form ( BC6ENTG )(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	CPR:3
BC6OTHER increased the number and area of BC6ENTC BC6OTHER - transferase placental form ( BC6ENTG )(+) liver cell foci and the numbers of proliferating and apoptotic cells in randomly selected areas in liver sections.	False
Secondary point mutations in the Fms - like BC6ENTC kinase 3 (FLT3) BC6OTHER kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6ENTG inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
Secondary point mutations in the Fms - like BC6ENTC kinase 3 (FLT3) BC6OTHER kinase domain ( BC6ENTG ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
We assessed the in vitro activity of BC6ENTC against clinically relevant BC6ENTG - ITD mutant isoforms that confer resistance to BC6OTHER or BC6OTHER .	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6ENTC kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6ENTG inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
Secondary point mutations in the BC6ENTG BC6ENTC kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6ENTC kinase domain ( BC6ENTG ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
We assessed the in vitro activity of BC6OTHER against clinically relevant BC6ENTG - ITD mutant isoforms that confer resistance to BC6ENTC or BC6OTHER .	False
We assessed the in vitro activity of BC6OTHER against clinically relevant BC6ENTG - ITD mutant isoforms that confer resistance to BC6OTHER or BC6ENTC .	False
"Substitution of the BC6ENTG ""gatekeeper"" BC6ENTC with BC6OTHER ( BC6OTHER ) conferred mild resistance to BC6OTHER , but substitutions at the BC6OTHER ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6ENTC with BC6OTHER ( BC6ENTG ) conferred mild resistance to BC6OTHER , but substitutions at the BC6OTHER ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6ENTC with BC6OTHER ( BC6OTHER ) conferred mild resistance to BC6OTHER , but substitutions at the BC6ENTG ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6ENTC with BC6OTHER ( BC6OTHER ) conferred mild resistance to BC6OTHER , but substitutions at the BC6OTHER ( BC6ENTG ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6ENTG ""gatekeeper"" BC6OTHER with BC6ENTC ( BC6OTHER ) conferred mild resistance to BC6OTHER , but substitutions at the BC6OTHER ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6OTHER with BC6ENTC ( BC6ENTG ) conferred mild resistance to BC6OTHER , but substitutions at the BC6OTHER ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6OTHER with BC6ENTC ( BC6OTHER ) conferred mild resistance to BC6OTHER , but substitutions at the BC6ENTG ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6OTHER with BC6ENTC ( BC6OTHER ) conferred mild resistance to BC6OTHER , but substitutions at the BC6OTHER ( BC6ENTG ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6ENTG ""gatekeeper"" BC6OTHER with BC6OTHER ( BC6OTHER ) conferred mild resistance to BC6ENTC , but substitutions at the BC6OTHER ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6OTHER with BC6OTHER ( BC6ENTG ) conferred mild resistance to BC6ENTC , but substitutions at the BC6OTHER ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6OTHER with BC6OTHER ( BC6OTHER ) conferred mild resistance to BC6ENTC , but substitutions at the BC6ENTG ( BC6OTHER ) residue D835 conferred a high degree of resistance."	False
"Substitution of the BC6OTHER ""gatekeeper"" BC6OTHER with BC6OTHER ( BC6OTHER ) conferred mild resistance to BC6ENTC , but substitutions at the BC6OTHER ( BC6ENTG ) residue D835 conferred a high degree of resistance."	False
Activity of BC6ENTC against clinically - relevant BC6OTHER - resistant BC6ENTG mutants of BC6OTHER - ITD.	False
Activity of BC6ENTC against clinically - relevant BC6OTHER - resistant BC6OTHER mutants of BC6ENTG - ITD.	False
Activity of BC6OTHER against clinically - relevant BC6ENTC - resistant BC6ENTG mutants of BC6OTHER - ITD.	False
Activity of BC6OTHER against clinically - relevant BC6ENTC - resistant BC6OTHER mutants of BC6ENTG - ITD.	False
The switch control inhibitor BC6ENTC was similarly inactive against BC6ENTG AL mutations.	False
On the basis of its in vitro activity against BC6ENTG TKI - resistant F691 substitutions, further clinical evaluation of BC6ENTC in TKI - naive and select TKI - resistant BC6OTHER - ITD+ AML patients is warranted.	False
On the basis of its in vitro activity against BC6OTHER TKI - resistant F691 substitutions, further clinical evaluation of BC6ENTC in TKI - naive and select TKI - resistant BC6ENTG - ITD+ AML patients is warranted.	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6OTHER kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6ENTG inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER .	CPR:4
Secondary point mutations in the BC6ENTG BC6OTHER kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER .	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6OTHER kinase domain ( BC6ENTG ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER .	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6OTHER kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6ENTG inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER .	CPR:4
Secondary point mutations in the BC6ENTG BC6OTHER kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER .	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6OTHER kinase domain ( BC6ENTG ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER .	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6OTHER kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6ENTG inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC .	CPR:4
Secondary point mutations in the BC6ENTG BC6OTHER kinase domain ( BC6OTHER ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC .	False
Secondary point mutations in the Fms - like BC6OTHER kinase 3 (FLT3) BC6OTHER kinase domain ( BC6ENTG ) are common causes of acquired clinical resistance to the BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC .	False
BC6ENTC ( BC6OTHER ) is a BC6ENTG inhibitor with in vitro and clinical activity in BC6OTHER kinase inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6OTHER mutation.	CPR:4
BC6ENTC ( BC6OTHER ) is a BC6OTHER inhibitor with in vitro and clinical activity in BC6ENTG inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6OTHER mutation.	False
BC6ENTC ( BC6OTHER ) is a BC6OTHER inhibitor with in vitro and clinical activity in BC6OTHER kinase inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6ENTG mutation.	False
BC6OTHER ( BC6ENTC ) is a BC6ENTG inhibitor with in vitro and clinical activity in BC6OTHER kinase inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6OTHER mutation.	CPR:4
BC6OTHER ( BC6ENTC ) is a BC6OTHER inhibitor with in vitro and clinical activity in BC6ENTG inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6OTHER mutation.	False
BC6OTHER ( BC6ENTC ) is a BC6OTHER inhibitor with in vitro and clinical activity in BC6OTHER kinase inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6ENTG mutation.	False
BC6OTHER ( BC6OTHER ) is a BC6ENTG inhibitor with in vitro and clinical activity in BC6ENTC kinase inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6OTHER mutation.	False
BC6OTHER ( BC6OTHER ) is a BC6OTHER inhibitor with in vitro and clinical activity in BC6ENTC kinase inhibitor (TKI) - resistant chronic myeloid leukemia, irrespective of BC6ENTG mutation.	False
BC6ENTC has demonstrated early clinical efficacy in chemotherapy - resistant acute myeloid leukemia (AML) patients with internal tandem duplication (ITD) mutations in BC6ENTG .	False
RESULTS: We first showed that expression of the genes encoding BC6ENTG and heparan BC6ENTC 2 - sulfotransferase decreased between E13.5 and E17.5.	False
BC6ENTG - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6ENTG ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6ENTG ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6ENTG ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6ENTG ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and BC6ENTG ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6ENTG ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6ENTC exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTG ).	False
BC6ENTG - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6ENTG ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6ENTG ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6ENTG ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6ENTG ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6ENTG ; previously known as BC6OTHER transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6ENTC transporter), member 2 ( BC6OTHER ; previously known as BC6ENTG ).	False
BC6ENTG - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6ENTG ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6ENTG ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6ENTG ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6ENTG ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and BC6ENTG ( BC6OTHER ; previously known as BC6ENTC transporter 2).	False
BC6OTHER - positive cells that developed in the presence of BC6OTHER exhibited a phenotype of mature cells with regard to the expression of the following genes: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ), BC6OTHER ( BC6OTHER ; previously known as BC6OTHER ) and solute carrier family 2 (facilitated BC6OTHER transporter), member 2 ( BC6ENTG ; previously known as BC6ENTC transporter 2).	False
Finally, we showed that BC6ENTC activated endocrine cell development by inducing BC6ENTG ( BC6OTHER ) expression in early endocrine progenitor cells.	CPR:3
Finally, we showed that BC6ENTC activated endocrine cell development by inducing BC6OTHER ( BC6ENTG ) expression in early endocrine progenitor cells.	CPR:3
 BC6ENTG knockdown can modify BC6OTHER and BC6OTHER in BC6ENTC - treated rats.	False
 BC6OTHER knockdown can modify BC6ENTG and BC6OTHER in BC6ENTC - treated rats.	False
 BC6OTHER knockdown can modify BC6OTHER and BC6ENTG in BC6ENTC - treated rats.	False
 BC6ENTG knockdown can modify BC6ENTC peroxidase and BC6OTHER in BC6OTHER - treated rats.	False
 BC6OTHER knockdown can modify BC6ENTC peroxidase and BC6ENTG in BC6OTHER - treated rats.	False
 BC6ENTG knockdown can modify BC6OTHER and BC6ENTC response element - binding protein in BC6OTHER - treated rats.	False
 BC6OTHER knockdown can modify BC6ENTG and BC6ENTC response element - binding protein in BC6OTHER - treated rats.	False
These results suggest that BC6ENTG participates in the reciprocal regulation of BC6OTHER , BC6OTHER , and BC6OTHER in the hypothalamus during BC6ENTC treatment in conscious rats.	False
These results suggest that BC6OTHER participates in the reciprocal regulation of BC6ENTG , BC6OTHER , and BC6OTHER in the hypothalamus during BC6ENTC treatment in conscious rats.	False
These results suggest that BC6OTHER participates in the reciprocal regulation of BC6OTHER , BC6ENTG , and BC6OTHER in the hypothalamus during BC6ENTC treatment in conscious rats.	False
These results suggest that BC6OTHER participates in the reciprocal regulation of BC6OTHER , BC6OTHER , and BC6ENTG in the hypothalamus during BC6ENTC treatment in conscious rats.	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6OTHER ), and BC6OTHER response element - binding protein ( BC6ENTG ) are involved in regulating BC6ENTC ( BC6OTHER ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6ENTG ( BC6OTHER ), and BC6OTHER response element - binding protein ( BC6OTHER ) are involved in regulating BC6ENTC ( BC6OTHER ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6ENTG ), and BC6OTHER response element - binding protein ( BC6OTHER ) are involved in regulating BC6ENTC ( BC6OTHER ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) are involved in regulating BC6ENTC ( BC6OTHER ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6OTHER ), and BC6OTHER response element - binding protein ( BC6ENTG ) are involved in regulating BC6OTHER ( BC6ENTC ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6ENTG ( BC6OTHER ), and BC6OTHER response element - binding protein ( BC6OTHER ) are involved in regulating BC6OTHER ( BC6ENTC ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6ENTG ), and BC6OTHER response element - binding protein ( BC6OTHER ) are involved in regulating BC6OTHER ( BC6ENTC ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) are involved in regulating BC6OTHER ( BC6ENTC ) - mediated appetite suppression.	False
Changes in the contents of BC6ENTG , BC6OTHER , BC6ENTC peroxidase ( BC6OTHER ), and BC6OTHER were assessed and compared.	False
Changes in the contents of BC6OTHER , BC6ENTG , BC6ENTC peroxidase ( BC6OTHER ), and BC6OTHER were assessed and compared.	False
Changes in the contents of BC6OTHER , BC6OTHER , BC6ENTC peroxidase ( BC6ENTG ), and BC6OTHER were assessed and compared.	False
Changes in the contents of BC6OTHER , BC6OTHER , BC6ENTC peroxidase ( BC6OTHER ), and BC6ENTG were assessed and compared.	False
By contrast, BC6ENTG decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during BC6ENTC treatment was opposite to those of BC6OTHER , BC6OTHER , and BC6OTHER .	False
By contrast, BC6OTHER decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during BC6ENTC treatment was opposite to those of BC6ENTG , BC6OTHER , and BC6OTHER .	False
By contrast, BC6OTHER decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during BC6ENTC treatment was opposite to those of BC6OTHER , BC6ENTG , and BC6OTHER .	False
By contrast, BC6OTHER decreased with a biggest reduction about 48 % on Day 2 and the pattern of expression during BC6ENTC treatment was opposite to those of BC6OTHER , BC6OTHER , and BC6ENTG .	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6OTHER ), and BC6ENTC response element - binding protein ( BC6ENTG ) are involved in regulating BC6OTHER ( BC6OTHER ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6ENTG ( BC6OTHER ), and BC6ENTC response element - binding protein ( BC6OTHER ) are involved in regulating BC6OTHER ( BC6OTHER ) - mediated appetite suppression.	False
It has been reported that antioxidative enzymes, BC6OTHER ( BC6ENTG ), and BC6ENTC response element - binding protein ( BC6OTHER ) are involved in regulating BC6OTHER ( BC6OTHER ) - mediated appetite suppression.	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6ENTG expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6OTHER and BC6OTHER (or BC6OTHER ), revealing an essential role of BC6OTHER in regulating BC6OTHER , BC6OTHER , and BC6OTHER .	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6OTHER expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6ENTG and BC6OTHER (or BC6OTHER ), revealing an essential role of BC6OTHER in regulating BC6OTHER , BC6OTHER , and BC6OTHER .	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6OTHER expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6OTHER and BC6ENTG (or BC6OTHER ), revealing an essential role of BC6OTHER in regulating BC6OTHER , BC6OTHER , and BC6OTHER .	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6OTHER expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6OTHER and BC6OTHER (or BC6ENTG ), revealing an essential role of BC6OTHER in regulating BC6OTHER , BC6OTHER , and BC6OTHER .	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6OTHER expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6OTHER and BC6OTHER (or BC6OTHER ), revealing an essential role of BC6ENTG in regulating BC6OTHER , BC6OTHER , and BC6OTHER .	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6OTHER expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6OTHER and BC6OTHER (or BC6OTHER ), revealing an essential role of BC6OTHER in regulating BC6ENTG , BC6OTHER , and BC6OTHER .	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6OTHER expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6OTHER and BC6OTHER (or BC6OTHER ), revealing an essential role of BC6OTHER in regulating BC6OTHER , BC6ENTG , and BC6OTHER .	False
Central knockdown (using antisense) or inhibition (using antagonist) of BC6OTHER expression modulated the anorectic response of BC6ENTC and the reciprocal regulation between BC6OTHER and BC6OTHER (or BC6OTHER ), revealing an essential role of BC6OTHER in regulating BC6OTHER , BC6OTHER , and BC6ENTG .	False
t - BC6ENTC was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of BC6ENTG AA and BC6OTHER 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).	False
t - BC6ENTC was higher in the CAD group than in controls (11.8 vs 10.4 microM, P < 0.0001) and in carriers of BC6OTHER AA and BC6ENTG 677TT than in those carrying the most frequent allele of both polymorphisms (13.8 vs 11.4 microM, P = 0.0102 and 12.5 vs 11.0 mM, P = 0.0065 respectively).	False
BC6ENTG polymorphism ( BC6OTHER BC6OTHER ) is an established determinant of BC6ENTC plasma level (t - BC6OTHER ) while its association with coronary artery disease (CAD) seems to be more limited.	False
BC6OTHER reductase polymorphism ( BC6ENTG BC6OTHER ) is an established determinant of BC6ENTC plasma level (t - BC6OTHER ) while its association with coronary artery disease (CAD) seems to be more limited.	False
BC6OTHER reductase polymorphism ( BC6OTHER BC6ENTG ) is an established determinant of BC6ENTC plasma level (t - BC6OTHER ) while its association with coronary artery disease (CAD) seems to be more limited.	False
Association of BC6ENTG BC6OTHER polymorphism (but not of BC6OTHER BC6OTHER and BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6ENTG polymorphism (but not of BC6OTHER BC6OTHER and BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6OTHER polymorphism (but not of BC6ENTG BC6OTHER and BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6OTHER polymorphism (but not of BC6OTHER BC6ENTG and BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6OTHER polymorphism (but not of BC6OTHER BC6OTHER and BC6ENTG , BC6OTHER BC6OTHER , BC6OTHER BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6OTHER polymorphism (but not of BC6OTHER BC6OTHER and BC6OTHER , BC6ENTG BC6OTHER , BC6OTHER BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6OTHER polymorphism (but not of BC6OTHER BC6OTHER and BC6OTHER , BC6OTHER BC6ENTG , BC6OTHER BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6OTHER polymorphism (but not of BC6OTHER BC6OTHER and BC6OTHER , BC6OTHER BC6OTHER , BC6ENTG BC6OTHER ) with BC6ENTC and coronary artery disease in the French population.	False
Association of BC6OTHER BC6OTHER polymorphism (but not of BC6OTHER BC6OTHER and BC6OTHER , BC6OTHER BC6OTHER , BC6OTHER BC6ENTG ) with BC6ENTC and coronary artery disease in the French population.	False
BC6ENTC reductase polymorphism ( BC6ENTG BC6OTHER ) is an established determinant of BC6OTHER plasma level (t - BC6OTHER ) while its association with coronary artery disease (CAD) seems to be more limited.	False
BC6ENTC reductase polymorphism ( BC6OTHER BC6ENTG ) is an established determinant of BC6OTHER plasma level (t - BC6OTHER ) while its association with coronary artery disease (CAD) seems to be more limited.	False
In multivariate analysis, t - BC6ENTC > median and BC6ENTG AA genotype were two significant independent predictors of CAD with respective odds ratios of 3.1 (95 % CI: 1.8 - 5.1, P < 0.0001) and 4.5 (95% CI: 1.5 - 13.1, P = 0.0051).	False
BC6ENTG polymorphism ( BC6OTHER BC6OTHER ) is an established determinant of BC6OTHER plasma level (t - BC6ENTC ) while its association with coronary artery disease (CAD) seems to be more limited.	False
BC6OTHER reductase polymorphism ( BC6ENTG BC6OTHER ) is an established determinant of BC6OTHER plasma level (t - BC6ENTC ) while its association with coronary artery disease (CAD) seems to be more limited.	False
BC6OTHER reductase polymorphism ( BC6OTHER BC6ENTG ) is an established determinant of BC6OTHER plasma level (t - BC6ENTC ) while its association with coronary artery disease (CAD) seems to be more limited.	False
In contrast, the association of the substitutions BC6ENTG of BC6ENTC synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTC synthase ( BC6ENTG ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTC synthase ( BC6OTHER ), BC6ENTG of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTC synthase ( BC6OTHER ), BC6OTHER of BC6ENTG ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTC synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6ENTG ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTC synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6ENTG of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTC synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6ENTG ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTC synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6ENTG ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6ENTG of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6ENTC synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTG ( BC6OTHER ), BC6OTHER of BC6ENTC synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6ENTG ), BC6OTHER of BC6ENTC synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6ENTG of BC6ENTC synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6ENTC synthase reductase ( BC6ENTG ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6ENTC synthase reductase ( BC6OTHER ) and BC6ENTG of BC6OTHER ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6ENTC synthase reductase ( BC6OTHER ) and BC6OTHER of BC6ENTG ( BC6OTHER ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6ENTC synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6ENTG ) to both t - BC6OTHER and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6ENTG of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6ENTG ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6ENTG ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6ENTG of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6ENTG ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6ENTG ) and BC6OTHER of BC6OTHER ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6ENTG of BC6OTHER ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6ENTG ( BC6OTHER ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
In contrast, the association of the substitutions BC6OTHER of BC6OTHER synthase ( BC6OTHER ), BC6OTHER of BC6OTHER synthase reductase ( BC6OTHER ) and BC6OTHER of BC6OTHER ( BC6ENTG ) to both t - BC6ENTC and CAD needs to be evaluated further.	False
This indicated that the BC6ENTC - terminal 46 BC6OTHER in BC6ENTG are required for high BC6OTHER potency.	False
This indicated that the BC6OTHER - terminal 46 BC6ENTC in BC6ENTG are required for high BC6OTHER potency.	False
This indicated that the BC6OTHER - terminal 46 BC6OTHER in BC6ENTG are required for high BC6ENTC potency.	False
BC6ENTG ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6ENTC cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two BC6ENTG , Anabaena BC6ENTC cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6ENTC cyclases, BC6ENTG BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6ENTC cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6ENTC cyclases, BC6OTHER BC6ENTG and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6ENTC cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6ENTC cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6ENTG ).	False
BC6ENTG ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTC - dependent protein kinases ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two BC6ENTG , Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTC - dependent protein kinases ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, BC6ENTG , BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTC - dependent protein kinases ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6ENTG BC6OTHER and a phosphorylation site for BC6ENTC - dependent protein kinases ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTC - dependent protein kinases ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6ENTG and a phosphorylation site for BC6ENTC - dependent protein kinases ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTC - dependent protein kinases ( BC6ENTG ).	False
Binding of BC6ENTC to BC6ENTG increases BC6OTHER phosphorylation of BC6OTHER and improves catalytic site affinity for BC6OTHER or inhibitors.	False
Binding of BC6ENTC to BC6OTHER increases BC6ENTG phosphorylation of BC6OTHER and improves catalytic site affinity for BC6OTHER or inhibitors.	CPR:3
Binding of BC6ENTC to BC6OTHER increases BC6OTHER phosphorylation of BC6ENTG and improves catalytic site affinity for BC6OTHER or inhibitors.	CPR:3
Binding of BC6OTHER to BC6ENTG increases BC6OTHER phosphorylation of BC6OTHER and improves catalytic site affinity for BC6ENTC or inhibitors.	False
Binding of BC6OTHER to BC6OTHER increases BC6ENTG phosphorylation of BC6OTHER and improves catalytic site affinity for BC6ENTC or inhibitors.	False
Binding of BC6OTHER to BC6OTHER increases BC6OTHER phosphorylation of BC6ENTG and improves catalytic site affinity for BC6ENTC or inhibitors.	False
BC6ENTG contributes to dimerization of BC6OTHER , inhibition of BC6ENTC binding to BC6OTHER , and sequestration of the phosphorylation site.	False
BC6OTHER contributes to dimerization of BC6ENTG , inhibition of BC6ENTC binding to BC6OTHER , and sequestration of the phosphorylation site.	False
BC6OTHER contributes to dimerization of BC6OTHER , inhibition of BC6ENTC binding to BC6ENTG , and sequestration of the phosphorylation site.	False
To probe potential BC6ENTG effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6ENTG contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6ENTG , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6ENTG ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6ENTG contained BC6OTHER ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6ENTG ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6ENTG contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6ENTG ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6ENTC - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6OTHER - terminal portion of BC6OTHER ; and BC6ENTG contained only C domain.	False
BC6ENTG ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two BC6ENTG , Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, BC6ENTG , BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6ENTG BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	CPR:9
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6ENTG and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6ENTC and a regulatory domain (R domain) that contains two mammalian BC6OTHER - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6ENTG ).	False
Truncated proteins with a complete BC6ENTG were dimers, but those lacking the BC6ENTC - terminal 46 BC6OTHER of BC6OTHER were monomers, indicating that these residues are vital for BC6OTHER - mediated BC6OTHER dimerization.	False
Truncated proteins with a complete BC6OTHER were dimers, but those lacking the BC6ENTC - terminal 46 BC6OTHER of BC6ENTG were monomers, indicating that these residues are vital for BC6OTHER - mediated BC6OTHER dimerization.	False
Truncated proteins with a complete BC6OTHER were dimers, but those lacking the BC6ENTC - terminal 46 BC6OTHER of BC6OTHER were monomers, indicating that these residues are vital for BC6ENTG - mediated BC6OTHER dimerization.	False
Truncated proteins with a complete BC6OTHER were dimers, but those lacking the BC6ENTC - terminal 46 BC6OTHER of BC6OTHER were monomers, indicating that these residues are vital for BC6OTHER - mediated BC6ENTG dimerization.	False
To probe potential BC6ENTG effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6ENTG contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6ENTG , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6ENTG ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6ENTG contained BC6OTHER ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6ENTG ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6ENTG contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6ENTG ; and BC6OTHER contained only C domain.	False
To probe potential BC6OTHER effects on catalytic site affinity for certain inhibitors, four BC6OTHER - terminal truncation mutants were generated: BC6OTHER contained BC6OTHER , C domain, and the sequence between BC6OTHER ; BC6OTHER contained BC6OTHER ; BC6OTHER contained the C domain and the BC6ENTC - terminal portion of BC6OTHER ; and BC6ENTG contained only C domain.	False
A 46 - BC6OTHER segment in BC6OTHER BC6OTHER provides for high BC6OTHER potency over BC6ENTC and BC6OTHER and is involved in BC6ENTG dimerization.	False
A 46 - BC6OTHER segment in BC6ENTG BC6OTHER provides for high BC6OTHER potency over BC6ENTC and BC6OTHER and is involved in BC6OTHER dimerization.	False
A 46 - BC6OTHER segment in BC6OTHER BC6ENTG provides for high BC6OTHER potency over BC6ENTC and BC6OTHER and is involved in BC6OTHER dimerization.	False
A 46 - BC6OTHER segment in BC6OTHER BC6OTHER provides for high BC6OTHER potency over BC6OTHER and BC6ENTC and is involved in BC6ENTG dimerization.	False
A 46 - BC6OTHER segment in BC6ENTG BC6OTHER provides for high BC6OTHER potency over BC6OTHER and BC6ENTC and is involved in BC6OTHER dimerization.	False
A 46 - BC6OTHER segment in BC6OTHER BC6ENTG provides for high BC6OTHER potency over BC6OTHER and BC6ENTC and is involved in BC6OTHER dimerization.	False
A 46 - BC6ENTC segment in BC6OTHER BC6OTHER provides for high BC6OTHER potency over BC6OTHER and BC6OTHER and is involved in BC6ENTG dimerization.	False
A 46 - BC6ENTC segment in BC6ENTG BC6OTHER provides for high BC6OTHER potency over BC6OTHER and BC6OTHER and is involved in BC6OTHER dimerization.	False
A 46 - BC6ENTC segment in BC6OTHER BC6ENTG provides for high BC6OTHER potency over BC6OTHER and BC6OTHER and is involved in BC6OTHER dimerization.	False
A 46 - BC6OTHER segment in BC6OTHER BC6OTHER provides for high BC6ENTC potency over BC6OTHER and BC6OTHER and is involved in BC6ENTG dimerization.	False
A 46 - BC6OTHER segment in BC6ENTG BC6OTHER provides for high BC6ENTC potency over BC6OTHER and BC6OTHER and is involved in BC6OTHER dimerization.	False
A 46 - BC6OTHER segment in BC6OTHER BC6ENTG provides for high BC6ENTC potency over BC6OTHER and BC6OTHER and is involved in BC6OTHER dimerization.	False
Truncated proteins with a complete BC6ENTG were dimers, but those lacking the BC6OTHER - terminal 46 BC6ENTC of BC6OTHER were monomers, indicating that these residues are vital for BC6OTHER - mediated BC6OTHER dimerization.	False
Truncated proteins with a complete BC6OTHER were dimers, but those lacking the BC6OTHER - terminal 46 BC6ENTC of BC6ENTG were monomers, indicating that these residues are vital for BC6OTHER - mediated BC6OTHER dimerization.	False
Truncated proteins with a complete BC6OTHER were dimers, but those lacking the BC6OTHER - terminal 46 BC6ENTC of BC6OTHER were monomers, indicating that these residues are vital for BC6ENTG - mediated BC6OTHER dimerization.	False
Truncated proteins with a complete BC6OTHER were dimers, but those lacking the BC6OTHER - terminal 46 BC6ENTC of BC6OTHER were monomers, indicating that these residues are vital for BC6OTHER - mediated BC6ENTG dimerization.	False
K(m) values of the mutants for BC6ENTC were similar to that of full - length BC6ENTG .	CPR:9
All BC6ENTG constructs had similar affinities for BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6ENTG had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6ENTG .	False
All BC6ENTG constructs had similar affinities for BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6ENTG had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6ENTG .	False
All BC6ENTG constructs had similar affinities for BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , but mutants containing a complete BC6ENTG had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6ENTG .	False
All BC6ENTG constructs had similar affinities for BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , but mutants containing a complete BC6ENTG had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6OTHER - based compounds compared with those lacking a complete BC6ENTG .	False
All BC6ENTG constructs had similar affinities for BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6ENTC - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6ENTG had 7 - to 18 - fold higher affinity for BC6ENTC - based compounds compared with those lacking a complete BC6OTHER .	False
All BC6OTHER constructs had similar affinities for BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , but mutants containing a complete BC6OTHER had 7 - to 18 - fold higher affinity for BC6ENTC - based compounds compared with those lacking a complete BC6ENTG .	False
BC6ENTG ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6ENTC - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6ENTC - binding phosphodiesterase, BC6ENTG , BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6ENTC - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6ENTG BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6ENTG ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6ENTC - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6ENTC - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6ENTG and a phosphorylation site for BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6ENTC - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6ENTG ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER ) contains a catalytic domain (C domain) that hydrolyzes BC6OTHER and a regulatory domain (R domain) that contains two mammalian BC6ENTC - binding phosphodiesterase, Anabaena BC6OTHER cyclases, BC6OTHER BC6OTHER and a phosphorylation site for BC6OTHER ( BC6ENTG ).	False
Although the BC6ENTC deprivation from pre - puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood ( BC6ENTG , BC6OTHER , BC6OTHER ).	False
Although the BC6ENTC deprivation from pre - puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood ( BC6OTHER , BC6ENTG , BC6OTHER ).	False
Although the BC6ENTC deprivation from pre - puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood ( BC6OTHER , BC6OTHER , BC6ENTG ).	False
Although the BC6OTHER deprivation from pre - puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood ( BC6ENTC receptor, BC6ENTG , BC6OTHER ).	False
Although the BC6OTHER deprivation from pre - puberty up to peripuberty did not alter the histological organization of the testes and epididymis either at puberty or at adulthood, the treatment impaired the expression of specific proteins in epididymal tissue at puberty and adulthood ( BC6ENTC receptor, BC6OTHER , BC6ENTG ).	False
Administration of BC6ENTC and BC6OTHER , both of which induce anorexic effects via BC6ENTG receptors and / or BC6OTHER receptors, suppressed food intake in 5 - and 8 - wk - old Ay mice, whereas the anorexic effects were attenuated in food - restricted Ay mice.	False
Administration of BC6ENTC and BC6OTHER , both of which induce anorexic effects via BC6OTHER receptors and / or BC6ENTG receptors, suppressed food intake in 5 - and 8 - wk - old Ay mice, whereas the anorexic effects were attenuated in food - restricted Ay mice.	False
Administration of BC6OTHER and BC6ENTC , both of which induce anorexic effects via BC6ENTG receptors and / or BC6OTHER receptors, suppressed food intake in 5 - and 8 - wk - old Ay mice, whereas the anorexic effects were attenuated in food - restricted Ay mice.	False
Administration of BC6OTHER and BC6ENTC , both of which induce anorexic effects via BC6OTHER receptors and / or BC6ENTG receptors, suppressed food intake in 5 - and 8 - wk - old Ay mice, whereas the anorexic effects were attenuated in food - restricted Ay mice.	False
BC6ENTG receptor mutant mice consume more food, which leads to late - onset obesity and impaired BC6ENTC tolerance.	False
Blockade of the BC6ENTG - BC6ENTC system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6OTHER assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6ENTC system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6ENTG , in vitro BC6OTHER assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6ENTC system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6ENTG assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6ENTC system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6OTHER assay, and reactive changes in plasma BC6ENTG levels.	False
Blockade of the BC6ENTG - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6ENTC , in vitro BC6OTHER assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6ENTG system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6ENTC , in vitro BC6OTHER assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6ENTC , in vitro BC6ENTG assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6ENTC , in vitro BC6OTHER assay, and reactive changes in plasma BC6ENTG levels.	False
Blockade of the BC6ENTG - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6ENTC receptor assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6ENTG system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6ENTC receptor assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6ENTG , in vitro BC6ENTC receptor assay, and reactive changes in plasma BC6OTHER levels.	False
Blockade of the BC6OTHER - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6ENTC receptor assay, and reactive changes in plasma BC6ENTG levels.	False
Blockade of the BC6ENTG - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6OTHER assay, and reactive changes in plasma BC6ENTC levels.	False
Blockade of the BC6OTHER - BC6ENTG system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6OTHER assay, and reactive changes in plasma BC6ENTC levels.	False
Blockade of the BC6OTHER - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6ENTG , in vitro BC6OTHER assay, and reactive changes in plasma BC6ENTC levels.	False
Blockade of the BC6OTHER - BC6OTHER system was assessed before and 4, 24, and 30 hours after drug intake by 3 independent methods: inhibition of the blood pressure response to exogenous BC6OTHER , in vitro BC6ENTG assay, and reactive changes in plasma BC6ENTC levels.	False
At 4 hours, CHEM blocked 43% of the BC6ENTG - induced systolic blood pressure increase; BC6ENTC , 51%; and BC6OTHER , 88% (P<0.01 between drugs).	CPR:4
At 4 hours, CHEM blocked 43% of the BC6ENTG - induced systolic blood pressure increase; BC6OTHER , 51%; and BC6ENTC , 88% (P<0.01 between drugs).	CPR:4
 BC6ENTC receptor blockade in normotensive subjects: A direct comparison of three BC6ENTG antagonists.	False
Similar results were obtained when BC6ENTC receptor blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma BC6ENTG levels.	False
Similar results were obtained when BC6ENTG blockade was assessed with an in vitro receptor assay and by the reactive rise in plasma BC6ENTC levels.	False
This study thus demonstrates that the first administration of the recommended starting dose of BC6ENTC induces a greater and longer lasting BC6ENTG blockade than that of BC6OTHER and BC6OTHER in normotensive subjects.	CPR:4
This study thus demonstrates that the first administration of the recommended starting dose of BC6OTHER induces a greater and longer lasting BC6ENTG blockade than that of BC6ENTC and BC6OTHER in normotensive subjects.	CPR:4
This study thus demonstrates that the first administration of the recommended starting dose of BC6OTHER induces a greater and longer lasting BC6ENTG blockade than that of BC6OTHER and BC6ENTC in normotensive subjects.	CPR:4
Dual inhibitors of BC6ENTG ( BC6OTHER ) and BC6ENTC synthase ( BC6OTHER ) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	False
Dual inhibitors of BC6OTHER ( BC6ENTG ) and BC6ENTC synthase ( BC6OTHER ) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	False
Dual inhibitors of BC6OTHER ( BC6OTHER ) and BC6ENTC synthase ( BC6ENTG ) are therefore proposed as a novel strategy for the adjuvant therapy to reduce the CVD risk for these patients.	False
By combining decisive structural features of BC6ENTG and BC6OTHER inhibitors into a common template, a series of BC6ENTC were designed and synthesized.	False
By combining decisive structural features of BC6OTHER and BC6ENTG inhibitors into a common template, a series of BC6ENTC were designed and synthesized.	False
 BC6ENTC type dual inhibitors of BC6ENTG / BC6OTHER synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.	CPR:4
 BC6ENTC type dual inhibitors of BC6OTHER / BC6ENTG as a novel strategy for breast cancer patients with elevated cardiovascular risks.	CPR:4
 BC6OTHER type dual inhibitors of BC6ENTG / BC6ENTC synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks.	False
 Presently, a combination of an antimuscarinic agent, e.g. BC6OTHER , BC6ENTG reactivator such as one of the recommended BC6OTHER ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) and BC6OTHER are used for the treatment of BC6OTHER poisoning in humans.	CPR:3
 Presently, a combination of an antimuscarinic agent, e.g. BC6OTHER , BC6ENTG reactivator such as one of the recommended BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) and BC6OTHER are used for the treatment of BC6OTHER poisoning in humans.	CPR:3
 Presently, a combination of an antimuscarinic agent, e.g. BC6OTHER , BC6ENTG reactivator such as one of the recommended BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) and BC6OTHER are used for the treatment of BC6OTHER poisoning in humans.	CPR:3
 Presently, a combination of an antimuscarinic agent, e.g. BC6OTHER , BC6ENTG reactivator such as one of the recommended BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and BC6ENTC are used for the treatment of BC6OTHER poisoning in humans.	CPR:3
 Presently, a combination of an antimuscarinic agent, e.g. BC6OTHER , BC6ENTG reactivator such as one of the recommended BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and BC6OTHER are used for the treatment of BC6ENTC poisoning in humans.	CPR:4
The mechanism of BC6ENTC poisoning involves inhibition of BC6ENTG ( BC6OTHER ) leading to inactivation of the enzyme which has an important role in neurotransmission.	CPR:4
The mechanism of BC6ENTC poisoning involves inhibition of BC6OTHER ( BC6ENTG ) leading to inactivation of the enzyme which has an important role in neurotransmission.	CPR:4
BC6ENTG inhibition results in the accumulation of BC6ENTC at cholinergic receptor sites, producing continuous stimulation of cholinergic fibers throughout the nervous systems.	False
They act by reactivation of BC6ENTG inhibited by BC6ENTC .	CPR:4
 Presently, a combination of an antimuscarinic agent, e.g. BC6ENTC , BC6ENTG reactivator such as one of the recommended BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and BC6OTHER are used for the treatment of BC6OTHER poisoning in humans.	CPR:3
 Presently, a combination of an antimuscarinic agent, e.g. BC6OTHER , BC6ENTG reactivator such as one of the recommended BC6ENTC ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and BC6OTHER are used for the treatment of BC6OTHER poisoning in humans.	CPR:3
 Presently, a combination of an antimuscarinic agent, e.g. BC6OTHER , BC6ENTG reactivator such as one of the recommended BC6OTHER ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) and BC6OTHER are used for the treatment of BC6OTHER poisoning in humans.	CPR:3
BC6ENTC and BC6OTHER significantly suppressed an increase in plasma total - BC6OTHER (total CHEM) and BC6ENTG BC6OTHER compared to HC - control group.	CPR:4
BC6OTHER and BC6ENTC significantly suppressed an increase in plasma total - BC6OTHER (total CHEM) and BC6ENTG BC6OTHER compared to HC - control group.	CPR:4
BC6OTHER and BC6OTHER significantly suppressed an increase in plasma total - BC6ENTC (total CHEM) and BC6ENTG BC6OTHER compared to HC - control group.	False
BC6OTHER and BC6OTHER significantly suppressed an increase in plasma total - BC6OTHER (total CHEM) and BC6ENTG BC6ENTC compared to HC - control group.	False
However, plasma BC6ENTG - BC6ENTC ( BC6OTHER - C) and BC6OTHER - C / total - C ratio levels and plasma BC6OTHER activity were only significantly higher in BC6OTHER group after 8 weeks.	False
However, plasma BC6OTHER - BC6ENTC ( BC6ENTG - C) and BC6OTHER - C / total - C ratio levels and plasma BC6OTHER activity were only significantly higher in BC6OTHER group after 8 weeks.	False
However, plasma BC6OTHER - BC6ENTC ( BC6OTHER - C) and BC6ENTG - C / total - C ratio levels and plasma BC6OTHER activity were only significantly higher in BC6OTHER group after 8 weeks.	False
However, plasma BC6OTHER - BC6ENTC ( BC6OTHER - C) and BC6OTHER - C / total - C ratio levels and plasma BC6ENTG activity were only significantly higher in BC6OTHER group after 8 weeks.	False
However, plasma BC6ENTG - BC6OTHER ( BC6OTHER - C) and BC6OTHER - C / total - C ratio levels and plasma BC6OTHER activity were only significantly higher in BC6ENTC group after 8 weeks.	CPR:3
However, plasma BC6OTHER - BC6OTHER ( BC6ENTG - C) and BC6OTHER - C / total - C ratio levels and plasma BC6OTHER activity were only significantly higher in BC6ENTC group after 8 weeks.	CPR:3
However, plasma BC6OTHER - BC6OTHER ( BC6OTHER - C) and BC6ENTG - C / total - C ratio levels and plasma BC6OTHER activity were only significantly higher in BC6ENTC group after 8 weeks.	CPR:3
However, plasma BC6OTHER - BC6OTHER ( BC6OTHER - C) and BC6OTHER - C / total - C ratio levels and plasma BC6ENTG activity were only significantly higher in BC6ENTC group after 8 weeks.	CPR:3
Hepatic BC6ENTG activity was significantly lower in both BC6ENTC and BC6OTHER groups than in HC - control group, while BC6OTHER activity was the highest only in the BC6OTHER group.	CPR:4
Hepatic BC6OTHER activity was significantly lower in both BC6ENTC and BC6OTHER groups than in HC - control group, while BC6ENTG activity was the highest only in the BC6OTHER group.	False
Hepatic BC6ENTG activity was significantly lower in both BC6OTHER and BC6ENTC groups than in HC - control group, while BC6OTHER activity was the highest only in the BC6OTHER group.	CPR:4
Hepatic BC6OTHER activity was significantly lower in both BC6OTHER and BC6ENTC groups than in HC - control group, while BC6ENTG activity was the highest only in the BC6OTHER group.	False
Hepatic BC6ENTG activity was significantly lower in both BC6OTHER and BC6OTHER groups than in HC - control group, while BC6ENTC reductase activity was the highest only in the BC6OTHER group.	False
Hepatic BC6ENTG activity was significantly lower in both BC6OTHER and BC6OTHER groups than in HC - control group, while BC6OTHER activity was the highest only in the BC6ENTC group.	False
Hepatic BC6OTHER activity was significantly lower in both BC6OTHER and BC6OTHER groups than in HC - control group, while BC6ENTG activity was the highest only in the BC6ENTC group.	CPR:3
 BC6ENTC supplementation alters BC6ENTG - BC6OTHER concentration and BC6OTHER activity in rabbits fed high - BC6OTHER diet: comparison with BC6OTHER .	False
 BC6ENTC supplementation alters BC6OTHER - BC6OTHER concentration and BC6ENTG activity in rabbits fed high - BC6OTHER diet: comparison with BC6OTHER .	False
 BC6OTHER supplementation alters BC6ENTG - BC6OTHER concentration and BC6OTHER activity in rabbits fed high - BC6ENTC diet: comparison with BC6OTHER .	False
 BC6OTHER supplementation alters BC6OTHER - BC6OTHER concentration and BC6ENTG activity in rabbits fed high - BC6ENTC diet: comparison with BC6OTHER .	False
 BC6OTHER supplementation alters BC6ENTG - BC6OTHER concentration and BC6OTHER activity in rabbits fed high - BC6OTHER diet: comparison with BC6ENTC .	False
 BC6OTHER supplementation alters BC6OTHER - BC6OTHER concentration and BC6ENTG activity in rabbits fed high - BC6OTHER diet: comparison with BC6ENTC .	False
 BC6OTHER supplementation alters BC6ENTG - BC6ENTC concentration and BC6OTHER activity in rabbits fed high - BC6OTHER diet: comparison with BC6OTHER .	False
 BC6OTHER supplementation alters BC6OTHER - BC6ENTC concentration and BC6ENTG activity in rabbits fed high - BC6OTHER diet: comparison with BC6OTHER .	False
Hepatic mRNA expressions of BC6ENTG and BC6OTHER were significantly lower in BC6ENTC group than in other groups.	CPR:4
Hepatic mRNA expressions of BC6OTHER and BC6ENTG were significantly lower in BC6ENTC group than in other groups.	CPR:4
BC6ENTC supplementation was found to alter the plasma BC6ENTG - C - related factors; meanwhile, BC6OTHER supplementation was very effective in enhancing BC6OTHER metabolism, except for a negative effect that reduced plasma BC6OTHER - C concentration.	False
BC6ENTC supplementation was found to alter the plasma BC6OTHER - C - related factors; meanwhile, BC6OTHER supplementation was very effective in enhancing BC6OTHER metabolism, except for a negative effect that reduced plasma BC6ENTG - C concentration.	False
BC6OTHER supplementation was found to alter the plasma BC6ENTG - C - related factors; meanwhile, BC6ENTC supplementation was very effective in enhancing BC6OTHER metabolism, except for a negative effect that reduced plasma BC6OTHER - C concentration.	False
BC6OTHER supplementation was found to alter the plasma BC6OTHER - C - related factors; meanwhile, BC6ENTC supplementation was very effective in enhancing BC6OTHER metabolism, except for a negative effect that reduced plasma BC6ENTG - C concentration.	CPR:4
BC6OTHER supplementation was found to alter the plasma BC6ENTG - C - related factors; meanwhile, BC6OTHER supplementation was very effective in enhancing BC6ENTC metabolism, except for a negative effect that reduced plasma BC6OTHER - C concentration.	False
BC6OTHER supplementation was found to alter the plasma BC6OTHER - C - related factors; meanwhile, BC6OTHER supplementation was very effective in enhancing BC6ENTC metabolism, except for a negative effect that reduced plasma BC6ENTG - C concentration.	False
On the other hand, ligands for the renal BC6ENTG ( BC6OTHER and BC6OTHER ) and for BC6OTHER recognition sites ( BC6OTHER , BC6ENTC and BC6OTHER ) displaced the binding of BC6OTHER to BC6OTHER - insensitive sites at micromolar concentrations.	False
On the other hand, ligands for the renal BC6ENTG ( BC6OTHER and BC6OTHER ) and for BC6OTHER recognition sites ( BC6OTHER , BC6OTHER and BC6ENTC ) displaced the binding of BC6OTHER to BC6OTHER - insensitive sites at micromolar concentrations.	False
On the other hand, ligands for the renal BC6ENTG ( BC6OTHER and BC6OTHER ) and for BC6OTHER recognition sites ( BC6OTHER , BC6OTHER and BC6OTHER ) displaced the binding of BC6ENTC to BC6OTHER - insensitive sites at micromolar concentrations.	False
On the other hand, ligands for the renal BC6ENTG ( BC6OTHER and BC6OTHER ) and for BC6OTHER recognition sites ( BC6OTHER , BC6OTHER and BC6OTHER ) displaced the binding of BC6OTHER to BC6ENTC - insensitive sites at micromolar concentrations.	False
Photoaffinity labeling with BC6ENTC showed BC6OTHER - insensitive labeling at around 100 kDa, a molecular size larger than that of BC6ENTG expressed in 293 cells (50 - 60 and 70 - 80 kDa, respectively) on electrophoresis.	False
Photoaffinity labeling with BC6OTHER showed BC6ENTC - insensitive labeling at around 100 kDa, a molecular size larger than that of BC6ENTG expressed in 293 cells (50 - 60 and 70 - 80 kDa, respectively) on electrophoresis.	False
In contrast, there was no detectable BC6ENTC - insensitive binding site but were BC6OTHER - sensitive BC6ENTG in human liver (pK(d)=10.0+ / - 0.06, B(max)=44+ / - 6 fmol mg( - 1) protein, n=3).	False
In contrast, there was no detectable BC6OTHER - insensitive binding site but were BC6ENTC - sensitive BC6ENTG in human liver (pK(d)=10.0+ / - 0.06, B(max)=44+ / - 6 fmol mg( - 1) protein, n=3).	False
However, other BC6OTHER antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6ENTG antagonism, and BC6ENTC , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	False
However, other BC6ENTG antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6OTHER antagonism, and BC6ENTC , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	False
In human kidney, we found unique BC6ENTC - binding sites that were insensitive to BC6OTHER and were thus unlikely to be BC6ENTG .	False
BC6ENTC bound to the BC6OTHER - insensitive sites monophasically with a high affinity (pK(d); 9.1+ / - 0.08, n=8), and the B(max) value (814+ / - 204 fmol mg( - 1) protein, n=8) was more than ten times that of the BC6OTHER - sensitive BC6ENTG (pK(d)=9.9+ / - 0.13, B(max)=66+ / - 23 fmol mg( - 1) protein, n=7).	False
BC6OTHER bound to the BC6ENTC - insensitive sites monophasically with a high affinity (pK(d); 9.1+ / - 0.08, n=8), and the B(max) value (814+ / - 204 fmol mg( - 1) protein, n=8) was more than ten times that of the BC6OTHER - sensitive BC6ENTG (pK(d)=9.9+ / - 0.13, B(max)=66+ / - 23 fmol mg( - 1) protein, n=7).	False
However, other BC6OTHER antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6ENTG antagonism, and BC6OTHER , BC6ENTC and BC6OTHER were without effect on the BC6OTHER binding.	False
However, other BC6ENTG antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6OTHER antagonism, and BC6OTHER , BC6ENTC and BC6OTHER were without effect on the BC6OTHER binding.	False
BC6OTHER bound to the BC6OTHER - insensitive sites monophasically with a high affinity (pK(d); 9.1+ / - 0.08, n=8), and the B(max) value (814+ / - 204 fmol mg( - 1) protein, n=8) was more than ten times that of the BC6ENTC - sensitive BC6ENTG (pK(d)=9.9+ / - 0.13, B(max)=66+ / - 23 fmol mg( - 1) protein, n=7).	False
In human kidney, we found unique BC6OTHER - binding sites that were insensitive to BC6ENTC and were thus unlikely to be BC6ENTG .	False
However, other BC6OTHER antagonists ( BC6ENTC , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6ENTG antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	False
However, other BC6ENTG antagonists ( BC6ENTC , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6OTHER antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	CPR:6
However, other BC6OTHER antagonists ( BC6OTHER , BC6ENTC and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6ENTG antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	False
However, other BC6ENTG antagonists ( BC6OTHER , BC6ENTC and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6OTHER antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	CPR:6
However, other BC6OTHER antagonists ( BC6OTHER , BC6OTHER and BC6ENTC ) did not inhibit the binding at a range of concentrations that generally exhibit BC6ENTG antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	False
However, other BC6ENTG antagonists ( BC6OTHER , BC6OTHER and BC6ENTC ) did not inhibit the binding at a range of concentrations that generally exhibit BC6OTHER antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6OTHER binding.	CPR:6
However, other BC6OTHER antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6ENTG antagonism, and BC6OTHER , BC6OTHER and BC6ENTC were without effect on the BC6OTHER binding.	False
However, other BC6ENTG antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6OTHER antagonism, and BC6OTHER , BC6OTHER and BC6ENTC were without effect on the BC6OTHER binding.	False
However, other BC6OTHER antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6ENTG antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6ENTC binding.	False
However, other BC6ENTG antagonists ( BC6OTHER , BC6OTHER and BC6OTHER ) did not inhibit the binding at a range of concentrations that generally exhibit BC6OTHER antagonism, and BC6OTHER , BC6OTHER and BC6OTHER were without effect on the BC6ENTC binding.	False
On the other hand, ligands for the renal BC6ENTG ( BC6ENTC and BC6OTHER ) and for BC6OTHER recognition sites ( BC6OTHER , BC6OTHER and BC6OTHER ) displaced the binding of BC6OTHER to BC6OTHER - insensitive sites at micromolar concentrations.	False
On the other hand, ligands for the renal BC6ENTG ( BC6OTHER and BC6ENTC ) and for BC6OTHER recognition sites ( BC6OTHER , BC6OTHER and BC6OTHER ) displaced the binding of BC6OTHER to BC6OTHER - insensitive sites at micromolar concentrations.	False
On the other hand, ligands for the renal BC6ENTG ( BC6OTHER and BC6OTHER ) and for BC6ENTC recognition sites ( BC6OTHER , BC6OTHER and BC6OTHER ) displaced the binding of BC6OTHER to BC6OTHER - insensitive sites at micromolar concentrations.	False
On the other hand, ligands for the renal BC6ENTG ( BC6OTHER and BC6OTHER ) and for BC6OTHER recognition sites ( BC6ENTC , BC6OTHER and BC6OTHER ) displaced the binding of BC6OTHER to BC6OTHER - insensitive sites at micromolar concentrations.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, BC6ENTG and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTG ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTG and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTC BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTG activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, BC6ENTG and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, aminopeptidase BC6OTHER and BC6ENTG ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTG and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6ENTC - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTG activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTG , aminopeptidase BC6ENTC and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6ENTC and BC6ENTG ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6ENTC and CHEM BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6ENTC and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6ENTC and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6ENTC and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6ENTC and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTG and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6ENTC and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTG activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTG , aminopeptidase BC6OTHER and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, BC6ENTG and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTG and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTC BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTG activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTG , aminopeptidase BC6OTHER and CHEM BC6ENTC - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, BC6ENTG and CHEM BC6ENTC - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6ENTC - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6ENTC - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6ENTC - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6ENTC - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6ENTC - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTG and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6ENTC - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTG activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTG , aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, BC6ENTG and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTG ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTG and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTC dehydrogenase and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTG activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTG , aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, BC6ENTG and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTG ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6ENTG and depleted BC6OTHER activities.	CPR:3
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6ENTC rats showed higher BC6OTHER and depleted BC6ENTG activities.	CPR:4
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTG , aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, BC6ENTG and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTG ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6OTHER activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTC reductase and depleted BC6ENTG activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher BC6ENTG , aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTC oxidase activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, BC6ENTG and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTC oxidase activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and BC6ENTG ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTC oxidase activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6ENTG ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTC oxidase activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6ENTG activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTC oxidase activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6ENTG and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTC oxidase activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6ENTG activities and PM - BC6OTHER rats showed higher BC6OTHER and depleted BC6ENTC oxidase activities.	False
Compared with normally - fed counterparts, PM - CP rats exhibited higher CHEM BC6OTHER - transferase, aminopeptidase BC6OTHER and CHEM BC6OTHER - conjugate beta - lyase ( BC6OTHER ) and lower BC6OTHER activities, PM - FU rats exhibited decreased BC6OTHER and BC6OTHER activities and PM - BC6OTHER rats showed higher BC6ENTG and depleted BC6ENTC oxidase activities.	False
Conclusively, protein malnutrition alters CP, FU and BC6ENTC metabolism in rat stomach by enhancing BC6ENTG pathway for CP activation, delaying FU elimination and activating two - electron reduction of BC6OTHER , potentiating their gastrotoxicity.	CPR:9
Conclusively, protein malnutrition alters CP, FU and BC6OTHER metabolism in rat stomach by enhancing BC6ENTG pathway for CP activation, delaying FU elimination and activating two - electron reduction of BC6ENTC , potentiating their gastrotoxicity.	False
 BC6ENTC (10 mg i.v.), a BC6ENTG inhibitor that potentiates the effects of BC6OTHER at the BC6OTHER , terminated VT in four of four patients, an effect that was reversed by BC6OTHER .	CPR:4
 BC6ENTC (10 mg i.v.), a BC6OTHER inhibitor that potentiates the effects of BC6OTHER at the BC6ENTG , terminated VT in four of four patients, an effect that was reversed by BC6OTHER .	False
 BC6OTHER (10 mg i.v.), a BC6ENTG inhibitor that potentiates the effects of BC6ENTC at the BC6OTHER , terminated VT in four of four patients, an effect that was reversed by BC6OTHER .	False
 BC6OTHER (10 mg i.v.), a BC6OTHER inhibitor that potentiates the effects of BC6ENTC at the BC6ENTG , terminated VT in four of four patients, an effect that was reversed by BC6OTHER .	False
 BC6OTHER (10 mg i.v.), a BC6ENTG inhibitor that potentiates the effects of BC6OTHER at the BC6OTHER , terminated VT in four of four patients, an effect that was reversed by BC6ENTC .	False
 BC6OTHER (10 mg i.v.), a BC6OTHER inhibitor that potentiates the effects of BC6OTHER at the BC6ENTG , terminated VT in four of four patients, an effect that was reversed by BC6ENTC .	CPR:4
It can be identified by termination of the tachycardia in response to activation of the BC6ENTC A1 or BC6ENTG , which results in inhibition of BC6OTHER .	False
It can be identified by termination of the tachycardia in response to activation of the BC6ENTC A1 or BC6OTHER , which results in inhibition of BC6ENTG .	False
It can be identified by termination of the tachycardia in response to activation of the BC6ENTG or BC6OTHER , which results in inhibition of BC6ENTC cyclase.	False
It can be identified by termination of the tachycardia in response to activation of the BC6OTHER or BC6ENTG , which results in inhibition of BC6ENTC cyclase.	False
The antiarrhythmic effects of exogenous BC6ENTC and Valsalva on this form of VT may be due to receptor - mediated inhibition of BC6ENTG or to noncardiac receptor - mediated effects, i.e., exogenous BC6OTHER may modulate VT through alterations in autonomic tone by activation of arterial BC6OTHER , and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	False
The antiarrhythmic effects of exogenous BC6ENTC and Valsalva on this form of VT may be due to receptor - mediated inhibition of BC6OTHER or to noncardiac receptor - mediated effects, i.e., exogenous BC6OTHER may modulate VT through alterations in autonomic tone by activation of arterial BC6ENTG , and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	False
The antiarrhythmic effects of exogenous BC6OTHER and Valsalva on this form of VT may be due to receptor - mediated inhibition of BC6ENTC cyclase or to noncardiac receptor - mediated effects, i.e., exogenous BC6OTHER may modulate VT through alterations in autonomic tone by activation of arterial BC6ENTG , and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	False
The antiarrhythmic effects of exogenous BC6OTHER and Valsalva on this form of VT may be due to receptor - mediated inhibition of BC6ENTG or to noncardiac receptor - mediated effects, i.e., exogenous BC6ENTC may modulate VT through alterations in autonomic tone by activation of arterial BC6OTHER , and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	False
The antiarrhythmic effects of exogenous BC6OTHER and Valsalva on this form of VT may be due to receptor - mediated inhibition of BC6OTHER or to noncardiac receptor - mediated effects, i.e., exogenous BC6ENTC may modulate VT through alterations in autonomic tone by activation of arterial BC6ENTG , and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.	CPR:3
VT recurred with the addition of BC6OTHER , a BC6ENTC BC6ENTG antagonist.	False
VT recurred with the addition of BC6ENTC , a BC6OTHER BC6ENTG antagonist.	CPR:6
Plasma S / R ratio of BC6ENTC co - varies with BC6ENTG haplotype.	False
We speculate that BC6ENTG haplotypes possibly are linked to some unidentified factors involved in the metabolic clearance of BC6ENTC enantiomers.	False
The aim of this study was to investigate whether patients with BC6ENTG *2 compared with patients carrying high - dose haplotypes BC6OTHER *3 or BC6OTHER *4 had different BC6ENTC ratios in their plasma, and whether that was related to BC6OTHER variants BC6OTHER *2 and BC6OTHER *3 or other factors.	False
The aim of this study was to investigate whether patients with BC6OTHER *2 compared with patients carrying high - dose haplotypes BC6ENTG *3 or BC6OTHER *4 had different BC6ENTC ratios in their plasma, and whether that was related to BC6OTHER variants BC6OTHER *2 and BC6OTHER *3 or other factors.	False
The aim of this study was to investigate whether patients with BC6OTHER *2 compared with patients carrying high - dose haplotypes BC6OTHER *3 or BC6ENTG *4 had different BC6ENTC ratios in their plasma, and whether that was related to BC6OTHER variants BC6OTHER *2 and BC6OTHER *3 or other factors.	False
The aim of this study was to investigate whether patients with BC6OTHER *2 compared with patients carrying high - dose haplotypes BC6OTHER *3 or BC6OTHER *4 had different BC6ENTC ratios in their plasma, and whether that was related to BC6ENTG variants BC6OTHER *2 and BC6OTHER *3 or other factors.	False
The aim of this study was to investigate whether patients with BC6OTHER *2 compared with patients carrying high - dose haplotypes BC6OTHER *3 or BC6OTHER *4 had different BC6ENTC ratios in their plasma, and whether that was related to BC6OTHER variants BC6ENTG *2 and BC6OTHER *3 or other factors.	False
The aim of this study was to investigate whether patients with BC6OTHER *2 compared with patients carrying high - dose haplotypes BC6OTHER *3 or BC6OTHER *4 had different BC6ENTC ratios in their plasma, and whether that was related to BC6OTHER variants BC6OTHER *2 and BC6ENTG *3 or other factors.	False
Samples from patients previously haplotyped for BC6ENTG and measured for plasma BC6ENTC concentration were genotyped for the BC6OTHER variants BC6OTHER *2 and BC6OTHER *3.	False
Samples from patients previously haplotyped for BC6OTHER and measured for plasma BC6ENTC concentration were genotyped for the BC6ENTG variants BC6OTHER *2 and BC6OTHER *3.	False
Samples from patients previously haplotyped for BC6OTHER and measured for plasma BC6ENTC concentration were genotyped for the BC6OTHER variants BC6ENTG *2 and BC6OTHER *3.	False
Samples from patients previously haplotyped for BC6OTHER and measured for plasma BC6ENTC concentration were genotyped for the BC6OTHER variants BC6OTHER *2 and BC6ENTG *3.	False
Our result shows that there is a significant difference (P<0.01) in BC6ENTC ratios between BC6OTHER *2 and BC6ENTG *3 or BC6OTHER *4 patients.	False
Our result shows that there is a significant difference (P<0.01) in BC6ENTC ratios between BC6OTHER *2 and BC6OTHER *3 or BC6ENTG *4 patients.	False
Our result shows that there is a significant difference (P<0.01) in BC6ENTC ratios between BC6ENTG *2 and BC6OTHER *3 or BC6OTHER *4 patients.	False
We recently reported that the low - dose BC6OTHER *2 haplotype is an important genetic determinant for BC6ENTC dose requirement and is associated with difficulties to attain stable therapeutic BC6ENTG time - - International Normalized Ratio in patients undergoing anticoagulation therapy.	False
We recently reported that the low - dose BC6ENTG *2 haplotype is an important genetic determinant for BC6ENTC dose requirement and is associated with difficulties to attain stable therapeutic BC6OTHER time - - International Normalized Ratio in patients undergoing anticoagulation therapy.	False
Apart from their role in cardiovascular homeostasis and immunomodulation, BC6OTHER and BC6ENTC are also implicated in the pathogenesis of BC6ENTG resistance and type 2 diabetes mellitus (T2DM).	False
Circulating very - BC6ENTG from subjects with impaired BC6OTHER tolerance accelerates adrenocortical BC6ENTC and BC6OTHER synthesis.	False
Circulating very - BC6ENTG from subjects with impaired BC6OTHER tolerance accelerates adrenocortical BC6OTHER and BC6ENTC synthesis.	False
Circulating very - BC6ENTG from subjects with impaired BC6ENTC tolerance accelerates adrenocortical BC6OTHER and BC6OTHER synthesis.	False
BC6ENTG induced a greater stimulating effect on adrenocortical BC6ENTC and BC6OTHER release compared to BC6OTHER and BC6OTHER .	False
BC6OTHER induced a greater stimulating effect on adrenocortical BC6ENTC and BC6OTHER release compared to BC6ENTG and BC6OTHER .	False
BC6OTHER induced a greater stimulating effect on adrenocortical BC6ENTC and BC6OTHER release compared to BC6OTHER and BC6ENTG .	False
BC6ENTG induced a greater stimulating effect on adrenocortical BC6OTHER and BC6ENTC release compared to BC6OTHER and BC6OTHER .	False
BC6OTHER induced a greater stimulating effect on adrenocortical BC6OTHER and BC6ENTC release compared to BC6ENTG and BC6OTHER .	False
BC6OTHER induced a greater stimulating effect on adrenocortical BC6OTHER and BC6ENTC release compared to BC6OTHER and BC6ENTG .	False
Apart from their role in cardiovascular homeostasis and immunomodulation, BC6ENTC and BC6OTHER are also implicated in the pathogenesis of BC6ENTG resistance and type 2 diabetes mellitus (T2DM).	False
These radiotracers are close analogues of BC6OTHER , a potent and selective ligand for the BC6ENTC transporter ( BC6ENTG ).	False
In vitro autoradiography studies (rat brain slices) with BC6ENTC produced a regional distribution pattern that was consistent with the reported distribution of BC6ENTG .	False
BC6ENTC has the potential to be the first successful PET ligand to image BC6ENTG .	False
These radiotracers are close analogues of BC6ENTC , a potent and selective ligand for the BC6ENTG ( BC6OTHER ).	False
These radiotracers are close analogues of BC6ENTC , a potent and selective ligand for the BC6OTHER ( BC6ENTG ).	False
These findings provide a structural basis for the development of BC6ENTG inhibitors for a proinflammatory pathway mediated by three BC6ENTC ligands whose stability and potency are different and by multiple BC6OTHER whose functions may be non - redundant.	False
These findings provide a structural basis for the development of BC6OTHER inhibitors for a proinflammatory pathway mediated by three BC6ENTC ligands whose stability and potency are different and by multiple BC6ENTG whose functions may be non - redundant.	False
These findings provide a structural basis for the development of BC6ENTG inhibitors for a proinflammatory pathway mediated by three BC6OTHER ligands whose stability and potency are different and by multiple BC6ENTC receptors whose functions may be non - redundant.	False
BC6ENTC synthase ( BC6ENTG ), the pivotal enzyme for the biosynthesis of BC6OTHER (ref.	False
BC6ENTG ( BC6OTHER ), the pivotal enzyme for the biosynthesis of BC6ENTC (ref.	CPR:9
BC6OTHER ( BC6ENTG ), the pivotal enzyme for the biosynthesis of BC6ENTC (ref.	CPR:9
Here we show the atomic structure of BC6OTHER in a complex with BC6OTHER at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6ENTC and BC6OTHER that distinguishes BC6ENTG from other BC6OTHER .	False
Here we show the atomic structure of BC6OTHER in a complex with BC6OTHER at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6ENTC and BC6OTHER that distinguishes BC6OTHER from other BC6ENTG .	False
Here we show the atomic structure of BC6ENTG in a complex with BC6OTHER at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6ENTC and BC6OTHER that distinguishes BC6OTHER from other BC6OTHER .	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6ENTC and BC6OTHER metabolism that includes BC6ENTG , microsomal BC6OTHER BC6OTHER - transferases ( BC6OTHER ), and microsomal BC6OTHER synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6ENTC and BC6OTHER metabolism that includes BC6OTHER , BC6ENTG BC6OTHER - transferases ( BC6OTHER ), and microsomal BC6OTHER synthase 1 (ref.	CPR:9
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6ENTC and BC6OTHER metabolism that includes BC6OTHER , microsomal BC6OTHER BC6OTHER - transferases ( BC6ENTG ), and microsomal BC6OTHER synthase 1 (ref.	CPR:9
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6ENTC and BC6OTHER metabolism that includes BC6OTHER , microsomal BC6OTHER BC6OTHER - transferases ( BC6OTHER ), and BC6ENTG (ref.	CPR:9
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6ENTC metabolism that includes BC6ENTG , microsomal BC6OTHER BC6OTHER - transferases ( BC6OTHER ), and microsomal BC6OTHER synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6ENTC metabolism that includes BC6OTHER , BC6ENTG BC6OTHER - transferases ( BC6OTHER ), and microsomal BC6OTHER synthase 1 (ref.	CPR:9
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6ENTC metabolism that includes BC6OTHER , microsomal BC6OTHER BC6OTHER - transferases ( BC6ENTG ), and microsomal BC6OTHER synthase 1 (ref.	CPR:9
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6ENTC metabolism that includes BC6OTHER , microsomal BC6OTHER BC6OTHER - transferases ( BC6OTHER ), and BC6ENTG (ref.	CPR:9
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6ENTG , microsomal BC6ENTC BC6OTHER - transferases ( BC6OTHER ), and microsomal BC6OTHER synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6OTHER , microsomal BC6ENTC BC6OTHER - transferases ( BC6ENTG ), and microsomal BC6OTHER synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6OTHER , microsomal BC6ENTC BC6OTHER - transferases ( BC6OTHER ), and BC6ENTG (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6ENTG , microsomal BC6OTHER BC6ENTC - transferases ( BC6OTHER ), and microsomal BC6OTHER synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6OTHER , BC6ENTG BC6ENTC - transferases ( BC6OTHER ), and microsomal BC6OTHER synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6OTHER , microsomal BC6OTHER BC6ENTC - transferases ( BC6ENTG ), and microsomal BC6OTHER synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6OTHER , microsomal BC6OTHER BC6ENTC - transferases ( BC6OTHER ), and BC6ENTG (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6ENTG , microsomal BC6OTHER BC6OTHER - transferases ( BC6OTHER ), and microsomal BC6ENTC synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6OTHER , BC6ENTG BC6OTHER - transferases ( BC6OTHER ), and microsomal BC6ENTC synthase 1 (ref.	False
10), is an 18 - kDa integral nuclear membrane protein that belongs to a superfamily of membrane - associated proteins in BC6OTHER and BC6OTHER metabolism that includes BC6OTHER , microsomal BC6OTHER BC6OTHER - transferases ( BC6ENTG ), and microsomal BC6ENTC synthase 1 (ref.	False
BC6ENTG conjugates BC6ENTC to BC6OTHER , the endogenous substrate derived from BC6OTHER through the BC6OTHER pathway.	False
BC6OTHER conjugates BC6ENTC to BC6OTHER , the endogenous substrate derived from BC6OTHER through the BC6ENTG pathway.	False
BC6ENTG conjugates BC6OTHER to BC6ENTC , the endogenous substrate derived from BC6OTHER through the BC6OTHER pathway.	False
BC6OTHER conjugates BC6OTHER to BC6ENTC , the endogenous substrate derived from BC6OTHER through the BC6ENTG pathway.	False
BC6ENTG conjugates BC6OTHER to BC6OTHER , the endogenous substrate derived from BC6ENTC through the BC6OTHER pathway.	False
BC6OTHER conjugates BC6OTHER to BC6OTHER , the endogenous substrate derived from BC6ENTC through the BC6ENTG pathway.	False
Here we show the atomic structure of BC6OTHER in a complex with BC6OTHER at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6OTHER and BC6ENTC that distinguishes BC6ENTG from other BC6OTHER .	False
Here we show the atomic structure of BC6OTHER in a complex with BC6OTHER at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6OTHER and BC6ENTC that distinguishes BC6OTHER from other BC6ENTG .	False
Here we show the atomic structure of BC6ENTG in a complex with BC6OTHER at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6OTHER and BC6ENTC that distinguishes BC6OTHER from other BC6OTHER .	False
In contrast with BC6ENTG and BC6OTHER (refs 15, 16), BC6OTHER does not conjugate BC6ENTC to xenobiotics.	False
In contrast with BC6OTHER and BC6ENTG (refs 15, 16), BC6OTHER does not conjugate BC6ENTC to xenobiotics.	False
In contrast with BC6OTHER and BC6OTHER (refs 15, 16), BC6ENTG does not conjugate BC6ENTC to xenobiotics.	False
Here we show the atomic structure of BC6OTHER in a complex with BC6ENTC at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6OTHER and BC6OTHER that distinguishes BC6ENTG from other BC6OTHER .	False
Here we show the atomic structure of BC6OTHER in a complex with BC6ENTC at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6OTHER and BC6OTHER that distinguishes BC6OTHER from other BC6ENTG .	False
Here we show the atomic structure of BC6ENTG in a complex with BC6ENTC at 3.3 A resolution by X - ray crystallography and provide insights into the high substrate specificity for BC6OTHER and BC6OTHER that distinguishes BC6OTHER from other BC6OTHER .	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6ENTC (a GABAergic enhancer and BC6ENTG inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	CPR:4
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6ENTC (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [ BC6ENTG ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6ENTC (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6ENTG ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6ENTC (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6ENTG potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6ENTG inhibitor) or BC6ENTC [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6ENTC [ BC6ENTG ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	CPR:5
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6ENTC [metabotropic BC6OTHER receptor 7 ( BC6ENTG ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	CPR:5
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6ENTC [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6ENTG potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6ENTG inhibitor) or BC6OTHER [metabotropic BC6ENTC receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6ENTC receptor 7 ( BC6ENTG ) agonist], while BC6OTHER or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6ENTC receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6ENTG potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6ENTG inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6ENTC or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [ BC6ENTG ( BC6OTHER ) agonist], while BC6ENTC or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6ENTG ) agonist], while BC6ENTC or BC6OTHER ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6ENTC or BC6OTHER ( BC6ENTG potentiator) failed to affect extinction acquisition in S1 mice.	CPR:3
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6ENTG inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6ENTC ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [ BC6ENTG ( BC6OTHER ) agonist], while BC6OTHER or BC6ENTC ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6ENTG ) agonist], while BC6OTHER or BC6ENTC ( BC6OTHER receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6ENTC ( BC6ENTG potentiator) failed to affect extinction acquisition in S1 mice.	CPR:3
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6ENTG inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6ENTC receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [ BC6ENTG ( BC6OTHER ) agonist], while BC6OTHER or BC6OTHER ( BC6ENTC receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of BC6OTHER (a GABAergic enhancer and BC6OTHER inhibitor) or BC6OTHER [metabotropic BC6OTHER receptor 7 ( BC6ENTG ) agonist], while BC6OTHER or BC6OTHER ( BC6ENTC receptor potentiator) failed to affect extinction acquisition in S1 mice.	False
Rescue of this impaired extinction consolidation / retrieval was achieved with BC6ENTC ( BC6OTHER partial agonist) or BC6OTHER ( BC6ENTG ( BC6OTHER ) inhibitor), applied after extinction training.	False
Rescue of this impaired extinction consolidation / retrieval was achieved with BC6ENTC ( BC6OTHER partial agonist) or BC6OTHER ( BC6OTHER ( BC6ENTG ) inhibitor), applied after extinction training.	False
Rescue of this impaired extinction consolidation / retrieval was achieved with BC6OTHER ( BC6ENTC partial agonist) or BC6OTHER ( BC6ENTG ( BC6OTHER ) inhibitor), applied after extinction training.	False
Rescue of this impaired extinction consolidation / retrieval was achieved with BC6OTHER ( BC6ENTC partial agonist) or BC6OTHER ( BC6OTHER ( BC6ENTG ) inhibitor), applied after extinction training.	False
Rescue of this impaired extinction consolidation / retrieval was achieved with BC6OTHER ( BC6OTHER partial agonist) or BC6ENTC ( BC6ENTG ( BC6OTHER ) inhibitor), applied after extinction training.	CPR:4
Rescue of this impaired extinction consolidation / retrieval was achieved with BC6OTHER ( BC6OTHER partial agonist) or BC6ENTC ( BC6OTHER ( BC6ENTG ) inhibitor), applied after extinction training.	CPR:4
The following AOD was examined: BC6ENTC dismutase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6ENTC dismutase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER peroxidase ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6ENTC dismutase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6ENTG ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6ENTG ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6ENTC , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6ENTC , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER peroxidase ( BC6OTHER ), BC6ENTC , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6ENTG ), BC6ENTC , and BC6OTHER .	False
The following AOD was examined: BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6ENTC , and BC6OTHER .	False
The following AOD was examined: BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6OTHER , and BC6ENTC .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6OTHER , and BC6ENTC .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER peroxidase ( BC6OTHER ), BC6OTHER , and BC6ENTC .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6ENTC .	False
The following AOD was examined: BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6ENTG ), BC6OTHER , and BC6ENTC .	False
The following AOD was examined: BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER peroxidase ( BC6OTHER ), BC6OTHER , and BC6ENTC .	False
RESULTS: BC6ENTC inhibited BC6ENTG BC6OTHER phosphorylation in a dose - dependent manner after 1.5 hours of exposure.	CPR:4
RESULTS: BC6ENTC inhibited BC6OTHER BC6ENTG phosphorylation in a dose - dependent manner after 1.5 hours of exposure.	CPR:4
Cellular effects of BC6ENTC on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated BC6ENTG mutations.	False
CONCLUSIONS: BC6ENTC inhibits BC6ENTG - mediated MTC cell growth affecting BC6OTHER protein levels in vitro in a dose - dependent manner.	CPR:4
CONCLUSIONS: BC6ENTC inhibits BC6OTHER - mediated MTC cell growth affecting BC6ENTG protein levels in vitro in a dose - dependent manner.	CPR:4
The concentration of BC6ENTC necessary to inhibit BC6ENTG in vitro, however, makes it impossible to conclude that BC6OTHER monotherapy will be a good option for systemic therapy of MTC.	CPR:4
The concentration of BC6OTHER necessary to inhibit BC6ENTG in vitro, however, makes it impossible to conclude that BC6ENTC monotherapy will be a good option for systemic therapy of MTC.	False
We evaluated BC6ENTC , a BC6ENTG inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC - derived cell lines expressing multiple endocrine neoplasia - associated mutant BC6OTHER .	CPR:4
We evaluated BC6ENTC , a BC6OTHER kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC - derived cell lines expressing multiple endocrine neoplasia - associated mutant BC6ENTG .	False
We evaluated BC6OTHER , a BC6ENTC kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC - derived cell lines expressing multiple endocrine neoplasia - associated mutant BC6ENTG .	False
BACKGROUND: Activating mutations in the BC6ENTG gene, which encodes a BC6ENTC kinase receptor, often cause medullary thyroid carcinoma (MTC).	False
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) receptor antagonist BC6ENTC ( BC6OTHER ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	CPR:6
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6OTHER ) receptor antagonist BC6ENTC ( BC6OTHER ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	CPR:6
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6OTHER ( BC6OTHER ) / BC6ENTG antagonist BC6ENTC ( BC6OTHER ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	CPR:6
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6ENTC ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	CPR:6
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6ENTC ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	CPR:6
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6OTHER ( BC6OTHER ) / BC6ENTG antagonist BC6OTHER ( BC6ENTC ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	CPR:6
Efficacy of the BC6ENTG / BC6ENTC receptor antagonist BC6OTHER against seizures and neuropathology in a CHEM - exposure model without pretreatment and its pharmacokinetics after intramuscular administration.	False
Efficacy of the BC6ENTG / BC6OTHER antagonist BC6ENTC against seizures and neuropathology in a CHEM - exposure model without pretreatment and its pharmacokinetics after intramuscular administration.	CPR:6
Efficacy of the BC6OTHER / BC6ENTG antagonist BC6ENTC against seizures and neuropathology in a CHEM - exposure model without pretreatment and its pharmacokinetics after intramuscular administration.	CPR:6
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6ENTG ( BC6OTHER ) / BC6ENTC ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	False
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6OTHER ( BC6ENTG ) / BC6ENTC ( BC6OTHER ) receptor antagonist BC6OTHER ( BC6OTHER ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	False
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6ENTG ( BC6OTHER ) / BC6OTHER ( BC6ENTC ) receptor antagonist BC6OTHER ( BC6OTHER ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	False
To determine if control of seizures and survival are still possible without pretreatment or immediate pharmacologic intervention, we studied the anticonvulsant efficacy of the BC6OTHER ( BC6ENTG ) / BC6OTHER ( BC6ENTC ) receptor antagonist BC6OTHER ( BC6OTHER ) in rats that did not receive any treatment until 20 minutes after exposure to the nerve agent CHEM.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER , relative to those in HFD control mice.	False
BC6ENTC supplementation altered expression profiles of several lipid metabolism - related genes, including BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG , relative to those in HFD control mice.	False
The selective BC6ENTG ligand BC6ENTC antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against BC6OTHER was 8.43.	False
The selective BC6ENTG ligand BC6OTHER antagonized acidification rate changes with an affinity independent of the agonist used; the affinity (mean pK(B)) against BC6ENTC was 8.43.	False
The selective BC6ENTG ligands BC6ENTC and BC6OTHER (each 3 microM) had no effect on BC6OTHER responses.	False
The selective BC6ENTG ligands BC6OTHER and BC6ENTC (each 3 microM) had no effect on BC6OTHER responses.	False
The selective BC6ENTG ligands BC6OTHER and BC6OTHER (each 3 microM) had no effect on BC6ENTC responses.	False
In BC6ENTG transfected cells the rank order of agonist potency was BC6ENTC (mean pEC(50)=8.96)> BC6OTHER (8.88)> BC6OTHER (8.42)> BC6OTHER (7.05)> BC6OTHER (6.92).	CPR:5
In BC6ENTG transfected cells the rank order of agonist potency was BC6OTHER (mean pEC(50)=8.96)> BC6ENTC (8.88)> BC6OTHER (8.42)> BC6OTHER (7.05)> BC6OTHER (6.92).	CPR:5
In BC6ENTG transfected cells the rank order of agonist potency was BC6OTHER (mean pEC(50)=8.96)> BC6OTHER (8.88)> BC6ENTC (8.42)> BC6OTHER (7.05)> BC6OTHER (6.92).	CPR:5
In BC6ENTG transfected cells the rank order of agonist potency was BC6OTHER (mean pEC(50)=8.96)> BC6OTHER (8.88)> BC6OTHER (8.42)> BC6ENTC (7.05)> BC6OTHER (6.92).	CPR:5
In BC6ENTG transfected cells the rank order of agonist potency was BC6OTHER (mean pEC(50)=8.96)> BC6OTHER (8.88)> BC6OTHER (8.42)> BC6OTHER (7.05)> BC6ENTC (6.92).	CPR:5
Univariate regression analyses showed that only the use of BC6ENTC was correlated with the decrease in BC6ENTG concentration (p <0.03).	CPR:4
Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of BC6OTHER (p <0.02), left ventricular dilation (p <0.03), and use of BC6ENTC (p <0.04) at baseline were predictive of a decrease in plasma concentration of BC6ENTG .	False
Multivariate analyses demonstrated that an ischemic cause of heart failure (p <0.02), high plasma concentration of BC6ENTG (p <0.02), left ventricular dilation (p <0.03), and use of BC6ENTC (p <0.04) at baseline were predictive of a decrease in plasma concentration of BC6OTHER .	False
After 12 months of treatment, BC6ENTC significantly improved all end points (plasma concentration of BC6ENTG [ BC6OTHER ] from 175 (35 to 209) to 106 (52 to 160) pg / ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not ( BC6OTHER concentration from 150 (114 to 186) to 174 (100 to 248) pg / ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	CPR:4
After 12 months of treatment, BC6ENTC significantly improved all end points (plasma concentration of BC6OTHER [ BC6ENTG ] from 175 (35 to 209) to 106 (52 to 160) pg / ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not ( BC6OTHER concentration from 150 (114 to 186) to 174 (100 to 248) pg / ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	CPR:4
After 12 months of treatment, BC6ENTC significantly improved all end points (plasma concentration of BC6OTHER [ BC6OTHER ] from 175 (35 to 209) to 106 (52 to 160) pg / ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not ( BC6ENTG concentration from 150 (114 to 186) to 174 (100 to 248) pg / ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).	False
Effects of BC6ENTC on BC6ENTG concentration and symptoms in patients with heart failure and preserved ejection fraction.	False
We have shown that BC6ENTC is more active in cells harboring epithelial phenotype with high BC6ENTG and low BC6OTHER expression.	False
We have shown that BC6ENTC is more active in cells harboring epithelial phenotype with high BC6OTHER and low BC6ENTG expression.	False
In addition, high BC6ENTG and BC6OTHER expression was correlated with sensitivity to BC6ENTC , whereas the presence of BC6OTHER activating mutations was associated with resistance.	False
In addition, high BC6OTHER and BC6ENTG expression was correlated with sensitivity to BC6ENTC , whereas the presence of BC6OTHER activating mutations was associated with resistance.	False
In addition, high BC6OTHER and BC6OTHER expression was correlated with sensitivity to BC6ENTC , whereas the presence of BC6ENTG activating mutations was associated with resistance.	False
In DU - PM cells with acquired resistance to BC6ENTC , BC6ENTG expression was decreased, while BC6OTHER was increased.	CPR:4
In DU - PM cells with acquired resistance to BC6ENTC , BC6OTHER expression was decreased, while BC6ENTG was increased.	CPR:3
BC6ENTC was shown to induce rapid oncosis in BC6ENTG - expressing cells.	False
BC6ENTG ( BC6OTHER ) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for BC6OTHER and of the residues modified in the inactivation of the enzyme by the enzyme - activated irreversible inhibitor, BC6ENTC ( BC6OTHER ).	CPR:4
Mouse BC6OTHER decarboxylase ( BC6ENTG ) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for BC6OTHER and of the residues modified in the inactivation of the enzyme by the enzyme - activated irreversible inhibitor, BC6ENTC ( BC6OTHER ).	CPR:4
BC6ENTG ( BC6OTHER ) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for BC6OTHER and of the residues modified in the inactivation of the enzyme by the enzyme - activated irreversible inhibitor, BC6OTHER ( BC6ENTC ).	CPR:4
Mouse BC6OTHER decarboxylase ( BC6ENTG ) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for BC6OTHER and of the residues modified in the inactivation of the enzyme by the enzyme - activated irreversible inhibitor, BC6OTHER ( BC6ENTC ).	CPR:4
The BC6ENTC binding BC6OTHER in BC6ENTG was identified as BC6OTHER 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6OTHER followed by digestion of the carboxymethylated protein with endoproteinase BC6OTHER , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
The BC6ENTC binding BC6OTHER in BC6OTHER was identified as BC6OTHER 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6OTHER followed by digestion of the carboxymethylated protein with BC6ENTG , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
The BC6OTHER binding BC6ENTC in BC6ENTG was identified as BC6OTHER 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6OTHER followed by digestion of the carboxymethylated protein with endoproteinase BC6OTHER , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
The BC6OTHER binding BC6ENTC in BC6OTHER was identified as BC6OTHER 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6OTHER followed by digestion of the carboxymethylated protein with BC6ENTG , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
Using a similar procedure to analyze BC6ENTG labeled by reaction with BC6ENTC , it was found that BC6OTHER 69 and BC6OTHER 360 formed covalent adducts with the inhibitor.	False
The BC6OTHER binding BC6OTHER in BC6ENTG was identified as BC6ENTC 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6OTHER followed by digestion of the carboxymethylated protein with endoproteinase BC6OTHER , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
The BC6OTHER binding BC6OTHER in BC6OTHER was identified as BC6ENTC 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6OTHER followed by digestion of the carboxymethylated protein with BC6ENTG , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
The BC6OTHER binding BC6OTHER in BC6ENTG was identified as BC6OTHER 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6ENTC followed by digestion of the carboxymethylated protein with endoproteinase BC6OTHER , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
The BC6OTHER binding BC6OTHER in BC6OTHER was identified as BC6OTHER 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6ENTC followed by digestion of the carboxymethylated protein with BC6ENTG , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
The BC6OTHER binding BC6OTHER in BC6ENTG was identified as BC6OTHER 69 of the mouse sequence by reduction of the purified holoenzyme form with BC6OTHER followed by digestion of the carboxymethylated protein with endoproteinase BC6ENTC , radioactive peptide mapping using reversed - phase high pressure liquid chromatography and gas - phase peptide sequencing.	False
Mouse BC6ENTC decarboxylase ( BC6ENTG ) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for BC6OTHER and of the residues modified in the inactivation of the enzyme by the enzyme - activated irreversible inhibitor, BC6OTHER ( BC6OTHER ).	False
This BC6ENTC is contained in the sequence BC6ENTG , which is found in all known BC6OTHER from eukaryotes.	False
This BC6ENTC is contained in the sequence BC6OTHER , which is found in all known BC6ENTG from eukaryotes.	False
This BC6OTHER is contained in the sequence BC6ENTC , which is found in all known BC6ENTG from eukaryotes.	False
The preceding BC6ENTC do not conform to the consensus sequence of BC6ENTG , which contains the BC6OTHER binding BC6OTHER in a number of other BC6OTHER including BC6OTHER from E. coli.	False
The preceding BC6ENTC do not conform to the consensus sequence of BC6OTHER , which contains the BC6OTHER binding BC6OTHER in a number of other BC6ENTG including BC6OTHER from E. coli.	False
The preceding BC6ENTC do not conform to the consensus sequence of BC6OTHER , which contains the BC6OTHER binding BC6OTHER in a number of other BC6OTHER including BC6ENTG from E. coli.	False
The preceding BC6OTHER do not conform to the consensus sequence of BC6ENTG , which contains the BC6ENTC binding BC6OTHER in a number of other BC6OTHER including BC6OTHER from E. coli.	False
The preceding BC6OTHER do not conform to the consensus sequence of BC6OTHER , which contains the BC6ENTC binding BC6OTHER in a number of other BC6ENTG including BC6OTHER from E. coli.	False
The preceding BC6OTHER do not conform to the consensus sequence of BC6OTHER , which contains the BC6ENTC binding BC6OTHER in a number of other BC6OTHER including BC6ENTG from E. coli.	False
The preceding BC6OTHER do not conform to the consensus sequence of BC6ENTG , which contains the BC6OTHER binding BC6ENTC in a number of other BC6OTHER including BC6OTHER from E. coli.	False
The preceding BC6OTHER do not conform to the consensus sequence of BC6OTHER , which contains the BC6OTHER binding BC6ENTC in a number of other BC6ENTG including BC6OTHER from E. coli.	False
The preceding BC6OTHER do not conform to the consensus sequence of BC6OTHER , which contains the BC6OTHER binding BC6ENTC in a number of other BC6OTHER including BC6ENTG from E. coli.	False
Using a similar procedure to analyze BC6ENTG labeled by reaction with BC6OTHER , it was found that BC6ENTC 69 and BC6OTHER 360 formed covalent adducts with the inhibitor.	False
Mechanism of the irreversible inactivation of BC6ENTG by BC6ENTC .	CPR:4
Using a similar procedure to analyze BC6ENTG labeled by reaction with BC6OTHER , it was found that BC6OTHER 69 and BC6ENTC 360 formed covalent adducts with the inhibitor.	False
BC6ENTC 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence - BC6ENTG - , which is present in all known BC6OTHER .	False
BC6ENTC 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence - BC6OTHER - , which is present in all known BC6ENTG .	False
BC6OTHER 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence - BC6ENTC - , which is present in all known BC6ENTG .	False
BC6ENTG ( BC6OTHER ) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for BC6ENTC and of the residues modified in the inactivation of the enzyme by the enzyme - activated irreversible inhibitor, BC6OTHER ( BC6OTHER ).	False
Mouse BC6OTHER decarboxylase ( BC6ENTG ) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for BC6ENTC and of the residues modified in the inactivation of the enzyme by the enzyme - activated irreversible inhibitor, BC6OTHER ( BC6OTHER ).	False
BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTC ) rapidly and reversibly inhibited BC6ENTG currents via mechanism(s) independent of BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER , and BC6ENTC ) rapidly and reversibly inhibited BC6OTHER currents via mechanism(s) independent of BC6ENTG .	False
When BC6ENTG was coexpressed with BC6OTHER ( BC6OTHER ), BC6ENTC was found to act as a BC6OTHER antagonist to inhibit BC6OTHER - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	False
When BC6OTHER was coexpressed with BC6ENTG ( BC6OTHER ), BC6ENTC was found to act as a BC6OTHER antagonist to inhibit BC6OTHER - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	False
When BC6OTHER was coexpressed with BC6OTHER ( BC6ENTG ), BC6ENTC was found to act as a BC6OTHER antagonist to inhibit BC6OTHER - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	False
When BC6OTHER was coexpressed with BC6OTHER ( BC6OTHER ), BC6ENTC was found to act as a BC6ENTG antagonist to inhibit BC6OTHER - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	CPR:6
When BC6OTHER was coexpressed with BC6OTHER ( BC6OTHER ), BC6ENTC was found to act as a BC6OTHER antagonist to inhibit BC6OTHER - evoked currents, but none of the other compounds inhibited BC6ENTG currents.	False
When BC6ENTG was coexpressed with BC6OTHER ( BC6OTHER ), BC6OTHER was found to act as a BC6OTHER antagonist to inhibit BC6ENTC - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	False
When BC6OTHER was coexpressed with BC6ENTG ( BC6OTHER ), BC6OTHER was found to act as a BC6OTHER antagonist to inhibit BC6ENTC - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	False
When BC6OTHER was coexpressed with BC6OTHER ( BC6ENTG ), BC6OTHER was found to act as a BC6OTHER antagonist to inhibit BC6ENTC - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	False
When BC6OTHER was coexpressed with BC6OTHER ( BC6OTHER ), BC6OTHER was found to act as a BC6ENTG antagonist to inhibit BC6ENTC - evoked currents, but none of the other compounds inhibited BC6OTHER currents.	False
When BC6OTHER was coexpressed with BC6OTHER ( BC6OTHER ), BC6OTHER was found to act as a BC6OTHER antagonist to inhibit BC6ENTC - evoked currents, but none of the other compounds inhibited BC6ENTG currents.	False
BC6ENTG is a widely expressed protein that shares structural, but not BC6ENTC , homology with gap junction proteins, the BC6OTHER .	False
BC6OTHER is a widely expressed protein that shares structural, but not BC6ENTC , homology with gap junction proteins, the BC6ENTG .	False
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6ENTC > BC6OTHER ( BC6OTHER ) approximately BC6OTHER approximately BC6OTHER > BC6OTHER >> BC6OTHER >> BC6OTHER = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6ENTC ( BC6OTHER ) approximately BC6OTHER approximately BC6OTHER > BC6OTHER >> BC6OTHER >> BC6OTHER = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6OTHER ( BC6ENTC ) approximately BC6OTHER approximately BC6OTHER > BC6OTHER >> BC6OTHER >> BC6OTHER = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6OTHER ( BC6OTHER ) approximately BC6ENTC approximately BC6OTHER > BC6OTHER >> BC6OTHER >> BC6OTHER = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6OTHER ( BC6OTHER ) approximately BC6OTHER approximately BC6ENTC > BC6OTHER >> BC6OTHER >> BC6OTHER = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6OTHER ( BC6OTHER ) approximately BC6OTHER approximately BC6OTHER > BC6ENTC >> BC6OTHER >> BC6OTHER = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6OTHER ( BC6OTHER ) approximately BC6OTHER approximately BC6OTHER > BC6OTHER >> BC6ENTC >> BC6OTHER = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6OTHER ( BC6OTHER ) approximately BC6OTHER approximately BC6OTHER > BC6OTHER >> BC6OTHER >> BC6ENTC = BC6OTHER .	CPR:4
We found compounds that inhibited BC6ENTG currents with a rank order of potency: BC6OTHER > BC6OTHER ( BC6OTHER ) approximately BC6OTHER approximately BC6OTHER > BC6OTHER >> BC6OTHER >> BC6OTHER = BC6ENTC .	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER , and BC6OTHER ) rapidly and reversibly inhibited BC6ENTG currents via mechanism(s) independent of BC6OTHER .	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER , and BC6OTHER ) rapidly and reversibly inhibited BC6OTHER currents via mechanism(s) independent of BC6ENTG .	False
BC6OTHER ( BC6ENTC , BC6OTHER , and BC6OTHER ) rapidly and reversibly inhibited BC6ENTG currents via mechanism(s) independent of BC6OTHER .	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER , and BC6OTHER ) rapidly and reversibly inhibited BC6OTHER currents via mechanism(s) independent of BC6ENTG .	False
BC6OTHER ( BC6OTHER , BC6ENTC , and BC6OTHER ) rapidly and reversibly inhibited BC6ENTG currents via mechanism(s) independent of BC6OTHER .	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC , and BC6OTHER ) rapidly and reversibly inhibited BC6OTHER currents via mechanism(s) independent of BC6ENTG .	False
To test the hypothesis that BC6ENTG inhibition builds sufficient BC6OTHER (CHEM) in the brain and facilitates BC6OTHER - dependent BC6ENTC transmission, we used whole - cell patch - clamp technique to record spontaneous BC6OTHER excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	False
To test the hypothesis that BC6OTHER inhibition builds sufficient BC6OTHER (CHEM) in the brain and facilitates BC6ENTG - dependent BC6ENTC transmission, we used whole - cell patch - clamp technique to record spontaneous BC6OTHER excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	False
To test the hypothesis that BC6ENTG inhibition builds sufficient BC6OTHER (CHEM) in the brain and facilitates BC6OTHER - dependent BC6OTHER transmission, we used whole - cell patch - clamp technique to record spontaneous BC6ENTC excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	False
To test the hypothesis that BC6OTHER inhibition builds sufficient BC6OTHER (CHEM) in the brain and facilitates BC6ENTG - dependent BC6OTHER transmission, we used whole - cell patch - clamp technique to record spontaneous BC6ENTC excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	False
 BC6ENTG inhibition reveals endogenous nicotinic modulation of BC6ENTC inputs to CA1 stratum radiatum interneurons in hippocampal slices.	False
Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible BC6ENTG inhibitor BC6ENTC (100nM).	CPR:4
These results support the concept that BC6ENTG inhibition is able to recruit BC6OTHER - dependent BC6ENTC transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of CHEM.	False
These results support the concept that BC6OTHER inhibition is able to recruit BC6ENTG - dependent BC6ENTC transmission in the hippocampus and such a mechanism can contribute to the acute neurotoxicological actions of CHEM.	False
The involvement of brain nicotinic BC6ENTC receptors ( BC6OTHER ) in the neurotoxicological effects of CHEM, a potent BC6ENTG ( BC6OTHER ) inhibitor and a chemical warfare agent, is not clear.	False
The involvement of brain nicotinic BC6ENTC receptors ( BC6OTHER ) in the neurotoxicological effects of CHEM, a potent BC6OTHER ( BC6ENTG ) inhibitor and a chemical warfare agent, is not clear.	False
The involvement of brain nicotinic BC6ENTC receptors ( BC6ENTG ) in the neurotoxicological effects of CHEM, a potent BC6OTHER ( BC6OTHER ) inhibitor and a chemical warfare agent, is not clear.	False
To test the hypothesis that BC6ENTG inhibition builds sufficient BC6ENTC (CHEM) in the brain and facilitates BC6OTHER - dependent BC6OTHER transmission, we used whole - cell patch - clamp technique to record spontaneous BC6OTHER excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	False
To test the hypothesis that BC6OTHER inhibition builds sufficient BC6ENTC (CHEM) in the brain and facilitates BC6ENTG - dependent BC6OTHER transmission, we used whole - cell patch - clamp technique to record spontaneous BC6OTHER excitatory postsynaptic currents (EPSCs) from CA1 stratum radiatum interneurons (SRI) in hippocampal slices.	False
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6OTHER ), BC6ENTC , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6ENTC and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6ENTC were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6ENTC were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	False
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6ENTC , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	False
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ) were very weak or inactive.	False
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6ENTC and BC6OTHER ( BC6OTHER ) were very weak or inactive.	False
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ) were very weak or inactive.	False
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6ENTC ( BC6OTHER ) were very weak or inactive.	False
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ) were very weak or inactive.	False
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6ENTC ) were very weak or inactive.	False
We conclude that despite small differences concerning the enantiomeric selectivity and affinity of BC6ENTC and BC6OTHER , the close pharmacological identity of BC6ENTG in rat stomach fundus and the recently cloned BC6OTHER receptor is maintained.	False
We conclude that despite small differences concerning the enantiomeric selectivity and affinity of BC6ENTC and BC6OTHER , the close pharmacological identity of BC6OTHER in rat stomach fundus and the recently cloned BC6ENTG receptor is maintained.	False
We conclude that despite small differences concerning the enantiomeric selectivity and affinity of BC6OTHER and BC6ENTC , the close pharmacological identity of BC6ENTG in rat stomach fundus and the recently cloned BC6OTHER receptor is maintained.	False
We conclude that despite small differences concerning the enantiomeric selectivity and affinity of BC6OTHER and BC6ENTC , the close pharmacological identity of BC6OTHER in rat stomach fundus and the recently cloned BC6ENTG receptor is maintained.	False
We conclude that despite small differences concerning the enantiomeric selectivity and affinity of BC6OTHER and BC6OTHER , the close pharmacological identity of BC6ENTC receptors in rat stomach fundus and the recently cloned BC6ENTG receptor is maintained.	False
 BC6ENTC , which demonstrates some selectivity for BC6ENTG in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of BC6OTHER function both in vitro and in vivo.	False
 BC6ENTC , which demonstrates some selectivity for BC6OTHER in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of BC6ENTG function both in vitro and in vivo.	False
 BC6OTHER , which demonstrates some selectivity for BC6ENTC receptors in rat stomach fundus, should provide a useful ligand for confirmation of this view and allow discrimination of BC6ENTG function both in vitro and in vivo.	False
Under these conditions, blockade of BC6ENTG with BC6ENTC (100 microM for 15 min) caused a leftward displacement of concentration - effect curves for both BC6OTHER ( BC6OTHER ) and BC6OTHER .	CPR:4
Under these conditions, blockade of BC6ENTG with BC6OTHER (100 microM for 15 min) caused a leftward displacement of concentration - effect curves for both BC6ENTC ( BC6OTHER ) and BC6OTHER .	False
Under these conditions, blockade of BC6ENTG with BC6OTHER (100 microM for 15 min) caused a leftward displacement of concentration - effect curves for both BC6OTHER ( BC6ENTC ) and BC6OTHER .	False
Under these conditions, blockade of BC6ENTG with BC6OTHER (100 microM for 15 min) caused a leftward displacement of concentration - effect curves for both BC6OTHER ( BC6OTHER ) and BC6ENTC .	False
Further characterization of BC6ENTC receptors (putative BC6ENTG ) in rat stomach fundus longitudinal muscle.	False
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6ENTC ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6ENTC ( BC6OTHER ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6ENTG or BC6OTHER receptors including BC6OTHER ( BC6ENTC ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
In addition several ligands known to act as agonists at either BC6OTHER or BC6ENTG receptors including BC6OTHER ( BC6ENTC ), BC6OTHER , BC6OTHER and BC6OTHER were also agonists in rat fundus whilst BC6OTHER , BC6OTHER and BC6OTHER ( BC6OTHER ) were very weak or inactive.	CPR:5
BC6ENTG were activated by BC6ENTC as assessed using a CHEM - responsive reporter plasmid, pTAT3 - CAT.	CPR:3
The BC6ENTG antagonist BC6ENTC ( BC6OTHER ) significantly counteracted the effect of BC6OTHER on BC6OTHER activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6OTHER .	CPR:6
The BC6OTHER antagonist BC6ENTC ( BC6OTHER ) significantly counteracted the effect of BC6OTHER on BC6ENTG activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6OTHER .	False
The BC6OTHER antagonist BC6ENTC ( BC6OTHER ) significantly counteracted the effect of BC6OTHER on BC6OTHER activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6ENTG .	False
The BC6ENTG antagonist BC6OTHER ( BC6ENTC ) significantly counteracted the effect of BC6OTHER on BC6OTHER activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6OTHER .	CPR:6
The BC6OTHER antagonist BC6OTHER ( BC6ENTC ) significantly counteracted the effect of BC6OTHER on BC6ENTG activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6OTHER .	False
The BC6OTHER antagonist BC6OTHER ( BC6ENTC ) significantly counteracted the effect of BC6OTHER on BC6OTHER activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6ENTG .	False
The BC6ENTG antagonist BC6OTHER ( BC6OTHER ) significantly counteracted the effect of BC6ENTC on BC6OTHER activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6OTHER .	False
The BC6OTHER antagonist BC6OTHER ( BC6OTHER ) significantly counteracted the effect of BC6ENTC on BC6ENTG activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6OTHER .	False
The BC6OTHER antagonist BC6OTHER ( BC6OTHER ) significantly counteracted the effect of BC6ENTC on BC6OTHER activation, indicating that the BC6OTHER effect is specific and is mediated through the BC6ENTG .	False
The BC6ENTG antagonist BC6OTHER ( BC6OTHER ) significantly counteracted the effect of BC6OTHER on BC6OTHER activation, indicating that the BC6ENTC effect is specific and is mediated through the BC6OTHER .	False
The BC6OTHER antagonist BC6OTHER ( BC6OTHER ) significantly counteracted the effect of BC6OTHER on BC6ENTG activation, indicating that the BC6ENTC effect is specific and is mediated through the BC6OTHER .	False
The BC6OTHER antagonist BC6OTHER ( BC6OTHER ) significantly counteracted the effect of BC6OTHER on BC6OTHER activation, indicating that the BC6ENTC effect is specific and is mediated through the BC6ENTG .	False
The presence of BC6ENTG confers their responsiveness to glucocorticoids and indicates that the airway epithelium may be a target for the anti - inflammatory effects of inhaled BC6ENTC .	False
BC6ENTG ( BC6OTHER ) convert protein - bound BC6OTHER residues into BC6OTHER residues in a BC6ENTC ion - dependent manner.	False
BC6OTHER ( BC6ENTG ) convert protein - bound BC6OTHER residues into BC6OTHER residues in a BC6ENTC ion - dependent manner.	False
BC6ENTG ( BC6OTHER ) convert protein - bound BC6ENTC residues into BC6OTHER residues in a BC6OTHER ion - dependent manner.	False
BC6OTHER ( BC6ENTG ) convert protein - bound BC6ENTC residues into BC6OTHER residues in a BC6OTHER ion - dependent manner.	False
BC6ENTG ( BC6OTHER ) convert protein - bound BC6OTHER residues into BC6ENTC residues in a BC6OTHER ion - dependent manner.	False
BC6OTHER ( BC6ENTG ) convert protein - bound BC6OTHER residues into BC6ENTC residues in a BC6OTHER ion - dependent manner.	False
We report that the radiation - induced activation of the BC6ENTG BC6OTHER [4] (also known as BC6OTHER [5]) is inhibited by BC6OTHER in vivo and that BC6OTHER BC6OTHER activity is directly inhibited by BC6ENTC in vitro.	False
We report that the radiation - induced activation of the BC6OTHER BC6ENTG [4] (also known as BC6OTHER [5]) is inhibited by BC6OTHER in vivo and that BC6OTHER BC6OTHER activity is directly inhibited by BC6ENTC in vitro.	False
We report that the radiation - induced activation of the BC6OTHER BC6OTHER [4] (also known as BC6ENTG [5]) is inhibited by BC6OTHER in vivo and that BC6OTHER BC6OTHER activity is directly inhibited by BC6ENTC in vitro.	False
We report that the radiation - induced activation of the BC6OTHER BC6OTHER [4] (also known as BC6OTHER [5]) is inhibited by BC6OTHER in vivo and that BC6ENTG BC6OTHER activity is directly inhibited by BC6ENTC in vitro.	CPR:4
We report that the radiation - induced activation of the BC6OTHER BC6OTHER [4] (also known as BC6OTHER [5]) is inhibited by BC6OTHER in vivo and that BC6OTHER BC6ENTG activity is directly inhibited by BC6ENTC in vitro.	CPR:4
Inhibition of BC6ENTG provides a molecular explanation of the attenuation of DNA - damage checkpoint responses and for the increased radiosensitivity of BC6ENTC - treated cells [6] [7] [8].	CPR:4
We report that the radiation - induced activation of the BC6ENTG BC6OTHER [4] (also known as BC6OTHER [5]) is inhibited by BC6ENTC in vivo and that BC6OTHER BC6OTHER activity is directly inhibited by BC6OTHER in vitro.	CPR:4
We report that the radiation - induced activation of the BC6OTHER BC6ENTG [4] (also known as BC6OTHER [5]) is inhibited by BC6ENTC in vivo and that BC6OTHER BC6OTHER activity is directly inhibited by BC6OTHER in vitro.	CPR:4
We report that the radiation - induced activation of the BC6OTHER BC6OTHER [4] (also known as BC6ENTG [5]) is inhibited by BC6ENTC in vivo and that BC6OTHER BC6OTHER activity is directly inhibited by BC6OTHER in vitro.	CPR:4
We report that the radiation - induced activation of the BC6OTHER BC6OTHER [4] (also known as BC6OTHER [5]) is inhibited by BC6ENTC in vivo and that BC6ENTG BC6OTHER activity is directly inhibited by BC6OTHER in vitro.	False
We report that the radiation - induced activation of the BC6OTHER BC6OTHER [4] (also known as BC6OTHER [5]) is inhibited by BC6ENTC in vivo and that BC6OTHER BC6ENTG activity is directly inhibited by BC6OTHER in vitro.	False
 BC6ENTC inhibits the checkpoint BC6ENTG BC6OTHER .	CPR:4
 BC6ENTC inhibits the checkpoint BC6OTHER BC6ENTG .	CPR:4
These results suggest that BC6ENTC - bound BC6ENTG (G BC6OTHER ), which acts as an endogenous seed for BC6OTHER fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	False
These results suggest that BC6ENTC - bound BC6OTHER (G BC6ENTG ), which acts as an endogenous seed for BC6OTHER fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	False
These results suggest that BC6ENTC - bound BC6OTHER (G BC6OTHER ), which acts as an endogenous seed for BC6ENTG fibril formation in AD brains, is generated on ASIGN on synaptosomal membranes.	False
We previously found that the BC6ENTC - enriched microdomains ( BC6OTHER clusters) in presynaptic neuronal membranes play a key role in the initiation of the BC6ENTG assembly process.	False
We previously found that the BC6OTHER - enriched microdomains ( BC6ENTC clusters) in presynaptic neuronal membranes play a key role in the initiation of the BC6ENTG assembly process.	False
However, not all BC6ENTC clusters accelerate BC6ENTG assembly.	False
The BC6ENTG assembly was generated on a distinctive BC6OTHER , which was characterized as the BC6OTHER - sensitive BC6ENTC nanocluster (ASIGN).	False
The BC6OTHER assembly was generated on a distinctive BC6ENTG , which was characterized as the BC6OTHER - sensitive BC6ENTC nanocluster (ASIGN).	False
The BC6OTHER assembly was generated on a distinctive BC6OTHER , which was characterized as the BC6ENTG - sensitive BC6ENTC nanocluster (ASIGN).	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6OTHER output, decreased BC6ENTC consumption, and blunted the effect of BC6ENTG or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6OTHER output, decreased BC6ENTC consumption, and blunted the effect of BC6OTHER or BC6ENTG on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6OTHER output, decreased BC6ENTC consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6OTHER output, decreased BC6ENTC consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6OTHER output, decreased BC6ENTC consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6OTHER output, decreased BC6ENTC consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expression.	False
Inhibition of BC6ENTG expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6OTHER output, decreased BC6ENTC consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
In hypothalamus of mice administered a high - fat diet, there is a reduction in BC6ENTG and BC6OTHER - induced BC6OTHER - p - BC6ENTC and nuclear translocation, which is reversed by reducing protein BC6OTHER phosphatase 1B expression.	False
In hypothalamus of mice administered a high - fat diet, there is a reduction in BC6OTHER and BC6ENTG - induced BC6OTHER - p - BC6ENTC and nuclear translocation, which is reversed by reducing protein BC6OTHER phosphatase 1B expression.	False
In hypothalamus of mice administered a high - fat diet, there is a reduction in BC6OTHER and BC6OTHER - induced BC6ENTG - p - BC6ENTC and nuclear translocation, which is reversed by reducing protein BC6OTHER phosphatase 1B expression.	False
In hypothalamus of mice administered a high - fat diet, there is a reduction in BC6OTHER and BC6OTHER - induced BC6OTHER - p - BC6ENTC and nuclear translocation, which is reversed by reducing BC6ENTG expression.	False
In hypothalamus of mice administered a high - fat diet, there is a reduction in BC6ENTG and BC6OTHER - induced BC6OTHER - p - BC6OTHER and nuclear translocation, which is reversed by reducing protein BC6ENTC phosphatase 1B expression.	False
In hypothalamus of mice administered a high - fat diet, there is a reduction in BC6OTHER and BC6ENTG - induced BC6OTHER - p - BC6OTHER and nuclear translocation, which is reversed by reducing protein BC6ENTC phosphatase 1B expression.	False
In hypothalamus of mice administered a high - fat diet, there is a reduction in BC6OTHER and BC6OTHER - induced BC6ENTG - p - BC6OTHER and nuclear translocation, which is reversed by reducing protein BC6ENTC phosphatase 1B expression.	False
In the current study, we investigated whether BC6ENTG , BC6OTHER , and obesity can modulate BC6OTHER in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic BC6ENTC metabolism.	False
In the current study, we investigated whether BC6OTHER , BC6ENTG , and obesity can modulate BC6OTHER in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic BC6ENTC metabolism.	False
In the current study, we investigated whether BC6OTHER , BC6OTHER , and obesity can modulate BC6ENTG in vivo in hypothalamic nuclei, and we investigated possible consequences on energy balance, neuropeptide expression, and hepatic BC6ENTC metabolism.	False
BC6ENTG BC6ENTC phosphorylation (Tub - p - BC6OTHER ) is modulated by nutritional status.	False
BC6ENTG BC6OTHER phosphorylation (Tub - p - BC6ENTC ) is modulated by nutritional status.	False
BC6ENTG is a substrate of insulin receptor BC6ENTC kinase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) in hypothalamic nuclei.	False
BC6OTHER is a substrate of insulin receptor BC6ENTC kinase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) in hypothalamic nuclei.	False
BC6OTHER is a substrate of insulin receptor BC6ENTC kinase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) - BC6OTHER ( BC6OTHER ) in hypothalamic nuclei.	False
BC6OTHER is a substrate of insulin receptor BC6ENTC kinase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) - BC6OTHER ( BC6OTHER ) in hypothalamic nuclei.	False
BC6OTHER is a substrate of insulin receptor BC6ENTC kinase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - BC6ENTG ( BC6OTHER ) in hypothalamic nuclei.	False
BC6OTHER is a substrate of insulin receptor BC6ENTC kinase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) - BC6OTHER ( BC6ENTG ) in hypothalamic nuclei.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6ENTC , and hepatic BC6OTHER output, decreased BC6OTHER consumption, and blunted the effect of BC6ENTG or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6ENTC , and hepatic BC6OTHER output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6ENTG on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6ENTC , and hepatic BC6OTHER output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6ENTC , and hepatic BC6OTHER output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6ENTC , and hepatic BC6OTHER output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6ENTC , and hepatic BC6OTHER output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expression.	False
Inhibition of BC6ENTG expression in hypothalamus by ASO increased food intake, fasting blood BC6ENTC , and hepatic BC6OTHER output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6ENTC output, decreased BC6OTHER consumption, and blunted the effect of BC6ENTG or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6ENTC output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6ENTG on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6ENTC output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6ENTC output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6ENTC output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER expression.	False
Inhibition of BC6OTHER expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6ENTC output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG expression.	False
Inhibition of BC6ENTG expression in hypothalamus by ASO increased food intake, fasting blood BC6OTHER , and hepatic BC6ENTC output, decreased BC6OTHER consumption, and blunted the effect of BC6OTHER or BC6OTHER on BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER expression.	False
Evaluation of animal models for intestinal first - pass metabolism of drug candidates to be metabolized by BC6ENTG enzymes via in vivo and in vitro oxidation of BC6ENTC and BC6OTHER .	False
Evaluation of animal models for intestinal first - pass metabolism of drug candidates to be metabolized by BC6ENTG enzymes via in vivo and in vitro oxidation of BC6OTHER and BC6ENTC .	False
Furthermore, BC6ENTC caused mechanism - based inactivation of BC6ENTG - dependent BC6OTHER 1' - hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.	CPR:4
Furthermore, BC6OTHER caused mechanism - based inactivation of BC6ENTG - dependent BC6ENTC 1' - hydroxylation in mouse, rat and human intestinal microsomes with similar potencies.	CPR:9
RESULTS: BC6ENTG increased VSMC proliferation in immortalized aortic A10 cells, determined by BC6ENTC incorporation.	False
Although the BC6ENTG , by itself, had no effect on VSMC proliferation, stimulation with BC6ENTC , a BC6OTHER agonist, inhibited the stimulatory effect of BC6OTHER .	False
Although the BC6OTHER , by itself, had no effect on VSMC proliferation, stimulation with BC6ENTC , a BC6ENTG agonist, inhibited the stimulatory effect of BC6OTHER .	CPR:5
Although the BC6OTHER , by itself, had no effect on VSMC proliferation, stimulation with BC6ENTC , a BC6OTHER agonist, inhibited the stimulatory effect of BC6ENTG .	CPR:4
The inhibitory effect of BC6ENTC on BC6ENTG - mediated VSMC proliferation was receptor specific, because its effect could be blocked by BC6OTHER , a BC6OTHER antagonist.	CPR:4
The inhibitory effect of BC6ENTC on BC6OTHER - mediated VSMC proliferation was receptor specific, because its effect could be blocked by BC6OTHER , a BC6ENTG antagonist.	False
The inhibitory effect of BC6OTHER on BC6ENTG - mediated VSMC proliferation was receptor specific, because its effect could be blocked by BC6ENTC , a BC6OTHER antagonist.	False
The inhibitory effect of BC6OTHER on BC6OTHER - mediated VSMC proliferation was receptor specific, because its effect could be blocked by BC6ENTC , a BC6ENTG antagonist.	CPR:6
BC6ENTC also inhibited BC6ENTG mRNA and protein expression, which was time dependent and concentration dependent.	CPR:4
A BC6ENTG or BC6OTHER inhibitor blocked the inhibitory effect of BC6ENTC on BC6OTHER expression, indicating that BC6OTHER and BC6OTHER were involved in the signaling pathway.	False
A BC6OTHER or BC6ENTG inhibitor blocked the inhibitory effect of BC6ENTC on BC6OTHER expression, indicating that BC6OTHER and BC6OTHER were involved in the signaling pathway.	False
A BC6OTHER or BC6OTHER inhibitor blocked the inhibitory effect of BC6ENTC on BC6ENTG expression, indicating that BC6OTHER and BC6OTHER were involved in the signaling pathway.	CPR:4
A BC6OTHER or BC6OTHER inhibitor blocked the inhibitory effect of BC6ENTC on BC6OTHER expression, indicating that BC6ENTG and BC6OTHER were involved in the signaling pathway.	False
A BC6OTHER or BC6OTHER inhibitor blocked the inhibitory effect of BC6ENTC on BC6OTHER expression, indicating that BC6OTHER and BC6ENTG were involved in the signaling pathway.	False
Our previous study showed that the stimulatory effect of BC6ENTC on VSMC proliferation is inhibited by BC6ENTG and the D3 BC6OTHER receptor, a member of the BC6OTHER family.	False
Our previous study showed that the stimulatory effect of BC6ENTC on VSMC proliferation is inhibited by BC6OTHER and the BC6ENTG , a member of the BC6OTHER family.	False
Our previous study showed that the stimulatory effect of BC6ENTC on VSMC proliferation is inhibited by BC6OTHER and the D3 BC6OTHER receptor, a member of the BC6ENTG family.	False
Our previous study showed that the stimulatory effect of BC6OTHER on VSMC proliferation is inhibited by BC6ENTG and the D3 BC6ENTC receptor, a member of the BC6OTHER family.	False
Our previous study showed that the stimulatory effect of BC6OTHER on VSMC proliferation is inhibited by BC6OTHER and the D3 BC6ENTC receptor, a member of the BC6ENTG family.	False
METHODS: VSMC proliferation was determined by BC6ENTC incorporation; BC6ENTG mRNA and protein expressions were determined by RT - PCR, immunoblotting, and immunohistochemistry.	False
An important effector of the ISR is BC6ENTG ( BC6OTHER ), a transcription factor that regulates genes involved in redox homeostasis and BC6ENTC metabolism and transport.	False
An important effector of the ISR is BC6OTHER ( BC6ENTG ), a transcription factor that regulates genes involved in redox homeostasis and BC6ENTC metabolism and transport.	False
We identified one compound, BC6ENTC BC6OTHER , that activated the ISR and dose - dependently increased levels of BC6ENTG in transformed cells.	CPR:3
We identified one compound, BC6OTHER BC6ENTC , that activated the ISR and dose - dependently increased levels of BC6ENTG in transformed cells.	CPR:3
A dose - dependent decrease in viability was observed in several mouse and human tumor cell lines, and knockdown of BC6ENTG significantly increased the antiproliferative effects of BC6ENTC .	False
BC6ENTC - mediated induction of senescence was not dependent on BC6ENTG or BC6OTHER ; however, BC6OTHER conferred protection against the growth inhibitory effects of BC6OTHER .	False
BC6ENTC - mediated induction of senescence was not dependent on BC6OTHER or BC6ENTG ; however, BC6OTHER conferred protection against the growth inhibitory effects of BC6OTHER .	False
BC6ENTC - mediated induction of senescence was not dependent on BC6OTHER or BC6OTHER ; however, BC6ENTG conferred protection against the growth inhibitory effects of BC6OTHER .	False
BC6OTHER - mediated induction of senescence was not dependent on BC6ENTG or BC6OTHER ; however, BC6OTHER conferred protection against the growth inhibitory effects of BC6ENTC .	False
BC6OTHER - mediated induction of senescence was not dependent on BC6OTHER or BC6ENTG ; however, BC6OTHER conferred protection against the growth inhibitory effects of BC6ENTC .	False
BC6OTHER - mediated induction of senescence was not dependent on BC6OTHER or BC6OTHER ; however, BC6ENTG conferred protection against the growth inhibitory effects of BC6ENTC .	False
BC6ENTC also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6ENTG , BC6OTHER , and BC6OTHER ( BC6OTHER ), although BC6OTHER does not appear to cause physical DNA damage.	CPR:3
BC6ENTC also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6OTHER , BC6ENTG , and BC6OTHER ( BC6OTHER ), although BC6OTHER does not appear to cause physical DNA damage.	CPR:3
BC6ENTC also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6OTHER , BC6OTHER , and BC6ENTG ( BC6OTHER ), although BC6OTHER does not appear to cause physical DNA damage.	CPR:3
BC6ENTC also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTG ), although BC6OTHER does not appear to cause physical DNA damage.	CPR:3
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6ENTC 15 - BC6ENTG , BC6OTHER , and BC6OTHER ( BC6OTHER ), although BC6OTHER does not appear to cause physical DNA damage.	False
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6ENTC 15 - BC6OTHER , BC6ENTG , and BC6OTHER ( BC6OTHER ), although BC6OTHER does not appear to cause physical DNA damage.	False
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6ENTC 15 - BC6OTHER , BC6OTHER , and BC6ENTG ( BC6OTHER ), although BC6OTHER does not appear to cause physical DNA damage.	False
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6ENTC 15 - BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTG ), although BC6OTHER does not appear to cause physical DNA damage.	False
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6ENTG , BC6OTHER , and BC6OTHER ( BC6OTHER ), although BC6ENTC does not appear to cause physical DNA damage.	False
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6OTHER , BC6ENTG , and BC6OTHER ( BC6OTHER ), although BC6ENTC does not appear to cause physical DNA damage.	False
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6OTHER , BC6OTHER , and BC6ENTG ( BC6OTHER ), although BC6ENTC does not appear to cause physical DNA damage.	False
BC6OTHER also activated DNA damage response signaling, resulting in increased levels of BC6OTHER 15 - BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTG ), although BC6ENTC does not appear to cause physical DNA damage.	False
BC6ENTC - - removed from widespread clinical use by 1962 because of severe teratogenicity - - has anti - angiogenic and immunomodulatory effects, including the inhibition of BC6ENTG .	CPR:4
Furthermore, elevations in blood neutrophil count, serum BC6ENTG , and other markers of inflammation corresponded to BC6ENTC exposure and toxicity and thus may have utility as safety biomarkers.	False
BC6ENTC is a small - molecule drug that triggers tumor cell apoptosis by selectively antagonizing BC6ENTG .	CPR:6
BC6ENTC induces BC6ENTG transcriptional activity leading to expression of several BC6OTHER and BC6OTHER , of which BC6OTHER ( BC6OTHER ) is the most important for single - agent tumor activity.	CPR:3
BC6ENTC induces BC6OTHER transcriptional activity leading to expression of several BC6ENTG and BC6OTHER , of which BC6OTHER ( BC6OTHER ) is the most important for single - agent tumor activity.	False
BC6ENTC induces BC6OTHER transcriptional activity leading to expression of several BC6OTHER and BC6ENTG , of which BC6OTHER ( BC6OTHER ) is the most important for single - agent tumor activity.	False
BC6ENTC induces BC6OTHER transcriptional activity leading to expression of several BC6OTHER and BC6OTHER , of which BC6ENTG ( BC6OTHER ) is the most important for single - agent tumor activity.	False
BC6ENTC induces BC6OTHER transcriptional activity leading to expression of several BC6OTHER and BC6OTHER , of which BC6OTHER ( BC6ENTG ) is the most important for single - agent tumor activity.	False
Toxicity profile of small - molecule BC6ENTG antagonist BC6ENTC is linked to BC6OTHER pharmacology.	CPR:6
Toxicity profile of small - molecule BC6OTHER antagonist BC6ENTC is linked to BC6ENTG pharmacology.	False
No differences in BC6ENTG expression or BC6ENTC and BC6OTHER transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.	False
No differences in BC6ENTG expression or BC6OTHER and BC6ENTC transport across the BBB were observed between male and female Fvb mice as well as between Swiss and Fvb mice.	False
Our results suggest that BC6ENTG - mediated transport across the BBB does not play a key - role in gender and strain - related variability in BC6ENTC and BC6OTHER - induced respiratory toxicity in mice.	False
Our results suggest that BC6ENTG - mediated transport across the BBB does not play a key - role in gender and strain - related variability in BC6OTHER and BC6ENTC - induced respiratory toxicity in mice.	False
We previously demonstrated that BC6ENTG ( BC6OTHER ) modulation at the blood - brain barrier (BBB) contributes highly to BC6ENTC - related respiratory toxicity, by limiting BC6OTHER entrance into the brain.	False
We previously demonstrated that BC6OTHER ( BC6ENTG ) modulation at the blood - brain barrier (BBB) contributes highly to BC6ENTC - related respiratory toxicity, by limiting BC6OTHER entrance into the brain.	False
We previously demonstrated that BC6ENTG ( BC6OTHER ) modulation at the blood - brain barrier (BBB) contributes highly to BC6OTHER - related respiratory toxicity, by limiting BC6ENTC entrance into the brain.	False
We previously demonstrated that BC6OTHER ( BC6ENTG ) modulation at the blood - brain barrier (BBB) contributes highly to BC6OTHER - related respiratory toxicity, by limiting BC6ENTC entrance into the brain.	False
In this work, we sought to investigate the role of BC6ENTG - mediated transport at the BBB in gender and strain - related variability of BC6ENTC and BC6OTHER - induced respiratory effects in mice.	False
In this work, we sought to investigate the role of BC6ENTG - mediated transport at the BBB in gender and strain - related variability of BC6OTHER and BC6ENTC - induced respiratory effects in mice.	False
BC6ENTG and BC6OTHER oxidase, but not BC6ENTC oxidase and BC6OTHER , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6OTHER dehydrogenase and BC6ENTG , but not BC6ENTC oxidase and BC6OTHER , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6OTHER dehydrogenase and BC6OTHER oxidase, but not BC6ENTC oxidase and BC6ENTG , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6ENTG and BC6OTHER oxidase, but not BC6OTHER and BC6ENTC reductase, require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6OTHER dehydrogenase and BC6ENTG , but not BC6OTHER and BC6ENTC reductase, require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6OTHER dehydrogenase and BC6OTHER oxidase, but not BC6ENTG and BC6ENTC reductase, require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6ENTG and BC6OTHER oxidase, but not BC6OTHER and BC6OTHER , require the post - translational sulfuration of their BC6ENTC - site for becoming active.	False
BC6OTHER dehydrogenase and BC6ENTG , but not BC6OTHER and BC6OTHER , require the post - translational sulfuration of their BC6ENTC - site for becoming active.	False
BC6OTHER dehydrogenase and BC6OTHER oxidase, but not BC6ENTG and BC6OTHER , require the post - translational sulfuration of their BC6ENTC - site for becoming active.	False
BC6OTHER dehydrogenase and BC6OTHER oxidase, but not BC6OTHER and BC6ENTG , require the post - translational sulfuration of their BC6ENTC - site for becoming active.	False
This final maturation step is catalyzed by a BC6ENTG enzyme, which mobilizes BC6ENTC from BC6OTHER in a BC6OTHER - dependent manner as typical for BC6OTHER .	False
This final maturation step is catalyzed by a BC6OTHER enzyme, which mobilizes BC6ENTC from BC6OTHER in a BC6OTHER - dependent manner as typical for BC6ENTG .	False
This final maturation step is catalyzed by a BC6ENTG enzyme, which mobilizes BC6OTHER from BC6ENTC in a BC6OTHER - dependent manner as typical for BC6OTHER .	False
This final maturation step is catalyzed by a BC6OTHER enzyme, which mobilizes BC6OTHER from BC6ENTC in a BC6OTHER - dependent manner as typical for BC6ENTG .	False
This final maturation step is catalyzed by a BC6ENTG enzyme, which mobilizes BC6OTHER from BC6OTHER in a BC6ENTC - dependent manner as typical for BC6OTHER .	False
This final maturation step is catalyzed by a BC6OTHER enzyme, which mobilizes BC6OTHER from BC6OTHER in a BC6ENTC - dependent manner as typical for BC6ENTG .	False
This final maturation step is catalyzed by a BC6ENTG enzyme, which mobilizes BC6OTHER from BC6OTHER in a BC6OTHER - dependent manner as typical for BC6ENTC desulfurases.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTC reductase, which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTC reductase, which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTC reductase, which catalyzes the key step in inorganic BC6OTHER assimilation.	False
With the exception of BC6ENTG , where BC6ENTC is a constituent of the BC6OTHER - cofactor, BC6OTHER is bound to a BC6OTHER , thus forming the BC6OTHER cofactor (Moco) which is the active compound at the catalytic site of all other BC6OTHER - enzymes.	False
With the exception of BC6ENTG , where BC6OTHER is a constituent of the BC6ENTC - cofactor, BC6OTHER is bound to a BC6OTHER , thus forming the BC6OTHER cofactor (Moco) which is the active compound at the catalytic site of all other BC6OTHER - enzymes.	False
With the exception of BC6ENTG , where BC6OTHER is a constituent of the BC6OTHER - cofactor, BC6ENTC is bound to a BC6OTHER , thus forming the BC6OTHER cofactor (Moco) which is the active compound at the catalytic site of all other BC6OTHER - enzymes.	False
With the exception of BC6ENTG , where BC6OTHER is a constituent of the BC6OTHER - cofactor, BC6OTHER is bound to a BC6ENTC , thus forming the BC6OTHER cofactor (Moco) which is the active compound at the catalytic site of all other BC6OTHER - enzymes.	False
With the exception of BC6ENTG , where BC6OTHER is a constituent of the BC6OTHER - cofactor, BC6OTHER is bound to a BC6OTHER , thus forming the BC6ENTC cofactor (Moco) which is the active compound at the catalytic site of all other BC6OTHER - enzymes.	False
With the exception of BC6ENTG , where BC6OTHER is a constituent of the BC6OTHER - cofactor, BC6OTHER is bound to a BC6OTHER , thus forming the BC6OTHER cofactor (Moco) which is the active compound at the catalytic site of all other BC6ENTC - enzymes.	False
In eukaryotes, the most prominent BC6ENTC - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6ENTC - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6ENTC - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6ENTC - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6ENTC - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6ENTC - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	CPR:9
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6ENTC - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6ENTC - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6ENTC assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6ENTC assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6ENTC assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6ENTC assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6ENTC and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6ENTC and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6ENTC and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6ENTC and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6ENTC , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6ENTC , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6ENTC , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6ENTC , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTC dehydrogenase, which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTC dehydrogenase, which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTC dehydrogenase, which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6ENTC catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6ENTC catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6ENTC catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6ENTC catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6ENTC production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6ENTC production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6ENTC production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6ENTC production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTC oxidase, which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTC oxidase, which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTC oxidase, which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6ENTC and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6ENTC and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6ENTC and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6ENTC and is essential for the biosynthesis of the CHEM BC6OTHER , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the phytohormone BC6ENTC , and in autotrophic organisms also (4) BC6ENTG , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6ENTG , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the phytohormone BC6ENTC , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6ENTG , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6OTHER , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the phytohormone BC6ENTC , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
In eukaryotes, the most prominent BC6OTHER - enzymes are (1) BC6OTHER , which catalyzes the final step in the degradation of BC6OTHER - containing BC6OTHER and is involved in detoxifying excess BC6OTHER , (2) BC6OTHER , which is involved in BC6OTHER catabolism and reactive BC6OTHER production, (3) BC6ENTG , which oxidizes a variety of BC6OTHER and is essential for the biosynthesis of the phytohormone BC6ENTC , and in autotrophic organisms also (4) BC6OTHER , which catalyzes the key step in inorganic BC6OTHER assimilation.	False
All BC6ENTC - enzymes, except BC6ENTG , need at least one more redox active center, many of them involving BC6OTHER in electron transfer.	False
All BC6OTHER - enzymes, except BC6ENTG , need at least one more redox active center, many of them involving BC6ENTC in electron transfer.	False
BC6ENTC dehydrogenase and BC6ENTG , but not BC6OTHER and BC6OTHER , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6ENTC dehydrogenase and BC6OTHER oxidase, but not BC6ENTG and BC6OTHER , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6ENTC dehydrogenase and BC6OTHER oxidase, but not BC6OTHER and BC6ENTG , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6ENTG and BC6ENTC oxidase, but not BC6OTHER and BC6OTHER , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6OTHER dehydrogenase and BC6ENTC oxidase, but not BC6ENTG and BC6OTHER , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
BC6OTHER dehydrogenase and BC6ENTC oxidase, but not BC6OTHER and BC6ENTG , require the post - translational sulfuration of their BC6OTHER - site for becoming active.	False
Oncogenic mutations in BC6ENTG , which encodes the BC6ENTC - 3 - kinase (PI3K) catalytic subunit p110α, occur in ∼25% of human breast cancers.	False
Whole - exome analysis of the BC6ENTG ( BC6OTHER ) - driven mammary tumors identified multiple mutations, including BC6ENTC 53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.	False
Whole - exome analysis of the BC6OTHER ( BC6ENTG ) - driven mammary tumors identified multiple mutations, including BC6ENTC 53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.	False
Further, we used this model to test the efficacy of BC6ENTC , a BC6ENTG inhibitor, in clinical development, and showed that the tumors respond to BC6OTHER inhibition.	CPR:4
Further, we used this model to test the efficacy of BC6ENTC , a BC6OTHER inhibitor, in clinical development, and showed that the tumors respond to BC6ENTG inhibition.	CPR:4
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two receptor BC6ENTC kinase inhibitors, BC6OTHER and BC6OTHER , were used to disrupt BC6ENTG - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6OTHER inhibition.	False
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two receptor BC6ENTC kinase inhibitors, BC6OTHER and BC6OTHER , were used to disrupt BC6OTHER - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6ENTG inhibition.	False
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two BC6ENTG inhibitors, BC6ENTC and BC6OTHER , were used to disrupt BC6OTHER - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6OTHER inhibition.	CPR:4
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two receptor BC6OTHER kinase inhibitors, BC6ENTC and BC6OTHER , were used to disrupt BC6ENTG - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6OTHER inhibition.	CPR:4
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two receptor BC6OTHER kinase inhibitors, BC6ENTC and BC6OTHER , were used to disrupt BC6OTHER - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6ENTG inhibition.	CPR:4
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two BC6ENTG inhibitors, BC6OTHER and BC6ENTC , were used to disrupt BC6OTHER - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6OTHER inhibition.	CPR:4
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two receptor BC6OTHER kinase inhibitors, BC6OTHER and BC6ENTC , were used to disrupt BC6ENTG - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6OTHER inhibition.	CPR:4
MATERIALS AND METHODS: Seeking to improve efficacy against otherwise intractable end - stage pancreatic islet tumors, two receptor BC6OTHER kinase inhibitors, BC6OTHER and BC6ENTC , were used to disrupt BC6OTHER - mediated pericyte support of tumor endothelial cells in concert with maximum - tolerated dose (MTD) or metronomic chemotherapy and / or BC6ENTG inhibition.	CPR:4
RESULTS: BC6ENTC , despite equivocal efficacy as monotherapy, reduced pericyte coverage of tumor vessels and enhanced efficacy in combination with metronomic chemotherapy or BC6ENTG inhibition.	CPR:4
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6ENTC reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6ENTC reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6ENTC reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6ENTC reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6ENTC reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6ENTC reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6ENTC , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6ENTC , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6ENTC , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6ENTC , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTC - ubiquinone oxidoreductase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTC - ubiquinone oxidoreductase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTC - ubiquinone oxidoreductase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTC - ubiquinone oxidoreductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTC - ubiquinone oxidoreductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC - cytochrome c oxidoreductase ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC - cytochrome c oxidoreductase ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Pre - irradiation administration of RP - 1 enhanced levels of BC6ENTC induced increase in BC6ENTG (upto 16 h), BC6OTHER (4 h) BC6OTHER activity (upto 24 h; p < 0.01) and inhibited the radiation - induced decrease in MMP significantly (24 h; p < 0.01).	CPR:3
Pre - irradiation administration of RP - 1 enhanced levels of BC6ENTC induced increase in BC6OTHER (upto 16 h), BC6ENTG (4 h) BC6OTHER activity (upto 24 h; p < 0.01) and inhibited the radiation - induced decrease in MMP significantly (24 h; p < 0.01).	CPR:3
Pre - irradiation administration of RP - 1 enhanced levels of BC6ENTC induced increase in BC6OTHER (upto 16 h), BC6OTHER (4 h) BC6ENTG activity (upto 24 h; p < 0.01) and inhibited the radiation - induced decrease in MMP significantly (24 h; p < 0.01).	CPR:3
Levels of BC6ENTC anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6ENTC anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6ENTC anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6ENTC anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6ENTC anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6ENTC anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6ENTC ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6ENTC ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6ENTC ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6ENTC ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6ENTC ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6ENTC ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6ENTC ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6ENTC ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6ENTC ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6ENTC ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6ENTC ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6ENTC ( BC6OTHER or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6ENTC or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6ENTC or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6ENTC or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6ENTC or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6ENTC or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6ENTC or BC6OTHER ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6ENTC ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6ENTC ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6ENTC ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6ENTC ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6ENTC ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Levels of BC6OTHER anion ( BC6OTHER ), reduced or oxidized BC6OTHER ( BC6OTHER or BC6ENTC ), BC6OTHER reactive substance (TBARS), protein CHEM (PC), BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and mitochondrial membrane potential (MMP) were studied in mitochondria isolated from liver of mice belonging to various treatment groups.	False
Among BC6OTHER , the four most potent compounds at the human BC6ENTC transporter were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTC transporter, BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC (K(D) 19 - 25 nM).	False
Among BC6OTHER , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC (K(D) 19 - 25 nM).	False
Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 BC6ENTC and one metabolite of a neuroleptic ( BC6OTHER metabolite) for the BC6ENTG BC6OTHER , and BC6OTHER transporters with BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	False
At the BC6ENTG , only BC6ENTC (K(D) = 69+ / - 3) BC6OTHER (K(D) = 76+ / - 5) had notable potency.	False
At the BC6ENTG , only BC6OTHER (K(D) = 69+ / - 3) BC6ENTC (K(D) = 76+ / - 5) had notable potency.	False
Pharmacological profile of BC6ENTC at BC6ENTG .	False
Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 BC6OTHER and one metabolite of a neuroleptic ( BC6ENTC metabolite) for the BC6ENTG BC6OTHER , and BC6OTHER transporters with BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	False
Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 BC6OTHER and one metabolite of a neuroleptic ( BC6OTHER metabolite) for the BC6ENTG BC6ENTC , and BC6OTHER transporters with BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	False
Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 BC6OTHER and one metabolite of a neuroleptic ( BC6OTHER metabolite) for the BC6ENTG BC6OTHER , and BC6ENTC transporters with BC6OTHER , BC6OTHER , and BC6OTHER , respectively.	False
Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 BC6OTHER and one metabolite of a neuroleptic ( BC6OTHER metabolite) for the BC6ENTG BC6OTHER , and BC6OTHER transporters with BC6ENTC , BC6OTHER , and BC6OTHER , respectively.	False
Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 BC6OTHER and one metabolite of a neuroleptic ( BC6OTHER metabolite) for the BC6ENTG BC6OTHER , and BC6OTHER transporters with BC6OTHER , BC6ENTC , and BC6OTHER , respectively.	False
Using radioligand binding techniques, we determined the equilibrium dissociation constants (K(D)) for 37 BC6OTHER and one metabolite of a neuroleptic ( BC6OTHER metabolite) for the BC6ENTG BC6OTHER , and BC6OTHER transporters with BC6OTHER , BC6OTHER , and BC6ENTC , respectively.	False
Among BC6ENTC , the four most potent compounds at the BC6ENTG were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
Among BC6ENTC , the four most potent compounds at the human BC6OTHER transporter were BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 24 - 39 nM); and at the BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER (K(D) 19 - 25 nM).	False
 BC6ENTC inhibits autophagic flux activating the BC6ENTG - BC6OTHER pathway in a BC6OTHER - dependent manner.	CPR:3
 BC6ENTC inhibits autophagic flux activating the BC6OTHER - BC6ENTG pathway in a BC6OTHER - dependent manner.	CPR:3
 BC6ENTC inhibits autophagic flux activating the BC6OTHER - BC6OTHER pathway in a BC6ENTG - dependent manner.	False
Collectively, these findings provide evidence that BC6ENTC causes prolonged activation of BC6ENTG through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of BC6OTHER found in certain human cancers.	CPR:3
Collectively, these findings provide evidence that BC6ENTC causes prolonged activation of BC6OTHER through autophagy dysfunction, possibly providing a similar scenario to constitutive activation of BC6ENTG found in certain human cancers.	CPR:3
BC6ENTC deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
BC6ENTC deregulates the autophagic pathway through blockage of autophagic flux, resulting in accumulation of autophagosomes and sequestration of BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
Thus, BC6ENTC activates BC6ENTG through a non - canonical mechanism ( BC6OTHER - dependent), leading to a chronic, sustained activation of BC6OTHER .	CPR:3
Thus, BC6ENTC activates BC6OTHER through a non - canonical mechanism ( BC6ENTG - dependent), leading to a chronic, sustained activation of BC6OTHER .	False
Thus, BC6ENTC activates BC6OTHER through a non - canonical mechanism ( BC6OTHER - dependent), leading to a chronic, sustained activation of BC6ENTG .	CPR:3
In contrast, activation of BC6ENTG by BC6ENTC and BC6OTHER depend upon BC6OTHER - C151 and not BC6OTHER (the canonical mechanism).	CPR:3
In contrast, activation of BC6OTHER by BC6ENTC and BC6OTHER depend upon BC6ENTG - C151 and not BC6OTHER (the canonical mechanism).	False
In contrast, activation of BC6OTHER by BC6ENTC and BC6OTHER depend upon BC6OTHER - C151 and not BC6ENTG (the canonical mechanism).	False
In contrast, activation of BC6ENTG by BC6OTHER and BC6ENTC depend upon BC6OTHER - C151 and not BC6OTHER (the canonical mechanism).	CPR:3
In contrast, activation of BC6OTHER by BC6OTHER and BC6ENTC depend upon BC6ENTG - C151 and not BC6OTHER (the canonical mechanism).	False
In contrast, activation of BC6OTHER by BC6OTHER and BC6ENTC depend upon BC6OTHER - C151 and not BC6ENTG (the canonical mechanism).	False
BC6ENTG acts as a BC6ENTC carboxypeptidase ( BC6OTHER ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6OTHER , and the neuropeptide BC6OTHER .	False
BC6OTHER acts as a BC6ENTC carboxypeptidase ( BC6ENTG ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6OTHER , and the neuropeptide BC6OTHER .	False
BC6ENTG acts as a BC6OTHER carboxypeptidase ( BC6OTHER ) on small molecule substrates, including BC6ENTC , the anticancer drug BC6OTHER , and the neuropeptide BC6OTHER .	CPR:9
BC6OTHER acts as a BC6ENTG ( BC6OTHER ) on small molecule substrates, including BC6ENTC , the anticancer drug BC6OTHER , and the neuropeptide BC6OTHER .	CPR:9
BC6OTHER acts as a BC6OTHER carboxypeptidase ( BC6ENTG ) on small molecule substrates, including BC6ENTC , the anticancer drug BC6OTHER , and the neuropeptide BC6OTHER .	CPR:9
BC6ENTG acts as a BC6OTHER carboxypeptidase ( BC6OTHER ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6ENTC , and the neuropeptide BC6OTHER .	CPR:9
BC6OTHER acts as a BC6ENTG ( BC6OTHER ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6ENTC , and the neuropeptide BC6OTHER .	CPR:9
BC6OTHER acts as a BC6OTHER carboxypeptidase ( BC6ENTG ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6ENTC , and the neuropeptide BC6OTHER .	CPR:9
BC6ENTG acts as a BC6OTHER carboxypeptidase ( BC6OTHER ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6OTHER , and the neuropeptide BC6ENTC .	CPR:9
BC6OTHER acts as a BC6ENTG ( BC6OTHER ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6OTHER , and the neuropeptide BC6ENTC .	CPR:9
BC6OTHER acts as a BC6OTHER carboxypeptidase ( BC6ENTG ) on small molecule substrates, including BC6OTHER , the anticancer drug BC6OTHER , and the neuropeptide BC6ENTC .	False
Here we present the 3.5 - A crystal structure of the BC6ENTG , which reveals a homodimer with structural similarity to BC6OTHER , a receptor for BC6ENTC - loaded BC6OTHER that lacks BC6OTHER activity.	False
Here we present the 3.5 - A crystal structure of the BC6OTHER , which reveals a homodimer with structural similarity to BC6ENTG , a receptor for BC6ENTC - loaded BC6OTHER that lacks BC6OTHER activity.	False
Here we present the 3.5 - A crystal structure of the BC6OTHER , which reveals a homodimer with structural similarity to BC6OTHER , a receptor for BC6ENTC - loaded BC6ENTG that lacks BC6OTHER activity.	False
Here we present the 3.5 - A crystal structure of the BC6OTHER , which reveals a homodimer with structural similarity to BC6OTHER , a receptor for BC6ENTC - loaded BC6OTHER that lacks BC6ENTG activity.	False
Unlike BC6ENTG , the BC6OTHER of BC6OTHER contains a binuclear BC6ENTC site, catalytic residues, and a proposed substrate - binding BC6OTHER patch.	False
Unlike BC6OTHER , the BC6ENTG of BC6OTHER contains a binuclear BC6ENTC site, catalytic residues, and a proposed substrate - binding BC6OTHER patch.	False
Unlike BC6OTHER , the BC6OTHER of BC6ENTG contains a binuclear BC6ENTC site, catalytic residues, and a proposed substrate - binding BC6OTHER patch.	False
Unlike BC6ENTG , the BC6OTHER of BC6OTHER contains a binuclear BC6OTHER site, catalytic residues, and a proposed substrate - binding BC6ENTC patch.	False
Unlike BC6OTHER , the BC6ENTG of BC6OTHER contains a binuclear BC6OTHER site, catalytic residues, and a proposed substrate - binding BC6ENTC patch.	False
Unlike BC6OTHER , the BC6OTHER of BC6ENTG contains a binuclear BC6OTHER site, catalytic residues, and a proposed substrate - binding BC6ENTC patch.	False
Elucidation of the BC6ENTG structure combined with docking studies and a proposed catalytic mechanism provides insight into the recognition of inhibitors and the natural substrate BC6ENTC .	CPR:9
Detailed structure - activity relationships of the C3 - BC6OTHER moiety that allow for the optimization of antiviral potency of a series of BC6ENTC inhibitors of BC6ENTG ( BC6OTHER ) assembly are described.	CPR:4
Detailed structure - activity relationships of the C3 - BC6OTHER moiety that allow for the optimization of antiviral potency of a series of BC6ENTC inhibitors of BC6OTHER ( BC6ENTG ) assembly are described.	CPR:4
Detailed structure - activity relationships of the C3 - BC6ENTC moiety that allow for the optimization of antiviral potency of a series of BC6OTHER inhibitors of BC6ENTG ( BC6OTHER ) assembly are described.	False
Detailed structure - activity relationships of the C3 - BC6ENTC moiety that allow for the optimization of antiviral potency of a series of BC6OTHER inhibitors of BC6OTHER ( BC6ENTG ) assembly are described.	False
Optimization of a BC6OTHER series of BC6ENTG assembly inhibitors 2: Structure - activity relationships (SAR) of the C3 - BC6ENTC moiety.	CPR:4
Optimization of a BC6ENTC series of BC6ENTG assembly inhibitors 2: Structure - activity relationships (SAR) of the C3 - BC6OTHER moiety.	CPR:4
The parallel pattern of accumulation of 24:6n - 3 and BC6OTHER in response to increasing concentrations of BC6OTHER suggests that the competition between 24:5n - 3 and BC6OTHER for BC6ENTG may contribute to the limited accumulation of BC6ENTC in cell membranes.	CPR:9
The use of BC6ENTG ( BC6OTHER ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6ENTC from BC6OTHER .	CPR:9
The use of BC6OTHER ( BC6ENTG ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6ENTC from BC6OTHER .	CPR:9
The use of BC6ENTG ( BC6OTHER ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6ENTC .	CPR:9
The use of BC6OTHER ( BC6ENTG ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6ENTC .	CPR:9
The use of BC6ENTG ( BC6OTHER ) twice in the conversion of BC6ENTC ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The use of BC6OTHER ( BC6ENTG ) twice in the conversion of BC6ENTC ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The accumulation of the post - BC6ENTG products of 22:5n - 3, 24:6n - 3 and BC6ENTC , in cell phospholipids was saturated at concentrations of >18 microM BC6OTHER .	CPR:9
The accumulation of the post - BC6ENTG products of 22:5n - 3, 24:6n - 3 and BC6OTHER , in cell phospholipids was saturated at concentrations of >18 microM BC6ENTC .	False
The use of BC6ENTG ( BC6OTHER ) twice in the conversion of BC6OTHER ( BC6ENTC ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The use of BC6OTHER ( BC6ENTG ) twice in the conversion of BC6OTHER ( BC6ENTC ; 18:3n - 3) to BC6OTHER ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The use of BC6ENTG ( BC6OTHER ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6ENTC ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The use of BC6OTHER ( BC6ENTG ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6ENTC ( BC6OTHER ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The parallel pattern of accumulation of 24:6n - 3 and BC6ENTC in response to increasing concentrations of BC6OTHER suggests that the competition between 24:5n - 3 and BC6OTHER for BC6ENTG may contribute to the limited accumulation of BC6OTHER in cell membranes.	False
The parallel pattern of accumulation of 24:6n - 3 and BC6OTHER in response to increasing concentrations of BC6ENTC suggests that the competition between 24:5n - 3 and BC6OTHER for BC6ENTG may contribute to the limited accumulation of BC6OTHER in cell membranes.	False
The use of BC6ENTG ( BC6OTHER ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6ENTC ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The use of BC6OTHER ( BC6ENTG ) twice in the conversion of BC6OTHER ( BC6OTHER ; 18:3n - 3) to BC6OTHER ( BC6ENTC ; 22:6n - 3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of BC6OTHER from BC6OTHER .	CPR:9
The parallel pattern of accumulation of 24:6n - 3 and BC6OTHER in response to increasing concentrations of BC6OTHER suggests that the competition between 24:5n - 3 and BC6ENTC for BC6ENTG may contribute to the limited accumulation of BC6OTHER in cell membranes.	CPR:9
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTG ( BC6OTHER ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6ENTC inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6ENTG ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6ENTC inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6OTHER ) - positive or BC6ENTG - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6ENTC inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTG ( BC6OTHER ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6ENTC ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6ENTG ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6ENTC ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6OTHER ) - positive or BC6ENTG - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6ENTC ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTC receptor ( BC6ENTG ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTC receptor ( BC6OTHER ) - positive or BC6ENTG - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTG ( BC6OTHER ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6ENTC , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6ENTG ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6ENTC , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6OTHER ) - positive or BC6ENTG - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6ENTC , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTG ( BC6OTHER ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6ENTC , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6ENTG ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6ENTC , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6OTHER ) - positive or BC6ENTG - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6ENTC , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTG ( BC6OTHER ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6ENTC inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6ENTG ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6ENTC inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6OTHER ) - positive or BC6ENTG - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6ENTC inverted question markCAF) or chemohormonal therapy (CHEM plus BC6OTHER and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6ENTG ( BC6OTHER ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6ENTC and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6ENTG ) - positive or BC6OTHER - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6ENTC and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with BC6OTHER receptor ( BC6OTHER ) - positive or BC6ENTG - unknown metastatic breast cancer were randomized to receive either chemotherapy ( BC6OTHER , BC6OTHER , and BC6OTHER inverted question markCAF) or chemohormonal therapy (CHEM plus BC6ENTC and BC6OTHER inverted question mark BC6OTHER ; Pharmacia - Upjohn, Kalamazoo, MI inverted question markCAFTH) as front - line therapy for metastatic breast cancer.	False
In the present study, we show that mice lacking BC6ENTG did not show BC6ENTC - induced flushing.	False
In addition, flushing in response to BC6ENTC was also abrogated in the absence of BC6ENTG , and mice lacking CHEM ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors had reduced flushing responses.	False
In addition, flushing in response to BC6ENTC was also abrogated in the absence of BC6OTHER , and mice lacking BC6ENTG BC6OTHER ( BC6OTHER ) receptors had reduced flushing responses.	False
In addition, flushing in response to BC6OTHER was also abrogated in the absence of BC6ENTG , and mice lacking BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) receptors had reduced flushing responses.	False
In addition, flushing in response to BC6OTHER was also abrogated in the absence of BC6ENTG , and mice lacking CHEM ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) receptors had reduced flushing responses.	False
In addition, flushing in response to BC6OTHER was also abrogated in the absence of BC6ENTG , and mice lacking CHEM ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) receptors had reduced flushing responses.	False
In addition, flushing in response to BC6OTHER was also abrogated in the absence of BC6OTHER , and mice lacking BC6ENTG BC6ENTC ( BC6OTHER ) receptors had reduced flushing responses.	False
In addition, flushing in response to BC6OTHER was also abrogated in the absence of BC6ENTG , and mice lacking CHEM ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) receptors had reduced flushing responses.	False
In addition, flushing in response to BC6OTHER was also abrogated in the absence of BC6OTHER , and mice lacking BC6ENTG BC6OTHER ( BC6ENTC ) receptors had reduced flushing responses.	False
 BC6ENTG ( BC6OTHER / BC6OTHER ) mediates BC6ENTC - induced flushing.	False
 BC6OTHER ( BC6OTHER / BC6ENTG ) mediates BC6ENTC - induced flushing.	False
 BC6OTHER ( BC6ENTG / BC6OTHER ) mediates BC6ENTC - induced flushing.	False
The mouse orthologue of BC6OTHER , BC6ENTG , is highly expressed in macrophages and other immune cells, and transplantation of wild - type bone marrow into irradiated BC6OTHER - deficient mice restored the BC6ENTC - induced flushing response.	False
The mouse orthologue of BC6OTHER , BC6OTHER , is highly expressed in macrophages and other immune cells, and transplantation of wild - type bone marrow into irradiated BC6ENTG - deficient mice restored the BC6ENTC - induced flushing response.	False
The mouse orthologue of BC6ENTG , BC6OTHER , is highly expressed in macrophages and other immune cells, and transplantation of wild - type bone marrow into irradiated BC6OTHER - deficient mice restored the BC6ENTC - induced flushing response.	False
Our data clearly indicate that BC6ENTG mediates BC6ENTC - induced flushing and that this effect involves release of BC6OTHER and BC6OTHER , most likely from immune cells of the skin.	False
Its special profile of actions, especially the rise in BC6ENTG - BC6ENTC levels induced by BC6OTHER , is unique among the currently available pharmacological tools to treat lipid disorders.	False
Our data clearly indicate that BC6ENTG mediates BC6OTHER - induced flushing and that this effect involves release of BC6ENTC and BC6OTHER , most likely from immune cells of the skin.	False
Our data clearly indicate that BC6ENTG mediates BC6OTHER - induced flushing and that this effect involves release of BC6OTHER and BC6ENTC , most likely from immune cells of the skin.	False
Its special profile of actions, especially the rise in BC6ENTG - BC6OTHER levels induced by BC6ENTC , is unique among the currently available pharmacological tools to treat lipid disorders.	CPR:3
Recently, a BC6ENTG , termed BC6OTHER ( BC6OTHER in humans, BC6OTHER in mice), was described and shown to mediate the BC6ENTC - induced antilipolytic effects in adipocytes.	False
Recently, a BC6OTHER , termed BC6ENTG ( BC6OTHER in humans, BC6OTHER in mice), was described and shown to mediate the BC6ENTC - induced antilipolytic effects in adipocytes.	False
Recently, a BC6OTHER , termed BC6OTHER ( BC6ENTG in humans, BC6OTHER in mice), was described and shown to mediate the BC6ENTC - induced antilipolytic effects in adipocytes.	False
Recently, a BC6OTHER , termed BC6OTHER ( BC6OTHER in humans, BC6ENTG in mice), was described and shown to mediate the BC6ENTC - induced antilipolytic effects in adipocytes.	False
[The effects of BC6ENTC on BC6ENTG of liver and sexual glands in burned rats].	False
CONCLUSION: BC6ENTC up - regulated the density of BC6ENTG in liver tissue, whereas it had no significant effects on the density of BC6OTHER in testis and ovary tissues.	CPR:3
CONCLUSION: BC6ENTC up - regulated the density of BC6OTHER in liver tissue, whereas it had no significant effects on the density of BC6ENTG in testis and ovary tissues.	False
OBJECTIVE: To assess the effects of BC6ENTC ( BC6OTHER ) on BC6ENTG ( BC6OTHER ) of liver and sexual glands in burned rats for supporting the clinical application of anabolic CHEM.	False
OBJECTIVE: To assess the effects of BC6ENTC ( BC6OTHER ) on BC6OTHER ( BC6ENTG ) of liver and sexual glands in burned rats for supporting the clinical application of anabolic CHEM.	False
OBJECTIVE: To assess the effects of BC6OTHER ( BC6ENTC ) on BC6ENTG ( BC6OTHER ) of liver and sexual glands in burned rats for supporting the clinical application of anabolic CHEM.	False
OBJECTIVE: To assess the effects of BC6OTHER ( BC6ENTC ) on BC6OTHER ( BC6ENTG ) of liver and sexual glands in burned rats for supporting the clinical application of anabolic CHEM.	False
RESULTS: The density of BC6ENTG in liver tissue in BC6ENTC group was higher than that in control group (P < 0.05).	CPR:3
The density of BC6ENTG in testis and ovary tissues showed no significant difference between BC6ENTC group and control group at every time - point (P > 0.05).	False
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ).	CPR:6
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6ENTG - BC6ENTC - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTC - BC6OTHER system at the level of the BC6ENTG receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTC - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTG , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTC - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6ENTG inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTG antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTC - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6ENTG - BC6OTHER - BC6ENTC system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTG - BC6ENTC system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6ENTC system at the level of the BC6ENTG receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6ENTC system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTG , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6ENTC system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6ENTG inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTG antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6ENTC system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6ENTG - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTC , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTG - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTC , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6ENTG receptor that mediates most, if not all, of the important actions of BC6ENTC , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTC , and avoid the nonspecificity of the BC6ENTG inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTG antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTC , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6ENTG - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6ENTC converting enzyme inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTG - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6ENTC converting enzyme inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6ENTG receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6ENTC converting enzyme inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6OTHER antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTG , and avoid the nonspecificity of the BC6ENTC converting enzyme inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTG antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6ENTC converting enzyme inhibitors.	False
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6OTHER 1, BC6OTHER 10, BC6OTHER (the active metabolite of BC6ENTC ) 10, BC6OTHER 20, BC6OTHER 50, BC6OTHER 100 and the prodrug BC6OTHER 280.	CPR:6
BC6ENTC was the first, but by no means remained the only, BC6ENTG receptor antagonist.	CPR:6
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTC type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6ENTG - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTC type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6ENTG - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTC type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6ENTG receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTC type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6ENTG , and avoid the nonspecificity of the BC6OTHER inhibitors.	False
The availability of selective, potent, orally active and long acting nonpeptide BC6ENTC type 1 (AT1) receptor antagonists has provided the opportunity to obtain the benefits of selectively blocking the BC6OTHER - BC6OTHER - BC6OTHER system at the level of the BC6OTHER receptor that mediates most, if not all, of the important actions of BC6OTHER , and avoid the nonspecificity of the BC6ENTG inhibitors.	False
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6OTHER 1, BC6OTHER 10, BC6OTHER (the active metabolite of BC6OTHER ) 10, BC6ENTC 20, BC6OTHER 50, BC6OTHER 100 and the prodrug BC6OTHER 280.	CPR:6
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6ENTC 1, BC6OTHER 10, BC6OTHER (the active metabolite of BC6OTHER ) 10, BC6OTHER 20, BC6OTHER 50, BC6OTHER 100 and the prodrug BC6OTHER 280.	CPR:6
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6OTHER 1, BC6ENTC 10, BC6OTHER (the active metabolite of BC6OTHER ) 10, BC6OTHER 20, BC6OTHER 50, BC6OTHER 100 and the prodrug BC6OTHER 280.	CPR:6
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6OTHER 1, BC6OTHER 10, BC6ENTC (the active metabolite of BC6OTHER ) 10, BC6OTHER 20, BC6OTHER 50, BC6OTHER 100 and the prodrug BC6OTHER 280.	CPR:6
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6OTHER 1, BC6OTHER 10, BC6OTHER (the active metabolite of BC6OTHER ) 10, BC6OTHER 20, BC6ENTC 50, BC6OTHER 100 and the prodrug BC6OTHER 280.	CPR:6
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6OTHER 1, BC6OTHER 10, BC6OTHER (the active metabolite of BC6OTHER ) 10, BC6OTHER 20, BC6OTHER 50, BC6ENTC 100 and the prodrug BC6OTHER 280.	CPR:6
Among the current BC6ENTG receptor antagonists, the rank order of the relative binding affinities (highest affinity = 1) is: BC6OTHER 1, BC6OTHER 10, BC6OTHER (the active metabolite of BC6OTHER ) 10, BC6OTHER 20, BC6OTHER 50, BC6OTHER 100 and the prodrug BC6ENTC 280.	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6ENTC , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6ENTC , BC6OTHER ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6ENTC ) or insurmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
The mode of (functional) BC6ENTG receptor antagonism has been characterized as surmountable / noncompetitive ( BC6OTHER , BC6OTHER , BC6OTHER ) or insurmountable / noncompetitive ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ).	CPR:6
BC6ENTC inhibits BC6ENTG and has shown therapeutic effects in patients with hematologic malignancies.	CPR:4
BC6OTHER treatment of the cells largely prevented the activation of BC6ENTG , a regulator of translation initiation and substrate of the mammalian target of BC6ENTC ( BC6OTHER ).	False
BC6OTHER treatment of the cells largely prevented the activation of BC6OTHER , a regulator of translation initiation and substrate of the mammalian target of BC6ENTC ( BC6ENTG ).	False
"By ""working upwards"" from BC6ENTG , we observed that BC6ENTC inhibited endogenous and BC6OTHER - induced BC6OTHER and BC6OTHER activation by interfering with BC6OTHER phosphorylation of BC6OTHER ."	False
"By ""working upwards"" from BC6OTHER , we observed that BC6ENTC inhibited endogenous and BC6ENTG - induced BC6OTHER and BC6OTHER activation by interfering with BC6OTHER phosphorylation of BC6OTHER ."	CPR:4
"By ""working upwards"" from BC6OTHER , we observed that BC6ENTC inhibited endogenous and BC6OTHER - induced BC6ENTG and BC6OTHER activation by interfering with BC6OTHER phosphorylation of BC6OTHER ."	CPR:4
"By ""working upwards"" from BC6OTHER , we observed that BC6ENTC inhibited endogenous and BC6OTHER - induced BC6OTHER and BC6ENTG activation by interfering with BC6OTHER phosphorylation of BC6OTHER ."	CPR:4
"By ""working upwards"" from BC6OTHER , we observed that BC6ENTC inhibited endogenous and BC6OTHER - induced BC6OTHER and BC6OTHER activation by interfering with BC6OTHER phosphorylation of BC6ENTG ."	False
"By ""working upwards"" from BC6ENTG , we observed that BC6OTHER inhibited endogenous and BC6OTHER - induced BC6OTHER and BC6OTHER activation by interfering with BC6ENTC phosphorylation of BC6OTHER ."	False
"By ""working upwards"" from BC6OTHER , we observed that BC6OTHER inhibited endogenous and BC6ENTG - induced BC6OTHER and BC6OTHER activation by interfering with BC6ENTC phosphorylation of BC6OTHER ."	False
"By ""working upwards"" from BC6OTHER , we observed that BC6OTHER inhibited endogenous and BC6OTHER - induced BC6ENTG and BC6OTHER activation by interfering with BC6ENTC phosphorylation of BC6OTHER ."	False
"By ""working upwards"" from BC6OTHER , we observed that BC6OTHER inhibited endogenous and BC6OTHER - induced BC6OTHER and BC6ENTG activation by interfering with BC6ENTC phosphorylation of BC6OTHER ."	False
"By ""working upwards"" from BC6OTHER , we observed that BC6OTHER inhibited endogenous and BC6OTHER - induced BC6OTHER and BC6OTHER activation by interfering with BC6ENTC phosphorylation of BC6ENTG ."	False
This inhibition was mediated by a BC6ENTC - induced secreted factor which was identified as BC6ENTG ( BC6OTHER ).	CPR:3
This inhibition was mediated by a BC6ENTC - induced secreted factor which was identified as BC6OTHER ( BC6ENTG ).	CPR:3
 BC6ENTC induces the expression of BC6ENTG in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on BC6OTHER toxicity.	CPR:3
 BC6OTHER induces the expression of BC6ENTG in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on BC6ENTC toxicity.	False
The induction of BC6ENTG protein was dependent on a functional BC6ENTC receptor and was preceded by a rapid increase in the level of BC6OTHER mRNA indicating that BC6OTHER is a previously unknown transcriptional target of BC6OTHER in 5L cells.	False
The induction of BC6OTHER protein was dependent on a functional BC6ENTC receptor and was preceded by a rapid increase in the level of BC6ENTG mRNA indicating that BC6OTHER is a previously unknown transcriptional target of BC6OTHER in 5L cells.	False
The induction of BC6OTHER protein was dependent on a functional BC6ENTC receptor and was preceded by a rapid increase in the level of BC6OTHER mRNA indicating that BC6ENTG is a previously unknown transcriptional target of BC6OTHER in 5L cells.	False
The induction of BC6ENTG protein was dependent on a functional BC6OTHER receptor and was preceded by a rapid increase in the level of BC6OTHER mRNA indicating that BC6OTHER is a previously unknown transcriptional target of BC6ENTC in 5L cells.	False
The induction of BC6OTHER protein was dependent on a functional BC6ENTG and was preceded by a rapid increase in the level of BC6OTHER mRNA indicating that BC6OTHER is a previously unknown transcriptional target of BC6ENTC in 5L cells.	False
The induction of BC6OTHER protein was dependent on a functional BC6OTHER receptor and was preceded by a rapid increase in the level of BC6ENTG mRNA indicating that BC6OTHER is a previously unknown transcriptional target of BC6ENTC in 5L cells.	CPR:4
The induction of BC6OTHER protein was dependent on a functional BC6OTHER receptor and was preceded by a rapid increase in the level of BC6OTHER mRNA indicating that BC6ENTG is a previously unknown transcriptional target of BC6ENTC in 5L cells.	False
BC6ENTG was not induced by BC6ENTC in the parental cell line of 5L cells, Fao, and in various closely related rat hepatoma cell lines as well as in other unrelated cell types.	False
The observations suggest that in 5L cells the BC6ENTG gene may have got under the control of a promoter containing BC6ENTC responsive element(s) leading to the induction of BC6OTHER by BC6OTHER .	False
The observations suggest that in 5L cells the BC6OTHER gene may have got under the control of a promoter containing BC6ENTC responsive element(s) leading to the induction of BC6ENTG by BC6OTHER .	False
The observations suggest that in 5L cells the BC6ENTG gene may have got under the control of a promoter containing BC6OTHER responsive element(s) leading to the induction of BC6OTHER by BC6ENTC .	False
The observations suggest that in 5L cells the BC6OTHER gene may have got under the control of a promoter containing BC6ENTG leading to the induction of BC6OTHER by BC6ENTC .	False
The observations suggest that in 5L cells the BC6OTHER gene may have got under the control of a promoter containing BC6OTHER responsive element(s) leading to the induction of BC6ENTG by BC6ENTC .	CPR:3
BC6ENTC treatment of the cells largely prevented the activation of BC6ENTG , a regulator of translation initiation and substrate of the mammalian target of BC6OTHER ( BC6OTHER ).	False
BC6ENTC treatment of the cells largely prevented the activation of BC6OTHER , a regulator of translation initiation and substrate of the BC6ENTG ( BC6OTHER ).	False
BC6ENTC treatment of the cells largely prevented the activation of BC6OTHER , a regulator of translation initiation and substrate of the mammalian target of BC6OTHER ( BC6ENTG ).	False
 BC6ENTC upregulates the expression of BC6ENTG in mouse aortic endothelial cells.	CPR:3
Finally, SA - induced BC6OTHER expression was found to be prevented both by CHEM and specific BC6ENTG inhibitor, BC6ENTC , strongly indicating that BC6OTHER upregulation is a result of the ROS - mediated activation of the BC6OTHER signaling pathway.	CPR:4
Finally, SA - induced BC6OTHER expression was found to be prevented both by CHEM and specific BC6OTHER inhibitor, BC6ENTC , strongly indicating that BC6ENTG upregulation is a result of the ROS - mediated activation of the BC6OTHER signaling pathway.	False
Finally, SA - induced BC6OTHER expression was found to be prevented both by CHEM and specific BC6OTHER inhibitor, BC6ENTC , strongly indicating that BC6OTHER upregulation is a result of the ROS - mediated activation of the BC6ENTG signaling pathway.	False
Finally, SA - induced BC6ENTG expression was found to be prevented both by CHEM and specific BC6OTHER inhibitor, BC6ENTC , strongly indicating that BC6OTHER upregulation is a result of the ROS - mediated activation of the BC6OTHER signaling pathway.	CPR:4
Taken together, our results indicate that BC6ENTC indeed upregulates the BC6ENTG expression, thus highlighting a role of BC6OTHER - induced aberrant BC6OTHER signaling in the pathogenesis of hypertension.	CPR:3
Taken together, our results indicate that BC6ENTC indeed upregulates the BC6OTHER expression, thus highlighting a role of BC6OTHER - induced aberrant BC6ENTG signaling in the pathogenesis of hypertension.	False
Taken together, our results indicate that BC6OTHER indeed upregulates the BC6ENTG expression, thus highlighting a role of BC6ENTC - induced aberrant BC6OTHER signaling in the pathogenesis of hypertension.	False
Taken together, our results indicate that BC6OTHER indeed upregulates the BC6OTHER expression, thus highlighting a role of BC6ENTC - induced aberrant BC6ENTG signaling in the pathogenesis of hypertension.	CPR:3
To delineate the pathogenesis, we examined changes in the mRNA levels of 2 BC6ENTG ( BC6OTHER ) subtypes, BC6OTHER and BC6OTHER , in a mouse aortic endothelial cell line, END - D. Quantitative real - time PCR analysis revealed significant increases in the mRNA levels of 2 BC6OTHER subtypes, BC6OTHER and BC6OTHER following BC6ENTC (SA) treatment.	False
To delineate the pathogenesis, we examined changes in the mRNA levels of 2 BC6OTHER ( BC6ENTG ) subtypes, BC6OTHER and BC6OTHER , in a mouse aortic endothelial cell line, END - D. Quantitative real - time PCR analysis revealed significant increases in the mRNA levels of 2 BC6OTHER subtypes, BC6OTHER and BC6OTHER following BC6ENTC (SA) treatment.	False
To delineate the pathogenesis, we examined changes in the mRNA levels of 2 BC6OTHER ( BC6OTHER ) subtypes, BC6ENTG and BC6OTHER , in a mouse aortic endothelial cell line, END - D. Quantitative real - time PCR analysis revealed significant increases in the mRNA levels of 2 BC6OTHER subtypes, BC6OTHER and BC6OTHER following BC6ENTC (SA) treatment.	False
To delineate the pathogenesis, we examined changes in the mRNA levels of 2 BC6OTHER ( BC6OTHER ) subtypes, BC6OTHER and BC6ENTG , in a mouse aortic endothelial cell line, END - D. Quantitative real - time PCR analysis revealed significant increases in the mRNA levels of 2 BC6OTHER subtypes, BC6OTHER and BC6OTHER following BC6ENTC (SA) treatment.	False
To delineate the pathogenesis, we examined changes in the mRNA levels of 2 BC6OTHER ( BC6OTHER ) subtypes, BC6OTHER and BC6OTHER , in a mouse aortic endothelial cell line, END - D. Quantitative real - time PCR analysis revealed significant increases in the mRNA levels of 2 BC6ENTG subtypes, BC6OTHER and BC6OTHER following BC6ENTC (SA) treatment.	CPR:3
To delineate the pathogenesis, we examined changes in the mRNA levels of 2 BC6OTHER ( BC6OTHER ) subtypes, BC6OTHER and BC6OTHER , in a mouse aortic endothelial cell line, END - D. Quantitative real - time PCR analysis revealed significant increases in the mRNA levels of 2 BC6OTHER subtypes, BC6ENTG and BC6OTHER following BC6ENTC (SA) treatment.	CPR:3
To delineate the pathogenesis, we examined changes in the mRNA levels of 2 BC6OTHER ( BC6OTHER ) subtypes, BC6OTHER and BC6OTHER , in a mouse aortic endothelial cell line, END - D. Quantitative real - time PCR analysis revealed significant increases in the mRNA levels of 2 BC6OTHER subtypes, BC6OTHER and BC6ENTG following BC6ENTC (SA) treatment.	CPR:3
In addition, western blot analysis revealed that SA enhances the phosphorylations of c - Jun BC6ENTC - terminal kinases ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
In addition, western blot analysis revealed that SA enhances the phosphorylations of c - Jun BC6ENTC - terminal kinases ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
In addition, western blot analysis revealed that SA enhances the phosphorylations of c - Jun BC6ENTC - terminal kinases ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
BC6OTHER is a more potent BC6ENTG inhibitor than is BC6ENTC .	CPR:4
Acetylation of BC6ENTC at the BC6OTHER position presumably interferes with the inhibition of the BC6ENTG enzymes for BC6OTHER and BC6OTHER .	CPR:4
Acetylation of BC6OTHER at the BC6ENTC position presumably interferes with the inhibition of the BC6ENTG enzymes for BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC is a relatively potent inhibitor of BC6ENTG and causes increases in whole - brain levels of BC6OTHER and BC6OTHER , and decreases in BC6OTHER , BC6OTHER , and BC6OTHER after acute i.p.	False
Acetylation of BC6OTHER at the BC6OTHER position presumably interferes with the inhibition of the BC6ENTG enzymes for BC6ENTC and BC6OTHER .	CPR:4
Acetylation of BC6OTHER at the BC6OTHER position presumably interferes with the inhibition of the BC6ENTG enzymes for BC6OTHER and BC6ENTC .	CPR:4
BC6OTHER is a relatively potent inhibitor of BC6ENTG and causes increases in whole - brain levels of BC6ENTC and BC6OTHER , and decreases in BC6OTHER , BC6OTHER , and BC6OTHER after acute i.p.	False
BC6OTHER is a relatively potent inhibitor of BC6ENTG and causes increases in whole - brain levels of BC6OTHER and BC6ENTC , and decreases in BC6OTHER , BC6OTHER , and BC6OTHER after acute i.p.	False
BC6OTHER is a relatively potent inhibitor of BC6ENTG and causes increases in whole - brain levels of BC6OTHER and BC6OTHER , and decreases in BC6ENTC , BC6OTHER , and BC6OTHER after acute i.p.	False
BC6OTHER is a relatively potent inhibitor of BC6ENTG and causes increases in whole - brain levels of BC6OTHER and BC6OTHER , and decreases in BC6OTHER , BC6ENTC , and BC6OTHER after acute i.p.	False
BC6OTHER is a relatively potent inhibitor of BC6ENTG and causes increases in whole - brain levels of BC6OTHER and BC6OTHER , and decreases in BC6OTHER , BC6OTHER , and BC6ENTC after acute i.p.	False
BC6ENTC is a more potent BC6ENTG inhibitor than is BC6OTHER .	CPR:4
Here, we tested the hypothesis that BC6ENTC receptors mediate BC6ENTG activation by measuring agonist - stimulated BC6OTHER ( BC6OTHER ) formation in BAEC cultures.	False
Here, we tested the hypothesis that BC6ENTG mediate BC6OTHER activation by measuring agonist - stimulated BC6ENTC ( BC6OTHER ) formation in BAEC cultures.	False
Here, we tested the hypothesis that BC6OTHER mediate BC6ENTG activation by measuring agonist - stimulated BC6ENTC ( BC6OTHER ) formation in BAEC cultures.	CPR:9
Here, we tested the hypothesis that BC6ENTG mediate BC6OTHER activation by measuring agonist - stimulated BC6OTHER ( BC6ENTC ) formation in BAEC cultures.	False
Here, we tested the hypothesis that BC6OTHER mediate BC6ENTG activation by measuring agonist - stimulated BC6OTHER ( BC6ENTC ) formation in BAEC cultures.	CPR:9
We found that BC6ENTC stimulated the conversion of BC6OTHER ( BC6OTHER ) to BC6OTHER , indicating BC6ENTG activation.	CPR:3
We found that BC6OTHER stimulated the conversion of BC6ENTC ( BC6OTHER ) to BC6OTHER , indicating BC6ENTG activation.	CPR:9
We found that BC6OTHER stimulated the conversion of BC6OTHER ( BC6ENTC ) to BC6OTHER , indicating BC6ENTG activation.	CPR:9
We found that BC6OTHER stimulated the conversion of BC6OTHER ( BC6OTHER ) to BC6ENTC , indicating BC6ENTG activation.	CPR:9
The high affinity BC6ENTG receptor agonist, BC6ENTC (5 - NOT) - stimulated BC6OTHER turnover responses were concentration - (0.01 nM to 100 microM) and time - dependent.	CPR:5
The high affinity BC6ENTG receptor agonist, BC6OTHER (5 - NOT) - stimulated BC6ENTC turnover responses were concentration - (0.01 nM to 100 microM) and time - dependent.	False
Activation of BC6ENTG ( BC6OTHER ) results in the production of BC6ENTC ( BC6OTHER ) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
Activation of endothelial BC6OTHER synthase ( BC6ENTG ) results in the production of BC6ENTC ( BC6OTHER ) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6ENTG selective antagonists (0.01 - 10 microM): BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:6
These responses were effectively blocked by the BC6ENTG receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6ENTG / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6ENTG antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Activation of BC6ENTG ( BC6OTHER ) results in the production of BC6OTHER ( BC6ENTC ) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
Activation of endothelial BC6OTHER synthase ( BC6ENTG ) results in the production of BC6OTHER ( BC6ENTC ) that mediates the vasorelaxing properties of endothelial cells.	CPR:9
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6ENTC , and the BC6ENTG selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
These responses were effectively blocked by the BC6ENTG receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6ENTC , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6ENTG / BC6OTHER antagonist, BC6ENTC , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:6
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6ENTG antagonist, BC6ENTC , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:6
 BC6ENTC evokes BC6ENTG activation in bovine aortic endothelial cell cultures.	CPR:3
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6ENTG selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	CPR:6
These responses were effectively blocked by the BC6ENTG receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6ENTG / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6ENTG antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6ENTG selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	CPR:6
These responses were effectively blocked by the BC6ENTG receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6ENTG / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6ENTG antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6ENTG selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	CPR:6
These responses were effectively blocked by the BC6ENTG receptor antagonist, CHEM, the BC6OTHER / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6ENTG / BC6OTHER antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
These responses were effectively blocked by the BC6OTHER receptor antagonist, CHEM, the BC6OTHER / BC6ENTG antagonist, BC6OTHER , and the BC6OTHER selective antagonists (0.01 - 10 microM): BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ).	False
These findings lend evidence of a BC6ENTG receptor / BC6OTHER pathway, accounting in part for the activation of BC6OTHER by BC6ENTC .	False
These findings lend evidence of a BC6OTHER receptor / BC6ENTG pathway, accounting in part for the activation of BC6OTHER by BC6ENTC .	False
These findings lend evidence of a BC6OTHER receptor / BC6OTHER pathway, accounting in part for the activation of BC6ENTG by BC6ENTC .	CPR:3
Further investigation is needed to determine the role of other vascular BC6ENTC receptors in the stimulation of BC6ENTG activity.	False
The goal of this project was to address the possibility that BC6ENTC ( BC6OTHER ) stimulates BC6ENTG activity in bovine aortic endothelial cell (BAEC) cultures.	False
The goal of this project was to address the possibility that BC6OTHER ( BC6ENTC ) stimulates BC6ENTG activity in bovine aortic endothelial cell (BAEC) cultures.	False
Activation of endothelial BC6ENTC synthase ( BC6ENTG ) results in the production of BC6OTHER ( BC6OTHER ) that mediates the vasorelaxing properties of endothelial cells.	False
Almost all patients with BC6ENTG (38 / 41) or BC6OTHER (5 / 7) mutations were resistant to BC6ENTC .	False
Almost all patients with BC6OTHER (38 / 41) or BC6ENTG (5 / 7) mutations were resistant to BC6ENTC .	False
Treatment using a combination of BC6ENTC and the BC6ENTG inhibitor BC6OTHER may have significantly better effects on sexual function and also seizure frequency than BC6OTHER alone.	False
Treatment using a combination of BC6OTHER and the BC6ENTG inhibitor BC6ENTC may have significantly better effects on sexual function and also seizure frequency than BC6OTHER alone.	CPR:4
Treatment using a combination of BC6OTHER and the BC6ENTG inhibitor BC6OTHER may have significantly better effects on sexual function and also seizure frequency than BC6ENTC alone.	False
To overcome this limitation, we de novo synthesized a conjugate that covalently combines a BC6ENTC - based MRI contrast agent, encaged with a chelating agent ( BC6OTHER ), with BC6OTHER , which is a widely used BC6OTHER inhibitor that binds to BC6ENTG in the stomach and colon.	False
To overcome this limitation, we de novo synthesized a conjugate that covalently combines a BC6ENTC - based MRI contrast agent, encaged with a chelating agent ( BC6OTHER ), with BC6OTHER , which is a widely used BC6ENTG inhibitor that binds to BC6OTHER in the stomach and colon.	CPR:4
To overcome this limitation, we de novo synthesized a conjugate that covalently combines a BC6OTHER - based MRI contrast agent, encaged with a chelating agent ( BC6ENTC ), with BC6OTHER , which is a widely used BC6OTHER inhibitor that binds to BC6ENTG in the stomach and colon.	False
To overcome this limitation, we de novo synthesized a conjugate that covalently combines a BC6OTHER - based MRI contrast agent, encaged with a chelating agent ( BC6ENTC ), with BC6OTHER , which is a widely used BC6ENTG inhibitor that binds to BC6OTHER in the stomach and colon.	CPR:4
To overcome this limitation, we de novo synthesized a conjugate that covalently combines a BC6OTHER - based MRI contrast agent, encaged with a chelating agent ( BC6OTHER ), with BC6ENTC , which is a widely used BC6OTHER inhibitor that binds to BC6ENTG in the stomach and colon.	False
To overcome this limitation, we de novo synthesized a conjugate that covalently combines a BC6OTHER - based MRI contrast agent, encaged with a chelating agent ( BC6OTHER ), with BC6ENTC , which is a widely used BC6ENTG inhibitor that binds to BC6OTHER in the stomach and colon.	CPR:4
Synthesis of a BC6ENTC ( BC6OTHER ) - conjugate of BC6ENTG inhibitor BC6OTHER for gastric wall imaging studies.	CPR:4
Synthesis of a BC6OTHER ( BC6ENTC ) - conjugate of BC6ENTG inhibitor BC6OTHER for gastric wall imaging studies.	CPR:4
Synthesis of a BC6OTHER ( BC6OTHER ) - conjugate of BC6ENTG inhibitor BC6ENTC for gastric wall imaging studies.	CPR:4
Polymeric micelles potentially able to carry to hepatocytes a BC6ENTC ( BC6OTHER ) prodrug, exploiting the presence of BC6ENTG , i.e., BC6OTHER , were prepared starting from a BC6OTHER conjugate.	False
Polymeric micelles potentially able to carry to hepatocytes a BC6ENTC ( BC6OTHER ) prodrug, exploiting the presence of BC6OTHER receptors, i.e., BC6ENTG , were prepared starting from a BC6OTHER conjugate.	False
Polymeric micelles potentially able to carry to hepatocytes a BC6OTHER ( BC6ENTC ) prodrug, exploiting the presence of BC6ENTG , i.e., BC6OTHER , were prepared starting from a BC6OTHER conjugate.	False
Polymeric micelles potentially able to carry to hepatocytes a BC6OTHER ( BC6ENTC ) prodrug, exploiting the presence of BC6OTHER receptors, i.e., BC6ENTG , were prepared starting from a BC6OTHER conjugate.	False
Polymeric micelles potentially able to carry to hepatocytes a BC6OTHER ( BC6OTHER ) prodrug, exploiting the presence of BC6ENTC receptors, i.e., BC6ENTG , were prepared starting from a BC6OTHER conjugate.	False
Polymeric micelles potentially able to carry to hepatocytes a BC6OTHER ( BC6OTHER ) prodrug, exploiting the presence of BC6ENTG , i.e., BC6OTHER , were prepared starting from a BC6ENTC conjugate.	False
Polymeric micelles potentially able to carry to hepatocytes a BC6OTHER ( BC6OTHER ) prodrug, exploiting the presence of BC6OTHER receptors, i.e., BC6ENTG , were prepared starting from a BC6ENTC conjugate.	False
We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the BC6ENTC - activated protein kinase ( BC6ENTG ) / BC6OTHER (CoA) fuel - sensing and signaling mechanism.	False
We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the BC6ENTG ( BC6OTHER ) / BC6ENTC (CoA) fuel - sensing and signaling mechanism.	False
We review here the hypothesis that, in many instances, the cause of these lipid abnormalities could be a dysregulation of the BC6OTHER ( BC6ENTG ) / BC6ENTC (CoA) fuel - sensing and signaling mechanism.	False
Such dysregulation could be reflected by isolated increases in BC6ENTC or by concurrent changes in BC6OTHER and BC6ENTG , both of which would alter intracellular CHEM partitioning.	False
Such dysregulation could be reflected by isolated increases in BC6OTHER or by concurrent changes in BC6ENTC and BC6ENTG , both of which would alter intracellular CHEM partitioning.	False
The possibility is also raised that pharmacological agents and other factors that activate BC6ENTG and / or decrease BC6ENTC could be therapeutic targets.	False
Metabolic syndrome: BC6ENTG and BC6ENTC .	False
Measurement of the rate of activation of BC6ENTC by the BC6ENTG ( BC6OTHER ) yielded a specificity constant (k(cat) / K(m)) 134 - fold lower than that for BC6OTHER .	False
Measurement of the rate of activation of BC6ENTC by the E. coli BC6OTHER - tRNA synthetase ( BC6ENTG ) yielded a specificity constant (k(cat) / K(m)) 134 - fold lower than that for BC6OTHER .	False
Measurement of the rate of activation of BC6OTHER by the E. coli BC6ENTC - tRNA synthetase ( BC6ENTG ) yielded a specificity constant (k(cat) / K(m)) 134 - fold lower than that for BC6OTHER .	False
Measurement of the rate of activation of BC6OTHER by the BC6ENTG ( BC6OTHER ) yielded a specificity constant (k(cat) / K(m)) 134 - fold lower than that for BC6ENTC .	False
Measurement of the rate of activation of BC6OTHER by the E. coli BC6OTHER - tRNA synthetase ( BC6ENTG ) yielded a specificity constant (k(cat) / K(m)) 134 - fold lower than that for BC6ENTC .	False
BC6ENTC was successfully introduced into the BC6ENTG BC6OTHER ( BC6OTHER ) at the encoded BC6OTHER positions.	False
BC6ENTC was successfully introduced into the BC6OTHER BC6ENTG ( BC6OTHER ) at the encoded BC6OTHER positions.	False
BC6ENTC was successfully introduced into the BC6OTHER BC6OTHER ( BC6ENTG ) at the encoded BC6OTHER positions.	False
BC6OTHER was successfully introduced into the BC6ENTG BC6OTHER ( BC6OTHER ) at the encoded BC6ENTC positions.	False
BC6OTHER was successfully introduced into the BC6OTHER BC6ENTG ( BC6OTHER ) at the encoded BC6ENTC positions.	False
BC6OTHER was successfully introduced into the BC6OTHER BC6OTHER ( BC6ENTG ) at the encoded BC6ENTC positions.	False
BC6ENTC yielded no evidence for in vivo incorporation into recombinant proteins, and no evidence for activation by BC6ENTG in vitro.	False
BC6ENTC was incorporated into a model target protein, BC6ENTG ( BC6OTHER ), in an BC6OTHER auxotrophic Escherichia coli host strain suspended in BC6OTHER - supplemented minimal medium depleted of BC6OTHER .	False
BC6ENTC was incorporated into a model target protein, murine BC6OTHER reductase ( BC6ENTG ), in an BC6OTHER auxotrophic Escherichia coli host strain suspended in BC6OTHER - supplemented minimal medium depleted of BC6OTHER .	False
BC6OTHER was incorporated into a model target protein, murine BC6ENTC reductase ( BC6ENTG ), in an BC6OTHER auxotrophic Escherichia coli host strain suspended in BC6OTHER - supplemented minimal medium depleted of BC6OTHER .	False
BC6OTHER was incorporated into a model target protein, BC6ENTG ( BC6OTHER ), in an BC6ENTC auxotrophic Escherichia coli host strain suspended in BC6OTHER - supplemented minimal medium depleted of BC6OTHER .	False
BC6OTHER was incorporated into a model target protein, murine BC6OTHER reductase ( BC6ENTG ), in an BC6ENTC auxotrophic Escherichia coli host strain suspended in BC6OTHER - supplemented minimal medium depleted of BC6OTHER .	False
BC6OTHER was incorporated into a model target protein, BC6ENTG ( BC6OTHER ), in an BC6OTHER auxotrophic Escherichia coli host strain suspended in BC6ENTC - supplemented minimal medium depleted of BC6OTHER .	False
BC6OTHER was incorporated into a model target protein, murine BC6OTHER reductase ( BC6ENTG ), in an BC6OTHER auxotrophic Escherichia coli host strain suspended in BC6ENTC - supplemented minimal medium depleted of BC6OTHER .	False
BC6OTHER was incorporated into a model target protein, BC6ENTG ( BC6OTHER ), in an BC6OTHER auxotrophic Escherichia coli host strain suspended in BC6OTHER - supplemented minimal medium depleted of BC6ENTC .	False
BC6OTHER was incorporated into a model target protein, murine BC6OTHER reductase ( BC6ENTG ), in an BC6OTHER auxotrophic Escherichia coli host strain suspended in BC6OTHER - supplemented minimal medium depleted of BC6ENTC .	False
Despite the presence of a BC6OTHER at the active site of BC6OTHER , isothermal titration calorimetry as well as nitrosation experiments using BC6ENTC demonstrate that GSNO binding does not precede BC6OTHER - nitrosation of BC6ENTG .	False
Despite the presence of a BC6ENTG at the active site of BC6OTHER , isothermal titration calorimetry as well as nitrosation experiments using BC6ENTC demonstrate that GSNO binding does not precede BC6OTHER - nitrosation of BC6OTHER .	False
Despite the presence of a BC6OTHER at the active site of BC6ENTG , isothermal titration calorimetry as well as nitrosation experiments using BC6ENTC demonstrate that GSNO binding does not precede BC6OTHER - nitrosation of BC6OTHER .	False
 BC6ENTC - nitrosation of BC6ENTG is controlled by the conformation of a dynamic active - site helix.	False
Despite the presence of a BC6OTHER at the active site of BC6OTHER , isothermal titration calorimetry as well as nitrosation experiments using BC6OTHER demonstrate that GSNO binding does not precede BC6ENTC - nitrosation of BC6ENTG .	False
Despite the presence of a BC6ENTG at the active site of BC6OTHER , isothermal titration calorimetry as well as nitrosation experiments using BC6OTHER demonstrate that GSNO binding does not precede BC6ENTC - nitrosation of BC6OTHER .	False
Despite the presence of a BC6OTHER at the active site of BC6ENTG , isothermal titration calorimetry as well as nitrosation experiments using BC6OTHER demonstrate that GSNO binding does not precede BC6ENTC - nitrosation of BC6OTHER .	False
C47 of BC6ENTG is BC6ENTC - nitrosated in two steps, with the chemical step limited by a pre - equilibrium between the open and closed conformations of helix α2 at the active site.	False
Since FFAs are known to be involved in the development of BC6ENTG resistance, these results suggest that BC6ENTC may be useful for lowering BC6OTHER resistance in PCOS patients.	False
Since FFAs are known to be involved in the development of BC6OTHER resistance, these results suggest that BC6ENTC may be useful for lowering BC6ENTG resistance in PCOS patients.	False
A BC6ENTC tolerance test with 75 g BC6OTHER load was performed before and after treatment, collecting blood at 0, 1 and 2 h for BC6ENTG , BC6OTHER , FFA and BC6OTHER .	False
A BC6OTHER tolerance test with 75 g BC6ENTC load was performed before and after treatment, collecting blood at 0, 1 and 2 h for BC6ENTG , BC6OTHER , FFA and BC6OTHER .	False
A BC6OTHER tolerance test with 75 g BC6OTHER load was performed before and after treatment, collecting blood at 0, 1 and 2 h for BC6ENTG , BC6ENTC , FFA and BC6OTHER .	False
A BC6OTHER tolerance test with 75 g BC6OTHER load was performed before and after treatment, collecting blood at 0, 1 and 2 h for BC6ENTG , BC6OTHER , FFA and BC6ENTC .	False
BC6ENTC (1) is a non - selective BC6ENTG antagonist that is used clinically for the treatment of urinary incontinence.	CPR:6
We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace BC6ENTC ( BC6OTHER ) binding on BC6ENTG .	False
We have prepared the enantiomers of 1 and 2 and evaluated their ability to displace BC6OTHER ( BC6ENTC ) binding on BC6ENTG .	False
Compounds 1 and 2 potently displaced BC6ENTC binding at BC6ENTG , but were less potent at the BC6OTHER and BC6OTHER subtypes.	False
Compounds 1 and 2 potently displaced BC6ENTC binding at BC6OTHER , but were less potent at the BC6ENTG and BC6OTHER subtypes.	False
Compounds 1 and 2 potently displaced BC6ENTC binding at BC6OTHER , but were less potent at the BC6OTHER and BC6ENTG subtypes.	False
The preparation and BC6ENTG profiling of BC6ENTC and BC6OTHER enantiomers.	False
The preparation and BC6ENTG profiling of BC6OTHER and BC6ENTC enantiomers.	False
The increased BC6ENTC peroxidase activity in rats suffering from hyperthyroidism was associated with a fall of the reduced BC6OTHER in the homogenate and a marked increase in the BC6ENTG activity.	False
The increased BC6OTHER activity in rats suffering from hyperthyroidism was associated with a fall of the reduced BC6ENTC in the homogenate and a marked increase in the BC6ENTG activity.	False
The increased BC6ENTG activity in rats suffering from hyperthyroidism was associated with a fall of the reduced BC6ENTC in the homogenate and a marked increase in the BC6OTHER reductase activity.	False
The increased BC6ENTG activity in rats suffering from hyperthyroidism was associated with a fall of the reduced BC6OTHER in the homogenate and a marked increase in the BC6ENTC reductase activity.	False
Thirty - week administration of BC6ENTC with or without BC6OTHER markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of BC6ENTG inhibition and the decrease of BC6OTHER activity in the tumor cells.	CPR:4
Thirty - week administration of BC6ENTC with or without BC6OTHER markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of BC6OTHER inhibition and the decrease of BC6ENTG activity in the tumor cells.	CPR:4
Thirty - week administration of BC6OTHER with or without BC6ENTC markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of BC6ENTG inhibition and the decrease of BC6OTHER activity in the tumor cells.	CPR:4
Thirty - week administration of BC6OTHER with or without BC6ENTC markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of BC6OTHER inhibition and the decrease of BC6ENTG activity in the tumor cells.	CPR:4
Thirty - week administration of BC6OTHER with or without BC6OTHER markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of BC6ENTC synthase inhibition and the decrease of BC6ENTG activity in the tumor cells.	False
Thirty - week administration of BC6OTHER with or without BC6OTHER markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of BC6ENTG inhibition and the decrease of BC6ENTC kinase activity in the tumor cells.	False
BC6ENTC synthase and BC6ENTG are key enzymes involved in the de novo and salvage pathways for BC6OTHER synthesis, respectively.	False
BC6ENTG and BC6OTHER kinase are key enzymes involved in the de novo and salvage pathways for BC6ENTC synthesis, respectively.	CPR:9
BC6OTHER and BC6ENTG are key enzymes involved in the de novo and salvage pathways for BC6ENTC synthesis, respectively.	CPR:9
BC6ENTG is inhibited by BC6ENTC , forming an inactive ternary complex with intracellular BC6OTHER .	CPR:4
BC6ENTG and BC6ENTC kinase are key enzymes involved in the de novo and salvage pathways for BC6OTHER synthesis, respectively.	False
BC6ENTG is inhibited by BC6OTHER , forming an inactive ternary complex with intracellular BC6ENTC .	False
These results indicate that BC6ENTC , BC6OTHER and BC6OTHER preferentially increase BC6OTHER release in the mPFC, compared to the CHEM via a BC6ENTG - related mechanism.	False
These results indicate that BC6OTHER , BC6ENTC and BC6OTHER preferentially increase BC6OTHER release in the mPFC, compared to the CHEM via a BC6ENTG - related mechanism.	False
These results indicate that BC6OTHER , BC6OTHER and BC6ENTC preferentially increase BC6OTHER release in the mPFC, compared to the CHEM via a BC6ENTG - related mechanism.	False
These results indicate that BC6OTHER , BC6OTHER and BC6OTHER preferentially increase BC6ENTC release in the mPFC, compared to the CHEM via a BC6ENTG - related mechanism.	False
However, BC6ENTG agonism may be important only for BC6ENTC - induced BC6OTHER release.	CPR:5
However, BC6ENTG agonism may be important only for BC6OTHER - induced BC6ENTC release.	False
Although only BC6ENTC and BC6OTHER are directly acting BC6ENTG agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6OTHER blockade.	CPR:5
Although only BC6ENTC and BC6OTHER are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6ENTG antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6OTHER blockade.	False
Although only BC6ENTC and BC6OTHER are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6ENTG and BC6OTHER blockade.	CPR:4
Although only BC6ENTC and BC6OTHER are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6ENTG blockade.	CPR:4
Although only BC6OTHER and BC6ENTC are directly acting BC6ENTG agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6OTHER blockade.	CPR:5
Although only BC6OTHER and BC6ENTC are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6ENTG antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6OTHER blockade.	False
Although only BC6OTHER and BC6ENTC are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6ENTG and BC6OTHER blockade.	CPR:4
Although only BC6OTHER and BC6ENTC are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6ENTG blockade.	CPR:4
Although only BC6OTHER and BC6OTHER are directly acting BC6ENTG agonists, BC6ENTC , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6OTHER blockade.	False
Although only BC6OTHER and BC6OTHER are directly acting BC6OTHER agonists, BC6ENTC , a selective BC6ENTG antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6OTHER blockade.	CPR:6
Although only BC6OTHER and BC6OTHER are directly acting BC6OTHER agonists, BC6ENTC , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6ENTG and BC6OTHER blockade.	CPR:4
Although only BC6OTHER and BC6OTHER are directly acting BC6OTHER agonists, BC6ENTC , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6OTHER release that may be due to combined BC6OTHER and BC6ENTG blockade.	CPR:4
Although only BC6OTHER and BC6OTHER are directly acting BC6ENTG agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6ENTC release that may be due to combined BC6OTHER and BC6OTHER blockade.	False
Although only BC6OTHER and BC6OTHER are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6ENTG antagonist, partially attenuates these atypical APD - induced increases in cortical BC6ENTC release that may be due to combined BC6OTHER and BC6OTHER blockade.	False
Although only BC6OTHER and BC6OTHER are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6ENTC release that may be due to combined BC6ENTG and BC6OTHER blockade.	False
Although only BC6OTHER and BC6OTHER are directly acting BC6OTHER agonists, BC6OTHER , a selective BC6OTHER antagonist, partially attenuates these atypical APD - induced increases in cortical BC6ENTC release that may be due to combined BC6OTHER and BC6ENTG blockade.	False
The present study determined whether BC6ENTC , BC6OTHER and BC6OTHER , BC6ENTG / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6ENTC , BC6OTHER and BC6OTHER , BC6OTHER / BC6ENTG antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6ENTC , BC6OTHER and BC6OTHER , BC6OTHER / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6ENTG agonism.	False
The present study determined whether BC6OTHER , BC6ENTC and BC6OTHER , BC6ENTG / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6ENTC and BC6OTHER , BC6OTHER / BC6ENTG antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6ENTC and BC6OTHER , BC6OTHER / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6ENTG agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6ENTC , BC6ENTG / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6ENTC , BC6OTHER / BC6ENTG antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6ENTC , BC6OTHER / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6OTHER release, and whether these effects are related to BC6ENTG agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG / BC6OTHER antagonist atypical APDs, also increase cortical BC6ENTC and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER / BC6ENTG antagonist atypical APDs, also increase cortical BC6ENTC and BC6OTHER release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER / BC6OTHER antagonist atypical APDs, also increase cortical BC6ENTC and BC6OTHER release, and whether these effects are related to BC6ENTG agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6ENTC release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER / BC6ENTG antagonist atypical APDs, also increase cortical BC6OTHER and BC6ENTC release, and whether these effects are related to BC6OTHER agonism.	False
The present study determined whether BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER / BC6OTHER antagonist atypical APDs, also increase cortical BC6OTHER and BC6ENTC release, and whether these effects are related to BC6ENTG agonism.	False
Atypical antipsychotic drugs, BC6OTHER , BC6OTHER , and BC6OTHER , preferentially increase BC6OTHER and BC6ENTC release in rat medial prefrontal cortex: role of BC6ENTG receptor agonism.	False
Atypical antipsychotic drugs, BC6ENTC , BC6OTHER , and BC6OTHER , preferentially increase BC6OTHER and BC6OTHER release in rat medial prefrontal cortex: role of BC6ENTG receptor agonism.	False
Atypical antipsychotic drugs, BC6OTHER , BC6ENTC , and BC6OTHER , preferentially increase BC6OTHER and BC6OTHER release in rat medial prefrontal cortex: role of BC6ENTG receptor agonism.	False
Atypical antipsychotic drugs, BC6OTHER , BC6OTHER , and BC6ENTC , preferentially increase BC6OTHER and BC6OTHER release in rat medial prefrontal cortex: role of BC6ENTG receptor agonism.	False
Atypical antipsychotic drugs, BC6OTHER , BC6OTHER , and BC6OTHER , preferentially increase BC6ENTC and BC6OTHER release in rat medial prefrontal cortex: role of BC6ENTG receptor agonism.	False
Only strains of P. aeruginosa producing large amounts of BC6ENTG may be resistant to both BC6ENTC and BC6OTHER .	False
Only strains of P. aeruginosa producing large amounts of BC6ENTG may be resistant to both BC6OTHER and BC6ENTC .	False
By contrast, neither BC6OTHER nor BC6ENTC can be considered as possible ligands of BC6ENTG and BC6OTHER receptors because their affinities for these sites are in the micromolar range (or even worse).	False
By contrast, neither BC6OTHER nor BC6ENTC can be considered as possible ligands of BC6OTHER and BC6ENTG receptors because their affinities for these sites are in the micromolar range (or even worse).	False
Interestingly, BC6ENTC binds with a good affinity (IC50 = 0.30 microM) to BC6ENTG receptors labelled by BC6OTHER in cortical membranes.	False
Interestingly, BC6OTHER binds with a good affinity (IC50 = 0.30 microM) to BC6ENTG receptors labelled by BC6ENTC in cortical membranes.	False
 Complementary experiments using the BC6ENTG - dependent Bezold - Jarisch reflex confirmed that BC6ENTC really acts in vivo as a BC6OTHER antagonist (IC50 = 50 micrograms / kg i.v.), whereas BC6OTHER is essentially inactive on BC6OTHER receptors.	False
 Complementary experiments using the BC6OTHER - dependent Bezold - Jarisch reflex confirmed that BC6ENTC really acts in vivo as a BC6ENTG antagonist (IC50 = 50 micrograms / kg i.v.), whereas BC6OTHER is essentially inactive on BC6OTHER receptors.	CPR:6
 Complementary experiments using the BC6OTHER - dependent Bezold - Jarisch reflex confirmed that BC6ENTC really acts in vivo as a BC6OTHER antagonist (IC50 = 50 micrograms / kg i.v.), whereas BC6OTHER is essentially inactive on BC6ENTG receptors.	False
 Complementary experiments using the BC6ENTG - dependent Bezold - Jarisch reflex confirmed that BC6OTHER really acts in vivo as a BC6OTHER antagonist (IC50 = 50 micrograms / kg i.v.), whereas BC6ENTC is essentially inactive on BC6OTHER receptors.	False
 Complementary experiments using the BC6OTHER - dependent Bezold - Jarisch reflex confirmed that BC6OTHER really acts in vivo as a BC6ENTG antagonist (IC50 = 50 micrograms / kg i.v.), whereas BC6ENTC is essentially inactive on BC6OTHER receptors.	False
 Complementary experiments using the BC6OTHER - dependent Bezold - Jarisch reflex confirmed that BC6OTHER really acts in vivo as a BC6OTHER antagonist (IC50 = 50 micrograms / kg i.v.), whereas BC6ENTC is essentially inactive on BC6ENTG receptors.	False
The second part of this study consisted of looking for possible changes in central BC6ENTG 24 h after either a single or a repeated (for 14 days) treatment with BC6ENTC (10 mg / kg i.p.	False
Finally we explored whether acute and / or chronic administration of BC6ENTC or BC6OTHER affected the levels of opioid peptides and the BC6ENTG in various regions of the brain and the spinal cord.	False
Finally we explored whether acute and / or chronic administration of BC6OTHER or BC6ENTC affected the levels of opioid peptides and the BC6ENTG in various regions of the brain and the spinal cord.	False
In vitro binding studies showed that both BC6ENTC and BC6OTHER interact in the nanomolar range with BC6ENTG receptors labelled by BC6OTHER in cortical membranes.	False
In vitro binding studies showed that both BC6OTHER and BC6ENTC interact in the nanomolar range with BC6ENTG receptors labelled by BC6OTHER in cortical membranes.	False
In vitro binding studies showed that both BC6OTHER and BC6OTHER interact in the nanomolar range with BC6ENTG receptors labelled by BC6ENTC in cortical membranes.	False
By contrast, neither BC6ENTC nor BC6OTHER can be considered as possible ligands of BC6ENTG and BC6OTHER receptors because their affinities for these sites are in the micromolar range (or even worse).	False
By contrast, neither BC6ENTC nor BC6OTHER can be considered as possible ligands of BC6OTHER and BC6ENTG receptors because their affinities for these sites are in the micromolar range (or even worse).	False
A combination strategy to inhibit BC6ENTG : synergism between noncompetitive and BC6ENTC - competitive inhibitors.	False
A synergistic effect in the inhibition of cell proliferation by BC6ENTC - competitive and BC6OTHER - noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all BC6ENTG inhibitors tested in showed synergism with the known anticancer agent, BC6OTHER .	False
A synergistic effect in the inhibition of cell proliferation by BC6OTHER - competitive and BC6ENTC - noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all BC6ENTG inhibitors tested in showed synergism with the known anticancer agent, BC6OTHER .	False
BC6ENTG is a BC6ENTC / BC6OTHER kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	False
A synergistic effect in the inhibition of cell proliferation by BC6OTHER - competitive and BC6OTHER - noncompetitive compounds was also observed in prostate cancer cell lines (PC3), where all BC6ENTG inhibitors tested in showed synergism with the known anticancer agent, BC6ENTC .	False
BC6ENTG is a BC6OTHER / BC6ENTC kinase critically involved in the initiation and progression of various types of cancer, especially leukemia, lymphomas and solid tumors such as prostate, pancreas and colon, and is considered a potential drug target against these malignancies.	False
In an effort to discover new potent BC6ENTG inhibitors, a previously identified BC6ENTC - competitive BC6OTHER scaffold was expanded to derive structure - activity relationship data.	False
In an effort to discover new potent BC6ENTG inhibitors, a previously identified BC6OTHER - competitive BC6ENTC scaffold was expanded to derive structure - activity relationship data.	False
We examined the critical roles played by the antioxidant, non - protein BC6ENTC , BC6OTHER and related enzyme, BC6ENTG in maintaining mitochondrial function during excitotoxicity caused by BC6OTHER ( BC6OTHER ), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	False
We examined the critical roles played by the antioxidant, non - protein BC6OTHER , BC6ENTC and related enzyme, BC6ENTG in maintaining mitochondrial function during excitotoxicity caused by BC6OTHER ( BC6OTHER ), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	False
We examined the critical roles played by the antioxidant, non - protein BC6OTHER , BC6OTHER and related enzyme, BC6ENTG in maintaining mitochondrial function during excitotoxicity caused by BC6ENTC ( BC6OTHER ), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	False
We examined the critical roles played by the antioxidant, non - protein BC6OTHER , BC6OTHER and related enzyme, BC6ENTG in maintaining mitochondrial function during excitotoxicity caused by BC6OTHER ( BC6ENTC ), the causative factor of neurolathyrism, a motor neuron disease involving the pyramidal system.	False
BC6ENTC causes loss of BC6OTHER and inhibition of BC6ENTG in lumbosacral cord of male mice through oxidation of BC6OTHER groups, while female mice are resistant.	CPR:4
BC6OTHER causes loss of BC6ENTC and inhibition of BC6ENTG in lumbosacral cord of male mice through oxidation of BC6OTHER groups, while female mice are resistant.	False
BC6OTHER causes loss of BC6OTHER and inhibition of BC6ENTG in lumbosacral cord of male mice through oxidation of BC6ENTC groups, while female mice are resistant.	False
Reducing BC6ENTC levels in female mice CNS by pretreatment with BC6OTHER or BC6OTHER did not result in inhibition of BC6ENTG activity, unlike male mice.	False
Reducing BC6OTHER levels in female mice CNS by pretreatment with BC6ENTC or BC6OTHER did not result in inhibition of BC6ENTG activity, unlike male mice.	False
Further, treatment of female mice depleted of BC6ENTC with BC6OTHER did not induce inhibition of BC6ENTG indicating that BC6OTHER levels were not critical for maintaining BC6OTHER activity in female mice unlike their male counterpart.	False
Further, treatment of female mice depleted of BC6ENTC with BC6OTHER did not induce inhibition of BC6OTHER indicating that BC6OTHER levels were not critical for maintaining BC6ENTG activity in female mice unlike their male counterpart.	False
Reducing BC6OTHER levels in female mice CNS by pretreatment with BC6OTHER or BC6ENTC did not result in inhibition of BC6ENTG activity, unlike male mice.	False
Downregulation of BC6ENTG but not BC6ENTC loss leads to mitochondrial dysfunction in female mice CNS: implications in excitotoxicity.	False
Further, treatment of female mice depleted of BC6OTHER with BC6ENTC did not induce inhibition of BC6ENTG indicating that BC6OTHER levels were not critical for maintaining BC6OTHER activity in female mice unlike their male counterpart.	False
Further, treatment of female mice depleted of BC6OTHER with BC6ENTC did not induce inhibition of BC6OTHER indicating that BC6OTHER levels were not critical for maintaining BC6ENTG activity in female mice unlike their male counterpart.	False
Further, treatment of female mice depleted of BC6OTHER with BC6OTHER did not induce inhibition of BC6ENTG indicating that BC6ENTC levels were not critical for maintaining BC6OTHER activity in female mice unlike their male counterpart.	False
Further, treatment of female mice depleted of BC6OTHER with BC6OTHER did not induce inhibition of BC6OTHER indicating that BC6ENTC levels were not critical for maintaining BC6ENTG activity in female mice unlike their male counterpart.	False
BC6ENTG , a CHEM BC6ENTC oxidoreductase helps maintain redox status of proteins and downregulation of BC6OTHER results in loss of BC6OTHER activity.	False
BC6OTHER , a CHEM BC6ENTC oxidoreductase helps maintain redox status of proteins and downregulation of BC6ENTG results in loss of BC6OTHER activity.	False
BC6OTHER , a CHEM BC6ENTC oxidoreductase helps maintain redox status of proteins and downregulation of BC6OTHER results in loss of BC6ENTG activity.	False
Female mice express higher levels of BC6ENTG in certain CNS regions and downregulation of BC6OTHER using antisense CHEM sensitizes them to BC6ENTC toxicity seen as BC6OTHER loss.	False
Female mice express higher levels of BC6OTHER in certain CNS regions and downregulation of BC6ENTG using antisense CHEM sensitizes them to BC6ENTC toxicity seen as BC6OTHER loss.	False
Female mice express higher levels of BC6OTHER in certain CNS regions and downregulation of BC6OTHER using antisense CHEM sensitizes them to BC6ENTC toxicity seen as BC6ENTG loss.	CPR:4
Ovariectomy downregulates BC6ENTG and renders female mice vulnerable to BC6ENTC toxicity as evidenced by activation of BC6OTHER , loss of BC6OTHER and BC6OTHER activity indicating the important role of BC6OTHER in neuroprotection.	False
Ovariectomy downregulates BC6OTHER and renders female mice vulnerable to BC6ENTC toxicity as evidenced by activation of BC6ENTG , loss of BC6OTHER and BC6OTHER activity indicating the important role of BC6OTHER in neuroprotection.	CPR:3
Ovariectomy downregulates BC6OTHER and renders female mice vulnerable to BC6ENTC toxicity as evidenced by activation of BC6OTHER , loss of BC6OTHER and BC6ENTG activity indicating the important role of BC6OTHER in neuroprotection.	CPR:3
Ovariectomy downregulates BC6OTHER and renders female mice vulnerable to BC6ENTC toxicity as evidenced by activation of BC6OTHER , loss of BC6OTHER and BC6OTHER activity indicating the important role of BC6ENTG in neuroprotection.	False
Ovariectomy downregulates BC6ENTG and renders female mice vulnerable to BC6OTHER toxicity as evidenced by activation of BC6OTHER , loss of BC6ENTC and BC6OTHER activity indicating the important role of BC6OTHER in neuroprotection.	False
Ovariectomy downregulates BC6OTHER and renders female mice vulnerable to BC6OTHER toxicity as evidenced by activation of BC6ENTG , loss of BC6ENTC and BC6OTHER activity indicating the important role of BC6OTHER in neuroprotection.	False
Ovariectomy downregulates BC6OTHER and renders female mice vulnerable to BC6OTHER toxicity as evidenced by activation of BC6OTHER , loss of BC6ENTC and BC6ENTG activity indicating the important role of BC6OTHER in neuroprotection.	False
Ovariectomy downregulates BC6OTHER and renders female mice vulnerable to BC6OTHER toxicity as evidenced by activation of BC6OTHER , loss of BC6ENTC and BC6OTHER activity indicating the important role of BC6ENTG in neuroprotection.	False
BC6ENTC protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of BC6ENTG in the CNS.	CPR:3
We report the discovery of a novel series of BC6OTHER - competitive BC6ENTG ( BC6OTHER ) inhibitors based on the BC6ENTC scaffold.	CPR:4
We report the discovery of a novel series of BC6OTHER - competitive BC6OTHER ( BC6ENTG ) inhibitors based on the BC6ENTC scaffold.	CPR:4
We report the discovery of a novel series of BC6ENTC - competitive BC6ENTG ( BC6OTHER ) inhibitors based on the BC6OTHER scaffold.	False
We report the discovery of a novel series of BC6ENTC - competitive BC6OTHER ( BC6ENTG ) inhibitors based on the BC6OTHER scaffold.	False
Discovery of a series of novel BC6ENTC , as potent BC6ENTG BC6OTHER inhibitors.	CPR:4
Discovery of a series of novel BC6ENTC , as potent BC6OTHER BC6ENTG inhibitors.	CPR:4
BC6ENTC - glucuronosyltransferases ( BC6ENTG ) are a group of drug - metabolizing enzymes that catalyse the conjugation of endogeonous compounds and xenobiotics to yield hydrophilic CHEM which subsequently undergo excretion.	False
The BC6ENTG mutant ribosome was characterized by increased BC6OTHER stability in low BC6ENTC concentrations.	False
The BC6OTHER mutant ribosome was characterized by increased BC6ENTG stability in low BC6ENTC concentrations.	False
We conclude that this aberrant protein synthesis ability in the Str(r) mutant, which is a result of increased stability of the BC6ENTG , is responsible for the remarkable BC6ENTC production enhancement obtained.	False
Increased productivity of BC6ENTC in the Str(r) mutant (containing the BC6ENTG mutation in the BC6OTHER protein) may be a result of an aberrant protein synthesis mechanism.	False
Increased productivity of BC6ENTC in the Str(r) mutant (containing the BC6OTHER mutation in the BC6ENTG protein) may be a result of an aberrant protein synthesis mechanism.	False
BC6ENTC ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6ENTG , and BC6OTHER transferase.	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	CPR:4
BC6ENTC ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6ENTG , BC6OTHER reductase, and BC6OTHER transferase.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6ENTC reductase, and BC6ENTG .	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6ENTG , BC6ENTC reductase, and BC6OTHER transferase.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6ENTG , and BC6ENTC transferase.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6ENTG , BC6OTHER reductase, and BC6ENTC transferase.	False
BC6OTHER ( BC6ENTC , BC6OTHER ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6ENTG , and BC6OTHER transferase.	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	CPR:4
BC6OTHER ( BC6ENTC , BC6OTHER ) is a novel, CHEM that inhibits BC6ENTG , BC6OTHER reductase, and BC6OTHER transferase.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6ENTG , and BC6OTHER transferase.	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is a novel, CHEM that inhibits BC6OTHER synthase, BC6OTHER reductase, and BC6ENTG .	CPR:4
BC6OTHER ( BC6OTHER , BC6ENTC ) is a novel, CHEM that inhibits BC6ENTG , BC6OTHER reductase, and BC6OTHER transferase.	CPR:4
BC6OTHER ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6ENTC synthase, BC6ENTG , and BC6OTHER transferase.	False
BC6OTHER ( BC6OTHER , BC6OTHER ) is a novel, CHEM that inhibits BC6ENTC synthase, BC6OTHER reductase, and BC6ENTG .	False
BC6ENTC - resistant acid phosphatase ( BC6ENTG ) staining revealed increased osteoclast numbers in tibias of 2 - month - old BC6OTHER - BC6OTHER mice, and increased numbers of osteoclasts co - cultured with BC6OTHER - BC6OTHER osteoblasts.	False
BC6ENTC - resistant acid phosphatase ( BC6OTHER ) staining revealed increased osteoclast numbers in tibias of 2 - month - old BC6ENTG - BC6OTHER mice, and increased numbers of osteoclasts co - cultured with BC6OTHER - BC6OTHER osteoblasts.	False
BC6ENTC - resistant acid phosphatase ( BC6OTHER ) staining revealed increased osteoclast numbers in tibias of 2 - month - old BC6OTHER - BC6ENTG mice, and increased numbers of osteoclasts co - cultured with BC6OTHER - BC6OTHER osteoblasts.	False
BC6ENTC - resistant acid phosphatase ( BC6OTHER ) staining revealed increased osteoclast numbers in tibias of 2 - month - old BC6OTHER - BC6OTHER mice, and increased numbers of osteoclasts co - cultured with BC6ENTG - BC6OTHER osteoblasts.	False
BC6ENTC - resistant acid phosphatase ( BC6OTHER ) staining revealed increased osteoclast numbers in tibias of 2 - month - old BC6OTHER - BC6OTHER mice, and increased numbers of osteoclasts co - cultured with BC6OTHER - BC6ENTG osteoblasts.	False
Plasma BC6ENTC , active BC6ENTG (7 - 36) BC6OTHER concentration and BC6OTHER levels were measured after BC6OTHER loading.	False
Plasma BC6ENTC , active BC6OTHER (7 - 36) BC6OTHER concentration and BC6ENTG levels were measured after BC6OTHER loading.	False
Plasma BC6OTHER , active BC6ENTG (7 - 36) BC6ENTC concentration and BC6OTHER levels were measured after BC6OTHER loading.	False
Plasma BC6OTHER , active BC6OTHER (7 - 36) BC6ENTC concentration and BC6ENTG levels were measured after BC6OTHER loading.	False
Plasma BC6OTHER , active BC6ENTG (7 - 36) BC6OTHER concentration and BC6OTHER levels were measured after BC6ENTC loading.	False
Plasma BC6OTHER , active BC6OTHER (7 - 36) BC6OTHER concentration and BC6ENTG levels were measured after BC6ENTC loading.	False
The docking data indicated that BC6ENTC bind to the BC6ENTG .	False
BC6ENTC decreased plasma BC6OTHER , increased plasma and pancreatic BC6ENTG , increased plasma and colonic active BC6OTHER (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6OTHER - BC6OTHER induced diabetic rats.	CPR:3
BC6ENTC decreased plasma BC6OTHER , increased plasma and pancreatic BC6OTHER , increased plasma and colonic active BC6ENTG (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6OTHER - BC6OTHER induced diabetic rats.	CPR:3
BC6OTHER decreased plasma BC6ENTC , increased plasma and pancreatic BC6ENTG , increased plasma and colonic active BC6OTHER (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6OTHER - BC6OTHER induced diabetic rats.	False
BC6OTHER decreased plasma BC6ENTC , increased plasma and pancreatic BC6OTHER , increased plasma and colonic active BC6ENTG (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6OTHER - BC6OTHER induced diabetic rats.	False
The objective of the present investigation was to evaluate BC6ENTC increases BC6ENTG ( BC6OTHER ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	CPR:3
The objective of the present investigation was to evaluate BC6ENTC increases BC6OTHER ( BC6ENTG ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	CPR:3
BC6OTHER decreased plasma BC6OTHER , increased plasma and pancreatic BC6ENTG , increased plasma and colonic active BC6OTHER (7 - 36) BC6ENTC secretion as well as decreased oxidative stress in BC6OTHER - BC6OTHER induced diabetic rats.	False
BC6OTHER decreased plasma BC6OTHER , increased plasma and pancreatic BC6OTHER , increased plasma and colonic active BC6ENTG (7 - 36) BC6ENTC secretion as well as decreased oxidative stress in BC6OTHER - BC6OTHER induced diabetic rats.	False
BC6OTHER decreased plasma BC6OTHER , increased plasma and pancreatic BC6ENTG , increased plasma and colonic active BC6OTHER (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6ENTC - BC6OTHER induced diabetic rats.	False
BC6OTHER decreased plasma BC6OTHER , increased plasma and pancreatic BC6OTHER , increased plasma and colonic active BC6ENTG (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6ENTC - BC6OTHER induced diabetic rats.	False
BC6OTHER decreased plasma BC6OTHER , increased plasma and pancreatic BC6ENTG , increased plasma and colonic active BC6OTHER (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6OTHER - BC6ENTC induced diabetic rats.	False
BC6OTHER decreased plasma BC6OTHER , increased plasma and pancreatic BC6OTHER , increased plasma and colonic active BC6ENTG (7 - 36) BC6OTHER secretion as well as decreased oxidative stress in BC6OTHER - BC6ENTC induced diabetic rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6ENTG ( BC6OTHER ) (7 - 36) BC6ENTC secretion in BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6OTHER ( BC6ENTG ) (7 - 36) BC6ENTC secretion in BC6OTHER - BC6OTHER ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6ENTG ( BC6OTHER ) (7 - 36) BC6OTHER secretion in BC6ENTC - BC6OTHER ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6OTHER ( BC6ENTG ) (7 - 36) BC6OTHER secretion in BC6ENTC - BC6OTHER ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6ENTG ( BC6OTHER ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6ENTC ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6OTHER ( BC6ENTG ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6ENTC ( BC6OTHER - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6ENTG ( BC6OTHER ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6OTHER ( BC6ENTC - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6OTHER ( BC6ENTG ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6OTHER ( BC6ENTC - BC6OTHER ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6ENTG ( BC6OTHER ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTC ) induced diabetic Sprague Dawley rats.	False
The objective of the present investigation was to evaluate BC6OTHER increases BC6OTHER ( BC6ENTG ) (7 - 36) BC6OTHER secretion in BC6OTHER - BC6OTHER ( BC6OTHER - BC6ENTC ) induced diabetic Sprague Dawley rats.	False
Glycosylated BC6ENTG , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6ENTC , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6ENTG ) (7 - 36) BC6ENTC , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6ENTC , mRNA expression of proglucagon BC6ENTG , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6ENTC , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6ENTG , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6ENTC , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6ENTG , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6ENTC , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6ENTC , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6ENTG ) were measured after 8week.	False
It decreased blood BC6ENTC , stimulated BC6ENTG secretion in type 2 diabetic patients.	False
Oral BC6OTHER increases active BC6ENTG (7 - 36) BC6OTHER secretion and improves glycemic control in BC6OTHER - BC6ENTC induced diabetic rats.	False
Oral BC6OTHER increases active BC6ENTG (7 - 36) BC6ENTC secretion and improves glycemic control in BC6OTHER - BC6OTHER induced diabetic rats.	False
Glycosylated BC6ENTG , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6ENTC , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6ENTG ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6ENTC , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6ENTG , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6ENTC , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6ENTG , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6ENTC , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6ENTG , reduced BC6ENTC , BC6OTHER , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6ENTC , BC6OTHER , BC6OTHER peroxidase, BC6ENTG ) were measured after 8week.	False
Oral BC6ENTC increases active BC6ENTG (7 - 36) BC6OTHER secretion and improves glycemic control in BC6OTHER - BC6OTHER induced diabetic rats.	CPR:3
Oral BC6OTHER increases active BC6ENTG (7 - 36) BC6OTHER secretion and improves glycemic control in BC6ENTC - BC6OTHER induced diabetic rats.	False
Glycosylated BC6ENTG , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6ENTC , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6ENTG ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6ENTC , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6ENTG , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6ENTC , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6ENTG , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6ENTC , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6ENTG , reduced BC6OTHER , BC6ENTC , BC6OTHER peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6ENTC , BC6OTHER peroxidase, BC6ENTG ) were measured after 8week.	False
Glycosylated BC6ENTG , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6ENTC peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6ENTG ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6ENTC peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6ENTG , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6ENTC peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6ENTG , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6ENTC peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6ENTG , reduced BC6OTHER , BC6OTHER , BC6ENTC peroxidase, BC6OTHER S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6ENTC peroxidase, BC6ENTG ) were measured after 8week.	False
Glycosylated BC6ENTG , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6ENTC S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6ENTG ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6ENTC S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6ENTG , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6ENTC S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6ENTG , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6ENTC S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6ENTG , reduced BC6OTHER , BC6OTHER , BC6OTHER peroxidase, BC6ENTC S transferase) were measured after 8week.	False
Glycosylated BC6OTHER , lipid profile, plasma and colonic active ( BC6OTHER ) (7 - 36) BC6OTHER , mRNA expression of proglucagon BC6OTHER , plasma and pancreatic BC6OTHER , histology of pancreata and biomarkers of oxidative stress ( BC6OTHER , reduced BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC S transferase) were measured after 8week.	False
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6OTHER compounds ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and of one BC6OTHER ( BC6ENTC ) were studied in human cell lines and primary cells; BC6OTHER was included as the classical non - endogenous BC6ENTG ligand.	False
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6OTHER compounds ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and of one BC6OTHER ( BC6OTHER ) were studied in human cell lines and primary cells; BC6ENTC was included as the classical non - endogenous BC6ENTG ligand.	False
Toxicological profiles of selected synthetic BC6ENTC showing high binding affinities to the BC6ENTG .	False
Furthermore, no impact on BC6ENTG release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6ENTG , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6ENTG , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6ENTG / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6ENTG and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6ENTG levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6ENTG and BC6OTHER / BC6OTHER .	CPR:4
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6ENTG / BC6OTHER .	CPR:4
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6ENTC and BC6OTHER which caused a decrease of BC6OTHER and BC6OTHER / BC6ENTG .	CPR:4
Furthermore, no impact on BC6ENTG release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6ENTG , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6ENTG , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6ENTG / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6ENTG and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6ENTG levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6OTHER / BC6OTHER .	False
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6ENTG and BC6OTHER / BC6OTHER .	CPR:4
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6ENTG / BC6OTHER .	CPR:4
Furthermore, no impact on BC6OTHER release (i.e., on BC6OTHER , BC6OTHER , BC6OTHER / BC6OTHER and BC6OTHER levels) was seen in LPS - stimulated human PBMCs, except with BC6OTHER and BC6ENTC which caused a decrease of BC6OTHER and BC6OTHER / BC6ENTG .	CPR:4
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6ENTC compounds ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and of one BC6OTHER ( BC6OTHER ) were studied in human cell lines and primary cells; BC6OTHER was included as the classical non - endogenous BC6ENTG ligand.	False
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6OTHER compounds ( BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER ) and of one BC6OTHER ( BC6OTHER ) were studied in human cell lines and primary cells; BC6OTHER was included as the classical non - endogenous BC6ENTG ligand.	False
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6OTHER compounds ( BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER ) and of one BC6OTHER ( BC6OTHER ) were studied in human cell lines and primary cells; BC6OTHER was included as the classical non - endogenous BC6ENTG ligand.	False
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6OTHER compounds ( BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER ) and of one BC6OTHER ( BC6OTHER ) were studied in human cell lines and primary cells; BC6OTHER was included as the classical non - endogenous BC6ENTG ligand.	False
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6OTHER compounds ( BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC ) and of one BC6OTHER ( BC6OTHER ) were studied in human cell lines and primary cells; BC6OTHER was included as the classical non - endogenous BC6ENTG ligand.	False
Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four BC6OTHER compounds ( BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER ) and of one BC6ENTC ( BC6OTHER ) were studied in human cell lines and primary cells; BC6OTHER was included as the classical non - endogenous BC6ENTG ligand.	False
Methylation of BC6ENTG on BC6ENTC 4 by the BC6OTHER methyltransferase BC6OTHER protein is needed for normal clock gene expression.	False
Methylation of BC6OTHER on BC6ENTC 4 by the BC6ENTG BC6OTHER protein is needed for normal clock gene expression.	False
Methylation of BC6OTHER on BC6ENTC 4 by the BC6OTHER methyltransferase BC6ENTG protein is needed for normal clock gene expression.	False
Methylation of BC6ENTG on BC6OTHER 4 by the BC6ENTC methyltransferase BC6OTHER protein is needed for normal clock gene expression.	False
Methylation of BC6OTHER on BC6OTHER 4 by the BC6ENTC methyltransferase BC6ENTG protein is needed for normal clock gene expression.	False
In contrast, BC6ENTC did not affect BC6ENTG and BC6OTHER expression in MC3T3 - E1 non - neoplastic cells.	False
In contrast, BC6ENTC did not affect BC6OTHER and BC6ENTG expression in MC3T3 - E1 non - neoplastic cells.	False
 BC6ENTC increases the expression of the pro - apoptotic gene BC6ENTG by epigenetic mechanisms in tumor cells.	CPR:3
Data suggest that BC6ENTC via modulation of the activity of small - BC6ENTG induce apoptosis in neoplastic cells by DNA - BC6OTHER - demethylation and stimulation of BC6OTHER - expression.	False
Data suggest that BC6ENTC via modulation of the activity of small - BC6OTHER induce apoptosis in neoplastic cells by DNA - BC6ENTG - demethylation and stimulation of BC6OTHER - expression.	False
Data suggest that BC6ENTC via modulation of the activity of small - BC6OTHER induce apoptosis in neoplastic cells by DNA - BC6OTHER - demethylation and stimulation of BC6ENTG - expression.	CPR:3
Data suggest that BC6OTHER via modulation of the activity of small - BC6ENTG induce apoptosis in neoplastic cells by DNA - BC6ENTC - demethylation and stimulation of BC6OTHER - expression.	False
Data suggest that BC6OTHER via modulation of the activity of small - BC6OTHER induce apoptosis in neoplastic cells by DNA - BC6ENTC - demethylation and stimulation of BC6ENTG - expression.	False
Further we found stimulation of BC6ENTG - expression as a result of epigenetic DNA demethylation that was due to down - regulation of BC6OTHER , which was rescued by re - isoprenylation by both BC6ENTC and BC6OTHER .	False
Further we found stimulation of BC6OTHER - expression as a result of epigenetic DNA demethylation that was due to down - regulation of BC6ENTG , which was rescued by re - isoprenylation by both BC6ENTC and BC6OTHER .	CPR:3
Further we found stimulation of BC6ENTG - expression as a result of epigenetic DNA demethylation that was due to down - regulation of BC6OTHER , which was rescued by re - isoprenylation by both BC6OTHER and BC6ENTC .	False
Further we found stimulation of BC6OTHER - expression as a result of epigenetic DNA demethylation that was due to down - regulation of BC6ENTG , which was rescued by re - isoprenylation by both BC6OTHER and BC6ENTC .	CPR:3
The presence of BC6ENTG ( BC6OTHER ), a 54 kD cytosolic glycoprotein, which is distinct from the BC6ENTC receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	False
The presence of BC6OTHER ( BC6ENTG ), a 54 kD cytosolic glycoprotein, which is distinct from the BC6ENTC receptor, was investigated in a pilot study of primary malignant melanomas and their metastases.	False
The presence of BC6ENTC binding protein ( BC6OTHER ), a 54 kD cytosolic glycoprotein, which is distinct from the BC6ENTG , was investigated in a pilot study of primary malignant melanomas and their metastases.	False
The presence of BC6ENTC binding protein ( BC6ENTG ), a 54 kD cytosolic glycoprotein, which is distinct from the BC6OTHER , was investigated in a pilot study of primary malignant melanomas and their metastases.	False
BC6ENTC did not prevent or reverse that modulatory activity; moreover, pretreatment with the acetylated peptide did not change the pA2 value displayed by the antagonist at the BC6ENTG .	False
The antinociceptive activity of the BC6ENTG agonist BC6ENTC was also increased in mice treated with alpha BC6OTHER beta - endorphin - (1 - 31).	CPR:5
The antinociceptive activity of the BC6ENTG agonist BC6OTHER was also increased in mice treated with alpha BC6ENTC beta - endorphin - (1 - 31).	False
The reducing activity of alpha BC6OTHER beta - endorphin - (1 - 31) upon BC6ENTC - and beta - endorphin - induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or BC6OTHER , agents known to impair the function of BC6ENTG / BC6OTHER transducer proteins.	False
The reducing activity of alpha BC6OTHER beta - endorphin - (1 - 31) upon BC6ENTC - and beta - endorphin - induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or BC6OTHER , agents known to impair the function of BC6OTHER / BC6ENTG transducer proteins.	False
The reducing activity of alpha BC6ENTC beta - endorphin - (1 - 31) upon BC6OTHER - and beta - endorphin - induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or BC6OTHER , agents known to impair the function of BC6ENTG / BC6OTHER transducer proteins.	False
The reducing activity of alpha BC6ENTC beta - endorphin - (1 - 31) upon BC6OTHER - and beta - endorphin - induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or BC6OTHER , agents known to impair the function of BC6OTHER / BC6ENTG transducer proteins.	False
The reducing activity of alpha BC6OTHER beta - endorphin - (1 - 31) upon BC6OTHER - and beta - endorphin - induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or BC6ENTC , agents known to impair the function of BC6ENTG / BC6OTHER transducer proteins.	False
The reducing activity of alpha BC6OTHER beta - endorphin - (1 - 31) upon BC6OTHER - and beta - endorphin - induced analgesia was not exhibited in mice undergoing treatment with pertussis toxin or BC6ENTC , agents known to impair the function of BC6OTHER / BC6ENTG transducer proteins.	False
These results confirm and strengthen the idea of alpha BC6ENTC beta - endorphin - (1 - 31) acting as a non - competitive regulator of BC6ENTG - and BC6OTHER - mediated supraspinal antinociception.	False
These results confirm and strengthen the idea of alpha BC6ENTC beta - endorphin - (1 - 31) acting as a non - competitive regulator of BC6OTHER - and BC6ENTG - mediated supraspinal antinociception.	False
BC6ENTC displayed excellent binding affinity to BC6ENTG plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice.	False
The results lend support that BC6ENTC may be a useful PET agent for detecting BC6ENTG plaques in the living human brain.	False
BC6ENTC ( BC6OTHER ) is such as an agent currently in phase III clinical studies for PET of BC6ENTG plaques in the brain.	False
BC6OTHER ( BC6ENTC ) is such as an agent currently in phase III clinical studies for PET of BC6ENTG plaques in the brain.	False
METHODS: In vitro binding of BC6ENTC to BC6ENTG plaques in the postmortem AD brain tissue was evaluated by in vitro binding assay and autoradiography.	False
In vivo biodistribution of BC6ENTC in mice and ex vivo autoradiography of AD transgenic mice ( BC6ENTG / BC6OTHER ) with BC6OTHER aggregates in the brain were performed.	False
In vivo biodistribution of BC6ENTC in mice and ex vivo autoradiography of AD transgenic mice ( BC6OTHER / BC6ENTG ) with BC6OTHER aggregates in the brain were performed.	False
In vivo biodistribution of BC6ENTC in mice and ex vivo autoradiography of AD transgenic mice ( BC6OTHER / BC6OTHER ) with BC6ENTG aggregates in the brain were performed.	False
RESULTS: BC6ENTC displayed a high binding affinity and specificity to BC6ENTG plaques (K(d), 3.72 + / - 0.30 nM).	False
Preclinical properties of BC6ENTC : a PET agent for BC6ENTG plaques in the brain.	False
The effect of BC6ENTC - a peripheral opiate agonist - on plasma BC6ENTG response to BC6OTHER ( BC6OTHER ) has been investigated in 6 patients with Addison's disease.	False
The effect of BC6ENTC - a peripheral opiate agonist - on plasma BC6OTHER response to BC6ENTG ( BC6OTHER ) has been investigated in 6 patients with Addison's disease.	False
The effect of BC6ENTC - a peripheral opiate agonist - on plasma BC6OTHER response to BC6OTHER ( BC6ENTG ) has been investigated in 6 patients with Addison's disease.	False
After BC6ENTC administration BC6OTHER levels fell to a nadir of 135 + / - 76 pg / ml, and then BC6OTHER was still able to induce an BC6OTHER increase; the pattern of BC6ENTG response to BC6OTHER was slightly delayed.	False
After BC6ENTC administration BC6OTHER levels fell to a nadir of 135 + / - 76 pg / ml, and then BC6OTHER was still able to induce an BC6OTHER increase; the pattern of BC6OTHER response to BC6ENTG was slightly delayed.	False
After BC6ENTC administration BC6ENTG levels fell to a nadir of 135 + / - 76 pg / ml, and then BC6OTHER was still able to induce an BC6OTHER increase; the pattern of BC6OTHER response to BC6OTHER was slightly delayed.	CPR:4
After BC6ENTC administration BC6OTHER levels fell to a nadir of 135 + / - 76 pg / ml, and then BC6ENTG was still able to induce an BC6OTHER increase; the pattern of BC6OTHER response to BC6OTHER was slightly delayed.	False
After BC6ENTC administration BC6OTHER levels fell to a nadir of 135 + / - 76 pg / ml, and then BC6OTHER was still able to induce an BC6ENTG increase; the pattern of BC6OTHER response to BC6OTHER was slightly delayed.	CPR:3
 BC6ENTC modifies but does not block the BC6ENTG - induced BC6OTHER response in patients with Addison's disease.	False
 BC6ENTC modifies but does not block the BC6OTHER - induced BC6ENTG response in patients with Addison's disease.	False
The interactions of chi - conopeptide MrIA with the human BC6ENTC transporter ( BC6OTHER ) were investigated by determining the effects of BC6ENTG point mutations on the inhibitory potency of MrIA.	False
The interactions of chi - conopeptide MrIA with the human BC6ENTC transporter ( BC6ENTG ) were investigated by determining the effects of BC6OTHER point mutations on the inhibitory potency of MrIA.	False
Of 18 mutations where BC6ENTG BC6OTHER residues were exchanged with those of the human BC6ENTC transporter, MrIA had increased potency for inhibition of BC6OTHER uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	False
Of 18 mutations where BC6ENTG BC6OTHER residues were exchanged with those of the human BC6OTHER transporter, MrIA had increased potency for inhibition of BC6ENTC uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	False
Of 18 mutations where BC6OTHER BC6OTHER residues were exchanged with those of the BC6ENTG , MrIA had increased potency for inhibition of BC6ENTC uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	False
chi - Conopeptide MrIA partially overlaps BC6ENTC and BC6OTHER binding sites on the BC6ENTG .	False
chi - Conopeptide MrIA partially overlaps CHEM and BC6ENTC binding sites on the BC6ENTG .	False
chi - Conopeptide MrIA partially overlaps BC6ENTG on the human BC6ENTC transporter.	False
A comparison of the results with previous data for BC6ENTC and CHEM inhibition of BC6OTHER uptake by the mutant BC6ENTG reveals that MrIA binding to BC6OTHER occurs at a site that is distinct from but overlaps with the binding sites for BC6OTHER antidepressants and BC6OTHER .	False
A comparison of the results with previous data for BC6ENTC and CHEM inhibition of BC6OTHER uptake by the mutant BC6OTHER reveals that MrIA binding to BC6ENTG occurs at a site that is distinct from but overlaps with the binding sites for BC6OTHER antidepressants and BC6OTHER .	False
A comparison of the results with previous data for BC6OTHER and CHEM inhibition of BC6ENTC uptake by the mutant BC6ENTG reveals that MrIA binding to BC6OTHER occurs at a site that is distinct from but overlaps with the binding sites for BC6OTHER antidepressants and BC6OTHER .	CPR:9
A comparison of the results with previous data for BC6OTHER and CHEM inhibition of BC6ENTC uptake by the mutant BC6OTHER reveals that MrIA binding to BC6ENTG occurs at a site that is distinct from but overlaps with the binding sites for BC6OTHER antidepressants and BC6OTHER .	False
A comparison of the results with previous data for BC6OTHER and CHEM inhibition of BC6OTHER uptake by the mutant BC6ENTG reveals that MrIA binding to BC6OTHER occurs at a site that is distinct from but overlaps with the binding sites for BC6ENTC antidepressants and BC6OTHER .	False
A comparison of the results with previous data for BC6OTHER and CHEM inhibition of BC6OTHER uptake by the mutant BC6OTHER reveals that MrIA binding to BC6ENTG occurs at a site that is distinct from but overlaps with the binding sites for BC6ENTC antidepressants and BC6OTHER .	False
A comparison of the results with previous data for BC6OTHER and CHEM inhibition of BC6OTHER uptake by the mutant BC6ENTG reveals that MrIA binding to BC6OTHER occurs at a site that is distinct from but overlaps with the binding sites for BC6OTHER antidepressants and BC6ENTC .	False
A comparison of the results with previous data for BC6OTHER and CHEM inhibition of BC6OTHER uptake by the mutant BC6OTHER reveals that MrIA binding to BC6ENTG occurs at a site that is distinct from but overlaps with the binding sites for BC6OTHER antidepressants and BC6ENTC .	False
The potency of MrIA was greater for inhibition of uptake by BC6ENTG of BC6ENTC (Ki 1.89 microM) than BC6OTHER (Ki 4.33 microM), and the human BC6OTHER transporter and BC6OTHER transporter were not inhibited by MrIA (to 7 microM).	CPR:9
The potency of MrIA was greater for inhibition of uptake by BC6OTHER of BC6ENTC (Ki 1.89 microM) than BC6OTHER (Ki 4.33 microM), and the BC6ENTG and BC6OTHER transporter were not inhibited by MrIA (to 7 microM).	False
The potency of MrIA was greater for inhibition of uptake by BC6OTHER of BC6ENTC (Ki 1.89 microM) than BC6OTHER (Ki 4.33 microM), and the human BC6OTHER transporter and BC6ENTG were not inhibited by MrIA (to 7 microM).	False
The potency of MrIA was greater for inhibition of uptake by BC6ENTG of BC6OTHER (Ki 1.89 microM) than BC6ENTC (Ki 4.33 microM), and the human BC6OTHER transporter and BC6OTHER transporter were not inhibited by MrIA (to 7 microM).	CPR:9
The potency of MrIA was greater for inhibition of uptake by BC6OTHER of BC6OTHER (Ki 1.89 microM) than BC6ENTC (Ki 4.33 microM), and the BC6ENTG and BC6OTHER transporter were not inhibited by MrIA (to 7 microM).	False
The potency of MrIA was greater for inhibition of uptake by BC6OTHER of BC6OTHER (Ki 1.89 microM) than BC6ENTC (Ki 4.33 microM), and the human BC6OTHER transporter and BC6ENTG were not inhibited by MrIA (to 7 microM).	False
The potency of MrIA was greater for inhibition of uptake by BC6ENTG of BC6OTHER (Ki 1.89 microM) than BC6OTHER (Ki 4.33 microM), and the human BC6ENTC transporter and BC6OTHER transporter were not inhibited by MrIA (to 7 microM).	False
The potency of MrIA was greater for inhibition of uptake by BC6OTHER of BC6OTHER (Ki 1.89 microM) than BC6OTHER (Ki 4.33 microM), and the human BC6ENTC transporter and BC6ENTG were not inhibited by MrIA (to 7 microM).	False
The potency of MrIA was greater for inhibition of uptake by BC6ENTG of BC6OTHER (Ki 1.89 microM) than BC6OTHER (Ki 4.33 microM), and the human BC6OTHER transporter and BC6ENTC transporter were not inhibited by MrIA (to 7 microM).	False
The potency of MrIA was greater for inhibition of uptake by BC6OTHER of BC6OTHER (Ki 1.89 microM) than BC6OTHER (Ki 4.33 microM), and the BC6ENTG and BC6ENTC transporter were not inhibited by MrIA (to 7 microM).	False
Of 18 mutations where BC6ENTG BC6ENTC residues were exchanged with those of the human BC6OTHER transporter, MrIA had increased potency for inhibition of BC6OTHER uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	False
Of 18 mutations where BC6OTHER BC6ENTC residues were exchanged with those of the BC6ENTG , MrIA had increased potency for inhibition of BC6OTHER uptake for three mutations (in predicted extracellular loops 3 and 4 and transmembrane domain (TMD) 8) and decreased potency for one mutation (in TMD6 and intracellular loop (IL) 3).	False
In contrast, the mutants BC6OTHER , BC6OTHER and BC6OTHER showed increased K(i) for BC6ENTC but no difference for BC6OTHER from the recombinant BC6ENTG .	CPR:4
In contrast, the mutants BC6ENTG , BC6OTHER and BC6OTHER showed increased K(i) for BC6ENTC but no difference for BC6OTHER from the recombinant BC6OTHER .	CPR:4
In contrast, the mutants BC6OTHER , BC6ENTG and BC6OTHER showed increased K(i) for BC6ENTC but no difference for BC6OTHER from the recombinant BC6OTHER .	CPR:4
In contrast, the mutants BC6OTHER , BC6OTHER and BC6ENTG showed increased K(i) for BC6ENTC but no difference for BC6OTHER from the recombinant BC6OTHER .	CPR:4
In contrast, the mutants BC6OTHER , BC6OTHER and BC6OTHER showed increased K(i) for BC6OTHER but no difference for BC6ENTC from the recombinant BC6ENTG .	CPR:4
In contrast, the mutants BC6ENTG , BC6OTHER and BC6OTHER showed increased K(i) for BC6OTHER but no difference for BC6ENTC from the recombinant BC6OTHER .	CPR:4
In contrast, the mutants BC6OTHER , BC6ENTG and BC6OTHER showed increased K(i) for BC6OTHER but no difference for BC6ENTC from the recombinant BC6OTHER .	CPR:4
In contrast, the mutants BC6OTHER , BC6OTHER and BC6ENTG showed increased K(i) for BC6OTHER but no difference for BC6ENTC from the recombinant BC6OTHER .	CPR:4
Identification of interaction sites of cyclic BC6OTHER BC6ENTG with BC6OTHER and BC6ENTC using molecular modeling and site - directed mutagenesis.	False
Identification of interaction sites of cyclic BC6ENTC BC6ENTG with BC6OTHER and BC6OTHER using molecular modeling and site - directed mutagenesis.	False
Identification of interaction sites of cyclic BC6OTHER BC6ENTG with BC6ENTC and BC6OTHER using molecular modeling and site - directed mutagenesis.	False
Molecular models show that the BC6ENTG inhibitors BC6ENTC and BC6OTHER share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against BC6OTHER active site.	CPR:4
Molecular models show that the BC6OTHER inhibitors BC6ENTC and BC6OTHER share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against BC6ENTG active site.	False
Molecular models show that the BC6ENTG inhibitors BC6OTHER and BC6ENTC share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against BC6OTHER active site.	CPR:4
Molecular models show that the BC6OTHER inhibitors BC6OTHER and BC6ENTC share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against BC6ENTG active site.	False
To identify BC6ENTC residues involved in BC6OTHER - selective inhibitor binding, we selected eight presumed interacting residues in the substrate - binding pocket of BC6ENTG using a model created on basis of homology to the BC6OTHER crystal structure.	False
To identify BC6ENTC residues involved in BC6OTHER - selective inhibitor binding, we selected eight presumed interacting residues in the substrate - binding pocket of BC6OTHER using a model created on basis of homology to the BC6ENTG crystal structure.	False
To identify BC6ENTC residues involved in BC6ENTG - selective inhibitor binding, we selected eight presumed interacting residues in the substrate - binding pocket of BC6OTHER using a model created on basis of homology to the BC6OTHER crystal structure.	False
Our study implies that highly conserved residuals Y751, D950 and F1004 in the BC6ENTG families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the BC6ENTC selectivity of BC6OTHER .	CPR:4
Our study implies that highly conserved residuals Y751, D950 and F1004 in the BC6OTHER families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the BC6ENTC selectivity of BC6ENTG .	CPR:4
We changed the residues to BC6ENTC using site - directed mutagenesis technique, expressed the mutants in a baculovirus / Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by BC6OTHER and BC6OTHER , specific inhibitors of BC6ENTG .	False
We changed the residues to BC6OTHER using site - directed mutagenesis technique, expressed the mutants in a baculovirus / Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by BC6ENTC and BC6OTHER , specific inhibitors of BC6ENTG .	CPR:4
We changed the residues to BC6OTHER using site - directed mutagenesis technique, expressed the mutants in a baculovirus / Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by BC6OTHER and BC6ENTC , specific inhibitors of BC6ENTG .	CPR:4
Mutants BC6ENTG , BC6OTHER , and BC6OTHER had reduced sensitivity to BC6ENTC (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6OTHER (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	CPR:4
Mutants BC6OTHER , BC6ENTG , and BC6OTHER had reduced sensitivity to BC6ENTC (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6OTHER (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	CPR:4
Mutants BC6OTHER , BC6OTHER , and BC6ENTG had reduced sensitivity to BC6ENTC (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6OTHER (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	CPR:4
Mutants BC6OTHER , BC6OTHER , and BC6OTHER had reduced sensitivity to BC6ENTC (K(i) changed from 0.66 microM for the recombinant BC6ENTG to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6OTHER (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	CPR:4
Mutants BC6OTHER , BC6OTHER , and BC6OTHER had reduced sensitivity to BC6ENTC (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6OTHER (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6ENTG ).	False
Mutants BC6ENTG , BC6OTHER , and BC6OTHER had reduced sensitivity to BC6OTHER (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6ENTC (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	False
Mutants BC6OTHER , BC6ENTG , and BC6OTHER had reduced sensitivity to BC6OTHER (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6ENTC (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	False
Mutants BC6OTHER , BC6OTHER , and BC6ENTG had reduced sensitivity to BC6OTHER (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6ENTC (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	False
Mutants BC6OTHER , BC6OTHER , and BC6OTHER had reduced sensitivity to BC6OTHER (K(i) changed from 0.66 microM for the recombinant BC6ENTG to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6ENTC (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6OTHER ).	False
Mutants BC6OTHER , BC6OTHER , and BC6OTHER had reduced sensitivity to BC6OTHER (K(i) changed from 0.66 microM for the recombinant BC6OTHER to 7.5 to 156 microM for the mutants), and diminished sensitivity to BC6ENTC (K(i) of the mutants were 18 - to 371 - fold higher than that of the recombinant BC6ENTG ).	CPR:4
While previous work from our lab suggests that BC6OTHER mediate the effect of BC6ENTC on excitatory transmission in other subregions of the extended amygdala, blockade of BC6ENTG in the CeAL failed to significantly alter effects of DA and BC6OTHER on glutamatergic transmission.	False
While previous work from our lab suggests that BC6ENTG mediate the effect of BC6ENTC on excitatory transmission in other subregions of the extended amygdala, blockade of BC6OTHER in the CeAL failed to significantly alter effects of DA and BC6OTHER on glutamatergic transmission.	False
 BC6ENTG and BC6ENTC enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala.	False
While previous work from our lab suggests that BC6OTHER mediate the effect of BC6OTHER on excitatory transmission in other subregions of the extended amygdala, blockade of BC6ENTG in the CeAL failed to significantly alter effects of DA and BC6ENTC on glutamatergic transmission.	False
While previous work from our lab suggests that BC6ENTG mediate the effect of BC6OTHER on excitatory transmission in other subregions of the extended amygdala, blockade of BC6OTHER in the CeAL failed to significantly alter effects of DA and BC6ENTC on glutamatergic transmission.	False
These findings suggest that BC6ENTC and BC6ENTG enhancement of glutamatergic transmission onto CeAL neurons occurs via distinct mechanisms.	False
While BC6ENTG increased spontaneous BC6ENTC release in the CeAL, BC6OTHER caused no significant changes to optogenetically evoked BC6OTHER release in this region.	False
While BC6OTHER increased spontaneous BC6ENTC release in the CeAL, BC6ENTG caused no significant changes to optogenetically evoked BC6OTHER release in this region.	False
While BC6ENTG increased spontaneous BC6OTHER release in the CeAL, BC6OTHER caused no significant changes to optogenetically evoked BC6ENTC release in this region.	False
While BC6OTHER increased spontaneous BC6OTHER release in the CeAL, BC6ENTG caused no significant changes to optogenetically evoked BC6ENTC release in this region.	False
While these behaviors can be modulated by BC6ENTG ( BC6OTHER ) and BC6ENTC signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.	False
While these behaviors can be modulated by BC6OTHER ( BC6ENTG ) and BC6ENTC signaling, the mechanism(s) by which these signals modify CeA glutamatergic neurotransmission remains unclear.	False
Utilizing whole - cell patch - clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that BC6ENTG , BC6ENTC (DA) and the β - adrenergic receptor agonist BC6OTHER ( BC6OTHER ) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic BC6OTHER release.	False
Utilizing whole - cell patch - clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that BC6ENTG , BC6OTHER (DA) and the β - adrenergic receptor agonist BC6ENTC ( BC6OTHER ) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic BC6OTHER release.	False
Utilizing whole - cell patch - clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that BC6OTHER , BC6ENTG agonist BC6ENTC ( BC6OTHER ) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic BC6OTHER release.	False
Utilizing whole - cell patch - clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that BC6ENTG , BC6OTHER (DA) and the β - adrenergic receptor agonist BC6OTHER ( BC6ENTC ) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic BC6OTHER release.	False
Utilizing whole - cell patch - clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that BC6OTHER , BC6ENTG agonist BC6OTHER ( BC6ENTC ) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic BC6OTHER release.	False
Utilizing whole - cell patch - clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that BC6ENTG , BC6OTHER (DA) and the β - adrenergic receptor agonist BC6OTHER ( BC6OTHER ) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic BC6ENTC release.	False
Utilizing whole - cell patch - clamp electrophysiology recordings from neurons in the lateral subdivision of the CeA (CeAL), we show that BC6OTHER , BC6ENTG agonist BC6OTHER ( BC6OTHER ) all enhance the frequency of spontaneous excitatory postsynaptic currents (sEPSC) without altering sEPSC kinetics, suggesting they increase presynaptic BC6ENTC release.	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6OTHER diet and BC6ENTC exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6ENTG (1.5mg / ml), BC6OTHER (1.0mg / ml) and BC6OTHER (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6OTHER .	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6OTHER diet and BC6ENTC exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6OTHER (1.5mg / ml), BC6ENTG (1.0mg / ml) and BC6OTHER (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6OTHER .	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6OTHER diet and BC6OTHER exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6ENTG (1.5mg / ml), BC6OTHER (1.0mg / ml) and BC6ENTC (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6OTHER .	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6OTHER diet and BC6OTHER exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6OTHER (1.5mg / ml), BC6ENTG (1.0mg / ml) and BC6ENTC (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6OTHER .	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6OTHER diet and BC6OTHER exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6ENTG (1.5mg / ml), BC6OTHER (1.0mg / ml) and BC6OTHER (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6ENTC .	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6OTHER diet and BC6OTHER exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6OTHER (1.5mg / ml), BC6ENTG (1.0mg / ml) and BC6OTHER (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6ENTC .	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6ENTC synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6ENTC synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), while causing no changes in endothelial BC6ENTC synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), while causing no changes in endothelial BC6ENTC synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6ENTC synthase ( BC6ENTG ) protein expression and BC6OTHER ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6ENTC ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6ENTC ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6ENTC ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6ENTC ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in BC6ENTG ( BC6OTHER ) protein expression and BC6ENTC ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6ENTG ) protein expression and BC6ENTC ( BC6OTHER ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6ENTC ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6ENTC ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6ENTC ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), while causing no changes in endothelial BC6OTHER synthase ( BC6OTHER ) protein expression and BC6OTHER ( BC6ENTC ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in BC6ENTG ( BC6OTHER ) protein expression and BC6OTHER ( BC6ENTC ) release.	False
NCM1 treatment did not affect cell viability, but increased cell size, disrupted cell membrane integrity, and decreased cell density, uptake of small peptides, release of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), while causing no changes in endothelial BC6OTHER synthase ( BC6ENTG ) protein expression and BC6OTHER ( BC6ENTC ) release.	False
In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, BC6ENTG protein expression, and BC6ENTC release and caused membrane damage, but caused no changes in the secretion of BC6OTHER , BC6OTHER and BC6OTHER .	False
In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, BC6OTHER protein expression, and BC6ENTC release and caused membrane damage, but caused no changes in the secretion of BC6ENTG , BC6OTHER and BC6OTHER .	False
In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, BC6OTHER protein expression, and BC6ENTC release and caused membrane damage, but caused no changes in the secretion of BC6OTHER , BC6OTHER and BC6ENTG .	False
In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, BC6ENTG protein expression, and BC6OTHER release and caused membrane damage, but caused no changes in the secretion of BC6OTHER , BC6ENTC and BC6OTHER .	False
In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, BC6OTHER protein expression, and BC6OTHER release and caused membrane damage, but caused no changes in the secretion of BC6ENTG , BC6ENTC and BC6OTHER .	False
In contrast, NCM2 decreased cell viability, total protein yield, uptake of small peptides, BC6OTHER protein expression, and BC6OTHER release and caused membrane damage, but caused no changes in the secretion of BC6OTHER , BC6ENTC and BC6ENTG .	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6ENTC diet and BC6OTHER exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6ENTG (1.5mg / ml), BC6OTHER (1.0mg / ml) and BC6OTHER (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6OTHER .	False
To determine if these contaminants may contribute to a cardiovascular health risk, especially when combined with a high fat and BC6ENTC diet and BC6OTHER exposure, we treated human coronary artery endothelial cells (HCAEC) with two mixtures of 4 organic (NCM1) or 22 organic and inorganic (NCM2) chemicals detected in Northerners' blood during 2004 - 2005 in the presence or absence of BC6OTHER (1.5mg / ml), BC6ENTG (1.0mg / ml) and BC6OTHER (10mmol / L) (LVG), and in the absence or presence of 0.1% BC6OTHER .	False
In this study, we report and analyze the functional consequences of three novel missense mutations, BC6ENTG , BC6OTHER and BC6OTHER , identified in the highly conserved C - BC6ENTC - finger (C - ZF) domain of BC6OTHER .	False
In this study, we report and analyze the functional consequences of three novel missense mutations, BC6OTHER , BC6ENTG and BC6OTHER , identified in the highly conserved C - BC6ENTC - finger (C - ZF) domain of BC6OTHER .	False
In this study, we report and analyze the functional consequences of three novel missense mutations, BC6OTHER , BC6OTHER and BC6ENTG , identified in the highly conserved C - BC6ENTC - finger (C - ZF) domain of BC6OTHER .	False
In this study, we report and analyze the functional consequences of three novel missense mutations, BC6OTHER , BC6OTHER and BC6OTHER , identified in the highly conserved C - BC6ENTC - finger (C - ZF) domain of BC6ENTG .	False
 BC6ENTG BC6ENTC - finger missense mutations lead to hypomorphic alleles and a mild Mowat - Wilson syndrome.	False
Store - operated BC6OTHER Entry (SOCE) Induced by BC6OTHER mediates BC6OTHER Phosphorylation to inhibit SOCE in Endothelial Cells through BC6ENTC - activated Protein Kinase and BC6ENTG BC6OTHER .	False
Store - operated BC6OTHER Entry (SOCE) Induced by BC6OTHER mediates BC6OTHER Phosphorylation to inhibit SOCE in Endothelial Cells through BC6ENTC - activated Protein Kinase and BC6OTHER BC6ENTG .	False
Store - operated BC6OTHER Entry (SOCE) Induced by BC6ENTG mediates BC6OTHER Phosphorylation to inhibit SOCE in Endothelial Cells through BC6ENTC - activated Protein Kinase and BC6OTHER BC6OTHER .	False
Store - operated BC6OTHER Entry (SOCE) Induced by BC6OTHER mediates BC6ENTG Phosphorylation to inhibit SOCE in Endothelial Cells through BC6ENTC - activated Protein Kinase and BC6OTHER BC6OTHER .	False
Store - operated BC6ENTC Entry (SOCE) Induced by BC6OTHER mediates BC6OTHER Phosphorylation to inhibit SOCE in Endothelial Cells through BC6ENTG and BC6OTHER BC6OTHER .	False
Store - operated BC6ENTC Entry (SOCE) Induced by BC6OTHER mediates BC6OTHER Phosphorylation to inhibit SOCE in Endothelial Cells through BC6OTHER and BC6ENTG BC6OTHER .	False
Store - operated BC6ENTC Entry (SOCE) Induced by BC6OTHER mediates BC6OTHER Phosphorylation to inhibit SOCE in Endothelial Cells through BC6OTHER and BC6OTHER BC6ENTG .	False
Store - operated BC6ENTC Entry (SOCE) Induced by BC6ENTG mediates BC6OTHER Phosphorylation to inhibit SOCE in Endothelial Cells through BC6OTHER and BC6OTHER BC6OTHER .	False
Store - operated BC6ENTC Entry (SOCE) Induced by BC6OTHER mediates BC6ENTG Phosphorylation to inhibit SOCE in Endothelial Cells through BC6OTHER and BC6OTHER BC6OTHER .	False
Interestingly, BC6OTHER , a selective inhibitor of BC6ENTG BC6OTHER , blocked BC6OTHER phosphorylation and led to sustained BC6OTHER - puncta formation and BC6ENTC entry.	False
Interestingly, BC6OTHER , a selective inhibitor of BC6OTHER BC6ENTG , blocked BC6OTHER phosphorylation and led to sustained BC6OTHER - puncta formation and BC6ENTC entry.	False
Interestingly, BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER , blocked BC6ENTG phosphorylation and led to sustained BC6OTHER - puncta formation and BC6ENTC entry.	False
Interestingly, BC6OTHER , a selective inhibitor of BC6OTHER BC6OTHER , blocked BC6OTHER phosphorylation and led to sustained BC6ENTG - puncta formation and BC6ENTC entry.	False
Here we show that SOCE activates BC6ENTC - activated protein kinase ( BC6ENTG ); its effector BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) phosphorylates BC6OTHER , thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	False
Here we show that SOCE activates BC6ENTC - activated protein kinase ( BC6OTHER ); its effector BC6ENTG BC6OTHER ( BC6OTHER BC6OTHER ) phosphorylates BC6OTHER , thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	False
Here we show that SOCE activates BC6ENTC - activated protein kinase ( BC6OTHER ); its effector BC6OTHER BC6ENTG ( BC6OTHER BC6OTHER ) phosphorylates BC6OTHER , thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	False
Here we show that SOCE activates BC6ENTC - activated protein kinase ( BC6OTHER ); its effector BC6OTHER BC6OTHER ( BC6ENTG BC6OTHER ) phosphorylates BC6OTHER , thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	False
Here we show that SOCE activates BC6ENTC - activated protein kinase ( BC6OTHER ); its effector BC6OTHER BC6OTHER ( BC6OTHER BC6ENTG ) phosphorylates BC6OTHER , thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	False
Here we show that SOCE activates BC6ENTC - activated protein kinase ( BC6OTHER ); its effector BC6OTHER BC6OTHER ( BC6OTHER BC6OTHER ) phosphorylates BC6ENTG , thus inhibiting SOCE in human lung microvascular endothelial cells (ECs).	False
The BC6ENTC sensor BC6OTHER is crucial for activation of store - operated BC6OTHER entry (SOCE) through BC6OTHER and BC6ENTG .	False
The BC6ENTC sensor BC6ENTG is crucial for activation of store - operated BC6OTHER entry (SOCE) through BC6OTHER and BC6OTHER .	False
The BC6ENTC sensor BC6OTHER is crucial for activation of store - operated BC6OTHER entry (SOCE) through BC6ENTG and BC6OTHER .	False
Activation of BC6ENTG using BC6ENTC resulted in BC6OTHER phosphorylation on BC6OTHER residues and prevented BC6OTHER - induced BC6OTHER entry.	CPR:3
Activation of BC6OTHER using BC6ENTC resulted in BC6ENTG phosphorylation on BC6OTHER residues and prevented BC6OTHER - induced BC6OTHER entry.	CPR:3
Activation of BC6OTHER using BC6ENTC resulted in BC6OTHER phosphorylation on BC6OTHER residues and prevented BC6ENTG - induced BC6OTHER entry.	CPR:4
Activation of BC6ENTG using BC6OTHER resulted in BC6OTHER phosphorylation on BC6ENTC residues and prevented BC6OTHER - induced BC6OTHER entry.	False
Activation of BC6OTHER using BC6OTHER resulted in BC6ENTG phosphorylation on BC6ENTC residues and prevented BC6OTHER - induced BC6OTHER entry.	False
Activation of BC6OTHER using BC6OTHER resulted in BC6OTHER phosphorylation on BC6ENTC residues and prevented BC6ENTG - induced BC6OTHER entry.	False
Activation of BC6ENTG using BC6OTHER resulted in BC6OTHER phosphorylation on BC6OTHER residues and prevented BC6OTHER - induced BC6ENTC entry.	False
Activation of BC6OTHER using BC6OTHER resulted in BC6ENTG phosphorylation on BC6OTHER residues and prevented BC6OTHER - induced BC6ENTC entry.	False
Activation of BC6OTHER using BC6OTHER resulted in BC6OTHER phosphorylation on BC6OTHER residues and prevented BC6ENTG - induced BC6ENTC entry.	False
Further, BC6ENTC pretreatment blocked BC6ENTG - induced increase in permeability of mouse - lung microvessels.	CPR:4
The BC6OTHER sensor BC6OTHER is crucial for activation of store - operated BC6ENTC entry (SOCE) through BC6OTHER and BC6ENTG .	False
The BC6OTHER sensor BC6ENTG is crucial for activation of store - operated BC6ENTC entry (SOCE) through BC6OTHER and BC6OTHER .	False
The BC6OTHER sensor BC6OTHER is crucial for activation of store - operated BC6ENTC entry (SOCE) through BC6ENTG and BC6OTHER .	False
Interestingly, BC6ENTC , a selective inhibitor of BC6ENTG BC6OTHER , blocked BC6OTHER phosphorylation and led to sustained BC6OTHER - puncta formation and BC6OTHER entry.	CPR:4
Interestingly, BC6ENTC , a selective inhibitor of BC6OTHER BC6ENTG , blocked BC6OTHER phosphorylation and led to sustained BC6OTHER - puncta formation and BC6OTHER entry.	CPR:4
Interestingly, BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER , blocked BC6ENTG phosphorylation and led to sustained BC6OTHER - puncta formation and BC6OTHER entry.	CPR:4
Interestingly, BC6ENTC , a selective inhibitor of BC6OTHER BC6OTHER , blocked BC6OTHER phosphorylation and led to sustained BC6ENTG - puncta formation and BC6OTHER entry.	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6ENTC 836, and BC6OTHER 840) within the membrane proximal region of the BC6ENTG BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6ENTC 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6ENTG - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6ENTC 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6ENTG .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6OTHER 836, and BC6ENTC 840) within the membrane proximal region of the BC6ENTG BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6OTHER 836, and BC6ENTC 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6ENTG - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6OTHER 836, and BC6ENTC 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6ENTG .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6ENTG BC6ENTC - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6ENTC - terminal domain that, in combination, are required for BC6ENTG - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6OTHER 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6ENTC - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6ENTG .	False
BC6ENTG activation is influenced by metabotropic BC6ENTC receptor ( BC6OTHER ) signaling, but the underlying mechanisms are not understood.	False
BC6OTHER activation is influenced by metabotropic BC6ENTC receptor ( BC6ENTG ) signaling, but the underlying mechanisms are not understood.	False
BC6ENTG ( BC6OTHER ), a family of ionotropic BC6ENTC receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	False
BC6OTHER ( BC6ENTG ), a family of ionotropic BC6ENTC receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	False
In hippocampal and cortical cultures, the BC6ENTC signal caused by activation of native BC6ENTG was potentiated by activation of BC6OTHER .	False
In hippocampal and cortical cultures, the BC6ENTC signal caused by activation of native BC6OTHER was potentiated by activation of BC6ENTG .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6ENTC chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6ENTG inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6ENTC chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6ENTG inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6ENTG by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6ENTC chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6ENTG activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6ENTC chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6ENTG or the BC6ENTC chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
Activation of group I metabotropic BC6ENTC receptors potentiates heteromeric BC6ENTG .	False
Activation of BC6ENTG potentiates heteromeric BC6ENTC receptors.	False
BC6ENTC receptors ( BC6ENTG ), a family of ionotropic BC6OTHER receptors, are widely expressed in the central nervous system and are critically involved in synaptic transmission.	False
BC6ENTC receptors ( BC6OTHER ), a family of BC6ENTG , are widely expressed in the central nervous system and are critically involved in synaptic transmission.	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6ENTC ( BC6OTHER ), prolonged by the BC6ENTG inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6ENTC ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6ENTG inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6ENTG by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6ENTC ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6ENTG activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6ENTC ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6ENTG or the BC6OTHER chelator BC6ENTC ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6ENTC ), prolonged by the BC6ENTG inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6ENTC ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6ENTG inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6ENTG by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6ENTC ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6ENTG activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6ENTC ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6ENTG or the BC6OTHER chelator BC6OTHER ( BC6ENTC ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6ENTG inhibitor BC6ENTC , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6ENTC , but unaffected by the BC6ENTG inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6ENTG by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6ENTC , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6ENTG activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6ENTC , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6ENTG or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6ENTC , but unaffected by the BC6OTHER kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6ENTG inhibitor BC6OTHER , but unaffected by the BC6ENTC kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6ENTG by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6ENTC kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6ENTG activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6ENTC kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6ENTG or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6ENTC kinase inhibitor BC6OTHER .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6ENTG inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6ENTC .	False
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6ENTG inhibitor BC6ENTC .	CPR:4
The potentiation of heteromeric BC6ENTG by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6ENTC .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6ENTG activation was attenuated by GDPβS, blocked by an inhibitor of BC6OTHER or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6ENTC .	CPR:4
The potentiation of heteromeric BC6OTHER by BC6OTHER activation was attenuated by GDPβS, blocked by an inhibitor of BC6ENTG or the BC6OTHER chelator BC6OTHER ( BC6OTHER ), prolonged by the BC6OTHER inhibitor BC6OTHER , but unaffected by the BC6OTHER kinase inhibitor BC6ENTC .	False
BC6ENTG ( BC6OTHER ) inhibition reduced the potentiation by BC6OTHER of BC6OTHER / BC6OTHER , and conversely, direct activation of BC6OTHER by BC6ENTC potentiated BC6OTHER / BC6OTHER .	False
BC6OTHER ( BC6ENTG ) inhibition reduced the potentiation by BC6OTHER of BC6OTHER / BC6OTHER , and conversely, direct activation of BC6OTHER by BC6ENTC potentiated BC6OTHER / BC6OTHER .	False
BC6OTHER ( BC6OTHER ) inhibition reduced the potentiation by BC6ENTG of BC6OTHER / BC6OTHER , and conversely, direct activation of BC6OTHER by BC6ENTC potentiated BC6OTHER / BC6OTHER .	False
BC6OTHER ( BC6OTHER ) inhibition reduced the potentiation by BC6OTHER of BC6ENTG / BC6OTHER , and conversely, direct activation of BC6OTHER by BC6ENTC potentiated BC6OTHER / BC6OTHER .	False
BC6OTHER ( BC6OTHER ) inhibition reduced the potentiation by BC6OTHER of BC6OTHER / BC6ENTG , and conversely, direct activation of BC6OTHER by BC6ENTC potentiated BC6OTHER / BC6OTHER .	False
BC6OTHER ( BC6OTHER ) inhibition reduced the potentiation by BC6OTHER of BC6OTHER / BC6OTHER , and conversely, direct activation of BC6ENTG by BC6ENTC potentiated BC6OTHER / BC6OTHER .	CPR:3
BC6OTHER ( BC6OTHER ) inhibition reduced the potentiation by BC6OTHER of BC6OTHER / BC6OTHER , and conversely, direct activation of BC6OTHER by BC6ENTC potentiated BC6ENTG / BC6OTHER .	CPR:3
BC6OTHER ( BC6OTHER ) inhibition reduced the potentiation by BC6OTHER of BC6OTHER / BC6OTHER , and conversely, direct activation of BC6OTHER by BC6ENTC potentiated BC6OTHER / BC6ENTG .	CPR:3
Using site - directed mutagenesis, we identified three BC6ENTC ( BC6OTHER 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6ENTG BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6ENTC ( BC6OTHER 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6ENTG - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6ENTC ( BC6OTHER 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6ENTG .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6ENTC 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6ENTG BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6ENTC 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6ENTG - mediated potentiation of BC6OTHER .	False
Using site - directed mutagenesis, we identified three BC6OTHER ( BC6ENTC 833, BC6OTHER 836, and BC6OTHER 840) within the membrane proximal region of the BC6OTHER BC6OTHER - terminal domain that, in combination, are required for BC6OTHER - mediated potentiation of BC6ENTG .	False
Little is known about the influence of BC6ENTC converting enzyme ( BC6OTHER ) inhibitors on BC6OTHER ( BC6ENTG ) in right ventricular remodeling.	False
Little is known about the influence of BC6ENTC converting enzyme ( BC6ENTG ) inhibitors on BC6OTHER ( BC6OTHER ) in right ventricular remodeling.	False
Little is known about the influence of BC6ENTC converting enzyme ( BC6OTHER ) inhibitors on BC6ENTG ( BC6OTHER ) in right ventricular remodeling.	False
 BC6ENTC attenuates BC6ENTG in BC6OTHER - induced right ventricular hypertrophy in rats.	False
 BC6OTHER attenuates BC6ENTG in BC6ENTC - induced right ventricular hypertrophy in rats.	False
BC6ENTG and BC6OTHER expressions and activities in right ventricles increased significantly in BC6ENTC - injected rats and BC6OTHER inhibited them.	CPR:3
BC6OTHER and BC6ENTG expressions and activities in right ventricles increased significantly in BC6ENTC - injected rats and BC6OTHER inhibited them.	CPR:3
BC6ENTG and BC6OTHER expressions and activities in right ventricles increased significantly in BC6OTHER - injected rats and BC6ENTC inhibited them.	CPR:4
BC6OTHER and BC6ENTG expressions and activities in right ventricles increased significantly in BC6OTHER - injected rats and BC6ENTC inhibited them.	CPR:4
These findings indicate that BC6ENTC attenuates the development of BC6OTHER - induced right ventricular hypertrophy in association with inhibition of BC6ENTG and BC6OTHER in rats.	CPR:4
These findings indicate that BC6ENTC attenuates the development of BC6OTHER - induced right ventricular hypertrophy in association with inhibition of BC6OTHER and BC6ENTG in rats.	CPR:4
These findings indicate that BC6OTHER attenuates the development of BC6ENTC - induced right ventricular hypertrophy in association with inhibition of BC6ENTG and BC6OTHER in rats.	CPR:3
These findings indicate that BC6OTHER attenuates the development of BC6ENTC - induced right ventricular hypertrophy in association with inhibition of BC6OTHER and BC6ENTG in rats.	CPR:3
We investigated the effect of BC6ENTC , an BC6ENTG inhibitor, on BC6OTHER and BC6OTHER in BC6OTHER - induced right ventricular hypertrophy.	CPR:4
We investigated the effect of BC6ENTC , an BC6OTHER inhibitor, on BC6ENTG and BC6OTHER in BC6OTHER - induced right ventricular hypertrophy.	False
We investigated the effect of BC6ENTC , an BC6OTHER inhibitor, on BC6OTHER and BC6ENTG in BC6OTHER - induced right ventricular hypertrophy.	False
We investigated the effect of BC6OTHER , an BC6ENTG inhibitor, on BC6OTHER and BC6OTHER in BC6ENTC - induced right ventricular hypertrophy.	False
We investigated the effect of BC6OTHER , an BC6OTHER inhibitor, on BC6ENTG and BC6OTHER in BC6ENTC - induced right ventricular hypertrophy.	False
We investigated the effect of BC6OTHER , an BC6OTHER inhibitor, on BC6OTHER and BC6ENTG in BC6ENTC - induced right ventricular hypertrophy.	False
In conclusion, BC6ENTG can transport BC6OTHER and BC6ENTC drugs, and sensitizes cells to their cytotoxicities.	CPR:9
DRG neurons display substantial capacity for accumulating BC6ENTC via a transport process mediated by BC6ENTG , but appear able to resist BC6OTHER toxicity and use alternative mechanisms to take up BC6OTHER .	CPR:9
DRG neurons display substantial capacity for accumulating BC6OTHER via a transport process mediated by BC6ENTG , but appear able to resist BC6ENTC toxicity and use alternative mechanisms to take up BC6OTHER .	False
DRG neurons display substantial capacity for accumulating BC6OTHER via a transport process mediated by BC6ENTG , but appear able to resist BC6OTHER toxicity and use alternative mechanisms to take up BC6ENTC .	CPR:9
This study aimed to understand the role of BC6ENTC transporter 1 ( BC6ENTG ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6ENTC transporter 1 ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6ENTG ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6ENTC transporter 1 ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6ENTG ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6ENTG ( BC6OTHER ) in the uptake and toxicity of BC6ENTC and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6ENTG ) in the uptake and toxicity of BC6ENTC and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6ENTC and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6ENTG ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6ENTC and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6ENTG ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6ENTG ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6ENTC drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6ENTG ) in the uptake and toxicity of BC6OTHER and BC6ENTC drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6ENTC drugs in cultured rat DRG neurons, and the functional activities of BC6ENTG ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6ENTC drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6ENTG ) as a membrane transporter of BC6OTHER and BC6OTHER drugs.	False
This study aimed to understand the role of BC6ENTG ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6ENTC and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6ENTG ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6ENTC and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6ENTG ( BC6OTHER ) as a membrane transporter of BC6ENTC and BC6OTHER drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6ENTG ) as a membrane transporter of BC6ENTC and BC6OTHER drugs.	False
This study aimed to understand the role of BC6ENTG ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6ENTC drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6ENTG ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6ENTC drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6ENTG ( BC6OTHER ) as a membrane transporter of BC6OTHER and BC6ENTC drugs.	False
This study aimed to understand the role of BC6OTHER ( BC6OTHER ) in the uptake and toxicity of BC6OTHER and BC6OTHER drugs in cultured rat DRG neurons, and the functional activities of BC6OTHER ( BC6ENTG ) as a membrane transporter of BC6OTHER and BC6ENTC drugs.	False
The uptake of BC6OTHER by both cultured rat DRG neurons and HEK / BC6OTHER cells was saturable and inhibited by cold temperature, BC6OTHER and BC6ENTC , consistent with it being mediated by BC6ENTG .	False
The uptake of BC6OTHER by both cultured rat DRG neurons and HEK / BC6ENTG cells was saturable and inhibited by cold temperature, BC6OTHER and BC6ENTC , consistent with it being mediated by BC6OTHER .	False
Heterologous expression of BC6ENTG in HEK293 cells (HEK / BC6OTHER cells) increased the uptake and cytotoxicity of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , in comparison to isogenic vector - transfected control cells.	CPR:9
Heterologous expression of BC6OTHER in HEK293 cells (HEK / BC6ENTG cells) increased the uptake and cytotoxicity of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , in comparison to isogenic vector - transfected control cells.	CPR:9
Heterologous expression of BC6ENTG in HEK293 cells (HEK / BC6OTHER cells) increased the uptake and cytotoxicity of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , in comparison to isogenic vector - transfected control cells.	CPR:9
Heterologous expression of BC6OTHER in HEK293 cells (HEK / BC6ENTG cells) increased the uptake and cytotoxicity of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , in comparison to isogenic vector - transfected control cells.	CPR:9
Heterologous expression of BC6ENTG in HEK293 cells (HEK / BC6OTHER cells) increased the uptake and cytotoxicity of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , in comparison to isogenic vector - transfected control cells.	CPR:9
Heterologous expression of BC6OTHER in HEK293 cells (HEK / BC6ENTG cells) increased the uptake and cytotoxicity of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , in comparison to isogenic vector - transfected control cells.	CPR:9
Heterologous expression of BC6ENTG in HEK293 cells (HEK / BC6OTHER cells) increased the uptake and cytotoxicity of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , in comparison to isogenic vector - transfected control cells.	CPR:9
Heterologous expression of BC6OTHER in HEK293 cells (HEK / BC6ENTG cells) increased the uptake and cytotoxicity of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , in comparison to isogenic vector - transfected control cells.	CPR:9
Cultured rat DRG neurons endogenously expressed BC6ENTG protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up BC6ENTC , but were resistant to BC6OTHER toxicity.	CPR:9
Cultured rat DRG neurons endogenously expressed BC6ENTG protein on their neuronal cell body plasma membranes and cytoplasm, and displayed substantial capacity for taking up BC6OTHER , but were resistant to BC6ENTC toxicity.	False
The uptake of BC6ENTC by both cultured rat DRG neurons and HEK / BC6OTHER cells was saturable and inhibited by cold temperature, BC6OTHER and BC6OTHER , consistent with it being mediated by BC6ENTG .	False
The uptake of BC6ENTC by both cultured rat DRG neurons and HEK / BC6ENTG cells was saturable and inhibited by cold temperature, BC6OTHER and BC6OTHER , consistent with it being mediated by BC6OTHER .	CPR:9
The uptake of BC6OTHER by both cultured rat DRG neurons and HEK / BC6OTHER cells was saturable and inhibited by cold temperature, BC6ENTC and BC6OTHER , consistent with it being mediated by BC6ENTG .	False
The uptake of BC6OTHER by both cultured rat DRG neurons and HEK / BC6ENTG cells was saturable and inhibited by cold temperature, BC6ENTC and BC6OTHER , consistent with it being mediated by BC6OTHER .	False
Contributions of BC6ENTG to the uptake and toxicity of BC6ENTC and BC6OTHER anticancer drugs in dorsal root ganglion neurons.	CPR:9
Contributions of BC6ENTG to the uptake and toxicity of BC6OTHER and BC6ENTC anticancer drugs in dorsal root ganglion neurons.	CPR:9
The accumulation of BC6ENTC by both cultured rat DRG neurons and HEK / BC6ENTG cells, during BC6OTHER exposure, was saturable and temperature dependent, but was inhibited by BC6OTHER only in HEK / BC6OTHER cells.	False
The accumulation of BC6ENTC by both cultured rat DRG neurons and HEK / BC6OTHER cells, during BC6OTHER exposure, was saturable and temperature dependent, but was inhibited by BC6OTHER only in HEK / BC6ENTG cells.	False
The accumulation of BC6OTHER by both cultured rat DRG neurons and HEK / BC6ENTG cells, during BC6ENTC exposure, was saturable and temperature dependent, but was inhibited by BC6OTHER only in HEK / BC6OTHER cells.	False
The accumulation of BC6OTHER by both cultured rat DRG neurons and HEK / BC6OTHER cells, during BC6ENTC exposure, was saturable and temperature dependent, but was inhibited by BC6OTHER only in HEK / BC6ENTG cells.	False
The accumulation of BC6OTHER by both cultured rat DRG neurons and HEK / BC6ENTG cells, during BC6OTHER exposure, was saturable and temperature dependent, but was inhibited by BC6ENTC only in HEK / BC6OTHER cells.	False
The accumulation of BC6OTHER by both cultured rat DRG neurons and HEK / BC6OTHER cells, during BC6OTHER exposure, was saturable and temperature dependent, but was inhibited by BC6ENTC only in HEK / BC6ENTG cells.	False
In conclusion, BC6ENTG can transport BC6ENTC and BC6OTHER drugs, and sensitizes cells to their cytotoxicities.	CPR:9
BC6ENTG is a lysosomal BC6ENTC protease whose biological function remains poorly defined.	False
Genotyping of the single BC6ENTC polymorphisms BC6OTHER - 129, BC6OTHER - 588, BC6OTHER - 52, BC6OTHER - 105 and BC6OTHER - 114 and deletions of BC6ENTG and BC6OTHER were performed with real - time PCR or ordinary PCR and subsequent agarose electrophoresis.	False
Genotyping of the single BC6ENTC polymorphisms BC6OTHER - 129, BC6OTHER - 588, BC6OTHER - 52, BC6OTHER - 105 and BC6OTHER - 114 and deletions of BC6OTHER and BC6ENTG were performed with real - time PCR or ordinary PCR and subsequent agarose electrophoresis.	False
Genotyping of the single BC6ENTC polymorphisms BC6ENTG - 129, BC6OTHER - 588, BC6OTHER - 52, BC6OTHER - 105 and BC6OTHER - 114 and deletions of BC6OTHER and BC6OTHER were performed with real - time PCR or ordinary PCR and subsequent agarose electrophoresis.	False
Genotyping of the single BC6ENTC polymorphisms BC6OTHER - 129, BC6ENTG - 588, BC6OTHER - 52, BC6OTHER - 105 and BC6OTHER - 114 and deletions of BC6OTHER and BC6OTHER were performed with real - time PCR or ordinary PCR and subsequent agarose electrophoresis.	False
Genotyping of the single BC6ENTC polymorphisms BC6OTHER - 129, BC6OTHER - 588, BC6ENTG - 52, BC6OTHER - 105 and BC6OTHER - 114 and deletions of BC6OTHER and BC6OTHER were performed with real - time PCR or ordinary PCR and subsequent agarose electrophoresis.	False
Genotyping of the single BC6ENTC polymorphisms BC6OTHER - 129, BC6OTHER - 588, BC6OTHER - 52, BC6ENTG - 105 and BC6OTHER - 114 and deletions of BC6OTHER and BC6OTHER were performed with real - time PCR or ordinary PCR and subsequent agarose electrophoresis.	False
Genotyping of the single BC6ENTC polymorphisms BC6OTHER - 129, BC6OTHER - 588, BC6OTHER - 52, BC6OTHER - 105 and BC6ENTG - 114 and deletions of BC6OTHER and BC6OTHER were performed with real - time PCR or ordinary PCR and subsequent agarose electrophoresis.	False
Furthermore, with respect to BC6ENTG and BC6OTHER there were statistically significant differences in BC6ENTC - levels between genotypes among exposed workers but not among controls.	False
Furthermore, with respect to BC6OTHER and BC6ENTG there were statistically significant differences in BC6ENTC - levels between genotypes among exposed workers but not among controls.	False
"When treatment is started, BC6ENTG agonists initially stimulate the release of BC6OTHER , causing a surge in serum BC6ENTC that can precipitate a ""flare"" phenomenon or worsening of disease, particularly in patients with bone metastatic disease."	False
"When treatment is started, BC6OTHER agonists initially stimulate the release of BC6ENTG , causing a surge in serum BC6ENTC that can precipitate a ""flare"" phenomenon or worsening of disease, particularly in patients with bone metastatic disease."	False
Results from 1 phase II and 3 phase III clinical trials demonstrate that CHEM produces medical castration more quickly and without causing BC6ENTC surge, as compared with BC6ENTG agonists with or without a nonsteroidal antagonist.	False
Lineage - tracing studies using sequential administration of BC6ENTC analogs, BC6OTHER - driven BC6ENTG - BC6OTHER , and low - frequency ubiquitous BC6OTHER - BC6OTHER reveal that PDL does not convert progenitors to the β - cell lineage.	False
Lineage - tracing studies using sequential administration of BC6ENTC analogs, BC6OTHER - driven BC6OTHER - BC6ENTG , and low - frequency ubiquitous BC6OTHER - BC6OTHER reveal that PDL does not convert progenitors to the β - cell lineage.	False
Lineage - tracing studies using sequential administration of BC6ENTC analogs, BC6OTHER - driven BC6OTHER - BC6OTHER , and low - frequency ubiquitous BC6ENTG - BC6OTHER reveal that PDL does not convert progenitors to the β - cell lineage.	False
Lineage - tracing studies using sequential administration of BC6ENTC analogs, BC6OTHER - driven BC6OTHER - BC6OTHER , and low - frequency ubiquitous BC6OTHER - BC6ENTG reveal that PDL does not convert progenitors to the β - cell lineage.	False
Lineage - tracing studies using sequential administration of BC6ENTC analogs, BC6ENTG - driven BC6OTHER - BC6OTHER , and low - frequency ubiquitous BC6OTHER - BC6OTHER reveal that PDL does not convert progenitors to the β - cell lineage.	False
METHODS: We measured the urinary excretion of products of platelet ( BC6ENTC [ BC6OTHER ]) and renal ( BC6OTHER [ BC6OTHER ]) BC6OTHER metabolism as in vivo indexes of the constitutive BC6ENTG pathway.	False
METHODS: We measured the urinary excretion of products of platelet ( BC6OTHER [ BC6ENTC ]) and renal ( BC6OTHER [ BC6OTHER ]) BC6OTHER metabolism as in vivo indexes of the constitutive BC6ENTG pathway.	False
METHODS: We measured the urinary excretion of products of platelet ( BC6OTHER [ BC6OTHER ]) and renal ( BC6ENTC [ BC6OTHER ]) BC6OTHER metabolism as in vivo indexes of the constitutive BC6ENTG pathway.	False
METHODS: We measured the urinary excretion of products of platelet ( BC6OTHER [ BC6OTHER ]) and renal ( BC6OTHER [ BC6ENTC ]) BC6OTHER metabolism as in vivo indexes of the constitutive BC6ENTG pathway.	False
METHODS: We measured the urinary excretion of products of platelet ( BC6OTHER [ BC6OTHER ]) and renal ( BC6OTHER [ BC6OTHER ]) BC6ENTC metabolism as in vivo indexes of the constitutive BC6ENTG pathway.	False
Moreover, the production of BC6ENTC during whole blood clotting was assessed as an index of the BC6ENTG activity of platelet BC6OTHER ex vivo.	CPR:9
Moreover, the production of BC6ENTC during whole blood clotting was assessed as an index of the BC6OTHER activity of platelet BC6ENTG ex vivo.	CPR:9
BACKGROUND: The active metabolite of the anti - inflammatory drug BC6ENTC has been characterized as a selective inhibitor of the inducible BC6ENTG ( BC6OTHER ).	CPR:4
BACKGROUND: The active metabolite of the anti - inflammatory drug BC6ENTC has been characterized as a selective inhibitor of the inducible BC6OTHER H synthase ( BC6ENTG ).	CPR:4
The daily administration of low - dose BC6ENTC (40 mg), a selective inhibitor of platelet BC6ENTG , caused a cumulative inhibition of urinary BC6OTHER and whole blood BC6OTHER production that recovered with a timecourse consistent with platelet turnover.	CPR:4
The daily administration of low - dose BC6OTHER (40 mg), a selective inhibitor of platelet BC6ENTG , caused a cumulative inhibition of urinary BC6ENTC and whole blood BC6OTHER production that recovered with a timecourse consistent with platelet turnover.	CPR:9
BACKGROUND: The active metabolite of the anti - inflammatory drug BC6OTHER has been characterized as a selective inhibitor of the inducible BC6ENTC H synthase ( BC6ENTG ).	False
The daily administration of low - dose BC6OTHER (40 mg), a selective inhibitor of platelet BC6ENTG , caused a cumulative inhibition of urinary BC6OTHER and whole blood BC6ENTC production that recovered with a timecourse consistent with platelet turnover.	CPR:9
CONCLUSIONS: BC6ENTC does dose - dependently inhibit the BC6ENTG activity of platelet BC6OTHER of healthy subjects both in vivo and ex vivo.	CPR:4
CONCLUSIONS: BC6ENTC does dose - dependently inhibit the BC6OTHER activity of platelet BC6ENTG of healthy subjects both in vivo and ex vivo.	CPR:4
In the African - American cohort, after excluding BC6ENTG carriers, homozygous carriers of BC6OTHER showed 27% higher BC6OTHER activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol BC6ENTC min( - 1) mg( - 1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038 / clpt.2013.69.	False
In the African - American cohort, after excluding BC6OTHER carriers, homozygous carriers of BC6ENTG showed 27% higher BC6OTHER activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol BC6ENTC min( - 1) mg( - 1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038 / clpt.2013.69.	False
In the African - American cohort, after excluding BC6OTHER carriers, homozygous carriers of BC6OTHER showed 27% higher BC6ENTG activity as compared with noncarriers (609 ± 152 and 480 ± 152 pmol BC6ENTC min( - 1) mg( - 1), respectively; P = 0.013).Clinical Pharmacology & Therapeutics (2013); advance online publication 1 May 2013. doi:10.1038 / clpt.2013.69.	False
The responses to BC6ENTC , with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme BC6ENTG ( BC6OTHER , encoded by the BC6OTHER gene).	False
The responses to BC6ENTC , with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme BC6OTHER ( BC6ENTG , encoded by the BC6OTHER gene).	False
The responses to BC6ENTC , with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme BC6OTHER ( BC6OTHER , encoded by the BC6ENTG gene).	False
The responses to BC6OTHER , with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme BC6ENTC dehydrogenase ( BC6ENTG , encoded by the BC6OTHER gene).	False
The responses to BC6OTHER , with respect to both toxicity and efficacy, vary among racial groups, potentially because of variability in the activity levels of the enzyme BC6ENTC dehydrogenase ( BC6OTHER , encoded by the BC6ENTG gene).	False
The BC6ENTG - BC6OTHER variant was unique to individuals of African ancestry, and BC6OTHER activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol BC6ENTC min( - 1) mg( - 1); P = 0.00029).	False
The BC6OTHER - BC6ENTG variant was unique to individuals of African ancestry, and BC6OTHER activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol BC6ENTC min( - 1) mg( - 1); P = 0.00029).	False
The BC6OTHER - BC6OTHER variant was unique to individuals of African ancestry, and BC6ENTG activity was 46% lower in carriers as compared with noncarriers (279 ± 35 vs. 514 ± 168 pmol BC6ENTC min( - 1) mg( - 1); P = 0.00029).	False
The progress of the enzymatic reaction of the hydrolysis of BC6ENTC at pH 8 in the presence of BC6ENTG and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product BC6OTHER (TCh).	CPR:9
The progress of the enzymatic reaction of the hydrolysis of BC6OTHER at pH 8 in the presence of BC6ENTG and the inhibitor studied is determined by measuring at 230 nm the peak area of the reaction product BC6ENTC (TCh).	False
In the method employed the capillary was first filled with 30 mM BC6ENTC - BC6OTHER buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) BC6ENTG solution, (iii) substrate solution with or without inhibitor, (iv) BC6OTHER solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	False
In the method employed the capillary was first filled with 30 mM BC6ENTC - BC6OTHER buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) BC6OTHER solution, (iii) substrate solution with or without inhibitor, (iv) BC6ENTG solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	False
In the method employed the capillary was first filled with 30 mM BC6OTHER - BC6ENTC buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) BC6ENTG solution, (iii) substrate solution with or without inhibitor, (iv) BC6OTHER solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	False
In the method employed the capillary was first filled with 30 mM BC6OTHER - BC6ENTC buffer (pH 8.0) and subsequently, plugs of: (i) water, (ii) BC6OTHER solution, (iii) substrate solution with or without inhibitor, (iv) BC6ENTG solution, and (v) water, were hydrodynamically injected into the capillary, and were allowed to stand (and react) during a waiting period of 2 min.	False
We report herein the therapeutic benefit that resulted for the administration of the VLNYYVWR human CRAC sequence to guinea pigs fed with a high BC6ENTC diet and BC6ENTG knock - out B6.129P2 - Apoetm1Unc / J mice.	False
CRAC treatment (3 and 30mg / kg once daily for 6 weeks) resulted in reduced circulating BC6ENTC levels in guinea pigs fed with 2% high BC6OTHER diet and BC6ENTG knock - out B6.129P2 - Apoetm1Unc / J mice.	False
CRAC treatment (3 and 30mg / kg once daily for 6 weeks) resulted in reduced circulating BC6OTHER levels in guinea pigs fed with 2% high BC6ENTC diet and BC6ENTG knock - out B6.129P2 - Apoetm1Unc / J mice.	False
Control of hypercholesterolemia and atherosclerosis using the BC6ENTC recognition / interaction BC6OTHER sequence of the BC6ENTG .	False
Control of hypercholesterolemia and atherosclerosis using the BC6OTHER recognition / interaction BC6ENTC sequence of the BC6ENTG .	False
The treatment also prevented the high BC6ENTC diet - induced increase in serum BC6ENTG , total and isoforms, markers of neurological, cardiac and muscular damage.	CPR:3
A domain in the BC6ENTC - terminus of BC6ENTG was identified and characterized as the BC6OTHER recognition / interaction BC6OTHER consensus (CRAC).	False
A domain in the BC6OTHER - terminus of BC6ENTG was identified and characterized as the BC6ENTC recognition / interaction BC6OTHER consensus (CRAC).	False
A domain in the BC6OTHER - terminus of BC6ENTG was identified and characterized as the BC6OTHER recognition / interaction BC6ENTC consensus (CRAC).	False
The BC6ENTG is an ubiquitous high affinity BC6ENTC - binding protein reported to be present in the endothelial and smooth muscle cells of the blood vessels; its expression dramatically increased in macrophages found in atherosclerotic plaques.	False
These results demonstrated for the first time that BC6ENTC induces apoptosis in HepG2 cells through inactivating BC6ENTG kinase and activating BC6OTHER and BC6OTHER BC6OTHER , and ROS stimulated by BC6OTHER is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	False
These results demonstrated for the first time that BC6ENTC induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6ENTG and BC6OTHER BC6OTHER , and ROS stimulated by BC6OTHER is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	CPR:3
These results demonstrated for the first time that BC6ENTC induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6OTHER and BC6ENTG BC6OTHER , and ROS stimulated by BC6OTHER is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	CPR:3
These results demonstrated for the first time that BC6ENTC induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6OTHER and BC6OTHER BC6ENTG , and ROS stimulated by BC6OTHER is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	CPR:3
These results demonstrated for the first time that BC6ENTC induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6OTHER and BC6OTHER BC6OTHER , and ROS stimulated by BC6OTHER is able to activate the BC6ENTG singaling pathway as the upstream signaling molecules.	False
These results demonstrated for the first time that BC6OTHER induces apoptosis in HepG2 cells through inactivating BC6ENTG kinase and activating BC6OTHER and BC6OTHER BC6OTHER , and ROS stimulated by BC6ENTC is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	False
These results demonstrated for the first time that BC6OTHER induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6ENTG and BC6OTHER BC6OTHER , and ROS stimulated by BC6ENTC is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	False
These results demonstrated for the first time that BC6OTHER induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6OTHER and BC6ENTG BC6OTHER , and ROS stimulated by BC6ENTC is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	False
These results demonstrated for the first time that BC6OTHER induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6OTHER and BC6OTHER BC6ENTG , and ROS stimulated by BC6ENTC is able to activate the BC6OTHER singaling pathway as the upstream signaling molecules.	False
These results demonstrated for the first time that BC6OTHER induces apoptosis in HepG2 cells through inactivating BC6OTHER kinase and activating BC6OTHER and BC6OTHER BC6OTHER , and ROS stimulated by BC6ENTC is able to activate the BC6ENTG singaling pathway as the upstream signaling molecules.	CPR:3
Initiating event of the mitochondrial - mediated apoptosis induced by BC6ENTC is BC6ENTG signals.	False
BC6ENTC is able to induce apoptosis through mitochondrial dysfunction and inhibition of BC6ENTG / BC6OTHER signaling pathway in HepG2 cells, however, the effects of BC6OTHER on BC6OTHER signaling pathways remain unknown.	CPR:4
BC6ENTC is able to induce apoptosis through mitochondrial dysfunction and inhibition of BC6OTHER / BC6ENTG signaling pathway in HepG2 cells, however, the effects of BC6OTHER on BC6OTHER signaling pathways remain unknown.	CPR:4
BC6ENTC is able to induce apoptosis through mitochondrial dysfunction and inhibition of BC6OTHER / BC6OTHER signaling pathway in HepG2 cells, however, the effects of BC6OTHER on BC6ENTG signaling pathways remain unknown.	False
BC6OTHER is able to induce apoptosis through mitochondrial dysfunction and inhibition of BC6ENTG / BC6OTHER signaling pathway in HepG2 cells, however, the effects of BC6ENTC on BC6OTHER signaling pathways remain unknown.	False
BC6OTHER is able to induce apoptosis through mitochondrial dysfunction and inhibition of BC6OTHER / BC6ENTG signaling pathway in HepG2 cells, however, the effects of BC6ENTC on BC6OTHER signaling pathways remain unknown.	False
BC6OTHER is able to induce apoptosis through mitochondrial dysfunction and inhibition of BC6OTHER / BC6OTHER signaling pathway in HepG2 cells, however, the effects of BC6ENTC on BC6ENTG signaling pathways remain unknown.	False
The present study investigated the effects of BC6ENTC on this pathway, and the roles of BC6ENTG BC6OTHER on mitochondrial - mediated apoptosis in HepG2 cells.	False
The present study investigated the effects of BC6ENTC on this pathway, and the roles of BC6OTHER BC6ENTG on mitochondrial - mediated apoptosis in HepG2 cells.	False
BC6ENTC significantly inhibited the levels of BC6ENTG kinase and increased the expression of BC6OTHER and BC6OTHER BC6OTHER .	False
BC6ENTC significantly inhibited the levels of BC6OTHER kinase and increased the expression of BC6ENTG and BC6OTHER BC6OTHER .	CPR:3
BC6ENTC significantly inhibited the levels of BC6OTHER kinase and increased the expression of BC6OTHER and BC6ENTG BC6OTHER .	CPR:3
BC6ENTC significantly inhibited the levels of BC6OTHER kinase and increased the expression of BC6OTHER and BC6OTHER BC6ENTG .	CPR:3
Furthermore, BC6ENTC (an BC6ENTG inhibitor) significantly enhanced the BC6OTHER - induced the BC6OTHER / BC6OTHER ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6OTHER .	False
Furthermore, BC6ENTC (an BC6OTHER inhibitor) significantly enhanced the BC6OTHER - induced the BC6ENTG / BC6OTHER ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6OTHER .	CPR:3
Furthermore, BC6ENTC (an BC6OTHER inhibitor) significantly enhanced the BC6OTHER - induced the BC6OTHER / BC6ENTG ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6OTHER .	CPR:3
Furthermore, BC6ENTC (an BC6OTHER inhibitor) significantly enhanced the BC6OTHER - induced the BC6OTHER / BC6OTHER ratio, the release of BC6ENTG to the cytosol fraction, and the levels of cleaved BC6OTHER .	False
Furthermore, BC6ENTC (an BC6OTHER inhibitor) significantly enhanced the BC6OTHER - induced the BC6OTHER / BC6OTHER ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6ENTG .	False
Furthermore, BC6OTHER (an BC6ENTG inhibitor) significantly enhanced the BC6ENTC - induced the BC6OTHER / BC6OTHER ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6OTHER .	False
Furthermore, BC6OTHER (an BC6OTHER inhibitor) significantly enhanced the BC6ENTC - induced the BC6ENTG / BC6OTHER ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6OTHER .	CPR:3
Furthermore, BC6OTHER (an BC6OTHER inhibitor) significantly enhanced the BC6ENTC - induced the BC6OTHER / BC6ENTG ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6OTHER .	CPR:3
Furthermore, BC6OTHER (an BC6OTHER inhibitor) significantly enhanced the BC6ENTC - induced the BC6OTHER / BC6OTHER ratio, the release of BC6ENTG to the cytosol fraction, and the levels of cleaved BC6OTHER .	False
Furthermore, BC6OTHER (an BC6OTHER inhibitor) significantly enhanced the BC6ENTC - induced the BC6OTHER / BC6OTHER ratio, the release of BC6OTHER to the cytosol fraction, and the levels of cleaved BC6ENTG .	False
 BC6ENTG signaling pathways regulate mitochondrial - mediated apoptosis induced by BC6ENTC in human hepatoblastoma cancer cells.	False
While BC6ENTC (a BC6ENTG inhibitor) and BC6OTHER (a BC6OTHER inhibitor) markedly prevented the expression of these proteins induced by BC6OTHER .	CPR:4
While BC6ENTC (a BC6OTHER inhibitor) and BC6OTHER (a BC6ENTG inhibitor) markedly prevented the expression of these proteins induced by BC6OTHER .	False
While BC6OTHER (a BC6ENTG inhibitor) and BC6ENTC (a BC6OTHER inhibitor) markedly prevented the expression of these proteins induced by BC6OTHER .	False
While BC6OTHER (a BC6OTHER inhibitor) and BC6ENTC (a BC6ENTG inhibitor) markedly prevented the expression of these proteins induced by BC6OTHER .	CPR:4
While BC6OTHER (a BC6ENTG inhibitor) and BC6OTHER (a BC6OTHER inhibitor) markedly prevented the expression of these proteins induced by BC6ENTC .	CPR:3
While BC6OTHER (a BC6OTHER inhibitor) and BC6OTHER (a BC6ENTG inhibitor) markedly prevented the expression of these proteins induced by BC6ENTC .	CPR:3
Furthermore, the ROS inhibitor ( BC6ENTC ) notably promoted the inhibited effect of BC6OTHER on the BC6ENTG kinase.	False
Furthermore, the ROS inhibitor ( BC6OTHER ) notably promoted the inhibited effect of BC6ENTC on the BC6ENTG kinase.	False
BC6ENTC also suppressed the p - BC6ENTG and BC6OTHER , but failed to reverse the effects of BC6OTHER .	CPR:4
BC6ENTC also suppressed the p - BC6OTHER and BC6ENTG , but failed to reverse the effects of BC6OTHER .	CPR:4
BC6OTHER also suppressed the p - BC6ENTG and BC6OTHER , but failed to reverse the effects of BC6ENTC .	False
BC6OTHER also suppressed the p - BC6OTHER and BC6ENTG , but failed to reverse the effects of BC6ENTC .	False
Besides providing the content of terminal groups and individual BC6ENTC and BC6OTHER residues with different BC6OTHER substituents, the HSQC - NMR spectra permitted us to evaluate and correlate the content of the BC6OTHER , AT - binding sequence BC6ENTG (AT - bs) through quantification of signals of the BC6OTHER sequence G - A*.	False
Besides providing the content of terminal groups and individual BC6OTHER and BC6ENTC residues with different BC6OTHER substituents, the HSQC - NMR spectra permitted us to evaluate and correlate the content of the BC6OTHER , AT - binding sequence BC6ENTG (AT - bs) through quantification of signals of the BC6OTHER sequence G - A*.	False
Besides providing the content of terminal groups and individual BC6OTHER and BC6OTHER residues with different BC6ENTC substituents, the HSQC - NMR spectra permitted us to evaluate and correlate the content of the BC6OTHER , AT - binding sequence BC6ENTG (AT - bs) through quantification of signals of the BC6OTHER sequence G - A*.	False
Besides providing the content of terminal groups and individual BC6OTHER and BC6OTHER residues with different BC6OTHER substituents, the HSQC - NMR spectra permitted us to evaluate and correlate the content of the BC6ENTC , AT - binding sequence BC6ENTG (AT - bs) through quantification of signals of the BC6OTHER sequence G - A*.	False
Besides providing the content of terminal groups and individual BC6OTHER and BC6OTHER residues with different BC6OTHER substituents, the HSQC - NMR spectra permitted us to evaluate and correlate the content of the BC6OTHER , AT - binding sequence BC6ENTG (AT - bs) through quantification of signals of the BC6ENTC sequence G - A*.	False
Hepatic mRNA expression of BC6ENTG , BC6OTHER , and BC6OTHER were increased more in CE than C, and in HE than CHEM. In duodenum, BC6OTHER , BC6OTHER , and BC6OTHER mRNA levels were increased in CE compared to C. In Experiment 2, hepatic BC6ENTC concentrations were higher in HIE than HI.	False
Hepatic mRNA expression of BC6OTHER , BC6ENTG , and BC6OTHER were increased more in CE than C, and in HE than CHEM. In duodenum, BC6OTHER , BC6OTHER , and BC6OTHER mRNA levels were increased in CE compared to C. In Experiment 2, hepatic BC6ENTC concentrations were higher in HIE than HI.	False
Hepatic mRNA expression of BC6OTHER , BC6OTHER , and BC6ENTG were increased more in CE than C, and in HE than CHEM. In duodenum, BC6OTHER , BC6OTHER , and BC6OTHER mRNA levels were increased in CE compared to C. In Experiment 2, hepatic BC6ENTC concentrations were higher in HIE than HI.	False
Hepatic mRNA expression of BC6OTHER , BC6OTHER , and BC6OTHER were increased more in CE than C, and in HE than CHEM. In duodenum, BC6ENTG , BC6OTHER , and BC6OTHER mRNA levels were increased in CE compared to C. In Experiment 2, hepatic BC6ENTC concentrations were higher in HIE than HI.	False
Hepatic mRNA expression of BC6OTHER , BC6OTHER , and BC6OTHER were increased more in CE than C, and in HE than CHEM. In duodenum, BC6OTHER , BC6ENTG , and BC6OTHER mRNA levels were increased in CE compared to C. In Experiment 2, hepatic BC6ENTC concentrations were higher in HIE than HI.	False
Hepatic mRNA expression of BC6OTHER , BC6OTHER , and BC6OTHER were increased more in CE than C, and in HE than CHEM. In duodenum, BC6OTHER , BC6OTHER , and BC6ENTG mRNA levels were increased in CE compared to C. In Experiment 2, hepatic BC6ENTC concentrations were higher in HIE than HI.	False
In duodenum, BC6ENTG mRNA was increased in HIE compared to CIE. BC6ENTC induced hepatic BC6OTHER uptake transporter expression in mice fed a high - fat diet, causing increased hepatic BC6OTHER concentrations.	False
In duodenum, BC6ENTG mRNA was increased in HIE compared to CIE. BC6OTHER induced hepatic BC6ENTC uptake transporter expression in mice fed a high - fat diet, causing increased hepatic BC6OTHER concentrations.	False
In duodenum, BC6ENTG mRNA was increased in HIE compared to CIE. BC6OTHER induced hepatic BC6OTHER uptake transporter expression in mice fed a high - fat diet, causing increased hepatic BC6ENTC concentrations.	False
Phlebotomy and dietary BC6ENTC restriction reduces BC6ENTG in NAFLD / NASH patients.	False
Activation of BC6ENTG , which is phosphorylated by the BC6OTHER signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by BC6OTHER and BC6ENTC .	CPR:3
Activation of BC6OTHER , which is phosphorylated by the BC6ENTG signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by BC6OTHER and BC6ENTC .	CPR:3
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6ENTC and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6ENTG , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6ENTC and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6ENTG activation.	False
Phosphorylation of BC6ENTG , which was shown to be activated by BC6OTHER ligands, was also increased by BC6ENTC and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	CPR:3
Phosphorylation of BC6OTHER , which was shown to be activated by BC6ENTG ligands, was also increased by BC6ENTC and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6ENTC and BC6OTHER , and blocking of BC6ENTG activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6ENTC and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6ENTG and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6ENTC and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6ENTG , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6ENTC , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6ENTG , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6ENTC , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6ENTG activation.	False
Phosphorylation of BC6ENTG , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6ENTC , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	CPR:3
Phosphorylation of BC6OTHER , which was shown to be activated by BC6ENTG ligands, was also increased by BC6OTHER and BC6ENTC , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6ENTC , and blocking of BC6ENTG activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6ENTC , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6ENTG and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6ENTC , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6ENTG , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6ENTC (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6ENTG , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6ENTC (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6ENTG activation.	False
Phosphorylation of BC6ENTG , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6ENTC (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6ENTG ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6ENTC (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6ENTG activity by BC6ENTC (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	CPR:4
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6ENTC (CHEM) inhibited phosphorylation of both BC6ENTG and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	CPR:4
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6ENTC (CHEM) inhibited phosphorylation of both BC6OTHER and BC6ENTG , raising a possibility that stimulatory activities of BC6OTHER and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	CPR:4
 BC6ENTC stimulates Th17 differentiation enhancing phosphorylation of BC6ENTG and BC6OTHER to worsen experimental autoimmune encephalomyelitis.	CPR:3
 BC6ENTC stimulates Th17 differentiation enhancing phosphorylation of BC6OTHER and BC6ENTG to worsen experimental autoimmune encephalomyelitis.	CPR:3
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6ENTC and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6ENTG , which in turn stimulates BC6OTHER activation.	CPR:3
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6ENTC and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6ENTG activation.	CPR:3
Phosphorylation of BC6ENTG , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6ENTC and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6ENTG ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6ENTC and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6ENTG activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6ENTC and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6ENTG and BC6OTHER , raising a possibility that stimulatory activities of BC6ENTC and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6ENTG , raising a possibility that stimulatory activities of BC6ENTC and BC6OTHER on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6ENTC on Th17 differentiation could be exerted via increased phosphorylation of BC6ENTG , which in turn stimulates BC6OTHER activation.	CPR:3
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6ENTC on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6ENTG activation.	CPR:3
Phosphorylation of BC6ENTG , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6ENTC on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6ENTG ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6ENTC on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6ENTG activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6ENTC on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6ENTG and BC6OTHER , raising a possibility that stimulatory activities of BC6OTHER and BC6ENTC on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Phosphorylation of BC6OTHER , which was shown to be activated by BC6OTHER ligands, was also increased by BC6OTHER and BC6OTHER , and blocking of BC6OTHER activity by BC6OTHER (CHEM) inhibited phosphorylation of both BC6OTHER and BC6ENTG , raising a possibility that stimulatory activities of BC6OTHER and BC6ENTC on Th17 differentiation could be exerted via increased phosphorylation of BC6OTHER , which in turn stimulates BC6OTHER activation.	False
Finally, we found that BC6ENTC worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of BC6ENTG - producing cells in draining lymph nodes.	CPR:3
In the present study, using in vitro Th17 differentiation model, we examined effects of BC6ENTG activation by BC6ENTC ( BC6OTHER ), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.	CPR:3
In the present study, using in vitro Th17 differentiation model, we examined effects of BC6ENTG activation by BC6OTHER ( BC6ENTC ), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.	CPR:3
BC6ENTC increased expression of BC6ENTG , the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as BC6OTHER ( BC6OTHER ), a prototypical BC6OTHER ligand.	CPR:3
BC6ENTC increased expression of BC6OTHER , the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as BC6OTHER ( BC6OTHER ), a prototypical BC6ENTG ligand.	False
BC6OTHER increased expression of BC6ENTG , the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as BC6ENTC ( BC6OTHER ), a prototypical BC6OTHER ligand.	False
BC6OTHER increased expression of BC6OTHER , the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as BC6ENTC ( BC6OTHER ), a prototypical BC6ENTG ligand.	False
BC6OTHER increased expression of BC6ENTG , the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as BC6OTHER ( BC6ENTC ), a prototypical BC6OTHER ligand.	False
BC6OTHER increased expression of BC6OTHER , the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as BC6OTHER ( BC6ENTC ), a prototypical BC6ENTG ligand.	False
Activation of BC6ENTG , which is phosphorylated by the BC6OTHER signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by BC6ENTC and BC6OTHER .	CPR:3
Activation of BC6OTHER , which is phosphorylated by the BC6ENTG signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by BC6ENTC and BC6OTHER .	CPR:3
BC6ENTC has an antidepressant effect through blocking the BC6ENTG .	CPR:4
After 3 weeks' BC6ENTC treatment we studied the change in BC6ENTG activity, which corresponds to the occupancy of BC6OTHER .	False
After 3 weeks' BC6OTHER treatment we studied the change in BC6ENTG activity, which corresponds to the occupancy of BC6ENTC .	False
The average occupancy of BC6ENTC on BC6ENTG was similar to the international findings at 20.84% in 9 depressed patients.	False
[Change of BC6ENTC transporter activity ( BC6ENTG ) during the action of BC6OTHER (in depression)].	False
[Change of BC6ENTG activity ( BC6OTHER ) during the action of BC6ENTC (in depression)].	False
[Change of BC6OTHER transporter activity ( BC6ENTG ) during the action of BC6ENTC (in depression)].	False
There was also an increase in BC6ENTG and BC6OTHER levels in BC6ENTC pretreated cells.	CPR:3
There was also an increase in BC6OTHER and BC6ENTG levels in BC6ENTC pretreated cells.	CPR:3
In the presence of BC6ENTC , BC6OTHER inhibited decrease in BC6OTHER level and BC6ENTG activity.	False
In the presence of BC6OTHER , BC6ENTC inhibited decrease in BC6OTHER level and BC6ENTG activity.	CPR:3
In the presence of BC6OTHER , BC6OTHER inhibited decrease in BC6ENTC level and BC6ENTG activity.	False
CONCLUSION: We provided documentation of neuroprotective effect of a natural CHEM, BC6ENTC , against BC6OTHER - induced oxidative stress in differentiated PC12 cells by modulating the level of BC6ENTG phosphorylation and BC6OTHER pathway.	False
CONCLUSION: We provided documentation of neuroprotective effect of a natural CHEM, BC6ENTC , against BC6OTHER - induced oxidative stress in differentiated PC12 cells by modulating the level of BC6OTHER phosphorylation and BC6ENTG pathway.	False
CONCLUSION: We provided documentation of neuroprotective effect of a natural CHEM, BC6OTHER , against BC6ENTC - induced oxidative stress in differentiated PC12 cells by modulating the level of BC6ENTG phosphorylation and BC6OTHER pathway.	False
CONCLUSION: We provided documentation of neuroprotective effect of a natural CHEM, BC6OTHER , against BC6ENTC - induced oxidative stress in differentiated PC12 cells by modulating the level of BC6OTHER phosphorylation and BC6ENTG pathway.	False
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6ENTC , on BC6OTHER - induced disruption of BC6ENTG system and BC6OTHER ( BC6OTHER ) phosphorylation.	False
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6ENTC , on BC6OTHER - induced disruption of BC6OTHER system and BC6ENTG ( BC6OTHER ) phosphorylation.	False
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6ENTC , on BC6OTHER - induced disruption of BC6OTHER system and BC6OTHER ( BC6ENTG ) phosphorylation.	False
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6OTHER , on BC6ENTC - induced disruption of BC6ENTG system and BC6OTHER ( BC6OTHER ) phosphorylation.	CPR:4
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6OTHER , on BC6ENTC - induced disruption of BC6OTHER system and BC6ENTG ( BC6OTHER ) phosphorylation.	CPR:4
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6OTHER , on BC6ENTC - induced disruption of BC6OTHER system and BC6OTHER ( BC6ENTG ) phosphorylation.	CPR:4
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6OTHER , on BC6OTHER - induced disruption of BC6ENTG system and BC6ENTC response element binding protein ( BC6OTHER ) phosphorylation.	False
Herein, we investigated the effect of a natural neuroprotective CHEM, BC6OTHER , on BC6OTHER - induced disruption of BC6OTHER system and BC6ENTC response element binding protein ( BC6ENTG ) phosphorylation.	False
The level of BC6ENTG , BC6OTHER ( BC6OTHER ), BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were measured by western blot method.	False
The level of BC6OTHER , BC6ENTG ( BC6OTHER ), BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were measured by western blot method.	False
The level of BC6OTHER , BC6OTHER ( BC6ENTG ), BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were measured by western blot method.	False
The level of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC synthetase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were measured by western blot method.	False
The level of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC synthetase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were measured by western blot method.	False
The level of BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) were measured by western blot method.	False
Involvement of BC6ENTG and BC6OTHER system in neuroprotection mediated by the CHEM BC6ENTC isolated from Dracocephalum kotschyi.	False
Involvement of BC6OTHER and BC6ENTG system in neuroprotection mediated by the CHEM BC6ENTC isolated from Dracocephalum kotschyi.	False
In BC6ENTC - treated cells, BC6OTHER also suppressed BC6ENTG release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.	False
In BC6OTHER - treated cells, BC6ENTC also suppressed BC6ENTG release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.	CPR:4
Moreover, BC6ENTC , in presence of BC6OTHER inhibited the decrease caused by oxidative stress in stress - sensing transcription factors, BC6ENTG and BC6OTHER , which play an important role in antioxidant capacity of the cell.	CPR:3
Moreover, BC6ENTC , in presence of BC6OTHER inhibited the decrease caused by oxidative stress in stress - sensing transcription factors, BC6OTHER and BC6ENTG , which play an important role in antioxidant capacity of the cell.	CPR:3
Moreover, BC6OTHER , in presence of BC6ENTC inhibited the decrease caused by oxidative stress in stress - sensing transcription factors, BC6ENTG and BC6OTHER , which play an important role in antioxidant capacity of the cell.	False
Moreover, BC6OTHER , in presence of BC6ENTC inhibited the decrease caused by oxidative stress in stress - sensing transcription factors, BC6OTHER and BC6ENTG , which play an important role in antioxidant capacity of the cell.	False
GTLE pretreatment completely reversed the damaging effects of BC6ENTC on AA and BC6ENTG activity, markedly corrected BC6OTHER and BC6OTHER activities, and moderately improved TGC.	CPR:4
GTLE pretreatment completely reversed the damaging effects of BC6ENTC on AA and BC6OTHER dismutase activity, markedly corrected BC6ENTG and BC6OTHER activities, and moderately improved TGC.	CPR:4
GTLE pretreatment completely reversed the damaging effects of BC6ENTC on AA and BC6OTHER dismutase activity, markedly corrected BC6OTHER and BC6ENTG activities, and moderately improved TGC.	CPR:4
GTLE pretreatment completely reversed the damaging effects of BC6OTHER on AA and BC6ENTC dismutase activity, markedly corrected BC6ENTG and BC6OTHER activities, and moderately improved TGC.	False
GTLE pretreatment completely reversed the damaging effects of BC6OTHER on AA and BC6ENTC dismutase activity, markedly corrected BC6OTHER and BC6ENTG activities, and moderately improved TGC.	False
BC6ENTC markedly reduced AA performance and activities of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in all regions.	CPR:4
BC6ENTC markedly reduced AA performance and activities of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) in all regions.	CPR:4
BC6ENTC markedly reduced AA performance and activities of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) in all regions.	CPR:4
BC6ENTC markedly reduced AA performance and activities of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) in all regions.	CPR:4
Mammalian mitochondrial BC6ENTC dehydrogenase ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6ENTG catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6ENTC dehydrogenase ( BC6ENTG , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6ENTC dehydrogenase ( BC6OTHER , BC6ENTG ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
BC6ENTG ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6ENTC ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6ENTG catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6ENTC ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6ENTG , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6ENTC ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6ENTG ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6ENTC ( BC6OTHER ).	False
BC6ENTG ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6ENTC ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6ENTG catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6ENTC ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6ENTG , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6ENTC ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6ENTG ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6ENTC ).	False
Rat brain mitochondrial extracts, used as the source of BC6ENTG , were resolved by nongradient BN - PAGE (9%), which was followed by BC6OTHER activity staining using BC6ENTC as the electron donor and BC6OTHER as the electron acceptor.	False
Rat brain mitochondrial extracts, used as the source of BC6OTHER , were resolved by nongradient BN - PAGE (9%), which was followed by BC6ENTG activity staining using BC6ENTC as the electron donor and BC6OTHER as the electron acceptor.	False
Rat brain mitochondrial extracts, used as the source of BC6ENTG , were resolved by nongradient BN - PAGE (9%), which was followed by BC6OTHER activity staining using BC6OTHER as the electron donor and BC6ENTC as the electron acceptor.	False
Rat brain mitochondrial extracts, used as the source of BC6OTHER , were resolved by nongradient BN - PAGE (9%), which was followed by BC6ENTG activity staining using BC6OTHER as the electron donor and BC6ENTC as the electron acceptor.	False
BC6ENTG ( BC6OTHER , BC6OTHER ) catalyzes BC6ENTC - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6OTHER ) catalyzes BC6ENTC - dependent oxidation of BC6OTHER in vivo and can also act as a BC6ENTG catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6ENTG , BC6OTHER ) catalyzes BC6ENTC - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6ENTG ) catalyzes BC6ENTC - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Histochemical staining and quantification of BC6ENTC dehydrogenase BC6ENTG activity using blue native PAGE.	False
Moreover, this in - gel activity - staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures BC6ENTG BC6OTHER activity using BC6ENTC as the substrate.	False
Moreover, this in - gel activity - staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures BC6OTHER BC6ENTG activity using BC6ENTC as the substrate.	False
BC6ENTG ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6ENTC in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6ENTC in vivo and can also act as a BC6ENTG catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6ENTG , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6ENTC in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6ENTG ) catalyzes BC6OTHER - dependent oxidation of BC6ENTC in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Finally, the effects of BC6ENTC - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6ENTG BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6ENTC - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6ENTG activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6ENTC - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6ENTG BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6ENTC - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6ENTG activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6ENTC - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6ENTG BC6OTHER activity.	False
Finally, the effects of BC6ENTC - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6ENTG activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6ENTC ( BC6OTHER ) and BC6OTHER donors on BC6ENTG BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6ENTC ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6ENTG activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6ENTC ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6ENTG BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6ENTC ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6ENTG activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6ENTC ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6ENTG BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6ENTC ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6ENTG activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6ENTC ) and BC6OTHER donors on BC6ENTG BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6ENTC ) and BC6OTHER donors on BC6OTHER BC6ENTG activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6ENTC ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6ENTG BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6ENTC ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6ENTG activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6ENTC ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6ENTG BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6ENTC ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6ENTG activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6ENTC donors on BC6ENTG BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6ENTC donors on BC6OTHER BC6ENTG activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6ENTC donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6ENTG BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6ENTC donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6ENTG activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6ENTC donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6ENTG BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6ENTC donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6OTHER - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6ENTG activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6ENTG BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6ENTC - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6ENTG activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6ENTC - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6ENTG BC6OTHER activity can be determined without having to remove these BC6ENTC - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6ENTG activity can be determined without having to remove these BC6ENTC - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6ENTC - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6ENTG BC6OTHER activity.	False
Finally, the effects of BC6OTHER - reactive reagents such as BC6OTHER ( BC6OTHER ) and BC6OTHER donors on BC6OTHER BC6OTHER activity were evaluated, demonstrating that, with this method, BC6OTHER BC6OTHER activity can be determined without having to remove these BC6ENTC - reactive reagents that may otherwise interfere with spectrophotometric measurement of BC6OTHER BC6ENTG activity.	False
BC6ENTG ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6ENTC ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6ENTG catalyzing in vitro BC6ENTC ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6ENTG , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6ENTC ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6ENTG ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6ENTC ( BC6OTHER ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
BC6ENTG ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6ENTC ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6ENTG catalyzing in vitro BC6OTHER ( BC6ENTC ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6ENTG , BC6OTHER ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6ENTC ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Mammalian mitochondrial BC6OTHER dehydrogenase ( BC6OTHER , BC6ENTG ) catalyzes BC6OTHER - dependent oxidation of BC6OTHER in vivo and can also act as a BC6OTHER catalyzing in vitro BC6OTHER ( BC6ENTC ) - dependent reduction of electron - accepting molecules such as ubiquinone and BC6OTHER ( BC6OTHER ).	False
Recent insights in the role of BC6ENTC - binding cassette (ABC) transporters BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6ENTG ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6ENTC - binding cassette (ABC) transporters BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6ENTG ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6ENTC - binding cassette (ABC) transporters BC6ENTG and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6ENTC - binding cassette (ABC) transporters BC6OTHER and BC6ENTG , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
The identification of defective structures in the BC6ENTG or BC6OTHER transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6ENTC efflux pumps regulating at least in parts the intestinal BC6OTHER absorption and the hepatic BC6OTHER output.	False
The identification of defective structures in the BC6OTHER or BC6ENTG transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6ENTC efflux pumps regulating at least in parts the intestinal BC6OTHER absorption and the hepatic BC6OTHER output.	False
The identification of defective structures in the BC6ENTG or BC6OTHER transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6OTHER regulating at least in parts the intestinal BC6ENTC absorption and the hepatic BC6OTHER output.	False
The identification of defective structures in the BC6OTHER or BC6ENTG transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6OTHER regulating at least in parts the intestinal BC6ENTC absorption and the hepatic BC6OTHER output.	False
The identification of defective structures in the BC6OTHER or BC6OTHER transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6ENTG regulating at least in parts the intestinal BC6ENTC absorption and the hepatic BC6OTHER output.	False
The identification of defective structures in the BC6ENTG or BC6OTHER transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6OTHER regulating at least in parts the intestinal BC6OTHER absorption and the hepatic BC6ENTC output.	False
The identification of defective structures in the BC6OTHER or BC6ENTG transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6OTHER regulating at least in parts the intestinal BC6OTHER absorption and the hepatic BC6ENTC output.	False
The identification of defective structures in the BC6OTHER or BC6OTHER transporters in patients with the rare disease of sitosterolemia elucidated their role as BC6ENTG regulating at least in parts the intestinal BC6OTHER absorption and the hepatic BC6ENTC output.	False
BC6ENTG and BC6OTHER themselves are regulated by BC6ENTC via BC6OTHER ( BC6OTHER ), which are also activated by CHEM and some derivatives of plant BC6OTHER .	False
BC6OTHER and BC6ENTG themselves are regulated by BC6ENTC via BC6OTHER ( BC6OTHER ), which are also activated by CHEM and some derivatives of plant BC6OTHER .	False
BC6OTHER and BC6OTHER themselves are regulated by BC6ENTC via BC6ENTG ( BC6OTHER ), which are also activated by CHEM and some derivatives of plant BC6OTHER .	False
BC6OTHER and BC6OTHER themselves are regulated by BC6ENTC via BC6OTHER ( BC6ENTG ), which are also activated by CHEM and some derivatives of plant BC6OTHER .	False
BC6ENTG and BC6OTHER themselves are regulated by BC6OTHER via BC6OTHER ( BC6OTHER ), which are also activated by CHEM and some derivatives of plant BC6ENTC .	False
BC6OTHER and BC6ENTG themselves are regulated by BC6OTHER via BC6OTHER ( BC6OTHER ), which are also activated by CHEM and some derivatives of plant BC6ENTC .	False
BC6OTHER and BC6OTHER themselves are regulated by BC6OTHER via BC6ENTG ( BC6OTHER ), which are also activated by CHEM and some derivatives of plant BC6ENTC .	False
BC6OTHER and BC6OTHER themselves are regulated by BC6OTHER via BC6OTHER ( BC6ENTG ), which are also activated by CHEM and some derivatives of plant BC6ENTC .	CPR:3
BC6ENTG could recently be identified as a major BC6ENTC transporter for the intestinal uptake of BC6OTHER as well as plant BC6OTHER .	False
BC6ENTG could recently be identified as a major BC6OTHER for the intestinal uptake of BC6ENTC as well as plant BC6OTHER .	CPR:9
BC6OTHER could recently be identified as a major BC6ENTG for the intestinal uptake of BC6ENTC as well as plant BC6OTHER .	CPR:9
BC6ENTG could recently be identified as a major BC6OTHER for the intestinal uptake of BC6OTHER as well as plant BC6ENTC .	CPR:9
BC6OTHER could recently be identified as a major BC6ENTG for the intestinal uptake of BC6OTHER as well as plant BC6ENTC .	CPR:9
Studies in BC6OTHER knockout mice indicate that this transporter is essential for the intestinal uptake of BC6ENTC and that BC6ENTG might also be involved in the mechanism of action of BC6OTHER .	False
Studies in BC6ENTG knockout mice indicate that this transporter is essential for the intestinal uptake of BC6ENTC and that BC6OTHER might also be involved in the mechanism of action of BC6OTHER .	False
 BC6ENTG : targets of natural BC6ENTC and new lipid lowering drugs.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6ENTC , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6ENTG ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6ENTC , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6ENTG ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6ENTG BC6OTHER and BC6OTHER , the discovery of BC6ENTC , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6ENTG and BC6OTHER , the discovery of BC6ENTC , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6ENTG , the discovery of BC6ENTC , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Studies in BC6OTHER knockout mice indicate that this transporter is essential for the intestinal uptake of BC6OTHER and that BC6ENTG might also be involved in the mechanism of action of BC6ENTC .	False
Studies in BC6ENTG knockout mice indicate that this transporter is essential for the intestinal uptake of BC6OTHER and that BC6OTHER might also be involved in the mechanism of action of BC6ENTC .	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6ENTC absorption inhibitor, as well as the identification of BC6ENTG ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6ENTC absorption inhibitor, as well as the identification of BC6OTHER ( BC6ENTG ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6ENTG BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6ENTC absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6ENTG and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6ENTC absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6ENTG , the discovery of BC6OTHER , the first approved direct BC6ENTC absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6ENTG ( BC6OTHER ) protein as BC6ENTC transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6ENTG ) protein as BC6ENTC transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6ENTG BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6ENTC transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6ENTG and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6ENTC transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6ENTG , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6ENTC transporter in the gut, focused attention on BC6OTHER transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6ENTG ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6ENTC transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6ENTG ) protein as BC6OTHER transporter in the gut, focused attention on BC6ENTC transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6ENTG BC6OTHER and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6ENTC transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6ENTG and BC6OTHER , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6ENTC transport processes in the small intestine and the liver.	False
Recent insights in the role of BC6OTHER BC6OTHER and BC6ENTG , the discovery of BC6OTHER , the first approved direct BC6OTHER absorption inhibitor, as well as the identification of BC6OTHER ( BC6OTHER ) protein as BC6OTHER transporter in the gut, focused attention on BC6ENTC transport processes in the small intestine and the liver.	False
Our results can provide the basis for additional experiments to optimize BC6OTHER supplementation in BC6ENTG deficiency, as increases in brain BC6OTHER are slow in patients after BC6ENTC supplementation.	False
BC6OTHER ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6OTHER absence ( BC6ENTG - / - ) were studied after BC6ENTC supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
BC6OTHER ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6ENTG absence ( BC6OTHER - / - ) were studied after BC6ENTC supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
BC6OTHER ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6OTHER absence ( BC6ENTG - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6ENTC for 35 days.	False
BC6OTHER ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6ENTG absence ( BC6OTHER - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6ENTC for 35 days.	False
Localized BC6ENTC magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus / hippocampus) and in hind leg muscle of BC6ENTG - / - mice before and after BC6OTHER supplementation and in control (Con) mice.	False
Localized BC6OTHER magnetic resonance spectroscopy (MRS) was performed in brain (cerebellum and thalamus / hippocampus) and in hind leg muscle of BC6ENTG - / - mice before and after BC6ENTC supplementation and in control (Con) mice.	False
As expected, a signal for BC6ENTC was hardly detectable in MR spectra of BC6ENTG - / - mice before BC6OTHER supplementation.	False
As expected, a signal for BC6OTHER was hardly detectable in MR spectra of BC6ENTG - / - mice before BC6ENTC supplementation.	False
BC6ENTC ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6OTHER absence ( BC6ENTG - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
BC6ENTC ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6ENTG absence ( BC6OTHER - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
BC6OTHER ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6ENTC deficiency caused by BC6OTHER absence ( BC6ENTG - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
BC6OTHER ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6ENTC deficiency caused by BC6ENTG absence ( BC6OTHER - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
BC6OTHER ( BC6OTHER ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6ENTC methyltransferase absence ( BC6ENTG - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
 BC6ENTC uptake in brain and skeletal muscle of mice lacking BC6ENTG assessed by magnetic resonance spectroscopy.	False
BC6OTHER ( BC6ENTC ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6OTHER absence ( BC6ENTG - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
BC6OTHER ( BC6ENTC ) levels in skeletal muscle and brain of a mouse model of BC6OTHER deficiency caused by BC6ENTG absence ( BC6OTHER - / - ) were studied after BC6OTHER supplementation with 2 g.kg body wt - 1.day - 1 BC6OTHER for 35 days.	False
Only because of the repeated MRS measurements performed in this longitudinal BC6ENTC supplementation study on BC6ENTG - / - mice were we able to discover the initial faster uptake of BC6OTHER in skeletal muscle compared with brain, which may represent muscular BC6OTHER uptake independent of BC6OTHER transporter expression.	False
Only because of the repeated MRS measurements performed in this longitudinal BC6OTHER supplementation study on BC6ENTG - / - mice were we able to discover the initial faster uptake of BC6ENTC in skeletal muscle compared with brain, which may represent muscular BC6OTHER uptake independent of BC6OTHER transporter expression.	False
Only because of the repeated MRS measurements performed in this longitudinal BC6OTHER supplementation study on BC6ENTG - / - mice were we able to discover the initial faster uptake of BC6OTHER in skeletal muscle compared with brain, which may represent muscular BC6ENTC uptake independent of BC6OTHER transporter expression.	False
Only because of the repeated MRS measurements performed in this longitudinal BC6OTHER supplementation study on BC6ENTG - / - mice were we able to discover the initial faster uptake of BC6OTHER in skeletal muscle compared with brain, which may represent muscular BC6OTHER uptake independent of BC6ENTC transporter expression.	False
Our results can provide the basis for additional experiments to optimize BC6ENTC supplementation in BC6ENTG deficiency, as increases in brain BC6OTHER are slow in patients after BC6OTHER supplementation.	False
Our results can provide the basis for additional experiments to optimize BC6OTHER supplementation in BC6ENTG deficiency, as increases in brain BC6ENTC are slow in patients after BC6OTHER supplementation.	False
The BC6ENTG - BC6ENTC structure is nearly superimposable on a previously solved closed structure in a ligand free state.	False
An X - ray crystal structure of BC6ENTG in complex with the drug BC6ENTC was solved at 2.14 Å resolution.	False
A Structural Snapshot of BC6ENTG in Complex with BC6ENTC Provides Insights into Ligand Binding and Clusters of Conformational States.	False
Baseline platelet aggregation to 1 microg mL( - 1) BC6ENTG , and postaspirin aggregations to 5 microm and 20 microm BC6ENTC and BC6OTHER , were greater in the upper than in the lower tertile of reticulated platelets.	False
Baseline platelet aggregation to 1 microg mL( - 1) BC6OTHER , and postaspirin aggregations to 5 microm and 20 microm BC6ENTC and BC6ENTG , were greater in the upper than in the lower tertile of reticulated platelets.	False
Reticulated platelets and uninhibited BC6ENTG and BC6OTHER decrease the antiplatelet effects of BC6ENTC .	False
Reticulated platelets and uninhibited BC6OTHER and BC6ENTG decrease the antiplatelet effects of BC6ENTC .	False
Stimulated BC6ENTG and BC6OTHER expression were also higher in the upper tertile both before and after BC6ENTC .	CPR:3
Stimulated BC6OTHER and BC6ENTG expression were also higher in the upper tertile both before and after BC6ENTC .	CPR:3
Immature (reticulated) platelets may modulate the antiplatelet effects of BC6ENTC through uninhibited BC6ENTG BC6OTHER and BC6OTHER .	False
Immature (reticulated) platelets may modulate the antiplatelet effects of BC6ENTC through uninhibited BC6OTHER BC6ENTG and BC6OTHER .	False
Immature (reticulated) platelets may modulate the antiplatelet effects of BC6ENTC through uninhibited BC6OTHER BC6OTHER and BC6ENTG .	False
CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of BC6ENTC and increased BC6OTHER resistance, possibly because of increased reactivity, and uninhibited BC6ENTG and BC6OTHER activity.	False
CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of BC6ENTC and increased BC6OTHER resistance, possibly because of increased reactivity, and uninhibited BC6OTHER and BC6ENTG activity.	False
CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of BC6OTHER and increased BC6ENTC resistance, possibly because of increased reactivity, and uninhibited BC6ENTG and BC6OTHER activity.	False
CONCLUSIONS: Reticulated platelets are associated with diminished antiplatelet effects of BC6OTHER and increased BC6ENTC resistance, possibly because of increased reactivity, and uninhibited BC6OTHER and BC6ENTG activity.	False
Platelet studies included light transmission aggregometry; BC6ENTG and BC6OTHER expression, and serum BC6ENTC ( BC6OTHER ) levels.	False
Platelet studies included light transmission aggregometry; BC6OTHER and BC6ENTG expression, and serum BC6ENTC ( BC6OTHER ) levels.	False
Platelet studies included light transmission aggregometry; BC6ENTG and BC6OTHER expression, and serum BC6OTHER ( BC6ENTC ) levels.	False
Platelet studies included light transmission aggregometry; BC6OTHER and BC6ENTG expression, and serum BC6OTHER ( BC6ENTC ) levels.	False
RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive BC6ENTC significantly decreased BC6OTHER translocation, pro - inflammatory BC6OTHER production such as BC6ENTG ( BC6OTHER ), and apoptosis ( BC6OTHER and BC6OTHER expression).	CPR:4
RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive BC6ENTC significantly decreased BC6OTHER translocation, pro - inflammatory BC6OTHER production such as BC6OTHER ( BC6ENTG ), and apoptosis ( BC6OTHER and BC6OTHER expression).	CPR:4
RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive BC6ENTC significantly decreased BC6OTHER translocation, pro - inflammatory BC6OTHER production such as BC6OTHER ( BC6OTHER ), and apoptosis ( BC6ENTG and BC6OTHER expression).	CPR:4
RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive BC6ENTC significantly decreased BC6OTHER translocation, pro - inflammatory BC6OTHER production such as BC6OTHER ( BC6OTHER ), and apoptosis ( BC6OTHER and BC6ENTG expression).	CPR:4
RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive BC6ENTC significantly decreased BC6ENTG translocation, pro - inflammatory BC6OTHER production such as BC6OTHER ( BC6OTHER ), and apoptosis ( BC6OTHER and BC6OTHER expression).	CPR:4
RESULTS: By Western blot analysis of spinal cord tissues, we have demonstrated that treatment with bioactive BC6ENTC significantly decreased BC6OTHER translocation, pro - inflammatory BC6ENTG production such as BC6OTHER ( BC6OTHER ), and apoptosis ( BC6OTHER and BC6OTHER expression).	CPR:4
Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in BC6ENTC , which upon BC6ENTG hydrolysis release the corresponding BC6OTHER .	CPR:9
Recent literature shows that Brassica vegetables (Cruciferae) possess therapeutic effects particularly ascribed due to their content in BC6OTHER , which upon BC6ENTG hydrolysis release the corresponding BC6ENTC .	CPR:9
CHEM) bioactivated with BC6ENTG (bioactive BC6ENTC ) (10 mg / kg / day intraperitoneally), in an experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis.	False
Protective Role of BC6ENTC Bioactivated with BC6ENTG in an Experimental Model of Multiple Sclerosis.	False
Following a 2 - h control period during which BC6ENTC infusion was stopped, there was a 2 - h experimental period in which the response to hyperglycemia plus either 4× basal BC6ENTG ( BC6OTHER ) or portal vein BC6OTHER infusion (PoG) was measured.	False
Following a 2 - h control period during which BC6ENTC infusion was stopped, there was a 2 - h experimental period in which the response to hyperglycemia plus either 4× basal BC6OTHER ( BC6ENTG ) or portal vein BC6OTHER infusion (PoG) was measured.	False
Following a 2 - h control period during which BC6OTHER infusion was stopped, there was a 2 - h experimental period in which the response to hyperglycemia plus either 4× basal BC6ENTG ( BC6OTHER ) or portal vein BC6ENTC infusion (PoG) was measured.	False
Following a 2 - h control period during which BC6OTHER infusion was stopped, there was a 2 - h experimental period in which the response to hyperglycemia plus either 4× basal BC6OTHER ( BC6ENTG ) or portal vein BC6ENTC infusion (PoG) was measured.	False
Increased hepatic glycogen reduced the percent of BC6ENTC taken up by the liver that was deposited in glycogen (74 ± 3 vs. 53 ± 5% in Gly+ BC6OTHER and SCGly+ BC6ENTG , respectively, and 72 ± 3 vs. 50 ± 6% in Gly+PoG and SCGly+PoG, respectively).	False
Increased hepatic glycogen reduced the percent of BC6ENTC taken up by the liver that was deposited in glycogen (74 ± 3 vs. 53 ± 5% in Gly+ BC6ENTG and SCGly+ BC6OTHER , respectively, and 72 ± 3 vs. 50 ± 6% in Gly+PoG and SCGly+PoG, respectively).	False
These compounds were evaluated for their BC6OTHER ( BC6OTHER ) inhibitory activity and BC6ENTC was found to be the most potent against BC6ENTG with IC50 4.16 μmol / L.	CPR:4
These compounds were evaluated for their BC6ENTG ( BC6OTHER ) inhibitory activity and BC6ENTC was found to be the most potent against BC6OTHER with IC50 4.16 μmol / L.	False
These compounds were evaluated for their BC6OTHER ( BC6ENTG ) inhibitory activity and BC6ENTC was found to be the most potent against BC6OTHER with IC50 4.16 μmol / L.	False
A one - pot domino synthesis and discovery of highly functionalized BC6ENTC as BC6ENTG inhibitors.	CPR:4
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6OTHER inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6ENTG BC6OTHER as well as basolateral membrane BC6ENTC channels.	False
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6OTHER inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6OTHER BC6ENTG as well as basolateral membrane BC6ENTC channels.	False
To determine whether this inhibition of CHEM was due to the inhibition of BC6ENTG , the effects of BC6ENTC and BC6OTHER on BC6OTHER BC6OTHER in excised, inside - out patches from L - cells were evaluated.	False
To determine whether this inhibition of CHEM was due to the inhibition of BC6OTHER , the effects of BC6ENTC and BC6OTHER on BC6ENTG BC6OTHER in excised, inside - out patches from L - cells were evaluated.	False
To determine whether this inhibition of CHEM was due to the inhibition of BC6OTHER , the effects of BC6ENTC and BC6OTHER on BC6OTHER BC6ENTG in excised, inside - out patches from L - cells were evaluated.	False
 BC6ENTC inhibits BC6ENTG - mediated CHEM - secretion.	CPR:4
To determine whether this inhibition of CHEM was due to the inhibition of BC6ENTG , the effects of BC6OTHER and BC6ENTC on BC6OTHER BC6OTHER in excised, inside - out patches from L - cells were evaluated.	False
To determine whether this inhibition of CHEM was due to the inhibition of BC6OTHER , the effects of BC6OTHER and BC6ENTC on BC6ENTG BC6OTHER in excised, inside - out patches from L - cells were evaluated.	False
To determine whether this inhibition of CHEM was due to the inhibition of BC6OTHER , the effects of BC6OTHER and BC6ENTC on BC6OTHER BC6ENTG in excised, inside - out patches from L - cells were evaluated.	False
BC6ENTC (300 microM) reduced BC6ENTG CHEM - current by 60+ / - 16% and this was explained by a short - lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+ / - 0.04 pA to 0.59+ / - 0.04 pA (n = 3).	CPR:4
Similarly, BC6ENTC (3 mM) reduced BC6ENTG CHEM - current by 50+ / - 8% with an apparent reduction in single channel amplitude from 1.08+ / - 0.03 pA to 0.48+ / - 0.06 pA (n = 4).	CPR:4
Based on these results, we conclude that the NSAIDs BC6ENTC and BC6OTHER inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6ENTG BC6OTHER as well as basolateral membrane BC6OTHER .	CPR:4
Based on these results, we conclude that the NSAIDs BC6ENTC and BC6OTHER inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6OTHER BC6ENTG as well as basolateral membrane BC6OTHER .	CPR:4
Based on these results, we conclude that the NSAIDs BC6ENTC and BC6OTHER inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6OTHER BC6OTHER as well as basolateral membrane BC6ENTG .	CPR:4
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6ENTC inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6ENTG BC6OTHER as well as basolateral membrane BC6OTHER .	CPR:4
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6ENTC inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6OTHER BC6ENTG as well as basolateral membrane BC6OTHER .	CPR:4
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6ENTC inhibit BC6OTHER - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6OTHER BC6OTHER as well as basolateral membrane BC6ENTG .	CPR:4
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6OTHER inhibit BC6ENTC - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6ENTG BC6OTHER as well as basolateral membrane BC6OTHER .	False
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6OTHER inhibit BC6ENTC - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6OTHER BC6ENTG as well as basolateral membrane BC6OTHER .	False
Based on these results, we conclude that the NSAIDs BC6OTHER and BC6OTHER inhibit BC6ENTC - mediated CHEM - secretion in human colonic and airway epithelia via a direct inhibition of BC6OTHER BC6OTHER as well as basolateral membrane BC6ENTG .	False
Inhibition of binding of both BC6ENTG and BC6OTHER to BC6OTHER by BC6ENTC was similar, although BC6OTHER inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	CPR:4
Inhibition of binding of both BC6OTHER and BC6ENTG to BC6OTHER by BC6ENTC was similar, although BC6OTHER inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	CPR:4
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6ENTG by BC6ENTC was similar, although BC6OTHER inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6ENTC was similar, although BC6OTHER inhibited the binding of BC6ENTG to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6ENTC was similar, although BC6OTHER inhibited the binding of BC6OTHER to BC6ENTG slightly more than the binding of BC6OTHER to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6ENTC was similar, although BC6OTHER inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6ENTG to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6ENTC was similar, although BC6OTHER inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6ENTG .	False
Inhibition of binding of both BC6ENTG and BC6OTHER to BC6OTHER by BC6OTHER was similar, although BC6ENTC inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6ENTG to BC6OTHER by BC6OTHER was similar, although BC6ENTC inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6ENTG by BC6OTHER was similar, although BC6ENTC inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6OTHER was similar, although BC6ENTC inhibited the binding of BC6ENTG to BC6OTHER slightly more than the binding of BC6OTHER to BC6OTHER .	CPR:4
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6OTHER was similar, although BC6ENTC inhibited the binding of BC6OTHER to BC6ENTG slightly more than the binding of BC6OTHER to BC6OTHER .	False
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6OTHER was similar, although BC6ENTC inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6ENTG to BC6OTHER .	CPR:4
Inhibition of binding of both BC6OTHER and BC6OTHER to BC6OTHER by BC6OTHER was similar, although BC6ENTC inhibited the binding of BC6OTHER to BC6OTHER slightly more than the binding of BC6OTHER to BC6ENTG .	False
This binding was not significantly inhibited by the BC6ENTC analogue BC6OTHER ( BC6OTHER ), indicating that BC6ENTG binding was not just through BC6OTHER binding sites as suggested for other BC6OTHER binding sites.	False
This binding was not significantly inhibited by the BC6ENTC analogue BC6OTHER ( BC6OTHER ), indicating that BC6OTHER binding was not just through BC6OTHER binding sites as suggested for other BC6ENTG binding sites.	False
This binding was not significantly inhibited by the BC6OTHER analogue BC6ENTC ( BC6OTHER ), indicating that BC6ENTG binding was not just through BC6OTHER binding sites as suggested for other BC6OTHER binding sites.	False
This binding was not significantly inhibited by the BC6OTHER analogue BC6ENTC ( BC6OTHER ), indicating that BC6OTHER binding was not just through BC6OTHER binding sites as suggested for other BC6ENTG binding sites.	False
This binding was not significantly inhibited by the BC6OTHER analogue BC6OTHER ( BC6ENTC ), indicating that BC6ENTG binding was not just through BC6OTHER binding sites as suggested for other BC6OTHER binding sites.	False
This binding was not significantly inhibited by the BC6OTHER analogue BC6OTHER ( BC6ENTC ), indicating that BC6OTHER binding was not just through BC6OTHER binding sites as suggested for other BC6ENTG binding sites.	False
This binding was not significantly inhibited by the BC6OTHER analogue BC6OTHER ( BC6OTHER ), indicating that BC6ENTG binding was not just through BC6ENTC binding sites as suggested for other BC6OTHER binding sites.	False
This binding was not significantly inhibited by the BC6OTHER analogue BC6OTHER ( BC6OTHER ), indicating that BC6OTHER binding was not just through BC6ENTC binding sites as suggested for other BC6ENTG binding sites.	False
These events are stimulated by BC6OTHER and by BC6OTHER , an BC6ENTG substrate, and they are blocked by BC6ENTC and the antidepressant BC6OTHER .	CPR:4
These events are stimulated by BC6OTHER and by BC6OTHER , an BC6ENTG substrate, and they are blocked by BC6OTHER and the antidepressant BC6ENTC .	CPR:4
Voltage - clamp data combined with BC6ENTC uptake data from these same cells indicate that BC6ENTG have two functional modes of conduction: a classical transporter mode (T - mode) and a novel channel mode (C - mode).	CPR:9
Here we report channel - like events from a presumably fixed stoichiometry [ BC6ENTC ( BC6OTHER )+, BC6OTHER , and BC6OTHER ], human BC6OTHER ( BC6ENTG ) in the BC6OTHER transporter gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6ENTC ( BC6OTHER )+, BC6OTHER , and BC6OTHER ], human BC6OTHER ( BC6OTHER ) in the BC6ENTG gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6ENTC )+, BC6OTHER , and BC6OTHER ], human BC6OTHER ( BC6ENTG ) in the BC6OTHER transporter gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6ENTC )+, BC6OTHER , and BC6OTHER ], human BC6OTHER ( BC6OTHER ) in the BC6ENTG gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6OTHER )+, BC6ENTC , and BC6OTHER ], human BC6OTHER ( BC6ENTG ) in the BC6OTHER transporter gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6OTHER )+, BC6ENTC , and BC6OTHER ], human BC6OTHER ( BC6OTHER ) in the BC6ENTG gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6OTHER )+, BC6OTHER , and BC6ENTC ], human BC6OTHER ( BC6ENTG ) in the BC6OTHER transporter gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6OTHER )+, BC6OTHER , and BC6ENTC ], human BC6OTHER ( BC6OTHER ) in the BC6ENTG gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6OTHER )+, BC6OTHER , and BC6OTHER ], human BC6ENTC ( BC6ENTG ) in the BC6OTHER transporter gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6OTHER )+, BC6OTHER , and BC6OTHER ], human BC6ENTC ( BC6OTHER ) in the BC6ENTG gene family.	False
Here we report channel - like events from a presumably fixed stoichiometry [ BC6OTHER ( BC6OTHER )+, BC6OTHER , and BC6OTHER ], human BC6OTHER ( BC6ENTG ) in the BC6ENTC transporter gene family.	False
These events are stimulated by BC6ENTC and by BC6OTHER , an BC6ENTG substrate, and they are blocked by BC6OTHER and the antidepressant BC6OTHER .	CPR:9
These events are stimulated by BC6OTHER and by BC6ENTC , an BC6ENTG substrate, and they are blocked by BC6OTHER and the antidepressant BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) catalyses the formation of BC6OTHER , a bioactive BC6ENTC .	CPR:9
BC6OTHER decarboxylase ( BC6ENTG ) catalyses the formation of BC6OTHER , a bioactive BC6ENTC .	CPR:9
BC6ENTC decarboxylase ( BC6ENTG ) catalyses the formation of BC6OTHER , a bioactive BC6OTHER .	False
Agents that control BC6ENTG activity are beneficial for treating BC6ENTC - mediated symptoms, such as allergies and stomach ulceration.	False
We searched for inhibitors of BC6ENTG from the BC6ENTC extract of the petal of Filipendula ulmaria, also called meadowsweet.	CPR:4
BC6ENTG ( BC6OTHER ) catalyses the formation of BC6ENTC , a bioactive BC6OTHER .	CPR:9
BC6OTHER decarboxylase ( BC6ENTG ) catalyses the formation of BC6ENTC , a bioactive BC6OTHER .	CPR:9
The BC6OTHER BC6ENTG polymorphism and BC6ENTC effects on plasma - BC6OTHER activity.	False
The BC6ENTG BC6OTHER polymorphism and BC6ENTC effects on plasma - BC6OTHER activity.	False
The BC6OTHER BC6OTHER polymorphism and BC6ENTC effects on plasma - BC6ENTG activity.	False
BC6ENTC reduced BC6OTHER - induced heart rate and contractility increases and diastolic blood pressure decreases more potently in CHEM389 - versus CHEM389 - BC6ENTG subjects.	False
BC6OTHER reduced BC6ENTC - induced heart rate and contractility increases and diastolic blood pressure decreases more potently in CHEM389 - versus CHEM389 - BC6ENTG subjects.	False
RESULTS: With regard to PRA, BC6ENTC increased PRA more potently in CHEM389 - BC6ENTG versus CHEM389 - BC6OTHER subjects.	False
RESULTS: With regard to PRA, BC6ENTC increased PRA more potently in CHEM389 - BC6OTHER versus CHEM389 - BC6ENTG subjects.	False
OBJECTIVES: The purpose of this research was to find out whether, in humans, BC6ENTC - induced hemodynamic effects and increase in plasma - BC6ENTG activity (PRA) might be BC6OTHER ( BC6OTHER ) genotype - dependent.	False
OBJECTIVES: The purpose of this research was to find out whether, in humans, BC6ENTC - induced hemodynamic effects and increase in plasma - BC6OTHER activity (PRA) might be BC6ENTG ( BC6OTHER ) genotype - dependent.	False
OBJECTIVES: The purpose of this research was to find out whether, in humans, BC6ENTC - induced hemodynamic effects and increase in plasma - BC6OTHER activity (PRA) might be BC6OTHER ( BC6ENTG ) genotype - dependent.	False
BC6ENTC markedly suppressed the BC6OTHER - induced PRA increase in CHEM389 - but only marginally in CHEM389 - BC6ENTG subjects.	False
BC6OTHER markedly suppressed the BC6ENTC - induced PRA increase in CHEM389 - but only marginally in CHEM389 - BC6ENTG subjects.	False
With regard to hemodynamics, BC6ENTC caused larger heart rate and contractility increases and diastolic blood pressure decreases in CHEM389 - versus CHEM389 - BC6ENTG subjects.	False
Number and area of preneoplastic foci positive for BC6ENTC BC6OTHER - transferase placental form ( BC6ENTG ) were consistently higher in these groups than the sum of individual values in the groups treated with BC6OTHER or BC6OTHER alone.	False
Number and area of preneoplastic foci positive for CHEM BC6ENTC - transferase placental form ( BC6ENTG ) were consistently higher in these groups than the sum of individual values in the groups treated with BC6OTHER or BC6OTHER alone.	False
Number and area of preneoplastic foci positive for BC6ENTG ( BC6OTHER ) were consistently higher in these groups than the sum of individual values in the groups treated with BC6ENTC or BC6OTHER alone.	CPR:3
Number and area of preneoplastic foci positive for CHEM BC6OTHER - transferase placental form ( BC6ENTG ) were consistently higher in these groups than the sum of individual values in the groups treated with BC6ENTC or BC6OTHER alone.	CPR:3
Number and area of preneoplastic foci positive for BC6ENTG ( BC6OTHER ) were consistently higher in these groups than the sum of individual values in the groups treated with BC6OTHER or BC6ENTC alone.	CPR:3
Number and area of preneoplastic foci positive for CHEM BC6OTHER - transferase placental form ( BC6ENTG ) were consistently higher in these groups than the sum of individual values in the groups treated with BC6OTHER or BC6ENTC alone.	CPR:3
Consistent with these findings, BC6OTHER and BC6OTHER had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and BC6ENTG induction, which may lead to more efficient metabolic activation of BC6ENTC and BC6OTHER .	False
Consistent with these findings, BC6ENTC and BC6OTHER had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and BC6ENTG induction, which may lead to more efficient metabolic activation of BC6OTHER and BC6OTHER .	False
Consistent with these findings, BC6OTHER and BC6ENTC had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and BC6ENTG induction, which may lead to more efficient metabolic activation of BC6OTHER and BC6OTHER .	False
Consistent with these findings, BC6OTHER and BC6OTHER had additive or synergistic effects on cell proliferation induction within the preneoplastic foci and BC6ENTG induction, which may lead to more efficient metabolic activation of BC6OTHER and BC6ENTC .	False
On the basis of these findings, we conclude that BC6ENTC and BC6OTHER have additive and synergistic effects on the development of BC6ENTG - positive foci and that higher risks are associated with a combination of residual BC6OTHER pesticides in foods than with individual residual BC6OTHER pesticides.	CPR:3
On the basis of these findings, we conclude that BC6OTHER and BC6ENTC have additive and synergistic effects on the development of BC6ENTG - positive foci and that higher risks are associated with a combination of residual BC6OTHER pesticides in foods than with individual residual BC6OTHER pesticides.	CPR:3
On the basis of these findings, we conclude that BC6OTHER and BC6OTHER have additive and synergistic effects on the development of BC6ENTG - positive foci and that higher risks are associated with a combination of residual BC6ENTC pesticides in foods than with individual residual BC6OTHER pesticides.	False
On the basis of these findings, we conclude that BC6OTHER and BC6OTHER have additive and synergistic effects on the development of BC6ENTG - positive foci and that higher risks are associated with a combination of residual BC6OTHER pesticides in foods than with individual residual BC6ENTC pesticides.	False
We investigated the mechanism by which BC6OTHER inhibits BC6ENTC and BC6OTHER by examining the level of BC6ENTG ( BC6OTHER ) activation within the BC6OTHER ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6OTHER inhibits BC6ENTC and BC6OTHER by examining the level of BC6OTHER ( BC6ENTG ) activation within the BC6OTHER ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6OTHER inhibits BC6ENTC and BC6OTHER by examining the level of BC6OTHER ( BC6OTHER ) activation within the BC6ENTG ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6OTHER inhibits BC6ENTC and BC6OTHER by examining the level of BC6OTHER ( BC6OTHER ) activation within the BC6OTHER ( BC6ENTG ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6OTHER inhibits BC6OTHER and BC6ENTC by examining the level of BC6ENTG ( BC6OTHER ) activation within the BC6OTHER ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6OTHER inhibits BC6OTHER and BC6ENTC by examining the level of BC6OTHER ( BC6ENTG ) activation within the BC6OTHER ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6OTHER inhibits BC6OTHER and BC6ENTC by examining the level of BC6OTHER ( BC6OTHER ) activation within the BC6ENTG ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6OTHER inhibits BC6OTHER and BC6ENTC by examining the level of BC6OTHER ( BC6OTHER ) activation within the BC6OTHER ( BC6ENTG ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
BC6ENTC inhibited LPS - induced phosphorylation of BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC inhibited LPS - induced phosphorylation of BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:4
BC6ENTC inhibited LPS - induced phosphorylation of BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:4
Furthermore, BC6ENTC inhibited the LPS - induced phosphorylation of BC6OTHER and BC6OTHER BC6ENTG .	CPR:4
Furthermore, BC6ENTC inhibited the LPS - induced phosphorylation of BC6ENTG and BC6OTHER BC6OTHER .	CPR:4
Furthermore, BC6ENTC inhibited the LPS - induced phosphorylation of BC6OTHER and BC6ENTG BC6OTHER .	CPR:4
Taken together, the results of this study demonstrate that BC6ENTC inhibits LPS - stimulated inflammation by blocking the BC6ENTG and BC6OTHER pathways in macrophages.	CPR:4
Taken together, the results of this study demonstrate that BC6ENTC inhibits LPS - stimulated inflammation by blocking the BC6OTHER and BC6ENTG pathways in macrophages.	CPR:4
BC6ENTC induced dose - dependent reduction of the protein levels of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
BC6ENTC induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6OTHER ).	CPR:4
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6ENTC synthase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6ENTC synthase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6ENTC synthase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6ENTC and BC6OTHER ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6ENTC and BC6OTHER ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) and concomitant reduction in the production of BC6ENTC and BC6OTHER ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) and concomitant reduction in the production of BC6ENTC and BC6OTHER ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6ENTC ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6ENTC ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6ENTC ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) and concomitant reduction in the production of BC6OTHER and BC6ENTC ( BC6OTHER ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6ENTC ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6ENTC ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6ENTC ).	False
BC6OTHER induced dose - dependent reduction of the protein levels of inducible BC6OTHER synthase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) and concomitant reduction in the production of BC6OTHER and BC6OTHER ( BC6ENTC ).	False
Additionally, BC6ENTC suppressed the production of inflammatory BC6ENTG , including BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER .	CPR:4
Additionally, BC6ENTC suppressed the production of inflammatory BC6OTHER , including BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER .	CPR:4
Additionally, BC6ENTC suppressed the production of inflammatory BC6OTHER , including BC6OTHER ( BC6ENTG ), BC6OTHER , and BC6OTHER .	CPR:4
Additionally, BC6ENTC suppressed the production of inflammatory BC6OTHER , including BC6OTHER ( BC6OTHER ), BC6ENTG , and BC6OTHER .	CPR:4
Additionally, BC6ENTC suppressed the production of inflammatory BC6OTHER , including BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTG .	CPR:4
We investigated the mechanism by which BC6ENTC inhibits BC6OTHER and BC6OTHER by examining the level of BC6ENTG ( BC6OTHER ) activation within the BC6OTHER ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6ENTC inhibits BC6OTHER and BC6OTHER by examining the level of BC6OTHER ( BC6ENTG ) activation within the BC6OTHER ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6ENTC inhibits BC6OTHER and BC6OTHER by examining the level of BC6OTHER ( BC6OTHER ) activation within the BC6ENTG ( BC6OTHER ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
We investigated the mechanism by which BC6ENTC inhibits BC6OTHER and BC6OTHER by examining the level of BC6OTHER ( BC6OTHER ) activation within the BC6OTHER ( BC6ENTG ) pathway, which is an inflammation - induced signaling pathway in RAW 264.7 cells.	False
A novel variant BC6ENTG in human BC6ENTC dehydrogenase 2 is associated with diminished enzyme activity.	False
A novel nonsynonymous variant BC6ENTG was identified, and the kinetic assay demonstrated that the BC6ENTC dehydrogenase activity of BC6OTHER variant was decreased to 10% of the wild - type.	False
A novel nonsynonymous variant BC6OTHER was identified, and the kinetic assay demonstrated that the BC6ENTC dehydrogenase activity of BC6ENTG variant was decreased to 10% of the wild - type.	False
The Ki for BC6ENTC inhibition of the BC6ENTG variant was comparable with the wild - type, and the variant Km for BC6OTHER and BC6OTHER did not change significantly.	CPR:4
The Ki for BC6OTHER inhibition of the BC6ENTG variant was comparable with the wild - type, and the variant Km for BC6ENTC and BC6OTHER did not change significantly.	False
The Ki for BC6OTHER inhibition of the BC6ENTG variant was comparable with the wild - type, and the variant Km for BC6OTHER and BC6ENTC did not change significantly.	False
CONCLUSIONS: BC6ENTG has low genetic diversity, but the nonsynonymous variant BC6OTHER has a significant impact on BC6ENTC dehydrogenase activity.	False
CONCLUSIONS: BC6OTHER has low genetic diversity, but the nonsynonymous variant BC6ENTG has a significant impact on BC6ENTC dehydrogenase activity.	False
Variants in the BC6ENTG gene may account for the large inter - individual variability in baseline enzyme activity, immunosuppressive efficacy and side effects in transplant recipients receiving BC6ENTC .	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6ENTG , any BC6ENTC allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6ENTC allele, and BC6ENTG , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6ENTC allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6ENTG BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6ENTG , any BC6OTHER allele, and BC6OTHER , any BC6ENTC allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6ENTG , any BC6ENTC allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6OTHER , any BC6ENTC allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6ENTG BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6ENTG , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6ENTC / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6ENTG , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6ENTC / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6ENTG BC6ENTC / BC6OTHER or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6ENTG , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6ENTC or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6ENTG , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6ENTC or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6ENTG BC6OTHER / BC6ENTC or BC6OTHER / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6ENTG , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6ENTC / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6ENTG , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6ENTC / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6ENTG BC6OTHER / BC6OTHER or BC6ENTC / BC6OTHER ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6ENTG , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6OTHER / BC6ENTC ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6ENTG , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6OTHER BC6OTHER / BC6OTHER or BC6OTHER / BC6ENTC ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Combined analysis of these two polymorphisms showed that patients with the favorable genotypes ( BC6OTHER , any BC6OTHER allele, and BC6OTHER , any BC6OTHER allele) showed a median CHEM of 3.7 months (95% CI, 2.4 to 4.4 months), whereas patients with any two unfavorable genotypes ( BC6ENTG BC6OTHER / BC6OTHER or BC6OTHER / BC6ENTC ) had a CHEM of 1.1 months (95% CI, 1.0 to 1.4 months; P = .004; log - rank test).	False
Among the transcription factors that play critical roles in BC6ENTC metabolism are BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
Among the transcription factors that play critical roles in BC6ENTC metabolism are BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
Among the transcription factors that play critical roles in BC6ENTC metabolism are BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
Among the transcription factors that play critical roles in BC6ENTC metabolism are BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
Here we show that BC6ENTC rapidly increases the levels of both BC6ENTG and BC6OTHER as well as BC6OTHER - and BC6OTHER - dependent gene transcription via distinct mechanisms.	CPR:3
Here we show that BC6ENTC rapidly increases the levels of both BC6OTHER and BC6ENTG as well as BC6OTHER - and BC6OTHER - dependent gene transcription via distinct mechanisms.	CPR:3
Here we show that BC6ENTC rapidly increases the levels of both BC6OTHER and BC6OTHER as well as BC6ENTG - and BC6OTHER - dependent gene transcription via distinct mechanisms.	CPR:3
Here we show that BC6ENTC rapidly increases the levels of both BC6OTHER and BC6OTHER as well as BC6OTHER - and BC6ENTG - dependent gene transcription via distinct mechanisms.	CPR:3
Concurrent Regulation of the Transcription Factors BC6ENTG and BC6OTHER Mediates the Enhancement of BC6OTHER Levels by the BC6ENTC BC6OTHER .	False
Concurrent Regulation of the Transcription Factors BC6OTHER and BC6ENTG Mediates the Enhancement of BC6OTHER Levels by the BC6ENTC BC6OTHER .	False
Concurrent Regulation of the Transcription Factors BC6ENTG and BC6OTHER Mediates the Enhancement of BC6OTHER Levels by the BC6OTHER BC6ENTC .	False
Concurrent Regulation of the Transcription Factors BC6OTHER and BC6ENTG Mediates the Enhancement of BC6OTHER Levels by the BC6OTHER BC6ENTC .	False
Concurrent Regulation of the Transcription Factors BC6ENTG and BC6OTHER Mediates the Enhancement of BC6ENTC Levels by the BC6OTHER BC6OTHER .	False
Concurrent Regulation of the Transcription Factors BC6OTHER and BC6ENTG Mediates the Enhancement of BC6ENTC Levels by the BC6OTHER BC6OTHER .	False
Although BC6ENTC greatly increases the stability of both BC6ENTG and BC6OTHER , only the effect on BC6OTHER is dependent on BC6OTHER activity.	CPR:3
Although BC6ENTC greatly increases the stability of both BC6OTHER and BC6ENTG , only the effect on BC6OTHER is dependent on BC6OTHER activity.	CPR:3
Although BC6ENTC greatly increases the stability of both BC6OTHER and BC6OTHER , only the effect on BC6ENTG is dependent on BC6OTHER activity.	False
Although BC6ENTC greatly increases the stability of both BC6OTHER and BC6OTHER , only the effect on BC6OTHER is dependent on BC6ENTG activity.	False
Using siRNA we found that BC6ENTG , but not BC6OTHER , is important for BC6ENTC 's ability to increase BC6OTHER levels under basal conditions whereas both BC6OTHER and BC6OTHER appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6ENTG , is important for BC6ENTC 's ability to increase BC6OTHER levels under basal conditions whereas both BC6OTHER and BC6OTHER appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6OTHER , is important for BC6ENTC 's ability to increase BC6OTHER levels under basal conditions whereas both BC6ENTG and BC6OTHER appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6OTHER , is important for BC6ENTC 's ability to increase BC6OTHER levels under basal conditions whereas both BC6OTHER and BC6ENTG appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6ENTG , but not BC6OTHER , is important for BC6OTHER 's ability to increase BC6ENTC levels under basal conditions whereas both BC6OTHER and BC6OTHER appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6ENTG , is important for BC6OTHER 's ability to increase BC6ENTC levels under basal conditions whereas both BC6OTHER and BC6OTHER appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6OTHER , is important for BC6OTHER 's ability to increase BC6ENTC levels under basal conditions whereas both BC6ENTG and BC6OTHER appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6OTHER , is important for BC6OTHER 's ability to increase BC6ENTC levels under basal conditions whereas both BC6OTHER and BC6ENTG appear to cooperate to increase BC6OTHER levels under oxidative stress conditions.	False
Using siRNA we found that BC6ENTG , but not BC6OTHER , is important for BC6OTHER 's ability to increase BC6OTHER levels under basal conditions whereas both BC6OTHER and BC6OTHER appear to cooperate to increase BC6ENTC levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6ENTG , is important for BC6OTHER 's ability to increase BC6OTHER levels under basal conditions whereas both BC6OTHER and BC6OTHER appear to cooperate to increase BC6ENTC levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6OTHER , is important for BC6OTHER 's ability to increase BC6OTHER levels under basal conditions whereas both BC6ENTG and BC6OTHER appear to cooperate to increase BC6ENTC levels under oxidative stress conditions.	False
Using siRNA we found that BC6OTHER , but not BC6OTHER , is important for BC6OTHER 's ability to increase BC6OTHER levels under basal conditions whereas both BC6OTHER and BC6ENTG appear to cooperate to increase BC6ENTC levels under oxidative stress conditions.	False
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6ENTG Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTG BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - FOXO1 Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTG BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTC - FoxO3a Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTG Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6ENTG , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6ENTG , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6ENTG BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTC - NF - κB CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTG Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTC - Rb BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTG Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTG BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6ENTC 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
Overexpression of BC6ENTG or BC6OTHER in TW2.6 cells rescued growth inhibition caused by BC6ENTC treatment.	False
Overexpression of BC6OTHER or BC6ENTG in TW2.6 cells rescued growth inhibition caused by BC6ENTC treatment.	False
 BC6ENTC Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of BC6ENTG Signaling.	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTG Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTG BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	CPR:4
Treatment with BC6ENTC decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	CPR:3
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTG Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTG BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC - Akt BC6OTHER 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6ENTG CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTG Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTG BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6ENTC 473, BC6OTHER - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
Treatment with BC6OTHER decreased protein abundance of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6ENTG Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6ENTG , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6ENTG CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6ENTG , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6ENTG BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6ENTG , and BC6OTHER , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6ENTG , but increased cell cycle inhibitor BC6OTHER .	False
Treatment with BC6OTHER decreased protein abundance of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER - Akt BC6OTHER 473, BC6ENTC - Akt CHEM 308, BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER Thr24, BC6OTHER Thr32, BC6OTHER , BC6OTHER CHEM536, BC6OTHER , BC6OTHER BC6OTHER 807 / 811, BC6OTHER , and BC6OTHER , but increased cell cycle inhibitor BC6ENTG .	False
There are seemingly conflicting data in the literature regarding the role of BC6OTHER ( BC6OTHER ) BC6OTHER receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6ENTG agonist BC6OTHER ( BC6ENTC ).	False
There are seemingly conflicting data in the literature regarding the role of BC6OTHER ( BC6OTHER ) BC6ENTG receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6OTHER agonist BC6OTHER ( BC6ENTC ).	False
The present experiments tested the hypothesis that both classes of BC6ENTG receptor compounds could attenuate the BC6ENTC - elicited - HTR in a single strain of mice, C57Bl / 6J.	False
Commercially - available BC6ENTG agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:5
Commercially - available BC6OTHER agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:5
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:5
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:5
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:5
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
There are seemingly conflicting data in the literature regarding the role of BC6ENTC ( BC6OTHER ) BC6OTHER receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6ENTG agonist BC6OTHER ( BC6OTHER ).	False
There are seemingly conflicting data in the literature regarding the role of BC6ENTC ( BC6OTHER ) BC6ENTG receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6OTHER agonist BC6OTHER ( BC6OTHER ).	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6ENTC ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6ENTC ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:5
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6ENTC ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6ENTC ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6ENTC ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6ENTC ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6ENTC ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6ENTC ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:5
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6ENTC ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6ENTC ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6ENTC ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6ENTC ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6ENTC - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6ENTC - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6ENTC - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6ENTC - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6ENTC - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6ENTC - elicited - HTR.	False
There are seemingly conflicting data in the literature regarding the role of BC6OTHER ( BC6ENTC ) BC6OTHER receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6ENTG agonist BC6OTHER ( BC6OTHER ).	False
There are seemingly conflicting data in the literature regarding the role of BC6OTHER ( BC6ENTC ) BC6ENTG receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6OTHER agonist BC6OTHER ( BC6OTHER ).	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:6
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6ENTC ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6ENTC ), and BC6OTHER ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	CPR:6
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), and BC6ENTG ( BC6OTHER ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6ENTG agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6ENTG agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6ENTG antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and BC6OTHER ( BC6ENTC ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Commercially - available BC6OTHER agonists ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER ), novel BC6OTHER ( BC6OTHER ) - type BC6OTHER agonists (with BC6OTHER antagonist activity), and antagonists selective for BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and BC6ENTG ( BC6ENTC ) receptors attenuated the BC6OTHER - elicited - HTR.	False
Support for BC6OTHER receptor functional selectivity in vivo utilizing structurally diverse, selective BC6ENTG receptor ligands and the BC6ENTC elicited head - twitch response model.	False
Support for BC6ENTG receptor functional selectivity in vivo utilizing structurally diverse, selective BC6OTHER receptor ligands and the BC6ENTC elicited head - twitch response model.	False
The BC6ENTG agonists and BC6ENTC decreased locomotion, BC6OTHER increased locomotion, BC6OTHER resulted in dose - dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	False
The BC6ENTG agonists and BC6OTHER decreased locomotion, BC6ENTC increased locomotion, BC6OTHER resulted in dose - dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	False
The BC6ENTG agonists and BC6OTHER decreased locomotion, BC6OTHER increased locomotion, BC6ENTC resulted in dose - dependent biphasic effects on locomotion, and the PATs did not alter locomotion.	False
In vitro molecular pharmacology studies showed that BC6ENTG agonists potent for attenuating the BC6ENTC - elicited - HTR also reduced the efficacy of BC6OTHER to activate BC6OTHER receptor - mediated BC6OTHER signaling in HEK cells.	False
In vitro molecular pharmacology studies showed that BC6OTHER agonists potent for attenuating the BC6ENTC - elicited - HTR also reduced the efficacy of BC6OTHER to activate BC6ENTG receptor - mediated BC6OTHER signaling in HEK cells.	False
In vitro molecular pharmacology studies showed that BC6OTHER agonists potent for attenuating the BC6ENTC - elicited - HTR also reduced the efficacy of BC6OTHER to activate BC6OTHER receptor - mediated BC6ENTG signaling in HEK cells.	False
In vitro molecular pharmacology studies showed that BC6ENTG agonists potent for attenuating the BC6OTHER - elicited - HTR also reduced the efficacy of BC6ENTC to activate BC6OTHER receptor - mediated BC6OTHER signaling in HEK cells.	False
In vitro molecular pharmacology studies showed that BC6OTHER agonists potent for attenuating the BC6OTHER - elicited - HTR also reduced the efficacy of BC6ENTC to activate BC6ENTG receptor - mediated BC6OTHER signaling in HEK cells.	CPR:3
In vitro molecular pharmacology studies showed that BC6OTHER agonists potent for attenuating the BC6OTHER - elicited - HTR also reduced the efficacy of BC6ENTC to activate BC6OTHER receptor - mediated BC6ENTG signaling in HEK cells.	False
Results indicate that BC6ENTG receptor agonists and antagonists attenuate the BC6ENTC - elicited - HTR in C57Bl / 6J mice, and suggest that structurally diverse BC6OTHER ligands result in different BC6OTHER receptor signaling outcomes compared to BC6OTHER .	False
Results indicate that BC6OTHER receptor agonists and antagonists attenuate the BC6ENTC - elicited - HTR in C57Bl / 6J mice, and suggest that structurally diverse BC6ENTG ligands result in different BC6OTHER receptor signaling outcomes compared to BC6OTHER .	False
Results indicate that BC6OTHER receptor agonists and antagonists attenuate the BC6ENTC - elicited - HTR in C57Bl / 6J mice, and suggest that structurally diverse BC6OTHER ligands result in different BC6ENTG receptor signaling outcomes compared to BC6OTHER .	False
Results indicate that BC6ENTG receptor agonists and antagonists attenuate the BC6OTHER - elicited - HTR in C57Bl / 6J mice, and suggest that structurally diverse BC6OTHER ligands result in different BC6OTHER receptor signaling outcomes compared to BC6ENTC .	False
Results indicate that BC6OTHER receptor agonists and antagonists attenuate the BC6OTHER - elicited - HTR in C57Bl / 6J mice, and suggest that structurally diverse BC6ENTG ligands result in different BC6OTHER receptor signaling outcomes compared to BC6ENTC .	False
Results indicate that BC6OTHER receptor agonists and antagonists attenuate the BC6OTHER - elicited - HTR in C57Bl / 6J mice, and suggest that structurally diverse BC6OTHER ligands result in different BC6ENTG receptor signaling outcomes compared to BC6ENTC .	False
There are seemingly conflicting data in the literature regarding the role of BC6OTHER ( BC6OTHER ) BC6OTHER receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6ENTG agonist BC6ENTC ( BC6OTHER ).	False
There are seemingly conflicting data in the literature regarding the role of BC6OTHER ( BC6OTHER ) BC6ENTG receptors in the mouse head - twitch response (HTR) elicited by the hallucinogenic BC6OTHER agonist BC6ENTC ( BC6OTHER ).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6ENTG peptide ( BC6ENTC (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6ENTG was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6ENTC (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6ENTG at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6ENTC (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6ENTG , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6ENTC (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6ENTG ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6ENTC (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTG of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6ENTC (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6ENTG , generating a truncated mature BC6OTHER peptide ( BC6ENTC (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6ENTG peptide ( BC6OTHER (289)↓ BC6ENTC (290)).	False
BC6OTHER - terminal sequencing indicated that BC6ENTG was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6ENTC (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6ENTG at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6ENTC (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6ENTG , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6ENTC (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6ENTG ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6ENTC (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTG of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6ENTC (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6ENTG , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6ENTC (290)).	False
Similarly, mature BC6ENTG was also cleaved to a truncated peptide within its BC6ENTC - terminal region ( BC6OTHER (289)↓ BC6OTHER (290)).	False
Similarly, mature BC6ENTG was also cleaved to a truncated peptide within its BC6OTHER - terminal region ( BC6ENTC (289)↓ BC6OTHER (290)).	False
Similarly, mature BC6ENTG was also cleaved to a truncated peptide within its BC6OTHER - terminal region ( BC6OTHER (289)↓ BC6ENTC (290)).	False
BC6ENTC - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6ENTG peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6ENTC - terminal sequencing indicated that BC6ENTG was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6ENTC - terminal sequencing indicated that BC6OTHER was cleaved by BC6ENTG at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6ENTC - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6ENTG , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6ENTC - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6ENTG ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6ENTC - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTG of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6ENTC - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6ENTG , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6ENTC (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6ENTG peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6ENTG was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6ENTC (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6ENTG at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6ENTC (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6ENTG , giving rise to mature BC6OTHER ( BC6ENTC (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6ENTG ( BC6ENTC (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6ENTC (282)↓ BC6OTHER (283)), as well as in the BC6ENTG of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6ENTC (282)↓ BC6OTHER (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6ENTG , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6ENTC (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6ENTG peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6ENTG was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6ENTC (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6ENTG at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6ENTC (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6ENTG , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6ENTC (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6ENTG ( BC6OTHER (282)↓ BC6ENTC (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6ENTC (283)), as well as in the BC6ENTG of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6ENTC (283)), as well as in the BC6OTHER - terminal heparin binding region of mature BC6ENTG , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTC - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6ENTG peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6ENTG was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTC - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6ENTG at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTC - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6ENTG , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTC - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6ENTG ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTC - terminal heparin binding region of mature BC6OTHER , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
BC6OTHER - terminal sequencing indicated that BC6OTHER was cleaved by BC6OTHER at the canonical BC6OTHER , giving rise to mature BC6OTHER ( BC6OTHER (282)↓ BC6OTHER (283)), as well as in the BC6ENTC - terminal heparin binding region of mature BC6ENTG , generating a truncated mature BC6OTHER peptide ( BC6OTHER (289)↓ BC6OTHER (290)).	False
We hypothesized that BC6ENTG ( BC6OTHER ) transcriptional processes would therefore be affected by BC6ENTC ( BC6OTHER ) incorporation into a promoter BC6OTHER .	False
We hypothesized that BC6OTHER ( BC6ENTG ) transcriptional processes would therefore be affected by BC6ENTC ( BC6OTHER ) incorporation into a promoter BC6OTHER .	False
We hypothesized that BC6OTHER ( BC6OTHER ) transcriptional processes would therefore be affected by BC6ENTC ( BC6OTHER ) incorporation into a promoter BC6ENTG .	False
We hypothesized that BC6ENTG ( BC6OTHER ) transcriptional processes would therefore be affected by BC6OTHER ( BC6ENTC ) incorporation into a promoter BC6OTHER .	False
We hypothesized that BC6OTHER ( BC6ENTG ) transcriptional processes would therefore be affected by BC6OTHER ( BC6ENTC ) incorporation into a promoter BC6OTHER .	False
We hypothesized that BC6OTHER ( BC6OTHER ) transcriptional processes would therefore be affected by BC6OTHER ( BC6ENTC ) incorporation into a promoter BC6ENTG .	False
With increasing amounts of HeLa extract, BC6ENTC substitution for BC6OTHER within the BC6ENTG decreased in vitro BC6OTHER transcription by approximately 35% compared with control substrates.	False
With increasing amounts of HeLa extract, BC6ENTC substitution for BC6OTHER within the BC6OTHER decreased in vitro BC6ENTG transcription by approximately 35% compared with control substrates.	False
With increasing amounts of HeLa extract, BC6OTHER substitution for BC6ENTC within the BC6ENTG decreased in vitro BC6OTHER transcription by approximately 35% compared with control substrates.	False
With increasing amounts of HeLa extract, BC6OTHER substitution for BC6ENTC within the BC6OTHER decreased in vitro BC6ENTG transcription by approximately 35% compared with control substrates.	False
In contrast, transcription on BC6ENTC - substituted BC6ENTG reached a plateau after 20 min.	False
Furthermore, BC6ENTC - substituted promoter sequences trapped or sequestered TBP, preventing its dissociation from DNA and subsequent binding to additional BC6ENTG to reinitiate transcription.	False
We demonstrated by in vitro gel - shift assays that binding interactions of the BC6ENTG ( BC6OTHER ) were disrupted on BC6ENTC ( BC6OTHER ) - substituted BC6OTHER .	False
We demonstrated by in vitro gel - shift assays that binding interactions of the BC6OTHER ( BC6ENTG ) were disrupted on BC6ENTC ( BC6OTHER ) - substituted BC6OTHER .	False
We demonstrated by in vitro gel - shift assays that binding interactions of the BC6OTHER ( BC6OTHER ) were disrupted on BC6ENTC ( BC6OTHER ) - substituted BC6ENTG .	False
We demonstrated by in vitro gel - shift assays that binding interactions of the BC6ENTG ( BC6OTHER ) were disrupted on BC6OTHER ( BC6ENTC ) - substituted BC6OTHER .	False
We demonstrated by in vitro gel - shift assays that binding interactions of the BC6OTHER ( BC6ENTG ) were disrupted on BC6OTHER ( BC6ENTC ) - substituted BC6OTHER .	False
We demonstrated by in vitro gel - shift assays that binding interactions of the BC6OTHER ( BC6OTHER ) were disrupted on BC6OTHER ( BC6ENTC ) - substituted BC6ENTG .	False
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6ENTG , with BC6ENTC , BC6OTHER , and BC6OTHER being efficient inhibitors against BC6OTHER (K(I)s of 65 - 138 nM), whereas BC6OTHER is a much weaker one (K(I) of 2520 nM).	False
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6OTHER , with BC6ENTC , BC6OTHER , and BC6OTHER being efficient inhibitors against BC6ENTG (K(I)s of 65 - 138 nM), whereas BC6OTHER is a much weaker one (K(I) of 2520 nM).	CPR:4
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6ENTG , with BC6OTHER , BC6ENTC , and BC6OTHER being efficient inhibitors against BC6OTHER (K(I)s of 65 - 138 nM), whereas BC6OTHER is a much weaker one (K(I) of 2520 nM).	False
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6OTHER , with BC6OTHER , BC6ENTC , and BC6OTHER being efficient inhibitors against BC6ENTG (K(I)s of 65 - 138 nM), whereas BC6OTHER is a much weaker one (K(I) of 2520 nM).	CPR:4
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6ENTG , with BC6OTHER , BC6OTHER , and BC6ENTC being efficient inhibitors against BC6OTHER (K(I)s of 65 - 138 nM), whereas BC6OTHER is a much weaker one (K(I) of 2520 nM).	False
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6OTHER , with BC6OTHER , BC6OTHER , and BC6ENTC being efficient inhibitors against BC6ENTG (K(I)s of 65 - 138 nM), whereas BC6OTHER is a much weaker one (K(I) of 2520 nM).	CPR:4
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6ENTG , with BC6OTHER , BC6OTHER , and BC6OTHER being efficient inhibitors against BC6OTHER (K(I)s of 65 - 138 nM), whereas BC6ENTC is a much weaker one (K(I) of 2520 nM).	False
Some of these structurally related compounds have a very different behavior against the widespread isozyme BC6OTHER , with BC6OTHER , BC6OTHER , and BC6OTHER being efficient inhibitors against BC6ENTG (K(I)s of 65 - 138 nM), whereas BC6ENTC is a much weaker one (K(I) of 2520 nM).	CPR:4
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6ENTC against BC6ENTG ; BC6OTHER against BC6OTHER , BC6OTHER against BC6OTHER , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6ENTC against BC6OTHER ; BC6OTHER against BC6ENTG , BC6OTHER against BC6OTHER , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6ENTC against BC6OTHER ; BC6OTHER against BC6OTHER , BC6OTHER against BC6ENTG , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6ENTC against BC6OTHER ; BC6OTHER against BC6OTHER , BC6OTHER against BC6OTHER , and BC6OTHER against BC6ENTG .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6ENTG ; BC6ENTC against BC6OTHER , BC6OTHER against BC6OTHER , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6ENTC against BC6ENTG , BC6OTHER against BC6OTHER , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6ENTC against BC6OTHER , BC6OTHER against BC6ENTG , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6ENTC against BC6OTHER , BC6OTHER against BC6OTHER , and BC6OTHER against BC6ENTG .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6ENTG ; BC6OTHER against BC6OTHER , BC6ENTC against BC6OTHER , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6OTHER against BC6ENTG , BC6ENTC against BC6OTHER , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6OTHER against BC6OTHER , BC6ENTC against BC6ENTG , and BC6OTHER against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6OTHER against BC6OTHER , BC6ENTC against BC6OTHER , and BC6OTHER against BC6ENTG .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6ENTG ; BC6OTHER against BC6OTHER , BC6OTHER against BC6OTHER , and BC6ENTC against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6OTHER against BC6ENTG , BC6OTHER against BC6OTHER , and BC6ENTC against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6OTHER against BC6OTHER , BC6OTHER against BC6ENTG , and BC6ENTC against BC6OTHER .	False
Furthermore, some of these diuretics are quite efficient (low nanomolar) inhibitors of other isoforms, for example, BC6OTHER against BC6OTHER ; BC6OTHER against BC6OTHER , BC6OTHER against BC6OTHER , and BC6ENTC against BC6ENTG .	False
Examining the four X - ray crystal structures of their BC6ENTG adducts, we observed several (2 - 3) active site water molecules interacting with the BC6ENTC , BC6OTHER , and BC6OTHER scaffolds which may be responsible for this important difference of activity.	False
Examining the four X - ray crystal structures of their BC6ENTG adducts, we observed several (2 - 3) active site water molecules interacting with the BC6OTHER , BC6ENTC , and BC6OTHER scaffolds which may be responsible for this important difference of activity.	False
BC6ENTC and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6ENTG , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6OTHER , BC6ENTG ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
BC6ENTC and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6ENTG ( BC6OTHER , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6OTHER , and BC6OTHER .	CPR:4
Examining the four X - ray crystal structures of their BC6ENTG adducts, we observed several (2 - 3) active site water molecules interacting with the BC6OTHER , BC6OTHER , and BC6ENTC scaffolds which may be responsible for this important difference of activity.	False
Indeed, BC6ENTC bound to BC6ENTG has no interactions with active site water molecules.	False
BC6ENTC bound within the BC6ENTG active site is in an enolic (lactimic) tautomeric form, with the enolic BC6OTHER also participating in two strong BC6OTHER bonds with Asn67 and a water molecule.	False
BC6OTHER bound within the BC6ENTG active site is in an enolic (lactimic) tautomeric form, with the enolic BC6ENTC also participating in two strong BC6OTHER bonds with Asn67 and a water molecule.	False
BC6OTHER bound within the BC6ENTG active site is in an enolic (lactimic) tautomeric form, with the enolic BC6OTHER also participating in two strong BC6ENTC bonds with Asn67 and a water molecule.	False
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6ENTG , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6OTHER , BC6ENTG ) with a very different profile as compared to classical inhibitors, such as BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6ENTG ( BC6OTHER , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6ENTG , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6OTHER , BC6ENTG ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6ENTG ( BC6OTHER , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6ENTG , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6OTHER ( BC6OTHER , BC6ENTG ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:4
BC6OTHER and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of BC6ENTG ( BC6OTHER , BC6OTHER ) with a very different profile as compared to classical inhibitors, such as BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:4
In previous studies, we have demonstrated that chronic BC6ENTC or BC6OTHER ( BC6OTHER ) treatment of rats results in the reduction of BC6ENTG binding activities as tolerance develops.	False
Therefore, in the present studies, animals were rendered tolerant to the BC6ENTG - selective agonist BC6OTHER ( BC6ENTC ), and receptor binding activities were measured.	CPR:5
In previous studies, we have demonstrated that chronic BC6OTHER or BC6ENTC ( BC6OTHER ) treatment of rats results in the reduction of BC6ENTG binding activities as tolerance develops.	False
When BC6ENTG binding was determined by using BC6ENTC , a 40 - 50% decrease in binding in the midbrain and cortex, and 25 - 35% decrease in binding in the striatum were observed after 3 or 4 days of BC6OTHER treatment.	False
In previous studies, we have demonstrated that chronic BC6OTHER or BC6OTHER ( BC6ENTC ) treatment of rats results in the reduction of BC6ENTG binding activities as tolerance develops.	False
Chronic effect of BC6ENTC on BC6ENTG .	False
When BC6ENTG binding was determined by using BC6OTHER , a 40 - 50% decrease in binding in the midbrain and cortex, and 25 - 35% decrease in binding in the striatum were observed after 3 or 4 days of BC6ENTC treatment.	False
To our surprise, when BC6ENTG binding was determined by using BC6ENTC ( BC6OTHER ), a 10 - 15% decrease in binding was also observed in the midbrain and cortex after 4 days of BC6OTHER treatment.	False
To our surprise, when BC6ENTG binding was determined by using BC6OTHER ( BC6ENTC ), a 10 - 15% decrease in binding was also observed in the midbrain and cortex after 4 days of BC6OTHER treatment.	False
To our surprise, when BC6ENTG binding was determined by using BC6OTHER ( BC6OTHER ), a 10 - 15% decrease in binding was also observed in the midbrain and cortex after 4 days of BC6ENTC treatment.	False
Our conclusion is that chronic BC6ENTC treatment preferentially reduces BC6ENTG binding activity.	CPR:4
As both BC6ENTC and BC6OTHER are relatively non - specific opioid ligands, interacting with both BC6ENTG , these studies could not determine whether down - regulation of a specific receptor type occurs.	False
As both BC6OTHER and BC6ENTC are relatively non - specific opioid ligands, interacting with both BC6ENTG , these studies could not determine whether down - regulation of a specific receptor type occurs.	False
Therefore, in the present studies, animals were rendered tolerant to the BC6ENTG - selective agonist BC6ENTC ( BC6OTHER ), and receptor binding activities were measured.	CPR:5
The metallic taste reported as a side effect after the treatment with systemic BC6ENTC may be due to the inhibition of the BC6ENTG .	CPR:4
Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant BC6ENTC hydrase activity of enamel BC6ENTG , which leads to the formation of protons and BC6OTHER and may have a role in cariogenesis.	CPR:9
Some of the compounds investigated in this study might be used as additives in toothpastes for reducing the acidification produced by the relevant BC6OTHER hydrase activity of enamel BC6ENTG , which leads to the formation of protons and BC6ENTC and may have a role in cariogenesis.	CPR:9
The kinetic parameters for the BC6ENTC hydration reaction proved BC6ENTG to possess a kcat of 3.4 x 10(5) s - 1 and kcat / KM of 4.9 x 10(7) M CHEM (at pH 7.5 and 20 degrees C).	CPR:9
Simple BC6ENTC were rather ineffective BC6ENTG inhibitors, with inhibition constants in the range of 1090 - 6680 nM.	False
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
DNA cloning, characterization, and inhibition studies of the BC6ENTG , a new target for BC6ENTC and BC6OTHER inhibitors.	CPR:4
DNA cloning, characterization, and inhibition studies of the BC6ENTG , a new target for BC6OTHER and BC6ENTC inhibitors.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , or the orphan drug BC6OTHER , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
Some clinically used compounds, such as BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER , or the orphan drug BC6ENTC , showed effective BC6ENTG inhibitory activity, with inhibition constants of 0.8 - 79 nM.	CPR:4
The best inhibitors were BC6ENTC and BC6OTHER (KI values of 0.8 - 0.9 nM), the latter compound being also a BC6ENTG - selective inhibitor.	CPR:4
The best inhibitors were BC6OTHER and BC6ENTC (KI values of 0.8 - 0.9 nM), the latter compound being also a BC6ENTG - selective inhibitor.	CPR:4
BC6ENTC on the other hand displayed an increase in anxiety - like behavior at a higher dose (10 mg / kg) that was significantly reduced by the BC6ENTG antagonist BC6OTHER .	False
BC6OTHER on the other hand displayed an increase in anxiety - like behavior at a higher dose (10 mg / kg) that was significantly reduced by the BC6ENTG antagonist BC6ENTC .	CPR:6
However the BC6ENTG antagonist BC6ENTC was unable to reverse these anxiety - like effects seen with BC6OTHER .	CPR:6
However the BC6ENTG antagonist BC6OTHER was unable to reverse these anxiety - like effects seen with BC6ENTC .	False
The α7 nicotinic BC6ENTC receptor ( BC6ENTG ) is highly expressed in different regions of the brain and is associated with cognitive function as well as anxiety.	False
Previously BC6ENTC , which activates both BC6ENTG , has been shown to have an anxiogenic effect in behavioral tests.	False
BC6ENTC and BC6OTHER also increased BC6ENTG activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).	CPR:3
BC6OTHER and BC6ENTC also increased BC6ENTG activity by about 150 and 240% and demonstrated mineralization up to 110 and 200% respectively as compared to control (which was considered as 100%).	CPR:3
Further, both the BC6ENTC were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:3
Further, both the BC6ENTC were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:3
Further, both the BC6ENTC were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	CPR:3
Further, both the BC6ENTC were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	CPR:3
Further, both the BC6ENTC were also found to increase the expression of some of the prominent markers for differentiation of osteoblast like BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	CPR:3
Also, the multicompartmentation of BC6ENTG in the plant cell suggests that the transported forms of BC6ENTC are unconjugated.	False
In organisms that synthesize BC6OTHER de novo, BC6ENTG ( BC6OTHER ) and BC6ENTC synthetase ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6ENTG ) and BC6ENTC synthetase ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6OTHER ) and BC6ENTC synthetase ( BC6ENTG ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) catalyze the attachment of BC6ENTC residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) catalyze the attachment of BC6ENTC residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) catalyze the attachment of BC6ENTC residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) catalyze the attachment of BC6ENTC residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6ENTC molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6ENTC molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6ENTC molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6OTHER synthetase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) catalyze the attachment of BC6OTHER residues to the BC6ENTC molecule.	False
The function of each enzyme was demonstrated by complementation of yeast mutants deficient in BC6ENTG or BC6OTHER activity, and by measuring in vitro BC6ENTC incorporation into BC6OTHER or BC6OTHER .	False
The function of each enzyme was demonstrated by complementation of yeast mutants deficient in BC6OTHER or BC6ENTG activity, and by measuring in vitro BC6ENTC incorporation into BC6OTHER or BC6OTHER .	False
The function of each enzyme was demonstrated by complementation of yeast mutants deficient in BC6ENTG or BC6OTHER activity, and by measuring in vitro BC6OTHER incorporation into BC6ENTC or BC6OTHER .	False
The function of each enzyme was demonstrated by complementation of yeast mutants deficient in BC6OTHER or BC6ENTG activity, and by measuring in vitro BC6OTHER incorporation into BC6ENTC or BC6OTHER .	False
The function of each enzyme was demonstrated by complementation of yeast mutants deficient in BC6ENTG or BC6OTHER activity, and by measuring in vitro BC6OTHER incorporation into BC6OTHER or BC6ENTC .	False
The function of each enzyme was demonstrated by complementation of yeast mutants deficient in BC6OTHER or BC6ENTG activity, and by measuring in vitro BC6OTHER incorporation into BC6OTHER or BC6ENTC .	False
BC6ENTG is present exclusively in the mitochondria, making this compartment the sole site of synthesis of BC6ENTC in the plant cell.	CPR:9
 BC6ENTC biosynthesis in plants: molecular and functional characterization of BC6OTHER and three isoforms of BC6ENTG in Arabidopsis thaliana.	False
 BC6ENTC biosynthesis in plants: molecular and functional characterization of BC6ENTG and three isoforms of BC6OTHER in Arabidopsis thaliana.	False
 BC6OTHER biosynthesis in plants: molecular and functional characterization of BC6ENTC synthetase and three isoforms of BC6ENTG in Arabidopsis thaliana.	False
The compartmentation of BC6OTHER isoforms is in agreement with the predominance of BC6ENTC derivatives and the presence of BC6ENTG and BC6OTHER interconverting enzymes in the cytosol, the mitochondria, and the plastids.	False
The compartmentation of BC6OTHER isoforms is in agreement with the predominance of BC6ENTC derivatives and the presence of BC6OTHER hydroxymethyltransferase and BC6ENTG in the cytosol, the mitochondria, and the plastids.	False
The compartmentation of BC6ENTG isoforms is in agreement with the predominance of BC6ENTC derivatives and the presence of BC6OTHER hydroxymethyltransferase and BC6OTHER interconverting enzymes in the cytosol, the mitochondria, and the plastids.	False
The compartmentation of BC6OTHER isoforms is in agreement with the predominance of BC6OTHER derivatives and the presence of BC6ENTC hydroxymethyltransferase and BC6ENTG in the cytosol, the mitochondria, and the plastids.	False
The compartmentation of BC6ENTG isoforms is in agreement with the predominance of BC6OTHER derivatives and the presence of BC6ENTC hydroxymethyltransferase and BC6OTHER interconverting enzymes in the cytosol, the mitochondria, and the plastids.	False
The compartmentation of BC6OTHER isoforms is in agreement with the predominance of BC6OTHER derivatives and the presence of BC6ENTG and BC6ENTC interconverting enzymes in the cytosol, the mitochondria, and the plastids.	False
The compartmentation of BC6ENTG isoforms is in agreement with the predominance of BC6OTHER derivatives and the presence of BC6OTHER hydroxymethyltransferase and BC6ENTC interconverting enzymes in the cytosol, the mitochondria, and the plastids.	False
In organisms that synthesize BC6ENTC de novo, BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6ENTC de novo, BC6OTHER synthetase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6ENTC de novo, BC6OTHER synthetase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6ENTC de novo, BC6OTHER synthetase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
Thus, the combination of BC6ENTG with these BC6ENTC - mediated reactions can supply each compartment with the polyglutamylated BC6OTHER coenzymes required for the reactions of BC6OTHER metabolism.	False
Thus, the combination of BC6ENTG with these BC6OTHER - mediated reactions can supply each compartment with the polyglutamylated BC6ENTC coenzymes required for the reactions of BC6OTHER metabolism.	False
Thus, the combination of BC6ENTG with these BC6OTHER - mediated reactions can supply each compartment with the polyglutamylated BC6OTHER coenzymes required for the reactions of BC6ENTC metabolism.	False
In organisms that synthesize BC6OTHER de novo, BC6ENTC synthetase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6ENTC synthetase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
In organisms that synthesize BC6OTHER de novo, BC6ENTC synthetase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) catalyze the attachment of BC6OTHER residues to the BC6OTHER molecule.	False
Quantification of endogenous BC6ENTC in SCRH may reveal important adaptive responses associated with exposure to known BC6ENTG inhibitors.	False
Inhibition of the BC6ENTC export pump ( BC6ENTG ) can cause intracellular accumulation of BC6OTHER and is a risk factor for drug - induced liver injury in humans.	False
Antiretroviral BC6ENTG inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are reported BC6OTHER inhibitors.	CPR:4
Antiretroviral BC6OTHER inhibitors BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are reported BC6ENTG inhibitors.	CPR:4
Antiretroviral BC6ENTG inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are reported BC6OTHER inhibitors.	CPR:4
Antiretroviral BC6OTHER inhibitors BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are reported BC6ENTG inhibitors.	CPR:4
Antiretroviral BC6ENTG inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are reported BC6OTHER inhibitors.	CPR:4
Antiretroviral BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are reported BC6ENTG inhibitors.	CPR:4
Antiretroviral BC6ENTG inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are reported BC6OTHER inhibitors.	CPR:4
Antiretroviral BC6OTHER inhibitors BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are reported BC6ENTG inhibitors.	CPR:4
Inhibition of the BC6ENTG ( BC6OTHER ) can cause intracellular accumulation of BC6ENTC and is a risk factor for drug - induced liver injury in humans.	False
Inhibition of the BC6OTHER ( BC6ENTG ) can cause intracellular accumulation of BC6ENTC and is a risk factor for drug - induced liver injury in humans.	False
Inhibition of the BC6ENTG signalling pathway to BC6OTHER was obtained with BC6OTHER , BC6OTHER or BC6ENTC , resulting in blockade of neurotrophic effects.	False
Inhibition of the BC6OTHER signalling pathway to BC6ENTG was obtained with BC6OTHER , BC6OTHER or BC6ENTC , resulting in blockade of neurotrophic effects.	False
These data suggest that BC6ENTC agonists increase dendritic arborizations of mesencephalic dopaminergic neurons via a direct effect on BC6ENTG , preferentially involving BC6OTHER - dependent neurotransmission.	False
These data suggest that BC6ENTC agonists increase dendritic arborizations of mesencephalic dopaminergic neurons via a direct effect on BC6OTHER , preferentially involving BC6ENTG - dependent neurotransmission.	False
However, it is unclear whether BC6ENTC agonists produce their neurotrophic effects by acting directly on receptors expressed by the mesencephalic dopaminergic neurons or indirectly on receptors expressed by astrocytes, via release of BC6ENTG .	False
In this study, we investigated the effects of the BC6ENTC D3 receptor - preferring agonists BC6OTHER and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6ENTG immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6ENTC D3 receptor - preferring agonists BC6OTHER and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6ENTG - IR).	False
In this study, we investigated the effects of the BC6ENTG - preferring agonists BC6ENTC and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6ENTC and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6ENTG immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6ENTC and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6ENTG - IR).	False
In this study, we investigated the effects of the BC6ENTG - preferring agonists BC6OTHER and BC6ENTC ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6OTHER and BC6ENTC ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6ENTG immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6OTHER and BC6ENTC ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6ENTG - IR).	False
In this study, we investigated the effects of the BC6ENTG - preferring agonists BC6OTHER and BC6OTHER ( BC6ENTC ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6OTHER and BC6OTHER ( BC6ENTC ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6ENTG immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6OTHER and BC6OTHER ( BC6ENTC ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6ENTG - IR).	False
In this study, we investigated the effects of the BC6ENTG - preferring agonists BC6OTHER and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6ENTC , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6OTHER and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6ENTC , on dopaminergic neurons identified by BC6ENTG immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6OTHER and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6ENTC , on dopaminergic neurons identified by BC6OTHER immunoreactivity ( BC6ENTG - IR).	False
In this study, we investigated the effects of the BC6ENTG - preferring agonists BC6OTHER and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6ENTC hydroxylase immunoreactivity ( BC6OTHER - IR).	False
In this study, we investigated the effects of the BC6OTHER - preferring agonists BC6OTHER and BC6OTHER ( BC6OTHER ), as well as of the indirect agonist BC6OTHER , on dopaminergic neurons identified by BC6ENTC hydroxylase immunoreactivity ( BC6ENTG - IR).	False
After 3 days of incubation, both BC6OTHER (1 - 10 microm) and BC6OTHER (5 - 500 nm) dose - dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and BC6ENTC uptake (P < 0.01) of BC6ENTG - IR - positive mesencephalic neurons.	False
After 3 days of incubation, both BC6ENTC (1 - 10 microm) and BC6OTHER (5 - 500 nm) dose - dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and BC6OTHER uptake (P < 0.01) of BC6ENTG - IR - positive mesencephalic neurons.	False
After 3 days of incubation, both BC6OTHER (1 - 10 microm) and BC6ENTC (5 - 500 nm) dose - dependently increased the maximal dendrite length (P < 0.001), number of primary dendrites (P < 0.01) and BC6OTHER uptake (P < 0.01) of BC6ENTG - IR - positive mesencephalic neurons.	False
 BC6ENTC D3 receptor - preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via BC6ENTG phosphorylation.	False
All neurotrophic effects were blocked by the unselective BC6ENTG antagonist BC6ENTC (5 microm) and by the selective BC6OTHER antagonist BC6OTHER at a low dose (50 nm).	False
All neurotrophic effects were blocked by the unselective BC6OTHER antagonist BC6ENTC (5 microm) and by the selective BC6ENTG antagonist BC6OTHER at a low dose (50 nm).	False
All neurotrophic effects were blocked by the unselective BC6ENTG antagonist BC6OTHER (5 microm) and by the selective BC6OTHER antagonist BC6ENTC at a low dose (50 nm).	False
All neurotrophic effects were blocked by the unselective BC6OTHER antagonist BC6OTHER (5 microm) and by the selective BC6ENTG antagonist BC6ENTC at a low dose (50 nm).	CPR:6
BC6ENTC and BC6OTHER also increased the phosphorylation of BC6ENTG ( BC6OTHER ) within minutes, an effect blocked by pretreatment with BC6OTHER .	CPR:3
BC6ENTC and BC6OTHER also increased the phosphorylation of BC6OTHER ( BC6ENTG ) within minutes, an effect blocked by pretreatment with BC6OTHER .	CPR:3
BC6OTHER and BC6ENTC also increased the phosphorylation of BC6ENTG ( BC6OTHER ) within minutes, an effect blocked by pretreatment with BC6OTHER .	CPR:3
BC6OTHER and BC6ENTC also increased the phosphorylation of BC6OTHER ( BC6ENTG ) within minutes, an effect blocked by pretreatment with BC6OTHER .	CPR:3
BC6OTHER and BC6OTHER also increased the phosphorylation of BC6ENTG ( BC6OTHER ) within minutes, an effect blocked by pretreatment with BC6ENTC .	CPR:4
BC6OTHER and BC6OTHER also increased the phosphorylation of BC6OTHER ( BC6ENTG ) within minutes, an effect blocked by pretreatment with BC6ENTC .	CPR:4
Inhibition of the BC6ENTG signalling pathway to BC6OTHER was obtained with BC6ENTC , BC6OTHER or BC6OTHER , resulting in blockade of neurotrophic effects.	False
Inhibition of the BC6OTHER signalling pathway to BC6ENTG was obtained with BC6ENTC , BC6OTHER or BC6OTHER , resulting in blockade of neurotrophic effects.	False
Inhibition of the BC6ENTG signalling pathway to BC6OTHER was obtained with BC6OTHER , BC6ENTC or BC6OTHER , resulting in blockade of neurotrophic effects.	False
Inhibition of the BC6OTHER signalling pathway to BC6ENTG was obtained with BC6OTHER , BC6ENTC or BC6OTHER , resulting in blockade of neurotrophic effects.	False
Nerve fibers immunoreactive for not only sensory neuromarkers, such as BC6ENTG ( BC6OTHER ), but also sympathetic neuromarkers, such as BC6ENTC hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were increased in the periodontal ligament during ETM.	False
Nerve fibers immunoreactive for not only sensory neuromarkers, such as BC6OTHER ( BC6ENTG ), but also sympathetic neuromarkers, such as BC6ENTC hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were increased in the periodontal ligament during ETM.	False
Nerve fibers immunoreactive for not only sensory neuromarkers, such as BC6OTHER ( BC6OTHER ), but also sympathetic neuromarkers, such as BC6ENTC hydroxylase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were increased in the periodontal ligament during ETM.	False
Nerve fibers immunoreactive for not only sensory neuromarkers, such as BC6OTHER ( BC6OTHER ), but also sympathetic neuromarkers, such as BC6ENTC hydroxylase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) were increased in the periodontal ligament during ETM.	False
Nerve fibers immunoreactive for not only sensory neuromarkers, such as BC6OTHER ( BC6OTHER ), but also sympathetic neuromarkers, such as BC6ENTC hydroxylase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) were increased in the periodontal ligament during ETM.	False
BC6OTHER irreversibly inhibits BC6ENTG , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6OTHER treatment of BC6OTHER causes this enzyme to form BC6OTHER ( BC6ENTC ) instead of CHEM.	False
BC6OTHER irreversibly inhibits BC6OTHER , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6OTHER treatment of BC6ENTG causes this enzyme to form BC6OTHER ( BC6ENTC ) instead of CHEM.	CPR:9
There are two isozymes of CHEM (PGH) synthase ( BC6OTHER ) called BC6OTHER or BC6ENTG .	False
There are two isozymes of CHEM (PGH) synthase ( BC6ENTG ) called BC6OTHER or BC6OTHER .	False
There are two isozymes of CHEM (PGH) synthase ( BC6OTHER ) called BC6ENTG or BC6OTHER .	False
BC6ENTC , BC6OTHER , and BC6OTHER were found to preferentially inhibit BC6ENTG .	CPR:4
BC6OTHER , BC6ENTC , and BC6OTHER were found to preferentially inhibit BC6ENTG .	CPR:4
BC6OTHER , BC6OTHER , and BC6ENTC were found to preferentially inhibit BC6ENTG .	CPR:4
BC6ENTC , the active metabolite of BC6OTHER , inhibits murine BC6ENTG preferentially.	CPR:4
BC6OTHER , the active metabolite of BC6ENTC , inhibits murine BC6ENTG preferentially.	CPR:4
BC6ENTC irreversibly inhibits BC6ENTG , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6OTHER treatment of BC6OTHER causes this enzyme to form BC6OTHER ( BC6OTHER ) instead of CHEM.	CPR:4
BC6ENTC irreversibly inhibits BC6OTHER , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6OTHER treatment of BC6ENTG causes this enzyme to form BC6OTHER ( BC6OTHER ) instead of CHEM.	False
BC6OTHER irreversibly inhibits BC6ENTG , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6ENTC treatment of BC6OTHER causes this enzyme to form BC6OTHER ( BC6OTHER ) instead of CHEM.	False
BC6OTHER irreversibly inhibits BC6OTHER , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6ENTC treatment of BC6ENTG causes this enzyme to form BC6OTHER ( BC6OTHER ) instead of CHEM.	False
BC6OTHER irreversibly inhibits BC6ENTG , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6OTHER treatment of BC6OTHER causes this enzyme to form BC6ENTC ( BC6OTHER ) instead of CHEM.	False
BC6OTHER irreversibly inhibits BC6OTHER , preventing this isozyme from forming CHEM or any other oxygenated product; in contrast, BC6OTHER treatment of BC6ENTG causes this enzyme to form BC6ENTC ( BC6OTHER ) instead of CHEM.	CPR:9
BC6ENTC dehydrogenase II ( BC6ENTG ) converts CHEM to the transcriptional regulator CHEM in the developing embryo.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6ENTC dehydrogenases of the same enzyme superfamily; a 20 - BC6OTHER span in the substrate access channel in BC6ENTG is disordered, whereas in other BC6OTHER dehydrogenases this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6ENTC dehydrogenases of the same enzyme superfamily; a 20 - BC6OTHER span in the substrate access channel in BC6OTHER dehydrogenase II is disordered, whereas in other BC6ENTG this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6OTHER of the same enzyme superfamily; a 20 - BC6ENTC span in the substrate access channel in BC6ENTG is disordered, whereas in other BC6OTHER dehydrogenases this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6OTHER of the same enzyme superfamily; a 20 - BC6ENTC span in the substrate access channel in BC6OTHER dehydrogenase II is disordered, whereas in other BC6ENTG this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6ENTG of the same enzyme superfamily; a 20 - BC6ENTC span in the substrate access channel in BC6OTHER dehydrogenase II is disordered, whereas in other BC6OTHER dehydrogenases this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6OTHER of the same enzyme superfamily; a 20 - BC6OTHER span in the substrate access channel in BC6ENTC dehydrogenase II is disordered, whereas in other BC6ENTG this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6ENTG of the same enzyme superfamily; a 20 - BC6OTHER span in the substrate access channel in BC6ENTC dehydrogenase II is disordered, whereas in other BC6OTHER dehydrogenases this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6OTHER of the same enzyme superfamily; a 20 - BC6OTHER span in the substrate access channel in BC6ENTG is disordered, whereas in other BC6ENTC dehydrogenases this region forms a well defined wall of the substrate access channel.	False
The x - ray structure of the enzyme revealed an important structural difference between this protein and other BC6ENTG of the same enzyme superfamily; a 20 - BC6OTHER span in the substrate access channel in BC6OTHER dehydrogenase II is disordered, whereas in other BC6ENTC dehydrogenases this region forms a well defined wall of the substrate access channel.	False
Initial in vitro studies utilizing HEP - G2 liver cells revealed that addition of BC6ENTC ( BC6OTHER ) blocked BC6ENTG activity, the terminal enzymatic step in BC6OTHER synthesis.	CPR:4
Initial in vitro studies utilizing HEP - G2 liver cells revealed that addition of BC6OTHER ( BC6ENTC ) blocked BC6ENTG activity, the terminal enzymatic step in BC6OTHER synthesis.	CPR:4
Initial in vitro studies utilizing HEP - G2 liver cells revealed that addition of BC6OTHER ( BC6OTHER ) blocked BC6ENTG activity, the terminal enzymatic step in BC6ENTC synthesis.	False
Recently, it was reported that BC6ENTC , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6ENTC , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
Recently, it was reported that BC6OTHER , BC6ENTC , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6OTHER , BC6ENTC , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6ENTC , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6ENTC , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6ENTC production in human embryonic kidney (HEK) - 293 cells expressing BC6ENTG ( BC6OTHER ).	False
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6ENTC production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6OTHER - associated receptor 1 ( BC6ENTG ).	False
EC50 values for BC6ENTC were 0.89, 0.92, and 4.44 microM for BC6ENTG , BC6OTHER , and BC6OTHER , respectively.	CPR:3
EC50 values for BC6ENTC were 0.89, 0.92, and 4.44 microM for BC6OTHER , BC6ENTG , and BC6OTHER , respectively.	CPR:3
EC50 values for BC6ENTC were 0.89, 0.92, and 4.44 microM for BC6OTHER , BC6OTHER , and BC6ENTG , respectively.	CPR:3
Recently, it was reported that BC6OTHER , BC6OTHER , BC6OTHER , and the TAs BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) stimulate BC6OTHER production in human embryonic kidney (HEK) - 293 cells expressing rat trace BC6ENTC - associated receptor 1 ( BC6ENTG ).	False
The discovery that BC6ENTC and BC6OTHER activate the BC6ENTG motivated us to study the effect of these drugs on the BC6OTHER ( BC6OTHER ) and a human - rat chimera ( BC6OTHER ).	CPR:3
The discovery that BC6ENTC and BC6OTHER activate the BC6OTHER motivated us to study the effect of these drugs on the BC6ENTG ( BC6OTHER ) and a human - rat chimera ( BC6OTHER ).	False
The discovery that BC6ENTC and BC6OTHER activate the BC6OTHER motivated us to study the effect of these drugs on the BC6OTHER ( BC6ENTG ) and a human - rat chimera ( BC6OTHER ).	False
The discovery that BC6ENTC and BC6OTHER activate the BC6OTHER motivated us to study the effect of these drugs on the BC6OTHER ( BC6OTHER ) and a human - rat chimera ( BC6ENTG ).	False
The discovery that BC6OTHER and BC6ENTC activate the BC6ENTG motivated us to study the effect of these drugs on the BC6OTHER ( BC6OTHER ) and a human - rat chimera ( BC6OTHER ).	CPR:3
The discovery that BC6OTHER and BC6ENTC activate the BC6OTHER motivated us to study the effect of these drugs on the BC6ENTG ( BC6OTHER ) and a human - rat chimera ( BC6OTHER ).	False
The discovery that BC6OTHER and BC6ENTC activate the BC6OTHER motivated us to study the effect of these drugs on the BC6OTHER ( BC6ENTG ) and a human - rat chimera ( BC6OTHER ).	False
The discovery that BC6OTHER and BC6ENTC activate the BC6OTHER motivated us to study the effect of these drugs on the BC6OTHER ( BC6OTHER ) and a human - rat chimera ( BC6ENTG ).	False
Furthermore, because CHEM - (+) - isomers of BC6ENTC and BC6OTHER are reported to be more potent and efficacious in vivo than R - ( - ), we determined the enantiomeric selectivity of all three species of BC6ENTG .	CPR:3
Furthermore, because CHEM - (+) - isomers of BC6OTHER and BC6ENTC are reported to be more potent and efficacious in vivo than R - ( - ), we determined the enantiomeric selectivity of all three species of BC6ENTG .	CPR:3
In response to BC6ENTC , BC6OTHER , or BC6OTHER exposure, the accumulation of BC6OTHER by HEK - 293 cells stably expressing different species of BC6ENTG was concentration - and isomer - dependent.	False
In response to BC6OTHER , BC6ENTC , or BC6OTHER exposure, the accumulation of BC6OTHER by HEK - 293 cells stably expressing different species of BC6ENTG was concentration - and isomer - dependent.	False
In response to BC6OTHER , BC6OTHER , or BC6ENTC exposure, the accumulation of BC6OTHER by HEK - 293 cells stably expressing different species of BC6ENTG was concentration - and isomer - dependent.	False
In response to BC6OTHER , BC6OTHER , or BC6OTHER exposure, the accumulation of BC6ENTC by HEK - 293 cells stably expressing different species of BC6ENTG was concentration - and isomer - dependent.	False
 BC6ENTG displays species - dependent stereoselectivity for isomers of BC6OTHER , BC6ENTC , and BC6OTHER .	False
 BC6ENTG displays species - dependent stereoselectivity for isomers of BC6OTHER , BC6OTHER , and BC6ENTC .	False
 BC6ENTG displays species - dependent stereoselectivity for isomers of BC6ENTC , BC6OTHER , and BC6OTHER .	False
BC6ENTC was a potent and full agonist at each species of BC6ENTG , whereas BC6OTHER was a full agonist for the BC6OTHER but was a partial agonist at BC6OTHER .	CPR:5
BC6ENTC was a potent and full agonist at each species of BC6OTHER , whereas BC6OTHER was a full agonist for the BC6ENTG but was a partial agonist at BC6OTHER .	False
BC6ENTC was a potent and full agonist at each species of BC6OTHER , whereas BC6OTHER was a full agonist for the BC6OTHER but was a partial agonist at BC6ENTG .	False
BC6OTHER was a potent and full agonist at each species of BC6ENTG , whereas BC6ENTC was a full agonist for the BC6OTHER but was a partial agonist at BC6OTHER .	False
BC6OTHER was a potent and full agonist at each species of BC6OTHER , whereas BC6ENTC was a full agonist for the BC6ENTG but was a partial agonist at BC6OTHER .	CPR:5
BC6OTHER was a potent and full agonist at each species of BC6OTHER , whereas BC6ENTC was a full agonist for the BC6OTHER but was a partial agonist at BC6ENTG .	CPR:5
Interestingly, both isomers of BC6ENTC were full agonists at BC6ENTG and BC6OTHER , whereas both were partial agonists at BC6OTHER .	CPR:5
Interestingly, both isomers of BC6ENTC were full agonists at BC6OTHER and BC6ENTG , whereas both were partial agonists at BC6OTHER .	CPR:5
Interestingly, both isomers of BC6ENTC were full agonists at BC6OTHER and BC6OTHER , whereas both were partial agonists at BC6ENTG .	CPR:5
The aim of the present study was therefore to investigate BC6ENTG apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among BC6ENTC - , BC6OTHER - and BC6OTHER - treated schizophrenia patients.	False
The aim of the present study was therefore to investigate BC6ENTG apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among BC6OTHER - , BC6ENTC - and BC6OTHER - treated schizophrenia patients.	False
The aim of the present study was therefore to investigate BC6ENTG apparent binding potential (BP(app)) and occupancy in midbrain and temporal cortex among BC6OTHER - , BC6OTHER - and BC6ENTC - treated schizophrenia patients.	False
METHODS: BC6ENTG binding was studied on single - photon emission computed tomography ligand BC6ENTC in 13 schizophrenia patients treated with medication (two with BC6OTHER , four with BC6OTHER and seven with BC6OTHER ), six drug - naive patients and seven healthy controls.	False
METHODS: BC6ENTG binding was studied on single - photon emission computed tomography ligand BC6OTHER in 13 schizophrenia patients treated with medication (two with BC6ENTC , four with BC6OTHER and seven with BC6OTHER ), six drug - naive patients and seven healthy controls.	False
METHODS: BC6ENTG binding was studied on single - photon emission computed tomography ligand BC6OTHER in 13 schizophrenia patients treated with medication (two with BC6OTHER , four with BC6ENTC and seven with BC6OTHER ), six drug - naive patients and seven healthy controls.	False
METHODS: BC6ENTG binding was studied on single - photon emission computed tomography ligand BC6OTHER in 13 schizophrenia patients treated with medication (two with BC6OTHER , four with BC6OTHER and seven with BC6ENTC ), six drug - naive patients and seven healthy controls.	False
RESULTS: Statistically significant differences in midbrain BC6ENTG BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the BC6OTHER , BC6OTHER and BC6ENTC groups.	False
RESULTS: Statistically significant differences in midbrain BC6ENTG BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the BC6ENTC , BC6OTHER and BC6OTHER groups.	False
RESULTS: Statistically significant differences in midbrain BC6ENTG BP(app) (P = 0.015) and occupancy (P = 0.016) were observed between the BC6OTHER , BC6ENTC and BC6OTHER groups.	False
 BC6ENTG binding potential and occupancy in midbrain and temporal cortex by BC6OTHER , BC6ENTC and BC6OTHER .	False
 BC6ENTG binding potential and occupancy in midbrain and temporal cortex by BC6OTHER , BC6OTHER and BC6ENTC .	False
 BC6ENTG binding potential and occupancy in midbrain and temporal cortex by BC6ENTC , BC6OTHER and BC6OTHER .	False
Observed differences in midbrain BC6ENTG occupancy between classical antipsychotics and second - generation antipsychotics may have clinical relevance by modulating altered nigrostriatal BC6ENTC neurotransmission during the acute phase of schizophrenia.	False
The importance of BC6OTHER chirality to central nervous system BC6ENTG targeting has culminated in human imaging studies revealing that BC6ENTC binds specifically to striatal structures, whereas BC6OTHER binding is nonspecific.	False
The importance of BC6OTHER chirality to central nervous system BC6ENTG targeting has culminated in human imaging studies revealing that BC6OTHER binds specifically to striatal structures, whereas BC6ENTC binding is nonspecific.	False
BC6OTHER inhibits the BC6ENTC transporter and the BC6ENTG , resulting in elevations of these BC6OTHER after impulse release.	False
BC6OTHER inhibits the BC6ENTG and the BC6ENTC transporter, resulting in elevations of these BC6OTHER after impulse release.	False
BC6OTHER inhibits the BC6ENTG and the BC6OTHER , resulting in elevations of these BC6ENTC after impulse release.	CPR:9
BC6OTHER inhibits the BC6OTHER and the BC6ENTG , resulting in elevations of these BC6ENTC after impulse release.	CPR:9
In both rodent and primate animal models, the binding of radiolabeled BC6ENTC to BC6ENTG was found to be selective, saturable, and reversible, whereas binding of BC6OTHER was diffuse and nonspecific.	False
In both rodent and primate animal models, the binding of radiolabeled BC6OTHER to BC6ENTG was found to be selective, saturable, and reversible, whereas binding of BC6ENTC was diffuse and nonspecific.	False
BC6ENTC inhibits the BC6ENTG and the BC6OTHER , resulting in elevations of these BC6OTHER after impulse release.	CPR:4
BC6ENTC inhibits the BC6OTHER and the BC6ENTG , resulting in elevations of these BC6OTHER after impulse release.	CPR:4
The importance of BC6ENTC chirality to central nervous system BC6ENTG targeting has culminated in human imaging studies revealing that BC6OTHER binds specifically to striatal structures, whereas BC6OTHER binding is nonspecific.	False
Furthermore, BC6ENTG - expressing SN cells are preferentially lost following BC6ENTC treatment.	False
Finally, SN mDA neurons in BC6ENTG hemizygous mice show increased sensitivity when exposed to BC6ENTC .	False
Thus, SN mDA neurons are represented by at least two distinct subpopulations including BC6ENTC - resistant BC6OTHER - autonomous, BC6OTHER - positive neurons, and BC6ENTG - negative BC6OTHER - dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	False
Thus, SN mDA neurons are represented by at least two distinct subpopulations including BC6ENTC - resistant BC6OTHER - autonomous, BC6OTHER - positive neurons, and BC6OTHER - negative BC6ENTG - dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	False
Thus, SN mDA neurons are represented by at least two distinct subpopulations including BC6ENTC - resistant BC6ENTG - autonomous, BC6OTHER - positive neurons, and BC6OTHER - negative BC6OTHER - dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	False
Thus, SN mDA neurons are represented by at least two distinct subpopulations including BC6ENTC - resistant BC6OTHER - autonomous, BC6ENTG - positive neurons, and BC6OTHER - negative BC6OTHER - dependent cells that display elevated vulnerability to toxic injury, and probably correspond to the subpopulation that degenerates in PD.	False
In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express BC6ENTG - BC6OTHER , a BC6ENTC - binding protein previously associated with resistance to injury in PD and in animal models.	False
In aphakia mice, virtually all surviving mDA neurons in the substantia nigra (SN) and the majority of neurons in the adjacent ventral tegmental area (VTA) also express BC6OTHER - BC6ENTG , a BC6ENTC - binding protein previously associated with resistance to injury in PD and in animal models.	False
Cell - mapping studies in wild - type mice revealed that BC6ENTG is primarily expressed in the ventral SN, a region particularly susceptible to BC6ENTC and other dopaminergic neurotoxins.	False
Here, various BC6OTHER ( BC6OTHER ) derivatives were further conjugated with BC6OTHER and BC6OTHER ( BC6ENTC and BC6OTHER ) to study the structure and activity relationship as both antioxidants and BC6ENTG inhibitors.	False
Here, various BC6OTHER ( BC6OTHER ) derivatives were further conjugated with BC6OTHER and BC6OTHER ( BC6OTHER and BC6ENTC ) to study the structure and activity relationship as both antioxidants and BC6ENTG inhibitors.	False
We previously reported that BC6OTHER ( BC6ENTC ) acted as both a good antioxidant and BC6ENTG inhibitor, in particular when BC6OTHER was conjugated with BC6OTHER or BC6OTHER having aromatic ring like BC6OTHER .	CPR:4
We previously reported that BC6OTHER ( BC6OTHER ) acted as both a good antioxidant and BC6ENTG inhibitor, in particular when BC6ENTC was conjugated with BC6OTHER or BC6OTHER having aromatic ring like BC6OTHER .	False
In addition, derivatives of BC6ENTC and BC6OTHER efficiently inhibited BC6ENTG activity and reduced melanin content in melanocytes Mel - Ab cell.	CPR:4
In addition, derivatives of BC6OTHER and BC6ENTC efficiently inhibited BC6ENTG activity and reduced melanin content in melanocytes Mel - Ab cell.	CPR:4
Synthesis and dual biological effects of BC6ENTC / BC6OTHER derivatives as BC6ENTG inhibitor and antioxidant.	CPR:4
Synthesis and dual biological effects of BC6OTHER / BC6ENTC derivatives as BC6ENTG inhibitor and antioxidant.	CPR:4
We previously reported that BC6OTHER ( BC6OTHER ) acted as both a good antioxidant and BC6ENTG inhibitor, in particular when BC6OTHER was conjugated with BC6ENTC or BC6OTHER having aromatic ring like BC6OTHER .	False
We previously reported that BC6OTHER ( BC6OTHER ) acted as both a good antioxidant and BC6ENTG inhibitor, in particular when BC6OTHER was conjugated with BC6OTHER or BC6ENTC having aromatic ring like BC6OTHER .	False
We previously reported that BC6OTHER ( BC6OTHER ) acted as both a good antioxidant and BC6ENTG inhibitor, in particular when BC6OTHER was conjugated with BC6OTHER or BC6OTHER having aromatic ring like BC6ENTC .	False
Here, various BC6ENTC ( BC6OTHER ) derivatives were further conjugated with BC6OTHER and BC6OTHER ( BC6OTHER and BC6OTHER ) to study the structure and activity relationship as both antioxidants and BC6ENTG inhibitors.	False
We previously reported that BC6ENTC ( BC6OTHER ) acted as both a good antioxidant and BC6ENTG inhibitor, in particular when BC6OTHER was conjugated with BC6OTHER or BC6OTHER having aromatic ring like BC6OTHER .	CPR:4
Here, various BC6OTHER ( BC6ENTC ) derivatives were further conjugated with BC6OTHER and BC6OTHER ( BC6OTHER and BC6OTHER ) to study the structure and activity relationship as both antioxidants and BC6ENTG inhibitors.	False
Here, various BC6OTHER ( BC6OTHER ) derivatives were further conjugated with BC6ENTC and BC6OTHER ( BC6OTHER and BC6OTHER ) to study the structure and activity relationship as both antioxidants and BC6ENTG inhibitors.	False
Here, various BC6OTHER ( BC6OTHER ) derivatives were further conjugated with BC6OTHER and BC6ENTC ( BC6OTHER and BC6OTHER ) to study the structure and activity relationship as both antioxidants and BC6ENTG inhibitors.	False
Finally, BC6OTHER binding studies performed with other BC6OTHER , such as BC6OTHER , BC6OTHER , and BC6OTHER , revealed that in this class of compounds only BC6ENTC appears to interact with the BC6ENTG .	False
BC6ENTC appears to be the first example of a non - BC6OTHER compound which binds competitively to both BC6ENTG and multiple BC6OTHER , suggesting that the ligand binding sites of these proteins share some features in common.	False
BC6ENTC appears to be the first example of a non - BC6OTHER compound which binds competitively to both BC6OTHER and multiple BC6ENTG , suggesting that the ligand binding sites of these proteins share some features in common.	False
BC6OTHER appears to be the first example of a non - BC6ENTC compound which binds competitively to both BC6ENTG and multiple BC6OTHER , suggesting that the ligand binding sites of these proteins share some features in common.	False
BC6OTHER appears to be the first example of a non - BC6ENTC compound which binds competitively to both BC6OTHER and multiple BC6ENTG , suggesting that the ligand binding sites of these proteins share some features in common.	False
BC6OTHER appears to be the first example of a non - BC6OTHER compound which binds competitively to both BC6ENTG and multiple BC6ENTC hormone receptors, suggesting that the ligand binding sites of these proteins share some features in common.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6ENTC for receptor proteins for glucocorticoids and BC6OTHER and for BC6ENTG ( BC6OTHER ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6ENTC for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6ENTG ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6ENTC for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6OTHER ), the binding of BC6OTHER to BC6ENTG ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6ENTC for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6OTHER ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6ENTG ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6ENTC and for BC6ENTG ( BC6OTHER ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6ENTC and for sex BC6OTHER binding globulin ( BC6ENTG ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6ENTC and for sex BC6OTHER binding globulin ( BC6OTHER ), the binding of BC6OTHER to BC6ENTG ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6ENTC and for sex BC6OTHER binding globulin ( BC6OTHER ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6ENTG ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6ENTC binding globulin ( BC6ENTG ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6ENTC binding globulin ( BC6OTHER ), the binding of BC6OTHER to BC6ENTG ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6ENTC binding globulin ( BC6OTHER ), the binding of BC6OTHER to human BC6OTHER receptors ( BC6ENTG ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for BC6ENTG ( BC6OTHER ), the binding of BC6ENTC to human BC6OTHER receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6ENTG ), the binding of BC6ENTC to human BC6OTHER receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6OTHER ), the binding of BC6ENTC to BC6ENTG ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6OTHER ), the binding of BC6ENTC to human BC6OTHER receptors ( BC6ENTG ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for BC6ENTG ( BC6OTHER ), the binding of BC6OTHER to human BC6ENTC receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6ENTG ), the binding of BC6OTHER to human BC6ENTC receptors ( BC6OTHER ) in vitro was also examined.	False
Based on these potent effects on gonadal function in vivo as well as previous work in vitro demonstrating affinity of BC6OTHER for receptor proteins for glucocorticoids and BC6OTHER and for sex BC6OTHER binding globulin ( BC6OTHER ), the binding of BC6OTHER to human BC6ENTC receptors ( BC6ENTG ) in vitro was also examined.	False
BC6ENTC competition with BC6OTHER ( BC6OTHER ) for BC6OTHER binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of BC6OTHER binding to BC6ENTG was achieved by 6.4 + / - 1.8 (SE) x 10( - 5) M BC6OTHER .	False
BC6OTHER competition with BC6ENTC ( BC6OTHER ) for BC6OTHER binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of BC6OTHER binding to BC6ENTG was achieved by 6.4 + / - 1.8 (SE) x 10( - 5) M BC6OTHER .	False
BC6OTHER competition with BC6OTHER ( BC6ENTC ) for BC6OTHER binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of BC6OTHER binding to BC6ENTG was achieved by 6.4 + / - 1.8 (SE) x 10( - 5) M BC6OTHER .	False
BC6OTHER competition with BC6OTHER ( BC6OTHER ) for BC6ENTC binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of BC6OTHER binding to BC6ENTG was achieved by 6.4 + / - 1.8 (SE) x 10( - 5) M BC6OTHER .	False
BC6OTHER competition with BC6OTHER ( BC6OTHER ) for BC6OTHER binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of BC6ENTC binding to BC6ENTG was achieved by 6.4 + / - 1.8 (SE) x 10( - 5) M BC6OTHER .	False
BC6OTHER competition with BC6OTHER ( BC6OTHER ) for BC6OTHER binding sites in dispersed, intact cultured human skin fibroblasts was determined at 22 degrees C. Fifty percent displacement of BC6OTHER binding to BC6ENTG was achieved by 6.4 + / - 1.8 (SE) x 10( - 5) M BC6ENTC .	False
Additional binding studies performed with BC6ENTC in the presence of increasing amounts of BC6OTHER showed that the interaction of BC6OTHER with BC6ENTG was competitive when the data were analyzed by the Scatchard method.	False
Additional binding studies performed with BC6OTHER in the presence of increasing amounts of BC6OTHER showed that the interaction of BC6ENTC with BC6ENTG was competitive when the data were analyzed by the Scatchard method.	False
Additional binding studies performed with BC6OTHER in the presence of increasing amounts of BC6ENTC showed that the interaction of BC6OTHER with BC6ENTG was competitive when the data were analyzed by the Scatchard method.	False
 BC6ENTC binds to the BC6ENTG .	False
It should be noted, however, that the dose of BC6ENTC required for 50% occupancy of the BC6ENTG is not likely to be achieved in vivo, at least in plasma.	False
Finally, BC6ENTC binding studies performed with other BC6OTHER , such as BC6OTHER , BC6OTHER , and BC6OTHER , revealed that in this class of compounds only BC6OTHER appears to interact with the BC6ENTG .	False
Finally, BC6OTHER binding studies performed with other BC6ENTC , such as BC6OTHER , BC6OTHER , and BC6OTHER , revealed that in this class of compounds only BC6OTHER appears to interact with the BC6ENTG .	False
Finally, BC6OTHER binding studies performed with other BC6OTHER , such as BC6ENTC , BC6OTHER , and BC6OTHER , revealed that in this class of compounds only BC6OTHER appears to interact with the BC6ENTG .	False
Finally, BC6OTHER binding studies performed with other BC6OTHER , such as BC6OTHER , BC6ENTC , and BC6OTHER , revealed that in this class of compounds only BC6OTHER appears to interact with the BC6ENTG .	False
Finally, BC6OTHER binding studies performed with other BC6OTHER , such as BC6OTHER , BC6OTHER , and BC6ENTC , revealed that in this class of compounds only BC6OTHER appears to interact with the BC6ENTG .	False
The structural left ventricular (LV) remodeling and contractile dysfunction of hearts with postinfarction LV remodeling are benefited by BC6ENTC type 1 receptor ( BC6ENTG ) blocker.	False
Animals with heart failure demonstrated reductions in both mitochondrial BC6ENTG expression and myocardial high - energy BC6ENTC levels.	False
Thus, severe LV dysfunction and accompanying abnormal myocardial bioenergetic phenotype were prevented by the BC6ENTG antagonist BC6ENTC .	CPR:6
Functional and bioenergetic consequences of BC6ENTG antagonist BC6ENTC in hearts with postinfarction LV remodeling.	CPR:6
METHODS: Different classes of antidepressants [ BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
RATIONALE: A recent study suggested that selective BC6ENTC reuptake inhibitors were inactive in 40 - week - old male mice in the mouse forced swimming test, possibly because of alteration of BC6ENTG receptors.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6ENTC (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6ENTC (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6ENTC (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6ENTC (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6ENTC and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6ENTC and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6ENTC and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6ENTC and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6ENTC reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6ENTC reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6ENTC reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6ENTC reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6ENTC and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6ENTC and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6ENTC and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6ENTC and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6ENTC (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6ENTC (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6ENTC (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6ENTC (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6ENTC reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6ENTC reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6ENTC reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6ENTC reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6ENTC (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6ENTC (partial BC6OTHER agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6ENTC (partial BC6ENTG agonist), BC6OTHER ( BC6OTHER agonist)] in the mouse forced swimming test.	CPR:5
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6ENTC (partial BC6OTHER agonist), BC6OTHER ( BC6ENTG agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6ENTG and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6ENTG receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6ENTC ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6ENTG agonist), BC6ENTC ( BC6OTHER agonist)] in the mouse forced swimming test.	False
METHODS: Different classes of antidepressants [ BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER reuptake inhibitor), BC6OTHER (mixed BC6OTHER and BC6OTHER reuptake inhibitors), BC6OTHER and BC6OTHER (selective BC6OTHER reuptake inhibitor)] were tested in the same randomised experimental session, alone and in combination with BC6OTHER and BC6OTHER receptor agonists [ BC6OTHER (partial BC6OTHER agonist), BC6ENTC ( BC6ENTG agonist)] in the mouse forced swimming test.	CPR:5
Hypermethlyation of BC6ENTG can be induced by treating mice with BC6ENTC , and these mice display brain and behavioral abnormalities similar to + / rl.	CPR:3
Brain abnormalities in + / rl are similar to psychotic brain and include a reduction in BC6ENTC de carboxylase 67 ( BC6ENTG ), dendritic arbors and spine density in cortex and hippocampus, and abnormalities in synaptic function including long - term potentiation (LTP).	False
The same sense BC6ENTC - to - BC6OTHER polymorphism (c. BC6ENTG ; BC6OTHER ) was shown to preferentially modulate early components in both modalities.	False
The same sense BC6ENTC - to - BC6OTHER polymorphism (c. BC6OTHER ; BC6ENTG ) was shown to preferentially modulate early components in both modalities.	False
The same sense BC6OTHER - to - BC6ENTC polymorphism (c. BC6ENTG ; BC6OTHER ) was shown to preferentially modulate early components in both modalities.	False
The same sense BC6OTHER - to - BC6ENTC polymorphism (c. BC6OTHER ; BC6ENTG ) was shown to preferentially modulate early components in both modalities.	False
 BC6ENTC receptor gene BC6ENTG modulates early event - related potentials in auditory and visual oddball target detection tasks.	False
When BC6ENTG was also inhibited, 10 nmol / l BC6OTHER caused 84% inhibition of the deamination of BC6ENTC by BC6OTHER in the lungs.	False
When BC6OTHER was also inhibited, 10 nmol / l BC6OTHER caused 84% inhibition of the deamination of BC6ENTC by BC6ENTG in the lungs.	False
In contrast, in hearts perfused with 10 nmol / l BC6ENTC under conditions where the CHEM was accumulated by BC6ENTG ( BC6OTHER , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6ENTC under conditions where the CHEM was accumulated by BC6OTHER ( BC6ENTG , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6ENTC under conditions where the CHEM was accumulated by BC6OTHER ( BC6OTHER , BC6ENTG and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6ENTG ( BC6OTHER , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6ENTC had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6OTHER ( BC6ENTG , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6ENTC had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6OTHER ( BC6OTHER , BC6ENTG and vesicular transport inhibited), 10 nmol / l BC6ENTC had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6ENTG ( BC6OTHER , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6ENTC caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6OTHER ( BC6ENTG , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6ENTC caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6OTHER ( BC6OTHER , BC6ENTG and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6ENTC caused only 36% inhibition of deamination of BC6OTHER .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6ENTG ( BC6OTHER , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6ENTC .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6OTHER ( BC6ENTG , BC6OTHER and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6ENTC .	False
In contrast, in hearts perfused with 10 nmol / l BC6OTHER under conditions where the CHEM was accumulated by BC6OTHER ( BC6OTHER , BC6ENTG and vesicular transport inhibited), 10 nmol / l BC6OTHER had no effect and 300 nmol / l BC6OTHER caused only 36% inhibition of deamination of BC6ENTC .	False
The results when considered with previous reports in the literature show that BC6ENTC is about 1000 times more potent and BC6OTHER is about 20 times more potent for BC6ENTG inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by BC6OTHER .	CPR:4
The results when considered with previous reports in the literature show that BC6ENTC is about 1000 times more potent and BC6OTHER is about 20 times more potent for BC6OTHER inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by BC6ENTG .	CPR:9
The results when considered with previous reports in the literature show that BC6OTHER is about 1000 times more potent and BC6ENTC is about 20 times more potent for BC6ENTG inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by BC6OTHER .	CPR:4
The results when considered with previous reports in the literature show that BC6OTHER is about 1000 times more potent and BC6ENTC is about 20 times more potent for BC6OTHER inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by BC6ENTG .	CPR:9
BC6ENTC is much less potent as a BC6ENTG inhibitor in cells with the BC6OTHER , such as the myocardial cells of the heart.	CPR:4
BC6ENTC is much less potent as a BC6OTHER inhibitor in cells with the BC6ENTG , such as the myocardial cells of the heart.	CPR:9
The results also confirmed previous reports that BC6ENTC is highly selective for BC6ENTG .	CPR:4
In the present study, the effects of BC6ENTC on the deamination of BC6OTHER were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the BC6OTHER transporter is non - neuronal BC6ENTG .	False
Previous studies have resulted in the classification of BC6OTHER as a selective inhibitor of neuronal BC6ENTC oxidase ( BC6ENTG ), because it is a much more potent BC6OTHER inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	False
Previous studies have resulted in the classification of BC6OTHER as a selective inhibitor of neuronal BC6ENTC oxidase ( BC6OTHER ), because it is a much more potent BC6ENTG inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	False
In the present study, the effects of BC6OTHER on the deamination of BC6ENTC were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the BC6OTHER transporter is non - neuronal BC6ENTG .	False
In the present study, the effects of BC6OTHER on the deamination of BC6OTHER were investigated in intact lungs of rats, since the pulmonary endothelial cells are a site where the BC6ENTC transporter is non - neuronal BC6ENTG .	False
Previous studies have resulted in the classification of BC6ENTC as a selective inhibitor of neuronal BC6ENTG ( BC6OTHER ), because it is a much more potent BC6OTHER inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	CPR:4
Previous studies have resulted in the classification of BC6ENTC as a selective inhibitor of neuronal BC6OTHER ( BC6ENTG ), because it is a much more potent BC6OTHER inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	CPR:4
Previous studies have resulted in the classification of BC6ENTC as a selective inhibitor of neuronal BC6OTHER ( BC6OTHER ), because it is a much more potent BC6ENTG inhibitor in intact tissues, in which it is accumulated in noradrenergic neurones by uptake1, than in tissue homogenates.	CPR:4
In addition, another drug that is both a substrate of BC6ENTG and a BC6OTHER inhibitor, BC6ENTC , was investigated in the study.	CPR:9
In addition, another drug that is both a substrate of BC6OTHER and a BC6ENTG inhibitor, BC6ENTC , was investigated in the study.	CPR:4
The first aim of the study was to show whether BC6ENTC and BC6OTHER are substrates of BC6ENTG in rat lungs.	False
The first aim of the study was to show whether BC6OTHER and BC6ENTC are substrates of BC6ENTG in rat lungs.	False
After loading of isolated perfused lungs with BC6ENTC ( BC6ENTG and CHEM - BC6OTHER - methyltransferase ( BC6OTHER ) inhibited), the efflux of BC6OTHER was measured for 30 min.	False
After loading of isolated perfused lungs with BC6ENTC ( BC6OTHER and BC6ENTG ( BC6OTHER ) inhibited), the efflux of BC6OTHER was measured for 30 min.	False
After loading of isolated perfused lungs with BC6ENTC ( BC6OTHER and CHEM - BC6OTHER - methyltransferase ( BC6ENTG ) inhibited), the efflux of BC6OTHER was measured for 30 min.	False
After loading of isolated perfused lungs with BC6OTHER ( BC6ENTG and BC6ENTC - BC6OTHER - methyltransferase ( BC6OTHER ) inhibited), the efflux of BC6OTHER was measured for 30 min.	False
After loading of isolated perfused lungs with BC6OTHER ( BC6OTHER and BC6ENTC - BC6OTHER - methyltransferase ( BC6ENTG ) inhibited), the efflux of BC6OTHER was measured for 30 min.	False
After loading of isolated perfused lungs with BC6OTHER ( BC6ENTG and CHEM - BC6ENTC - methyltransferase ( BC6OTHER ) inhibited), the efflux of BC6OTHER was measured for 30 min.	False
After loading of isolated perfused lungs with BC6OTHER ( BC6OTHER and CHEM - BC6ENTC - methyltransferase ( BC6ENTG ) inhibited), the efflux of BC6OTHER was measured for 30 min.	False
After loading of isolated perfused lungs with BC6OTHER ( BC6ENTG and CHEM - BC6OTHER - methyltransferase ( BC6OTHER ) inhibited), the efflux of BC6ENTC was measured for 30 min.	False
After loading of isolated perfused lungs with BC6OTHER ( BC6OTHER and BC6ENTG ( BC6OTHER ) inhibited), the efflux of BC6ENTC was measured for 30 min.	False
After loading of isolated perfused lungs with BC6OTHER ( BC6OTHER and CHEM - BC6OTHER - methyltransferase ( BC6ENTG ) inhibited), the efflux of BC6ENTC was measured for 30 min.	False
 BC6ENTC and BC6OTHER are substrates of BC6ENTG and potent inhibitors of BC6OTHER in perfused lungs of rats.	CPR:9
 BC6ENTC and BC6OTHER are substrates of BC6OTHER and potent inhibitors of BC6ENTG in perfused lungs of rats.	CPR:4
 BC6OTHER and BC6ENTC are substrates of BC6ENTG and potent inhibitors of BC6OTHER in perfused lungs of rats.	CPR:9
 BC6OTHER and BC6ENTC are substrates of BC6OTHER and potent inhibitors of BC6ENTG in perfused lungs of rats.	CPR:4
 BC6OTHER and BC6OTHER are substrates of BC6ENTG and potent inhibitors of BC6ENTC oxidase in perfused lungs of rats.	False
In lungs perfused with 1 nmol / l BC6ENTC ( BC6ENTG inhibited), 10, 30 and 300 nmol / l BC6OTHER caused 58%, 76% and 74% inhibition of BC6OTHER deamination, respectively, and 30, 300 and 3000 nmol / l BC6OTHER caused 56%, 89% and 96% inhibition of BC6OTHER deamination, respectively.	False
In lungs perfused with 1 nmol / l BC6OTHER ( BC6ENTG inhibited), 10, 30 and 300 nmol / l BC6ENTC caused 58%, 76% and 74% inhibition of BC6OTHER deamination, respectively, and 30, 300 and 3000 nmol / l BC6OTHER caused 56%, 89% and 96% inhibition of BC6OTHER deamination, respectively.	False
In lungs perfused with 1 nmol / l BC6OTHER ( BC6ENTG inhibited), 10, 30 and 300 nmol / l BC6OTHER caused 58%, 76% and 74% inhibition of BC6ENTC deamination, respectively, and 30, 300 and 3000 nmol / l BC6OTHER caused 56%, 89% and 96% inhibition of BC6OTHER deamination, respectively.	False
In lungs perfused with 1 nmol / l BC6OTHER ( BC6ENTG inhibited), 10, 30 and 300 nmol / l BC6OTHER caused 58%, 76% and 74% inhibition of BC6OTHER deamination, respectively, and 30, 300 and 3000 nmol / l BC6ENTC caused 56%, 89% and 96% inhibition of BC6OTHER deamination, respectively.	False
In lungs perfused with 1 nmol / l BC6OTHER ( BC6ENTG inhibited), 10, 30 and 300 nmol / l BC6OTHER caused 58%, 76% and 74% inhibition of BC6OTHER deamination, respectively, and 30, 300 and 3000 nmol / l BC6OTHER caused 56%, 89% and 96% inhibition of BC6ENTC deamination, respectively.	False
When BC6ENTG was also inhibited, 10 nmol / l BC6ENTC caused 84% inhibition of the deamination of BC6OTHER by BC6OTHER in the lungs.	False
When BC6OTHER was also inhibited, 10 nmol / l BC6ENTC caused 84% inhibition of the deamination of BC6OTHER by BC6ENTG in the lungs.	CPR:4
Reversal of inhibition by BC6ENTG agonist BC6OTHER was produced by BC6OTHER (50 µM) and by BC6ENTC (5 - 10 nM).	CPR:3
Reversal of BC6ENTC D2 agonist - induced inhibition of ventral tegmental area neurons by BC6OTHER - linked neurotransmitters is dependent on BC6ENTG , BC6OTHER , and BC6OTHER .	False
Reversal of BC6ENTC D2 agonist - induced inhibition of ventral tegmental area neurons by BC6OTHER - linked neurotransmitters is dependent on BC6OTHER , BC6ENTG , and BC6OTHER .	False
Reversal of BC6ENTC D2 agonist - induced inhibition of ventral tegmental area neurons by BC6OTHER - linked neurotransmitters is dependent on BC6OTHER , BC6OTHER , and BC6ENTG .	False
Reversal of BC6ENTC D2 agonist - induced inhibition of ventral tegmental area neurons by BC6ENTG - linked neurotransmitters is dependent on BC6OTHER , BC6OTHER , and BC6OTHER .	False
BC6ENTC - induced or BC6ENTG - induced reversal was blocked by β - ARK1 inhibitor, dynasore, or BC6OTHER antagonist BC6OTHER ( BC6OTHER ).	False
BC6ENTC - induced or BC6OTHER - induced reversal was blocked by β - ARK1 inhibitor, dynasore, or BC6ENTG antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - induced or BC6ENTC - induced reversal was blocked by β - ARK1 inhibitor, dynasore, or BC6ENTG antagonist BC6OTHER ( BC6OTHER ).	False
BC6OTHER - induced or BC6ENTG - induced reversal was blocked by β - ARK1 inhibitor, dynasore, or BC6OTHER antagonist BC6ENTC ( BC6OTHER ).	False
BC6OTHER - induced or BC6OTHER - induced reversal was blocked by β - ARK1 inhibitor, dynasore, or BC6ENTG antagonist BC6ENTC ( BC6OTHER ).	CPR:6
BC6OTHER - induced or BC6ENTG - induced reversal was blocked by β - ARK1 inhibitor, dynasore, or BC6OTHER antagonist BC6OTHER ( BC6ENTC ).	False
BC6OTHER - induced or BC6OTHER - induced reversal was blocked by β - ARK1 inhibitor, dynasore, or BC6ENTG antagonist BC6OTHER ( BC6ENTC ).	CPR:6
DIR is mediated by BC6ENTG and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6ENTC (2) or BC6OTHER receptors.	False
DIR is mediated by BC6OTHER and BC6ENTG ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6ENTC (2) or BC6OTHER receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6ENTG ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6ENTC (2) or BC6OTHER receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6ENTG and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6ENTC (2) or BC6OTHER receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6ENTG , or by BC6OTHER stimulation concurrent with activation of BC6ENTC (2) or BC6OTHER receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6ENTG stimulation concurrent with activation of BC6ENTC (2) or BC6OTHER receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6ENTC (2) or BC6ENTG .	False
DIR is mediated by BC6ENTG and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6OTHER (2) or BC6ENTC receptors.	False
DIR is mediated by BC6OTHER and BC6ENTG ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6OTHER (2) or BC6ENTC receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6ENTG ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6OTHER (2) or BC6ENTC receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6ENTG and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6OTHER (2) or BC6ENTC receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6ENTG , or by BC6OTHER stimulation concurrent with activation of BC6OTHER (2) or BC6ENTC receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6ENTG stimulation concurrent with activation of BC6OTHER (2) or BC6ENTC receptors.	False
DIR is mediated by BC6OTHER and BC6OTHER ( BC6OTHER ) through concurrent stimulation of BC6OTHER and BC6OTHER , or by BC6OTHER stimulation concurrent with activation of BC6ENTG or BC6ENTC receptors.	False
Reversal of inhibition by BC6ENTG agonist BC6ENTC was produced by BC6OTHER (50 µM) and by BC6OTHER (5 - 10 nM).	CPR:5
Reversal of inhibition by BC6OTHER agonist BC6ENTC was produced by BC6OTHER (50 µM) and by BC6ENTG (5 - 10 nM).	False
Reversal of inhibition by BC6ENTG agonist BC6OTHER was produced by BC6ENTC (50 µM) and by BC6OTHER (5 - 10 nM).	CPR:3
Reversal of inhibition by BC6OTHER agonist BC6OTHER was produced by BC6ENTC (50 µM) and by BC6ENTG (5 - 10 nM).	False
Role of the BC6ENTG in the development of the BC6ENTC projections.	False
Ipsilateral BC6OTHER axons remained exuberant in the BC6ENTG ( - / - ) mice, with overlapping BC6ENTC projections from both eyes in the superior colliculus and the visual thalamus.	False
Thus, only BC6ENTG is required for the maturation of the BC6ENTC axon terminals whereas BC6OTHER and BC6OTHER are not needed.	False
Thus, only BC6OTHER is required for the maturation of the BC6ENTC axon terminals whereas BC6ENTG and BC6OTHER are not needed.	False
Thus, only BC6OTHER is required for the maturation of the BC6ENTC axon terminals whereas BC6OTHER and BC6ENTG are not needed.	False
Transmembrane isoforms of BC6ENTG ( BC6OTHER ) integrate a wide variety of extracellular signals from neurotransmitters to CHEM and can also regulate BC6ENTC production in response to BC6OTHER entry.	CPR:9
Transmembrane isoforms of BC6OTHER cyclases ( BC6ENTG ) integrate a wide variety of extracellular signals from neurotransmitters to CHEM and can also regulate BC6ENTC production in response to BC6OTHER entry.	CPR:9
Transmembrane isoforms of BC6ENTG ( BC6OTHER ) integrate a wide variety of extracellular signals from neurotransmitters to CHEM and can also regulate BC6OTHER production in response to BC6ENTC entry.	False
Transmembrane isoforms of BC6OTHER cyclases ( BC6ENTG ) integrate a wide variety of extracellular signals from neurotransmitters to CHEM and can also regulate BC6OTHER production in response to BC6ENTC entry.	False
Transmembrane isoforms of BC6ENTC cyclases ( BC6ENTG ) integrate a wide variety of extracellular signals from neurotransmitters to CHEM and can also regulate BC6OTHER production in response to BC6OTHER entry.	False
Based on observations in the barrelless mouse strain, the BC6ENTG gene ( BC6OTHER ) was involved in the segregation of binocular BC6ENTC inputs.	False
Based on observations in the barrelless mouse strain, the BC6OTHER gene ( BC6ENTG ) was involved in the segregation of binocular BC6ENTC inputs.	False
Using a genetic approach we tested the role of the BC6ENTC modulated cyclases BC6ENTG , BC6OTHER and BC6OTHER for the segregation BC6OTHER fibres.	False
Using a genetic approach we tested the role of the BC6ENTC modulated cyclases BC6OTHER , BC6ENTG and BC6OTHER for the segregation BC6OTHER fibres.	False
Using a genetic approach we tested the role of the BC6ENTC modulated cyclases BC6OTHER , BC6OTHER and BC6ENTG for the segregation BC6OTHER fibres.	False
Using a genetic approach we tested the role of the BC6ENTG BC6OTHER , BC6OTHER and BC6OTHER for the segregation BC6ENTC fibres.	False
Using a genetic approach we tested the role of the BC6OTHER modulated cyclases BC6ENTG , BC6OTHER and BC6OTHER for the segregation BC6ENTC fibres.	False
Using a genetic approach we tested the role of the BC6OTHER modulated cyclases BC6OTHER , BC6ENTG and BC6OTHER for the segregation BC6ENTC fibres.	False
Using a genetic approach we tested the role of the BC6OTHER modulated cyclases BC6OTHER , BC6OTHER and BC6ENTG for the segregation BC6ENTC fibres.	False
Ipsilateral BC6ENTC axons remained exuberant in the BC6ENTG ( - / - ) mice, with overlapping BC6OTHER projections from both eyes in the superior colliculus and the visual thalamus.	False
During base excision repair of this mispair, BC6ENTG is confronted with gap filling opposite BC6ENTC .	False
To determine how BC6ENTG discriminates between BC6ENTC , we introduced a point mutation ( BC6OTHER ) to alter insertion specificity.	False
To determine how BC6OTHER discriminates between BC6ENTC , we introduced a point mutation ( BC6ENTG ) to alter insertion specificity.	False
Structural studies with BC6ENTG BC6OTHER show that the binary DNA complex has BC6ENTC in equilibrium between anti - and syn - forms.	False
Structural studies with BC6OTHER BC6ENTG show that the binary DNA complex has BC6ENTC in equilibrium between anti - and syn - forms.	False
 BC6ENTG interactions modulate mutagenic bypass of a templating BC6ENTC lesion.	False
In contrast to wild - type BC6ENTG , the ternary complex of the BC6OTHER mutant with an incoming BC6ENTC - analogue and templating BC6OTHER resembles a G - A mismatched structure with BC6OTHER adopting an anti - conformation.	False
In contrast to wild - type BC6OTHER , the ternary complex of the BC6ENTG mutant with an incoming BC6ENTC - analogue and templating BC6OTHER resembles a G - A mismatched structure with BC6OTHER adopting an anti - conformation.	False
In contrast to wild - type BC6ENTG , the ternary complex of the BC6OTHER mutant with an incoming BC6OTHER - analogue and templating BC6ENTC resembles a G - A mismatched structure with BC6OTHER adopting an anti - conformation.	False
In contrast to wild - type BC6OTHER , the ternary complex of the BC6ENTG mutant with an incoming BC6OTHER - analogue and templating BC6ENTC resembles a G - A mismatched structure with BC6OTHER adopting an anti - conformation.	False
In contrast to wild - type BC6ENTG , the ternary complex of the BC6OTHER mutant with an incoming BC6OTHER - analogue and templating BC6OTHER resembles a G - A mismatched structure with BC6ENTC adopting an anti - conformation.	False
In contrast to wild - type BC6OTHER , the ternary complex of the BC6ENTG mutant with an incoming BC6OTHER - analogue and templating BC6OTHER resembles a G - A mismatched structure with BC6ENTC adopting an anti - conformation.	False
These results demonstrate that the incoming BC6ENTC is unable to induce a BC6OTHER conformation without BC6ENTG BC6OTHER interactions that influence templating (anti - / syn - equilibrium) of BC6OTHER while modulating fidelity.	False
These results demonstrate that the incoming BC6ENTC is unable to induce a BC6OTHER conformation without BC6OTHER BC6ENTG interactions that influence templating (anti - / syn - equilibrium) of BC6OTHER while modulating fidelity.	False
These results demonstrate that the incoming BC6OTHER is unable to induce a BC6ENTC conformation without BC6ENTG BC6OTHER interactions that influence templating (anti - / syn - equilibrium) of BC6OTHER while modulating fidelity.	False
These results demonstrate that the incoming BC6OTHER is unable to induce a BC6ENTC conformation without BC6OTHER BC6ENTG interactions that influence templating (anti - / syn - equilibrium) of BC6OTHER while modulating fidelity.	False
These results demonstrate that the incoming BC6OTHER is unable to induce a BC6OTHER conformation without BC6ENTG BC6OTHER interactions that influence templating (anti - / syn - equilibrium) of BC6ENTC while modulating fidelity.	False
These results demonstrate that the incoming BC6OTHER is unable to induce a BC6OTHER conformation without BC6OTHER BC6ENTG interactions that influence templating (anti - / syn - equilibrium) of BC6ENTC while modulating fidelity.	False
Finally, BC6ENTC 53 in the BC6ENTG is required for functional expression of BC6OTHER but is not critical for subunit self - assembly.	False
Finally, BC6ENTC 53 in the BC6OTHER is required for functional expression of BC6ENTG but is not critical for subunit self - assembly.	False
 BC6ENTG , an inactivating 2P domain BC6ENTC channel.	False
BC6ENTG is the first reported 2P domain BC6ENTC channel that inactivates.	False
The base - line, transient, and delayed activities of BC6ENTG suggest that this novel 2P domain BC6ENTC channel may play an important functional role in cell electrogenesis.	False
BC6ENTG currents are about 15 times larger than BC6OTHER currents, but both exhibit outward rectification in a physiological BC6ENTC gradient and mild inward rectification in symmetrical BC6OTHER conditions.	False
BC6OTHER currents are about 15 times larger than BC6ENTG currents, but both exhibit outward rectification in a physiological BC6ENTC gradient and mild inward rectification in symmetrical BC6OTHER conditions.	False
BC6ENTG currents are about 15 times larger than BC6OTHER currents, but both exhibit outward rectification in a physiological BC6OTHER gradient and mild inward rectification in symmetrical BC6ENTC conditions.	False
BC6OTHER currents are about 15 times larger than BC6ENTG currents, but both exhibit outward rectification in a physiological BC6OTHER gradient and mild inward rectification in symmetrical BC6ENTC conditions.	False
We cloned human and rat BC6ENTG and expressed this novel 2P domain BC6ENTC channel in transiently transfected COS cells.	False
In a physiological BC6ENTC gradient, BC6ENTG is half inhibited by 0.1 mm BC6OTHER , BC6OTHER , and BC6OTHER .	False
In a physiological BC6OTHER gradient, BC6ENTG is half inhibited by 0.1 mm BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:4
In a physiological BC6OTHER gradient, BC6ENTG is half inhibited by 0.1 mm BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:4
In a physiological BC6OTHER gradient, BC6ENTG is half inhibited by 0.1 mm BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:4
Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to BC6ENTG , the very low affinity of BC6ENTC at BC6OTHER sites may suggest that acting on the BC6OTHER sites may not be the requisite for mediating the anticonvulsant activity of these BC6OTHER analogs.	False
Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to BC6ENTG , the very low affinity of BC6OTHER at BC6ENTC sites may suggest that acting on the BC6OTHER sites may not be the requisite for mediating the anticonvulsant activity of these BC6OTHER analogs.	False
Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to BC6ENTG , the very low affinity of BC6OTHER at BC6OTHER sites may suggest that acting on the BC6ENTC sites may not be the requisite for mediating the anticonvulsant activity of these BC6OTHER analogs.	False
Furthermore, since they have equipotent anticonvulsant effects and similar binding affinities to BC6ENTG , the very low affinity of BC6OTHER at BC6OTHER sites may suggest that acting on the BC6OTHER sites may not be the requisite for mediating the anticonvulsant activity of these BC6ENTC analogs.	False
This study therefore characterized the binding of BC6ENTC to the BC6ENTG and BC6OTHER - linked BC6OTHER sites and examined the anticonvulsant as well as locomotor effects of BC6OTHER in mice in comparison with those of BC6OTHER and BC6OTHER .	False
This study therefore characterized the binding of BC6OTHER to the BC6ENTG and BC6ENTC - linked BC6OTHER sites and examined the anticonvulsant as well as locomotor effects of BC6OTHER in mice in comparison with those of BC6OTHER and BC6OTHER .	False
This study therefore characterized the binding of BC6OTHER to the BC6ENTG and BC6OTHER - linked BC6ENTC sites and examined the anticonvulsant as well as locomotor effects of BC6OTHER in mice in comparison with those of BC6OTHER and BC6OTHER .	False
This study therefore characterized the binding of BC6OTHER to the BC6ENTG and BC6OTHER - linked BC6OTHER sites and examined the anticonvulsant as well as locomotor effects of BC6ENTC in mice in comparison with those of BC6OTHER and BC6OTHER .	False
This study therefore characterized the binding of BC6OTHER to the BC6ENTG and BC6OTHER - linked BC6OTHER sites and examined the anticonvulsant as well as locomotor effects of BC6OTHER in mice in comparison with those of BC6ENTC and BC6OTHER .	False
This study therefore characterized the binding of BC6OTHER to the BC6ENTG and BC6OTHER - linked BC6OTHER sites and examined the anticonvulsant as well as locomotor effects of BC6OTHER in mice in comparison with those of BC6OTHER and BC6ENTC .	False
We found that BC6ENTC , BC6OTHER , and BC6OTHER were relative high - affinity ligands at BC6OTHER (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at BC6ENTG (Ki=4 - 11 microM).	False
We found that BC6ENTC , BC6OTHER , and BC6OTHER were relative high - affinity ligands at BC6ENTG (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at BC6OTHER (Ki=4 - 11 microM).	False
We found that BC6OTHER , BC6ENTC , and BC6OTHER were relative high - affinity ligands at BC6OTHER (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at BC6ENTG (Ki=4 - 11 microM).	False
We found that BC6OTHER , BC6ENTC , and BC6OTHER were relative high - affinity ligands at BC6ENTG (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at BC6OTHER (Ki=4 - 11 microM).	False
We found that BC6OTHER , BC6OTHER , and BC6ENTC were relative high - affinity ligands at BC6OTHER (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at BC6ENTG (Ki=4 - 11 microM).	False
We found that BC6OTHER , BC6OTHER , and BC6ENTC were relative high - affinity ligands at BC6ENTG (Ki=151, 205, 144 nM, respectively) while all of them were with low affinity at BC6OTHER (Ki=4 - 11 microM).	False
Binding of BC6OTHER to BC6ENTG and its anticonvulsant and locomotor effects in mice, compared with BC6ENTC and BC6OTHER .	False
Binding of BC6ENTC to BC6ENTG and its anticonvulsant and locomotor effects in mice, compared with BC6OTHER and BC6OTHER .	False
Binding of BC6OTHER to BC6ENTG and its anticonvulsant and locomotor effects in mice, compared with BC6OTHER and BC6ENTC .	False
BC6ENTG binds directly to the BC6OTHER BC6ENTC terminus and can deubiquitinate and stabilize BC6OTHER .	False
BC6OTHER binds directly to the BC6ENTG BC6ENTC terminus and can deubiquitinate and stabilize BC6OTHER .	False
BC6OTHER binds directly to the BC6OTHER BC6ENTC terminus and can deubiquitinate and stabilize BC6ENTG .	False
Cellular responses to DNA damage induced by BC6ENTC or BC6OTHER include down - regulation of endogenous BC6ENTG coincident with increases in BC6OTHER .	CPR:4
Cellular responses to DNA damage induced by BC6ENTC or BC6OTHER include down - regulation of endogenous BC6OTHER coincident with increases in BC6ENTG .	CPR:3
Cellular responses to DNA damage induced by BC6OTHER or BC6ENTC include down - regulation of endogenous BC6ENTG coincident with increases in BC6OTHER .	CPR:4
Cellular responses to DNA damage induced by BC6OTHER or BC6ENTC include down - regulation of endogenous BC6OTHER coincident with increases in BC6ENTG .	CPR:3
Dual function inhibitors targeting BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) may balance the BC6ENTC (AA) metabolic network and be used as new anti - inflammatory drugs.	CPR:9
Dual function inhibitors targeting BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) may balance the BC6ENTC (AA) metabolic network and be used as new anti - inflammatory drugs.	CPR:9
Dual function inhibitors targeting BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) may balance the BC6ENTC (AA) metabolic network and be used as new anti - inflammatory drugs.	CPR:9
Dual function inhibitors targeting BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) may balance the BC6ENTC (AA) metabolic network and be used as new anti - inflammatory drugs.	CPR:9
In previous study, we discovered multi - target drugs towards the AA metabolic network, among which a dual - target inhibitor ( BC6ENTC ) for BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) was found.	CPR:4
In previous study, we discovered multi - target drugs towards the AA metabolic network, among which a dual - target inhibitor ( BC6ENTC ) for BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) was found.	CPR:4
In previous study, we discovered multi - target drugs towards the AA metabolic network, among which a dual - target inhibitor ( BC6ENTC ) for BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) was found.	CPR:4
In previous study, we discovered multi - target drugs towards the AA metabolic network, among which a dual - target inhibitor ( BC6ENTC ) for BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) was found.	CPR:4
Optimization of BC6ENTC as dual function inhibitors targeting BC6ENTG and BC6OTHER .	CPR:4
Optimization of BC6ENTC as dual function inhibitors targeting BC6OTHER and BC6ENTG .	CPR:4
A., Ventura, F. V., Houten, S. M. BC6ENTG and BC6OTHER / BC6OTHER translocase are involved in the mitochondrial synthesis and export of BC6ENTC .	CPR:9
A., Ventura, F. V., Houten, S. M. BC6OTHER palmitoyltransferase 2 and BC6ENTG are involved in the mitochondrial synthesis and export of BC6ENTC .	CPR:9
We used lentiviral shRNA to knock down the expression of medium - chain BC6ENTC dehydrogenase ( BC6ENTG ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6ENTC dehydrogenase ( BC6OTHER ) in control and BC6ENTG ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6ENTC dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6ENTG ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6ENTC dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , BC6ENTG ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6ENTC dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6ENTG ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6ENTC dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTG ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6ENTC dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6ENTG ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of BC6ENTG ( BC6OTHER ) in control and BC6ENTC palmitoyltransferase 2 ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6ENTG ) in control and BC6ENTC palmitoyltransferase 2 ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTC palmitoyltransferase 2 ( BC6ENTG ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTC palmitoyltransferase 2 ( BC6OTHER ) - , BC6ENTG ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTC palmitoyltransferase 2 ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6ENTG ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTC palmitoyltransferase 2 ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTG ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTC palmitoyltransferase 2 ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6ENTG ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of BC6ENTG ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , BC6ENTC / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6ENTG ) in control and BC6OTHER ( BC6OTHER ) - , BC6ENTC / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTG ( BC6OTHER ) - , BC6ENTC / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6ENTG ) - , BC6ENTC / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , BC6ENTC / BC6OTHER translocase ( BC6ENTG ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , BC6ENTC / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTG ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , BC6ENTC / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6ENTG ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of BC6ENTG ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6ENTC translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6ENTG ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6ENTC translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTG ( BC6OTHER ) - , CHEM / BC6ENTC translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6ENTG ) - , CHEM / BC6ENTC translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6ENTC translocase ( BC6ENTG ) - , and plasmalemmal BC6OTHER ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6ENTC translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTG ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6ENTC translocase ( BC6OTHER ) - , and plasmalemmal BC6OTHER ( BC6ENTG ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of BC6ENTG ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTC transporter ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6ENTG ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTC transporter ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6ENTG ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTC transporter ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6ENTG ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTC transporter ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , BC6ENTG ( BC6OTHER ) - , and plasmalemmal BC6ENTC transporter ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6ENTG ) - , and plasmalemmal BC6ENTC transporter ( BC6OTHER ) - deficient human fibroblasts.	False
We used lentiviral shRNA to knock down the expression of medium - chain BC6OTHER dehydrogenase ( BC6OTHER ) in control and BC6OTHER ( BC6OTHER ) - , CHEM / BC6OTHER translocase ( BC6OTHER ) - , and plasmalemmal BC6ENTC transporter ( BC6ENTG ) - deficient human fibroblasts.	False
In control fibroblasts, BC6ENTG knockdown markedly increased the production of BC6ENTC (3 - fold, P<0.01).	False
 BC6ENTC palmitoyltransferase 2 and BC6ENTG are involved in the mitochondrial synthesis and export of BC6OTHER .	False
 BC6ENTG and CHEM / BC6OTHER translocase are involved in the mitochondrial synthesis and export of BC6ENTC .	CPR:9
 BC6OTHER and BC6ENTG are involved in the mitochondrial synthesis and export of BC6ENTC .	CPR:9
 BC6ENTG and BC6ENTC / BC6OTHER translocase are involved in the mitochondrial synthesis and export of BC6OTHER .	False
 BC6ENTG and CHEM / BC6ENTC translocase are involved in the mitochondrial synthesis and export of BC6OTHER .	False
BC6OTHER - deficient cell lines also showed extracellular accumulation of BC6ENTC (2.8 - fold, P<0.01), suggesting that the cellular export of BC6OTHER does not depend on BC6ENTG .	False
BC6ENTG - deficient cell lines also showed extracellular accumulation of BC6ENTC (2.8 - fold, P<0.01), suggesting that the cellular export of BC6OTHER does not depend on BC6OTHER .	False
BC6OTHER - deficient cell lines also showed extracellular accumulation of BC6OTHER (2.8 - fold, P<0.01), suggesting that the cellular export of BC6ENTC does not depend on BC6ENTG .	False
BC6ENTG - deficient cell lines also showed extracellular accumulation of BC6OTHER (2.8 - fold, P<0.01), suggesting that the cellular export of BC6ENTC does not depend on BC6OTHER .	False
In contrast, in BC6ENTG - and BC6OTHER - deficient cells, the accumulation of BC6ENTC in the medium did not significantly increase in the BC6OTHER knockdown.	False
In contrast, in BC6OTHER - and BC6ENTG - deficient cells, the accumulation of BC6ENTC in the medium did not significantly increase in the BC6OTHER knockdown.	False
In contrast, in BC6OTHER - and BC6OTHER - deficient cells, the accumulation of BC6ENTC in the medium did not significantly increase in the BC6ENTG knockdown.	False
This shows that BC6ENTG and BC6OTHER are crucial for mitochondrial BC6ENTC formation and export to the extracellular fluids in mFAOD. - Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J.	CPR:9
This shows that BC6OTHER and BC6ENTG are crucial for mitochondrial BC6ENTC formation and export to the extracellular fluids in mFAOD. - Violante, S., IJlst, L., te Brinke, H., Tavares de Almeida, I., Wanders, R. J.	CPR:9
A., Ventura, F. V., Houten, S. M. BC6ENTC palmitoyltransferase 2 and BC6ENTG are involved in the mitochondrial synthesis and export of BC6OTHER .	False
A., Ventura, F. V., Houten, S. M. BC6ENTG and BC6ENTC / BC6OTHER translocase are involved in the mitochondrial synthesis and export of BC6OTHER .	False
A., Ventura, F. V., Houten, S. M. BC6ENTG and BC6OTHER / BC6ENTC translocase are involved in the mitochondrial synthesis and export of BC6OTHER .	False
Female C57BL / 6 mice were exposed to dextran BC6ENTC (DSS) and treated by intrarectal administration with either CD.siRNA BC6ENTG or a control solution.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6ENTG and BC6OTHER genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6ENTG genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6ENTG and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6ENTG genes, but a significant negative correlation between dietary intake of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6ENTG and BC6OTHER genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6ENTG genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6ENTG and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6ENTG genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) and the expression of PBMC BC6ENTG and BC6OTHER genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6ENTG genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6ENTG and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6ENTG genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) and the expression of PBMC BC6ENTG and BC6OTHER genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) and the expression of PBMC BC6OTHER and BC6ENTG genes.	CPR:4
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6ENTG and BC6OTHER genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
A significant positive correlation was found between dietary intake of total CHEM and total MUFAs and expression of PBMC BC6OTHER and BC6ENTG genes, but a significant negative correlation between dietary intake of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) and the expression of PBMC BC6OTHER and BC6OTHER genes.	False
CONCLUSION: Intake of high BC6ENTC and BC6OTHER appears to increase expression of PBMC BC6ENTG and BC6OTHER genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6OTHER and BC6OTHER genes.	CPR:3
CONCLUSION: Intake of high BC6ENTC and BC6OTHER appears to increase expression of PBMC BC6OTHER and BC6ENTG genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6OTHER and BC6OTHER genes.	CPR:3
CONCLUSION: Intake of high BC6ENTC and BC6OTHER appears to increase expression of PBMC BC6OTHER and BC6OTHER genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6ENTG and BC6OTHER genes.	False
CONCLUSION: Intake of high BC6ENTC and BC6OTHER appears to increase expression of PBMC BC6OTHER and BC6OTHER genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6OTHER and BC6ENTG genes.	False
CONCLUSION: Intake of high BC6OTHER and BC6ENTC appears to increase expression of PBMC BC6ENTG and BC6OTHER genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6OTHER and BC6OTHER genes.	CPR:3
CONCLUSION: Intake of high BC6OTHER and BC6ENTC appears to increase expression of PBMC BC6OTHER and BC6ENTG genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6OTHER and BC6OTHER genes.	CPR:3
CONCLUSION: Intake of high BC6OTHER and BC6ENTC appears to increase expression of PBMC BC6OTHER and BC6OTHER genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6ENTG and BC6OTHER genes.	False
CONCLUSION: Intake of high BC6OTHER and BC6ENTC appears to increase expression of PBMC BC6OTHER and BC6OTHER genes, whilst high BC6OTHER intake appears to decrease expression of PBMC BC6OTHER and BC6ENTG genes.	False
CONCLUSION: Intake of high BC6OTHER and BC6OTHER appears to increase expression of PBMC BC6ENTG and BC6OTHER genes, whilst high BC6ENTC intake appears to decrease expression of PBMC BC6OTHER and BC6OTHER genes.	False
CONCLUSION: Intake of high BC6OTHER and BC6OTHER appears to increase expression of PBMC BC6OTHER and BC6ENTG genes, whilst high BC6ENTC intake appears to decrease expression of PBMC BC6OTHER and BC6OTHER genes.	False
CONCLUSION: Intake of high BC6OTHER and BC6OTHER appears to increase expression of PBMC BC6OTHER and BC6OTHER genes, whilst high BC6ENTC intake appears to decrease expression of PBMC BC6ENTG and BC6OTHER genes.	CPR:4
CONCLUSION: Intake of high BC6OTHER and BC6OTHER appears to increase expression of PBMC BC6OTHER and BC6OTHER genes, whilst high BC6ENTC intake appears to decrease expression of PBMC BC6OTHER and BC6ENTG genes.	CPR:4
A follow - up study of the expression of BC6ENTG and BC6OTHER genes in Chinese who live in European countries with high BC6ENTC and BC6OTHER diets would be of interest.	False
A follow - up study of the expression of BC6OTHER and BC6ENTG genes in Chinese who live in European countries with high BC6ENTC and BC6OTHER diets would be of interest.	False
A follow - up study of the expression of BC6ENTG and BC6OTHER genes in Chinese who live in European countries with high BC6OTHER and BC6ENTC diets would be of interest.	False
A follow - up study of the expression of BC6OTHER and BC6ENTG genes in Chinese who live in European countries with high BC6OTHER and BC6ENTC diets would be of interest.	False
AIM: To compare the composition of BC6ENTC ( BC6OTHER ) in diet, and the expression of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
AIM: To compare the composition of BC6ENTC ( BC6OTHER ) in diet, and the expression of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
AIM: To compare the composition of BC6ENTC ( BC6OTHER ) in diet, and the expression of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
AIM: To compare the composition of BC6ENTC ( BC6OTHER ) in diet, and the expression of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
AIM: To compare the composition of BC6OTHER ( BC6ENTC ) in diet, and the expression of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
AIM: To compare the composition of BC6OTHER ( BC6ENTC ) in diet, and the expression of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
AIM: To compare the composition of BC6OTHER ( BC6ENTC ) in diet, and the expression of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
AIM: To compare the composition of BC6OTHER ( BC6ENTC ) in diet, and the expression of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) genes in peripheral blood mononuclear cells (PBMCs) between Chinese and Europeans.	False
The in vivo blood level and tissue distribution studies in albino rats also demonstrated potential of dual targeted system towards BC6ENTG and BC6ENTC receptors.	False
In addition, when BC6OTHER was given to conscious rats, the inhibitory effect on BC6ENTG - induced blood pressure responses persisted during the 24 - hour period despite nondetectable plasma concentrations of BC6ENTC at 24 hours.	False
At clinically relevant concentrations, BC6ENTC is an insurmountable and long - lasting antagonist of the vascular contractile responses to BC6ENTG .	CPR:4
In both vascular preparations, BC6ENTC caused a marked decrease in the maximal contractile response of the BC6ENTG ( BC6OTHER ) concentration - response curve.	CPR:4
In both vascular preparations, BC6ENTC caused a marked decrease in the maximal contractile response of the BC6OTHER ( BC6ENTG ) concentration - response curve.	CPR:4
In both vascular preparations, BC6OTHER caused a marked decrease in the maximal contractile response of the BC6ENTC ( BC6ENTG ) concentration - response curve.	False
In both vascular preparations, BC6OTHER caused a marked decrease in the maximal contractile response of the BC6ENTG ( BC6ENTC ) concentration - response curve.	False
BC6ENTC , BC6OTHER , and BC6OTHER caused a rightward parallel shift without any major effects on the maximal response to BC6ENTG .	False
BC6OTHER , BC6ENTC , and BC6OTHER caused a rightward parallel shift without any major effects on the maximal response to BC6ENTG .	False
The functional inhibitory characteristics of the BC6ENTG blockers (ARB) BC6OTHER ; BC6ENTC ; and BC6OTHER and its active metabolite BC6OTHER ( BC6OTHER ) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
BC6OTHER , BC6OTHER , and BC6ENTC caused a rightward parallel shift without any major effects on the maximal response to BC6ENTG .	False
The functional inhibitory characteristics of the BC6ENTG blockers (ARB) BC6ENTC ; BC6OTHER ; and BC6OTHER and its active metabolite BC6OTHER ( BC6OTHER ) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
Cooling of the rat portal vein preparations to 4 degrees C before administration of BC6ENTC prevented the persistent inhibition of BC6ENTG response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the BC6OTHER response were independent of the incubation temperature before washing.	False
Cooling of the rat portal vein preparations to 4 degrees C before administration of BC6ENTC prevented the persistent inhibition of BC6OTHER response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the BC6ENTG response were independent of the incubation temperature before washing.	False
The functional inhibitory characteristics of the BC6ENTG blockers (ARB) BC6OTHER ; BC6OTHER ; and BC6ENTC and its active metabolite BC6OTHER ( BC6OTHER ) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
Cooling of the rat portal vein preparations to 4 degrees C before administration of BC6OTHER prevented the persistent inhibition of BC6ENTC response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the BC6ENTG response were independent of the incubation temperature before washing.	False
Cooling of the rat portal vein preparations to 4 degrees C before administration of BC6OTHER prevented the persistent inhibition of BC6ENTG response seen at 37 degrees C. For the other ARBs studied, the magnitude of inhibition and the speed of recovery of the BC6ENTC response were independent of the incubation temperature before washing.	False
In addition, when BC6ENTC was given to conscious rats, the inhibitory effect on BC6ENTG - induced blood pressure responses persisted during the 24 - hour period despite nondetectable plasma concentrations of BC6OTHER at 24 hours.	CPR:4
The functional inhibitory characteristics of the BC6ENTG blockers (ARB) BC6OTHER ; BC6OTHER ; and BC6OTHER and its active metabolite BC6ENTC ( BC6OTHER ) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
The functional inhibitory characteristics of the BC6ENTG blockers (ARB) BC6OTHER ; BC6OTHER ; and BC6OTHER and its active metabolite BC6OTHER ( BC6ENTC ) were studied in rabbit aortic strips and rat portal vein preparations in vitro.	CPR:4
However, the heterogeneity of the BC6ENTC receptors, frequently composed of BC6ENTG and BC6OTHER subunits, has been less studied.	False
However, the heterogeneity of the BC6ENTC receptors, frequently composed of BC6OTHER and BC6ENTG subunits, has been less studied.	False
Thus, we determined the contribution of BC6ENTC receptor subtypes on BC6ENTG toxicity in HEK293 cells transiently expressing BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER subunits.	False
Thus, we determined the contribution of BC6ENTC receptor subtypes on BC6OTHER toxicity in HEK293 cells transiently expressing BC6ENTG / BC6OTHER or BC6OTHER / BC6OTHER subunits.	False
Thus, we determined the contribution of BC6ENTC receptor subtypes on BC6OTHER toxicity in HEK293 cells transiently expressing BC6OTHER / BC6ENTG or BC6OTHER / BC6OTHER subunits.	False
Thus, we determined the contribution of BC6ENTC receptor subtypes on BC6OTHER toxicity in HEK293 cells transiently expressing BC6OTHER / BC6OTHER or BC6ENTG / BC6OTHER subunits.	False
Thus, we determined the contribution of BC6ENTC receptor subtypes on BC6OTHER toxicity in HEK293 cells transiently expressing BC6OTHER / BC6OTHER or BC6OTHER / BC6ENTG subunits.	False
Analysis of BC6ENTC dehydrogenase ( BC6ENTG ) release and BC6OTHER exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6ENTC dehydrogenase ( BC6OTHER ) release and BC6OTHER exclusion revealed an increase in BC6ENTG toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6ENTC dehydrogenase ( BC6OTHER ) release and BC6OTHER exclusion revealed an increase in BC6OTHER toxicity upon BC6ENTG / BC6OTHER expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6ENTC dehydrogenase ( BC6OTHER ) release and BC6OTHER exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6ENTG expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6ENTC dehydrogenase ( BC6OTHER ) release and BC6OTHER exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6ENTG / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6ENTC dehydrogenase ( BC6OTHER ) release and BC6OTHER exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6OTHER / BC6ENTG , indicating loss of plasma membrane integrity.	False
Analysis of BC6ENTG ( BC6OTHER ) release and BC6ENTC exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6OTHER ( BC6ENTG ) release and BC6ENTC exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6OTHER ( BC6OTHER ) release and BC6ENTC exclusion revealed an increase in BC6ENTG toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6OTHER ( BC6OTHER ) release and BC6ENTC exclusion revealed an increase in BC6OTHER toxicity upon BC6ENTG / BC6OTHER expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6OTHER ( BC6OTHER ) release and BC6ENTC exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6ENTG expression, compared to BC6OTHER / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6OTHER ( BC6OTHER ) release and BC6ENTC exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6ENTG / BC6OTHER , indicating loss of plasma membrane integrity.	False
Analysis of BC6OTHER ( BC6OTHER ) release and BC6ENTC exclusion revealed an increase in BC6OTHER toxicity upon BC6OTHER / BC6OTHER expression, compared to BC6OTHER / BC6ENTG , indicating loss of plasma membrane integrity.	False
Neurotoxicity induced by BC6OTHER ( BC6OTHER ) involves BC6ENTC toxicity, resulting from overactivation of BC6ENTG and elevation of intracellular BC6OTHER .	False
Neurotoxicity induced by BC6ENTG ( BC6OTHER ) involves BC6ENTC toxicity, resulting from overactivation of CHEM ( BC6OTHER ) receptors and elevation of intracellular BC6OTHER .	False
Neurotoxicity induced by BC6OTHER ( BC6ENTG ) involves BC6ENTC toxicity, resulting from overactivation of CHEM ( BC6OTHER ) receptors and elevation of intracellular BC6OTHER .	False
Furthermore, BC6ENTG decreased intracellular BC6ENTC in cells expressing BC6OTHER / BC6OTHER .	False
Furthermore, BC6OTHER decreased intracellular BC6ENTC in cells expressing BC6ENTG / BC6OTHER .	False
Furthermore, BC6OTHER decreased intracellular BC6ENTC in cells expressing BC6OTHER / BC6ENTG .	False
BC6ENTC ( BC6OTHER ), a noncompetitive BC6ENTG antagonist, partially prevented the decrease in cell viability and the energy impairment.	CPR:6
BC6OTHER ( BC6ENTC ), a noncompetitive BC6ENTG antagonist, partially prevented the decrease in cell viability and the energy impairment.	CPR:6
Toxicity of BC6ENTG in HEK293 cells expressing BC6OTHER / BC6OTHER or BC6OTHER / BC6OTHER BC6ENTC receptor subunits.	False
Toxicity of BC6OTHER in HEK293 cells expressing BC6ENTG / BC6OTHER or BC6OTHER / BC6OTHER BC6ENTC receptor subunits.	False
Toxicity of BC6OTHER in HEK293 cells expressing BC6OTHER / BC6ENTG or BC6OTHER / BC6OTHER BC6ENTC receptor subunits.	False
Toxicity of BC6OTHER in HEK293 cells expressing BC6OTHER / BC6OTHER or BC6ENTG / BC6OTHER BC6ENTC receptor subunits.	False
Toxicity of BC6OTHER in HEK293 cells expressing BC6OTHER / BC6OTHER or BC6OTHER / BC6ENTG BC6ENTC receptor subunits.	False
Neurotoxicity induced by BC6ENTG ( BC6OTHER ) involves BC6OTHER toxicity, resulting from overactivation of BC6ENTC ( BC6OTHER ) receptors and elevation of intracellular BC6OTHER .	False
Neurotoxicity induced by BC6OTHER ( BC6ENTG ) involves BC6OTHER toxicity, resulting from overactivation of BC6ENTC ( BC6OTHER ) receptors and elevation of intracellular BC6OTHER .	False
Functional BC6ENTG / BC6OTHER and BC6OTHER / BC6OTHER receptor subtypes were further evidenced by single - cell BC6ENTC imaging.	False
Functional BC6OTHER / BC6ENTG and BC6OTHER / BC6OTHER receptor subtypes were further evidenced by single - cell BC6ENTC imaging.	False
Functional BC6OTHER / BC6OTHER and BC6ENTG / BC6OTHER receptor subtypes were further evidenced by single - cell BC6ENTC imaging.	False
Functional BC6OTHER / BC6OTHER and BC6OTHER / BC6ENTG receptor subtypes were further evidenced by single - cell BC6ENTC imaging.	False
Stimulation of BC6ENTG / BC6OTHER receptors with BC6ENTC / BC6OTHER revealed an increase in intracellular BC6OTHER in cells pre - exposed to BC6OTHER .	False
Stimulation of BC6OTHER / BC6ENTG receptors with BC6ENTC / BC6OTHER revealed an increase in intracellular BC6OTHER in cells pre - exposed to BC6OTHER .	False
Stimulation of BC6OTHER / BC6OTHER receptors with BC6ENTC / BC6OTHER revealed an increase in intracellular BC6OTHER in cells pre - exposed to BC6ENTG .	False
Stimulation of BC6ENTG / BC6OTHER receptors with BC6OTHER / BC6ENTC revealed an increase in intracellular BC6OTHER in cells pre - exposed to BC6OTHER .	False
Stimulation of BC6OTHER / BC6ENTG receptors with BC6OTHER / BC6ENTC revealed an increase in intracellular BC6OTHER in cells pre - exposed to BC6OTHER .	False
Stimulation of BC6OTHER / BC6OTHER receptors with BC6OTHER / BC6ENTC revealed an increase in intracellular BC6OTHER in cells pre - exposed to BC6ENTG .	False
Stimulation of BC6ENTG / BC6OTHER receptors with BC6OTHER / BC6OTHER revealed an increase in intracellular BC6ENTC in cells pre - exposed to BC6OTHER .	False
Stimulation of BC6OTHER / BC6ENTG receptors with BC6OTHER / BC6OTHER revealed an increase in intracellular BC6ENTC in cells pre - exposed to BC6OTHER .	False
Stimulation of BC6OTHER / BC6OTHER receptors with BC6OTHER / BC6OTHER revealed an increase in intracellular BC6ENTC in cells pre - exposed to BC6ENTG .	False
Neurotoxicity induced by BC6ENTG ( BC6OTHER ) involves BC6OTHER toxicity, resulting from overactivation of CHEM ( BC6ENTC ) receptors and elevation of intracellular BC6OTHER .	False
Neurotoxicity induced by BC6OTHER ( BC6ENTG ) involves BC6OTHER toxicity, resulting from overactivation of CHEM ( BC6ENTC ) receptors and elevation of intracellular BC6OTHER .	False
These results suggest that BC6ENTG / BC6OTHER - composed BC6ENTC receptors mediate necrotic cell death in HEK293 cells exposed to BC6OTHER through changes in BC6OTHER homeostasis.	False
These results suggest that BC6OTHER / BC6ENTG - composed BC6ENTC receptors mediate necrotic cell death in HEK293 cells exposed to BC6OTHER through changes in BC6OTHER homeostasis.	False
These results suggest that BC6OTHER / BC6OTHER - composed BC6ENTC receptors mediate necrotic cell death in HEK293 cells exposed to BC6ENTG through changes in BC6OTHER homeostasis.	False
These results suggest that BC6ENTG / BC6OTHER - composed BC6OTHER receptors mediate necrotic cell death in HEK293 cells exposed to BC6OTHER through changes in BC6ENTC homeostasis.	False
These results suggest that BC6OTHER / BC6ENTG - composed BC6OTHER receptors mediate necrotic cell death in HEK293 cells exposed to BC6OTHER through changes in BC6ENTC homeostasis.	False
These results suggest that BC6OTHER / BC6OTHER - composed BC6ENTG mediate necrotic cell death in HEK293 cells exposed to BC6OTHER through changes in BC6ENTC homeostasis.	False
These results suggest that BC6OTHER / BC6OTHER - composed BC6OTHER receptors mediate necrotic cell death in HEK293 cells exposed to BC6ENTG through changes in BC6ENTC homeostasis.	False
Neurotoxicity induced by BC6OTHER ( BC6OTHER ) involves BC6OTHER toxicity, resulting from overactivation of BC6ENTG and elevation of intracellular BC6ENTC .	False
Neurotoxicity induced by BC6ENTG ( BC6OTHER ) involves BC6OTHER toxicity, resulting from overactivation of CHEM ( BC6OTHER ) receptors and elevation of intracellular BC6ENTC .	False
Neurotoxicity induced by BC6OTHER ( BC6ENTG ) involves BC6OTHER toxicity, resulting from overactivation of CHEM ( BC6OTHER ) receptors and elevation of intracellular BC6ENTC .	False
Schild analyses for the antagonists against BC6OTHER yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BC6ENTC (7.8), BC6OTHER (5.8) and for BC6OTHER (6.0) suggesting the presence of functional BC6ENTG .	CPR:6
Schild analyses for the antagonists against BC6OTHER yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BC6OTHER (7.8), BC6ENTC (5.8) and for BC6OTHER (6.0) suggesting the presence of functional BC6ENTG .	CPR:6
Schild analyses for the antagonists against BC6OTHER yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BC6OTHER (7.8), BC6OTHER (5.8) and for BC6ENTC (6.0) suggesting the presence of functional BC6ENTG .	CPR:6
CONCLUSIONS: The BC6ENTG agonists BC6ENTC , BC6OTHER , and BC6OTHER are potent vasoconstrictors in the porcine ciliary artery.	CPR:5
CONCLUSIONS: The BC6ENTG agonists BC6OTHER , BC6ENTC , and BC6OTHER are potent vasoconstrictors in the porcine ciliary artery.	CPR:5
CONCLUSIONS: The BC6ENTG agonists BC6OTHER , BC6OTHER , and BC6ENTC are potent vasoconstrictors in the porcine ciliary artery.	CPR:5
The segments were contracted with the BC6ENTG agonists BC6ENTC , BC6OTHER , and BC6OTHER .	CPR:5
The segments were contracted with the BC6ENTG agonists BC6OTHER , BC6ENTC , and BC6OTHER .	CPR:5
The segments were contracted with the BC6ENTG agonists BC6OTHER , BC6OTHER , and BC6ENTC .	CPR:5
To determine which subtypes of the BC6ENTG mediate this contraction, antagonists subselective for the different BC6OTHER were added to the vessel bath before concentration - response curves for BC6ENTC were obtained.	False
To determine which subtypes of the BC6OTHER mediate this contraction, antagonists subselective for the different BC6ENTG were added to the vessel bath before concentration - response curves for BC6ENTC were obtained.	False
RESULTS: The BC6ENTG agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: BC6ENTC 2.11, BC6OTHER 5.26, and BC6OTHER 13.0.	CPR:5
The following BC6ENTG antagonists were applied: BC6ENTC ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6ENTC ( BC6ENTG - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	CPR:6
The following BC6OTHER antagonists were applied: BC6ENTC ( BC6OTHER - selective), BC6OTHER ( BC6ENTG - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6ENTC ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6ENTG - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6ENTC ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6ENTG - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6ENTC ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6ENTG - selective).	False
The following BC6ENTG antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6ENTC ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6ENTG - selective), BC6ENTC ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6ENTC ( BC6ENTG - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	CPR:6
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6ENTC ( BC6OTHER - and BC6ENTG - selective), and BC6OTHER ( BC6OTHER - and BC6OTHER - selective).	CPR:6
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6ENTC ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6ENTG - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6ENTC ( BC6OTHER - and BC6OTHER - selective), and BC6OTHER ( BC6OTHER - and BC6ENTG - selective).	False
The following BC6ENTG antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6ENTC ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6ENTG - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6ENTC ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6OTHER ( BC6ENTG - and BC6OTHER - selective), and BC6ENTC ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6ENTG - selective), and BC6ENTC ( BC6OTHER - and BC6OTHER - selective).	False
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6ENTC ( BC6ENTG - and BC6OTHER - selective).	CPR:6
The following BC6OTHER antagonists were applied: BC6OTHER ( BC6OTHER - selective), BC6OTHER ( BC6OTHER - and BC6OTHER - selective), and BC6ENTC ( BC6OTHER - and BC6ENTG - selective).	CPR:6
Potent BC6ENTG - mediated vasoconstriction by BC6ENTC in porcine ciliary arteries.	False
RESULTS: The BC6ENTG agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: BC6OTHER 2.11, BC6ENTC 5.26, and BC6OTHER 13.0.	CPR:5
RESULTS: The BC6ENTG agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: BC6OTHER 2.11, BC6OTHER 5.26, and BC6ENTC 13.0.	CPR:5
Schild analyses for the antagonists against BC6ENTC yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BC6OTHER (7.8), BC6OTHER (5.8) and for BC6OTHER (6.0) suggesting the presence of functional BC6ENTG .	False
Furthermore, whereas BC6ENTG induce BC6OTHER ( BC6ENTC ) production in peritubular and Sertoli cells, little or no upregulation of BC6OTHER transport by BC6OTHER was observed in these cells.	False
Furthermore, whereas BC6OTHER induce BC6OTHER ( BC6ENTC ) production in peritubular and Sertoli cells, little or no upregulation of BC6OTHER transport by BC6ENTG was observed in these cells.	False
Furthermore, whereas BC6ENTG induce BC6OTHER ( BC6OTHER ) production in peritubular and Sertoli cells, little or no upregulation of BC6ENTC transport by BC6OTHER was observed in these cells.	False
Furthermore, whereas BC6OTHER induce BC6OTHER ( BC6OTHER ) production in peritubular and Sertoli cells, little or no upregulation of BC6ENTC transport by BC6ENTG was observed in these cells.	False
We assessed the BC6ENTC uptake kinetics, BC6OTHER dependence of transport, profiles of cis inhibition of uptake by cationic and neutral BC6OTHER , and sensitivity to trans stimulation of BC6ENTG , and studied the expression of the genes encoding them by RT - PCR.	False
We assessed the BC6OTHER uptake kinetics, BC6ENTC dependence of transport, profiles of cis inhibition of uptake by cationic and neutral BC6OTHER , and sensitivity to trans stimulation of BC6ENTG , and studied the expression of the genes encoding them by RT - PCR.	False
We assessed the BC6OTHER uptake kinetics, BC6OTHER dependence of transport, profiles of cis inhibition of uptake by cationic and neutral BC6ENTC , and sensitivity to trans stimulation of BC6ENTG , and studied the expression of the genes encoding them by RT - PCR.	False
Our data suggest that BC6ENTC is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ( BC6ENTG / BC6OTHER ) and system y(+) ( BC6OTHER and BC6OTHER ), with system B(0+) making a minor contribution.	CPR:9
Our data suggest that BC6ENTC is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ( BC6OTHER / BC6ENTG ) and system y(+) ( BC6OTHER and BC6OTHER ), with system B(0+) making a minor contribution.	False
Our data suggest that BC6ENTC is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ( BC6OTHER / BC6OTHER ) and system y(+) ( BC6ENTG and BC6OTHER ), with system B(0+) making a minor contribution.	False
Our data suggest that BC6ENTC is taken up by Sertoli cells and peritubular cells, principally via system y(+)L ( BC6OTHER / BC6OTHER ) and system y(+) ( BC6OTHER and BC6ENTG ), with system B(0+) making a minor contribution.	False
By contrast, CHEM, associated with system y(+)L ( BC6ENTG / BC6OTHER and BC6OTHER ), made a major contribution to the transport of cationic BC6ENTC in CHEM spermatocytes and early spermatids.	False
By contrast, CHEM, associated with system y(+)L ( BC6OTHER / BC6ENTG and BC6OTHER ), made a major contribution to the transport of cationic BC6ENTC in CHEM spermatocytes and early spermatids.	False
By contrast, CHEM, associated with system y(+)L ( BC6OTHER / BC6OTHER and BC6ENTG ), made a major contribution to the transport of cationic BC6ENTC in CHEM spermatocytes and early spermatids.	False
Furthermore, whereas BC6ENTG induce BC6ENTC ( BC6OTHER ) production in peritubular and Sertoli cells, little or no upregulation of BC6OTHER transport by BC6OTHER was observed in these cells.	False
Furthermore, whereas BC6OTHER induce BC6ENTC ( BC6OTHER ) production in peritubular and Sertoli cells, little or no upregulation of BC6OTHER transport by BC6ENTG was observed in these cells.	False
The mRNA levels of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER were increased significantly (P<0.05) in the combined BC6OTHER + BC6ENTC treatment group.	CPR:4
The mRNA levels of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER were increased significantly (P<0.05) in the combined BC6OTHER + BC6ENTC treatment group.	CPR:4
The mRNA levels of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER were increased significantly (P<0.05) in the combined BC6OTHER + BC6ENTC treatment group.	CPR:4
The mRNA levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG were increased significantly (P<0.05) in the combined BC6OTHER + BC6ENTC treatment group.	CPR:4
The expressions of BC6ENTG and BC6OTHER were significantly (P<0.05) increased in the BC6ENTC group and reduced in the combined treatment group.	CPR:3
The expressions of BC6OTHER and BC6ENTG were significantly (P<0.05) increased in the BC6ENTC group and reduced in the combined treatment group.	CPR:3
The mRNA levels of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER were increased significantly (P<0.05) in the combined BC6ENTC + BC6OTHER treatment group.	CPR:3
The mRNA levels of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER were increased significantly (P<0.05) in the combined BC6ENTC + BC6OTHER treatment group.	CPR:3
The mRNA levels of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER were increased significantly (P<0.05) in the combined BC6ENTC + BC6OTHER treatment group.	CPR:3
The mRNA levels of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG were increased significantly (P<0.05) in the combined BC6ENTC + BC6OTHER treatment group.	CPR:4
Competitive radioligand binding assays were performed using cells expressing either the human BC6ENTC ( BC6OTHER ) transporter ( BC6ENTG ) or CHEM ( BC6OTHER ) transporter ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6ENTC ( BC6OTHER ) transporter ( BC6OTHER ) or BC6ENTG ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6ENTC ( BC6OTHER ) transporter ( BC6OTHER ) or CHEM ( BC6OTHER ) transporter ( BC6ENTG ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the BC6ENTG BC6ENTC ) transporter ( BC6OTHER ) or CHEM ( BC6OTHER ) transporter ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6ENTC ) transporter ( BC6ENTG ) or CHEM ( BC6OTHER ) transporter ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6ENTC ) transporter ( BC6OTHER ) or BC6ENTG ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6ENTC ) transporter ( BC6OTHER ) or CHEM ( BC6OTHER ) transporter ( BC6ENTG ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the BC6ENTG BC6OTHER ) transporter ( BC6OTHER ) or BC6ENTC ( BC6OTHER ) transporter ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) or BC6ENTC ( BC6OTHER ) transporter ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) or BC6ENTC ( BC6OTHER ) transporter ( BC6ENTG ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the BC6ENTG BC6OTHER ) transporter ( BC6OTHER ) or CHEM ( BC6ENTC ) transporter ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) or CHEM ( BC6ENTC ) transporter ( BC6OTHER ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) or CHEM ( BC6ENTC ) transporter ( BC6ENTG ) with K(i) values for BC6OTHER of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	False
Competitive radioligand binding assays were performed using cells expressing either the BC6ENTG BC6OTHER ) transporter ( BC6OTHER ) or CHEM ( BC6OTHER ) transporter ( BC6OTHER ) with K(i) values for BC6ENTC of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	CPR:4
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6OTHER ) transporter ( BC6ENTG ) or CHEM ( BC6OTHER ) transporter ( BC6OTHER ) with K(i) values for BC6ENTC of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	CPR:4
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) or BC6ENTG ( BC6OTHER ) with K(i) values for BC6ENTC of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	CPR:4
Competitive radioligand binding assays were performed using cells expressing either the human BC6OTHER ( BC6OTHER ) transporter ( BC6OTHER ) or CHEM ( BC6OTHER ) transporter ( BC6ENTG ) with K(i) values for BC6ENTC of 40.2 + / - 1.6 and 558.4 + / - 121.6 nM, respectively.	CPR:4
BC6ENTC showed weak binding affinity (62% inhibition at 100 microM) at the BC6ENTG BC6OTHER ) transporter.	False
BC6OTHER showed weak binding affinity (62% inhibition at 100 microM) at the BC6ENTG BC6ENTC ) transporter.	False
Inhibition of BC6ENTC or BC6OTHER uptake by BC6OTHER for the BC6ENTG or BC6OTHER produced IC50 values of 47.3 + / - 19.4 and 531.3 + / - 113.0 nM, respectively.	CPR:9
Inhibition of BC6ENTC or BC6OTHER uptake by BC6OTHER for the BC6OTHER or BC6ENTG produced IC50 values of 47.3 + / - 19.4 and 531.3 + / - 113.0 nM, respectively.	False
Inhibition of BC6OTHER or BC6ENTC uptake by BC6OTHER for the BC6ENTG or BC6OTHER produced IC50 values of 47.3 + / - 19.4 and 531.3 + / - 113.0 nM, respectively.	False
Inhibition of BC6OTHER or BC6ENTC uptake by BC6OTHER for the BC6OTHER or BC6ENTG produced IC50 values of 47.3 + / - 19.4 and 531.3 + / - 113.0 nM, respectively.	CPR:9
Inhibition of BC6OTHER or BC6OTHER uptake by BC6ENTC for the BC6ENTG or BC6OTHER produced IC50 values of 47.3 + / - 19.4 and 531.3 + / - 113.0 nM, respectively.	False
Inhibition of BC6OTHER or BC6OTHER uptake by BC6ENTC for the BC6OTHER or BC6ENTG produced IC50 values of 47.3 + / - 19.4 and 531.3 + / - 113.0 nM, respectively.	False
To mimic chronic selective BC6ENTC reuptake inhibitor treatment and to block the inhibitory BC6ENTG autoreceptors, a BC6OTHER antagonist, BC6OTHER ( BC6OTHER ) (0.3 mg / kg s.c.), was administered with BC6OTHER (30 mg / kg orally).	False
To mimic chronic selective BC6ENTC reuptake inhibitor treatment and to block the inhibitory BC6OTHER autoreceptors, a BC6ENTG antagonist, BC6OTHER ( BC6OTHER ) (0.3 mg / kg s.c.), was administered with BC6OTHER (30 mg / kg orally).	False
To mimic chronic selective BC6OTHER reuptake inhibitor treatment and to block the inhibitory BC6ENTG autoreceptors, a BC6OTHER antagonist, BC6ENTC ( BC6OTHER ) (0.3 mg / kg s.c.), was administered with BC6OTHER (30 mg / kg orally).	False
To mimic chronic selective BC6OTHER reuptake inhibitor treatment and to block the inhibitory BC6OTHER autoreceptors, a BC6ENTG antagonist, BC6ENTC ( BC6OTHER ) (0.3 mg / kg s.c.), was administered with BC6OTHER (30 mg / kg orally).	CPR:6
To mimic chronic selective BC6OTHER reuptake inhibitor treatment and to block the inhibitory BC6ENTG autoreceptors, a BC6OTHER antagonist, BC6OTHER ( BC6ENTC ) (0.3 mg / kg s.c.), was administered with BC6OTHER (30 mg / kg orally).	False
To mimic chronic selective BC6OTHER reuptake inhibitor treatment and to block the inhibitory BC6OTHER autoreceptors, a BC6ENTG antagonist, BC6OTHER ( BC6ENTC ) (0.3 mg / kg s.c.), was administered with BC6OTHER (30 mg / kg orally).	CPR:6
To mimic chronic selective BC6OTHER reuptake inhibitor treatment and to block the inhibitory BC6ENTG autoreceptors, a BC6OTHER antagonist, BC6OTHER ( BC6OTHER ) (0.3 mg / kg s.c.), was administered with BC6ENTC (30 mg / kg orally).	False
To mimic chronic selective BC6OTHER reuptake inhibitor treatment and to block the inhibitory BC6OTHER autoreceptors, a BC6ENTG antagonist, BC6OTHER ( BC6OTHER ) (0.3 mg / kg s.c.), was administered with BC6ENTC (30 mg / kg orally).	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , respectively.	False
Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , respectively.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6ENTC kinase, enzyme that converts BC6OTHER to BC6OTHER ) driven by the strong promoters (the regulated BC6ENTG or constitutive BC6OTHER ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6ENTC kinase, enzyme that converts BC6OTHER to BC6OTHER ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6ENTG ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6ENTG gene (encoding the BC6ENTC kinase, enzyme that converts BC6OTHER to BC6OTHER ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6OTHER ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6OTHER , enzyme that converts BC6ENTC to BC6OTHER ) driven by the strong promoters (the regulated BC6ENTG or constitutive BC6OTHER ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6OTHER , enzyme that converts BC6ENTC to BC6OTHER ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6ENTG ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6ENTG gene (encoding the BC6OTHER , enzyme that converts BC6ENTC to BC6OTHER ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6OTHER ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6ENTG , enzyme that converts BC6ENTC to BC6OTHER ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6OTHER ) were isolated.	CPR:9
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6OTHER , enzyme that converts BC6OTHER to BC6ENTC ) driven by the strong promoters (the regulated BC6ENTG or constitutive BC6OTHER ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6OTHER , enzyme that converts BC6OTHER to BC6ENTC ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6ENTG ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6ENTG gene (encoding the BC6OTHER , enzyme that converts BC6OTHER to BC6ENTC ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6OTHER ) were isolated.	False
The recombinant strains of the flavinogenic yeast Candida famata, which contain the DNA fragment consisting of the BC6OTHER gene (encoding the BC6ENTG , enzyme that converts BC6OTHER to BC6ENTC ) driven by the strong promoters (the regulated BC6OTHER or constitutive BC6OTHER ) were isolated.	CPR:9
The 6 - 8 - fold increase of the BC6ENTC kinase activity was shown in the recombinant strains containing the integrated BC6ENTG gene under the strong constitutive BC6OTHER .	False
The 6 - 8 - fold increase of the BC6ENTC kinase activity was shown in the recombinant strains containing the integrated BC6OTHER gene under the strong constitutive BC6ENTG .	False
In conclusion, the BC6ENTG length dependent effect of BC6ENTC on BC6OTHER activity in PNT1A, but not in PC - 3 cells, indicates as a cell - specific effect of BC6OTHER on BC6OTHER activity.	False
In conclusion, the BC6OTHER length dependent effect of BC6ENTC on BC6ENTG activity in PNT1A, but not in PC - 3 cells, indicates as a cell - specific effect of BC6OTHER on BC6OTHER activity.	False
In conclusion, the BC6OTHER length dependent effect of BC6ENTC on BC6OTHER activity in PNT1A, but not in PC - 3 cells, indicates as a cell - specific effect of BC6OTHER on BC6ENTG activity.	False
In conclusion, the BC6ENTG length dependent effect of BC6OTHER on BC6OTHER activity in PNT1A, but not in PC - 3 cells, indicates as a cell - specific effect of BC6ENTC on BC6OTHER activity.	False
In conclusion, the BC6OTHER length dependent effect of BC6OTHER on BC6ENTG activity in PNT1A, but not in PC - 3 cells, indicates as a cell - specific effect of BC6ENTC on BC6OTHER activity.	False
In conclusion, the BC6OTHER length dependent effect of BC6OTHER on BC6OTHER activity in PNT1A, but not in PC - 3 cells, indicates as a cell - specific effect of BC6ENTC on BC6ENTG activity.	False
 BC6ENTC receptor BC6ENTG length modifies the effect of BC6OTHER on receptor activity in human prostate cells.	False
 BC6ENTG BC6OTHER length modifies the effect of BC6ENTC on receptor activity in human prostate cells.	False
 BC6OTHER BC6ENTG length modifies the effect of BC6ENTC on receptor activity in human prostate cells.	False
BC6ENTC acts through the BC6ENTG ( BC6OTHER ), which interacts with the BC6OTHER receptor ( BC6OTHER ).	False
BC6ENTC acts through the BC6OTHER receptor ( BC6ENTG ), which interacts with the BC6OTHER receptor ( BC6OTHER ).	False
BC6ENTC acts through the BC6OTHER receptor ( BC6OTHER ), which interacts with the BC6ENTG ( BC6OTHER ).	False
BC6ENTC acts through the BC6OTHER receptor ( BC6OTHER ), which interacts with the BC6OTHER receptor ( BC6ENTG ).	False
BC6OTHER acts through the BC6ENTC receptor ( BC6ENTG ), which interacts with the BC6OTHER receptor ( BC6OTHER ).	False
BC6OTHER acts through the BC6ENTC receptor ( BC6OTHER ), which interacts with the BC6ENTG ( BC6OTHER ).	False
BC6OTHER acts through the BC6ENTC receptor ( BC6OTHER ), which interacts with the BC6OTHER receptor ( BC6ENTG ).	False
BC6OTHER acts through the BC6ENTG ( BC6OTHER ), which interacts with the BC6ENTC receptor ( BC6OTHER ).	False
BC6OTHER acts through the BC6OTHER receptor ( BC6ENTG ), which interacts with the BC6ENTC receptor ( BC6OTHER ).	False
BC6OTHER acts through the BC6OTHER receptor ( BC6OTHER ), which interacts with the BC6ENTC receptor ( BC6ENTG ).	False
We investigated the influence of BC6ENTC on prostate cancer cells (PC - 3) and non - tumor prostate cells (PNT1A) on BC6OTHER - activated BC6ENTG containing BC6OTHER within normal length range (16, 22, and 28).	False
We investigated the influence of BC6ENTC on prostate cancer cells (PC - 3) and non - tumor prostate cells (PNT1A) on BC6OTHER - activated BC6OTHER containing BC6ENTG within normal length range (16, 22, and 28).	False
We investigated the influence of BC6OTHER on prostate cancer cells (PC - 3) and non - tumor prostate cells (PNT1A) on BC6ENTC - activated BC6ENTG containing BC6OTHER within normal length range (16, 22, and 28).	False
We investigated the influence of BC6OTHER on prostate cancer cells (PC - 3) and non - tumor prostate cells (PNT1A) on BC6ENTC - activated BC6OTHER containing BC6ENTG within normal length range (16, 22, and 28).	False
The BC6ENTG target gene BC6OTHER mRNA expression was induced by BC6ENTC , but was not affected by the BC6OTHER BC6OTHER length.	False
The BC6OTHER target gene BC6ENTG mRNA expression was induced by BC6ENTC , but was not affected by the BC6OTHER BC6OTHER length.	CPR:3
The BC6OTHER target gene BC6OTHER mRNA expression was induced by BC6ENTC , but was not affected by the BC6ENTG BC6OTHER length.	False
The BC6OTHER target gene BC6OTHER mRNA expression was induced by BC6ENTC , but was not affected by the BC6OTHER BC6ENTG length.	False
BC6ENTC had no effect on BC6ENTG activity in PC - 3 cells, whereas the shortest BC6OTHER variant was induced by BC6OTHER in PNT1A cells.	False
BC6ENTC had no effect on BC6OTHER activity in PC - 3 cells, whereas the shortest BC6ENTG variant was induced by BC6OTHER in PNT1A cells.	False
BC6OTHER had no effect on BC6ENTG activity in PC - 3 cells, whereas the shortest BC6OTHER variant was induced by BC6ENTC in PNT1A cells.	False
BC6OTHER had no effect on BC6OTHER activity in PC - 3 cells, whereas the shortest BC6ENTG variant was induced by BC6ENTC in PNT1A cells.	CPR:3
BC6ENTC is a reversible oral BC6ENTG receptor antagonist that has been studied in ACS patients in comparison with BC6OTHER (DISPERSE - 2 study).	CPR:6
BC6OTHER is a reversible oral BC6ENTG receptor antagonist that has been studied in ACS patients in comparison with BC6ENTC (DISPERSE - 2 study).	CPR:6
Inhibition of platelet aggregation by BC6OTHER , a reversible oral BC6ENTG receptor antagonist, compared with BC6ENTC in patients with acute coronary syndromes.	CPR:6
Inhibition of platelet aggregation by BC6ENTC , a reversible oral BC6ENTG receptor antagonist, compared with BC6OTHER in patients with acute coronary syndromes.	CPR:6
When evaluated for their effects on human α3β4 or α4β2 nicotinic BC6ENTC receptors ( BC6ENTG ), several of these compounds were shown to be active as BC6OTHER antagonists.	False
When evaluated for their effects on human α3β4 or α4β2 nicotinic BC6ENTC receptors ( BC6OTHER ), several of these compounds were shown to be active as BC6ENTG antagonists.	False
As a result of this study, BC6ENTC (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit BC6OTHER antagonistic activity for both the BC6ENTG subtypes.	False
As a result of this study, BC6ENTC (1) was found to be a selective cytotoxic agent for colon cancer cells over normal colon cells and to exhibit BC6ENTG antagonistic activity for both the BC6OTHER subtypes.	CPR:6
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6ENTC D2 receptor ( BC6ENTG ) agonist, BC6OTHER , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6OTHER - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6ENTC D2 receptor ( BC6OTHER ) agonist, BC6OTHER , triggered an increase in the expression of BC6ENTG that was temporally preceded by an increase in the levels of BC6OTHER - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6ENTC D2 receptor ( BC6OTHER ) agonist, BC6OTHER , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6ENTG ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6ENTC D2 receptor ( BC6OTHER ) agonist, BC6OTHER , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6OTHER - finger protein 268 ( BC6ENTG ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6ENTG ( BC6OTHER ) agonist, BC6ENTC , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6OTHER - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	CPR:5
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6OTHER ( BC6ENTG ) agonist, BC6ENTC , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6OTHER - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	CPR:5
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6OTHER ( BC6OTHER ) agonist, BC6ENTC , triggered an increase in the expression of BC6ENTG that was temporally preceded by an increase in the levels of BC6OTHER - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	CPR:3
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6OTHER ( BC6OTHER ) agonist, BC6ENTC , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6ENTG ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	CPR:3
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6OTHER ( BC6OTHER ) agonist, BC6ENTC , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6OTHER - finger protein 268 ( BC6ENTG ), a DNA - binding transcription factor encoded by an immediate - early gene.	CPR:3
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6ENTG ( BC6OTHER ) agonist, BC6OTHER , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6ENTC - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6OTHER ( BC6ENTG ) agonist, BC6OTHER , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6ENTC - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6OTHER ( BC6OTHER ) agonist, BC6OTHER , triggered an increase in the expression of BC6ENTG that was temporally preceded by an increase in the levels of BC6ENTC - finger protein 268 ( BC6OTHER ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
We found that treatment of both differentiated dopaminergic - like CHEM - SY5Y cells and rat midbrain slices with the BC6OTHER ( BC6OTHER ) agonist, BC6OTHER , triggered an increase in the expression of BC6OTHER that was temporally preceded by an increase in the levels of BC6ENTC - finger protein 268 ( BC6ENTG ), a DNA - binding transcription factor encoded by an immediate - early gene.	False
Moreover, the BC6ENTG inhibitor BC6ENTC blocked the increase of both BC6OTHER and BC6OTHER expression following BC6OTHER - evoked BC6OTHER release in SH - SY5Y cells.	CPR:4
Moreover, the BC6OTHER inhibitor BC6ENTC blocked the increase of both BC6ENTG and BC6OTHER expression following BC6OTHER - evoked BC6OTHER release in SH - SY5Y cells.	CPR:4
Moreover, the BC6OTHER inhibitor BC6ENTC blocked the increase of both BC6OTHER and BC6ENTG expression following BC6OTHER - evoked BC6OTHER release in SH - SY5Y cells.	CPR:4
Moreover, the BC6ENTG inhibitor BC6OTHER blocked the increase of both BC6OTHER and BC6OTHER expression following BC6ENTC - evoked BC6OTHER release in SH - SY5Y cells.	False
Moreover, the BC6OTHER inhibitor BC6OTHER blocked the increase of both BC6ENTG and BC6OTHER expression following BC6ENTC - evoked BC6OTHER release in SH - SY5Y cells.	False
Moreover, the BC6OTHER inhibitor BC6OTHER blocked the increase of both BC6OTHER and BC6ENTG expression following BC6ENTC - evoked BC6OTHER release in SH - SY5Y cells.	False
Moreover, the BC6ENTG inhibitor BC6OTHER blocked the increase of both BC6OTHER and BC6OTHER expression following BC6OTHER - evoked BC6ENTC release in SH - SY5Y cells.	False
Moreover, the BC6OTHER inhibitor BC6OTHER blocked the increase of both BC6ENTG and BC6OTHER expression following BC6OTHER - evoked BC6ENTC release in SH - SY5Y cells.	False
Moreover, the BC6OTHER inhibitor BC6OTHER blocked the increase of both BC6OTHER and BC6ENTG expression following BC6OTHER - evoked BC6ENTC release in SH - SY5Y cells.	False
 BC6ENTC D2 receptor activation leads to an up - regulation of BC6OTHER via Gβγ - BC6ENTG - dependent induction of BC6OTHER .	False
 BC6ENTC D2 receptor activation leads to an up - regulation of BC6OTHER via Gβγ - BC6OTHER - dependent induction of BC6ENTG .	False
 BC6ENTC D2 receptor activation leads to an up - regulation of BC6ENTG via Gβγ - BC6OTHER - dependent induction of BC6OTHER .	False
Ex vivo samples of human oral mucosa were exposed to BC6ENTC or BC6OTHER , and immunohistochemical staining was performed to evaluate active BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	False
Ex vivo samples of human oral mucosa were exposed to BC6OTHER or BC6ENTC , and immunohistochemical staining was performed to evaluate active BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	False
Ex vivo samples of human oral mucosa were exposed to BC6OTHER or BC6OTHER , and immunohistochemical staining was performed to evaluate active BC6ENTG , BC6ENTC ( BC6OTHER ), and BC6OTHER ( BC6OTHER ).	False
Ex vivo samples of human oral mucosa were exposed to BC6OTHER or BC6OTHER , and immunohistochemical staining was performed to evaluate active BC6ENTG , BC6OTHER ( BC6ENTC ), and BC6OTHER ( BC6OTHER ).	False
Ex vivo samples of human oral mucosa were exposed to BC6OTHER or BC6OTHER , and immunohistochemical staining was performed to evaluate active BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6ENTC ( BC6OTHER ).	False
Ex vivo samples of human oral mucosa were exposed to BC6OTHER or BC6OTHER , and immunohistochemical staining was performed to evaluate active BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER ( BC6ENTC ).	False
BC6ENTC and BC6OTHER treatments significantly increased active BC6ENTG levels in a time - dependent manner.	CPR:3
BC6OTHER and BC6ENTC treatments significantly increased active BC6ENTG levels in a time - dependent manner.	CPR:3
In conclusion, BC6ENTC modulates, both alone and together with BC6OTHER reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at BC6ENTG , BC6OTHER , and BC6OTHER receptors.	False
In conclusion, BC6ENTC modulates, both alone and together with BC6OTHER reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at BC6OTHER , BC6ENTG , and BC6OTHER receptors.	False
In conclusion, BC6ENTC modulates, both alone and together with BC6OTHER reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at BC6OTHER , BC6OTHER , and BC6ENTG receptors.	False
BC6ENTC , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6OTHER BC6ENTG , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6ENTC , which possesses significant affinity for BC6ENTG , BC6OTHER , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6ENTC , which possesses significant affinity for BC6OTHER , BC6ENTG , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6ENTC , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6ENTG BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
In conclusion, BC6OTHER modulates, both alone and together with BC6ENTC reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at BC6ENTG , BC6OTHER , and BC6OTHER receptors.	False
In conclusion, BC6OTHER modulates, both alone and together with BC6ENTC reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at BC6OTHER , BC6ENTG , and BC6OTHER receptors.	False
In conclusion, BC6OTHER modulates, both alone and together with BC6ENTC reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at BC6OTHER , BC6OTHER , and BC6ENTG receptors.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6OTHER BC6ENTG , dose - dependently increased extracellular levels of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6ENTG , BC6OTHER , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6ENTG , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6ENTG BC6OTHER , dose - dependently increased extracellular levels of BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6OTHER BC6ENTG , dose - dependently increased extracellular levels of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6ENTG , BC6OTHER , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6ENTG , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6ENTG BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6OTHER BC6ENTG , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6ENTG , BC6OTHER , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6ENTG , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6ENTG BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6OTHER BC6ENTG , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6ENTG , BC6OTHER , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6ENTG , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6ENTG BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) versus BC6OTHER , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6OTHER BC6ENTG , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6ENTC , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6ENTG , BC6OTHER , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6ENTC , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6ENTG , and BC6OTHER BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6ENTC , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
BC6OTHER , which possesses significant affinity for BC6OTHER , BC6OTHER , and BC6ENTG BC6OTHER , dose - dependently increased extracellular levels of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) versus BC6ENTC , in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely - moving rats.	False
In distinction, the preferential BC6ENTG antagonist, BC6ENTC , and the preferential BC6OTHER antagonist, BC6OTHER , did not increase basal levels of BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:6
In distinction, the preferential BC6OTHER antagonist, BC6ENTC , and the preferential BC6ENTG antagonist, BC6OTHER , did not increase basal levels of BC6OTHER , BC6OTHER , or BC6OTHER .	False
In distinction, the preferential BC6ENTG antagonist, BC6OTHER , and the preferential BC6OTHER antagonist, BC6ENTC , did not increase basal levels of BC6OTHER , BC6OTHER , or BC6OTHER .	False
In distinction, the preferential BC6OTHER antagonist, BC6OTHER , and the preferential BC6ENTG antagonist, BC6ENTC , did not increase basal levels of BC6OTHER , BC6OTHER , or BC6OTHER .	CPR:6
In distinction, the preferential BC6ENTG antagonist, BC6OTHER , and the preferential BC6OTHER antagonist, BC6OTHER , did not increase basal levels of BC6ENTC , BC6OTHER , or BC6OTHER .	False
In distinction, the preferential BC6OTHER antagonist, BC6OTHER , and the preferential BC6ENTG antagonist, BC6OTHER , did not increase basal levels of BC6ENTC , BC6OTHER , or BC6OTHER .	False
In distinction, the preferential BC6ENTG antagonist, BC6OTHER , and the preferential BC6OTHER antagonist, BC6OTHER , did not increase basal levels of BC6OTHER , BC6ENTC , or BC6OTHER .	False
In distinction, the preferential BC6OTHER antagonist, BC6OTHER , and the preferential BC6ENTG antagonist, BC6OTHER , did not increase basal levels of BC6OTHER , BC6ENTC , or BC6OTHER .	False
In distinction, the preferential BC6ENTG antagonist, BC6OTHER , and the preferential BC6OTHER antagonist, BC6OTHER , did not increase basal levels of BC6OTHER , BC6OTHER , or BC6ENTC .	False
In distinction, the preferential BC6OTHER antagonist, BC6OTHER , and the preferential BC6ENTG antagonist, BC6OTHER , did not increase basal levels of BC6OTHER , BC6OTHER , or BC6ENTC .	False
The selective BC6ENTG receptor antagonist, BC6ENTC , slightly attenuated the BC6OTHER - induced increase in BC6OTHER and BC6OTHER levels, while the selective BC6OTHER antagonist, BC6OTHER , was ineffective.	CPR:6
The selective BC6OTHER receptor antagonist, BC6ENTC , slightly attenuated the BC6OTHER - induced increase in BC6OTHER and BC6OTHER levels, while the selective BC6ENTG antagonist, BC6OTHER , was ineffective.	False
The selective BC6ENTG receptor antagonist, BC6OTHER , slightly attenuated the BC6ENTC - induced increase in BC6OTHER and BC6OTHER levels, while the selective BC6OTHER antagonist, BC6OTHER , was ineffective.	False
The selective BC6OTHER receptor antagonist, BC6OTHER , slightly attenuated the BC6ENTC - induced increase in BC6OTHER and BC6OTHER levels, while the selective BC6ENTG antagonist, BC6OTHER , was ineffective.	False
The selective BC6ENTG receptor antagonist, BC6OTHER , slightly attenuated the BC6OTHER - induced increase in BC6ENTC and BC6OTHER levels, while the selective BC6OTHER antagonist, BC6OTHER , was ineffective.	False
The selective BC6OTHER receptor antagonist, BC6OTHER , slightly attenuated the BC6OTHER - induced increase in BC6ENTC and BC6OTHER levels, while the selective BC6ENTG antagonist, BC6OTHER , was ineffective.	False
The selective BC6ENTG receptor antagonist, BC6OTHER , slightly attenuated the BC6OTHER - induced increase in BC6OTHER and BC6ENTC levels, while the selective BC6OTHER antagonist, BC6OTHER , was ineffective.	False
The selective BC6OTHER receptor antagonist, BC6OTHER , slightly attenuated the BC6OTHER - induced increase in BC6OTHER and BC6ENTC levels, while the selective BC6ENTG antagonist, BC6OTHER , was ineffective.	False
The selective BC6ENTG receptor antagonist, BC6OTHER , slightly attenuated the BC6OTHER - induced increase in BC6OTHER and BC6OTHER levels, while the selective BC6OTHER antagonist, BC6ENTC , was ineffective.	False
The selective BC6OTHER receptor antagonist, BC6OTHER , slightly attenuated the BC6OTHER - induced increase in BC6OTHER and BC6OTHER levels, while the selective BC6ENTG antagonist, BC6ENTC , was ineffective.	CPR:6
These data suggest that BC6ENTC facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of BC6OTHER and, to a lesser degree, by stimulation of BC6OTHER receptors, whereas BC6ENTG receptors are not involved.	False
These data suggest that BC6ENTC facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of BC6ENTG and, to a lesser degree, by stimulation of BC6OTHER receptors, whereas BC6OTHER receptors are not involved.	False
These data suggest that BC6ENTC facilitates frontocortical dopaminergic (and adrenergic) transmission primarily by activation of BC6OTHER and, to a lesser degree, by stimulation of BC6ENTG receptors, whereas BC6OTHER receptors are not involved.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6ENTC alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6ENTG and BC6OTHER receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6ENTC alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6OTHER and BC6ENTG receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6ENTC reuptake inhibitors: comparative roles of beta - adrenergic, BC6ENTG and BC6OTHER receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6ENTC reuptake inhibitors: comparative roles of beta - adrenergic, BC6OTHER and BC6ENTG receptors.	False
Modulation of dialysate levels of BC6ENTC , BC6OTHER , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6ENTG and BC6OTHER receptors.	False
Modulation of dialysate levels of BC6ENTC , BC6OTHER , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6OTHER and BC6ENTG receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6ENTC , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6ENTG and BC6OTHER receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6ENTC , and BC6OTHER ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6OTHER and BC6ENTG receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6ENTC ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6ENTG and BC6OTHER receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6ENTC ( BC6OTHER ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6OTHER and BC6ENTG receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6ENTG and BC6OTHER receptors.	False
Modulation of dialysate levels of BC6OTHER , BC6OTHER , and BC6OTHER ( BC6ENTC ) in the frontal cortex of freely - moving rats by BC6OTHER alone and in association with BC6OTHER reuptake inhibitors: comparative roles of beta - adrenergic, BC6OTHER and BC6ENTG receptors.	False
New series of BC6ENTC , BC6OTHER , and BC6OTHER BC6ENTG inhibitors (MMPIs) were designed, synthesized, and evaluated.	CPR:4
Exhibiting unique properties over other MMPIs (e.g., BC6ENTC ), these newly reported compounds are capable of modulating activities of several BC6ENTG in the low nanomolar range, including BC6OTHER (~2 to 50 nM), BC6OTHER (~2 to 50 nM), and BC6OTHER (~4 to 60 nM).	CPR:4
Exhibiting unique properties over other MMPIs (e.g., BC6ENTC ), these newly reported compounds are capable of modulating activities of several BC6OTHER in the low nanomolar range, including BC6ENTG (~2 to 50 nM), BC6OTHER (~2 to 50 nM), and BC6OTHER (~4 to 60 nM).	CPR:4
Exhibiting unique properties over other MMPIs (e.g., BC6ENTC ), these newly reported compounds are capable of modulating activities of several BC6OTHER in the low nanomolar range, including BC6OTHER (~2 to 50 nM), BC6ENTG (~2 to 50 nM), and BC6OTHER (~4 to 60 nM).	CPR:4
Exhibiting unique properties over other MMPIs (e.g., BC6ENTC ), these newly reported compounds are capable of modulating activities of several BC6OTHER in the low nanomolar range, including BC6OTHER (~2 to 50 nM), BC6OTHER (~2 to 50 nM), and BC6ENTG (~4 to 60 nM).	CPR:4
New series of BC6OTHER , BC6ENTC , and BC6OTHER BC6ENTG inhibitors (MMPIs) were designed, synthesized, and evaluated.	CPR:4
Our previous work with the BC6ENTC functionality attached to both BC6OTHER and BC6OTHER frameworks demonstrated that the cis - (3S,4R) - stereochemistry was optimal for all of the BC6ENTG tested.	False
Our previous work with the BC6OTHER functionality attached to both BC6ENTC and BC6OTHER frameworks demonstrated that the cis - (3S,4R) - stereochemistry was optimal for all of the BC6ENTG tested.	False
Our previous work with the BC6OTHER functionality attached to both BC6OTHER and BC6ENTC frameworks demonstrated that the cis - (3S,4R) - stereochemistry was optimal for all of the BC6ENTG tested.	False
New series of BC6OTHER , BC6OTHER , and BC6ENTC BC6ENTG inhibitors (MMPIs) were designed, synthesized, and evaluated.	CPR:4
 BC6ENTG Inhibitors Based on the BC6ENTC Core.	CPR:4
Involvement of BC6ENTG was established as mydriatic responses were inhibited by systemic administration of nonselective BC6OTHER antagonists, BC6ENTC (0.3 - 3 mg / kg) and BC6OTHER (0.03 - 0.3 mg / kg), as well as by the selective BC6OTHER antagonist, BC6OTHER (0.3 mg / kg).	False
Involvement of BC6OTHER was established as mydriatic responses were inhibited by systemic administration of nonselective BC6ENTG antagonists, BC6ENTC (0.3 - 3 mg / kg) and BC6OTHER (0.03 - 0.3 mg / kg), as well as by the selective BC6OTHER antagonist, BC6OTHER (0.3 mg / kg).	CPR:6
Involvement of BC6OTHER was established as mydriatic responses were inhibited by systemic administration of nonselective BC6OTHER antagonists, BC6ENTC (0.3 - 3 mg / kg) and BC6OTHER (0.03 - 0.3 mg / kg), as well as by the selective BC6ENTG antagonist, BC6OTHER (0.3 mg / kg).	False
Involvement of BC6ENTG was established as mydriatic responses were inhibited by systemic administration of nonselective BC6OTHER antagonists, BC6OTHER (0.3 - 3 mg / kg) and BC6ENTC (0.03 - 0.3 mg / kg), as well as by the selective BC6OTHER antagonist, BC6OTHER (0.3 mg / kg).	False
Involvement of BC6OTHER was established as mydriatic responses were inhibited by systemic administration of nonselective BC6ENTG antagonists, BC6OTHER (0.3 - 3 mg / kg) and BC6ENTC (0.03 - 0.3 mg / kg), as well as by the selective BC6OTHER antagonist, BC6OTHER (0.3 mg / kg).	CPR:6
Involvement of BC6OTHER was established as mydriatic responses were inhibited by systemic administration of nonselective BC6OTHER antagonists, BC6OTHER (0.3 - 3 mg / kg) and BC6ENTC (0.03 - 0.3 mg / kg), as well as by the selective BC6ENTG antagonist, BC6OTHER (0.3 mg / kg).	False
Involvement of BC6ENTG was established as mydriatic responses were inhibited by systemic administration of nonselective BC6OTHER antagonists, BC6OTHER (0.3 - 3 mg / kg) and BC6OTHER (0.03 - 0.3 mg / kg), as well as by the selective BC6OTHER antagonist, BC6ENTC (0.3 mg / kg).	False
Involvement of BC6OTHER was established as mydriatic responses were inhibited by systemic administration of nonselective BC6ENTG antagonists, BC6OTHER (0.3 - 3 mg / kg) and BC6OTHER (0.03 - 0.3 mg / kg), as well as by the selective BC6OTHER antagonist, BC6ENTC (0.3 mg / kg).	False
Involvement of BC6OTHER was established as mydriatic responses were inhibited by systemic administration of nonselective BC6OTHER antagonists, BC6OTHER (0.3 - 3 mg / kg) and BC6OTHER (0.03 - 0.3 mg / kg), as well as by the selective BC6ENTG antagonist, BC6ENTC (0.3 mg / kg).	CPR:6
The BC6ENTG antagonist, BC6ENTC (0.5 mg / kg), was without antagonistic effects.	CPR:6
BC6OTHER selective antagonists, BC6ENTC ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6ENTC ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6ENTC ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6ENTG subtypes involved.	False
BC6ENTG selective antagonists, BC6ENTC ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	CPR:6
BC6OTHER selective antagonists, BC6OTHER ( BC6ENTC ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6ENTC ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6ENTC ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6ENTG subtypes involved.	False
BC6ENTG selective antagonists, BC6OTHER ( BC6ENTC ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	CPR:6
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6ENTC (0.1 - 1 mg / kg), the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6ENTC (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6ENTC (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6ENTG subtypes involved.	False
BC6ENTG selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6ENTC (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	CPR:6
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6ENTG selective antagonist, BC6ENTC ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	CPR:6
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6ENTC ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6ENTC ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6ENTG subtypes involved.	False
BC6ENTG selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6ENTC ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6ENTG selective antagonist, BC6OTHER ( BC6ENTC ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	CPR:6
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6ENTC ; 0.3 - 1 mg / kg), as well as the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6ENTC ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6ENTG subtypes involved.	False
BC6ENTG selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6ENTC ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6ENTC ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6ENTG selective antagonist, BC6ENTC ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	CPR:6
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6ENTC ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6ENTG subtypes involved.	False
BC6ENTG selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6ENTC ( BC6OTHER ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6ENTG selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6ENTC ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6ENTG selective antagonist, BC6OTHER ( BC6ENTC ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	CPR:6
BC6OTHER selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6ENTC ; 1 mg / kg), were used to delineate the BC6ENTG subtypes involved.	False
BC6ENTG selective antagonists, BC6OTHER ( BC6OTHER ; 0.1 - 1 mg / kg) and BC6OTHER (0.1 - 1 mg / kg), the BC6OTHER selective antagonist, BC6OTHER ( BC6OTHER ; 0.3 - 1 mg / kg), as well as the BC6OTHER selective antagonist, BC6OTHER ( BC6ENTC ; 1 mg / kg), were used to delineate the BC6OTHER subtypes involved.	False
BC6ENTG mutants were hypersensitive to BC6ENTC ( BC6OTHER ), BC6OTHER , and UV - B light but only mildly sensitive to gamma - radiation.	False
BC6ENTG mutants were hypersensitive to BC6OTHER ( BC6ENTC ), BC6OTHER , and UV - B light but only mildly sensitive to gamma - radiation.	False
BC6ENTG mutants were hypersensitive to BC6OTHER ( BC6OTHER ), BC6ENTC , and UV - B light but only mildly sensitive to gamma - radiation.	False
G2 arrest also was observed in wild - type plants in response to BC6ENTC but was defective in BC6ENTG mutants, resulting in compaction of nuclei and subsequent cell death.	False
Analysis of the results of this paper reveals that normal plasma components, BC6ENTC and BC6ENTG , exert major regulatory roles on the ability of BC6OTHER to be activated by two - chain rec - BC6OTHER , in in vitro systems.	False
Analysis of the results of this paper reveals that normal plasma components, BC6ENTC and BC6OTHER , exert major regulatory roles on the ability of BC6ENTG to be activated by two - chain rec - BC6OTHER , in in vitro systems.	False
Analysis of the results of this paper reveals that normal plasma components, BC6ENTC and BC6OTHER , exert major regulatory roles on the ability of BC6OTHER to be activated by two - chain rec - BC6ENTG , in in vitro systems.	False
The presence of BC6ENTC inhibits the stimulation of BC6ENTG activation that would normally occur in the presence of BC6OTHER , a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of BC6OTHER .	CPR:4
The presence of BC6ENTC inhibits the stimulation of BC6OTHER activation that would normally occur in the presence of BC6ENTG , a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of BC6OTHER .	False
The presence of BC6ENTC inhibits the stimulation of BC6OTHER activation that would normally occur in the presence of BC6OTHER , a result of possible importance to the observation that some degree of systemic fibrinogenolysis accompanies therapeutic use of BC6ENTG .	False
The activation of BC6OTHER [ BC6OTHER ) by human recombinant (rec) two - chain BC6OTHER ( BC6ENTG ) is inhibited by BC6ENTC , at physiological concentrations, and stimulated by BC6OTHER ( BC6OTHER ), as well as fibrin(ogen).	CPR:4
The activation of BC6ENTG [ BC6OTHER ) by human recombinant (rec) two - chain BC6OTHER ( BC6OTHER ) is inhibited by BC6ENTC , at physiological concentrations, and stimulated by BC6OTHER ( BC6OTHER ), as well as fibrin(ogen).	CPR:4
The activation of BC6OTHER [ BC6ENTG ) by human recombinant (rec) two - chain BC6OTHER ( BC6OTHER ) is inhibited by BC6ENTC , at physiological concentrations, and stimulated by BC6OTHER ( BC6OTHER ), as well as fibrin(ogen).	CPR:4
The activation of BC6OTHER [ BC6OTHER ) by human recombinant (rec) two - chain BC6ENTG ( BC6OTHER ) is inhibited by BC6ENTC , at physiological concentrations, and stimulated by BC6OTHER ( BC6OTHER ), as well as fibrin(ogen).	CPR:4
The activation of BC6OTHER [ BC6OTHER ) by human recombinant (rec) two - chain BC6OTHER ( BC6ENTG ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6ENTC ( BC6OTHER ), as well as fibrin(ogen).	CPR:3
The activation of BC6ENTG [ BC6OTHER ) by human recombinant (rec) two - chain BC6OTHER ( BC6OTHER ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6ENTC ( BC6OTHER ), as well as fibrin(ogen).	CPR:3
The activation of BC6OTHER [ BC6ENTG ) by human recombinant (rec) two - chain BC6OTHER ( BC6OTHER ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6ENTC ( BC6OTHER ), as well as fibrin(ogen).	CPR:3
The activation of BC6OTHER [ BC6OTHER ) by human recombinant (rec) two - chain BC6ENTG ( BC6OTHER ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6ENTC ( BC6OTHER ), as well as fibrin(ogen).	CPR:3
The activation of BC6OTHER [ BC6OTHER ) by human recombinant (rec) two - chain BC6OTHER ( BC6ENTG ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6OTHER ( BC6ENTC ), as well as fibrin(ogen).	CPR:3
The activation of BC6ENTG [ BC6OTHER ) by human recombinant (rec) two - chain BC6OTHER ( BC6OTHER ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6OTHER ( BC6ENTC ), as well as fibrin(ogen).	CPR:3
The activation of BC6OTHER [ BC6ENTG ) by human recombinant (rec) two - chain BC6OTHER ( BC6OTHER ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6OTHER ( BC6ENTC ), as well as fibrin(ogen).	CPR:3
The activation of BC6OTHER [ BC6OTHER ) by human recombinant (rec) two - chain BC6ENTG ( BC6OTHER ) is inhibited by BC6OTHER , at physiological concentrations, and stimulated by BC6OTHER ( BC6ENTC ), as well as fibrin(ogen).	CPR:3
BC6ENTC functions as a result of its binding to BC6ENTG , with a Ki of approximately 9.0 mM, thereby rendering BC6OTHER a less effective substrate for two - chain rec - BC6OTHER .	False
BC6ENTC functions as a result of its binding to BC6OTHER , with a Ki of approximately 9.0 mM, thereby rendering BC6ENTG a less effective substrate for two - chain rec - BC6OTHER .	False
BC6ENTC functions as a result of its binding to BC6OTHER , with a Ki of approximately 9.0 mM, thereby rendering BC6OTHER a less effective substrate for two - chain rec - BC6ENTG .	False
BC6ENTG appears to exert its stimulatory properties mainly through effects on the enzyme, two - chain rec - BC6OTHER , with a Ka of approximately 3.7 microM in activation systems containing physiological levels of BC6ENTC .	False
BC6OTHER appears to exert its stimulatory properties mainly through effects on the enzyme, two - chain rec - BC6ENTG , with a Ka of approximately 3.7 microM in activation systems containing physiological levels of BC6ENTC .	False
BC6ENTC desaturase - 1 ( BC6ENTG ) plays a pivotal role in an increase of BC6OTHER by an excess of dietary BC6OTHER intake.	False
BC6ENTG ( BC6OTHER ) plays a pivotal role in an increase of BC6OTHER by an excess of dietary BC6ENTC intake.	False
BC6OTHER desaturase - 1 ( BC6ENTG ) plays a pivotal role in an increase of BC6OTHER by an excess of dietary BC6ENTC intake.	False
Dietary BC6ENTC increase BC6ENTG gene expression in liver by BC6OTHER response element binding protein (SREBP) - 1c - dependent and BC6OTHER - independent pathways.	CPR:3
Dietary BC6ENTC increase BC6OTHER gene expression in liver by BC6ENTG - dependent and BC6OTHER - independent pathways.	False
Dietary BC6ENTC increase BC6OTHER gene expression in liver by BC6OTHER response element binding protein (SREBP) - 1c - dependent and BC6ENTG - independent pathways.	False
Dietary BC6OTHER increase BC6ENTG gene expression in liver by BC6ENTC response element binding protein (SREBP) - 1c - dependent and BC6OTHER - independent pathways.	False
Dietary BC6OTHER increase BC6OTHER gene expression in liver by BC6ENTC response element binding protein (SREBP) - 1c - dependent and BC6ENTG - independent pathways.	False
Previous report demonstrated that BC6ENTC (TH) negatively regulates BC6ENTG before BC6OTHER was revealed.	CPR:4
Previous report demonstrated that BC6ENTC (TH) negatively regulates BC6OTHER before BC6ENTG was revealed.	False
BC6ENTG ( BC6OTHER ) plays a pivotal role in an increase of BC6ENTC by an excess of dietary BC6OTHER intake.	False
BC6OTHER desaturase - 1 ( BC6ENTG ) plays a pivotal role in an increase of BC6ENTC by an excess of dietary BC6OTHER intake.	False
 BC6ENTG ( BC6OTHER ) gene expression is negatively regulated by BC6OTHER without direct binding of BC6ENTC receptor to the gene promoter.	False
Human BC6OTHER desaturase 1 ( BC6ENTG ) gene expression is negatively regulated by BC6OTHER without direct binding of BC6ENTC receptor to the gene promoter.	False
Human BC6ENTC desaturase 1 ( BC6OTHER ) gene expression is negatively regulated by BC6OTHER without direct binding of BC6ENTG to the gene promoter.	False
Human BC6ENTC desaturase 1 ( BC6ENTG ) gene expression is negatively regulated by BC6OTHER without direct binding of BC6OTHER receptor to the gene promoter.	False
 BC6ENTG ( BC6OTHER ) gene expression is negatively regulated by BC6ENTC without direct binding of BC6OTHER receptor to the gene promoter.	CPR:4
Human BC6OTHER desaturase 1 ( BC6OTHER ) gene expression is negatively regulated by BC6ENTC without direct binding of BC6ENTG to the gene promoter.	False
Human BC6OTHER desaturase 1 ( BC6ENTG ) gene expression is negatively regulated by BC6ENTC without direct binding of BC6OTHER receptor to the gene promoter.	CPR:4
Cell proliferation analysis indicated that BC6ENTC or BC6OTHER reduced cell viability in a dose - dependent manner; however, BC6ENTG prevented this inhibition, which further demonstrated BC6OTHER triggered anti - apoptotic machinery through activating BC6OTHER and BC6OTHER expression.	False
Cell proliferation analysis indicated that BC6ENTC or BC6OTHER reduced cell viability in a dose - dependent manner; however, BC6OTHER prevented this inhibition, which further demonstrated BC6ENTG triggered anti - apoptotic machinery through activating BC6OTHER and BC6OTHER expression.	False
Cell proliferation analysis indicated that BC6ENTC or BC6OTHER reduced cell viability in a dose - dependent manner; however, BC6OTHER prevented this inhibition, which further demonstrated BC6OTHER triggered anti - apoptotic machinery through activating BC6ENTG and BC6OTHER expression.	False
Cell proliferation analysis indicated that BC6ENTC or BC6OTHER reduced cell viability in a dose - dependent manner; however, BC6OTHER prevented this inhibition, which further demonstrated BC6OTHER triggered anti - apoptotic machinery through activating BC6OTHER and BC6ENTG expression.	False
Cell proliferation analysis indicated that BC6OTHER or BC6ENTC reduced cell viability in a dose - dependent manner; however, BC6ENTG prevented this inhibition, which further demonstrated BC6OTHER triggered anti - apoptotic machinery through activating BC6OTHER and BC6OTHER expression.	False
Cell proliferation analysis indicated that BC6OTHER or BC6ENTC reduced cell viability in a dose - dependent manner; however, BC6OTHER prevented this inhibition, which further demonstrated BC6ENTG triggered anti - apoptotic machinery through activating BC6OTHER and BC6OTHER expression.	False
Cell proliferation analysis indicated that BC6OTHER or BC6ENTC reduced cell viability in a dose - dependent manner; however, BC6OTHER prevented this inhibition, which further demonstrated BC6OTHER triggered anti - apoptotic machinery through activating BC6ENTG and BC6OTHER expression.	False
Cell proliferation analysis indicated that BC6OTHER or BC6ENTC reduced cell viability in a dose - dependent manner; however, BC6OTHER prevented this inhibition, which further demonstrated BC6OTHER triggered anti - apoptotic machinery through activating BC6OTHER and BC6ENTG expression.	False
These PCSCs possessed BC6ENTC receptors and BC6ENTG , but not BC6OTHER receptor as determined by RT - PCR and Western blot, respectively.	False
These PCSCs possessed BC6ENTC receptors and BC6OTHER , but not BC6ENTG as determined by RT - PCR and Western blot, respectively.	False
These PCSCs possessed BC6ENTG and BC6OTHER , but not BC6ENTC receptor as determined by RT - PCR and Western blot, respectively.	False
These PCSCs possessed BC6OTHER receptors and BC6ENTG , but not BC6ENTC receptor as determined by RT - PCR and Western blot, respectively.	False
RESULTS: BC6ENTC tended to lower mean AP, it slightly increased heart rate (HR) (p<0.05), and markedly increased circulating BC6ENTG levels (p<0.01).	CPR:3
 BC6ENTG antagonism by BC6ENTC lowers heart rate variability and baroreflex gain.	CPR:6
CONCLUSIONS: BC6ENTG antagonism by BC6ENTC lowers heart rate variability and baroreflex gain.	CPR:6
We speculate that these findings are due to the marked increase in circulating BC6ENTC ( BC6ENTG ).	False
We speculate that these findings are due to the marked increase in circulating BC6ENTG ( BC6ENTC ).	False
Further studies are needed to clarify whether BC6ENTC type 1 ( BC6ENTG ) blockers with potential actions inside the blood - brain barrier (BBB) may have different effects on HRV and BRG.	False
INTRODUCTION: Blockade of the BC6ENTG - BC6ENTC system (RAS) by BC6OTHER inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	False
INTRODUCTION: Blockade of the BC6OTHER - BC6ENTC system (RAS) by BC6ENTG inhibitors has been demonstrated to reduce total mortality in cardiovascular diseases.	False
We sought to assess the effects of the BC6ENTG blocker BC6ENTC on HRV and BRG.	CPR:4
BC6ENTC - and BC6OTHER - dependent secretion of BC6OTHER was absent in osteoclasts prepared from BC6ENTG - / - knockout mice.	False
BC6OTHER - and BC6ENTC - dependent secretion of BC6OTHER was absent in osteoclasts prepared from BC6ENTG - / - knockout mice.	False
BC6OTHER - and BC6OTHER - dependent secretion of BC6ENTC was absent in osteoclasts prepared from BC6ENTG - / - knockout mice.	False
Osteoclasts express BC6ENTG , a class III metabotropic BC6ENTC receptor.	False
Upon differentiation, osteoclasts express vesicular BC6ENTC transporter 1 ( BC6ENTG ), which is essential for vesicular storage and subsequent exocytosis of BC6OTHER in neurons.	False
Upon differentiation, osteoclasts express BC6ENTG ( BC6OTHER ), which is essential for vesicular storage and subsequent exocytosis of BC6ENTC in neurons.	CPR:9
Upon differentiation, osteoclasts express vesicular BC6OTHER transporter 1 ( BC6ENTG ), which is essential for vesicular storage and subsequent exocytosis of BC6ENTC in neurons.	CPR:9
BC6ENTG is localized in transcytotic vesicles and accumulates BC6ENTC .	CPR:9
The specific ligand for BC6ENTG ( BC6OTHER ), BC6OTHER , significantly suppressed PS liposome - induced BC6ENTC production.	False
The specific ligand for BC6OTHER ( BC6ENTG ), BC6OTHER , significantly suppressed PS liposome - induced BC6ENTC production.	False
The specific ligand for BC6OTHER ( BC6OTHER ), BC6ENTG , significantly suppressed PS liposome - induced BC6ENTC production.	False
BC6OTHER BC6OTHER and membrane - bound BC6ENTC synthase - 1 ( BC6ENTG ) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	False
BC6ENTG BC6OTHER and membrane - bound BC6ENTC synthase - 1 ( BC6OTHER ) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	False
BC6OTHER BC6ENTG and membrane - bound BC6ENTC synthase - 1 ( BC6OTHER ) were induced by treatment with lipopolysaccharide (LPS) but not with PS liposomes.	False
Involvement of BC6ENTG and up - regulated BC6OTHER in BC6OTHER liposome - induced BC6ENTC production by microglia.	CPR:9
Involvement of BC6OTHER and up - regulated BC6ENTG in BC6OTHER liposome - induced BC6ENTC production by microglia.	CPR:9
Involvement of BC6ENTG and up - regulated BC6ENTC synthases in BC6OTHER liposome - induced BC6OTHER production by microglia.	False
Involvement of BC6ENTG and up - regulated BC6OTHER in BC6ENTC liposome - induced BC6OTHER production by microglia.	False
Involvement of BC6OTHER and up - regulated BC6ENTG in BC6ENTC liposome - induced BC6OTHER production by microglia.	False
Furthermore, PS liposome - induced BC6ENTC production was significantly suppressed by BC6OTHER , a preferential BC6ENTG inhibitor, but not by BC6OTHER , a selective BC6OTHER inhibitor.	False
Furthermore, PS liposome - induced BC6ENTC production was significantly suppressed by BC6OTHER , a preferential BC6OTHER inhibitor, but not by BC6OTHER , a selective BC6ENTG inhibitor.	False
Furthermore, PS liposome - induced BC6OTHER production was significantly suppressed by BC6ENTC , a preferential BC6ENTG inhibitor, but not by BC6OTHER , a selective BC6OTHER inhibitor.	CPR:4
Furthermore, PS liposome - induced BC6OTHER production was significantly suppressed by BC6ENTC , a preferential BC6OTHER inhibitor, but not by BC6OTHER , a selective BC6ENTG inhibitor.	False
Furthermore, PS liposome - induced BC6OTHER production was significantly suppressed by BC6OTHER , a preferential BC6ENTG inhibitor, but not by BC6ENTC , a selective BC6OTHER inhibitor.	False
Furthermore, PS liposome - induced BC6OTHER production was significantly suppressed by BC6OTHER , a preferential BC6OTHER inhibitor, but not by BC6ENTC , a selective BC6ENTG inhibitor.	CPR:4
These observations strongly suggest that the up - regulation of terminal BC6ENTG that are preferentially coupled with BC6OTHER , especially BC6OTHER , plays the pivotal role in PS liposome - induced BC6ENTC production by microglia.	CPR:9
These observations strongly suggest that the up - regulation of terminal BC6OTHER that are preferentially coupled with BC6ENTG , especially BC6OTHER , plays the pivotal role in PS liposome - induced BC6ENTC production by microglia.	CPR:9
These observations strongly suggest that the up - regulation of terminal BC6OTHER that are preferentially coupled with BC6OTHER , especially BC6ENTG , plays the pivotal role in PS liposome - induced BC6ENTC production by microglia.	CPR:9
Although BC6ENTG plays an essential role in PS liposome - induced BC6ENTC production, other BC6OTHER , possibly BC6OTHER , could also promote BC6OTHER production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6ENTC production, other BC6ENTG , possibly BC6OTHER , could also promote BC6OTHER production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6ENTC production, other BC6OTHER , possibly BC6ENTG , could also promote BC6OTHER production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6ENTC production, other BC6OTHER , possibly BC6OTHER , could also promote BC6OTHER production by transducing intracellular signals including BC6ENTG / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6ENTC production, other BC6OTHER , possibly BC6OTHER , could also promote BC6OTHER production by transducing intracellular signals including BC6OTHER / BC6ENTG BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6ENTC production, other BC6OTHER , possibly BC6OTHER , could also promote BC6OTHER production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6ENTG after PS liposomes treatment.	False
Although BC6ENTG plays an essential role in PS liposome - induced BC6OTHER production, other BC6OTHER , possibly BC6OTHER , could also promote BC6ENTC production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6OTHER production, other BC6ENTG , possibly BC6OTHER , could also promote BC6ENTC production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6OTHER production, other BC6OTHER , possibly BC6ENTG , could also promote BC6ENTC production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6OTHER production, other BC6OTHER , possibly BC6OTHER , could also promote BC6ENTC production by transducing intracellular signals including BC6ENTG / BC6OTHER BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6OTHER production, other BC6OTHER , possibly BC6OTHER , could also promote BC6ENTC production by transducing intracellular signals including BC6OTHER / BC6ENTG BC6OTHER after PS liposomes treatment.	False
Although BC6OTHER plays an essential role in PS liposome - induced BC6OTHER production, other BC6OTHER , possibly BC6OTHER , could also promote BC6ENTC production by transducing intracellular signals including BC6OTHER / BC6OTHER BC6ENTG after PS liposomes treatment.	False
BC6OTHER at 50 mM was demonstrated to elevate both the mRNA and protein expression of BC6ENTG and BC6ENTC oxygenase - 1 ( BC6OTHER ), but also caused a reduction in BC6OTHER protein expression.	False
BC6OTHER at 50 mM was demonstrated to elevate both the mRNA and protein expression of BC6OTHER and BC6ENTC oxygenase - 1 ( BC6ENTG ), but also caused a reduction in BC6OTHER protein expression.	False
BC6OTHER at 50 mM was demonstrated to elevate both the mRNA and protein expression of BC6OTHER and BC6ENTC oxygenase - 1 ( BC6OTHER ), but also caused a reduction in BC6ENTG protein expression.	False
In addition, BC6ENTC attenuated BC6ENTG protein stability via the proteasomal proteolytic pathway, as well as inducing BC6OTHER nuclear accumulation.	CPR:4
In addition, BC6ENTC attenuated BC6OTHER protein stability via the proteasomal proteolytic pathway, as well as inducing BC6ENTG nuclear accumulation.	CPR:3
Altogether, our results suggest that a high dose of BC6ENTC may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0) / G(1) phase, and that this occurs, at least in part, by a reduction in BC6ENTG phosphorylation together with modulation of BC6OTHER , BC6OTHER and BC6OTHER expression, and nuclear BC6OTHER accumulation.	CPR:4
Altogether, our results suggest that a high dose of BC6ENTC may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0) / G(1) phase, and that this occurs, at least in part, by a reduction in BC6OTHER phosphorylation together with modulation of BC6ENTG , BC6OTHER and BC6OTHER expression, and nuclear BC6OTHER accumulation.	False
Altogether, our results suggest that a high dose of BC6ENTC may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0) / G(1) phase, and that this occurs, at least in part, by a reduction in BC6OTHER phosphorylation together with modulation of BC6OTHER , BC6ENTG and BC6OTHER expression, and nuclear BC6OTHER accumulation.	False
Altogether, our results suggest that a high dose of BC6ENTC may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0) / G(1) phase, and that this occurs, at least in part, by a reduction in BC6OTHER phosphorylation together with modulation of BC6OTHER , BC6OTHER and BC6ENTG expression, and nuclear BC6OTHER accumulation.	False
Altogether, our results suggest that a high dose of BC6ENTC may inhibit cell proliferation through apoptosis and disturb cell cycle progression with a halt at G(0) / G(1) phase, and that this occurs, at least in part, by a reduction in BC6OTHER phosphorylation together with modulation of BC6OTHER , BC6OTHER and BC6OTHER expression, and nuclear BC6ENTG accumulation.	CPR:3
Examination of phosphorylation in BC6ENTG , we found an inhibitory effect by BC6ENTC at 20 and 50 mM.	CPR:4
BC6ENTC at 50 mM was demonstrated to elevate both the mRNA and protein expression of BC6ENTG and BC6OTHER ( BC6OTHER ), but also caused a reduction in BC6OTHER protein expression.	CPR:3
BC6ENTC at 50 mM was demonstrated to elevate both the mRNA and protein expression of BC6OTHER and BC6ENTG ( BC6OTHER ), but also caused a reduction in BC6OTHER protein expression.	CPR:3
BC6ENTC at 50 mM was demonstrated to elevate both the mRNA and protein expression of BC6OTHER and BC6OTHER ( BC6ENTG ), but also caused a reduction in BC6OTHER protein expression.	False
BC6ENTC at 50 mM was demonstrated to elevate both the mRNA and protein expression of BC6OTHER and BC6OTHER ( BC6OTHER ), but also caused a reduction in BC6ENTG protein expression.	CPR:4
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6ENTC ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6ENTG , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6ENTC ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6ENTG antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6ENTC ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6ENTG formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6ENTG - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6ENTC ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTG systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6ENTC ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6ENTC ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6ENTG ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6ENTC ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6ENTG ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6ENTC and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6ENTG , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6ENTC and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6ENTG antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6ENTC and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6ENTG formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6ENTG - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6ENTC and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTG systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6ENTC and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6ENTC and intracerebroventricularly with the BC6ENTG ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6ENTC and intracerebroventricularly with the BC6OTHER ( BC6ENTG ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6ENTC ; (v) is via classical BC6ENTG , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6ENTC ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6ENTG antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6ENTC ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6ENTG formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6ENTG - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6ENTC ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTG systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6ENTC ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6ENTG ( BC6OTHER ) antagonist BC6ENTC ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	CPR:6
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6ENTG ) antagonist BC6ENTC ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	CPR:6
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6ENTG , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6ENTC ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	CPR:6
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6ENTG antagonist BC6ENTC ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	CPR:6
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6ENTC ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6ENTG formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6ENTG - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6ENTC ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTG systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6ENTC ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6ENTG ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6ENTC ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6ENTG ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6ENTC ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
Although there is a high probability that the action of BC6ENTC to cause cardiac fibrosis in this experimental model is an effect via non - epithelial BC6ENTG , the locus of BC6OTHER action remains to be established, as do the molecular mechanisms linking BC6OTHER occupancy by BC6OTHER and collagen deposition.	False
Although there is a high probability that the action of BC6ENTC to cause cardiac fibrosis in this experimental model is an effect via non - epithelial BC6OTHER , the locus of BC6OTHER action remains to be established, as do the molecular mechanisms linking BC6ENTG occupancy by BC6OTHER and collagen deposition.	False
Although there is a high probability that the action of BC6OTHER to cause cardiac fibrosis in this experimental model is an effect via non - epithelial BC6ENTG , the locus of BC6ENTC action remains to be established, as do the molecular mechanisms linking BC6OTHER occupancy by BC6OTHER and collagen deposition.	False
Although there is a high probability that the action of BC6OTHER to cause cardiac fibrosis in this experimental model is an effect via non - epithelial BC6OTHER , the locus of BC6ENTC action remains to be established, as do the molecular mechanisms linking BC6ENTG occupancy by BC6OTHER and collagen deposition.	False
Although there is a high probability that the action of BC6OTHER to cause cardiac fibrosis in this experimental model is an effect via non - epithelial BC6ENTG , the locus of BC6OTHER action remains to be established, as do the molecular mechanisms linking BC6OTHER occupancy by BC6ENTC and collagen deposition.	False
Although there is a high probability that the action of BC6OTHER to cause cardiac fibrosis in this experimental model is an effect via non - epithelial BC6OTHER , the locus of BC6OTHER action remains to be established, as do the molecular mechanisms linking BC6ENTG occupancy by BC6ENTC and collagen deposition.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTC systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6ENTG , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTC systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6ENTG antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTC systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6ENTG formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6ENTG - BC6ENTC systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTC systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6ENTG ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTC systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6ENTG ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6ENTC or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6ENTG , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6ENTC or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6ENTG antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6ENTC or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6ENTG formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6ENTG - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6ENTC or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTG systems, as fibrosis is largely unaffected by concurrent administration of BC6ENTC or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6ENTC or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6ENTG ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6ENTC or BC6OTHER ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6ENTG ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6ENTC ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6ENTG , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6ENTC ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6ENTG antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6ENTC ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6ENTG formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6ENTG - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6ENTC ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6ENTG systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6ENTC ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6ENTC ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6ENTG ( BC6OTHER ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid - induced hypokalemia; (ii) appears not to involve the plasma or tissue BC6OTHER - BC6OTHER systems, as fibrosis is largely unaffected by concurrent administration of BC6OTHER or BC6ENTC ; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of BC6OTHER ; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with BC6OTHER and intracerebroventricularly with the BC6OTHER ( BC6ENTG ) antagonist BC6OTHER ; (v) is via classical BC6OTHER , in that it is blocked by concurrent administration of the BC6OTHER antagonist BC6OTHER ; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on BC6OTHER formation by cardiac fibroblasts are conflicting.	False
We examined whether the BC6ENTC receptor gene ( BC6ENTG ) single BC6OTHER polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict / constraint) and economic stress on post - traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	False
We examined whether the BC6ENTG gene ( BC6OTHER ) single BC6ENTC polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict / constraint) and economic stress on post - traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	False
We examined whether the BC6OTHER gene ( BC6ENTG ) single BC6ENTC polymorphism (SNP) rs53576 genotype buffers the combined impact of negative social environments (e.g., interpersonal conflict / constraint) and economic stress on post - traumatic stress (PTS) symptoms and impaired daily functioning following collective stress (September 11th terrorist attacks).	False
Environmental stress, BC6ENTC receptor gene ( BC6ENTG ) polymorphism, and mental health following collective stress.	False
The BC6ENTG / BC6OTHER T2D locus is associated with decreased BC6OTHER secretion in response to oral BC6ENTC stimulation in humans.	False
The BC6OTHER / BC6ENTG T2D locus is associated with decreased BC6OTHER secretion in response to oral BC6ENTC stimulation in humans.	False
The BC6OTHER / BC6OTHER T2D locus is associated with decreased BC6ENTG secretion in response to oral BC6ENTC stimulation in humans.	False
We find that BC6ENTC stimulated BC6ENTG secretion (GSIS) is decreased in BC6OTHER KO mice due to impaired replenishment of the releasable pool of granules and that the BC6OTHER gene is haploinsufficient.	False
We find that BC6ENTC stimulated BC6OTHER secretion (GSIS) is decreased in BC6ENTG KO mice due to impaired replenishment of the releasable pool of granules and that the BC6OTHER gene is haploinsufficient.	False
We find that BC6ENTC stimulated BC6OTHER secretion (GSIS) is decreased in BC6OTHER KO mice due to impaired replenishment of the releasable pool of granules and that the BC6ENTG gene is haploinsufficient.	False
However, chronic treatment of cLH rats with BC6ENTC did not reverse learned helplessness, indicating that the enhanced BC6ENTG function is not the only player in the behavioral phenotype of this genetic model of depression.	CPR:3
We also examined BC6ENTG receptor signaling by in vivo measurement of BC6ENTC - stimulated BC6OTHER hydrolysis.	False
We also examined BC6ENTG receptor signaling by in vivo measurement of BC6OTHER - stimulated BC6ENTC hydrolysis.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6ENTG ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6ENTG and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6ENTG after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6OTHER (PNS) on mRNA expressions of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC specific protease - 1 ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6ENTG after cerebral ischemia - reperfusion in rats.	False
OBJECTIVE: To investigate the effects of Panax notoginseng BC6ENTC (PNS) on mRNA expressions of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER and BC6OTHER after cerebral ischemia - reperfusion in rats.	False
[Effects of Panax notoginseng BC6OTHER on mRNA expressions of BC6ENTG , its correlative factors and BC6ENTC specific protease after cerebral ischemia - reperfusion in rats].	False
[Effects of Panax notoginseng BC6ENTC on mRNA expressions of BC6OTHER , its correlative factors and BC6ENTG after cerebral ischemia - reperfusion in rats].	False
[Effects of Panax notoginseng BC6ENTC on mRNA expressions of BC6ENTG , its correlative factors and BC6OTHER after cerebral ischemia - reperfusion in rats].	False
These findings suggest that oral consumption of BC6ENTC enhances the efficacy of BC6ENTG .	CPR:3
Electroencephalographic recordings during substance consumption showed reduced alpha activity and BC6ENTG latencies in the BC6ENTC group compared to the control group.	CPR:4
Autoradiography of BC6ENTC gels of cross - linked BC6ENTG showed only three protein bands specifically binding salmon calcitonin.	False
High expression levels of BC6ENTG ( BC6OTHER ) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with BC6ENTC - containing chemotherapy.	False
High expression levels of BC6OTHER ( BC6ENTG ) in cancers have been positively associated with the DNA repair capacity and a poor prognosis in NSCLC patients treated with BC6ENTC - containing chemotherapy.	False
In this current study, BC6ENTC was found to increase phosphorylation of BC6ENTG (MAPK) kinase 3 / 6 ( BC6OTHER ) - BC6OTHER BC6OTHER as well as protein and mRNA levels of BC6OTHER in H1650 and H1703 cells.	CPR:3
In this current study, BC6ENTC was found to increase phosphorylation of BC6OTHER (MAPK) kinase 3 / 6 ( BC6ENTG ) - BC6OTHER BC6OTHER as well as protein and mRNA levels of BC6OTHER in H1650 and H1703 cells.	False
In this current study, BC6ENTC was found to increase phosphorylation of BC6OTHER (MAPK) kinase 3 / 6 ( BC6OTHER ) - BC6ENTG BC6OTHER as well as protein and mRNA levels of BC6OTHER in H1650 and H1703 cells.	CPR:3
In this current study, BC6ENTC was found to increase phosphorylation of BC6OTHER (MAPK) kinase 3 / 6 ( BC6OTHER ) - BC6OTHER BC6ENTG as well as protein and mRNA levels of BC6OTHER in H1650 and H1703 cells.	CPR:3
In this current study, BC6ENTC was found to increase phosphorylation of BC6OTHER (MAPK) kinase 3 / 6 ( BC6OTHER ) - BC6OTHER BC6OTHER as well as protein and mRNA levels of BC6ENTG in H1650 and H1703 cells.	CPR:3
Moreover, BC6ENTC - induced BC6ENTG protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6OTHER BC6OTHER inhibitor BC6OTHER or BC6OTHER knockdown with specific small interfering RNA (siRNA).	CPR:3
Moreover, BC6ENTC - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6ENTG activity by either a BC6OTHER BC6OTHER inhibitor BC6OTHER or BC6OTHER knockdown with specific small interfering RNA (siRNA).	False
Moreover, BC6ENTC - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6ENTG BC6OTHER inhibitor BC6OTHER or BC6OTHER knockdown with specific small interfering RNA (siRNA).	False
Moreover, BC6ENTC - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6OTHER BC6ENTG inhibitor BC6OTHER or BC6OTHER knockdown with specific small interfering RNA (siRNA).	False
Moreover, BC6ENTC - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6OTHER BC6OTHER inhibitor BC6OTHER or BC6ENTG knockdown with specific small interfering RNA (siRNA).	False
Moreover, BC6OTHER - induced BC6ENTG protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6OTHER BC6OTHER inhibitor BC6ENTC or BC6OTHER knockdown with specific small interfering RNA (siRNA).	False
Moreover, BC6OTHER - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6ENTG activity by either a BC6OTHER BC6OTHER inhibitor BC6ENTC or BC6OTHER knockdown with specific small interfering RNA (siRNA).	CPR:4
Moreover, BC6OTHER - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6ENTG BC6OTHER inhibitor BC6ENTC or BC6OTHER knockdown with specific small interfering RNA (siRNA).	CPR:4
Moreover, BC6OTHER - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6OTHER BC6ENTG inhibitor BC6ENTC or BC6OTHER knockdown with specific small interfering RNA (siRNA).	CPR:4
Moreover, BC6OTHER - induced BC6OTHER protein and mRNA levels significantly decreased via the downregulation of BC6OTHER activity by either a BC6OTHER BC6OTHER inhibitor BC6ENTC or BC6ENTG knockdown with specific small interfering RNA (siRNA).	False
 BC6ENTC - mediated downregulation of BC6ENTG BC6OTHER - dependent excision repair cross - complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to BC6OTHER .	CPR:4
 BC6ENTC - mediated downregulation of BC6OTHER BC6ENTG - dependent excision repair cross - complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to BC6OTHER .	CPR:4
 BC6OTHER - mediated downregulation of BC6ENTG BC6OTHER - dependent excision repair cross - complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to BC6ENTC .	False
 BC6OTHER - mediated downregulation of BC6OTHER BC6ENTG - dependent excision repair cross - complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to BC6ENTC .	False
Specific inhibition of BC6ENTG with siRNA was found to enhance the BC6ENTC - induced cytotoxic effect and growth inhibition.	False
Furthermore, BC6ENTC was able to not only decrease the BC6OTHER - induced BC6ENTG BC6OTHER - mediated BC6OTHER expression, but also augment the cytotoxic effect induced by BC6OTHER .	CPR:4
Furthermore, BC6ENTC was able to not only decrease the BC6OTHER - induced BC6OTHER BC6ENTG - mediated BC6OTHER expression, but also augment the cytotoxic effect induced by BC6OTHER .	CPR:4
Furthermore, BC6ENTC was able to not only decrease the BC6OTHER - induced BC6OTHER BC6OTHER - mediated BC6ENTG expression, but also augment the cytotoxic effect induced by BC6OTHER .	CPR:4
Furthermore, BC6OTHER was able to not only decrease the BC6ENTC - induced BC6ENTG BC6OTHER - mediated BC6OTHER expression, but also augment the cytotoxic effect induced by BC6OTHER .	CPR:3
Furthermore, BC6OTHER was able to not only decrease the BC6ENTC - induced BC6OTHER BC6ENTG - mediated BC6OTHER expression, but also augment the cytotoxic effect induced by BC6OTHER .	CPR:3
Furthermore, BC6OTHER was able to not only decrease the BC6ENTC - induced BC6OTHER BC6OTHER - mediated BC6ENTG expression, but also augment the cytotoxic effect induced by BC6OTHER .	CPR:3
Furthermore, BC6OTHER was able to not only decrease the BC6OTHER - induced BC6ENTG BC6OTHER - mediated BC6OTHER expression, but also augment the cytotoxic effect induced by BC6ENTC .	False
Furthermore, BC6OTHER was able to not only decrease the BC6OTHER - induced BC6OTHER BC6ENTG - mediated BC6OTHER expression, but also augment the cytotoxic effect induced by BC6ENTC .	False
Furthermore, BC6OTHER was able to not only decrease the BC6OTHER - induced BC6OTHER BC6OTHER - mediated BC6ENTG expression, but also augment the cytotoxic effect induced by BC6ENTC .	False
Finally, expression of constitutive activate BC6ENTG or HA - BC6OTHER BC6OTHER vectors in lung cancer cells was able to abrogate BC6OTHER downregulation by BC6ENTC and BC6OTHER as well as cell viability and DNA repair capacity.	False
Finally, expression of constitutive activate BC6OTHER or HA - BC6ENTG BC6OTHER vectors in lung cancer cells was able to abrogate BC6OTHER downregulation by BC6ENTC and BC6OTHER as well as cell viability and DNA repair capacity.	False
Finally, expression of constitutive activate BC6OTHER or HA - BC6OTHER BC6ENTG vectors in lung cancer cells was able to abrogate BC6OTHER downregulation by BC6ENTC and BC6OTHER as well as cell viability and DNA repair capacity.	False
Finally, expression of constitutive activate BC6OTHER or HA - BC6OTHER BC6OTHER vectors in lung cancer cells was able to abrogate BC6ENTG downregulation by BC6ENTC and BC6OTHER as well as cell viability and DNA repair capacity.	CPR:4
Finally, expression of constitutive activate BC6ENTG or HA - BC6OTHER BC6OTHER vectors in lung cancer cells was able to abrogate BC6OTHER downregulation by BC6OTHER and BC6ENTC as well as cell viability and DNA repair capacity.	False
Finally, expression of constitutive activate BC6OTHER or HA - BC6ENTG BC6OTHER vectors in lung cancer cells was able to abrogate BC6OTHER downregulation by BC6OTHER and BC6ENTC as well as cell viability and DNA repair capacity.	False
Finally, expression of constitutive activate BC6OTHER or HA - BC6OTHER BC6ENTG vectors in lung cancer cells was able to abrogate BC6OTHER downregulation by BC6OTHER and BC6ENTC as well as cell viability and DNA repair capacity.	False
Finally, expression of constitutive activate BC6OTHER or HA - BC6OTHER BC6OTHER vectors in lung cancer cells was able to abrogate BC6ENTG downregulation by BC6OTHER and BC6ENTC as well as cell viability and DNA repair capacity.	CPR:4
Overall, our results suggest that inhibition of the BC6ENTG BC6OTHER signaling by BC6ENTC coupled with BC6OTHER therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	CPR:4
Overall, our results suggest that inhibition of the BC6OTHER BC6ENTG signaling by BC6ENTC coupled with BC6OTHER therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	CPR:4
Overall, our results suggest that inhibition of the BC6ENTG BC6OTHER signaling by BC6OTHER coupled with BC6ENTC therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	False
Overall, our results suggest that inhibition of the BC6OTHER BC6ENTG signaling by BC6OTHER coupled with BC6ENTC therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.	False
Since BC6ENTG is supposed to be part of a multimeric repressor of BC6OTHER symporter ( BC6OTHER ) expression, in this study the effect of the BC6OTHER inhibitor BC6ENTC on several properties of thyroid cancer cell lines was investigated.	False
Since BC6OTHER is supposed to be part of a multimeric repressor of BC6ENTG ( BC6OTHER ) expression, in this study the effect of the BC6OTHER inhibitor BC6ENTC on several properties of thyroid cancer cell lines was investigated.	False
Since BC6OTHER is supposed to be part of a multimeric repressor of BC6OTHER symporter ( BC6ENTG ) expression, in this study the effect of the BC6OTHER inhibitor BC6ENTC on several properties of thyroid cancer cell lines was investigated.	False
Since BC6OTHER is supposed to be part of a multimeric repressor of BC6OTHER symporter ( BC6OTHER ) expression, in this study the effect of the BC6ENTG inhibitor BC6ENTC on several properties of thyroid cancer cell lines was investigated.	CPR:4
In TPC1, BCPAP, FRO, WRO cell lines BC6ENTC induced a strong increase in BC6ENTG mRNA levels.	CPR:3
Accordingly, in transfection experiments performed in TPC1 cells, treatment with BC6ENTC increased BC6ENTG activity without affecting BC6OTHER binding to the promoter sequence.	CPR:3
Accordingly, in transfection experiments performed in TPC1 cells, treatment with BC6ENTC increased BC6OTHER activity without affecting BC6ENTG binding to the promoter sequence.	False
We also investigated the epigenetic status of BC6ENTG after BC6ENTC treatment in TPC1 cell line: in addition to an increase of BC6OTHER ( BC6OTHER , BC6OTHER ), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	False
We also investigated the epigenetic status of BC6OTHER after BC6ENTC treatment in TPC1 cell line: in addition to an increase of BC6ENTG ( BC6OTHER , BC6OTHER ), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	CPR:3
We also investigated the epigenetic status of BC6OTHER after BC6ENTC treatment in TPC1 cell line: in addition to an increase of BC6OTHER ( BC6ENTG , BC6OTHER ), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	CPR:3
We also investigated the epigenetic status of BC6OTHER after BC6ENTC treatment in TPC1 cell line: in addition to an increase of BC6OTHER ( BC6OTHER , BC6ENTG ), surprisingly we observed also an increase of H3K27me3, a classical repressive mark.	CPR:3
Since BC6ENTG is supposed to be part of a multimeric repressor of BC6ENTC symporter ( BC6OTHER ) expression, in this study the effect of the BC6OTHER inhibitor BC6OTHER on several properties of thyroid cancer cell lines was investigated.	False
Since BC6OTHER is supposed to be part of a multimeric repressor of BC6ENTC symporter ( BC6ENTG ) expression, in this study the effect of the BC6OTHER inhibitor BC6OTHER on several properties of thyroid cancer cell lines was investigated.	False
Since BC6OTHER is supposed to be part of a multimeric repressor of BC6ENTC symporter ( BC6OTHER ) expression, in this study the effect of the BC6ENTG inhibitor BC6OTHER on several properties of thyroid cancer cell lines was investigated.	False
The BC6OTHER inhibitor BC6ENTC modifies proliferation, BC6ENTG expression and epigenetic marks in thyroid cancer cell lines.	False
The BC6ENTG inhibitor BC6ENTC modifies proliferation, BC6OTHER expression and epigenetic marks in thyroid cancer cell lines.	CPR:4
The BC6OTHER of BC6ENTG associates with BC6OTHER and is prerequisite to BC6OTHER - induced BC6ENTC release in Jurkat T lymphocytes.	False
The BC6ENTG of BC6OTHER associates with BC6OTHER and is prerequisite to BC6OTHER - induced BC6ENTC release in Jurkat T lymphocytes.	False
The BC6OTHER of BC6OTHER associates with BC6ENTG and is prerequisite to BC6OTHER - induced BC6ENTC release in Jurkat T lymphocytes.	False
The BC6OTHER of BC6OTHER associates with BC6OTHER and is prerequisite to BC6ENTG - induced BC6ENTC release in Jurkat T lymphocytes.	False
BC6ENTG is a BC6ENTC exchange factor that is expressed specifically in hematopoietic cells and plays important roles in T cell development and activation.	False
The defect persisted even when BC6ENTG was fully activated, indicating a prerequisite role of BC6OTHER in BC6ENTC signaling.	False
The defect persisted even when BC6OTHER was fully activated, indicating a prerequisite role of BC6ENTG in BC6ENTC signaling.	False
The results suggest that BC6ENTG and BC6OTHER function cooperatively to potentiate BC6OTHER - induced BC6ENTC release.	False
The results suggest that BC6OTHER and BC6ENTG function cooperatively to potentiate BC6OTHER - induced BC6ENTC release.	False
The results suggest that BC6OTHER and BC6OTHER function cooperatively to potentiate BC6ENTG - induced BC6ENTC release.	False
This study unveiled a mechanism by which the BC6ENTG is involved in BC6ENTC signaling and provides insight into our understanding of the role of BC6OTHER in T cell activation.	False
This study unveiled a mechanism by which the BC6OTHER is involved in BC6ENTC signaling and provides insight into our understanding of the role of BC6ENTG in T cell activation.	False
BC6ENTG consists of multiple structural domains so as to facilitate both its BC6ENTC exchange activity and scaffold function following BC6OTHER ( BC6OTHER ) engagement.	False
BC6OTHER consists of multiple structural domains so as to facilitate both its BC6ENTC exchange activity and scaffold function following BC6ENTG ( BC6OTHER ) engagement.	False
BC6OTHER consists of multiple structural domains so as to facilitate both its BC6ENTC exchange activity and scaffold function following BC6OTHER ( BC6ENTG ) engagement.	False
Previous studies demonstrated that the BC6ENTG of BC6OTHER is required for BC6OTHER - stimulated BC6ENTC mobilization and thus downstream activation of BC6OTHER .	False
Previous studies demonstrated that the BC6OTHER of BC6ENTG is required for BC6OTHER - stimulated BC6ENTC mobilization and thus downstream activation of BC6OTHER .	False
Previous studies demonstrated that the BC6OTHER of BC6OTHER is required for BC6ENTG - stimulated BC6ENTC mobilization and thus downstream activation of BC6OTHER .	False
Previous studies demonstrated that the BC6OTHER of BC6OTHER is required for BC6OTHER - stimulated BC6ENTC mobilization and thus downstream activation of BC6ENTG .	False
However, it remained obscure how BC6ENTG functions in regulating BC6ENTC flux.	False
In an effort to explore molecules interacting with BC6ENTG , we found that BC6OTHER bound to BC6OTHER in a BC6ENTC - dependent and BC6OTHER activation - independent manner.	False
In an effort to explore molecules interacting with BC6OTHER , we found that BC6ENTG bound to BC6OTHER in a BC6ENTC - dependent and BC6OTHER activation - independent manner.	False
In an effort to explore molecules interacting with BC6OTHER , we found that BC6OTHER bound to BC6ENTG in a BC6ENTC - dependent and BC6OTHER activation - independent manner.	False
In an effort to explore molecules interacting with BC6OTHER , we found that BC6OTHER bound to BC6OTHER in a BC6ENTC - dependent and BC6ENTG activation - independent manner.	False
Reconstitution of BC6OTHER - null Jurkat T cells (J. BC6OTHER ) with BC6OTHER - deleted BC6OTHER exhibited a severe deficiency in BC6ENTC release to the same extent as that of Jurkat cells treated with the BC6ENTG inhibitor or J. BC6OTHER cells.	False
Reconstitution of BC6OTHER - null Jurkat T cells (J. BC6OTHER ) with BC6OTHER - deleted BC6OTHER exhibited a severe deficiency in BC6ENTC release to the same extent as that of Jurkat cells treated with the BC6OTHER inhibitor or J. BC6ENTG cells.	False
Reconstitution of BC6ENTG - null Jurkat T cells (J. BC6OTHER ) with BC6OTHER - deleted BC6OTHER exhibited a severe deficiency in BC6ENTC release to the same extent as that of Jurkat cells treated with the BC6OTHER inhibitor or J. BC6OTHER cells.	False
Reconstitution of BC6OTHER - null Jurkat T cells (J. BC6ENTG ) with BC6OTHER - deleted BC6OTHER exhibited a severe deficiency in BC6ENTC release to the same extent as that of Jurkat cells treated with the BC6OTHER inhibitor or J. BC6OTHER cells.	False
Reconstitution of BC6OTHER - null Jurkat T cells (J. BC6OTHER ) with BC6ENTG - deleted BC6OTHER exhibited a severe deficiency in BC6ENTC release to the same extent as that of Jurkat cells treated with the BC6OTHER inhibitor or J. BC6OTHER cells.	False
Reconstitution of BC6OTHER - null Jurkat T cells (J. BC6OTHER ) with BC6OTHER - deleted BC6ENTG exhibited a severe deficiency in BC6ENTC release to the same extent as that of Jurkat cells treated with the BC6OTHER inhibitor or J. BC6OTHER cells.	False
The reduction of BiFC signal mediated by BC6ENTC was correlated with an increase in BC6ENTG transactivation, BC6OTHER cleavage, and cell death.	CPR:3
The reduction of BiFC signal mediated by BC6ENTC was correlated with an increase in BC6OTHER transactivation, BC6ENTG cleavage, and cell death.	CPR:3
We used BC6ENTC , a well - known disruptor of BC6ENTG - BC6OTHER interaction, to validate the specificity of the assay.	CPR:4
We used BC6ENTC , a well - known disruptor of BC6OTHER - BC6ENTG interaction, to validate the specificity of the assay.	CPR:4
In humans, prolonged administration of the BC6OTHER agonist BC6OTHER leads to a desensitization of BC6ENTG - mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug BC6ENTC .	False
In humans, prolonged administration of the BC6ENTG agonist BC6OTHER leads to a desensitization of BC6OTHER - mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug BC6ENTC .	False
This study investigated the effect of BC6ENTC , another antiallergic drug, on BC6OTHER - induced desensitization of BC6ENTG - mediated cardiovascular and noncardiovascular responses.	False
This study investigated the effect of BC6OTHER , another antiallergic drug, on BC6ENTC - induced desensitization of BC6ENTG - mediated cardiovascular and noncardiovascular responses.	False
In humans, prolonged administration of the BC6OTHER agonist BC6ENTC leads to a desensitization of BC6ENTG - mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug BC6OTHER .	False
In humans, prolonged administration of the BC6ENTG agonist BC6ENTC leads to a desensitization of BC6OTHER - mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug BC6OTHER .	CPR:5
BC6ENTG cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective BC6OTHER agonist BC6ENTC ; BC6OTHER cardiovascular function was assessed by exercise - induced tachycardia.	False
BC6OTHER cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective BC6ENTG agonist BC6ENTC ; BC6OTHER cardiovascular function was assessed by exercise - induced tachycardia.	CPR:5
BC6OTHER cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective BC6OTHER agonist BC6ENTC ; BC6ENTG cardiovascular function was assessed by exercise - induced tachycardia.	False
 BC6ENTC does not prevent BC6OTHER - induced desensitization of BC6ENTG - mediated cardiovascular in vivo functions in human volunteers.	False
 BC6OTHER does not prevent BC6ENTC - induced desensitization of BC6ENTG - mediated cardiovascular in vivo functions in human volunteers.	False
BC6ENTC affected neither the rightward shift of BC6ENTG - mediated responses nor the small rightward shift in BC6OTHER - mediated exercise tachycardia after 2 weeks' administration of BC6OTHER .	False
BC6ENTC affected neither the rightward shift of BC6OTHER - mediated responses nor the small rightward shift in BC6ENTG - mediated exercise tachycardia after 2 weeks' administration of BC6OTHER .	False
BC6OTHER affected neither the rightward shift of BC6ENTG - mediated responses nor the small rightward shift in BC6OTHER - mediated exercise tachycardia after 2 weeks' administration of BC6ENTC .	False
BC6OTHER affected neither the rightward shift of BC6OTHER - mediated responses nor the small rightward shift in BC6ENTG - mediated exercise tachycardia after 2 weeks' administration of BC6ENTC .	False
Tremulousness observed during the first few days of BC6ENTC administration disappeared after 4 to 8 days, indicating development of desensitization of BC6ENTG - mediated noncardiovascular responses.	False
 These results confirm that long - term BC6ENTG agonist therapy leads to a desensitization of BC6OTHER - mediated cardiovascular and noncardiovascular effects in humans in vivo. However, unlike BC6ENTC , BC6OTHER is not able to attenuate this desensitization.	False
 These results confirm that long - term BC6OTHER agonist therapy leads to a desensitization of BC6ENTG - mediated cardiovascular and noncardiovascular effects in humans in vivo. However, unlike BC6ENTC , BC6OTHER is not able to attenuate this desensitization.	False
 These results confirm that long - term BC6ENTG agonist therapy leads to a desensitization of BC6OTHER - mediated cardiovascular and noncardiovascular effects in humans in vivo. However, unlike BC6OTHER , BC6ENTC is not able to attenuate this desensitization.	False
 These results confirm that long - term BC6OTHER agonist therapy leads to a desensitization of BC6ENTG - mediated cardiovascular and noncardiovascular effects in humans in vivo. However, unlike BC6OTHER , BC6ENTC is not able to attenuate this desensitization.	False
Oral BC6ENTC is likely to be a useful addition to oral formulations of other BC6ENTG r antagonists in preventing CINV in patients receiving MEC.	CPR:6
BC6OTHER is a second - generation BC6ENTC 5 - HT3 receptor antagonist, with a distinct pharmacological profile that differs from first - generation BC6ENTG antagonists.	False
BC6ENTC is a second - generation BC6OTHER antagonist, with a distinct pharmacological profile that differs from first - generation BC6ENTG antagonists.	CPR:6
BC6ENTC is a second - generation BC6ENTG antagonist, with a distinct pharmacological profile that differs from first - generation BC6OTHER antagonists.	CPR:6
We report that two common variants of BC6ENTG ( BC6OTHER ) that increase the inherited risk of neovascular age - related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of BC6OTHER that convert common codons for BC6ENTC 34 and BC6OTHER 36 to less frequently used codons.	False
We report that two common variants of BC6OTHER ( BC6ENTG ) that increase the inherited risk of neovascular age - related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of BC6OTHER that convert common codons for BC6ENTC 34 and BC6OTHER 36 to less frequently used codons.	False
We report that two common variants of BC6OTHER ( BC6OTHER ) that increase the inherited risk of neovascular age - related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of BC6ENTG that convert common codons for BC6ENTC 34 and BC6OTHER 36 to less frequently used codons.	False
We report that two common variants of BC6ENTG ( BC6OTHER ) that increase the inherited risk of neovascular age - related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of BC6OTHER that convert common codons for BC6OTHER 34 and BC6ENTC 36 to less frequently used codons.	False
We report that two common variants of BC6OTHER ( BC6ENTG ) that increase the inherited risk of neovascular age - related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of BC6OTHER that convert common codons for BC6OTHER 34 and BC6ENTC 36 to less frequently used codons.	False
We report that two common variants of BC6OTHER ( BC6OTHER ) that increase the inherited risk of neovascular age - related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of BC6ENTG that convert common codons for BC6OTHER 34 and BC6ENTC 36 to less frequently used codons.	False
The carboxylation of BC6OTHER residues to BC6OTHER ( BC6OTHER ) by the BC6OTHER - dependent BC6ENTC carboxylase ( BC6ENTG ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	False
The carboxylation of BC6ENTC residues to BC6OTHER ( BC6OTHER ) by the BC6ENTG ( BC6OTHER ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
The carboxylation of BC6ENTC residues to BC6OTHER ( BC6OTHER ) by the BC6OTHER - dependent BC6OTHER carboxylase ( BC6ENTG ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
The carboxylation of BC6OTHER residues to BC6ENTC ( BC6OTHER ) by the BC6ENTG ( BC6OTHER ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
The carboxylation of BC6OTHER residues to BC6ENTC ( BC6OTHER ) by the BC6OTHER - dependent BC6OTHER carboxylase ( BC6ENTG ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
Heterozygous mice carrying a null mutation at the BC6ENTG ( BC6OTHER ) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the BC6ENTC - dependent clotting factors IX, X, and BC6OTHER .	False
Heterozygous mice carrying a null mutation at the BC6OTHER ( BC6ENTG ) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the BC6ENTC - dependent clotting factors IX, X, and BC6OTHER .	False
Heterozygous mice carrying a null mutation at the BC6OTHER ( BC6OTHER ) gene exhibit normal development and survival with no evidence of hemorrhage and normal functional activity of the BC6ENTC - dependent clotting factors IX, X, and BC6ENTG .	False
The carboxylation of BC6OTHER residues to BC6OTHER ( BC6ENTC ) by the BC6ENTG ( BC6OTHER ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
The carboxylation of BC6OTHER residues to BC6OTHER ( BC6ENTC ) by the BC6OTHER - dependent BC6OTHER carboxylase ( BC6ENTG ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	CPR:9
The carboxylation of BC6OTHER residues to BC6OTHER ( BC6OTHER ) by the BC6ENTC - dependent BC6OTHER carboxylase ( BC6ENTG ) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
Renal clearance of unbound BC6ENTC and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6OTHER may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER .	False
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER .	False
Renal clearance of unbound BC6OTHER and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that BC6ENTC may be a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , and M1 a substrate of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG .	False
The disposition of BC6OTHER , an orally active, highly selective BC6ENTG inhibitor, was investigated after a single oral dose of 100 mg / 1.92 MBq BC6ENTC to six healthy men.	False
The disposition of BC6ENTC , an orally active, highly selective BC6ENTG inhibitor, was investigated after a single oral dose of 100 mg / 1.92 MBq BC6OTHER to six healthy men.	CPR:4
Pharmacokinetics and metabolism of BC6ENTC , a novel BC6ENTG inhibitor, in humans.	CPR:4
Hydrophobic BC6ENTC in the hinge region of the BC6OTHER mimetic peptide are essential for promoting BC6OTHER efflux by the BC6ENTG transporter.	False
Hydrophobic BC6ENTC in the hinge region of the BC6ENTG mimetic peptide are essential for promoting BC6OTHER efflux by the BC6OTHER transporter.	False
These results provide a rationale for future design of therapeutic BC6ENTG mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with CHEM in the lipid microdomain created by the BC6OTHER transporter during the BC6ENTC efflux process.	False
These results provide a rationale for future design of therapeutic BC6OTHER mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with CHEM in the lipid microdomain created by the BC6ENTG transporter during the BC6ENTC efflux process.	CPR:9
The bihelical BC6ENTG effluxes BC6ENTC from cells and reduces inflammation and atherosclerosis in animal models.	CPR:9
Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10 - fold less effective in effluxing BC6ENTC by the BC6ENTG transporter.	CPR:9
Hydrophobic BC6OTHER in the hinge region of the BC6OTHER mimetic peptide are essential for promoting BC6ENTC efflux by the BC6ENTG transporter.	CPR:9
Hydrophobic BC6OTHER in the hinge region of the BC6ENTG mimetic peptide are essential for promoting BC6ENTC efflux by the BC6OTHER transporter.	False
BC6ENTC induced rapid and transient expression of BC6ENTG and downstream targets of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER [ BC6OTHER ]) in endothelial and smooth muscle cells and induced endothelial cell - specific proliferation.	CPR:3
BC6ENTC induced rapid and transient expression of BC6OTHER and downstream targets of BC6ENTG ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER [ BC6OTHER ]) in endothelial and smooth muscle cells and induced endothelial cell - specific proliferation.	CPR:3
BC6ENTC induced rapid and transient expression of BC6OTHER and downstream targets of BC6OTHER ( BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER [ BC6OTHER ]) in endothelial and smooth muscle cells and induced endothelial cell - specific proliferation.	CPR:3
BC6ENTC induced rapid and transient expression of BC6OTHER and downstream targets of BC6OTHER ( BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER [ BC6OTHER ]) in endothelial and smooth muscle cells and induced endothelial cell - specific proliferation.	CPR:3
BC6ENTC induced rapid and transient expression of BC6OTHER and downstream targets of BC6OTHER ( BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER [ BC6OTHER ]) in endothelial and smooth muscle cells and induced endothelial cell - specific proliferation.	CPR:3
BC6ENTC induced rapid and transient expression of BC6OTHER and downstream targets of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG [ BC6OTHER ]) in endothelial and smooth muscle cells and induced endothelial cell - specific proliferation.	CPR:3
BC6ENTC induced rapid and transient expression of BC6OTHER and downstream targets of BC6OTHER ( BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER [ BC6ENTG ]) in endothelial and smooth muscle cells and induced endothelial cell - specific proliferation.	CPR:3
BC6ENTC dose - dependently inhibited BC6ENTG activity and induced nonhydroxylated BC6OTHER , evidence for BC6OTHER stabilization specifically by inhibition of BC6OTHER enzyme activity.	CPR:4
BC6ENTC dose - dependently inhibited BC6OTHER activity and induced nonhydroxylated BC6ENTG , evidence for BC6OTHER stabilization specifically by inhibition of BC6OTHER enzyme activity.	CPR:3
BC6ENTC dose - dependently inhibited BC6OTHER activity and induced nonhydroxylated BC6OTHER , evidence for BC6ENTG stabilization specifically by inhibition of BC6OTHER enzyme activity.	False
BC6ENTC dose - dependently inhibited BC6OTHER activity and induced nonhydroxylated BC6OTHER , evidence for BC6OTHER stabilization specifically by inhibition of BC6ENTG enzyme activity.	CPR:4
In vivo, BC6ENTC induced BC6OTHER and BC6OTHER protein in tissue extracts and elevated plasma BC6ENTG levels.	CPR:3
In vivo, BC6ENTC induced BC6ENTG and BC6OTHER protein in tissue extracts and elevated plasma BC6OTHER levels.	CPR:3
In vivo, BC6ENTC induced BC6OTHER and BC6ENTG protein in tissue extracts and elevated plasma BC6OTHER levels.	CPR:3
Novel mechanism of action for BC6OTHER : induction of BC6ENTG , BC6OTHER , and angiogenesis by inhibition of BC6ENTC hydroxylases.	False
Novel mechanism of action for BC6OTHER : induction of BC6OTHER , BC6ENTG , and angiogenesis by inhibition of BC6ENTC hydroxylases.	False
Novel mechanism of action for BC6ENTC : induction of BC6OTHER , BC6OTHER , and angiogenesis by inhibition of BC6ENTG .	CPR:4
Novel mechanism of action for BC6ENTC : induction of BC6ENTG , BC6OTHER , and angiogenesis by inhibition of BC6OTHER .	CPR:3
Novel mechanism of action for BC6ENTC : induction of BC6OTHER , BC6ENTG , and angiogenesis by inhibition of BC6OTHER .	CPR:3
Thus, BC6ENTC activates the BC6ENTG pathway through inhibition of BC6OTHER activity and initiates a pro - angiogenic phenotype.	CPR:3
Thus, BC6ENTC activates the BC6OTHER pathway through inhibition of BC6ENTG activity and initiates a pro - angiogenic phenotype.	CPR:4
This represents a novel mechanism of action for BC6ENTC and presents BC6ENTG as a potential target for treatment of ischemic disease.	False
BC6ENTG is a known target of BC6ENTC .	False
We therefore investigated whether inhibition of other members of this enzyme family, namely the BC6ENTG ( BC6OTHER ) - regulating BC6ENTC - dependent BC6OTHER hydroxylase domain ( BC6OTHER ) enzymes, could represent a novel mechanism of action.	False
We therefore investigated whether inhibition of other members of this enzyme family, namely the BC6OTHER ( BC6ENTG ) - regulating BC6ENTC - dependent BC6OTHER hydroxylase domain ( BC6OTHER ) enzymes, could represent a novel mechanism of action.	False
We therefore investigated whether inhibition of other members of this enzyme family, namely the BC6OTHER ( BC6OTHER ) - regulating BC6ENTC - dependent BC6ENTG ( BC6OTHER ) enzymes, could represent a novel mechanism of action.	False
We therefore investigated whether inhibition of other members of this enzyme family, namely the BC6OTHER ( BC6OTHER ) - regulating BC6ENTC - dependent BC6OTHER hydroxylase domain ( BC6ENTG ) enzymes, could represent a novel mechanism of action.	False
We therefore investigated whether inhibition of other members of this enzyme family, namely the BC6ENTG ( BC6OTHER ) - regulating BC6OTHER - dependent BC6ENTC hydroxylase domain ( BC6OTHER ) enzymes, could represent a novel mechanism of action.	False
We therefore investigated whether inhibition of other members of this enzyme family, namely the BC6OTHER ( BC6ENTG ) - regulating BC6OTHER - dependent BC6ENTC hydroxylase domain ( BC6OTHER ) enzymes, could represent a novel mechanism of action.	False
We therefore investigated whether inhibition of other members of this enzyme family, namely the BC6OTHER ( BC6OTHER ) - regulating BC6OTHER - dependent BC6ENTC hydroxylase domain ( BC6ENTG ) enzymes, could represent a novel mechanism of action.	False
BC6ENTC may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including BC6ENTG , BC6OTHER , and BC6OTHER .	False
BC6ENTC may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including BC6OTHER , BC6ENTG , and BC6OTHER .	False
BC6ENTC may provide clinical benefit by simultaneously targeting multiple pathways of importance in MTC, including BC6OTHER , BC6OTHER , and BC6ENTG .	False
PURPOSE: BC6OTHER ( BC6ENTC ) is a potent inhibitor of BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
PURPOSE: BC6OTHER ( BC6ENTC ) is a potent inhibitor of BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
PURPOSE: BC6OTHER ( BC6ENTC ) is a potent inhibitor of BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
PURPOSE: BC6OTHER ( BC6ENTC ) is a potent inhibitor of BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
PURPOSE: BC6ENTC ( BC6OTHER ) is a potent inhibitor of BC6OTHER , BC6OTHER ( BC6ENTG ), and BC6OTHER , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
PURPOSE: BC6ENTC ( BC6OTHER ) is a potent inhibitor of BC6OTHER , BC6OTHER ( BC6OTHER ), and BC6ENTG , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
PURPOSE: BC6ENTC ( BC6OTHER ) is a potent inhibitor of BC6ENTG , BC6OTHER ( BC6OTHER ), and BC6OTHER , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
PURPOSE: BC6ENTC ( BC6OTHER ) is a potent inhibitor of BC6OTHER , BC6ENTG ( BC6OTHER ), and BC6OTHER , with robust antiangiogenic, antitumor, and anti - invasive effects in preclinical models.	CPR:4
Activity of BC6ENTC ( BC6OTHER ), an oral BC6ENTG inhibitor, in patients with medullary thyroid cancer.	CPR:4
Activity of BC6OTHER ( BC6ENTC ), an oral BC6ENTG inhibitor, in patients with medullary thyroid cancer.	CPR:4
A number of selective BC6ENTG antagonists have been developed including BC6OTHER , BC6OTHER , BC6OTHER BC6OTHER and BC6ENTC .	CPR:6
While the substituted BC6ENTC prokinetics (for example, BC6OTHER , BC6OTHER ) also block BC6ENTG receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative BC6OTHER receptor.	CPR:4
While the substituted BC6ENTC prokinetics (for example, BC6OTHER , BC6OTHER ) also block BC6OTHER receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative BC6ENTG receptor.	CPR:5
While the substituted BC6OTHER prokinetics (for example, BC6ENTC , BC6OTHER ) also block BC6ENTG receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative BC6OTHER receptor.	CPR:4
While the substituted BC6OTHER prokinetics (for example, BC6ENTC , BC6OTHER ) also block BC6OTHER receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative BC6ENTG receptor.	CPR:5
While the substituted BC6OTHER prokinetics (for example, BC6OTHER , BC6ENTC ) also block BC6ENTG receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative BC6OTHER receptor.	CPR:4
While the substituted BC6OTHER prokinetics (for example, BC6OTHER , BC6ENTC ) also block BC6OTHER receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative BC6ENTG receptor.	CPR:5
Some BC6OTHER antagonists have BC6OTHER agonist activity (for example, BC6ENTC , BC6OTHER ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6OTHER in high concentrations is a BC6ENTG antagonist.	False
Some BC6ENTG antagonists have BC6OTHER agonist activity (for example, BC6ENTC , BC6OTHER ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	CPR:6
Some BC6OTHER antagonists have BC6ENTG agonist activity (for example, BC6ENTC , BC6OTHER ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	CPR:5
Some BC6OTHER antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6ENTC ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6OTHER in high concentrations is a BC6ENTG antagonist.	False
Some BC6ENTG antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6ENTC ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	CPR:6
Some BC6OTHER antagonists have BC6ENTG agonist activity (for example, BC6OTHER , BC6ENTC ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	CPR:5
Some BC6OTHER antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6ENTC , BC6OTHER ), while BC6OTHER in high concentrations is a BC6ENTG antagonist.	False
Some BC6ENTG antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6ENTC , BC6OTHER ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	False
Some BC6OTHER antagonists have BC6ENTG agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6ENTC , BC6OTHER ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	False
Some BC6OTHER antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6OTHER , BC6ENTC ), while BC6OTHER in high concentrations is a BC6ENTG antagonist.	False
Some BC6ENTG antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6OTHER , BC6ENTC ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	False
Some BC6OTHER antagonists have BC6ENTG agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6OTHER , BC6ENTC ), while BC6OTHER in high concentrations is a BC6OTHER antagonist.	False
Some BC6OTHER antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6ENTC in high concentrations is a BC6ENTG antagonist.	CPR:6
Some BC6ENTG antagonists have BC6OTHER agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6ENTC in high concentrations is a BC6OTHER antagonist.	False
Some BC6OTHER antagonists have BC6ENTG agonist activity (for example, BC6OTHER , BC6OTHER ) and others do not (for example, BC6OTHER , BC6OTHER ), while BC6ENTC in high concentrations is a BC6OTHER antagonist.	False
A number of selective BC6ENTG antagonists have been developed including BC6ENTC , BC6OTHER , BC6OTHER BC6OTHER and BC6OTHER .	CPR:6
A number of selective BC6ENTG antagonists have been developed including BC6OTHER , BC6ENTC , BC6OTHER BC6OTHER and BC6OTHER .	CPR:6
A number of selective BC6ENTG antagonists have been developed including BC6OTHER , BC6OTHER , BC6ENTC BC6OTHER and BC6OTHER .	CPR:6
A number of selective BC6ENTG antagonists have been developed including BC6OTHER , BC6OTHER , BC6OTHER BC6ENTC and BC6OTHER .	CPR:6
The present work evaluated the effects of BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
BC6OTHER also increased the phosphorylation of BC6ENTG in a similar fashion as BC6ENTC .	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
BC6ENTC also increased the phosphorylation of BC6ENTG in a similar fashion as BC6OTHER .	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
The present work evaluated the effects of BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6ENTG ( BC6OTHER ).	False
The present work evaluated the effects of BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) on memory extinction and the following biochemical parameters of the hippocampus: lipid peroxidation (LPO), antioxidant capacity (AC) and the phosphorylation of BC6OTHER ( BC6ENTG ).	False
While BC6OTHER is essential for BC6ENTG activity in vitro, BC6OTHER had no effect, and BC6ENTC or BC6OTHER efficiently inhibited the activity of all three BC6OTHER , demonstrating different functions of these antioxidants.	False
While BC6OTHER is essential for BC6OTHER activity in vitro, BC6OTHER had no effect, and BC6ENTC or BC6OTHER efficiently inhibited the activity of all three BC6ENTG , demonstrating different functions of these antioxidants.	CPR:4
While BC6OTHER is essential for BC6ENTG activity in vitro, BC6OTHER had no effect, and BC6OTHER or BC6ENTC efficiently inhibited the activity of all three BC6OTHER , demonstrating different functions of these antioxidants.	False
While BC6OTHER is essential for BC6OTHER activity in vitro, BC6OTHER had no effect, and BC6OTHER or BC6ENTC efficiently inhibited the activity of all three BC6ENTG , demonstrating different functions of these antioxidants.	CPR:4
Cellular BC6OTHER is sensed by BC6ENTC - 4 - hydroxylase domain (PHD) proteins that BC6OTHER BC6ENTG subunits.	False
Thus, the BC6ENTG BC6ENTC sensors themselves represent effectors of cellular signalling pathways as well as potential drug targets.	False
Cellular BC6OTHER is sensed by BC6ENTG that BC6ENTC BC6OTHER subunits.	False
Cellular BC6OTHER is sensed by BC6OTHER that BC6ENTC BC6ENTG subunits.	False
Here, a cell - free in vitro microtiter plate - based peptide hydroxylation assay was used to investigate the influence of BC6ENTC , Krebs cycle intermediates, CHEM, and BC6OTHER and other antioxidants on the activity of purified BC6ENTG .	False
Here, a cell - free in vitro microtiter plate - based peptide hydroxylation assay was used to investigate the influence of BC6OTHER , Krebs cycle intermediates, CHEM, and BC6ENTC and other antioxidants on the activity of purified BC6ENTG .	False
Cellular BC6ENTC is sensed by BC6ENTG that BC6OTHER BC6OTHER subunits.	False
Cellular BC6ENTC is sensed by BC6OTHER that BC6OTHER BC6ENTG subunits.	False
BC6ENTG activity depends not only on BC6ENTC availability but is also regulated by BC6OTHER , BC6OTHER , and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	False
BC6ENTG activity depends not only on BC6OTHER availability but is also regulated by BC6ENTC , BC6OTHER , and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	False
BC6ENTG activity depends not only on BC6OTHER availability but is also regulated by BC6OTHER , BC6ENTC , and Krebs cycle intermediates, suggesting a physiological relevance of their cellular concentrations.	False
While BC6ENTC is essential for BC6ENTG activity in vitro, BC6OTHER had no effect, and BC6OTHER or BC6OTHER efficiently inhibited the activity of all three BC6OTHER , demonstrating different functions of these antioxidants.	False
While BC6ENTC is essential for BC6OTHER activity in vitro, BC6OTHER had no effect, and BC6OTHER or BC6OTHER efficiently inhibited the activity of all three BC6ENTG , demonstrating different functions of these antioxidants.	False
While BC6OTHER is essential for BC6ENTG activity in vitro, BC6ENTC had no effect, and BC6OTHER or BC6OTHER efficiently inhibited the activity of all three BC6OTHER , demonstrating different functions of these antioxidants.	False
While BC6OTHER is essential for BC6OTHER activity in vitro, BC6ENTC had no effect, and BC6OTHER or BC6OTHER efficiently inhibited the activity of all three BC6ENTG , demonstrating different functions of these antioxidants.	False
While studies of BC6ENTC , BC6ENTG , opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics.	False
We apply DFTB in a QM / MM framework to perform vibrational analysis of buried BC6ENTC in BC6ENTG and BC6OTHER .	False
We apply DFTB in a QM / MM framework to perform vibrational analysis of buried BC6ENTC in BC6OTHER and BC6ENTG .	False
Administration of BC6ENTC , an BC6ENTG agonist (10 mg / kg for 7 days po), but not BC6OTHER (0.3 mg / kg for 7 days po), recovered the BC6OTHER protein level reduced by CHEM and increased the BC6OTHER protein level above the control one.	CPR:5
Administration of BC6ENTC , an BC6OTHER agonist (10 mg / kg for 7 days po), but not BC6OTHER (0.3 mg / kg for 7 days po), recovered the BC6ENTG protein level reduced by CHEM and increased the BC6OTHER protein level above the control one.	CPR:3
Administration of BC6ENTC , an BC6OTHER agonist (10 mg / kg for 7 days po), but not BC6OTHER (0.3 mg / kg for 7 days po), recovered the BC6OTHER protein level reduced by CHEM and increased the BC6ENTG protein level above the control one.	CPR:3
Administration of BC6OTHER , an BC6ENTG agonist (10 mg / kg for 7 days po), but not BC6ENTC (0.3 mg / kg for 7 days po), recovered the BC6OTHER protein level reduced by CHEM and increased the BC6OTHER protein level above the control one.	False
Administration of BC6OTHER , an BC6OTHER agonist (10 mg / kg for 7 days po), but not BC6ENTC (0.3 mg / kg for 7 days po), recovered the BC6ENTG protein level reduced by CHEM and increased the BC6OTHER protein level above the control one.	False
Administration of BC6OTHER , an BC6OTHER agonist (10 mg / kg for 7 days po), but not BC6ENTC (0.3 mg / kg for 7 days po), recovered the BC6OTHER protein level reduced by CHEM and increased the BC6ENTG protein level above the control one.	False
The mRNA level of BC6ENTG was scarcely affected by CHEM and BC6ENTC administration.	False
Administration of BC6ENTC (50 mg / kg for 7 days po), a denaturant of lysosomes, increased the BC6ENTG protein level reduced by CHEM.	CPR:3
Degradation of submandibular gland BC6OTHER by parasympathetic denervation of chorda tympani and its recovery by BC6ENTC , an BC6ENTG agonist.	CPR:5
Degradation of submandibular gland BC6ENTG by parasympathetic denervation of chorda tympani and its recovery by BC6ENTC , an BC6OTHER agonist.	CPR:3
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6ENTG / BC6OTHER complex was cleaved by chondroitin BC6ENTC ABC lyase, suggesting that cross - linking by chondroitin BC6OTHER is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6ENTG complex was cleaved by chondroitin BC6ENTC ABC lyase, suggesting that cross - linking by chondroitin BC6OTHER is required for the stability of the complex.	False
Experiments with recombinant BC6ENTG and BC6OTHER purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6ENTC ABC lyase, suggesting that cross - linking by chondroitin BC6OTHER is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6ENTG purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6ENTC ABC lyase, suggesting that cross - linking by chondroitin BC6OTHER is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6ENTG / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6ENTC ABC lyase, suggesting that cross - linking by chondroitin BC6OTHER is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6OTHER / BC6ENTG complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6ENTC ABC lyase, suggesting that cross - linking by chondroitin BC6OTHER is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6ENTG / BC6OTHER complex was cleaved by chondroitin BC6OTHER ABC lyase, suggesting that cross - linking by chondroitin BC6ENTC is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6ENTG complex was cleaved by chondroitin BC6OTHER ABC lyase, suggesting that cross - linking by chondroitin BC6ENTC is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by BC6ENTG , suggesting that cross - linking by chondroitin BC6ENTC is required for the stability of the complex.	False
Experiments with recombinant BC6ENTG and BC6OTHER purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6OTHER ABC lyase, suggesting that cross - linking by chondroitin BC6ENTC is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6ENTG purified from human serum showed that the BC6OTHER / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6OTHER ABC lyase, suggesting that cross - linking by chondroitin BC6ENTC is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6ENTG / BC6OTHER complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6OTHER ABC lyase, suggesting that cross - linking by chondroitin BC6ENTC is required for the stability of the complex.	False
Experiments with recombinant BC6OTHER and BC6OTHER purified from human serum showed that the BC6OTHER / BC6ENTG complex is rapidly formed even in the apparent absence of other proteins at 37 degrees C, but not at 4 degrees C. The BC6OTHER / BC6OTHER complex was cleaved by chondroitin BC6OTHER ABC lyase, suggesting that cross - linking by chondroitin BC6ENTC is required for the stability of the complex.	False
The BC6ENTC - terminal half of BC6ENTG contains a so - called BC6OTHER , characteristic for developmentally regulated proteins.	False
The BC6ENTC - terminal half of BC6OTHER contains a so - called BC6ENTG , characteristic for developmentally regulated proteins.	False
The BC6ENTC - terminal portion of BC6OTHER shows sequence homology to members of the cartilage link protein family of BC6ENTG .	False
The BC6ENTC - terminal portion of BC6ENTG shows sequence homology to members of the cartilage link protein family of BC6OTHER .	False
The protein that binds BC6ENTG was purified from human serum and identified as BC6OTHER ( BC6OTHER ) by BC6ENTC - terminal microsequencing.	False
The protein that binds BC6OTHER was purified from human serum and identified as BC6ENTG ( BC6OTHER ) by BC6ENTC - terminal microsequencing.	False
The protein that binds BC6OTHER was purified from human serum and identified as BC6OTHER ( BC6ENTG ) by BC6ENTC - terminal microsequencing.	False
Pharmacologic advances in the field in the past decades, including BC6ENTC and the BC6ENTG inhibitors, have contributed significantly to the reduced mortality of BC6OTHER - sensitive breast cancer.	False
Pharmacologic advances in the field in the past decades, including BC6OTHER and the BC6ENTG inhibitors, have contributed significantly to the reduced mortality of BC6ENTC - sensitive breast cancer.	False
BC6ENTC , a pure BC6ENTG downregulator, is a new addition to the antiestrogen therapeutic armamentarium since its FDA approval in 2002.	CPR:4
BC6ENTG expression did not correlate with tumor sensitivity to BC6ENTC , whereas BC6OTHER expression showed an inverse correlation (p < 0.01).	False
BC6OTHER expression did not correlate with tumor sensitivity to BC6ENTC , whereas BC6ENTG expression showed an inverse correlation (p < 0.01).	False
BC6ENTG expression was a stronger predictor of BC6ENTC resistance compared to BC6OTHER , BC6OTHER , or BC6OTHER .	False
BC6OTHER expression was a stronger predictor of BC6ENTC resistance compared to BC6ENTG , BC6OTHER , or BC6OTHER .	False
BC6OTHER expression was a stronger predictor of BC6ENTC resistance compared to BC6OTHER , BC6ENTG , or BC6OTHER .	False
BC6OTHER expression was a stronger predictor of BC6ENTC resistance compared to BC6OTHER , BC6OTHER , or BC6ENTG .	False
CONCLUSION: These results support a role of BC6ENTG in BC6ENTC resistance in human patient tumors.	False
We investigated the relationship between BC6ENTG expression and BC6ENTC activity in tumors from bladder, breast, head and neck, ovarian, and prostate cancer patients.	False
Bladder tumors were treated with BC6ENTC for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6OTHER were quantified and correlated with expression of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6ENTC for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6OTHER were quantified and correlated with expression of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6ENTC for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6OTHER were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6ENTC for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6OTHER were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6ENTC for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6OTHER were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG , and BC6OTHER .	False
Bladder tumors were treated with BC6ENTC for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6OTHER were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTG .	False
Bladder tumors were treated with BC6OTHER for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6ENTC were quantified and correlated with expression of BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6OTHER for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6ENTC were quantified and correlated with expression of BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6OTHER for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6ENTC were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6OTHER for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6ENTC were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG ), BC6OTHER , and BC6OTHER .	False
Bladder tumors were treated with BC6OTHER for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6ENTC were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6ENTG , and BC6OTHER .	False
Bladder tumors were treated with BC6OTHER for 2 h, and the other tumors for 24 h. Antiproliferative and proapoptotic effects of BC6ENTC were quantified and correlated with expression of BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER ), BC6OTHER , and BC6ENTG .	False
Expression of BC6ENTG correlates with resistance to BC6ENTC in human patient tumors.	False
We also analyzed the formation of BC6OTHER - BC6ENTG - inhibitor complexes by BC6OTHER BC6ENTC gel electrophoresis (SDS - PAGE).	False
In purified systems, the bimolecular rate constants for the reactions of BC6ENTG with BC6ENTC - 1 - inhibitor, BC6OTHER , and BC6OTHER were 18.5, 0.91, and 0.32 X 10(4) M - 1 min - 1, respectively.	False
In purified systems, the bimolecular rate constants for the reactions of BC6OTHER with BC6ENTC - 1 - inhibitor, BC6ENTG , and BC6OTHER were 18.5, 0.91, and 0.32 X 10(4) M - 1 min - 1, respectively.	False
In purified systems, the bimolecular rate constants for the reactions of BC6OTHER with BC6ENTC - 1 - inhibitor, BC6OTHER , and BC6ENTG were 18.5, 0.91, and 0.32 X 10(4) M - 1 min - 1, respectively.	False
Furthermore, SDS - PAGE analysis revealed that 1:1 stoichiometric complexes were formed between BC6ENTC - BC6ENTG and each of these three inhibitors.	False
This constant was reduced to 1.8 X 10( - 2) min - 1 when BC6ENTG was inactivated by BC6OTHER - deficient plasma that had been immunodepleted (less than 5%) of BC6ENTC - 1 - inhibitor.	False
This constant was reduced to 1.8 X 10( - 2) min - 1 when BC6OTHER was inactivated by BC6ENTG - deficient plasma that had been immunodepleted (less than 5%) of BC6ENTC - 1 - inhibitor.	False
In addition, after inactivation in normal plasma, 74% of the active BC6ENTC - BC6ENTG was found to form a complex with BC6OTHER - 1 - inhibitor, whereas 26% of the enzyme formed complexes with BC6OTHER and BC6OTHER .	False
In addition, after inactivation in normal plasma, 74% of the active BC6ENTC - BC6OTHER was found to form a complex with BC6ENTG , whereas 26% of the enzyme formed complexes with BC6OTHER and BC6OTHER .	False
In addition, after inactivation in normal plasma, 74% of the active BC6ENTC - BC6OTHER was found to form a complex with BC6OTHER - 1 - inhibitor, whereas 26% of the enzyme formed complexes with BC6ENTG and BC6OTHER .	False
In addition, after inactivation in normal plasma, 74% of the active BC6ENTC - BC6OTHER was found to form a complex with BC6OTHER - 1 - inhibitor, whereas 26% of the enzyme formed complexes with BC6OTHER and BC6ENTG .	False
In addition, after inactivation in normal plasma, 74% of the active BC6OTHER - BC6ENTG was found to form a complex with BC6ENTC - 1 - inhibitor, whereas 26% of the enzyme formed complexes with BC6OTHER and BC6OTHER .	False
In addition, after inactivation in normal plasma, 74% of the active BC6OTHER - BC6OTHER was found to form a complex with BC6ENTC - 1 - inhibitor, whereas 26% of the enzyme formed complexes with BC6ENTG and BC6OTHER .	False
In addition, after inactivation in normal plasma, 74% of the active BC6OTHER - BC6OTHER was found to form a complex with BC6ENTC - 1 - inhibitor, whereas 26% of the enzyme formed complexes with BC6OTHER and BC6ENTG .	False
Furthermore, 42% of the labeled enzyme was still complexed with BC6ENTC - 1 - inhibitor when BC6OTHER - BC6ENTG was inactivated in hereditary angioedema plasma that contained 32% of functional BC6OTHER - 1 - inhibitor.	False
Furthermore, 42% of the labeled enzyme was still complexed with BC6ENTC - 1 - inhibitor when BC6OTHER - BC6OTHER was inactivated in hereditary angioedema plasma that contained 32% of functional BC6ENTG .	False
Furthermore, 42% of the labeled enzyme was still complexed with BC6ENTG when BC6ENTC - BC6OTHER was inactivated in hereditary angioedema plasma that contained 32% of functional BC6OTHER - 1 - inhibitor.	False
Furthermore, 42% of the labeled enzyme was still complexed with BC6OTHER - 1 - inhibitor when BC6ENTC - BC6ENTG was inactivated in hereditary angioedema plasma that contained 32% of functional BC6OTHER - 1 - inhibitor.	False
Furthermore, 42% of the labeled enzyme was still complexed with BC6OTHER - 1 - inhibitor when BC6ENTC - BC6OTHER was inactivated in hereditary angioedema plasma that contained 32% of functional BC6ENTG .	False
Furthermore, 42% of the labeled enzyme was still complexed with BC6ENTG when BC6OTHER - BC6OTHER was inactivated in hereditary angioedema plasma that contained 32% of functional BC6ENTC - 1 - inhibitor.	False
Furthermore, 42% of the labeled enzyme was still complexed with BC6OTHER - 1 - inhibitor when BC6OTHER - BC6ENTG was inactivated in hereditary angioedema plasma that contained 32% of functional BC6ENTC - 1 - inhibitor.	False
This study quantitatively demonstrates the dominant role of BC6ENTC - 1 - inhibitor in the inactivation of BC6ENTG in the plasma milieu.	False
We also analyzed the formation of BC6ENTC - BC6ENTG - inhibitor complexes by BC6OTHER BC6OTHER gel electrophoresis (SDS - PAGE).	False
We also analyzed the formation of BC6OTHER - BC6ENTG - inhibitor complexes by BC6ENTC BC6OTHER gel electrophoresis (SDS - PAGE).	False
Endocrine therapy is first - line therapy for patients with BC6ENTC receptor - positive or BC6ENTG - positive metastatic breast cancer.	False
The BC6ENTG inhibitors are currently used as second - line therapy after BC6ENTC failure.	False
A recent study showed that BC6ENTC , an BC6ENTG inhibitor, is as effective or even superior to BC6OTHER when used as a first - line therapy.	CPR:4
A recent study showed that BC6OTHER , an BC6ENTG inhibitor, is as effective or even superior to BC6ENTC when used as a first - line therapy.	False
Endocrine therapy is first - line therapy for patients with BC6ENTG - positive or BC6ENTC receptor - positive metastatic breast cancer.	False
BC6ENTC , the first agent in this new class, not only induces the degradation of the BC6ENTG but also is an BC6OTHER antagonist; further, its lack of agonist activity provides a better safety profile.	CPR:4
BC6OTHER , the first agent in this new class, not only induces the degradation of the BC6ENTG but also is an BC6ENTC antagonist; further, its lack of agonist activity provides a better safety profile.	False
Commonly used endocrine therapies are BC6ENTC , BC6OTHER , and BC6ENTG inhibitors.	False
Commonly used endocrine therapies are BC6OTHER , BC6ENTC , and BC6ENTG inhibitors.	False
Previous studies have explored the protective effect of BC6OTHER (non - selective BC6ENTG - inhibitor) or BC6ENTC (selective BC6OTHER inhibitor) against chemical kindling in mice.	False
Previous studies have explored the protective effect of BC6OTHER (non - selective BC6OTHER - inhibitor) or BC6ENTC (selective BC6ENTG inhibitor) against chemical kindling in mice.	CPR:4
With this background, the present study was designed to explore the possible effect of BC6ENTC (a preferential BC6ENTG inhibitor) against BC6OTHER ( BC6OTHER ) - induced kindling epilepsy in mice.	CPR:4
With this background, the present study was designed to explore the possible effect of BC6OTHER (a preferential BC6ENTG inhibitor) against BC6ENTC ( BC6OTHER ) - induced kindling epilepsy in mice.	False
With this background, the present study was designed to explore the possible effect of BC6OTHER (a preferential BC6ENTG inhibitor) against BC6OTHER ( BC6ENTC ) - induced kindling epilepsy in mice.	False
Brain BC6OTHER ( BC6ENTG ), the rate - limiting enzyme in BC6ENTC synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.	CPR:9
Brain BC6ENTG ( BC6OTHER ), the rate - limiting enzyme in BC6ENTC synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.	CPR:9
Compared with normal control group, BC6ENTC - kindled mice had significantly higher levels of BC6OTHER , BC6OTHER , BC6ENTG but had lower levels of reduced BC6OTHER in the whole brain homogenate.	CPR:3
Neuroprotective effect of BC6ENTC , a preferential BC6ENTG inhibitor, against BC6OTHER ( BC6OTHER ) - induced chemical kindling and associated biochemical parameters in mice.	CPR:4
Neuroprotective effect of BC6OTHER , a preferential BC6ENTG inhibitor, against BC6ENTC ( BC6OTHER ) - induced chemical kindling and associated biochemical parameters in mice.	False
Neuroprotective effect of BC6OTHER , a preferential BC6ENTG inhibitor, against BC6OTHER ( BC6ENTC ) - induced chemical kindling and associated biochemical parameters in mice.	False
Compared with normal control group, BC6OTHER - kindled mice had significantly higher levels of BC6ENTC , BC6OTHER , BC6ENTG but had lower levels of reduced BC6OTHER in the whole brain homogenate.	False
Compared with normal control group, BC6OTHER - kindled mice had significantly higher levels of BC6OTHER , BC6ENTC , BC6ENTG but had lower levels of reduced BC6OTHER in the whole brain homogenate.	False
Compared with normal control group, BC6OTHER - kindled mice had significantly higher levels of BC6OTHER , BC6OTHER , BC6ENTG but had lower levels of reduced BC6ENTC in the whole brain homogenate.	False
These results suggested that BC6ENTC , a preferential BC6ENTG inhibitor offered neuroprotection against BC6OTHER - induced kindling in mice.	CPR:4
These results suggested that BC6OTHER , a preferential BC6ENTG inhibitor offered neuroprotection against BC6ENTC - induced kindling in mice.	False
Previous studies have explored the protective effect of BC6ENTC (non - selective BC6ENTG - inhibitor) or BC6OTHER (selective BC6OTHER inhibitor) against chemical kindling in mice.	CPR:4
Previous studies have explored the protective effect of BC6ENTC (non - selective BC6OTHER - inhibitor) or BC6OTHER (selective BC6ENTG inhibitor) against chemical kindling in mice.	False
Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose - dependent correlation between cumulative exposure to BC6ENTC from CHEM and urinary levels of BC6ENTG , after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of BC6OTHER .	False
Overall, the present study, using a different and more sensitive statistical model than the parent study, revealed a statistically significant dose - dependent correlation between cumulative exposure to BC6ENTC from CHEM and urinary levels of BC6OTHER , after covariate adjustment; where as, a nonsignificant relationship was observed with urinary levels of BC6ENTG .	False
It was hypothesized that because BC6ENTC accumulates in the proximal tubules (PTs), BC6ENTG (suggestive of kidney damage at the level of PT) would be expected to be more related to BC6OTHER exposure than BC6OTHER (suggestive of kidney damage at the level of the distal tubules).	False
It was hypothesized that because BC6ENTC accumulates in the proximal tubules (PTs), BC6OTHER - BC6OTHER - transferases (GST) - α (suggestive of kidney damage at the level of PT) would be expected to be more related to BC6OTHER exposure than BC6ENTG (suggestive of kidney damage at the level of the distal tubules).	False
It was hypothesized that because BC6OTHER accumulates in the proximal tubules (PTs), BC6ENTC - BC6OTHER - transferases (GST) - α (suggestive of kidney damage at the level of PT) would be expected to be more related to BC6OTHER exposure than BC6ENTG (suggestive of kidney damage at the level of the distal tubules).	False
It was hypothesized that because BC6OTHER accumulates in the proximal tubules (PTs), BC6OTHER - BC6ENTC - transferases (GST) - α (suggestive of kidney damage at the level of PT) would be expected to be more related to BC6OTHER exposure than BC6ENTG (suggestive of kidney damage at the level of the distal tubules).	False
It was hypothesized that because BC6OTHER accumulates in the proximal tubules (PTs), BC6ENTG (suggestive of kidney damage at the level of PT) would be expected to be more related to BC6ENTC exposure than BC6OTHER (suggestive of kidney damage at the level of the distal tubules).	False
It was hypothesized that because BC6OTHER accumulates in the proximal tubules (PTs), BC6OTHER - BC6OTHER - transferases (GST) - α (suggestive of kidney damage at the level of PT) would be expected to be more related to BC6ENTC exposure than BC6ENTG (suggestive of kidney damage at the level of the distal tubules).	False
Our study determined whether there was a significant dose - dependent correlation between increasing BC6ENTC exposure from CHEM and BC6ENTG and BC6OTHER as biomarkers of kidney integrity.	False
Our study determined whether there was a significant dose - dependent correlation between increasing BC6ENTC exposure from CHEM and BC6OTHER and BC6ENTG as biomarkers of kidney integrity.	False
BC6ENTG , a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to BC6ENTC treatment.	CPR:4
Consistent with BC6ENTC finger E - box binding homeobox 2, which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6ENTG decreased in the BC6OTHER - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	False
Consistent with BC6ENTC finger E - box binding homeobox 2, which was confirmed as a direct target of BC6ENTG in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6OTHER decreased in the BC6OTHER - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	False
Consistent with BC6ENTC finger E - box binding homeobox 2, which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6ENTG and BC6OTHER increased, whereas BC6OTHER decreased in the BC6OTHER - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	False
Consistent with BC6ENTC finger E - box binding homeobox 2, which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6ENTG increased, whereas BC6OTHER decreased in the BC6OTHER - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	False
Although BC6ENTC ( BC6OTHER ), a selective BC6ENTG modulator, has been widely used in the treatment of hormone - responsive breast cancer, its BC6OTHER - like effect increases the risk of endometrial cancer.	False
 BC6ENTC represses BC6OTHER microRNAs and promotes epithelial - to - mesenchymal transition by up - regulating BC6ENTG in endometrial carcinoma cell lines.	CPR:3
 BC6ENTC represses BC6ENTG microRNAs and promotes epithelial - to - mesenchymal transition by up - regulating BC6OTHER in endometrial carcinoma cell lines.	CPR:4
Consistent with BC6OTHER , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6ENTG decreased in the BC6ENTC - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	CPR:4
Consistent with BC6ENTG , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6OTHER decreased in the BC6ENTC - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	False
Consistent with BC6OTHER , which was confirmed as a direct target of BC6ENTG in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6OTHER decreased in the BC6ENTC - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	False
Consistent with BC6OTHER , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6ENTG and BC6OTHER increased, whereas BC6OTHER decreased in the BC6ENTC - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	CPR:3
Consistent with BC6OTHER , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6ENTG increased, whereas BC6OTHER decreased in the BC6ENTC - treated cells, contributing to BC6OTHER - induced EMT in these endometrial cancer cells.	CPR:3
Consistent with BC6OTHER , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6ENTG decreased in the BC6OTHER - treated cells, contributing to BC6ENTC - induced EMT in these endometrial cancer cells.	False
Consistent with BC6ENTG , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6OTHER decreased in the BC6OTHER - treated cells, contributing to BC6ENTC - induced EMT in these endometrial cancer cells.	False
Consistent with BC6OTHER , which was confirmed as a direct target of BC6ENTG in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6OTHER increased, whereas BC6OTHER decreased in the BC6OTHER - treated cells, contributing to BC6ENTC - induced EMT in these endometrial cancer cells.	False
Consistent with BC6OTHER , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6ENTG and BC6OTHER increased, whereas BC6OTHER decreased in the BC6OTHER - treated cells, contributing to BC6ENTC - induced EMT in these endometrial cancer cells.	False
Consistent with BC6OTHER , which was confirmed as a direct target of BC6OTHER in endometrial cancer cell lines, some other key factors of EMT such as BC6OTHER and BC6ENTG increased, whereas BC6OTHER decreased in the BC6OTHER - treated cells, contributing to BC6ENTC - induced EMT in these endometrial cancer cells.	False
In addition, we showed that BC6ENTG directly binds to and represses the promoter of BC6OTHER miRNAs, and its up - regulation in BC6ENTC - treated endometrial cancer cells leads to the down - regulation of BC6OTHER and eventually to EMT.	False
In addition, we showed that BC6OTHER directly binds to and represses the promoter of BC6ENTG miRNAs, and its up - regulation in BC6ENTC - treated endometrial cancer cells leads to the down - regulation of BC6OTHER and eventually to EMT.	False
In addition, we showed that BC6OTHER directly binds to and represses the promoter of BC6OTHER miRNAs, and its up - regulation in BC6ENTC - treated endometrial cancer cells leads to the down - regulation of BC6ENTG and eventually to EMT.	CPR:4
Collectively, our data suggest that BC6ENTC can repress the BC6ENTG family and induce EMT via the up - regulation of BC6OTHER in endometrial cancer cells.	CPR:4
Collectively, our data suggest that BC6ENTC can repress the BC6OTHER family and induce EMT via the up - regulation of BC6ENTG in endometrial cancer cells.	CPR:3
Although BC6OTHER ( BC6OTHER ), a selective BC6ENTG modulator, has been widely used in the treatment of hormone - responsive breast cancer, its BC6ENTC - like effect increases the risk of endometrial cancer.	False
Although BC6OTHER ( BC6ENTC ), a selective BC6ENTG modulator, has been widely used in the treatment of hormone - responsive breast cancer, its BC6OTHER - like effect increases the risk of endometrial cancer.	False
In this report, we explored the role of microRNAs (miRNAs) in BC6ENTC - induced epithelial - mesenchymal transition (EMT) in ECC - 1 and Ishikawa endometrial cancer cell lines and found BC6ENTG is involved in this process via the regulation of BC6OTHER .	False
In this report, we explored the role of microRNAs (miRNAs) in BC6ENTC - induced epithelial - mesenchymal transition (EMT) in ECC - 1 and Ishikawa endometrial cancer cell lines and found BC6OTHER is involved in this process via the regulation of BC6ENTG .	False
 BC6ENTC was chosen as a model to study the mechanisms underlying the cardiovascular effects of i.v. BC6ENTG inhibitors.	CPR:4
The BC6ENTG antagonist BC6ENTC or the BC6OTHER antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6OTHER partially but significantly reduced BC6OTHER pressor effect and mostly abolished it when administered concomitantly.	CPR:6
The BC6OTHER antagonist BC6ENTC or the BC6ENTG antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6OTHER partially but significantly reduced BC6OTHER pressor effect and mostly abolished it when administered concomitantly.	False
The BC6OTHER antagonist BC6ENTC or the BC6OTHER antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6ENTG partially but significantly reduced BC6OTHER pressor effect and mostly abolished it when administered concomitantly.	False
The BC6ENTG antagonist BC6OTHER or the BC6ENTC V1 receptor antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6OTHER partially but significantly reduced BC6OTHER pressor effect and mostly abolished it when administered concomitantly.	False
The BC6OTHER antagonist BC6OTHER or the BC6ENTC V1 receptor antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6ENTG partially but significantly reduced BC6OTHER pressor effect and mostly abolished it when administered concomitantly.	False
The cardiovascular effects of three different BC6ENTG inhibitors: BC6ENTC , BC6OTHER and BC6OTHER injected by intravenous (i.v.)	CPR:4
 The BC6ENTC pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6ENTG antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6ENTC pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6ENTC pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6ENTC pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6ENTG antagonist BC6OTHER (ID50 = 31.19 microg).	False
The BC6ENTG antagonist BC6OTHER or the BC6OTHER antagonist, BC6ENTC partially but significantly reduced BC6OTHER pressor effect and mostly abolished it when administered concomitantly.	False
The BC6OTHER antagonist BC6OTHER or the BC6ENTG antagonist, BC6ENTC partially but significantly reduced BC6OTHER pressor effect and mostly abolished it when administered concomitantly.	CPR:6
The cardiovascular effects of three different BC6ENTG inhibitors: BC6OTHER , BC6ENTC and BC6OTHER injected by intravenous (i.v.)	CPR:4
The BC6ENTG antagonist BC6OTHER or the BC6OTHER antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6OTHER partially but significantly reduced BC6ENTC pressor effect and mostly abolished it when administered concomitantly.	False
The BC6OTHER antagonist BC6OTHER or the BC6ENTG antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6OTHER partially but significantly reduced BC6ENTC pressor effect and mostly abolished it when administered concomitantly.	False
The BC6OTHER antagonist BC6OTHER or the BC6OTHER antagonist, [beta - mercapto - beta,beta - cyclopenta - methylenepropionyl1, CHEM, Arg8] BC6ENTG partially but significantly reduced BC6ENTC pressor effect and mostly abolished it when administered concomitantly.	False
Pressor and bradycardic effects of BC6ENTC and other BC6ENTG inhibitors in the rat.	False
The cardiovascular effects of three different BC6ENTG inhibitors: BC6OTHER , BC6OTHER and BC6ENTC injected by intravenous (i.v.)	CPR:4
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6ENTG antagonist BC6ENTC (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	CPR:6
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6ENTC (ID50 = 1.45 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6ENTC (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6ENTC (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6ENTG antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6ENTG antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6ENTC (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6ENTG antagonist BC6ENTC (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	CPR:6
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6ENTC (ID50 = 4.33 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6ENTC (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6ENTG antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6ENTG antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6ENTC (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6ENTC (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6ENTG antagonist BC6ENTC (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6OTHER (ID50 = 31.19 microg).	CPR:6
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6ENTC (ID50 = 1.39 microg) and the BC6ENTG antagonist BC6OTHER (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6ENTG antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6ENTC (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6ENTC (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6ENTG antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6OTHER antagonist BC6ENTC (ID50 = 31.19 microg).	False
 The BC6OTHER pressor response was inhibited in a dose - dependent manner by the i.c.v. administration of the non - selective BC6OTHER antagonist BC6OTHER (ID50 = 1.45 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 4.33 microg), the BC6OTHER antagonist BC6OTHER (ID50 = 1.39 microg) and the BC6ENTG antagonist BC6ENTC (ID50 = 31.19 microg).	CPR:6
Central injection of such BC6ENTG antagonists did not affect BC6ENTC - induced bradycardia.	False
Our results show that BC6ENTG inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central BC6OTHER inducing a secondary increase in sympathetic outflow and BC6ENTC release.	False
Our results show that BC6OTHER inhibitors induce significant cardiovascular effects with a pressor response mediated mainly by the stimulation of central BC6ENTG inducing a secondary increase in sympathetic outflow and BC6ENTC release.	False
Thus, the current study suggests that coadministration of clinical doses of BC6OTHER and BC6OTHER increases the Css of BC6OTHER and reduced BC6OTHER via the inhibitory effects on the BC6ENTG - catalyzed metabolism of BC6OTHER and reduced BC6ENTC .	CPR:9
The effects of BC6OTHER H1 - receptor antagonists, BC6OTHER and BC6OTHER , both of which are inhibitors of BC6ENTG , on the steady - state plasma concentrations (Css) of BC6ENTC and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	False
The effects of BC6ENTG antagonists, BC6OTHER and BC6OTHER , both of which are inhibitors of BC6OTHER , on the steady - state plasma concentrations (Css) of BC6ENTC and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	False
The effects of BC6OTHER H1 - receptor antagonists, BC6OTHER and BC6OTHER , both of which are inhibitors of BC6ENTG , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6ENTC were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	False
The effects of BC6ENTG antagonists, BC6OTHER and BC6OTHER , both of which are inhibitors of BC6OTHER , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6ENTC were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	False
The effects of BC6OTHER H1 - receptor antagonists, BC6OTHER and BC6OTHER , both of which are inhibitors of BC6ENTG , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6ENTC , 12 to 36 mg / d, for 2 to 29 weeks.	False
The effects of BC6ENTG antagonists, BC6OTHER and BC6OTHER , both of which are inhibitors of BC6OTHER , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6ENTC , 12 to 36 mg / d, for 2 to 29 weeks.	False
The effects of BC6OTHER H1 - receptor antagonists, BC6ENTC and BC6OTHER , both of which are inhibitors of BC6ENTG , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	CPR:4
The effects of BC6ENTG antagonists, BC6ENTC and BC6OTHER , both of which are inhibitors of BC6OTHER , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	CPR:6
The effects of BC6OTHER H1 - receptor antagonists, BC6OTHER and BC6ENTC , both of which are inhibitors of BC6ENTG , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	CPR:4
The effects of BC6ENTG antagonists, BC6OTHER and BC6ENTC , both of which are inhibitors of BC6OTHER , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	CPR:6
 BC6ENTG antagonists, BC6OTHER and BC6OTHER , increase the steady - state plasma concentrations of BC6ENTC and reduced BC6OTHER .	False
 BC6ENTG antagonists, BC6OTHER and BC6OTHER , increase the steady - state plasma concentrations of BC6OTHER and reduced BC6ENTC .	False
 BC6ENTG antagonists, BC6ENTC and BC6OTHER , increase the steady - state plasma concentrations of BC6OTHER and reduced BC6OTHER .	CPR:6
 BC6ENTG antagonists, BC6OTHER and BC6ENTC , increase the steady - state plasma concentrations of BC6OTHER and reduced BC6OTHER .	CPR:6
The effects of BC6ENTC H1 - receptor antagonists, BC6OTHER and BC6OTHER , both of which are inhibitors of BC6ENTG , on the steady - state plasma concentrations (Css) of BC6OTHER and reduced BC6OTHER were studied in 23 schizophrenic inpatients receiving BC6OTHER , 12 to 36 mg / d, for 2 to 29 weeks.	False
Thus, the current study suggests that coadministration of clinical doses of BC6ENTC and BC6OTHER increases the Css of BC6OTHER and reduced BC6OTHER via the inhibitory effects on the BC6ENTG - catalyzed metabolism of BC6OTHER and reduced BC6OTHER .	CPR:4
Thus, the current study suggests that coadministration of clinical doses of BC6OTHER and BC6ENTC increases the Css of BC6OTHER and reduced BC6OTHER via the inhibitory effects on the BC6ENTG - catalyzed metabolism of BC6OTHER and reduced BC6OTHER .	CPR:4
Thus, the current study suggests that coadministration of clinical doses of BC6OTHER and BC6OTHER increases the Css of BC6ENTC and reduced BC6OTHER via the inhibitory effects on the BC6ENTG - catalyzed metabolism of BC6OTHER and reduced BC6OTHER .	False
Thus, the current study suggests that coadministration of clinical doses of BC6OTHER and BC6OTHER increases the Css of BC6OTHER and reduced BC6ENTC via the inhibitory effects on the BC6ENTG - catalyzed metabolism of BC6OTHER and reduced BC6OTHER .	False
Thus, the current study suggests that coadministration of clinical doses of BC6OTHER and BC6OTHER increases the Css of BC6OTHER and reduced BC6OTHER via the inhibitory effects on the BC6ENTG - catalyzed metabolism of BC6ENTC and reduced BC6OTHER .	CPR:9
BC6OTHER potentiates BC6ENTC - stimulated BC6ENTG secretion and induces energy accumulation into adipose tissue, resulting in obesity.	CPR:3
BC6ENTG potentiates BC6ENTC - stimulated BC6OTHER secretion and induces energy accumulation into adipose tissue, resulting in obesity.	False
BC6OTHER is a well known BC6ENTG blocker and has been shown to affect presynaptic BC6ENTC currents as well postsynaptic potentials.	False
BC6ENTG is a well known P / Q - type BC6OTHER channel blocker and has been shown to affect presynaptic BC6ENTC currents as well postsynaptic potentials.	False
Administration of BC6ENTC , a BC6ENTG inhibitor, isolated a single response to BC6OTHER , which was characterized by a reduction in network activity.	CPR:4
Administration of BC6ENTC , a BC6OTHER inhibitor, isolated a single response to BC6ENTG , which was characterized by a reduction in network activity.	CPR:4
BC6ENTG is a well known P / Q - type BC6ENTC channel blocker and has been shown to affect presynaptic BC6OTHER currents as well postsynaptic potentials.	False
This methodology was subsequently used to assess the relative contribution of BC6ENTG uptake in human hepatocytes for BC6OTHER (42% - 62%), BC6OTHER (28% - 81%), BC6OTHER (64% - 72%), BC6ENTC (84% - 98%) and BC6OTHER (64% - 89%).	CPR:9
This methodology was subsequently used to assess the relative contribution of BC6ENTG uptake in human hepatocytes for BC6OTHER (42% - 62%), BC6OTHER (28% - 81%), BC6OTHER (64% - 72%), BC6OTHER (84% - 98%) and BC6ENTC (64% - 89%).	CPR:9
Uptake of BC6ENTC (5 nM) by BC6ENTG was reduced by 82% - 95%.	CPR:9
This methodology was subsequently used to assess the relative contribution of BC6ENTG uptake in human hepatocytes for BC6ENTC (42% - 62%), BC6OTHER (28% - 81%), BC6OTHER (64% - 72%), BC6OTHER (84% - 98%) and BC6OTHER (64% - 89%).	CPR:9
This methodology was subsequently used to assess the relative contribution of BC6ENTG uptake in human hepatocytes for BC6OTHER (42% - 62%), BC6ENTC (28% - 81%), BC6OTHER (64% - 72%), BC6OTHER (84% - 98%) and BC6OTHER (64% - 89%).	CPR:9
This methodology was subsequently used to assess the relative contribution of BC6ENTG uptake in human hepatocytes for BC6OTHER (42% - 62%), BC6OTHER (28% - 81%), BC6ENTC (64% - 72%), BC6OTHER (84% - 98%) and BC6OTHER (64% - 89%).	CPR:9
In the kinetic analyses using Lineweaver - Burk plots of 1 / velocity and 1 / substrate, BC6ENTC showed competitive inhibition of BC6ENTG .	CPR:4
As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on BC6ENTC reductase ( BC6ENTG ) and BC6OTHER formation in rat lenses with high levels of BC6OTHER .	False
As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on BC6ENTG ( BC6OTHER ) and BC6ENTC formation in rat lenses with high levels of BC6OTHER .	False
As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on BC6OTHER reductase ( BC6ENTG ) and BC6ENTC formation in rat lenses with high levels of BC6OTHER .	False
As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on BC6ENTG ( BC6OTHER ) and BC6OTHER formation in rat lenses with high levels of BC6ENTC .	False
As part of our ongoing search for natural sources of therapeutic and preventive agents for diabetic complications, we evaluated the inhibitory effects of components of the fruit of Xanthium strumarium (X. strumarium) on BC6OTHER reductase ( BC6ENTG ) and BC6OTHER formation in rat lenses with high levels of BC6ENTC .	False
From the 10 isolated compounds, BC6ENTC showed the most potent inhibition, with IC50 values of 0.30 and 0.67 μM for BC6ENTG and BC6OTHER , respectively.	CPR:4
From the 10 isolated compounds, BC6ENTC showed the most potent inhibition, with IC50 values of 0.30 and 0.67 μM for BC6OTHER and BC6ENTG , respectively.	CPR:4
BC6ENTC block of BC6ENTG and rat skeletal (mu1) muscle BC6OTHER channels was examined under whole - cell voltage clamp in transiently transfected HEK293t cells.	CPR:4
BC6ENTC block of BC6OTHER and BC6ENTG was examined under whole - cell voltage clamp in transiently transfected HEK293t cells.	CPR:4
BC6ENTC block of BC6ENTG was greater than block of BC6OTHER at voltages between - 120 mV and - 90 mV, suggesting that greater steady - state inactivation of BC6OTHER in this voltage range makes them more susceptible to BC6OTHER block.	CPR:4
BC6ENTC block of BC6OTHER was greater than block of BC6ENTG at voltages between - 120 mV and - 90 mV, suggesting that greater steady - state inactivation of BC6OTHER in this voltage range makes them more susceptible to BC6OTHER block.	CPR:4
BC6ENTC block of BC6OTHER was greater than block of BC6OTHER at voltages between - 120 mV and - 90 mV, suggesting that greater steady - state inactivation of BC6ENTG in this voltage range makes them more susceptible to BC6OTHER block.	CPR:4
BC6OTHER block of BC6ENTG was greater than block of BC6OTHER at voltages between - 120 mV and - 90 mV, suggesting that greater steady - state inactivation of BC6OTHER in this voltage range makes them more susceptible to BC6ENTC block.	False
BC6OTHER block of BC6OTHER was greater than block of BC6ENTG at voltages between - 120 mV and - 90 mV, suggesting that greater steady - state inactivation of BC6OTHER in this voltage range makes them more susceptible to BC6ENTC block.	False
BC6OTHER block of BC6OTHER was greater than block of BC6OTHER at voltages between - 120 mV and - 90 mV, suggesting that greater steady - state inactivation of BC6ENTG in this voltage range makes them more susceptible to BC6ENTC block.	CPR:4
BC6OTHER block of BC6ENTG and rat skeletal (mu1) muscle BC6ENTC channels was examined under whole - cell voltage clamp in transiently transfected HEK293t cells.	False
State - dependent BC6ENTC block of BC6ENTG isoforms, chimeras, and channels coexpressed with the beta1 subunit.	CPR:4
These data suggest that TP treatment could alter the hepatic redox status, reduce serum BC6ENTC and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in BC6ENTG signaling pathway, BC6OTHER metabolism pathway and cell stress pathway, all of which might contribute to the overall TP - induced hepatotoxicity.	False
These data suggest that TP treatment could alter the hepatic redox status, reduce serum BC6OTHER and induce hepatocyte apoptosis, consistent with the differential expression of genes involved in BC6ENTG signaling pathway, BC6ENTC metabolism pathway and cell stress pathway, all of which might contribute to the overall TP - induced hepatotoxicity.	False
Analyses of these genes identified over - represented functions associated with BC6ENTG signaling pathway, BC6ENTC metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6ENTC metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6ENTG activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6ENTC metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6ENTG and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6ENTC metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6ENTG activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6ENTG signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6ENTC , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6ENTG activity and reduction of serum BC6ENTC , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6ENTC , BC6OTHER / BC6OTHER ratio, BC6ENTG and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6ENTC , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6ENTG activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6ENTG signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6ENTC / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6ENTG activity and reduction of serum BC6OTHER , BC6ENTC / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6ENTC / BC6OTHER ratio, BC6ENTG and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6ENTC / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6ENTG activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6ENTG signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6ENTC ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6ENTG activity and reduction of serum BC6OTHER , BC6OTHER / BC6ENTC ratio, BC6OTHER - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6ENTC ratio, BC6ENTG and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6ENTC ratio, BC6OTHER - 6 - phosphatase and BC6ENTG activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6ENTG signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6ENTC - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6ENTG activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6ENTC - 6 - phosphatase and BC6OTHER carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6ENTC - 6 - phosphatase and BC6ENTG activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6ENTG signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6ENTC carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6ENTG activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6OTHER - 6 - phosphatase and BC6ENTC carboxykinase activities, liver glycogen.	False
Analyses of these genes identified over - represented functions associated with BC6OTHER signaling pathway, BC6OTHER metabolism, cell cycle, oxidative stress and apoptosis, which were consistent with the results of significant increase of BC6OTHER activity and reduction of serum BC6OTHER , BC6OTHER / BC6OTHER ratio, BC6ENTG and BC6ENTC carboxykinase activities, liver glycogen.	False
The 2.0 - A resolution structure of BC6ENTG reveals a distorted BC6OTHER and a BC6OTHER located above the BC6ENTC - terminal ends of the strands of the barrel.	False
The 2.0 - A resolution structure of BC6OTHER reveals a distorted BC6ENTG and a BC6OTHER located above the BC6ENTC - terminal ends of the strands of the barrel.	False
The 2.0 - A resolution structure of BC6OTHER reveals a distorted BC6OTHER and a BC6ENTG located above the BC6ENTC - terminal ends of the strands of the barrel.	False
BC6ENTC dehydrogenase ( BC6ENTG ) and BC6OTHER dehydrogenase ( BC6OTHER ) catalyze the two - step oxidation of BC6OTHER to BC6OTHER .	False
BC6ENTC dehydrogenase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) catalyze the two - step oxidation of BC6OTHER to BC6OTHER .	False
BC6ENTC dehydrogenase ( BC6OTHER ) and BC6OTHER dehydrogenase ( BC6ENTG ) catalyze the two - step oxidation of BC6OTHER to BC6OTHER .	False
BC6ENTG ( BC6OTHER ) and BC6OTHER dehydrogenase ( BC6OTHER ) catalyze the two - step oxidation of BC6ENTC to BC6OTHER .	CPR:9
BC6OTHER dehydrogenase ( BC6ENTG ) and BC6OTHER dehydrogenase ( BC6OTHER ) catalyze the two - step oxidation of BC6ENTC to BC6OTHER .	CPR:9
BC6OTHER dehydrogenase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) catalyze the two - step oxidation of BC6ENTC to BC6OTHER .	CPR:9
BC6OTHER dehydrogenase ( BC6OTHER ) and BC6OTHER dehydrogenase ( BC6ENTG ) catalyze the two - step oxidation of BC6ENTC to BC6OTHER .	CPR:9
BC6ENTG ( BC6OTHER ) and BC6OTHER dehydrogenase ( BC6OTHER ) catalyze the two - step oxidation of BC6OTHER to BC6ENTC .	CPR:9
BC6OTHER dehydrogenase ( BC6ENTG ) and BC6OTHER dehydrogenase ( BC6OTHER ) catalyze the two - step oxidation of BC6OTHER to BC6ENTC .	CPR:9
BC6OTHER dehydrogenase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) catalyze the two - step oxidation of BC6OTHER to BC6ENTC .	CPR:9
BC6OTHER dehydrogenase ( BC6OTHER ) and BC6OTHER dehydrogenase ( BC6ENTG ) catalyze the two - step oxidation of BC6OTHER to BC6ENTC .	CPR:9
Finally, we demonstrate that BC6ENTG reacts with BC6ENTC producing BC6OTHER .	CPR:9
Finally, we demonstrate that BC6ENTG reacts with BC6OTHER producing BC6ENTC .	CPR:9
This is significant because BC6ENTC production underlies the role of BC6ENTG in BC6OTHER - mediated apoptosis, implying commonalities between BC6OTHER .	CPR:9
This is significant because BC6ENTC production underlies the role of BC6OTHER in BC6ENTG - mediated apoptosis, implying commonalities between BC6OTHER .	False
This is significant because BC6ENTC production underlies the role of BC6OTHER in BC6OTHER - mediated apoptosis, implying commonalities between BC6ENTG .	False
BC6ENTG ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6OTHER ) catalyze the two - step oxidation of BC6OTHER to BC6OTHER .	False
BC6OTHER dehydrogenase ( BC6ENTG ) and BC6ENTC dehydrogenase ( BC6OTHER ) catalyze the two - step oxidation of BC6OTHER to BC6OTHER .	False
BC6OTHER dehydrogenase ( BC6OTHER ) and BC6ENTC dehydrogenase ( BC6ENTG ) catalyze the two - step oxidation of BC6OTHER to BC6OTHER .	False
BC6ENTC bound with high affinity to BC6ENTG from macaque (K(d) = 1.36+ / - 0.07 nM) and human (K(d) = 0.86 + / - 0.08 nM), but was found to dissociate approximately 10 - fold more quickly from BC6OTHER .	False
BC6ENTC bound with high affinity to BC6OTHER from macaque (K(d) = 1.36+ / - 0.07 nM) and human (K(d) = 0.86 + / - 0.08 nM), but was found to dissociate approximately 10 - fold more quickly from BC6ENTG .	False
However, as with the human receptor, BC6ENTC was shown to be a high affinity, potent functional antagonist of BC6ENTG thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism - related toxicology of novel BC6OTHER antagonists.	CPR:6
However, as with the human receptor, BC6ENTC was shown to be a high affinity, potent functional antagonist of BC6OTHER thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism - related toxicology of novel BC6ENTG antagonists.	CPR:6
The aim of this study was to determine if macaque represents a suitable species for the pre - clinical evaluation of novel BC6ENTG antagonists, such as BC6ENTC ( BC6OTHER ).	CPR:6
The aim of this study was to determine if macaque represents a suitable species for the pre - clinical evaluation of novel BC6ENTG antagonists, such as BC6OTHER ( BC6ENTC ).	CPR:6
To do this we cloned and expressed BC6ENTG from rhesus macaque and compared the binding properties of [ BC6ENTC ] - MIP - 1beta and BC6OTHER with BC6OTHER .	False
To do this we cloned and expressed BC6OTHER from rhesus macaque and compared the binding properties of [ BC6ENTC ] - MIP - 1beta and BC6OTHER with BC6ENTG .	False
To do this we cloned and expressed BC6ENTG from rhesus macaque and compared the binding properties of [ BC6OTHER ] - MIP - 1beta and BC6ENTC with BC6OTHER .	False
To do this we cloned and expressed BC6OTHER from rhesus macaque and compared the binding properties of [ BC6OTHER ] - MIP - 1beta and BC6ENTC with BC6ENTG .	False
[ BC6ENTC ] - MIP - 1beta bound with similar high affinity to BC6ENTG from macaque (K(d) = 0.24 + / - 0.05 nM) and human (K(d) = 0.23 + / - 0.05 nM) and with similar kinetic properties.	False
BC6ENTC inhibited binding of [ BC6OTHER ] - MIP - 1beta to BC6ENTG from macaque and human with similar potency (IC50 = 17.50 + / - 1.24 nM and 7.18 + / - 0.93 nM, respectively) and antagonised MIP - 1beta induced intracellular BC6OTHER release mediated through BC6OTHER from macaque and human with similar potency (IC50 = 17.50 + / - 3.30 nM and 12.07 + / - 1.89, respectively).	False
BC6ENTC inhibited binding of [ BC6OTHER ] - MIP - 1beta to BC6OTHER from macaque and human with similar potency (IC50 = 17.50 + / - 1.24 nM and 7.18 + / - 0.93 nM, respectively) and antagonised MIP - 1beta induced intracellular BC6OTHER release mediated through BC6ENTG from macaque and human with similar potency (IC50 = 17.50 + / - 3.30 nM and 12.07 + / - 1.89, respectively).	CPR:6
BC6OTHER inhibited binding of [ BC6ENTC ] - MIP - 1beta to BC6ENTG from macaque and human with similar potency (IC50 = 17.50 + / - 1.24 nM and 7.18 + / - 0.93 nM, respectively) and antagonised MIP - 1beta induced intracellular BC6OTHER release mediated through BC6OTHER from macaque and human with similar potency (IC50 = 17.50 + / - 3.30 nM and 12.07 + / - 1.89, respectively).	False
BC6OTHER inhibited binding of [ BC6ENTC ] - MIP - 1beta to BC6OTHER from macaque and human with similar potency (IC50 = 17.50 + / - 1.24 nM and 7.18 + / - 0.93 nM, respectively) and antagonised MIP - 1beta induced intracellular BC6OTHER release mediated through BC6ENTG from macaque and human with similar potency (IC50 = 17.50 + / - 3.30 nM and 12.07 + / - 1.89, respectively).	False
BC6OTHER inhibited binding of [ BC6OTHER ] - MIP - 1beta to BC6ENTG from macaque and human with similar potency (IC50 = 17.50 + / - 1.24 nM and 7.18 + / - 0.93 nM, respectively) and antagonised MIP - 1beta induced intracellular BC6ENTC release mediated through BC6OTHER from macaque and human with similar potency (IC50 = 17.50 + / - 3.30 nM and 12.07 + / - 1.89, respectively).	False
BC6OTHER inhibited binding of [ BC6OTHER ] - MIP - 1beta to BC6OTHER from macaque and human with similar potency (IC50 = 17.50 + / - 1.24 nM and 7.18 + / - 0.93 nM, respectively) and antagonised MIP - 1beta induced intracellular BC6ENTC release mediated through BC6ENTG from macaque and human with similar potency (IC50 = 17.50 + / - 3.30 nM and 12.07 + / - 1.89, respectively).	False
BC6ENTC apparently reduces translational efficiency of BC6ENTG mRNA into protein, a process that may involve an interaction with BC6OTHER and / or an BC6OTHER - responsive element.	CPR:4
BC6OTHER apparently reduces translational efficiency of BC6ENTG mRNA into protein, a process that may involve an interaction with BC6ENTC and / or an BC6OTHER - responsive element.	False
BC6OTHER apparently reduces translational efficiency of BC6ENTG mRNA into protein, a process that may involve an interaction with BC6OTHER and / or an BC6ENTC - responsive element.	False
 As a consequence, BC6ENTC reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6ENTG , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6ENTC reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6ENTG inhibitor and can be dosed much higher.	False
 As a consequence, BC6ENTC reduces BC6ENTG peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	CPR:4
 As a consequence, BC6ENTC reduces BC6OTHER peptide ( BC6ENTG ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	CPR:4
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6ENTC is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6ENTG , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6ENTC is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6ENTG inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6ENTG peptide ( BC6OTHER ) formation in vitro and in vivo. BC6ENTC is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6ENTG ) formation in vitro and in vivo. BC6ENTC is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
BC6ENTC , a derivative of BC6OTHER , was first described as an inhibitor of BC6OTHER ( BC6ENTG ) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
BC6ENTC , a derivative of BC6OTHER , was first described as an inhibitor of BC6ENTG ( BC6OTHER ) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6ENTC is the active enantiomer for inhibition of BC6ENTG , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	CPR:4
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6ENTC is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6ENTG inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6ENTG peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6ENTC is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6ENTG ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6ENTC is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6ENTG , whereas BC6ENTC (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6ENTC (' BC6OTHER ') has weak activity as an BC6ENTG inhibitor and can be dosed much higher.	CPR:4
 As a consequence, BC6OTHER reduces BC6ENTG peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6ENTC (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6ENTG ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6ENTC (' BC6OTHER ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6ENTG , whereas BC6OTHER (' BC6ENTC ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6ENTC ') has weak activity as an BC6ENTG inhibitor and can be dosed much higher.	CPR:4
 As a consequence, BC6OTHER reduces BC6ENTG peptide ( BC6OTHER ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6ENTC ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
 As a consequence, BC6OTHER reduces BC6OTHER peptide ( BC6ENTG ) formation in vitro and in vivo. BC6OTHER is also unique because of differing actions of its enantiomers: BC6OTHER is the active enantiomer for inhibition of BC6OTHER , whereas BC6OTHER (' BC6ENTC ') has weak activity as an BC6OTHER inhibitor and can be dosed much higher.	False
BC6OTHER , a derivative of BC6ENTC , was first described as an inhibitor of BC6OTHER ( BC6ENTG ) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
BC6OTHER , a derivative of BC6ENTC , was first described as an inhibitor of BC6ENTG ( BC6OTHER ) and was shown to improve cognition in various experimental paradigms in rodents and dogs.	CPR:4
BC6ENTC deserves attention for an additional quality of action: in addition to inhibiting BC6ENTG , it modulates the amount of BC6OTHER ( BC6OTHER ) in neuronal cell culture by reducing BC6OTHER translation.	CPR:4
BC6ENTC deserves attention for an additional quality of action: in addition to inhibiting BC6OTHER , it modulates the amount of BC6ENTG ( BC6OTHER ) in neuronal cell culture by reducing BC6OTHER translation.	False
BC6ENTC deserves attention for an additional quality of action: in addition to inhibiting BC6OTHER , it modulates the amount of BC6OTHER ( BC6ENTG ) in neuronal cell culture by reducing BC6OTHER translation.	False
BC6ENTC deserves attention for an additional quality of action: in addition to inhibiting BC6OTHER , it modulates the amount of BC6OTHER ( BC6OTHER ) in neuronal cell culture by reducing BC6ENTG translation.	CPR:4
This effect probably involves interaction of BC6ENTC with a regulatory element in the 5' - untranslated region of the BC6ENTG gene that controls BC6OTHER expression.	False
This effect probably involves interaction of BC6ENTC with a regulatory element in the 5' - untranslated region of the BC6OTHER gene that controls BC6ENTG expression.	False
In the present study, we investigated the possible effects of BC6ENTC on BC6ENTG - signaling molecules and BC6OTHER oxidation in skeletal muscle of male rat.	False
In the present study, we investigated the possible effects of BC6OTHER on BC6ENTG - signaling molecules and BC6ENTC oxidation in skeletal muscle of male rat.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC transporter - 4 ( BC6OTHER ) messenger RNA, BC6OTHER significantly decreased the BC6OTHER , BC6ENTG and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC transporter - 4 ( BC6OTHER ) messenger RNA, BC6OTHER significantly decreased the BC6OTHER , BC6OTHER and BC6ENTG protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC transporter - 4 ( BC6OTHER ) messenger RNA, BC6OTHER significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6ENTC transporter - 4 ( BC6OTHER ) messenger RNA, BC6OTHER significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6ENTC transporter - 4 ( BC6OTHER ) messenger RNA, BC6OTHER significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6ENTC transporter - 4 ( BC6OTHER ) messenger RNA, BC6OTHER significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC transporter - 4 ( BC6ENTG ) messenger RNA, BC6OTHER significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC transporter - 4 ( BC6OTHER ) messenger RNA, BC6OTHER significantly decreased the BC6ENTG , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6ENTG and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	CPR:4
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6OTHER and BC6ENTG protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	CPR:4
Although there was no change in the levels of BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) messenger RNA, BC6ENTC significantly decreased the BC6OTHER , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	False
Although there was no change in the levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) messenger RNA, BC6ENTC significantly decreased the BC6ENTG , BC6OTHER and BC6OTHER protein levels (both plasma membrane and cytosolic fraction) of the gastrocnemius muscle.	CPR:4
Effect of BC6ENTC on BC6ENTG signal transduction and BC6OTHER oxidation in skeletal muscle of adult male albino rat.	False
Effect of BC6OTHER on BC6ENTG signal transduction and BC6ENTC oxidation in skeletal muscle of adult male albino rat.	False
There was an increase in serum BC6ENTG and decrease in serum BC6ENTC levels but fasting blood BC6OTHER level remained unaltered.	False
There was an increase in serum BC6ENTG and decrease in serum BC6OTHER levels but fasting blood BC6ENTC level remained unaltered.	False
In conclusion, BC6ENTC has adverse effects on phosphorylation of BC6ENTG , BC6OTHER translocation and BC6OTHER oxidation.	CPR:4
In conclusion, BC6ENTC has adverse effects on phosphorylation of BC6OTHER , BC6ENTG translocation and BC6OTHER oxidation.	CPR:4
In conclusion, BC6OTHER has adverse effects on phosphorylation of BC6ENTG , BC6OTHER translocation and BC6ENTC oxidation.	False
In conclusion, BC6OTHER has adverse effects on phosphorylation of BC6OTHER , BC6ENTG translocation and BC6ENTC oxidation.	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6ENTG inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6ENTC ( BC6OTHER ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6ENTG antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6ENTC ( BC6OTHER ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6ENTC ( BC6OTHER ), an inhibitor of platelet BC6ENTG / BC6OTHER interaction (10 mg / kg i.v. bolus).	CPR:4
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6ENTC ( BC6OTHER ), an inhibitor of platelet BC6OTHER / BC6ENTG interaction (10 mg / kg i.v. bolus).	CPR:4
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6ENTG (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6ENTC ( BC6OTHER ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6ENTG (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6ENTC ( BC6OTHER ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6ENTG inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6OTHER ( BC6ENTC ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6ENTG antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6OTHER ( BC6ENTC ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6OTHER ( BC6ENTC ), an inhibitor of platelet BC6ENTG / BC6OTHER interaction (10 mg / kg i.v. bolus).	CPR:4
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6OTHER ( BC6ENTC ), an inhibitor of platelet BC6OTHER / BC6ENTG interaction (10 mg / kg i.v. bolus).	CPR:4
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6ENTG (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6OTHER (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6OTHER ( BC6ENTC ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
 After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra - arterial infusion of BC6OTHER (0.1 mg / kg / min for 10 min); 9 animals received AP - 1, a monoclonal antibody against BC6ENTG (0.1 mg / kg i.v. bolus); 7 animals received CHEM, a dual BC6OTHER inhibitor and BC6OTHER antagonist (10 mg / kg i.v. bolus); finally, 8 rabbits received BC6OTHER ( BC6ENTC ), an inhibitor of platelet BC6OTHER / BC6OTHER interaction (10 mg / kg i.v. bolus).	False
Infusion of BC6ENTG failed to restore CFVs in CHEM BC6ENTC treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by BC6OTHER was overcome by inhibition of platelet function.	False
Infusion of BC6OTHER failed to restore CFVs in CHEM BC6ENTC treated rabbits (1 of 7 and 0 of 8 rabbits, respectively), showing that activation of extrinsic coagulation by BC6ENTG was overcome by inhibition of platelet function.	False
Activated partial thromboplastin time, and ex vivo platelet aggregation in response to BC6ENTC and BC6ENTG , were not different after BC6OTHER infusion, while prothrombin time was slightly but significantly prolonged as compared to baseline values.	False
Activated partial thromboplastin time, and ex vivo platelet aggregation in response to BC6ENTC and BC6OTHER , were not different after BC6ENTG infusion, while prothrombin time was slightly but significantly prolonged as compared to baseline values.	False
LPO was increased while as BC6ENTC , BC6ENTG and BC6OTHER decreased by the administration of CHEM and TAA (p<0.001); co - administration of BC6OTHER restored these liver markers to normal levels (p<0.001).	False
LPO was increased while as BC6ENTC , BC6OTHER and BC6ENTG decreased by the administration of CHEM and TAA (p<0.001); co - administration of BC6OTHER restored these liver markers to normal levels (p<0.001).	False
LPO was increased while as BC6OTHER , BC6ENTG and BC6OTHER decreased by the administration of CHEM and TAA (p<0.001); co - administration of BC6ENTC restored these liver markers to normal levels (p<0.001).	CPR:3
LPO was increased while as BC6OTHER , BC6OTHER and BC6ENTG decreased by the administration of CHEM and TAA (p<0.001); co - administration of BC6ENTC restored these liver markers to normal levels (p<0.001).	CPR:3
Serum markers of liver damage ( BC6ENTG , BC6OTHER , BC6OTHER and BC6ENTC ) were increased by BC6OTHER and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	False
Serum markers of liver damage ( BC6OTHER , BC6ENTG , BC6OTHER and BC6ENTC ) were increased by BC6OTHER and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	False
Serum markers of liver damage ( BC6OTHER , BC6OTHER , BC6ENTG and BC6ENTC ) were increased by BC6OTHER and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	False
BC6ENTC aminotransferase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6ENTC aminotransferase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6ENTC aminotransferase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6ENTC aminotransferase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6ENTC aminotransferase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER were measured in serum.	False
BC6ENTG ( BC6OTHER ), BC6ENTC aminotransferase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6OTHER ( BC6ENTG ), BC6ENTC aminotransferase ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6OTHER ( BC6OTHER ), BC6ENTC aminotransferase ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6OTHER ( BC6OTHER ), BC6ENTC aminotransferase ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER were measured in serum.	False
BC6OTHER ( BC6OTHER ), BC6ENTC aminotransferase ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER were measured in serum.	False
BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC were measured in serum.	False
BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC were measured in serum.	False
BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTC were measured in serum.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), BC6ENTC were measured in serum.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), BC6ENTC were measured in serum.	False
BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), BC6ENTC were measured in serum.	False
BC6ENTC (HP), lipid peroxidation (LPO), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6ENTC (HP), lipid peroxidation (LPO), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6ENTC (HP), lipid peroxidation (LPO), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6ENTC (HP), lipid peroxidation (LPO), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6ENTG ( BC6OTHER ), BC6ENTC peroxidase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6ENTG ), BC6ENTC peroxidase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6OTHER ), BC6ENTC peroxidase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6ENTC ( BC6OTHER ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) were determined in liver samples by colorimetric methods.	False
BC6OTHER (HP), lipid peroxidation (LPO), BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6ENTC ) were determined in liver samples by colorimetric methods.	False
BC6ENTG ( BC6OTHER ), activity was determined as hydroxylation of BC6ENTC in liver microsomes.	CPR:9
BC6OTHER ( BC6ENTG ), activity was determined as hydroxylation of BC6ENTC in liver microsomes.	CPR:9
Serum markers of liver damage ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) were increased by BC6ENTC and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	CPR:3
Serum markers of liver damage ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) were increased by BC6ENTC and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	CPR:3
Serum markers of liver damage ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) were increased by BC6ENTC and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	CPR:3
Serum markers of liver damage ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) were increased by BC6OTHER and BC6ENTC intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	CPR:3
Serum markers of liver damage ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) were increased by BC6OTHER and BC6ENTC intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	CPR:3
Serum markers of liver damage ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) were increased by BC6OTHER and BC6ENTC intoxication (p<0.001), whereas co - treatment with BC6OTHER reversed such changes (p<0.001).	CPR:3
Serum markers of liver damage ( BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER ) were increased by BC6OTHER and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6ENTC reversed such changes (p<0.001).	CPR:4
Serum markers of liver damage ( BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER ) were increased by BC6OTHER and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6ENTC reversed such changes (p<0.001).	CPR:4
Serum markers of liver damage ( BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER ) were increased by BC6OTHER and BC6OTHER intoxication (p<0.001), whereas co - treatment with BC6ENTC reversed such changes (p<0.001).	CPR:4
Scratch wound - healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down - regulation of cellular BC6ENTG levels and in the absence and presence of sublethal BC6OTHER ( BC6OTHER ; BC6ENTC ) concentrations.	False
The direct inhibition of BC6ENTG by BC6ENTC is likely a contributing factor.	CPR:4
We therefore sought to establish a role for BC6ENTG in malignant glioma cell motility, migration, and invasion and determine the effects of BC6ENTC on these cell movement - related processes.	False
Scratch wound - healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down - regulation of cellular BC6ENTG levels and in the absence and presence of sublethal BC6ENTC ( BC6OTHER ; BC6OTHER ) concentrations.	False
Scratch wound - healing recovery, Boyden chamber migration, Matrigel invasion, and organotypic slice invasion assays were performed before and after the down - regulation of cellular BC6ENTG levels and in the absence and presence of sublethal BC6OTHER ( BC6ENTC ; BC6OTHER ) concentrations.	False
In addition, BC6ENTC treatment significantly reduced the specific BC6ENTG activity after SCI as compared to that of vehicle control.	CPR:4
Furthermore, RT - PCR analyses revealed that BC6ENTC treatment increased expression of BC6ENTG mRNA but decreased BC6OTHER expression.	CPR:3
Furthermore, RT - PCR analyses revealed that BC6ENTC treatment increased expression of BC6OTHER mRNA but decreased BC6ENTG expression.	CPR:4
These data suggest that, after CHEM, BC6ENTC treatment modulated expression of BC6ENTG , attenuated cell death and the size of lesions, and improved functional recovery in the injured rat.	False
Effect of BC6ENTC ( BC6ENTG / BC6OTHER receptor antagonist) on metabolic changes during stress and diabetes.	CPR:6
Effect of BC6ENTC ( BC6OTHER / BC6ENTG receptor antagonist) on metabolic changes during stress and diabetes.	CPR:6
BC6ENTC partially prevented stress - induced both hyperglycemia and decrease in glycogen content while it completely blocked the stress - induced decrease in BC6ENTG level in normoglycemic stressed rats.	False
BC6ENTC also decreased serum BC6OTHER level without any effect on BC6ENTG secretion in mild diabetic rats and potentiated the hypoglycemic action of BC6OTHER .	False
BC6ENTC also decreased serum BC6OTHER level without any effect on BC6OTHER secretion in mild diabetic rats and potentiated the hypoglycemic action of BC6ENTG .	False
BC6OTHER also decreased serum BC6ENTC level without any effect on BC6ENTG secretion in mild diabetic rats and potentiated the hypoglycemic action of BC6OTHER .	False
BC6OTHER also decreased serum BC6ENTC level without any effect on BC6OTHER secretion in mild diabetic rats and potentiated the hypoglycemic action of BC6ENTG .	False
To test this, we studied the possible effect of the BC6ENTG antagonist, BC6ENTC (50 and 100 mg kg( - 1)) on serum BC6OTHER and BC6OTHER levels as well as on liver glycogen contents in normoglycemic stressed animals.	CPR:6
To test this, we studied the possible effect of the BC6OTHER antagonist, BC6ENTC (50 and 100 mg kg( - 1)) on serum BC6OTHER and BC6ENTG levels as well as on liver glycogen contents in normoglycemic stressed animals.	False
To test this, we studied the possible effect of the BC6ENTG antagonist, BC6OTHER (50 and 100 mg kg( - 1)) on serum BC6ENTC and BC6OTHER levels as well as on liver glycogen contents in normoglycemic stressed animals.	False
To test this, we studied the possible effect of the BC6OTHER antagonist, BC6OTHER (50 and 100 mg kg( - 1)) on serum BC6ENTC and BC6ENTG levels as well as on liver glycogen contents in normoglycemic stressed animals.	False
In addition, the effect of BC6ENTC on serum BC6OTHER and BC6ENTG levels in both mild and severely diabetic rats and its effect on BC6OTHER - induced hypoglycemia were also determined.	False
In addition, the effect of BC6ENTC on serum BC6OTHER and BC6OTHER levels in both mild and severely diabetic rats and its effect on BC6ENTG - induced hypoglycemia were also determined.	False
In addition, the effect of BC6OTHER on serum BC6ENTC and BC6ENTG levels in both mild and severely diabetic rats and its effect on BC6OTHER - induced hypoglycemia were also determined.	False
In addition, the effect of BC6OTHER on serum BC6ENTC and BC6OTHER levels in both mild and severely diabetic rats and its effect on BC6ENTG - induced hypoglycemia were also determined.	False
Here, we have perturbed vibrational motions in BC6ENTC reductase ( BC6ENTG ) by isotopic substitution where all non - exchangeable atoms were replaced with the corresponding heavy isotope ( BC6OTHER , BC6OTHER , and BC6OTHER ).	False
Here, we have perturbed vibrational motions in BC6OTHER ( BC6ENTG ) by isotopic substitution where all non - exchangeable atoms were replaced with the corresponding heavy isotope ( BC6ENTC , BC6OTHER , and BC6OTHER ).	False
Here, we have perturbed vibrational motions in BC6ENTG ( BC6OTHER ) by isotopic substitution where all non - exchangeable atoms were replaced with the corresponding heavy isotope ( BC6ENTC , BC6OTHER , and BC6OTHER ).	False
Here, we have perturbed vibrational motions in BC6OTHER ( BC6ENTG ) by isotopic substitution where all non - exchangeable atoms were replaced with the corresponding heavy isotope ( BC6OTHER , BC6ENTC , and BC6OTHER ).	False
Here, we have perturbed vibrational motions in BC6ENTG ( BC6OTHER ) by isotopic substitution where all non - exchangeable atoms were replaced with the corresponding heavy isotope ( BC6OTHER , BC6ENTC , and BC6OTHER ).	False
Here, we have perturbed vibrational motions in BC6OTHER ( BC6ENTG ) by isotopic substitution where all non - exchangeable atoms were replaced with the corresponding heavy isotope ( BC6OTHER , BC6OTHER , and BC6ENTC ).	False
Here, we have perturbed vibrational motions in BC6ENTG ( BC6OTHER ) by isotopic substitution where all non - exchangeable atoms were replaced with the corresponding heavy isotope ( BC6OTHER , BC6OTHER , and BC6ENTC ).	False
BC6ENTC , thought to be responsible for the chemopreventive properties of this food group, are conjugated to BC6OTHER by BC6ENTG ( BC6OTHER ) before urinary excretion.	False
BC6ENTC , thought to be responsible for the chemopreventive properties of this food group, are conjugated to BC6OTHER by BC6OTHER BC6OTHER - transferases ( BC6ENTG ) before urinary excretion.	False
BC6OTHER , thought to be responsible for the chemopreventive properties of this food group, are conjugated to BC6ENTC by BC6ENTG ( BC6OTHER ) before urinary excretion.	False
BC6OTHER , thought to be responsible for the chemopreventive properties of this food group, are conjugated to BC6ENTC by BC6OTHER BC6OTHER - transferases ( BC6ENTG ) before urinary excretion.	False
BC6OTHER , thought to be responsible for the chemopreventive properties of this food group, are conjugated to BC6OTHER by BC6ENTC BC6OTHER - transferases ( BC6ENTG ) before urinary excretion.	False
BC6OTHER , thought to be responsible for the chemopreventive properties of this food group, are conjugated to BC6OTHER by BC6OTHER BC6ENTC - transferases ( BC6ENTG ) before urinary excretion.	False
As a prodrug BC6ENTC is completely converted to its active metabolite BC6OTHER (M1) which blocks the BC6ENTG , a key enzyme of the BC6OTHER de novo synthesis.	CPR:4
As a prodrug BC6OTHER is completely converted to its active metabolite BC6ENTC (M1) which blocks the BC6ENTG , a key enzyme of the BC6OTHER de novo synthesis.	CPR:4
As a prodrug BC6OTHER is completely converted to its active metabolite BC6OTHER (M1) which blocks the BC6ENTG , a key enzyme of the BC6ENTC de novo synthesis.	False
), BC6ENTG by BC6ENTC (1 mg / kg i.p.	CPR:4
), both BC6ENTG and BC6OTHER by BC6ENTC (75 mg / kg i.p.)	CPR:4
), both BC6OTHER and BC6ENTG by BC6ENTC (75 mg / kg i.p.)	CPR:4
Levels of BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6ENTG ( BC6OTHER ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6OTHER ( BC6ENTC ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6OTHER oxidase type A ( BC6ENTG ) by BC6OTHER (4 mg / kg i.p.	False
or peripheral neuronal BC6ENTG by BC6ENTC (40 mg / kg i.p.).	CPR:4
Levels of BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6ENTG ( BC6OTHER ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6OTHER ( BC6OTHER ), BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6OTHER oxidase type A ( BC6ENTG ) by BC6OTHER (4 mg / kg i.p.	False
The results suggest that most of the BC6OTHER in plasma is derived from deamination of BC6ENTC by BC6ENTG in peripheral neurons; that BC6OTHER in plasma is derived from cells outside the central nervous system; that BC6OTHER in plasma is derived virtually exclusively from the metabolism of BC6OTHER in sympathetic nerve endings and that residual levels of BC6OTHER after treatment with BC6OTHER provide an improved but limited indication of central dopaminergic activity.	CPR:9
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6ENTG ( BC6OTHER ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6OTHER oxidase type A ( BC6ENTG ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6ENTG ( BC6OTHER ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6OTHER oxidase type A ( BC6ENTG ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6ENTG ( BC6OTHER ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6ENTC ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6OTHER oxidase type A ( BC6ENTG ) by BC6OTHER (4 mg / kg i.p.	False
The results suggest that most of the BC6ENTC in plasma is derived from deamination of BC6OTHER by BC6ENTG in peripheral neurons; that BC6OTHER in plasma is derived from cells outside the central nervous system; that BC6OTHER in plasma is derived virtually exclusively from the metabolism of BC6OTHER in sympathetic nerve endings and that residual levels of BC6OTHER after treatment with BC6OTHER provide an improved but limited indication of central dopaminergic activity.	CPR:9
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) in plasma and the striatium were measured after inhibition of BC6ENTG ( BC6OTHER ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) in plasma and the striatium were measured after inhibition of BC6OTHER oxidase type A ( BC6ENTG ) by BC6OTHER (4 mg / kg i.p.	False
Effects of BC6ENTG inhibitors on levels of BC6ENTC and BC6OTHER in striatum and plasma.	False
Effects of BC6ENTG inhibitors on levels of BC6OTHER and BC6ENTC in striatum and plasma.	False
The results suggest that most of the BC6OTHER in plasma is derived from deamination of BC6OTHER by BC6ENTG in peripheral neurons; that BC6ENTC in plasma is derived from cells outside the central nervous system; that BC6OTHER in plasma is derived virtually exclusively from the metabolism of BC6OTHER in sympathetic nerve endings and that residual levels of BC6OTHER after treatment with BC6OTHER provide an improved but limited indication of central dopaminergic activity.	False
The results suggest that most of the BC6OTHER in plasma is derived from deamination of BC6OTHER by BC6ENTG in peripheral neurons; that BC6OTHER in plasma is derived from cells outside the central nervous system; that BC6ENTC in plasma is derived virtually exclusively from the metabolism of BC6OTHER in sympathetic nerve endings and that residual levels of BC6OTHER after treatment with BC6OTHER provide an improved but limited indication of central dopaminergic activity.	False
The results suggest that most of the BC6OTHER in plasma is derived from deamination of BC6OTHER by BC6ENTG in peripheral neurons; that BC6OTHER in plasma is derived from cells outside the central nervous system; that BC6OTHER in plasma is derived virtually exclusively from the metabolism of BC6ENTC in sympathetic nerve endings and that residual levels of BC6OTHER after treatment with BC6OTHER provide an improved but limited indication of central dopaminergic activity.	False
The results suggest that most of the BC6OTHER in plasma is derived from deamination of BC6OTHER by BC6ENTG in peripheral neurons; that BC6OTHER in plasma is derived from cells outside the central nervous system; that BC6OTHER in plasma is derived virtually exclusively from the metabolism of BC6OTHER in sympathetic nerve endings and that residual levels of BC6ENTC after treatment with BC6OTHER provide an improved but limited indication of central dopaminergic activity.	False
The results suggest that most of the BC6OTHER in plasma is derived from deamination of BC6OTHER by BC6ENTG in peripheral neurons; that BC6OTHER in plasma is derived from cells outside the central nervous system; that BC6OTHER in plasma is derived virtually exclusively from the metabolism of BC6OTHER in sympathetic nerve endings and that residual levels of BC6OTHER after treatment with BC6ENTC provide an improved but limited indication of central dopaminergic activity.	False
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6ENTC oxidase type A ( BC6ENTG ) by BC6OTHER (4 mg / kg i.p.	False
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6ENTG ( BC6OTHER ) by BC6ENTC (4 mg / kg i.p.	CPR:4
Levels of BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) in plasma and the striatium were measured after inhibition of BC6OTHER oxidase type A ( BC6ENTG ) by BC6ENTC (4 mg / kg i.p.	CPR:4
Our results imply that BC6ENTG has the potential to be inhibited by BC6ENTC / BC6OTHER analogs, and it suggests that BC6OTHER acts as a target of new drugs that inhibit platelet aggregation.	CPR:4
Our results imply that BC6OTHER has the potential to be inhibited by BC6ENTC / BC6OTHER analogs, and it suggests that BC6ENTG acts as a target of new drugs that inhibit platelet aggregation.	False
Our results imply that BC6ENTG has the potential to be inhibited by BC6OTHER / BC6ENTC analogs, and it suggests that BC6OTHER acts as a target of new drugs that inhibit platelet aggregation.	CPR:4
Our results imply that BC6OTHER has the potential to be inhibited by BC6OTHER / BC6ENTC analogs, and it suggests that BC6ENTG acts as a target of new drugs that inhibit platelet aggregation.	False
BC6ENTC initiates platelet aggregation by 'simultaneous activation of two BC6ENTG , BC6OTHER and BC6OTHER .	CPR:3
BC6ENTC initiates platelet aggregation by 'simultaneous activation of two BC6OTHER , BC6ENTG and BC6OTHER .	CPR:3
BC6ENTC initiates platelet aggregation by 'simultaneous activation of two BC6OTHER , BC6OTHER and BC6ENTG .	CPR:3
BC6ENTG has been shown to be the target of the BC6ENTC drugs, BC6OTHER and BC6OTHER .	False
BC6ENTG has been shown to be the target of the BC6OTHER drugs, BC6ENTC and BC6OTHER .	False
BC6ENTG has been shown to be the target of the BC6OTHER drugs, BC6OTHER and BC6ENTC .	False
Here, the active sites of BC6ENTG for BC6ENTC as well as BC6OTHER are predicted by bioinformatics and molecular modeling.	False
Here, the active sites of BC6ENTG for BC6OTHER as well as BC6ENTC are predicted by bioinformatics and molecular modeling.	False
BC6ENTG are a class of cell surface receptors for BC6ENTC that prefer BC6OTHER or BC6OTHER over BC6OTHER .	False
"And the most probable active sites of BC6ENTG were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6ENTC , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6ENTC , 87 - 96), ""middle area"" ( BC6ENTG , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6ENTC , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6ENTG , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6ENTC , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6ENTG , 222 - 231)."	False
BC6ENTG are a class of cell surface receptors for BC6OTHER that prefer BC6ENTC or BC6OTHER over BC6OTHER .	False
BC6ENTG are a class of cell surface receptors for BC6OTHER that prefer BC6OTHER or BC6ENTC over BC6OTHER .	False
BC6ENTG are a class of cell surface receptors for BC6OTHER that prefer BC6OTHER or BC6OTHER over BC6ENTC .	False
"And the most probable active sites of BC6ENTG were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6ENTC , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6ENTG , 87 - 96), ""middle area"" ( BC6ENTC , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6ENTC , 38 - 47, and BC6ENTG , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6ENTC , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6ENTG , 222 - 231)."	False
"And the most probable active sites of BC6ENTG were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6ENTC , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6ENTG , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6ENTC , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6ENTG , 38 - 47, and BC6ENTC , 139 - 148), and ""bottom area"" ( BC6OTHER , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6ENTC , 139 - 148), and ""bottom area"" ( BC6ENTG , 222 - 231)."	False
"And the most probable active sites of BC6ENTG were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6ENTC , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6ENTG , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6ENTC , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6ENTG , 38 - 47, and BC6OTHER , 139 - 148), and ""bottom area"" ( BC6ENTC , 222 - 231)."	False
"And the most probable active sites of BC6OTHER were predicted using the scoring matrix, which include three distant areas: ""head area"" ( BC6OTHER , 87 - 96), ""middle area"" ( BC6OTHER , 38 - 47, and BC6ENTG , 139 - 148), and ""bottom area"" ( BC6ENTC , 222 - 231)."	False
Subsequently the structural model of BC6ENTG was docked with BC6ENTC / BC6OTHER in comparison with BC6OTHER ( BC6OTHER ).	False
Subsequently the structural model of BC6OTHER was docked with BC6ENTC / BC6OTHER in comparison with BC6ENTG ( BC6OTHER ).	False
Subsequently the structural model of BC6OTHER was docked with BC6ENTC / BC6OTHER in comparison with BC6OTHER ( BC6ENTG ).	False
Subsequently the structural model of BC6ENTG was docked with BC6OTHER / BC6ENTC in comparison with BC6OTHER ( BC6OTHER ).	False
Subsequently the structural model of BC6OTHER was docked with BC6OTHER / BC6ENTC in comparison with BC6ENTG ( BC6OTHER ).	False
Subsequently the structural model of BC6OTHER was docked with BC6OTHER / BC6ENTC in comparison with BC6OTHER ( BC6ENTG ).	False
The surface receptors for extracellular BC6ENTC are called BC6ENTG .	False
"We aim to ""tilt"" the stability of the BC6ENTG structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the BC6ENTC sequence of the BC6OTHER , BC6OTHER , and proximal residues."	False
"We aim to ""tilt"" the stability of the BC6OTHER structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the BC6ENTC sequence of the BC6ENTG , BC6OTHER , and proximal residues."	False
"We aim to ""tilt"" the stability of the BC6OTHER structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the BC6ENTC sequence of the BC6OTHER , BC6ENTG , and proximal residues."	False
Utilizing primary mesencephalic neurons, we found expression of both BC6ENTC receptor alpha ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) with a predominance of BC6OTHER on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6ENTC receptor alpha ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) with a predominance of BC6OTHER on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6ENTC receptor alpha ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) with a predominance of BC6OTHER on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6ENTC receptor alpha ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) with a predominance of BC6ENTG on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6ENTG ( BC6OTHER ) and BC6ENTC receptor beta ( BC6OTHER ) with a predominance of BC6OTHER on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6OTHER ( BC6ENTG ) and BC6ENTC receptor beta ( BC6OTHER ) with a predominance of BC6OTHER on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6OTHER ( BC6OTHER ) and BC6ENTC receptor beta ( BC6ENTG ) with a predominance of BC6OTHER on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6OTHER ( BC6OTHER ) and BC6ENTC receptor beta ( BC6OTHER ) with a predominance of BC6ENTG on both BC6OTHER neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) with a predominance of BC6OTHER on both BC6ENTC neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ) with a predominance of BC6OTHER on both BC6ENTC neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ) with a predominance of BC6OTHER on both BC6ENTC neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ) with a predominance of BC6OTHER on both BC6ENTC neurons and astrocytes.	False
Utilizing primary mesencephalic neurons, we found expression of both BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) with a predominance of BC6ENTG on both BC6ENTC neurons and astrocytes.	False
We also found that BC6ENTC protects BC6OTHER neurons from injury induced by the complex I inhibitor, BC6OTHER ( BC6OTHER ) in a time - and BC6ENTG - dependent manner.	False
We also found that BC6OTHER protects BC6ENTC neurons from injury induced by the complex I inhibitor, BC6OTHER ( BC6OTHER ) in a time - and BC6ENTG - dependent manner.	False
We also found that BC6OTHER protects BC6OTHER neurons from injury induced by the complex I inhibitor, BC6ENTC ( BC6OTHER ) in a time - and BC6ENTG - dependent manner.	False
We also found that BC6OTHER protects BC6OTHER neurons from injury induced by the complex I inhibitor, BC6OTHER ( BC6ENTC ) in a time - and BC6ENTG - dependent manner.	False
At least 4 h of BC6ENTC pre - treatment was required to elicit protection, an effect that was blocked by the BC6ENTG antagonist, BC6OTHER .	False
At least 4 h of BC6OTHER pre - treatment was required to elicit protection, an effect that was blocked by the BC6ENTG antagonist, BC6ENTC .	CPR:6
Moreover, BC6ENTG mediated the protection afforded by BC6ENTC since only the BC6OTHER agonist, CHEM, but not the BC6OTHER agonist, BC6OTHER , protected against BC6OTHER cell loss.	False
Moreover, BC6OTHER mediated the protection afforded by BC6ENTC since only the BC6ENTG agonist, CHEM, but not the BC6OTHER agonist, BC6OTHER , protected against BC6OTHER cell loss.	False
Moreover, BC6OTHER mediated the protection afforded by BC6ENTC since only the BC6OTHER agonist, CHEM, but not the BC6ENTG agonist, BC6OTHER , protected against BC6OTHER cell loss.	False
Neuroprotection by BC6ENTC against BC6OTHER - induced BC6OTHER neuron death is mediated by BC6ENTG in primary cultures of mouse mesencephalon.	False
Neuroprotection by BC6OTHER against BC6ENTC - induced BC6OTHER neuron death is mediated by BC6ENTG in primary cultures of mouse mesencephalon.	False
Neuroprotection by BC6OTHER against BC6OTHER - induced BC6ENTC neuron death is mediated by BC6ENTG in primary cultures of mouse mesencephalon.	False
Moreover, BC6ENTG mediated the protection afforded by BC6OTHER since only the BC6OTHER agonist, CHEM, but not the BC6OTHER agonist, BC6ENTC , protected against BC6OTHER cell loss.	False
Moreover, BC6OTHER mediated the protection afforded by BC6OTHER since only the BC6ENTG agonist, CHEM, but not the BC6OTHER agonist, BC6ENTC , protected against BC6OTHER cell loss.	False
Moreover, BC6OTHER mediated the protection afforded by BC6OTHER since only the BC6OTHER agonist, CHEM, but not the BC6ENTG agonist, BC6ENTC , protected against BC6OTHER cell loss.	CPR:5
Moreover, BC6ENTG mediated the protection afforded by BC6OTHER since only the BC6OTHER agonist, CHEM, but not the BC6OTHER agonist, BC6OTHER , protected against BC6ENTC cell loss.	False
Moreover, BC6OTHER mediated the protection afforded by BC6OTHER since only the BC6ENTG agonist, CHEM, but not the BC6OTHER agonist, BC6OTHER , protected against BC6ENTC cell loss.	False
Moreover, BC6OTHER mediated the protection afforded by BC6OTHER since only the BC6OTHER agonist, CHEM, but not the BC6ENTG agonist, BC6OTHER , protected against BC6ENTC cell loss.	False
Since glial cells were shown to express significant levels of BC6ENTG , we investigated a possible indirect mechanism of BC6ENTC - mediated neuroprotection through glial cell interaction.	False
These data indicate that neuroprotection provided by BC6ENTC against BC6OTHER toxicity is mediated by BC6ENTG and involves an interplay among at least two cell types.	False
These data indicate that neuroprotection provided by BC6OTHER against BC6ENTC toxicity is mediated by BC6ENTG and involves an interplay among at least two cell types.	False
This lack of difference was unexpected since the genes for BC6ENTG and BC6OTHER , also called BC6ENTC hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.	False
This lack of difference was unexpected since the genes for BC6OTHER and BC6ENTG , also called BC6ENTC hydrolase, which are two detoxication enzymes, are deleted in case of microdeletion of 11p and 13q, respectively.	False
We also examined the effects of BC6ENTC , a BC6ENTG antagonist, in parallel.	CPR:6
From sequence analysis of the cDNA and the BC6OTHER - and BC6OTHER - terminal BC6OTHER analyses of the purified protein, it is deduced that BC6ENTG consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 BC6OTHER with BC6ENTC at the BC6OTHER - terminus.	False
From sequence analysis of the cDNA and the BC6OTHER - and BC6OTHER - terminal BC6OTHER analyses of the purified protein, it is deduced that BC6ENTG consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 BC6OTHER with BC6OTHER at the BC6ENTC - terminus.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6ENTC aminohydrolase, BC6ENTG ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6ENTC aminohydrolase, BC6OTHER ) [ BC6ENTG ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6ENTC aminohydrolase, BC6OTHER ) [ BC6OTHER ], a dimeric BC6ENTG having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6ENTG ( BC6ENTC aminohydrolase, BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
The BC6ENTC sequence deduced from the BC6OTHER sequence of the cDNA from porcine liver was identical to that deduced for BC6ENTG .	False
The BC6OTHER sequence deduced from the BC6ENTC sequence of the cDNA from porcine liver was identical to that deduced for BC6ENTG .	False
Comparison of the BC6ENTC sequence of BC6OTHER with those of other BC6ENTG showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	False
Comparison of the BC6ENTC sequence of BC6ENTG with those of other BC6OTHER - binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	False
Comparison of the BC6OTHER sequence of BC6ENTG with those of other BC6ENTC - binding metalloenzymes showed no significant homologies in either the overall sequence or the consensus sequences for the metal binding sites.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6ENTG ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6ENTC in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6ENTG ], a dimeric BC6OTHER having two BC6ENTC in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6ENTG having two BC6ENTC in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6ENTG ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6ENTC in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6ENTG , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6ENTC in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6ENTG ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6ENTC except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6ENTG ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6ENTC except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6ENTG having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6ENTC except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
A cDNA encoding the complete BC6OTHER sequence of BC6ENTG ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6ENTC except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6ENTG , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6ENTC except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	CPR:9
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6ENTG ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6ENTC , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6ENTG ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6ENTC , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6ENTG having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6ENTC , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6ENTG ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6ENTC , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6OTHER sequence of BC6OTHER ( BC6ENTG , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6ENTC , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6ENTC sequence of BC6OTHER ( BC6OTHER , BC6ENTG ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6ENTC sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6ENTG ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6ENTC sequence of BC6OTHER ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6ENTG having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6ENTC sequence of BC6ENTG ( BC6OTHER , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
A cDNA encoding the complete BC6ENTC sequence of BC6OTHER ( BC6ENTG , BC6OTHER ) [ BC6OTHER ], a dimeric BC6OTHER having two BC6OTHER in the molecule, which catalyzes the deacylation of BC6OTHER except BC6OTHER , has been isolated from porcine kidney lambda gt10 cDNA library and sequenced.	False
From sequence analysis of the cDNA and the BC6ENTC - and BC6OTHER - terminal BC6OTHER analyses of the purified protein, it is deduced that BC6ENTG consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 BC6OTHER with BC6OTHER at the BC6OTHER - terminus.	False
From sequence analysis of the cDNA and the BC6OTHER - and BC6ENTC - terminal BC6OTHER analyses of the purified protein, it is deduced that BC6ENTG consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 BC6OTHER with BC6OTHER at the BC6OTHER - terminus.	False
From sequence analysis of the cDNA and the BC6OTHER - and BC6OTHER - terminal BC6ENTC analyses of the purified protein, it is deduced that BC6ENTG consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 BC6OTHER with BC6OTHER at the BC6OTHER - terminus.	False
From sequence analysis of the cDNA and the BC6OTHER - and BC6OTHER - terminal BC6OTHER analyses of the purified protein, it is deduced that BC6ENTG consists of two identical subunits (M(r) 45,260), each of which consists of a single chain of 406 BC6ENTC with BC6OTHER at the BC6OTHER - terminus.	False
Immunofluorescence staining and western blotting demonstrated that BC6ENTC treatment reduced BC6OTHER and BC6ENTG expression in the retinas of OLETF rats.	CPR:4
Immunofluorescence staining and western blotting demonstrated that BC6ENTC treatment reduced BC6ENTG and BC6OTHER expression in the retinas of OLETF rats.	CPR:4
We report the effects of BC6OTHER intake and BC6ENTC treatment (at doses of 100μg / 100gBW / day) on sex hormones and BC6ENTG in the ovaries, oviducts and uteri of BC6OTHER - preferring rats.	False
We report the effects of BC6OTHER intake and BC6OTHER treatment (at doses of 100μg / 100gBW / day) on sex hormones and BC6ENTG in the ovaries, oviducts and uteri of BC6ENTC - preferring rats.	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor subunits ( BC6ENTG , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6ENTG and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6ENTC , BC6OTHER and BC6OTHER receptor subunits ( BC6ENTG , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6ENTC , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6ENTG and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6ENTC , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6ENTC , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6ENTC , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6ENTC , BC6OTHER and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTG BC6ENTC and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6ENTC and BC6OTHER receptor subunits ( BC6ENTG , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6ENTC and BC6OTHER receptor subunits ( BC6OTHER , BC6ENTG and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6ENTC and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6ENTC and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6ENTC and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6ENTC and BC6OTHER receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate BC6ENTG BC6OTHER and BC6ENTC receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6OTHER and BC6ENTC receptor subunits ( BC6ENTG , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6OTHER and BC6ENTC receptor subunits ( BC6OTHER , BC6ENTG and BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6OTHER and BC6ENTC receptor subunits ( BC6OTHER , BC6OTHER and BC6ENTG , BC6OTHER , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6OTHER and BC6ENTC receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6ENTG , BC6OTHER and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6OTHER and BC6ENTC receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6ENTG and BC6OTHER , respectively).	False
After 150 days of treatment, animals were euthanized, and tissue samples were harvested to evaluate CHEM, BC6OTHER , BC6OTHER and BC6ENTC receptor subunits ( BC6OTHER , BC6OTHER and BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTG , respectively).	False
Conversely, ovarian BC6OTHER and BC6OTHER were positively regulated by BC6ENTC and BC6OTHER - BC6OTHER combination, whereas BC6ENTG was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Conversely, ovarian BC6ENTG and BC6OTHER were positively regulated by BC6ENTC and BC6OTHER - BC6OTHER combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Conversely, ovarian BC6OTHER and BC6ENTG were positively regulated by BC6ENTC and BC6OTHER - BC6OTHER combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Ovarian BC6ENTG was not influenced by either treatment, and oviduct BC6OTHER was reduced after BC6ENTC - BC6OTHER combination.	False
Ovarian BC6OTHER was not influenced by either treatment, and oviduct BC6ENTG was reduced after BC6ENTC - BC6OTHER combination.	CPR:4
Ovarian BC6ENTG was not influenced by either treatment, and oviduct BC6OTHER was reduced after BC6OTHER - BC6ENTC combination.	False
Ovarian BC6OTHER was not influenced by either treatment, and oviduct BC6ENTG was reduced after BC6OTHER - BC6ENTC combination.	CPR:4
Oviduct BC6ENTG , BC6OTHER and uterine BC6OTHER were down - regulated by either BC6ENTC or BC6OTHER .	CPR:4
Oviduct BC6OTHER , BC6ENTG and uterine BC6OTHER were down - regulated by either BC6ENTC or BC6OTHER .	CPR:4
Oviduct BC6OTHER , BC6OTHER and uterine BC6ENTG were down - regulated by either BC6ENTC or BC6OTHER .	CPR:4
Oviduct BC6ENTG , BC6OTHER and uterine BC6OTHER were down - regulated by either BC6OTHER or BC6ENTC .	CPR:4
Oviduct BC6OTHER , BC6ENTG and uterine BC6OTHER were down - regulated by either BC6OTHER or BC6ENTC .	CPR:4
Oviduct BC6OTHER , BC6OTHER and uterine BC6ENTG were down - regulated by either BC6OTHER or BC6ENTC .	CPR:4
Conversely, ovarian BC6OTHER and BC6OTHER were positively regulated by BC6OTHER and BC6ENTC - BC6OTHER combination, whereas BC6ENTG was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Conversely, ovarian BC6ENTG and BC6OTHER were positively regulated by BC6OTHER and BC6ENTC - BC6OTHER combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Conversely, ovarian BC6OTHER and BC6ENTG were positively regulated by BC6OTHER and BC6ENTC - BC6OTHER combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
 BC6ENTC and BC6OTHER intake exert opposite effects on circulating BC6OTHER and BC6OTHER and differentially regulate BC6ENTG in the ovaries, oviducts, and uteri of adult rats.	False
 BC6OTHER and BC6ENTC intake exert opposite effects on circulating BC6OTHER and BC6OTHER and differentially regulate BC6ENTG in the ovaries, oviducts, and uteri of adult rats.	False
 BC6OTHER and BC6OTHER intake exert opposite effects on circulating BC6ENTC and BC6OTHER and differentially regulate BC6ENTG in the ovaries, oviducts, and uteri of adult rats.	False
 BC6OTHER and BC6OTHER intake exert opposite effects on circulating BC6OTHER and BC6ENTC and differentially regulate BC6ENTG in the ovaries, oviducts, and uteri of adult rats.	False
Conversely, ovarian BC6OTHER and BC6OTHER were positively regulated by BC6OTHER and BC6OTHER - BC6ENTC combination, whereas BC6ENTG was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Conversely, ovarian BC6ENTG and BC6OTHER were positively regulated by BC6OTHER and BC6OTHER - BC6ENTC combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Conversely, ovarian BC6OTHER and BC6ENTG were positively regulated by BC6OTHER and BC6OTHER - BC6ENTC combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6OTHER consumption.	False
Conversely, ovarian BC6OTHER and BC6OTHER were positively regulated by BC6OTHER and BC6OTHER - BC6OTHER combination, whereas BC6ENTG was down - regulated in the uterus and oviduct after BC6ENTC consumption.	CPR:4
Conversely, ovarian BC6ENTG and BC6OTHER were positively regulated by BC6OTHER and BC6OTHER - BC6OTHER combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6ENTC consumption.	False
Conversely, ovarian BC6OTHER and BC6ENTG were positively regulated by BC6OTHER and BC6OTHER - BC6OTHER combination, whereas BC6OTHER was down - regulated in the uterus and oviduct after BC6ENTC consumption.	False
BC6ENTG was increased in ovaries and uteri of BC6ENTC - treated rats.	CPR:3
BC6ENTC and BC6OTHER exert opposite effects on E2 and P4, and they differentially regulate the expression of BC6ENTG in female reproductive tissues.	False
BC6OTHER and BC6ENTC exert opposite effects on E2 and P4, and they differentially regulate the expression of BC6ENTG in female reproductive tissues.	False
We report the effects of BC6ENTC intake and BC6OTHER treatment (at doses of 100μg / 100gBW / day) on sex hormones and BC6ENTG in the ovaries, oviducts and uteri of BC6OTHER - preferring rats.	False
The aim of this study was to determine the effects of BC6ENTG gene polymorphism and its effects on BC6OTHER and BC6OTHER enzyme activities in individuals who were exposed to BC6ENTC insecticides due to occupational reasons, and to profile the probability of susceptibility to BC6OTHER compounds.	False
The aim of this study was to determine the effects of BC6OTHER gene polymorphism and its effects on BC6ENTG and BC6OTHER enzyme activities in individuals who were exposed to BC6ENTC insecticides due to occupational reasons, and to profile the probability of susceptibility to BC6OTHER compounds.	False
The aim of this study was to determine the effects of BC6OTHER gene polymorphism and its effects on BC6OTHER and BC6ENTG enzyme activities in individuals who were exposed to BC6ENTC insecticides due to occupational reasons, and to profile the probability of susceptibility to BC6OTHER compounds.	False
The aim of this study was to determine the effects of BC6ENTG gene polymorphism and its effects on BC6OTHER and BC6OTHER enzyme activities in individuals who were exposed to BC6OTHER insecticides due to occupational reasons, and to profile the probability of susceptibility to BC6ENTC compounds.	False
The aim of this study was to determine the effects of BC6OTHER gene polymorphism and its effects on BC6ENTG and BC6OTHER enzyme activities in individuals who were exposed to BC6OTHER insecticides due to occupational reasons, and to profile the probability of susceptibility to BC6ENTC compounds.	False
The aim of this study was to determine the effects of BC6OTHER gene polymorphism and its effects on BC6OTHER and BC6ENTG enzyme activities in individuals who were exposed to BC6OTHER insecticides due to occupational reasons, and to profile the probability of susceptibility to BC6ENTC compounds.	False
Effect of BC6ENTG BC6OTHER polymorphism on BC6OTHER and BC6OTHER enzyme activities in Turkish population exposed to BC6ENTC .	False
Effect of BC6OTHER BC6ENTG polymorphism on BC6OTHER and BC6OTHER enzyme activities in Turkish population exposed to BC6ENTC .	False
Effect of BC6OTHER BC6OTHER polymorphism on BC6ENTG and BC6OTHER enzyme activities in Turkish population exposed to BC6ENTC .	False
Effect of BC6OTHER BC6OTHER polymorphism on BC6OTHER and BC6ENTG enzyme activities in Turkish population exposed to BC6ENTC .	False
As a potent synthetic BC6ENTG inhibitor (IC50=850nM, versus BC6ENTC of 8.1μM), BC6OTHER was determined to have more significant block effects to cancer cell invasion and angiogenesis than BC6OTHER .	CPR:4
As a potent synthetic BC6ENTG inhibitor (IC50=850nM, versus BC6OTHER of 8.1μM), BC6ENTC was determined to have more significant block effects to cancer cell invasion and angiogenesis than BC6OTHER .	CPR:4
As a potent synthetic BC6ENTG inhibitor (IC50=850nM, versus BC6OTHER of 8.1μM), BC6OTHER was determined to have more significant block effects to cancer cell invasion and angiogenesis than BC6ENTC .	CPR:4
BC6ENTC is the first synthetic BC6ENTG inhibitor to be evaluated for both of its anti - invasion and anti - angiogenesis effects.	CPR:4
Discovery of a synthetic BC6ENTG inhibitor BC6ENTC as a potential anticancer agent.	CPR:4
BC6ENTC - dependent insulinotropic polypeptide ( BC6ENTG ) is an BC6OTHER that also plays a regulatory role in fat metabolism.	False
BC6ENTC - dependent insulinotropic polypeptide ( BC6OTHER ) is an BC6ENTG that also plays a regulatory role in fat metabolism.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6ENTG ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6ENTG ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6ENTG ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6ENTG ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6ENTG / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6ENTG / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6ENTG were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6ENTG ( - / - ) mice.	False
In addition, genes encoding BC6ENTG ( BC6OTHER ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
In addition, genes encoding BC6OTHER ( BC6ENTG ), BC6OTHER ( BC6OTHER ), and the signaling proteins BC6OTHER ( BC6OTHER ) / Jun BC6ENTC - terminal kinase ( BC6OTHER ), were downregulated, and phosphorylated levels of BC6OTHER / BC6OTHER / BC6OTHER were decreased in BC6OTHER ( - / - ) mice.	False
Chromatin immunoprecipitation assays were used to identify a BC6ENTC ( BC6OTHER ) - response element ( BC6ENTG ) responsible for BC6OTHER - mediated transcriptional activation of BC6OTHER .	False
Chromatin immunoprecipitation assays were used to identify a BC6ENTC ( BC6OTHER ) - response element ( BC6OTHER ) responsible for BC6ENTG - mediated transcriptional activation of BC6OTHER .	False
Chromatin immunoprecipitation assays were used to identify a BC6ENTC ( BC6OTHER ) - response element ( BC6OTHER ) responsible for BC6OTHER - mediated transcriptional activation of BC6ENTG .	False
Chromatin immunoprecipitation assays were used to identify a BC6OTHER ( BC6ENTC ) - response element ( BC6ENTG ) responsible for BC6OTHER - mediated transcriptional activation of BC6OTHER .	False
Chromatin immunoprecipitation assays were used to identify a BC6OTHER ( BC6ENTC ) - response element ( BC6OTHER ) responsible for BC6ENTG - mediated transcriptional activation of BC6OTHER .	False
Chromatin immunoprecipitation assays were used to identify a BC6OTHER ( BC6ENTC ) - response element ( BC6OTHER ) responsible for BC6OTHER - mediated transcriptional activation of BC6ENTG .	False
In 3T3 - L1 cells, BC6ENTG was demonstrated to be a key mediator of BC6OTHER stimulation of BC6OTHER ( BC6OTHER ) activity, involving activation of BC6OTHER ( BC6OTHER ) and reduced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6ENTG stimulation of BC6OTHER ( BC6OTHER ) activity, involving activation of BC6OTHER ( BC6OTHER ) and reduced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6OTHER stimulation of BC6ENTG ( BC6OTHER ) activity, involving activation of BC6OTHER ( BC6OTHER ) and reduced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6OTHER stimulation of BC6OTHER ( BC6ENTG ) activity, involving activation of BC6OTHER ( BC6OTHER ) and reduced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6OTHER stimulation of BC6OTHER ( BC6OTHER ) activity, involving activation of BC6ENTG ( BC6OTHER ) and reduced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6OTHER stimulation of BC6OTHER ( BC6OTHER ) activity, involving activation of BC6OTHER ( BC6ENTG ) and reduced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6OTHER stimulation of BC6OTHER ( BC6OTHER ) activity, involving activation of BC6OTHER ( BC6OTHER ) and reduced phosphorylation of BC6ENTG ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6OTHER stimulation of BC6OTHER ( BC6OTHER ) activity, involving activation of BC6OTHER ( BC6OTHER ) and reduced phosphorylation of BC6OTHER ( BC6ENTG ) and BC6ENTC - activated protein kinase ( BC6OTHER ).	False
In 3T3 - L1 cells, BC6OTHER was demonstrated to be a key mediator of BC6OTHER stimulation of BC6OTHER ( BC6OTHER ) activity, involving activation of BC6OTHER ( BC6OTHER ) and reduced phosphorylation of BC6OTHER ( BC6OTHER ) and BC6ENTC - activated protein kinase ( BC6ENTG ).	False
Analysis of primary adipocytes isolated from BC6ENTG ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6ENTG (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6ENTG (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6ENTG stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6ENTG / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6ENTG / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6ENTG / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6ENTG pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6ENTG (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6ENTG signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6ENTG responsiveness were compromised in BC6OTHER (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6ENTG (+ / - ) and BC6OTHER ( - / - ) adipocytes.	False
Analysis of primary adipocytes isolated from BC6OTHER ( - / - ), BC6OTHER (+ / - ), and BC6OTHER (+ / +) mice found that BC6OTHER stimulated the BC6OTHER / BC6OTHER / BC6OTHER / BC6OTHER pathway and BC6ENTC uptake only in BC6OTHER (+ / +) adipocytes, suggesting that BC6OTHER signaling and / or BC6OTHER responsiveness were compromised in BC6OTHER (+ / - ) and BC6ENTG ( - / - ) adipocytes.	False
 BC6ENTG knockout mice exhibit impaired adipocyte BC6ENTC - dependent insulinotropic polypeptide receptor ( BC6OTHER ) expression.	False
 BC6OTHER knockout mice exhibit impaired adipocyte BC6ENTC - dependent insulinotropic polypeptide receptor ( BC6ENTG ) expression.	False
Overexpression of BC6ENTG induces BC6ENTC - dependent and mitochondria - mediated apoptosis.	CPR:9
BC6ENTC oxidase ( BC6ENTG ), a mitochondrial inner - membrane protein, catalyzes the rate - limiting oxidation of BC6OTHER to BC6OTHER ( BC6OTHER ).	False
We conclude that in the presence of BC6ENTC , high BC6ENTG activity is sufficient to induce mitochondria - mediated apoptosis.	CPR:9
BC6ENTG ( BC6OTHER ), a mitochondrial inner - membrane protein, catalyzes the rate - limiting oxidation of BC6ENTC to BC6OTHER ( BC6OTHER ).	CPR:9
BC6OTHER oxidase ( BC6ENTG ), a mitochondrial inner - membrane protein, catalyzes the rate - limiting oxidation of BC6ENTC to BC6OTHER ( BC6OTHER ).	CPR:9
BC6ENTG ( BC6OTHER ), a mitochondrial inner - membrane protein, catalyzes the rate - limiting oxidation of BC6OTHER to BC6ENTC ( BC6OTHER ).	CPR:9
BC6OTHER oxidase ( BC6ENTG ), a mitochondrial inner - membrane protein, catalyzes the rate - limiting oxidation of BC6OTHER to BC6ENTC ( BC6OTHER ).	CPR:9
BC6ENTG ( BC6OTHER ), a mitochondrial inner - membrane protein, catalyzes the rate - limiting oxidation of BC6OTHER to BC6OTHER ( BC6ENTC ).	CPR:9
BC6OTHER oxidase ( BC6ENTG ), a mitochondrial inner - membrane protein, catalyzes the rate - limiting oxidation of BC6OTHER to BC6OTHER ( BC6ENTC ).	CPR:9
Previously we showed that overexpression of BC6ENTG is associated with generation of reactive BC6ENTC species (ROS) and apoptosis in BC6OTHER - inducible colorectal cancer cells, DLD - 1.	False
Previously we showed that overexpression of BC6OTHER is associated with generation of reactive BC6ENTC species (ROS) and apoptosis in BC6ENTG - inducible colorectal cancer cells, DLD - 1.	False
BC6ENTG cells to show that cells overproducing BC6OTHER exhibit an BC6ENTC - dependent apoptotic response.	False
BC6OTHER cells to show that cells overproducing BC6ENTG exhibit an BC6ENTC - dependent apoptotic response.	CPR:9
The apoptotic effect is specific for BC6ENTC , detectable at 0.2 mM, maximal at 1 mM, and occurs during 48 - 72 h following the addition of BC6OTHER to cells with maximally induced BC6ENTG .	False
The apoptotic effect is specific for BC6OTHER , detectable at 0.2 mM, maximal at 1 mM, and occurs during 48 - 72 h following the addition of BC6ENTC to cells with maximally induced BC6ENTG .	CPR:9
HeLa cells transfected with the BC6ENTG gene exhibited inhibition of BC6ENTC cyclase in response to BC6OTHER .	False
HeLa cells transfected with the BC6ENTG gene exhibited inhibition of BC6OTHER in response to BC6ENTC .	False
HeLa cells transfected with the BC6OTHER gene exhibited inhibition of BC6ENTG in response to BC6ENTC .	CPR:4
BC6ENTG thus represents a BC6ENTC receptor of the BC6OTHER class, and we propose that, based on the pharmacological characterization, BC6OTHER represents an additional BC6OTHER - like receptor.	False
BC6OTHER thus represents a BC6ENTC receptor of the BC6ENTG class, and we propose that, based on the pharmacological characterization, BC6OTHER represents an additional BC6OTHER - like receptor.	False
BC6OTHER thus represents a BC6ENTC receptor of the BC6OTHER class, and we propose that, based on the pharmacological characterization, BC6ENTG represents an additional BC6OTHER - like receptor.	False
BC6OTHER thus represents a BC6ENTC receptor of the BC6OTHER class, and we propose that, based on the pharmacological characterization, BC6OTHER represents an additional BC6ENTG - like receptor.	False
Degenerate BC6ENTC corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6ENTG , BC6OTHER , and BC6OTHER ; BC6OTHER is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6ENTC corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6ENTG , and BC6OTHER ; BC6OTHER is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6ENTC corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6OTHER , and BC6ENTG ; BC6OTHER is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6ENTC from transmembrane domains III, V, and VI of known receptors [ BC6ENTG , BC6OTHER , and BC6OTHER ; BC6OTHER is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6ENTC from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6ENTG , and BC6OTHER ; BC6OTHER is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6ENTC from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6OTHER , and BC6ENTG ; BC6OTHER is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6ENTG , BC6OTHER , and BC6OTHER ; BC6ENTC is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6ENTG , and BC6OTHER ; BC6ENTC is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6OTHER , and BC6ENTG ; BC6ENTC is BC6OTHER ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6ENTG , BC6OTHER , and BC6OTHER ; BC6OTHER is BC6ENTC ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6ENTG , and BC6OTHER ; BC6OTHER is BC6ENTC ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6OTHER , and BC6ENTG ; BC6OTHER is BC6ENTC ( BC6OTHER )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6ENTG , BC6OTHER , and BC6OTHER ; BC6OTHER is BC6OTHER ( BC6ENTC )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6ENTG , and BC6OTHER ; BC6OTHER is BC6OTHER ( BC6ENTC )] were used as primers for the sequential reactions.	False
Degenerate BC6OTHER corresponding to conserved BC6OTHER from transmembrane domains III, V, and VI of known receptors [ BC6OTHER , BC6OTHER , and BC6ENTG ; BC6OTHER is BC6OTHER ( BC6ENTC )] were used as primers for the sequential reactions.	False
The resulting product was subcloned and used to screen a rat genomic library to identify a full - length clone ( BC6ENTG ) containing an BC6OTHER encoding a 366 - BC6ENTC seven - transmembrane domain protein.	False
The resulting product was subcloned and used to screen a rat genomic library to identify a full - length clone ( BC6OTHER ) containing an BC6ENTG encoding a 366 - BC6ENTC seven - transmembrane domain protein.	False
Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% BC6ENTC identity with the known BC6ENTG , BC6OTHER , BC6OTHER , and BC6OTHER receptors, respectively.	False
Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% BC6ENTC identity with the known BC6OTHER , BC6ENTG , BC6OTHER , and BC6OTHER receptors, respectively.	False
Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% BC6ENTC identity with the known BC6OTHER , BC6OTHER , BC6ENTG , and BC6OTHER receptors, respectively.	False
Within the conserved transmembrane domains, the sequences exhibit approximately 52%, 59%, 65%, and 68% BC6ENTC identity with the known BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTG receptors, respectively.	False
Molecular cloning and functional expression of BC6ENTG - like rat and human BC6ENTC receptor genes.	False
The specific binding is displaced by the selective BC6ENTG agonist BC6ENTC but not by the mixed BC6OTHER agonist BC6OTHER .	CPR:5
The specific binding is displaced by the selective BC6OTHER agonist BC6ENTC but not by the mixed BC6ENTG agonist BC6OTHER .	False
The specific binding is displaced by the selective BC6ENTG agonist BC6OTHER but not by the mixed BC6OTHER agonist BC6ENTC .	False
The specific binding is displaced by the selective BC6OTHER agonist BC6OTHER but not by the mixed BC6ENTG agonist BC6ENTC .	False
At doses ranging from 0.02 to 0.2 microg / kg, exenatide dose - dependently reduced postprandial plasma BC6ENTC excursion by insulinotropism, suppression of plasma BC6ENTG , and slowing of gastric emptying.	False
On the other hand, BC6OTHER ( BC6ENTG ) mRNA levels were markedly low in the deficient animals, and increased upon BC6ENTC injection.	CPR:3
On the other hand, BC6ENTG ( BC6OTHER ) mRNA levels were markedly low in the deficient animals, and increased upon BC6ENTC injection.	CPR:3
"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for BC6ENTC effects on specific genes and proteins, such as BC6ENTG and BC6OTHER , and on their proteomes."	False
"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for BC6ENTC effects on specific genes and proteins, such as BC6OTHER and BC6ENTG , and on their proteomes."	False
"To probe into the ""logic"" of this enigma, we have started comparative studies among evolutionarily distant organisms, such as mouse and Saccharomyces cerevisiae, and we are now looking for BC6OTHER effects on specific genes and proteins, such as BC6ENTC and BC6ENTG , and on their proteomes."	False
This article summarizes some findings of a research that I have pursued for the past 25 years, whose roots are immersed in the field of inherited metabolic disorders, and deal with different aspects of the CHEM , starting with a patient with multiple BC6ENTG deficiency (MCD).	False
A reporter construct driven by 4 kb of the BC6ENTG 5' - flanking region, containing six putative BC6OTHER and two potential BC6OTHER , was highly activated in embryonic pituitary cells and up - regulated by BC6ENTC .	CPR:3
A reporter construct driven by 4 kb of the BC6OTHER 5' - flanking region, containing six putative BC6ENTG and two potential BC6OTHER , was highly activated in embryonic pituitary cells and up - regulated by BC6ENTC .	CPR:3
A reporter construct driven by 4 kb of the BC6OTHER 5' - flanking region, containing six putative BC6OTHER and two potential BC6ENTG , was highly activated in embryonic pituitary cells and up - regulated by BC6ENTC .	CPR:3
However, mutating putative BC6ENTG did not substantially reduce induction of BC6OTHER activity by BC6ENTC , suggesting additional BC6OTHER within the 5' - flanking region are responsible for glucocorticoid regulation.	CPR:3
However, mutating putative BC6OTHER did not substantially reduce induction of BC6ENTG activity by BC6ENTC , suggesting additional BC6OTHER within the 5' - flanking region are responsible for glucocorticoid regulation.	CPR:3
However, mutating putative BC6OTHER did not substantially reduce induction of BC6OTHER activity by BC6ENTC , suggesting additional BC6ENTG within the 5' - flanking region are responsible for glucocorticoid regulation.	False
Contractile tension of the vas deferens in response to BC6ENTC was markedly decreased in BC6ENTG KO mice, and this contraction was completely abolished in BC6OTHER triple - KO mice.	False
Contractile tension of the vas deferens in response to BC6ENTC was markedly decreased in BC6OTHER KO mice, and this contraction was completely abolished in BC6ENTG triple - KO mice.	False
Structural Basis for the BC6ENTC - Induced Isomerization of BC6ENTG .	False
BC6ENTG ( BC6OTHER ) are BC6OTHER driven by the energy derived from the hydrolysis of BC6ENTC .	False
BC6OTHER ( BC6ENTG ) are BC6OTHER driven by the energy derived from the hydrolysis of BC6ENTC .	False
BC6OTHER ( BC6OTHER ) are BC6ENTG driven by the energy derived from the hydrolysis of BC6ENTC .	False
Previous studies have revealed that the BC6ENTC binding step is crucial both for the power stroke to produce motility and for the inter - domain regulation of BC6ENTG activity to guarantee the processive movement of dimeric BC6OTHER .	False
Previous studies have revealed that the BC6ENTC binding step is crucial both for the power stroke to produce motility and for the inter - domain regulation of BC6OTHER activity to guarantee the processive movement of dimeric BC6ENTG .	False
Here, we report the first crystal structure of BC6ENTG complexed with the non - hydrolyzable BC6ENTC analog, BC6OTHER ( BC6OTHER ), at 1.7Å resolution.	False
Here, we report the first crystal structure of BC6ENTG complexed with the non - hydrolyzable BC6OTHER analog, BC6ENTC ( BC6OTHER ), at 1.7Å resolution.	False
Here, we report the first crystal structure of BC6ENTG complexed with the non - hydrolyzable BC6OTHER analog, BC6OTHER ( BC6ENTC ), at 1.7Å resolution.	False
By combining our structure with previously solved BC6ENTG structures complexed with two BC6ENTC analogs, molecular snapshots during BC6OTHER binding reveal that the closure of the BC6OTHER - binding pocket during BC6OTHER binding is achieved by closure of the backdoor.	False
By combining our structure with previously solved BC6ENTG structures complexed with two BC6OTHER analogs, molecular snapshots during BC6ENTC binding reveal that the closure of the BC6OTHER - binding pocket during BC6OTHER binding is achieved by closure of the backdoor.	False
By combining our structure with previously solved BC6ENTG structures complexed with two BC6OTHER analogs, molecular snapshots during BC6OTHER binding reveal that the closure of the BC6ENTC - binding pocket during BC6OTHER binding is achieved by closure of the backdoor.	False
By combining our structure with previously solved BC6ENTG structures complexed with two BC6OTHER analogs, molecular snapshots during BC6OTHER binding reveal that the closure of the BC6OTHER - binding pocket during BC6ENTC binding is achieved by closure of the backdoor.	False
BC6ENTG , obtained by treatment with BC6ENTC , displays one binding site for BC6OTHER , the association constants for BC6OTHER being 1.9.10(6) and 4.2.10(5) M( - 1), respectively.	False
BC6ENTG , obtained by treatment with BC6OTHER , displays one binding site for BC6ENTC , the association constants for BC6OTHER being 1.9.10(6) and 4.2.10(5) M( - 1), respectively.	False
BC6ENTG , obtained by treatment with BC6OTHER , displays one binding site for BC6OTHER , the association constants for BC6ENTC being 1.9.10(6) and 4.2.10(5) M( - 1), respectively.	False
However, BC6ENTG was unable to bind BC6ENTC as measured by this technique.	False
Likewise, no BC6ENTC bound to BC6ENTG , isolated using nondenaturing conditions, were detected by gas chromatography.	False
These results demonstrate that the conformational change induced in BC6ENTG by the removal of BC6ENTC enables the protein to interact with CHEM.	False
The interaction of holo - and apo - forms of BC6ENTG with BC6ENTC was studied by a partition equilibrium method.	False
Interaction of BC6ENTG with BC6ENTC : determination of binding parameters.	False
BC6ENTC is one of the first BC6ENTG hormones to be described functionally and subsequently approached as a drug target.	False
Because BC6ENTC (1) affects both menstruation and gestation via the BC6ENTG ( BC6OTHER ), research aimed at modulating its activity is usually surrounded by controversy.	False
Because BC6ENTC (1) affects both menstruation and gestation via the BC6OTHER receptor ( BC6ENTG ), research aimed at modulating its activity is usually surrounded by controversy.	False
Because BC6OTHER (1) affects both menstruation and gestation via the BC6ENTC receptor ( BC6ENTG ), research aimed at modulating its activity is usually surrounded by controversy.	False
However, ligands for BC6ENTG were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6ENTC that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6OTHER with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6OTHER BC6OTHER ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6OTHER were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6ENTC that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6OTHER with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6OTHER BC6ENTG ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6ENTG were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6ENTC ; (2) drug - like BC6OTHER with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6OTHER BC6OTHER ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6OTHER were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6ENTC ; (2) drug - like BC6OTHER with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6OTHER BC6ENTG ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6ENTG were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6ENTC with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6OTHER BC6OTHER ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6OTHER were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6ENTC with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6OTHER BC6ENTG ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6ENTG were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6OTHER with different properties from BC6ENTC and expanded therapeutic applications; and (3) non - BC6OTHER BC6OTHER ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6OTHER were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6OTHER with different properties from BC6ENTC and expanded therapeutic applications; and (3) non - BC6OTHER BC6ENTG ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6ENTG were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6OTHER with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6ENTC BC6OTHER ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
However, ligands for BC6OTHER were developed into drugs, and their evolution can be crudely divided into three periods: (1) drug - like BC6OTHER that mimic the gestational properties of BC6OTHER ; (2) drug - like BC6OTHER with different properties from BC6OTHER and expanded therapeutic applications; and (3) non - BC6ENTC BC6ENTG ligands with improved selectivity and modulator properties and further expanded therapeutic applications.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6ENTG , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6ENTG , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6ENTG ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6ENTG / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6ENTG / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6ENTG ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6ENTG ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6ENTG ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6ENTG , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6ENTG , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6ENTG ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), as well as positivity for the messenger RNA of the BC6OTHER gene by in situ hybridization analysis.	False
The ETTAG was histologically indistinguishable from normal orthotopic thyroid tissue, and its follicular nature was confirmed by immunohistochemical positivity for BC6OTHER , BC6OTHER , BC6OTHER ( BC6OTHER / BC6OTHER / BC6OTHER ), BC6OTHER ( BC6OTHER ) AE1 / AE3, BC6OTHER , BC6OTHER , human BC6ENTC symporter ( BC6OTHER ), BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), as well as positivity for the messenger RNA of the BC6ENTG gene by in situ hybridization analysis.	False
Cellular release of BC6ENTG by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6ENTC .	CPR:4
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the BC6ENTG ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6ENTC .	False
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6ENTG ) agonists BC6OTHER or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6ENTC .	False
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6OTHER blocked by the BC6ENTG antagonist BC6ENTC .	CPR:6
Since BC6ENTG does not possess a BC6OTHER , its anchorage in the membrane is established via the BC6ENTC Rich Membrane Anchor ( BC6OTHER ), a transmembrane protein.	False
Since BC6OTHER does not possess a BC6ENTG , its anchorage in the membrane is established via the BC6ENTC Rich Membrane Anchor ( BC6OTHER ), a transmembrane protein.	False
Since BC6OTHER does not possess a BC6OTHER , its anchorage in the membrane is established via the BC6ENTC Rich Membrane Anchor ( BC6ENTG ), a transmembrane protein.	False
Although BC6OTHER ( BC6ENTG ) is primarily a hydrolytic enzyme, metabolising the neurotransmitter BC6ENTC in cholinergic synapses, it also has some non - catalytic functions in the brain which are far less well characterised.	CPR:9
Although BC6ENTG ( BC6OTHER ) is primarily a hydrolytic enzyme, metabolising the neurotransmitter BC6ENTC in cholinergic synapses, it also has some non - catalytic functions in the brain which are far less well characterised.	CPR:9
In an effort to understand the shedding process of BC6ENTG , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6ENTC - and BC6OTHER - sensitive, but BC6OTHER - insensitive BC6OTHER , with the possible additional involvement of a BC6OTHER isomerase.	False
In an effort to understand the shedding process of BC6OTHER , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6ENTC - and BC6OTHER - sensitive, but BC6OTHER - insensitive BC6ENTG , with the possible additional involvement of a BC6OTHER isomerase.	False
In an effort to understand the shedding process of BC6OTHER , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6ENTC - and BC6OTHER - sensitive, but BC6OTHER - insensitive BC6OTHER , with the possible additional involvement of a BC6ENTG .	False
In an effort to understand the shedding process of BC6ENTG , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6ENTC - sensitive, but BC6OTHER - insensitive BC6OTHER , with the possible additional involvement of a BC6OTHER isomerase.	False
In an effort to understand the shedding process of BC6OTHER , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6ENTC - sensitive, but BC6OTHER - insensitive BC6ENTG , with the possible additional involvement of a BC6OTHER isomerase.	False
In an effort to understand the shedding process of BC6OTHER , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6ENTC - sensitive, but BC6OTHER - insensitive BC6OTHER , with the possible additional involvement of a BC6ENTG .	False
In an effort to understand the shedding process of BC6ENTG , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6OTHER - sensitive, but BC6ENTC - insensitive BC6OTHER , with the possible additional involvement of a BC6OTHER isomerase.	False
In an effort to understand the shedding process of BC6OTHER , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6OTHER - sensitive, but BC6ENTC - insensitive BC6ENTG , with the possible additional involvement of a BC6OTHER isomerase.	False
In an effort to understand the shedding process of BC6OTHER , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6OTHER - sensitive, but BC6ENTC - insensitive BC6OTHER , with the possible additional involvement of a BC6ENTG .	False
In an effort to understand the shedding process of BC6ENTG , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6OTHER - sensitive, but BC6OTHER - insensitive BC6OTHER , with the possible additional involvement of a BC6ENTC isomerase.	False
In an effort to understand the shedding process of BC6OTHER , we have used several pharmacological treatments, which showed that it is likely to be mediated in part by an BC6OTHER - and BC6OTHER - sensitive, but BC6OTHER - insensitive BC6ENTG , with the possible additional involvement of a BC6ENTC isomerase.	False
Cellular release of BC6ENTG by CHEM - SY5Y is significantly enhanced by the muscarinic BC6ENTC receptor ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	False
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6ENTC receptor ( BC6ENTG ) agonists BC6OTHER or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	False
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6ENTC receptor ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6OTHER blocked by the BC6ENTG antagonist BC6OTHER .	False
Cellular release of BC6ENTG by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6ENTC or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	CPR:3
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the BC6ENTG ( BC6OTHER ) agonists BC6ENTC or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	CPR:5
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6ENTG ) agonists BC6ENTC or BC6OTHER , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	CPR:5
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6ENTC or BC6OTHER , with the effect of BC6OTHER blocked by the BC6ENTG antagonist BC6OTHER .	False
Cellular release of BC6ENTG by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6OTHER or BC6ENTC , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	CPR:3
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the BC6ENTG ( BC6OTHER ) agonists BC6OTHER or BC6ENTC , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	CPR:5
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6ENTG ) agonists BC6OTHER or BC6ENTC , with the effect of BC6OTHER blocked by the BC6OTHER antagonist BC6OTHER .	CPR:5
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6OTHER or BC6ENTC , with the effect of BC6OTHER blocked by the BC6ENTG antagonist BC6OTHER .	False
Cellular release of BC6ENTG by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6ENTC blocked by the BC6OTHER antagonist BC6OTHER .	CPR:3
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the BC6ENTG ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6ENTC blocked by the BC6OTHER antagonist BC6OTHER .	False
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6ENTG ) agonists BC6OTHER or BC6OTHER , with the effect of BC6ENTC blocked by the BC6OTHER antagonist BC6OTHER .	False
Cellular release of BC6OTHER by CHEM - SY5Y is significantly enhanced by the muscarinic BC6OTHER receptor ( BC6OTHER ) agonists BC6OTHER or BC6OTHER , with the effect of BC6ENTC blocked by the BC6ENTG antagonist BC6OTHER .	False
By 7 days following BC6ENTC withdrawal, gene expression, cell proliferation and tissue morphology were undistinguishable from control animals.In conclusion, these results demonstrate that the reversal of BC6ENTG signaling by inhibitors should ideally be studied within hours of treatment.	False
 A BC6ENTC - inducible transgenic mouse model expressing truncated BC6ENTG (ΔN89 BC6OTHER ) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic BC6OTHER expression both in 3D 'crypt culture' and in vivo. Oncogenic BC6OTHER signaling was rapidly and completely reversed.	False
 A BC6ENTC - inducible transgenic mouse model expressing truncated BC6OTHER (ΔN89 BC6ENTG ) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic BC6OTHER expression both in 3D 'crypt culture' and in vivo. Oncogenic BC6OTHER signaling was rapidly and completely reversed.	False
 A BC6ENTC - inducible transgenic mouse model expressing truncated BC6OTHER (ΔN89 BC6OTHER ) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic BC6ENTG expression both in 3D 'crypt culture' and in vivo. Oncogenic BC6OTHER signaling was rapidly and completely reversed.	False
 A BC6ENTC - inducible transgenic mouse model expressing truncated BC6OTHER (ΔN89 BC6OTHER ) that exhibited a strong intestinal hyperplasia was analyzed during the removal of oncogenic BC6OTHER expression both in 3D 'crypt culture' and in vivo. Oncogenic BC6ENTG signaling was rapidly and completely reversed.	False
Direct and exome sequencing identified the presence of a T - to - C exchange in exon 1 of BC6ENTG , corresponding to a BC6ENTC - to - BC6OTHER mutation at residue 107.	False
Direct and exome sequencing identified the presence of a T - to - C exchange in exon 1 of BC6ENTG , corresponding to a CHEM - to - BC6ENTC mutation at residue 107.	False
Expression of BC6ENTG - BC6OTHER in BC6OTHER - producing cells resulted in overproduction of BC6ENTC , BC6OTHER , and BC6OTHER .	False
Expression of BC6OTHER - BC6ENTG in BC6OTHER - producing cells resulted in overproduction of BC6ENTC , BC6OTHER , and BC6OTHER .	False
Expression of BC6OTHER - BC6OTHER in BC6ENTG - producing cells resulted in overproduction of BC6ENTC , BC6OTHER , and BC6OTHER .	False
Expression of BC6OTHER - BC6OTHER in BC6OTHER - producing cells resulted in overproduction of BC6ENTC , BC6ENTG , and BC6OTHER .	False
Expression of BC6OTHER - BC6OTHER in BC6OTHER - producing cells resulted in overproduction of BC6ENTC , BC6OTHER , and BC6ENTG .	False
Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several BC6ENTG in mice and replacement of plasmid by BC6ENTC reduced the elevation of all assayed BC6OTHER .	False
Systemic injection to mice of siRNA lipoplexes, rather than of cationic liposome, triggered a production of several BC6OTHER in mice and replacement of plasmid by BC6ENTC reduced the elevation of all assayed BC6ENTG .	CPR:4
BC6ENTC , a specific BC6ENTG / BC6OTHER inhibitor, selectively activated the BC6OTHER BC6OTHER BC6OTHER pathway and enhanced BC6OTHER phosphorylation, but did not activate BC6OTHER .	CPR:4
BC6ENTC , a specific BC6OTHER / BC6ENTG inhibitor, selectively activated the BC6OTHER BC6OTHER BC6OTHER pathway and enhanced BC6OTHER phosphorylation, but did not activate BC6OTHER .	CPR:4
BC6ENTC , a specific BC6OTHER / BC6OTHER inhibitor, selectively activated the BC6ENTG BC6OTHER BC6OTHER pathway and enhanced BC6OTHER phosphorylation, but did not activate BC6OTHER .	CPR:3
BC6ENTC , a specific BC6OTHER / BC6OTHER inhibitor, selectively activated the BC6OTHER BC6ENTG BC6OTHER pathway and enhanced BC6OTHER phosphorylation, but did not activate BC6OTHER .	CPR:3
BC6ENTC , a specific BC6OTHER / BC6OTHER inhibitor, selectively activated the BC6OTHER BC6OTHER BC6ENTG pathway and enhanced BC6OTHER phosphorylation, but did not activate BC6OTHER .	CPR:3
BC6ENTC , a specific BC6OTHER / BC6OTHER inhibitor, selectively activated the BC6OTHER BC6OTHER BC6OTHER pathway and enhanced BC6ENTG phosphorylation, but did not activate BC6OTHER .	CPR:3
BC6ENTC , a specific BC6OTHER / BC6OTHER inhibitor, selectively activated the BC6OTHER BC6OTHER BC6OTHER pathway and enhanced BC6OTHER phosphorylation, but did not activate BC6ENTG .	False
The pharmacological inhibitors BC6ENTC ( BC6ENTG inhibitor) and BC6OTHER (a BC6OTHER inhibitor) protected primary cultures of rat CGCs from BC6OTHER - induced apoptosis.	CPR:4
The pharmacological inhibitors BC6ENTC ( BC6OTHER inhibitor) and BC6OTHER (a BC6ENTG inhibitor) protected primary cultures of rat CGCs from BC6OTHER - induced apoptosis.	False
The pharmacological inhibitors BC6OTHER ( BC6ENTG inhibitor) and BC6ENTC (a BC6OTHER inhibitor) protected primary cultures of rat CGCs from BC6OTHER - induced apoptosis.	False
The pharmacological inhibitors BC6OTHER ( BC6OTHER inhibitor) and BC6ENTC (a BC6ENTG inhibitor) protected primary cultures of rat CGCs from BC6OTHER - induced apoptosis.	CPR:4
The pharmacological inhibitors BC6OTHER ( BC6ENTG inhibitor) and BC6OTHER (a BC6OTHER inhibitor) protected primary cultures of rat CGCs from BC6ENTC - induced apoptosis.	False
The pharmacological inhibitors BC6OTHER ( BC6OTHER inhibitor) and BC6OTHER (a BC6ENTG inhibitor) protected primary cultures of rat CGCs from BC6ENTC - induced apoptosis.	False
Nevertheless, low BC6ENTC concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, BC6ENTG and BC6OTHER activity, expression of the endoplasmic reticulum (ER) stress marker BC6OTHER , and enhanced phosphorylation of BC6OTHER in SH - SY5Y cells.	CPR:3
Nevertheless, low BC6ENTC concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, BC6OTHER and BC6ENTG activity, expression of the endoplasmic reticulum (ER) stress marker BC6OTHER , and enhanced phosphorylation of BC6OTHER in SH - SY5Y cells.	CPR:3
Nevertheless, low BC6ENTC concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, BC6OTHER and BC6OTHER activity, expression of the endoplasmic reticulum (ER) stress marker BC6ENTG , and enhanced phosphorylation of BC6OTHER in SH - SY5Y cells.	CPR:3
Nevertheless, low BC6ENTC concentrations (≥ 0.1mM, 48 h) increased protein ubiquitination, BC6OTHER and BC6OTHER activity, expression of the endoplasmic reticulum (ER) stress marker BC6OTHER , and enhanced phosphorylation of BC6ENTG in SH - SY5Y cells.	CPR:3
 BC6ENTC induced ER stress and enhanced BC6ENTG cleavage in human neuroblastoma SH - SY5Y cells at low nonexcitotoxic concentrations.	CPR:3
Diabetic rats showed significant (p<0.05) increased in plasma BC6ENTC , BC6ENTG and significant (p<0.05) decreased in circulating BC6OTHER and BC6OTHER .	False
Diabetic rats showed significant (p<0.05) increased in plasma BC6ENTC , BC6OTHER and significant (p<0.05) decreased in circulating BC6ENTG and BC6OTHER .	False
Diabetic rats showed significant (p<0.05) increased in plasma BC6ENTC , BC6OTHER and significant (p<0.05) decreased in circulating BC6OTHER and BC6ENTG .	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6ENTG ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6ENTG of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6ENTG , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTG , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTG and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6ENTC - 6 - phosphatase and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTG ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6ENTG ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The altered activities of key enzymes such as BC6ENTG and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6ENTG , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTG , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTG and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTC - 1,6 - bisphosphatase of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTG ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6ENTG ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The altered activities of key enzymes such as BC6ENTG and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:9
The altered activities of key enzymes such as BC6OTHER and BC6ENTG of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	CPR:9
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6ENTG , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTG , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTG and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6ENTC metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTG ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6ENTG ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The altered activities of key enzymes such as BC6ENTG and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTG of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6ENTG , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6ENTG and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTC kinase, BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTG ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6ENTG ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The altered activities of key enzymes such as BC6ENTG and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTG of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6ENTG , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTG , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTC dehydrogenase and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTG ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6ENTG ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The altered activities of key enzymes such as BC6ENTG and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTG of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6ENTG , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTG , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTG and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTC transaminase ( BC6OTHER ), BC6OTHER transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6ENTG ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6ENTG ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6ENTG ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6ENTG ).	False
The altered activities of key enzymes such as BC6ENTG and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6ENTG of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6ENTG , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6ENTG , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6ENTG and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6OTHER ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The altered activities of key enzymes such as BC6OTHER and BC6OTHER of BC6OTHER metabolism significantly (p<0.05) increased whereas BC6OTHER , BC6OTHER , BC6OTHER and glycogen content significantly (p<0.05) decreased in the liver of diabetic rats and also increased activities of BC6ENTG ( BC6OTHER ), BC6ENTC transaminase ( BC6OTHER ) and BC6OTHER ( BC6OTHER ).	False
The aim of this study was to compare, by quantitative real time PCR, the amount of BC6ENTC receptor mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the BC6ENTG mRNA levels observed in control phimosis subjects with eutopic urethral opening.	False
The aim of this study was to compare, by quantitative real time PCR, the amount of BC6ENTG mRNA in cells obtained from the urethral mucosa of patients with middle idiopathic hypospadias with the BC6ENTC receptor mRNA levels observed in control phimosis subjects with eutopic urethral opening.	False
BC6ENTC action is exerted through the BC6ENTG .	False
The normal 46,XY genital virilization depends on BC6ENTC receptor gene expression, which is tissue specific, and requires normal BC6ENTG mRNA levels in BC6OTHER sensitive tissues.	False
We also established the number of BC6ENTG in exon 1 of the BC6ENTC receptor gene by GeneScan analysis.	False
The normal 46,XY genital virilization depends on BC6ENTG gene expression, which is tissue specific, and requires normal BC6ENTC receptor mRNA levels in BC6OTHER sensitive tissues.	False
The normal 46,XY genital virilization depends on BC6ENTG gene expression, which is tissue specific, and requires normal BC6OTHER receptor mRNA levels in BC6ENTC sensitive tissues.	False
The normal 46,XY genital virilization depends on BC6OTHER receptor gene expression, which is tissue specific, and requires normal BC6ENTG mRNA levels in BC6ENTC sensitive tissues.	False
BC6ENTC inhibited the phosphorylation and activation of BC6OTHER and BC6ENTG through BC6OTHER signaling blockade.	CPR:4
BC6ENTC inhibited the phosphorylation and activation of BC6OTHER and BC6OTHER through BC6ENTG signaling blockade.	CPR:4
BC6ENTC inhibited the phosphorylation and activation of BC6ENTG and BC6OTHER through BC6OTHER signaling blockade.	CPR:4
These data show that the BC6ENTC is a promising new approach to decrease glioblastoma proliferation and recurrence by downregulation of BC6ENTG pathway.	CPR:4
 BC6ENTC depletes cancer stem - like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of BC6ENTG pathway.	CPR:4
In this paper a series of new BC6ENTC derivatives has been designed, synthesized and evaluated as the BC6ENTG inhibitors.	CPR:4
Synthesis and biological evaluation of BC6ENTC analogues as novel BC6ENTG and BC6OTHER inhibitors.	CPR:4
Synthesis and biological evaluation of BC6ENTC analogues as novel BC6OTHER and BC6ENTG inhibitors.	CPR:4
BC6ENTC (0.1%) failed to significantly attenuate either CHEM or platelet - activating - factor induced vascular permeability changes indicating high selectivity for the BC6ENTG .	False
Preclinical efficacy of BC6ENTC , a potent, selective BC6ENTG antagonist for topical ocular use.	CPR:6
BC6ENTC ( BC6OTHER ) has been shown to inhibit both BC6OTHER and BC6ENTG and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
BC6ENTC ( BC6OTHER ) has been shown to inhibit both BC6ENTG and BC6OTHER decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
BC6OTHER ( BC6ENTC ) has been shown to inhibit both BC6OTHER and BC6ENTG and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
BC6OTHER ( BC6ENTC ) has been shown to inhibit both BC6ENTG and BC6OTHER decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	CPR:4
BC6OTHER ( BC6OTHER ) has been shown to inhibit both BC6ENTG and BC6ENTC decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.	False
Elevated BC6ENTC AUC in virtual rheumatoid arthritis patients, following 100 pg / mL of BC6ENTG was comparable to observed clinical data (59% versus 58%).	False
In virtual bone marrow transplant (BMT) patients, 500 pg / ml of BC6ENTG resulted in increase in BC6ENTC AUC that was in good agreement with the observed data (45% versus 39%).	False
In a different group of BMT patients treated with BC6ENTC , the magnitude of interaction with BC6ENTG was under predicted ~3 - fold.	False
There are few reports describing the mechanism of BC6ENTG - elevating action of BC6ENTC reductase inhibitors (CHEM).	False
Based on BC6ENTG inhibition, BC6OTHER - induced BC6OTHER more efficiently than BC6ENTC and BC6OTHER .	False
Based on BC6OTHER reductase inhibition, BC6OTHER - induced BC6ENTG more efficiently than BC6ENTC and BC6OTHER .	CPR:3
Based on BC6ENTG inhibition, BC6OTHER - induced BC6OTHER more efficiently than BC6OTHER and BC6ENTC .	False
Based on BC6OTHER reductase inhibition, BC6OTHER - induced BC6ENTG more efficiently than BC6OTHER and BC6ENTC .	CPR:3
Further study revealed that BC6ENTC increased BC6ENTG mRNA in BC6OTHER - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6OTHER ) increased BC6OTHER production in the HepG2 cells.	CPR:3
Further study revealed that BC6ENTC increased BC6OTHER mRNA in BC6ENTG - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6OTHER ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6ENTC increased BC6OTHER mRNA in BC6OTHER - dependent manner and that BC6ENTG and BC6OTHER inhibitor (C3T and BC6OTHER ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6ENTC increased BC6OTHER mRNA in BC6OTHER - dependent manner and that BC6OTHER and BC6ENTG inhibitor (C3T and BC6OTHER ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6ENTC increased BC6OTHER mRNA in BC6OTHER - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6OTHER ) increased BC6ENTG production in the HepG2 cells.	False
Further study revealed that BC6OTHER increased BC6ENTG mRNA in BC6ENTC reductase - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6OTHER ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6OTHER increased BC6OTHER mRNA in BC6ENTC reductase - dependent manner and that BC6ENTG and BC6OTHER inhibitor (C3T and BC6OTHER ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6OTHER increased BC6OTHER mRNA in BC6ENTC reductase - dependent manner and that BC6OTHER and BC6ENTG inhibitor (C3T and BC6OTHER ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6OTHER increased BC6OTHER mRNA in BC6ENTC reductase - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6OTHER ) increased BC6ENTG production in the HepG2 cells.	False
Further study revealed that BC6OTHER increased BC6ENTG mRNA in BC6OTHER - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6ENTC ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6OTHER increased BC6OTHER mRNA in BC6ENTG - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6ENTC ) increased BC6OTHER production in the HepG2 cells.	False
Further study revealed that BC6OTHER increased BC6OTHER mRNA in BC6OTHER - dependent manner and that BC6ENTG and BC6OTHER inhibitor (C3T and BC6ENTC ) increased BC6OTHER production in the HepG2 cells.	CPR:4
Further study revealed that BC6OTHER increased BC6OTHER mRNA in BC6OTHER - dependent manner and that BC6OTHER and BC6ENTG inhibitor (C3T and BC6ENTC ) increased BC6OTHER production in the HepG2 cells.	CPR:4
Further study revealed that BC6OTHER increased BC6OTHER mRNA in BC6OTHER - dependent manner and that BC6OTHER and BC6OTHER inhibitor (C3T and BC6ENTC ) increased BC6ENTG production in the HepG2 cells.	CPR:3
Effect of BC6ENTC on BC6ENTG production in HepG2 cell.	False
These results suggest that BC6ENTC efficiently increases BC6ENTG in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6OTHER reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	CPR:3
These results suggest that BC6ENTC efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6ENTG production through inhibition of BC6OTHER reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	CPR:3
These results suggest that BC6ENTC efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6ENTG and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	CPR:4
These results suggest that BC6ENTC efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6OTHER reductase and suppression of BC6ENTG activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	CPR:4
These results suggest that BC6ENTC efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6OTHER reductase and suppression of BC6OTHER activity and by protecting BC6ENTG from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	False
These results suggest that BC6ENTC efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6OTHER reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6ENTG induction and lipidation of BC6OTHER .	CPR:3
These results suggest that BC6ENTC efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6OTHER reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6ENTG .	CPR:3
These results suggest that BC6OTHER efficiently increases BC6ENTG in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6ENTC reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	False
These results suggest that BC6OTHER efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6ENTG production through inhibition of BC6ENTC reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	False
These results suggest that BC6OTHER efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6ENTC reductase and suppression of BC6ENTG activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	False
These results suggest that BC6OTHER efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6ENTC reductase and suppression of BC6OTHER activity and by protecting BC6ENTG from catabolism through BC6OTHER induction and lipidation of BC6OTHER .	False
These results suggest that BC6OTHER efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6ENTC reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6ENTG induction and lipidation of BC6OTHER .	False
These results suggest that BC6OTHER efficiently increases BC6OTHER in the culture medium of HepG2 cells by promoting BC6OTHER production through inhibition of BC6ENTC reductase and suppression of BC6OTHER activity and by protecting BC6OTHER from catabolism through BC6OTHER induction and lipidation of BC6ENTG .	False
Each CHEM induced BC6ENTG expression (mRNA and protein) dose - dependently: the rank order of the BC6OTHER induction BC6ENTC (3 microM)> BC6OTHER (10 microM)> BC6OTHER (30 microM).	False
Each CHEM induced BC6OTHER expression (mRNA and protein) dose - dependently: the rank order of the BC6ENTG induction BC6ENTC (3 microM)> BC6OTHER (10 microM)> BC6OTHER (30 microM).	CPR:3
Each CHEM induced BC6ENTG expression (mRNA and protein) dose - dependently: the rank order of the BC6OTHER induction BC6OTHER (3 microM)> BC6ENTC (10 microM)> BC6OTHER (30 microM).	False
Each CHEM induced BC6OTHER expression (mRNA and protein) dose - dependently: the rank order of the BC6ENTG induction BC6OTHER (3 microM)> BC6ENTC (10 microM)> BC6OTHER (30 microM).	CPR:3
Each CHEM induced BC6ENTG expression (mRNA and protein) dose - dependently: the rank order of the BC6OTHER induction BC6OTHER (3 microM)> BC6OTHER (10 microM)> BC6ENTC (30 microM).	False
Each CHEM induced BC6OTHER expression (mRNA and protein) dose - dependently: the rank order of the BC6ENTG induction BC6OTHER (3 microM)> BC6OTHER (10 microM)> BC6ENTC (30 microM).	CPR:3
The induction of BC6ENTG by CHEM disappeared with addition of BC6ENTC , which indicates that the effect is BC6OTHER reductase inhibition - dependent.	CPR:4
The induction of BC6OTHER by CHEM disappeared with addition of BC6ENTC , which indicates that the effect is BC6ENTG inhibition - dependent.	False
The induction of BC6ENTG by CHEM disappeared with addition of BC6OTHER , which indicates that the effect is BC6ENTC reductase inhibition - dependent.	False
Based on BC6ENTC reductase inhibition, BC6OTHER - induced BC6ENTG more efficiently than BC6OTHER and BC6OTHER .	False
Based on BC6ENTG inhibition, BC6ENTC - induced BC6OTHER more efficiently than BC6OTHER and BC6OTHER .	False
Based on BC6OTHER reductase inhibition, BC6ENTC - induced BC6ENTG more efficiently than BC6OTHER and BC6OTHER .	CPR:3
Liver microsomes and recombinant BC6ENTG were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs BC6OTHER of BC6OTHER of BC6OTHER ( BC6ENTC ) and BC6OTHER .	False
Liver microsomes and recombinant BC6ENTG were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs BC6OTHER of BC6OTHER of BC6OTHER ( BC6OTHER ) and BC6ENTC .	False
Contrary to the hypothesis, CHEM at 1 nM inhibited BC6ENTG activity by 75% but no inhibition on BC6OTHER , placing BC6OTHER one of the most sensitive targets of BC6ENTC .	CPR:4
Contrary to the hypothesis, CHEM at 1 nM inhibited BC6OTHER activity by 75% but no inhibition on BC6ENTG , placing BC6OTHER one of the most sensitive targets of BC6ENTC .	False
Contrary to the hypothesis, CHEM at 1 nM inhibited BC6OTHER activity by 75% but no inhibition on BC6OTHER , placing BC6ENTG one of the most sensitive targets of BC6ENTC .	CPR:4
 BC6ENTG is a highly sensitive target of the antiobesity agent BC6ENTC with profound implications in the activation of anticancer prodrugs.	False
BC6ENTC has been the most used anti - obesity drug and the mechanism of its action is to reduce lipid absorption by inhibiting gastrointestinal BC6ENTG .	CPR:4
Inhibition of this BC6ENTG probably presents a major source for altered therapeutic activity of these medicines if co - administered with BC6ENTC .	CPR:4
This study was designed to test the hypothesis that BC6ENTC inhibits BC6ENTG with higher potency toward BC6OTHER than BC6OTHER , a BC6OTHER with little BC6OTHER activity.	CPR:4
This study was designed to test the hypothesis that BC6ENTC inhibits BC6OTHER with higher potency toward BC6ENTG than BC6OTHER , a BC6OTHER with little BC6OTHER activity.	CPR:4
This study was designed to test the hypothesis that BC6ENTC inhibits BC6OTHER with higher potency toward BC6OTHER than BC6ENTG , a BC6OTHER with little BC6OTHER activity.	CPR:4
This study was designed to test the hypothesis that BC6ENTC inhibits BC6OTHER with higher potency toward BC6OTHER than BC6OTHER , a BC6ENTG with little BC6OTHER activity.	CPR:4
This study was designed to test the hypothesis that BC6ENTC inhibits BC6OTHER with higher potency toward BC6OTHER than BC6OTHER , a BC6OTHER with little BC6ENTG activity.	CPR:4
Liver microsomes and recombinant BC6ENTG were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs BC6ENTC of BC6OTHER of BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
Liver microsomes and recombinant BC6ENTG were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs BC6OTHER of BC6ENTC of BC6OTHER ( BC6OTHER ) and BC6OTHER .	False
Liver microsomes and recombinant BC6ENTG were tested for the inhibition of the hydrolysis of standard substrates and the anticancer prodrugs BC6OTHER of BC6OTHER of BC6ENTC ( BC6OTHER ) and BC6OTHER .	False
 Lessons from the dissection of the BC6ENTG ( BC6OTHER and BC6OTHER ) of the BC6OTHER receptor alpha in vivo. BC6ENTC influence most of the physiological processes in mammals, including but not limited to reproduction, cognition, behavior, vascular system, metabolism and bone integrity.	False
 Lessons from the dissection of the BC6OTHER ( BC6ENTG and BC6OTHER ) of the BC6OTHER receptor alpha in vivo. BC6ENTC influence most of the physiological processes in mammals, including but not limited to reproduction, cognition, behavior, vascular system, metabolism and bone integrity.	False
 Lessons from the dissection of the BC6OTHER ( BC6OTHER and BC6ENTG ) of the BC6OTHER receptor alpha in vivo. BC6ENTC influence most of the physiological processes in mammals, including but not limited to reproduction, cognition, behavior, vascular system, metabolism and bone integrity.	False
 Lessons from the dissection of the BC6OTHER ( BC6OTHER and BC6OTHER ) of the BC6ENTG in vivo. BC6ENTC influence most of the physiological processes in mammals, including but not limited to reproduction, cognition, behavior, vascular system, metabolism and bone integrity.	False
However, the use of these BC6ENTC or selective BC6ENTG modulators (SERMs) have also induced undesired effects.	False
These actions are mediated by the activation of BC6ENTC receptors (ER) alpha (ERα) and beta ( BC6ENTG ), which regulate target gene transcription (genomic action) through two independent BC6OTHER BC6OTHER and BC6OTHER , but can also elicit rapid membrane initiated BC6OTHER signals (MISS).	False
These actions are mediated by the activation of BC6ENTC receptors (ER) alpha (ERα) and beta ( BC6OTHER ), which regulate target gene transcription (genomic action) through two independent BC6ENTG BC6OTHER and BC6OTHER , but can also elicit rapid membrane initiated BC6OTHER signals (MISS).	False
These actions are mediated by the activation of BC6ENTC receptors (ER) alpha (ERα) and beta ( BC6OTHER ), which regulate target gene transcription (genomic action) through two independent BC6OTHER BC6ENTG and BC6OTHER , but can also elicit rapid membrane initiated BC6OTHER signals (MISS).	False
These actions are mediated by the activation of BC6ENTC receptors (ER) alpha (ERα) and beta ( BC6OTHER ), which regulate target gene transcription (genomic action) through two independent BC6OTHER BC6OTHER and BC6ENTG , but can also elicit rapid membrane initiated BC6OTHER signals (MISS).	False
These actions are mediated by the activation of BC6ENTG ( BC6OTHER ), which regulate target gene transcription (genomic action) through two independent BC6OTHER BC6OTHER and BC6OTHER , but can also elicit rapid membrane initiated BC6ENTC signals (MISS).	False
These actions are mediated by the activation of BC6OTHER receptors (ER) alpha (ERα) and beta ( BC6ENTG ), which regulate target gene transcription (genomic action) through two independent BC6OTHER BC6OTHER and BC6OTHER , but can also elicit rapid membrane initiated BC6ENTC signals (MISS).	False
These actions are mediated by the activation of BC6OTHER receptors (ER) alpha (ERα) and beta ( BC6OTHER ), which regulate target gene transcription (genomic action) through two independent BC6ENTG BC6OTHER and BC6OTHER , but can also elicit rapid membrane initiated BC6ENTC signals (MISS).	False
These actions are mediated by the activation of BC6OTHER receptors (ER) alpha (ERα) and beta ( BC6OTHER ), which regulate target gene transcription (genomic action) through two independent BC6OTHER BC6ENTG and BC6OTHER , but can also elicit rapid membrane initiated BC6ENTC signals (MISS).	False
These actions are mediated by the activation of BC6OTHER receptors (ER) alpha (ERα) and beta ( BC6OTHER ), which regulate target gene transcription (genomic action) through two independent BC6OTHER BC6OTHER and BC6ENTG , but can also elicit rapid membrane initiated BC6ENTC signals (MISS).	False
 Lessons from the dissection of the BC6ENTG ( BC6OTHER and BC6OTHER ) of the BC6ENTC receptor alpha in vivo. BC6OTHER influence most of the physiological processes in mammals, including but not limited to reproduction, cognition, behavior, vascular system, metabolism and bone integrity.	False
 Lessons from the dissection of the BC6OTHER ( BC6ENTG and BC6OTHER ) of the BC6ENTC receptor alpha in vivo. BC6OTHER influence most of the physiological processes in mammals, including but not limited to reproduction, cognition, behavior, vascular system, metabolism and bone integrity.	False
 Lessons from the dissection of the BC6OTHER ( BC6OTHER and BC6ENTG ) of the BC6ENTC receptor alpha in vivo. BC6OTHER influence most of the physiological processes in mammals, including but not limited to reproduction, cognition, behavior, vascular system, metabolism and bone integrity.	False
Effects of BC6OTHER on BC6ENTG mRNA were antagonized by BC6ENTC .	False
Mobility shift assays on whole cell extracts showed that BC6ENTC increased BC6ENTG binding in 3T3 cells prior to increasing BC6OTHER synthesis.	False
Mobility shift assays on whole cell extracts showed that BC6ENTC increased BC6OTHER binding in 3T3 cells prior to increasing BC6ENTG synthesis.	CPR:3
BC6ENTC was without effect on BC6ENTG mRNA levels in L929 cells, whereas BC6OTHER caused significant increases in both BC6OTHER mRNA and protein levels in both 3T3 and L929 cells.	False
BC6ENTC was without effect on BC6OTHER mRNA levels in L929 cells, whereas BC6OTHER caused significant increases in both BC6ENTG mRNA and protein levels in both 3T3 and L929 cells.	False
BC6OTHER was without effect on BC6ENTG mRNA levels in L929 cells, whereas BC6ENTC caused significant increases in both BC6OTHER mRNA and protein levels in both 3T3 and L929 cells.	False
BC6OTHER was without effect on BC6OTHER mRNA levels in L929 cells, whereas BC6ENTC caused significant increases in both BC6ENTG mRNA and protein levels in both 3T3 and L929 cells.	CPR:3
Pharmacological modulation of BC6OTHER synthesis: a mechanistic comparison of BC6ENTC receptor and BC6ENTG agonists.	False
Pharmacological modulation of BC6ENTG synthesis: a mechanistic comparison of BC6ENTC receptor and BC6OTHER agonists.	False
Binding to the BC6ENTC nuclear receptor ( BC6ENTG ), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of BC6OTHER and maintained up to 24 h. Increased BC6OTHER binding preceded increased BC6OTHER mRNA.	False
Binding to the BC6ENTC nuclear receptor ( BC6OTHER ), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of BC6OTHER and maintained up to 24 h. Increased BC6ENTG binding preceded increased BC6OTHER mRNA.	False
Binding to the BC6ENTC nuclear receptor ( BC6OTHER ), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of BC6OTHER and maintained up to 24 h. Increased BC6OTHER binding preceded increased BC6ENTG mRNA.	False
Binding to the BC6ENTG ( BC6OTHER ), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of BC6ENTC and maintained up to 24 h. Increased BC6OTHER binding preceded increased BC6OTHER mRNA.	False
Binding to the BC6OTHER nuclear receptor ( BC6ENTG ), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of BC6ENTC and maintained up to 24 h. Increased BC6OTHER binding preceded increased BC6OTHER mRNA.	False
Binding to the BC6OTHER nuclear receptor ( BC6OTHER ), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of BC6ENTC and maintained up to 24 h. Increased BC6ENTG binding preceded increased BC6OTHER mRNA.	False
Binding to the BC6OTHER nuclear receptor ( BC6OTHER ), which acts as a transcription factor itself, was increased as early as 30 min after exposure to of BC6ENTC and maintained up to 24 h. Increased BC6OTHER binding preceded increased BC6ENTG mRNA.	False
This study demonstrates that BC6ENTC and BC6OTHER stimulate BC6ENTG levels in vitro and that BC6OTHER binding could be a commonality between the mechanism of BC6OTHER induction of these two compounds.	CPR:3
This study demonstrates that BC6ENTC and BC6OTHER stimulate BC6OTHER levels in vitro and that BC6ENTG binding could be a commonality between the mechanism of BC6OTHER induction of these two compounds.	False
This study demonstrates that BC6ENTC and BC6OTHER stimulate BC6OTHER levels in vitro and that BC6OTHER binding could be a commonality between the mechanism of BC6ENTG induction of these two compounds.	CPR:3
This study demonstrates that BC6OTHER and BC6ENTC stimulate BC6ENTG levels in vitro and that BC6OTHER binding could be a commonality between the mechanism of BC6OTHER induction of these two compounds.	CPR:3
This study demonstrates that BC6OTHER and BC6ENTC stimulate BC6OTHER levels in vitro and that BC6ENTG binding could be a commonality between the mechanism of BC6OTHER induction of these two compounds.	False
This study demonstrates that BC6OTHER and BC6ENTC stimulate BC6OTHER levels in vitro and that BC6OTHER binding could be a commonality between the mechanism of BC6ENTG induction of these two compounds.	CPR:3
 The present studies were undertaken to compare two compounds, a BC6ENTC analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6ENTG agonist, both of which induce BC6OTHER synthesis in vivo. BC6OTHER caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	False
 The present studies were undertaken to compare two compounds, a BC6ENTC analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6OTHER agonist, both of which induce BC6ENTG synthesis in vivo. BC6OTHER caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	CPR:4
 The present studies were undertaken to compare two compounds, a BC6ENTC analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6OTHER agonist, both of which induce BC6OTHER synthesis in vivo. BC6OTHER caused significant increases in both BC6ENTG mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	False
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6ENTC ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6ENTG agonist, both of which induce BC6OTHER synthesis in vivo. BC6OTHER caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	False
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6ENTC ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6OTHER agonist, both of which induce BC6ENTG synthesis in vivo. BC6OTHER caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	CPR:3
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6ENTC ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6OTHER agonist, both of which induce BC6OTHER synthesis in vivo. BC6OTHER caused significant increases in both BC6ENTG mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	False
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6ENTC , a long - acting BC6ENTG agonist, both of which induce BC6OTHER synthesis in vivo. BC6OTHER caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	CPR:5
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6ENTC , a long - acting BC6OTHER agonist, both of which induce BC6ENTG synthesis in vivo. BC6OTHER caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	CPR:3
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6ENTC , a long - acting BC6OTHER agonist, both of which induce BC6OTHER synthesis in vivo. BC6OTHER caused significant increases in both BC6ENTG mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	False
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6ENTG agonist, both of which induce BC6OTHER synthesis in vivo. BC6ENTC caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	False
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6OTHER agonist, both of which induce BC6ENTG synthesis in vivo. BC6ENTC caused significant increases in both BC6OTHER mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	False
 The present studies were undertaken to compare two compounds, a BC6OTHER analogue ( BC6OTHER ) with minimal calcaemic effects, and BC6OTHER , a long - acting BC6OTHER agonist, both of which induce BC6OTHER synthesis in vivo. BC6ENTC caused significant increases in both BC6ENTG mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8 - 12 h exposure.	CPR:3
Effects of BC6ENTC on BC6ENTG mRNA were antagonized by BC6OTHER .	False
Genetic analysis has demonstrated complete linkage between the human BC6ENTC - sensitive BC6OTHER cotransporter gene ( BC6ENTG or BC6OTHER ) and Gitelman's syndrome (GS).	False
Genetic analysis has demonstrated complete linkage between the human BC6ENTC - sensitive BC6OTHER cotransporter gene ( BC6OTHER or BC6ENTG ) and Gitelman's syndrome (GS).	False
Genetic analysis has demonstrated complete linkage between the human BC6OTHER - sensitive BC6ENTC cotransporter gene ( BC6ENTG or BC6OTHER ) and Gitelman's syndrome (GS).	False
Genetic analysis has demonstrated complete linkage between the human BC6OTHER - sensitive BC6ENTC cotransporter gene ( BC6OTHER or BC6ENTG ) and Gitelman's syndrome (GS).	False
Genetic analysis has demonstrated complete linkage between the BC6ENTG BC6ENTC cotransporter gene ( BC6OTHER or BC6OTHER ) and Gitelman's syndrome (GS).	False
Peripheral blood mononuclear cells express mutated BC6ENTG mRNA in Gitelman's syndrome: evidence for abnormal BC6ENTC - sensitive BC6OTHER cotransport.	False
Peripheral blood mononuclear cells express mutated BC6ENTG mRNA in Gitelman's syndrome: evidence for abnormal BC6OTHER - sensitive BC6ENTC cotransport.	False
Furthermore, functional evidence is provided that the underlying cause of GS is defective BC6ENTG BC6ENTC cotransport.	False
This study was performed to determine whether peripheral blood mononuclear cells (PBMC) express BC6ENTG mRNA and whether defective PBMC BC6ENTC cotransport could be demonstrated in GS.	False
Today, we used BC6ENTC , a hypoxia mimetic that inhibits proteasomal BC6ENTG degradation and generates reactive BC6OTHER species (ROS).	CPR:3
Today, we used BC6OTHER , a hypoxia mimetic that inhibits proteasomal BC6ENTG degradation and generates reactive BC6ENTC species (ROS).	False
We focused on BC6ENTC - induced cell death in a DNA - binding mutated BC6ENTG neuroblastoma cell line (SKNBE(2c)).	False
An autophagic signaling was evidenced by an increase of BC6ENTG , BC6OTHER , and BC6OTHER expression whereas the BC6OTHER (mut) presence decreased with BC6ENTC time exposure.	False
An autophagic signaling was evidenced by an increase of BC6OTHER , BC6ENTG , and BC6OTHER expression whereas the BC6OTHER (mut) presence decreased with BC6ENTC time exposure.	False
An autophagic signaling was evidenced by an increase of BC6OTHER , BC6OTHER , and BC6ENTG expression whereas the BC6OTHER (mut) presence decreased with BC6ENTC time exposure.	False
An autophagic signaling was evidenced by an increase of BC6OTHER , BC6OTHER , and BC6OTHER expression whereas the BC6ENTG (mut) presence decreased with BC6ENTC time exposure.	CPR:4
Autophagy takes place in mutated BC6ENTG neuroblastoma cells in response to hypoxia mimetic BC6ENTC .	False
BC6ENTC and CHEM interfere with the biosynthesis of BC6ENTG and can also improve the clearance of BC6OTHER / BC6OTHER .	False
BC6ENTC and CHEM interfere with the biosynthesis of BC6OTHER and can also improve the clearance of BC6ENTG / BC6OTHER .	False
BC6ENTC and CHEM interfere with the biosynthesis of BC6OTHER and can also improve the clearance of BC6OTHER / BC6ENTG .	False
 BC6ENTC acts by a newly described mechanism, i.e. accelerating reverse transport of BC6OTHER from BC6ENTG to BC6OTHER .	False
 BC6ENTC acts by a newly described mechanism, i.e. accelerating reverse transport of BC6OTHER from BC6OTHER to BC6ENTG .	False
 BC6OTHER acts by a newly described mechanism, i.e. accelerating reverse transport of BC6ENTC from BC6ENTG to BC6OTHER .	CPR:9
 BC6OTHER acts by a newly described mechanism, i.e. accelerating reverse transport of BC6ENTC from BC6OTHER to BC6ENTG .	CPR:9
Finally, BC6ENTC reductase inhibitors, interfering with the biosynthesis of BC6OTHER , can induce an increased expression of liver high - affinity BC6ENTG .	False
Finally, BC6OTHER inhibitors, interfering with the biosynthesis of BC6ENTC , can induce an increased expression of liver high - affinity BC6ENTG .	False
Finally, BC6ENTG inhibitors, interfering with the biosynthesis of BC6ENTC , can induce an increased expression of liver high - affinity BC6OTHER .	False
Absorbable drugs ( BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	False
Absorbable drugs ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6ENTG ( BC6OTHER ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6ENTG ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6OTHER ( BC6ENTG ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	False
Absorbable drugs ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6ENTG ( BC6OTHER ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6ENTG ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6OTHER ( BC6ENTG ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	False
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER reductase inhibitors) reduce BC6ENTG ( BC6OTHER ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6ENTG ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6OTHER ( BC6ENTG ) by a variety of mechanisms.	CPR:4
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC reductase inhibitors) reduce BC6ENTG ( BC6OTHER ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	False
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC reductase inhibitors) reduce BC6OTHER ( BC6ENTG ) and / or BC6OTHER ( BC6OTHER ) by a variety of mechanisms.	False
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6ENTG ( BC6OTHER ) by a variety of mechanisms.	False
Absorbable drugs ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC reductase inhibitors) reduce BC6OTHER ( BC6OTHER ) and / or BC6OTHER ( BC6ENTG ) by a variety of mechanisms.	False
BC6ENTC , in particular, act by stimulating the catabolism of BC6ENTG and also, as a consequence, improving BC6OTHER delipidation, thus favoring receptor uptake.	CPR:4
BC6ENTC , in particular, act by stimulating the catabolism of BC6OTHER and also, as a consequence, improving BC6ENTG delipidation, thus favoring receptor uptake.	False
BC6ENTC ( BC6OTHER , 33 mM) and the c - jun BC6OTHER - terminal kinase ( BC6ENTG ) inhibitor ( BC6OTHER , 33 μM) further decreased the viability in the presence of DEP (200 μg / ml) and 3.3% FCS.	False
BC6ENTC ( BC6OTHER , 33 mM) and the BC6ENTG ( BC6OTHER ) inhibitor ( BC6OTHER , 33 μM) further decreased the viability in the presence of DEP (200 μg / ml) and 3.3% FCS.	False
BC6OTHER ( BC6ENTC , 33 mM) and the c - jun BC6OTHER - terminal kinase ( BC6ENTG ) inhibitor ( BC6OTHER , 33 μM) further decreased the viability in the presence of DEP (200 μg / ml) and 3.3% FCS.	False
BC6OTHER ( BC6ENTC , 33 mM) and the BC6ENTG ( BC6OTHER ) inhibitor ( BC6OTHER , 33 μM) further decreased the viability in the presence of DEP (200 μg / ml) and 3.3% FCS.	False
BC6OTHER ( BC6OTHER , 33 mM) and the c - jun BC6ENTC - terminal kinase ( BC6ENTG ) inhibitor ( BC6OTHER , 33 μM) further decreased the viability in the presence of DEP (200 μg / ml) and 3.3% FCS.	False
BC6OTHER ( BC6OTHER , 33 mM) and the c - jun BC6OTHER - terminal kinase ( BC6ENTG ) inhibitor ( BC6ENTC , 33 μM) further decreased the viability in the presence of DEP (200 μg / ml) and 3.3% FCS.	CPR:4
BC6OTHER ( BC6OTHER , 33 mM) and the BC6ENTG ( BC6OTHER ) inhibitor ( BC6ENTC , 33 μM) further decreased the viability in the presence of DEP (200 μg / ml) and 3.3% FCS.	CPR:4
Only when the BC6ENTG nears its target membrane, which provides a high local concentration of target lipid, is the effective BC6OTHER affinity increased by the coupled binding equilibrium to a level that enables substantial BC6ENTC activation and target docking.	False
The BC6ENTG of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), for example, are known to dock to different membrane surfaces during an intracellular BC6ENTC signal.	False
The BC6OTHER of BC6ENTG ( BC6OTHER ) and BC6OTHER ( BC6OTHER ), for example, are known to dock to different membrane surfaces during an intracellular BC6ENTC signal.	False
The BC6OTHER of BC6OTHER ( BC6ENTG ) and BC6OTHER ( BC6OTHER ), for example, are known to dock to different membrane surfaces during an intracellular BC6ENTC signal.	False
The BC6OTHER of BC6OTHER ( BC6OTHER ) and BC6ENTG ( BC6OTHER ), for example, are known to dock to different membrane surfaces during an intracellular BC6ENTC signal.	False
The BC6OTHER of BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTG ), for example, are known to dock to different membrane surfaces during an intracellular BC6ENTC signal.	False
BC6ENTC activation targets the BC6ENTG to the plasma membrane and the BC6OTHER to the internal membranes, with no detectable spatial overlap.	False
BC6ENTC activation targets the BC6OTHER to the plasma membrane and the BC6ENTG to the internal membranes, with no detectable spatial overlap.	False
For the isolated BC6OTHER in the presence of physiological BC6ENTC levels, the target lipids BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are together sufficient to recruit the BC6ENTG n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6ENTG in the presence of physiological BC6ENTC levels, the target lipids BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are together sufficient to recruit the BC6OTHER n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6OTHER in the presence of physiological BC6OTHER levels, the target lipids BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are together sufficient to recruit the BC6ENTG n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6ENTG in the presence of physiological BC6OTHER levels, the target lipids BC6ENTC ( BC6OTHER ) and BC6OTHER ( BC6OTHER ) are together sufficient to recruit the BC6OTHER n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6OTHER in the presence of physiological BC6OTHER levels, the target lipids BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are together sufficient to recruit the BC6ENTG n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6ENTG in the presence of physiological BC6OTHER levels, the target lipids BC6OTHER ( BC6ENTC ) and BC6OTHER ( BC6OTHER ) are together sufficient to recruit the BC6OTHER n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6OTHER in the presence of physiological BC6OTHER levels, the target lipids BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are together sufficient to recruit the BC6ENTG n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6ENTG in the presence of physiological BC6OTHER levels, the target lipids BC6OTHER ( BC6OTHER ) and BC6ENTC ( BC6OTHER ) are together sufficient to recruit the BC6OTHER n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6OTHER in the presence of physiological BC6OTHER levels, the target lipids BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are together sufficient to recruit the BC6ENTG n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
For the isolated BC6ENTG in the presence of physiological BC6OTHER levels, the target lipids BC6OTHER ( BC6OTHER ) and BC6OTHER ( BC6ENTC ) are together sufficient to recruit the BC6OTHER n to a lipid mixture mimicking the plasma membrane inner leaflet.	False
Mechanism of specific membrane targeting by BC6ENTG : localized pools of target lipids enhance BC6ENTC affinity.	False
For the BC6ENTG , the target lipid BC6ENTC ( BC6OTHER ) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological BC6OTHER levels, although the results do not rule out a second, unknown target molecule.	False
For the BC6ENTG , the target lipid BC6OTHER ( BC6ENTC ) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological BC6OTHER levels, although the results do not rule out a second, unknown target molecule.	False
For the BC6ENTG , the target lipid BC6OTHER ( BC6OTHER ) appears to be sufficient to drive membrane targeting to an internal membrane mimic at physiological BC6ENTC levels, although the results do not rule out a second, unknown target molecule.	False
In principle, BC6ENTG - directed intracellular targeting, which requires coincidence detection of multiple signals ( BC6ENTC and one or more target lipids), can exhibit two different mechanisms: messenger - activated target affinity (MATA) and target - activated messenger affinity (TAMA).	False
The BC6ENTG studied here both utilize the TAMA mechanism, in which the BC6OTHER BC6ENTC affinity is too low to be activated by physiological BC6OTHER signals in most regions of the cell.	False
The BC6OTHER studied here both utilize the TAMA mechanism, in which the BC6ENTG BC6ENTC affinity is too low to be activated by physiological BC6OTHER signals in most regions of the cell.	False
The BC6ENTG studied here both utilize the TAMA mechanism, in which the BC6OTHER BC6OTHER affinity is too low to be activated by physiological BC6ENTC signals in most regions of the cell.	False
The BC6OTHER studied here both utilize the TAMA mechanism, in which the BC6ENTG BC6OTHER affinity is too low to be activated by physiological BC6ENTC signals in most regions of the cell.	False
Although considerable functional diversity exists, most BC6ENTG are activated by BC6ENTC binding and then dock to a specific cellular membrane.	CPR:3
Only when the BC6ENTG nears its target membrane, which provides a high local concentration of target lipid, is the effective BC6ENTC affinity increased by the coupled binding equilibrium to a level that enables substantial BC6OTHER activation and target docking.	False
In BC6ENTG , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6ENTC - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6OTHER .	False
In BC6OTHER , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6ENTC - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6ENTG .	False
In BC6ENTG , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6ENTC - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6OTHER .	False
In BC6OTHER , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6ENTC - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6ENTG .	False
In BC6ENTG , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6ENTC - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6OTHER .	False
In BC6OTHER , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6ENTC - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6ENTG .	False
In BC6ENTG , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6ENTC - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6OTHER .	False
In BC6OTHER , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6ENTC - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6ENTG .	False
In BC6ENTG , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6ENTC and impaired the interaction with BC6OTHER .	False
In BC6OTHER , mutations of putative BC6OTHER binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6ENTC and impaired the interaction with BC6ENTG .	False
The four BC6ENTC residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6ENTG to BC6OTHER and to BC6OTHER and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6ENTC residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6OTHER to BC6OTHER and to BC6ENTG and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6ENTC - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6ENTG to BC6OTHER and to BC6OTHER and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6ENTC - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6OTHER to BC6OTHER and to BC6ENTG and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6ENTC - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6ENTG to BC6OTHER and to BC6OTHER and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6ENTC - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6OTHER to BC6OTHER and to BC6ENTG and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6ENTC - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6ENTG to BC6OTHER and to BC6OTHER and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6ENTC - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6OTHER to BC6OTHER and to BC6ENTG and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6ENTC - 268, also play an important role in mediating the sensitivity of BC6ENTG to BC6OTHER and to BC6OTHER and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6ENTC - 268, also play an important role in mediating the sensitivity of BC6OTHER to BC6OTHER and to BC6ENTG and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6ENTG to BC6ENTC and to BC6OTHER and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	CPR:4
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6OTHER to BC6ENTC and to BC6ENTG and appear to be involved in transducing and enhancing the signal given by BC6OTHER for the closure of the catalytic domain.	False
 BC6ENTG regulation, an enzyme - enzyme activity control: identification of residues of BC6ENTC carbamoyltransferase and BC6OTHER responsible for enzyme catalytic and regulatory activities.	False
 BC6OTHER regulation, an enzyme - enzyme activity control: identification of residues of BC6ENTC carbamoyltransferase and BC6ENTG responsible for enzyme catalytic and regulatory activities.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6ENTG to BC6OTHER and to BC6OTHER and appear to be involved in transducing and enhancing the signal given by BC6ENTC for the closure of the catalytic domain.	False
The four BC6OTHER residues located in the SMG loop, BC6OTHER - 260, BC6OTHER - 263, BC6OTHER - 265, and BC6OTHER - 268, also play an important role in mediating the sensitivity of BC6OTHER to BC6OTHER and to BC6ENTG and appear to be involved in transducing and enhancing the signal given by BC6ENTC for the closure of the catalytic domain.	False
In the presence of BC6ENTC and BC6OTHER , BC6OTHER carbamoyltransferase ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6ENTG is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6ENTC and BC6OTHER , BC6OTHER carbamoyltransferase ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6ENTG remains catalytically active.	False
In the presence of BC6ENTC and BC6OTHER , BC6ENTG ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6ENTC and BC6OTHER , BC6OTHER carbamoyltransferase ( BC6ENTG ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6ENTC and BC6OTHER , BC6OTHER carbamoyltransferase ( BC6OTHER ) and BC6ENTG form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6OTHER and BC6ENTC , BC6OTHER carbamoyltransferase ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6ENTG is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6OTHER and BC6ENTC , BC6OTHER carbamoyltransferase ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6ENTG remains catalytically active.	False
In the presence of BC6OTHER and BC6ENTC , BC6ENTG ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6OTHER and BC6ENTC , BC6OTHER carbamoyltransferase ( BC6ENTG ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6OTHER and BC6ENTC , BC6OTHER carbamoyltransferase ( BC6OTHER ) and BC6ENTG form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6OTHER and BC6OTHER , BC6ENTC carbamoyltransferase ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6ENTG is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6OTHER and BC6OTHER , BC6ENTC carbamoyltransferase ( BC6OTHER ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6ENTG remains catalytically active.	False
In the presence of BC6OTHER and BC6OTHER , BC6ENTC carbamoyltransferase ( BC6ENTG ) and BC6OTHER form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In the presence of BC6OTHER and BC6OTHER , BC6ENTC carbamoyltransferase ( BC6OTHER ) and BC6ENTG form a one - to - one enzyme complex in which the activity of BC6OTHER is inhibited whereas BC6OTHER remains catalytically active.	False
In BC6ENTG , two BC6ENTC at the BC6OTHER terminus of the protein are crucial for its BC6OTHER function but not for its catalytic activity and trimeric structure.	False
In BC6OTHER , two BC6ENTC at the BC6OTHER terminus of the protein are crucial for its BC6ENTG function but not for its catalytic activity and trimeric structure.	False
In BC6ENTG , two BC6OTHER at the BC6ENTC terminus of the protein are crucial for its BC6OTHER function but not for its catalytic activity and trimeric structure.	False
In BC6OTHER , two BC6OTHER at the BC6ENTC terminus of the protein are crucial for its BC6ENTG function but not for its catalytic activity and trimeric structure.	False
In BC6ENTG , mutations of putative BC6ENTC binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6OTHER .	False
In BC6OTHER , mutations of putative BC6ENTC binding residues, BC6OTHER - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6ENTG .	False
In BC6ENTG , mutations of putative BC6OTHER binding residues, BC6ENTC - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6OTHER .	False
In BC6OTHER , mutations of putative BC6OTHER binding residues, BC6ENTC - 182, BC6OTHER - 184, BC6OTHER - 185, BC6OTHER - 289, and BC6OTHER - 256 greatly reduced the affinity for BC6OTHER and impaired the interaction with BC6ENTG .	False
A series of novel BC6ENTC were designed, synthesized and biologically evaluated for BC6ENTG inhibition.	False
Novel BC6ENTC derivatives as potent BC6ENTG inhibitors.	CPR:4
BC6OTHER levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6OTHER - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6OTHER completely abolished the BC6OTHER - induced increase in brain BC6OTHER , suggesting, as with BC6ENTC , that a metabolite of BC6OTHER formed by the action of BC6ENTG is responsible for the elevation of brain BC6OTHER observed.	False
BC6OTHER levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6OTHER - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6OTHER completely abolished the BC6OTHER - induced increase in brain BC6OTHER , suggesting, as with BC6OTHER , that a metabolite of BC6ENTC formed by the action of BC6ENTG is responsible for the elevation of brain BC6OTHER observed.	CPR:9
BC6OTHER levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6OTHER - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6OTHER completely abolished the BC6OTHER - induced increase in brain BC6OTHER , suggesting, as with BC6OTHER , that a metabolite of BC6OTHER formed by the action of BC6ENTG is responsible for the elevation of brain BC6ENTC observed.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6OTHER ( BC6ENTG ), markedly increasing brain BC6ENTC levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6ENTG ( BC6OTHER ), also inhibits BC6OTHER ( BC6OTHER - T), markedly increasing brain BC6ENTC levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6ENTG ), also inhibits BC6OTHER ( BC6OTHER - T), markedly increasing brain BC6ENTC levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6ENTG ( BC6OTHER - T), markedly increasing brain BC6ENTC levels.	False
BC6ENTC is also a substrate for BC6ENTG , and studies suggest that a metabolite formed by the action of this enzyme on BC6OTHER may be responsible for the increase in BC6OTHER observed.	CPR:9
BC6OTHER is also a substrate for BC6ENTG , and studies suggest that a metabolite formed by the action of this enzyme on BC6ENTC may be responsible for the increase in BC6OTHER observed.	False
BC6OTHER is also a substrate for BC6ENTG , and studies suggest that a metabolite formed by the action of this enzyme on BC6OTHER may be responsible for the increase in BC6ENTC observed.	False
BC6ENTC ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6OTHER ( BC6ENTG ), markedly increasing brain BC6OTHER levels.	CPR:4
BC6ENTC ( BC6OTHER ), a nonselective irreversible inhibitor of BC6ENTG ( BC6OTHER ), also inhibits BC6OTHER ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	CPR:4
BC6ENTC ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6ENTG ), also inhibits BC6OTHER ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	CPR:4
BC6ENTC ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6ENTG ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	CPR:4
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6OTHER ), also inhibits BC6OTHER ( BC6ENTG ), markedly increasing brain BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6ENTG ), also inhibits BC6OTHER ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6ENTC oxidase ( BC6OTHER ), also inhibits BC6ENTG ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	False
To determine whether a metabolite formed by the action of BC6ENTG on BC6ENTC may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6OTHER on BC6ENTC may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6ENTG on BC6OTHER may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) before vehicle or BC6ENTC (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6OTHER on BC6OTHER may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) before vehicle or BC6ENTC (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6ENTG on BC6OTHER may be responsible for the elevation in brain BC6ENTC observed, animals were pretreated with vehicle or the BC6OTHER inhibitor BC6OTHER ( BC6OTHER ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6OTHER on BC6OTHER may be responsible for the elevation in brain BC6ENTC observed, animals were pretreated with vehicle or the BC6ENTG inhibitor BC6OTHER ( BC6OTHER ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6ENTG on BC6OTHER may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6OTHER inhibitor BC6ENTC ( BC6OTHER ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6OTHER on BC6OTHER may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6ENTG inhibitor BC6ENTC ( BC6OTHER ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	CPR:4
To determine whether a metabolite formed by the action of BC6ENTG on BC6OTHER may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6OTHER inhibitor BC6OTHER ( BC6ENTC ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	False
To determine whether a metabolite formed by the action of BC6OTHER on BC6OTHER may be responsible for the elevation in brain BC6OTHER observed, animals were pretreated with vehicle or the BC6ENTG inhibitor BC6OTHER ( BC6ENTC ) before vehicle or BC6OTHER (15 mg / kg), and brains collected 3 h later.	CPR:4
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6ENTC - transaminase ( BC6ENTG ), markedly increasing brain BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6ENTG ( BC6OTHER ), also inhibits BC6ENTC - transaminase ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6ENTG ), also inhibits BC6ENTC - transaminase ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	False
 BC6ENTC causes an increase in brain CHEM that is prevented by prior BC6ENTG inhibition.	CPR:4
BC6ENTC levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6OTHER - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6OTHER completely abolished the BC6OTHER - induced increase in brain BC6OTHER , suggesting, as with BC6OTHER , that a metabolite of BC6OTHER formed by the action of BC6ENTG is responsible for the elevation of brain BC6OTHER observed.	False
BC6OTHER levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6ENTC - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6OTHER completely abolished the BC6OTHER - induced increase in brain BC6OTHER , suggesting, as with BC6OTHER , that a metabolite of BC6OTHER formed by the action of BC6ENTG is responsible for the elevation of brain BC6OTHER observed.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6ENTG ( BC6OTHER ), also inhibits BC6OTHER ( BC6ENTC - T), markedly increasing brain BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6ENTG ), also inhibits BC6OTHER ( BC6ENTC - T), markedly increasing brain BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6ENTG ( BC6ENTC - T), markedly increasing brain BC6OTHER levels.	False
BC6OTHER ( BC6ENTC ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6OTHER ( BC6ENTG ), markedly increasing brain BC6OTHER levels.	CPR:4
BC6OTHER ( BC6ENTC ), a nonselective irreversible inhibitor of BC6ENTG ( BC6OTHER ), also inhibits BC6OTHER ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	CPR:4
BC6OTHER ( BC6ENTC ), a nonselective irreversible inhibitor of BC6OTHER ( BC6ENTG ), also inhibits BC6OTHER ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	CPR:4
BC6OTHER ( BC6ENTC ), a nonselective irreversible inhibitor of BC6OTHER ( BC6OTHER ), also inhibits BC6ENTG ( BC6OTHER - T), markedly increasing brain BC6OTHER levels.	CPR:4
BC6OTHER levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6OTHER - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6ENTC completely abolished the BC6OTHER - induced increase in brain BC6OTHER , suggesting, as with BC6OTHER , that a metabolite of BC6OTHER formed by the action of BC6ENTG is responsible for the elevation of brain BC6OTHER observed.	False
BC6OTHER levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6OTHER - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6OTHER completely abolished the BC6ENTC - induced increase in brain BC6OTHER , suggesting, as with BC6OTHER , that a metabolite of BC6OTHER formed by the action of BC6ENTG is responsible for the elevation of brain BC6OTHER observed.	False
BC6OTHER levels (measured by an HPLC procedure) were dose - and time - dependently increased in BC6OTHER - treated animals, with levels reaching approximately 650% of control at 6 and 12 h. Pretreatment with BC6OTHER completely abolished the BC6OTHER - induced increase in brain BC6ENTC , suggesting, as with BC6OTHER , that a metabolite of BC6OTHER formed by the action of BC6ENTG is responsible for the elevation of brain BC6OTHER observed.	False
Two cytosolic forms of BC6ENTG [ BC6OTHER : BC6OTHER oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6ENTC oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases BC6ENTG BC6OTHER oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6ENTC oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6OTHER : BC6OTHER oxidoreductase 1 ( BC6ENTG ) and CHEM: BC6ENTC oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6OTHER : BC6OTHER oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6ENTC oxidoreductase 2 ( BC6ENTG )] were previously identified, purified, and cloned.	False
A role of cytosolic BC6ENTG in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of BC6ENTC was established.	CPR:9
The BC6ENTG activity showed significantly higher affinity for BC6ENTC than BC6OTHER as electron donors and catalyzed reduction of BC6OTHER and BC6OTHER .	False
The BC6ENTG activity showed significantly higher affinity for BC6OTHER than BC6ENTC as electron donors and catalyzed reduction of BC6OTHER and BC6OTHER .	False
The BC6ENTG activity showed significantly higher affinity for BC6OTHER than BC6OTHER as electron donors and catalyzed reduction of BC6ENTC and BC6OTHER .	CPR:9
The BC6ENTG activity showed significantly higher affinity for BC6OTHER than BC6OTHER as electron donors and catalyzed reduction of BC6OTHER and BC6ENTC .	CPR:9
The BC6ENTG activity was insensitive to BC6ENTC , a potent inhibitor of cytosolic BC6OTHER .	False
The BC6OTHER activity was insensitive to BC6ENTC , a potent inhibitor of cytosolic BC6ENTG .	CPR:4
BC6ENTG are flavoproteins that catalyze two - electron reduction and detoxification of BC6ENTC .	CPR:9
The BC6ENTG activity was partially purified by solubilization of microsomes with detergent Chaps, BC6ENTC fractionation, and BC6OTHER - Sephacel column chromatography.	False
The BC6ENTG activity was partially purified by solubilization of microsomes with detergent Chaps, BC6OTHER fractionation, and BC6ENTC - Sephacel column chromatography.	False
The microsomal BC6ENTG proteins are expected to provide additional protection after cytosolic BC6OTHER against BC6ENTC toxicity and mutagenicity.	False
The microsomal BC6OTHER proteins are expected to provide additional protection after cytosolic BC6ENTG against BC6ENTC toxicity and mutagenicity.	False
Two cytosolic forms of BC6ENTC oxidoreductases BC6ENTG BC6OTHER oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6ENTC oxidoreductases [ BC6OTHER : BC6OTHER oxidoreductase 1 ( BC6ENTG ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6ENTC oxidoreductases [ BC6OTHER : BC6OTHER oxidoreductase 1 ( BC6OTHER ) and BC6ENTG ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6ENTC oxidoreductases [ BC6OTHER : BC6OTHER oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6ENTG )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6ENTG [ BC6ENTC : BC6OTHER oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6ENTC : BC6OTHER oxidoreductase 1 ( BC6ENTG ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6ENTC : BC6OTHER oxidoreductase 1 ( BC6OTHER ) and BC6ENTG ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6ENTC : BC6OTHER oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6ENTG )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6ENTG [ BC6OTHER : BC6ENTC oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases BC6ENTG BC6ENTC oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6OTHER : BC6ENTC oxidoreductase 1 ( BC6ENTG ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6OTHER : BC6ENTC oxidoreductase 1 ( BC6OTHER ) and BC6ENTG ( BC6OTHER )] were previously identified, purified, and cloned.	False
Two cytosolic forms of BC6OTHER oxidoreductases [ BC6OTHER : BC6ENTC oxidoreductase 1 ( BC6OTHER ) and CHEM: BC6OTHER oxidoreductase 2 ( BC6ENTG )] were previously identified, purified, and cloned.	False
Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the BC6ENTG family led to the cloning of a partial, near full length, cDNA clone with approximately 70% BC6OTHER and deduced BC6ENTC sequence identity to BC6OTHER .	False
Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the BC6OTHER family led to the cloning of a partial, near full length, cDNA clone with approximately 70% BC6OTHER and deduced BC6ENTC sequence identity to BC6ENTG .	False
 BC6ENTG , peroxisomal enzymes and BC6ENTC cofactors in koala liver.	False
Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the BC6ENTG family led to the cloning of a partial, near full length, cDNA clone with approximately 70% BC6ENTC and deduced BC6OTHER sequence identity to BC6OTHER .	False
Reverse transcription of koala liver mRNA, followed by polymerase chain reaction using primers based on highly conserved areas in the BC6OTHER family led to the cloning of a partial, near full length, cDNA clone with approximately 70% BC6ENTC and deduced BC6OTHER sequence identity to BC6ENTG .	False
We also investigated the effect of Phα1β on BC6ENTC transients in cultured dorsal root ganglia (DRG) neurons and HEK293 cells expressing the BC6ENTG receptor.	False
Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by BC6ENTC similarly to that observed with BC6OTHER , a specific BC6ENTG antagonist.	False
Intraplantar or intrathecal administered Phα1β reduced both nocifensive behavior and mechanical hypersensitivity induced by BC6OTHER similarly to that observed with BC6ENTC , a specific BC6ENTG antagonist.	CPR:6
Phα1β toxin prevents BC6ENTC - induced nociceptive behavior and mechanical hypersensitivity without acting on BC6ENTG channels.	False
Moreover, Phα1β did not inhibit BC6ENTC - activated currents in patch - clamp recordings of HEK293 cells that expressed BC6ENTG receptors.	False
We took advantage of the previous observations that BC6ENTC inhibits BC6ENTG (reviewed by Sakane, F., Imai, S., Kai, M., Wada, I., and CHEM, CHEM. (1996) J. Biol.	CPR:4
Constitutively active BC6ENTG inhibited the nuclear stimulated activity, whereas BC6ENTC did not have an inhibitory effect.	False
Previous work from our laboratory showed that stimulation of quiescent fibroblasts with BC6ENTG leads to the production of two lipid second messengers in the nucleus: an increase in nuclear BC6ENTC mass and an activation of phospholipase D, which catalyzes the hydrolysis of BC6OTHER to generate BC6OTHER .	False
Previous work from our laboratory showed that stimulation of quiescent fibroblasts with BC6ENTG leads to the production of two lipid second messengers in the nucleus: an increase in nuclear BC6OTHER mass and an activation of phospholipase D, which catalyzes the hydrolysis of BC6ENTC to generate BC6OTHER .	False
Previous work from our laboratory showed that stimulation of quiescent fibroblasts with BC6ENTG leads to the production of two lipid second messengers in the nucleus: an increase in nuclear BC6OTHER mass and an activation of phospholipase D, which catalyzes the hydrolysis of BC6OTHER to generate BC6ENTC .	False
BC6ENTC kinase ( BC6ENTG ) catalyzes the conversion of BC6OTHER to BC6OTHER , making it an attractive candidate for a signal transduction component.	False
BC6ENTG ( BC6OTHER ) catalyzes the conversion of BC6ENTC to BC6OTHER , making it an attractive candidate for a signal transduction component.	CPR:9
BC6OTHER kinase ( BC6ENTG ) catalyzes the conversion of BC6ENTC to BC6OTHER , making it an attractive candidate for a signal transduction component.	CPR:9
BC6ENTG ( BC6OTHER ) catalyzes the conversion of BC6OTHER to BC6ENTC , making it an attractive candidate for a signal transduction component.	CPR:9
BC6OTHER kinase ( BC6ENTG ) catalyzes the conversion of BC6OTHER to BC6ENTC , making it an attractive candidate for a signal transduction component.	CPR:9
Nuclear BC6ENTC kinase - theta is activated in response to BC6ENTG .	False
The earliest known BC6ENTG inhibitors, namely, BC6ENTC and BC6OTHER , performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).	CPR:4
The earliest known BC6ENTG inhibitors, namely, BC6OTHER and BC6ENTC , performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).	CPR:4
BC6ENTC inaugurates a new class of BC6ENTG inhibitors with longer and more selective action and with manageable adverse effects.	CPR:4
BC6ENTG carrier status had no influence on BC6OTHER oral clearance or its inhibition by BC6ENTC .	CPR:4
This is the first study showing that BC6ENTC pharmacokinetics is linear in a 30,000 - fold concentration range, and therefore that nano - and microgram doses of BC6OTHER can reliably predict the pharmacokinetics of BC6OTHER in therapeutic doses and can be used to assess BC6ENTG activity even in the presence of strong BC6OTHER inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038 / clpt.2013.27.	False
This is the first study showing that BC6ENTC pharmacokinetics is linear in a 30,000 - fold concentration range, and therefore that nano - and microgram doses of BC6OTHER can reliably predict the pharmacokinetics of BC6OTHER in therapeutic doses and can be used to assess BC6OTHER activity even in the presence of strong BC6ENTG inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038 / clpt.2013.27.	False
A Nanogram Dose of the BC6ENTG Probe Substrate BC6ENTC to Evaluate Drug Interactions.	CPR:9
This is the first study showing that BC6OTHER pharmacokinetics is linear in a 30,000 - fold concentration range, and therefore that nano - and microgram doses of BC6ENTC can reliably predict the pharmacokinetics of BC6OTHER in therapeutic doses and can be used to assess BC6ENTG activity even in the presence of strong BC6OTHER inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038 / clpt.2013.27.	False
This is the first study showing that BC6OTHER pharmacokinetics is linear in a 30,000 - fold concentration range, and therefore that nano - and microgram doses of BC6ENTC can reliably predict the pharmacokinetics of BC6OTHER in therapeutic doses and can be used to assess BC6OTHER activity even in the presence of strong BC6ENTG inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038 / clpt.2013.27.	False
This is the first study showing that BC6OTHER pharmacokinetics is linear in a 30,000 - fold concentration range, and therefore that nano - and microgram doses of BC6OTHER can reliably predict the pharmacokinetics of BC6ENTC in therapeutic doses and can be used to assess BC6ENTG activity even in the presence of strong BC6OTHER inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038 / clpt.2013.27.	False
This is the first study showing that BC6OTHER pharmacokinetics is linear in a 30,000 - fold concentration range, and therefore that nano - and microgram doses of BC6OTHER can reliably predict the pharmacokinetics of BC6ENTC in therapeutic doses and can be used to assess BC6OTHER activity even in the presence of strong BC6ENTG inhibitors.Clinical Pharmacology & Therapeutics (2013); advance online publication 20 March 2013. doi:10.1038 / clpt.2013.27.	False
The objective of the study was to establish an in vivo method for assessing BC6ENTG ( BC6OTHER ) activity using therapeutically inert nanogram doses of BC6ENTC .	False
The objective of the study was to establish an in vivo method for assessing BC6OTHER ( BC6ENTG ) activity using therapeutically inert nanogram doses of BC6ENTC .	False
We administered four escalating single doses of oral BC6ENTC (0.0001 - 3 mg) to 12 healthy participants, stratified according to BC6ENTG carrier status, to assess pharmacokinetics linearity.	False
We then evaluated the interactions with the BC6ENTG inhibitor BC6ENTC (400 mg q.d.)	CPR:4
BC6ENTG carrier status had no influence on BC6ENTC oral clearance or its inhibition by BC6OTHER .	CPR:9
 Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. BC6ENTG , BC6OTHER and BC6OTHER ) and increased expression of aminopeptidase - BC6ENTC ( BC6OTHER ).	False
 Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. BC6OTHER , BC6ENTG and BC6OTHER ) and increased expression of aminopeptidase - BC6ENTC ( BC6OTHER ).	False
 Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. BC6OTHER , BC6OTHER and BC6ENTG ) and increased expression of aminopeptidase - BC6ENTC ( BC6OTHER ).	False
 Although many of the receptors we have examined are expressed at reduced levels on apoptotic neutrophils, we found that there was differential loss of certain receptors (e.g. BC6OTHER , BC6OTHER and BC6OTHER ) and increased expression of aminopeptidase - BC6ENTC ( BC6ENTG ).	False
(2) Exposure histories vary in secondary 11q23 leukemia, as the only BC6ENTG inhibitor was BC6ENTC in one case, and, in another case, no BC6OTHER inhibitor was administered.	CPR:4
(2) Exposure histories vary in secondary 11q23 leukemia, as the only BC6OTHER inhibitor was BC6ENTC in one case, and, in another case, no BC6ENTG inhibitor was administered.	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	CPR:4
RESULTS: BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
CONCLUSIONS AND CLINICAL RELEVANCE: BC6ENTG was selectively inhibited by BC6ENTC , BC6OTHER , and BC6OTHER ; BC6OTHER and BC6OTHER also appeared to be preferential BC6OTHER inhibitors in dogs.	CPR:4
CONCLUSIONS AND CLINICAL RELEVANCE: BC6OTHER was selectively inhibited by BC6ENTC , BC6OTHER , and BC6OTHER ; BC6OTHER and BC6OTHER also appeared to be preferential BC6ENTG inhibitors in dogs.	False
CONCLUSIONS AND CLINICAL RELEVANCE: BC6ENTG was selectively inhibited by BC6OTHER , BC6ENTC , and BC6OTHER ; BC6OTHER and BC6OTHER also appeared to be preferential BC6OTHER inhibitors in dogs.	CPR:4
CONCLUSIONS AND CLINICAL RELEVANCE: BC6OTHER was selectively inhibited by BC6OTHER , BC6ENTC , and BC6OTHER ; BC6OTHER and BC6OTHER also appeared to be preferential BC6ENTG inhibitors in dogs.	False
CONCLUSIONS AND CLINICAL RELEVANCE: BC6ENTG was selectively inhibited by BC6OTHER , BC6OTHER , and BC6ENTC ; BC6OTHER and BC6OTHER also appeared to be preferential BC6OTHER inhibitors in dogs.	CPR:4
CONCLUSIONS AND CLINICAL RELEVANCE: BC6OTHER was selectively inhibited by BC6OTHER , BC6OTHER , and BC6ENTC ; BC6OTHER and BC6OTHER also appeared to be preferential BC6ENTG inhibitors in dogs.	False
CONCLUSIONS AND CLINICAL RELEVANCE: BC6ENTG was selectively inhibited by BC6OTHER , BC6OTHER , and BC6OTHER ; BC6ENTC and BC6OTHER also appeared to be preferential BC6OTHER inhibitors in dogs.	False
CONCLUSIONS AND CLINICAL RELEVANCE: BC6OTHER was selectively inhibited by BC6OTHER , BC6OTHER , and BC6OTHER ; BC6ENTC and BC6OTHER also appeared to be preferential BC6ENTG inhibitors in dogs.	CPR:4
CONCLUSIONS AND CLINICAL RELEVANCE: BC6ENTG was selectively inhibited by BC6OTHER , BC6OTHER , and BC6OTHER ; BC6OTHER and BC6ENTC also appeared to be preferential BC6OTHER inhibitors in dogs.	False
CONCLUSIONS AND CLINICAL RELEVANCE: BC6OTHER was selectively inhibited by BC6OTHER , BC6OTHER , and BC6OTHER ; BC6OTHER and BC6ENTC also appeared to be preferential BC6ENTG inhibitors in dogs.	CPR:4
RESULTS: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	False
RESULTS: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	False
RESULTS: BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	False
RESULTS: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	False
RESULTS: BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6ENTG than BC6OTHER .	False
RESULTS: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6OTHER isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6ENTG .	False
RESULTS: BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER had little selectivity toward BC6ENTG isozymes, whereas BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , and BC6OTHER had more than 5 times greater preference for inhibiting BC6OTHER than BC6OTHER .	False
Moreover, limited cleavage of BC6OTHER was conferred onto the BC6OTHER from BC6OTHER when fused to the BC6ENTC - terminus of BC6ENTG .	False
Moreover, limited cleavage of BC6ENTG was conferred onto the BC6OTHER from BC6OTHER when fused to the BC6ENTC - terminus of BC6OTHER .	False
Moreover, limited cleavage of BC6OTHER was conferred onto the BC6ENTG from BC6OTHER when fused to the BC6ENTC - terminus of BC6OTHER .	False
Moreover, limited cleavage of BC6OTHER was conferred onto the BC6OTHER from BC6ENTG when fused to the BC6ENTC - terminus of BC6OTHER .	False
BC6ENTC - sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BC6ENTG despite cleaving <20% of the BC6OTHER .	False
BC6ENTC - sensitive spontaneous cholinergic neurotransmission was blocked >80% by 1 pM BC6OTHER despite cleaving <20% of the BC6ENTG .	False
Both BC6ENTC also decreased CSE - induced ROS production, BC6OTHER formation and reduced the increase in BC6ENTG and BC6OTHER expressions caused by CSE.	CPR:4
Both BC6ENTC also decreased CSE - induced ROS production, BC6OTHER formation and reduced the increase in BC6OTHER and BC6ENTG expressions caused by CSE.	CPR:4
Both BC6OTHER also decreased CSE - induced ROS production, BC6ENTC formation and reduced the increase in BC6ENTG and BC6OTHER expressions caused by CSE.	False
Both BC6OTHER also decreased CSE - induced ROS production, BC6ENTC formation and reduced the increase in BC6OTHER and BC6ENTG expressions caused by CSE.	False
The sCT released from NP stimulated BC6ENTC production in human T47D breast cancer cells expressing BC6ENTG .	False
Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease - associated putative morpheeins BC6ENTC hydroxylase, BC6ENTG , BC6OTHER , and BC6OTHER .	False
Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease - associated putative morpheeins BC6ENTC hydroxylase, BC6OTHER , BC6ENTG , and BC6OTHER .	False
Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease - associated putative morpheeins BC6ENTC hydroxylase, BC6OTHER , BC6OTHER , and BC6ENTG .	False
Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease - associated putative morpheeins BC6ENTG , BC6OTHER , BC6ENTC kinase, and BC6OTHER .	False
Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease - associated putative morpheeins BC6OTHER , BC6ENTG , BC6ENTC kinase, and BC6OTHER .	False
Herein we discuss quaternary structure dynamics aspects to drug discovery for the disease - associated putative morpheeins BC6OTHER , BC6OTHER , BC6ENTC kinase, and BC6ENTG .	False
The case study of BC6ENTC synthase ( BC6ENTG ) illustrates how such an equilibrium holds lessons for disease mechanisms, drug discovery, understanding drug side effects, and identifying proteins wherein drug discovery efforts might focus on quaternary structure dynamics.	False
BC6ENTG ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6ENTC ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	False
BC6OTHER ( BC6ENTG ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6ENTC ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6ENTC ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6ENTG and BC6OTHER levels.	False
BC6ENTG ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6ENTC levels.	False
BC6OTHER ( BC6ENTG ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6ENTC levels.	False
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6ENTG , ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6ENTC levels.	False
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6ENTG and BC6ENTC levels.	False
However, this reduction is accompanied by a well described increase or 'surge' in BC6ENTG and BC6ENTC levels, necessitating the concomitant administration of an antiandrogen to combat the potential effects of transient acceleration in cancer activity.	False
Two pure BC6ENTC antagonists have been developed, BC6OTHER and BC6OTHER , that are devoid of any agonist effect on the BC6ENTG and consequently do not result in BC6OTHER flare.	False
Two pure BC6ENTG antagonists have been developed, BC6ENTC and BC6OTHER , that are devoid of any agonist effect on the BC6OTHER and consequently do not result in BC6OTHER flare.	CPR:6
Two pure BC6OTHER antagonists have been developed, BC6ENTC and BC6OTHER , that are devoid of any agonist effect on the BC6ENTG and consequently do not result in BC6OTHER flare.	False
Two pure BC6ENTG antagonists have been developed, BC6OTHER and BC6ENTC , that are devoid of any agonist effect on the BC6OTHER and consequently do not result in BC6OTHER flare.	CPR:6
Two pure BC6OTHER antagonists have been developed, BC6OTHER and BC6ENTC , that are devoid of any agonist effect on the BC6ENTG and consequently do not result in BC6OTHER flare.	False
Two pure BC6ENTG antagonists have been developed, BC6OTHER and BC6OTHER , that are devoid of any agonist effect on the BC6ENTC receptor and consequently do not result in BC6OTHER flare.	False
Two pure BC6ENTG antagonists have been developed, BC6OTHER and BC6OTHER , that are devoid of any agonist effect on the BC6OTHER and consequently do not result in BC6ENTC flare.	False
Two pure BC6OTHER antagonists have been developed, BC6OTHER and BC6OTHER , that are devoid of any agonist effect on the BC6ENTG and consequently do not result in BC6ENTC flare.	False
BC6ENTC was the first BC6ENTG antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone - dependent prostate carcinoma, when rapid BC6OTHER suppression is necessary.	CPR:6
BC6OTHER was the first BC6ENTG antagonist to be developed and was approved by the USA Food and Drug Administration in 2004 for the initiation of hormonal castration in advanced or metastasizing hormone - dependent prostate carcinoma, when rapid BC6ENTC suppression is necessary.	False
 BC6ENTC and other BC6ENTG antagonists in prostate cancer.	False
BC6ENTG ( BC6OTHER ) agonists, such as BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6ENTG ) agonists, such as BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6OTHER ) agonists, such as BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6ENTG , ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:3
BC6OTHER ( BC6OTHER ) agonists, such as BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6ENTG and BC6OTHER levels.	CPR:4
BC6ENTG ( BC6OTHER ) agonists, such as BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6ENTG ) agonists, such as BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6ENTG , ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:3
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6ENTG and BC6OTHER levels.	CPR:4
BC6ENTG ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6ENTG ) agonists, such as BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , stimulate the pituitary's BC6ENTG , ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:3
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6ENTG and BC6OTHER levels.	CPR:4
BC6ENTG ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6ENTG ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:5
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , stimulate the pituitary's BC6ENTG , ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	CPR:3
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC , stimulate the pituitary's BC6OTHER ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6ENTG and BC6OTHER levels.	CPR:4
BC6ENTG ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6ENTC ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	False
BC6OTHER ( BC6ENTG ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6ENTC ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6OTHER and BC6OTHER levels.	False
BC6OTHER ( BC6OTHER ) agonists, such as BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER , stimulate the pituitary's BC6ENTC ( BC6OTHER ) receptor, ultimately leading to its de - sensitization and subsequent reduction of BC6ENTG and BC6OTHER levels.	False
Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of BC6ENTG , BC6OTHER , and BC6OTHER and up - regulation of antiapoptotic factors BC6OTHER , BC6OTHER , and BC6OTHER , These effects could be completely blocked by BC6ENTC .	CPR:4
Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of BC6OTHER , BC6ENTG , and BC6OTHER and up - regulation of antiapoptotic factors BC6OTHER , BC6OTHER , and BC6OTHER , These effects could be completely blocked by BC6ENTC .	CPR:4
Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of BC6OTHER , BC6OTHER , and BC6ENTG and up - regulation of antiapoptotic factors BC6OTHER , BC6OTHER , and BC6OTHER , These effects could be completely blocked by BC6ENTC .	CPR:4
Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of BC6OTHER , BC6OTHER , and BC6OTHER and up - regulation of antiapoptotic factors BC6ENTG , BC6OTHER , and BC6OTHER , These effects could be completely blocked by BC6ENTC .	CPR:4
Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of BC6OTHER , BC6OTHER , and BC6OTHER and up - regulation of antiapoptotic factors BC6OTHER , BC6ENTG , and BC6OTHER , These effects could be completely blocked by BC6ENTC .	CPR:4
Both CE and E(2) alone increased DNA synthesis and reduced apoptosis with activation of BC6OTHER , BC6OTHER , and BC6OTHER and up - regulation of antiapoptotic factors BC6OTHER , BC6OTHER , and BC6ENTG , These effects could be completely blocked by BC6ENTC .	CPR:4
Gene expression studies demonstrated that CE and E(2) were equally potent on expression of BC6ENTG , BC6OTHER , and BC6OTHER , whereas the stimulatory effects of CE on BC6ENTC receptor and BC6OTHER expression were weaker than E(2).	False
Gene expression studies demonstrated that CE and E(2) were equally potent on expression of BC6OTHER , BC6ENTG , and BC6OTHER , whereas the stimulatory effects of CE on BC6ENTC receptor and BC6OTHER expression were weaker than E(2).	False
Gene expression studies demonstrated that CE and E(2) were equally potent on expression of BC6OTHER , BC6OTHER , and BC6ENTG , whereas the stimulatory effects of CE on BC6ENTC receptor and BC6OTHER expression were weaker than E(2).	False
Gene expression studies demonstrated that CE and E(2) were equally potent on expression of BC6OTHER , BC6OTHER , and BC6OTHER , whereas the stimulatory effects of CE on BC6ENTC receptor and BC6ENTG expression were weaker than E(2).	False
Molecular analysis of BC6ENTG gene in Korean patients with BC6ENTC acidemia.	False
It is caused by a deficiency of BC6ENTC carboxylase ( BC6ENTG , BC6OTHER ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6OTHER .	False
It is caused by a deficiency of BC6ENTC carboxylase ( BC6OTHER , BC6ENTG ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6OTHER .	False
It is caused by a deficiency of BC6ENTG ( BC6OTHER , BC6OTHER ), a BC6ENTC - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6OTHER .	False
It is caused by a deficiency of BC6OTHER carboxylase ( BC6ENTG , BC6OTHER ), a BC6ENTC - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6OTHER .	False
It is caused by a deficiency of BC6OTHER carboxylase ( BC6OTHER , BC6ENTG ), a BC6ENTC - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6OTHER .	False
It is caused by a deficiency of BC6ENTG ( BC6OTHER , BC6OTHER ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6ENTC to BC6OTHER .	CPR:9
It is caused by a deficiency of BC6OTHER carboxylase ( BC6ENTG , BC6OTHER ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6ENTC to BC6OTHER .	CPR:9
It is caused by a deficiency of BC6OTHER carboxylase ( BC6OTHER , BC6ENTG ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6ENTC to BC6OTHER .	CPR:9
It is caused by a deficiency of BC6ENTG ( BC6OTHER , BC6OTHER ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6ENTC .	CPR:9
It is caused by a deficiency of BC6OTHER carboxylase ( BC6ENTG , BC6OTHER ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6ENTC .	CPR:9
It is caused by a deficiency of BC6OTHER carboxylase ( BC6OTHER , BC6ENTG ), a BC6OTHER - dependent enzyme that catalyzes the carboxylation of BC6OTHER to BC6ENTC .	CPR:9
Sequence alignments of various BC6OTHER allowed placing BC6ENTC - 269 at a position occupied by BC6OTHER - 220, the residue contacting BC6ENTG in the crystallographic structure of BC6OTHER - tRNA(Asp) complex.	False
Sequence alignments of various BC6OTHER allowed placing BC6ENTC - 269 at a position occupied by BC6OTHER - 220, the residue contacting BC6OTHER in the crystallographic structure of BC6ENTG - tRNA(Asp) complex.	False
Sequence alignments of various BC6ENTG allowed placing BC6ENTC - 269 at a position occupied by BC6OTHER - 220, the residue contacting BC6OTHER in the crystallographic structure of BC6OTHER - tRNA(Asp) complex.	False
Sequence alignments of various BC6OTHER allowed placing BC6OTHER - 269 at a position occupied by BC6ENTC - 220, the residue contacting BC6ENTG in the crystallographic structure of BC6OTHER - tRNA(Asp) complex.	False
Sequence alignments of various BC6OTHER allowed placing BC6OTHER - 269 at a position occupied by BC6ENTC - 220, the residue contacting BC6OTHER in the crystallographic structure of BC6ENTG - tRNA(Asp) complex.	False
Sequence alignments of various BC6ENTG allowed placing BC6OTHER - 269 at a position occupied by BC6ENTC - 220, the residue contacting BC6OTHER in the crystallographic structure of BC6OTHER - tRNA(Asp) complex.	False
Replacing this BC6ENTC by an BC6OTHER renders BC6ENTG more discriminative to BC6OTHER .	False
Replacing this BC6ENTC by an BC6OTHER renders BC6OTHER more discriminative to BC6ENTG .	False
Replacing this BC6OTHER by an BC6ENTC renders BC6ENTG more discriminative to BC6OTHER .	False
Replacing this BC6OTHER by an BC6ENTC renders BC6OTHER more discriminative to BC6ENTG .	False
In mammalian mitochondria the translational machinery is of dual origin with tRNAs encoded by a simplified and rapidly evolving mitochondrial (mt) genome and BC6ENTC - tRNA synthetases ( BC6ENTG ) coded by the nuclear genome, and imported.	False
We have explored here the human mt - BC6ENTC system in which a BC6ENTG , highly similar to the Escherichia coli enzyme, recognizes a bizarre tRNA(Asp).	False
This position is otherwise known as the site of a universally conserved major BC6ENTC identity element, BC6ENTG , also known as a primordial identity signal.	False
This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm - specific enzyme, BC6ENTC dehydrogenase - X ( BC6ENTG ), and serum BC6OTHER levels.	False
This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm - specific enzyme, BC6ENTG ( BC6OTHER ), and serum BC6ENTC levels.	False
This study was designed to examine the testicular maturation in both jaundiced (jj) and nonjaundiced (Jj) male Gunn rats as indicated by the activity of a testis and sperm - specific enzyme, BC6OTHER dehydrogenase - X ( BC6ENTG ), and serum BC6ENTC levels.	False
Testicular cytosolic BC6ENTG activity was determined by oxidation of reduced BC6ENTC ( BC6OTHER ).	False
Testicular cytosolic BC6ENTG activity was determined by oxidation of reduced BC6OTHER ( BC6ENTC ).	False
BC6ENTG activity and serum BC6ENTC levels were similar for both genotypes at 180 days of age.	False
The delay of testicular maturation in the jaundiced males seems to be due to lower BC6ENTG activity and serum BC6ENTC levels.	False
The hippocampi were collected on PND 50 or PND 85 after the completion of the novel object recognition test, and the expression levels of BC6ENTG and the BC6ENTC receptor and its signal transduction pathway - related genes were examined using real - time RT - PCR.	False
The BC6ENTC receptor subunits CHEM and NR2B and the related protein BC6ENTG BC6OTHER / calmodulin - dependent protein kinase (CaMK) - IV and the transcription factor BC6OTHER responsive element binding protein (CREB) - 1 mRNA levels were reduced in the PND 50 mice.	False
The BC6ENTC receptor subunits CHEM and NR2B and the related protein BC6OTHER BC6ENTG and the transcription factor BC6OTHER responsive element binding protein (CREB) - 1 mRNA levels were reduced in the PND 50 mice.	False
The BC6ENTC receptor subunits CHEM and NR2B and the related protein BC6OTHER BC6OTHER / calmodulin - dependent protein kinase (CaMK) - IV and the transcription factor BC6ENTG mRNA levels were reduced in the PND 50 mice.	False
The BC6ENTG and the related protein BC6OTHER BC6ENTC / calmodulin - dependent protein kinase (CaMK) - IV and the transcription factor BC6OTHER responsive element binding protein (CREB) - 1 mRNA levels were reduced in the PND 50 mice.	False
The BC6OTHER receptor subunits CHEM and NR2B and the related protein BC6ENTG BC6ENTC / calmodulin - dependent protein kinase (CaMK) - IV and the transcription factor BC6OTHER responsive element binding protein (CREB) - 1 mRNA levels were reduced in the PND 50 mice.	False
The BC6OTHER receptor subunits CHEM and NR2B and the related protein BC6OTHER BC6ENTC / calmodulin - dependent protein kinase (CaMK) - IV and the transcription factor BC6ENTG mRNA levels were reduced in the PND 50 mice.	False
The BC6ENTG and the related protein BC6OTHER BC6OTHER / calmodulin - dependent protein kinase (CaMK) - IV and the transcription factor BC6ENTC responsive element binding protein (CREB) - 1 mRNA levels were reduced in the PND 50 mice.	False
The BC6OTHER receptor subunits CHEM and NR2B and the related protein BC6ENTG BC6OTHER / calmodulin - dependent protein kinase (CaMK) - IV and the transcription factor BC6ENTC responsive element binding protein (CREB) - 1 mRNA levels were reduced in the PND 50 mice.	False
The BC6OTHER receptor subunits CHEM and NR2B and the related protein BC6OTHER BC6ENTG and the transcription factor BC6ENTC responsive element binding protein (CREB) - 1 mRNA levels were reduced in the PND 50 mice.	False
These results indicate that neonatal BC6ENTC exposure impaired the hippocampus - dependent novel object recognition ability, accompanied by a modulation in the expressions of the BC6ENTG and neurotrophin in young adult and adult mice.	False
The present study investigated the effect of neonatal exposure to BC6ENTC on hippocampus - dependent novel object recognition test performance and the expression of the BC6ENTG and its signal transduction pathway - related genes in the hippocampi of young adult and adult mice.	False
BC6ENTC reductase ( BC6ENTG ) is responsible for the de novo conversion of the BC6OTHER to BC6OTHER , which are essential for DNA synthesis and repair.	False
BC6OTHER ( BC6ENTG ) is responsible for the de novo conversion of the BC6OTHER to BC6ENTC , which are essential for DNA synthesis and repair.	CPR:9
BC6ENTG ( BC6OTHER ) is responsible for the de novo conversion of the BC6OTHER to BC6ENTC , which are essential for DNA synthesis and repair.	CPR:9
In PC3 cells, BC6ENTC inhibited BC6ENTG and resulted in increased sensitivity to UV irradiation.	CPR:4
In this study, we investigated the expression and function of BC6ENTG and BC6OTHER after UV treatment in human prostate cancer PC3 cells, which possess mutant BC6OTHER with a truncated BC6ENTC - terminal, and in human oropharyngeal cancer KB cells, which possess wild - type BC6OTHER .	False
In this study, we investigated the expression and function of BC6OTHER and BC6ENTG after UV treatment in human prostate cancer PC3 cells, which possess mutant BC6OTHER with a truncated BC6ENTC - terminal, and in human oropharyngeal cancer KB cells, which possess wild - type BC6OTHER .	False
In this study, we investigated the expression and function of BC6OTHER and BC6OTHER after UV treatment in human prostate cancer PC3 cells, which possess mutant BC6ENTG with a truncated BC6ENTC - terminal, and in human oropharyngeal cancer KB cells, which possess wild - type BC6OTHER .	False
In this study, we investigated the expression and function of BC6OTHER and BC6OTHER after UV treatment in human prostate cancer PC3 cells, which possess mutant BC6OTHER with a truncated BC6ENTC - terminal, and in human oropharyngeal cancer KB cells, which possess wild - type BC6ENTG .	False
BC6OTHER ( BC6ENTG ) is responsible for the de novo conversion of the BC6ENTC to BC6OTHER , which are essential for DNA synthesis and repair.	CPR:9
BC6ENTG ( BC6OTHER ) is responsible for the de novo conversion of the BC6ENTC to BC6OTHER , which are essential for DNA synthesis and repair.	CPR:9
The human BC6ENTC reductase subunit hRRM2 complements BC6OTHER in response to UV - induced DNA repair in cells with mutant BC6ENTG .	False
The human BC6ENTC reductase subunit hRRM2 complements BC6ENTG in response to UV - induced DNA repair in cells with mutant BC6OTHER .	False
Novel BC6ENTC derivatives that modulate body weight through enhancement of hypothalamic BC6OTHER ( BC6ENTG ) and / or decreased BC6OTHER ( BC6OTHER ).	CPR:3
Novel BC6ENTC derivatives that modulate body weight through enhancement of hypothalamic BC6OTHER ( BC6OTHER ) and / or decreased BC6ENTG ( BC6OTHER ).	CPR:4
Novel BC6ENTC derivatives that modulate body weight through enhancement of hypothalamic BC6OTHER ( BC6OTHER ) and / or decreased BC6OTHER ( BC6ENTG ).	CPR:4
Novel BC6ENTC derivatives that modulate body weight through enhancement of hypothalamic BC6ENTG ( BC6OTHER ) and / or decreased BC6OTHER ( BC6OTHER ).	CPR:3
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER .	CPR:9
Using recombinant BC6ENTG , we found that it catalyzes the N - glucuronidation of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC .	CPR:9
This preference is partial because BC6ENTG did not conjugate the BC6ENTC in BC6OTHER .	False
These are drugs that were previously reported to be substrates for BC6ENTG or BC6OTHER and that contain in their structure either BC6ENTC , BC6OTHER , or an BC6OTHER group.	False
These are drugs that were previously reported to be substrates for BC6OTHER or BC6ENTG and that contain in their structure either BC6ENTC , BC6OTHER , or an BC6OTHER group.	False
These are drugs that were previously reported to be substrates for BC6ENTG or BC6OTHER and that contain in their structure either BC6OTHER , BC6ENTC , or an BC6OTHER group.	False
These are drugs that were previously reported to be substrates for BC6OTHER or BC6ENTG and that contain in their structure either BC6OTHER , BC6ENTC , or an BC6OTHER group.	False
These are drugs that were previously reported to be substrates for BC6ENTG or BC6OTHER and that contain in their structure either BC6OTHER , BC6OTHER , or an BC6ENTC group.	False
These are drugs that were previously reported to be substrates for BC6OTHER or BC6ENTG and that contain in their structure either BC6OTHER , BC6OTHER , or an BC6ENTC group.	False
BC6ENTG was inactive in the glucuronidation of BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER .	False
BC6ENTG was inactive in the glucuronidation of BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER .	False
BC6ENTG was inactive in the glucuronidation of BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER .	False
BC6ENTG was inactive in the glucuronidation of BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC .	False
This group of drugs contains BC6ENTC , and these results suggest that BC6ENTG preferably conjugates BC6OTHER .	False
This group of drugs contains BC6OTHER , and these results suggest that BC6ENTG preferably conjugates BC6ENTC .	CPR:9
This preference is partial because BC6ENTG did not conjugate the BC6OTHER in BC6ENTC .	False
Recent observations revealed that BC6ENTG catalyzes CHEM - glucuronidation of BC6ENTC - containing compounds.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6ENTG for BC6ENTC , BC6OTHER , and BC6OTHER are significantly higher than the corresponding values of BC6OTHER and BC6OTHER , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6ENTC , BC6OTHER , and BC6OTHER are significantly higher than the corresponding values of BC6ENTG and BC6OTHER , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6ENTC , BC6OTHER , and BC6OTHER are significantly higher than the corresponding values of BC6OTHER and BC6ENTG , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	False
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6ENTC , BC6OTHER , and BC6OTHER are significantly higher than the corresponding values of BC6OTHER and BC6OTHER , although the Vmax values of BC6ENTG toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6ENTG for BC6OTHER , BC6ENTC , and BC6OTHER are significantly higher than the corresponding values of BC6OTHER and BC6OTHER , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6OTHER , BC6ENTC , and BC6OTHER are significantly higher than the corresponding values of BC6ENTG and BC6OTHER , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6OTHER , BC6ENTC , and BC6OTHER are significantly higher than the corresponding values of BC6OTHER and BC6ENTG , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6OTHER , BC6ENTC , and BC6OTHER are significantly higher than the corresponding values of BC6OTHER and BC6OTHER , although the Vmax values of BC6ENTG toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6ENTG for BC6OTHER , BC6OTHER , and BC6ENTC are significantly higher than the corresponding values of BC6OTHER and BC6OTHER , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6OTHER , BC6OTHER , and BC6ENTC are significantly higher than the corresponding values of BC6ENTG and BC6OTHER , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6OTHER , BC6OTHER , and BC6ENTC are significantly higher than the corresponding values of BC6OTHER and BC6ENTG , although the Vmax values of BC6OTHER toward these drugs are considerably higher.	CPR:9
Kinetic analyses revealed that the affinity and clearance of BC6OTHER for BC6OTHER , BC6OTHER , and BC6ENTC are significantly higher than the corresponding values of BC6OTHER and BC6OTHER , although the Vmax values of BC6ENTG toward these drugs are considerably higher.	CPR:9
In conclusion, this study expands the understanding of the substrate specificity of BC6ENTG , highlighting its preference for BC6ENTC with higher affinities and clearance values than those of BC6OTHER and BC6OTHER .	CPR:9
In conclusion, this study expands the understanding of the substrate specificity of BC6OTHER , highlighting its preference for BC6ENTC with higher affinities and clearance values than those of BC6ENTG and BC6OTHER .	CPR:9
In conclusion, this study expands the understanding of the substrate specificity of BC6OTHER , highlighting its preference for BC6ENTC with higher affinities and clearance values than those of BC6OTHER and BC6ENTG .	CPR:9
RATIONALE: Several drugs used to treat bipolar disorder ( BC6OTHER and BC6OTHER ), when administered chronically to rats, reduce the turnover of BC6OTHER , but not BC6ENTC , in brain phospholipids by decreasing the activity of an BC6OTHER - selective BC6ENTG .	False
RATIONALE: Several drugs used to treat bipolar disorder ( BC6OTHER and BC6OTHER ), when administered chronically to rats, reduce the turnover of BC6OTHER , but not BC6OTHER , in brain phospholipids by decreasing the activity of an BC6ENTC - selective BC6ENTG .	False
Although chronic BC6ENTC produces similar effects on brain BC6OTHER and BC6OTHER turnover, it does not alter BC6ENTG activity, suggesting that it targets a different enzyme in the turnover pathway.	False
Although chronic BC6OTHER produces similar effects on brain BC6ENTC and BC6OTHER turnover, it does not alter BC6ENTG activity, suggesting that it targets a different enzyme in the turnover pathway.	False
Although chronic BC6OTHER produces similar effects on brain BC6OTHER and BC6ENTC turnover, it does not alter BC6ENTG activity, suggesting that it targets a different enzyme in the turnover pathway.	False
RATIONALE: Several drugs used to treat bipolar disorder ( BC6ENTC and BC6OTHER ), when administered chronically to rats, reduce the turnover of BC6OTHER , but not BC6OTHER , in brain phospholipids by decreasing the activity of an BC6OTHER - selective BC6ENTG .	CPR:4
MATERIALS AND METHODS / RESULTS: By isolating rat brain microsomal BC6ENTC synthetases ( BC6ENTG ), we show in vitro that BC6OTHER is a non - competitive inhibitor of BC6OTHER , as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	False
MATERIALS AND METHODS / RESULTS: By isolating rat brain microsomal BC6ENTC synthetases ( BC6OTHER ), we show in vitro that BC6OTHER is a non - competitive inhibitor of BC6ENTG , as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	False
MATERIALS AND METHODS / RESULTS: By isolating BC6ENTG ( BC6OTHER ), we show in vitro that BC6ENTC is a non - competitive inhibitor of BC6OTHER , as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	False
MATERIALS AND METHODS / RESULTS: By isolating rat brain microsomal BC6OTHER synthetases ( BC6ENTG ), we show in vitro that BC6ENTC is a non - competitive inhibitor of BC6OTHER , as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	False
MATERIALS AND METHODS / RESULTS: By isolating rat brain microsomal BC6OTHER synthetases ( BC6OTHER ), we show in vitro that BC6ENTC is a non - competitive inhibitor of BC6ENTG , as it reduces the maximal velocity of the reaction without changing the affinity of the substrate for the enzyme.	CPR:4
RATIONALE: Several drugs used to treat bipolar disorder ( BC6OTHER and BC6ENTC ), when administered chronically to rats, reduce the turnover of BC6OTHER , but not BC6OTHER , in brain phospholipids by decreasing the activity of an BC6OTHER - selective BC6ENTG .	CPR:4
 BC6ENTC selectively inhibits conversion of BC6OTHER to BC6OTHER by BC6ENTG : relevance to bipolar disorder.	CPR:4
 BC6OTHER selectively inhibits conversion of BC6ENTC to BC6OTHER by BC6ENTG : relevance to bipolar disorder.	CPR:9
 BC6OTHER selectively inhibits conversion of BC6OTHER to BC6ENTC by BC6ENTG : relevance to bipolar disorder.	CPR:9
Furthermore, BC6ENTG did not produce BC6ENTC .	False
CONCLUSIONS: This study shows that BC6ENTC acts as a non - competitive inhibitor of BC6ENTG , and that inhibition is substrate - selective.	CPR:4
RATIONALE: Several drugs used to treat bipolar disorder ( BC6OTHER and BC6OTHER ), when administered chronically to rats, reduce the turnover of BC6ENTC , but not BC6OTHER , in brain phospholipids by decreasing the activity of an BC6OTHER - selective BC6ENTG .	False
A 59 - year - old female suffering from malignant lymphoma developed therapy - related acute myeloblastic leukemia (t - AML) after chemotherapy consisting of treatment with BC6ENTG inhibitors, BC6ENTC and BC6OTHER , and an alkylating agent, BC6OTHER .	CPR:4
A 59 - year - old female suffering from malignant lymphoma developed therapy - related acute myeloblastic leukemia (t - AML) after chemotherapy consisting of treatment with BC6ENTG inhibitors, BC6OTHER and BC6ENTC , and an alkylating agent, BC6OTHER .	CPR:4
A 59 - year - old female suffering from malignant lymphoma developed therapy - related acute myeloblastic leukemia (t - AML) after chemotherapy consisting of treatment with BC6ENTG inhibitors, BC6OTHER and BC6OTHER , and an alkylating agent, BC6ENTC .	False
A case of therapy - related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with BC6ENTG inhibitors, BC6ENTC and BC6OTHER , and the alkylating agent, BC6OTHER .	CPR:4
A case of therapy - related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with BC6ENTG inhibitors, BC6OTHER and BC6ENTC , and the alkylating agent, BC6OTHER .	CPR:4
A case of therapy - related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with BC6ENTG inhibitors, BC6OTHER and BC6OTHER , and the alkylating agent, BC6ENTC .	False
Dose - dependent inhibition of platelet BC6ENTG and monocyte BC6OTHER by BC6ENTC in healthy subjects.	CPR:4
Dose - dependent inhibition of platelet BC6OTHER and monocyte BC6ENTG by BC6ENTC in healthy subjects.	CPR:4
In contrast, the administration of 7.5 and 15 mg of BC6ENTC caused dose - dependent reductions in monocyte BC6ENTG activity by 51% and 70%, respectively, and in platelet BC6OTHER activity by 25% and 35%, respectively.	CPR:4
In contrast, the administration of 7.5 and 15 mg of BC6ENTC caused dose - dependent reductions in monocyte BC6OTHER activity by 51% and 70%, respectively, and in platelet BC6ENTG activity by 25% and 35%, respectively.	CPR:4
Although the IC50 value of BC6ENTC for inhibition of BC6ENTG was 10 - fold higher than the IC50 value of BC6OTHER in vitro, this biochemical selectivity was inadequate to clearly separate the effects of BC6OTHER on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady - state plasma levels.	CPR:4
Although the IC50 value of BC6ENTC for inhibition of BC6OTHER was 10 - fold higher than the IC50 value of BC6ENTG in vitro, this biochemical selectivity was inadequate to clearly separate the effects of BC6OTHER on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady - state plasma levels.	CPR:4
Although the IC50 value of BC6OTHER for inhibition of BC6ENTG was 10 - fold higher than the IC50 value of BC6OTHER in vitro, this biochemical selectivity was inadequate to clearly separate the effects of BC6ENTC on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady - state plasma levels.	False
Although the IC50 value of BC6OTHER for inhibition of BC6OTHER was 10 - fold higher than the IC50 value of BC6ENTG in vitro, this biochemical selectivity was inadequate to clearly separate the effects of BC6ENTC on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady - state plasma levels.	False
Concentration - response curves for the inhibition of monocyte BC6ENTG and platelet BC6OTHER were obtained in vitro after the incubation of BC6ENTC with whole blood samples.	CPR:4
Concentration - response curves for the inhibition of monocyte BC6OTHER and platelet BC6ENTG were obtained in vitro after the incubation of BC6ENTC with whole blood samples.	CPR:4
We evaluated whether therapeutic blood levels of BC6ENTC are associated with selective inhibition of monocyte BC6ENTG in vitro and ex vivo.	False
Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram / ml) for 24 h at 37 degrees C, and BC6ENTC was measured in plasma as an index of monocyte BC6ENTG activity.	CPR:9
The production of BC6ENTC in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet BC6ENTG activity.	CPR:9
By modulating expression levels of endogenous BC6ENTG in primary cortical neurons, the frequency and amplitude of BC6ENTC oscillations is modified, implying a key role for BC6OTHER in maintaining neuronal BC6OTHER homeostasis essential for synaptic transmission.	False
By modulating expression levels of endogenous BC6OTHER in primary cortical neurons, the frequency and amplitude of BC6ENTC oscillations is modified, implying a key role for BC6ENTG in maintaining neuronal BC6OTHER homeostasis essential for synaptic transmission.	False
By modulating expression levels of endogenous BC6ENTG in primary cortical neurons, the frequency and amplitude of BC6OTHER oscillations is modified, implying a key role for BC6OTHER in maintaining neuronal BC6ENTC homeostasis essential for synaptic transmission.	False
By modulating expression levels of endogenous BC6OTHER in primary cortical neurons, the frequency and amplitude of BC6OTHER oscillations is modified, implying a key role for BC6ENTG in maintaining neuronal BC6ENTC homeostasis essential for synaptic transmission.	False
BC6OTHER inhibits BC6ENTC production, but betagamma regulates several molecular pathways, including BC6OTHER ( BC6ENTG ).	False
BC6ENTG inhibits BC6ENTC production, but betagamma regulates several molecular pathways, including BC6OTHER ( BC6OTHER ).	False
BC6OTHER inhibits BC6ENTC production, but betagamma regulates several molecular pathways, including BC6ENTG ( BC6OTHER ).	False
In rats self - administering BC6ENTC , BC6ENTG antisense in the NAc core, but not shell, eliminates reinstatement of BC6OTHER - seeking behavior, a model of human relapse.	False
In rats self - administering BC6OTHER , BC6ENTG antisense in the NAc core, but not shell, eliminates reinstatement of BC6ENTC - seeking behavior, a model of human relapse.	False
Thus, BC6ENTG / BC6OTHER appears to mediate BC6OTHER activation of BC6OTHER signaling as well as BC6ENTC - seeking behavior.	False
Thus, BC6OTHER / BC6ENTG appears to mediate BC6OTHER activation of BC6OTHER signaling as well as BC6ENTC - seeking behavior.	False
Thus, BC6OTHER / BC6OTHER appears to mediate BC6ENTG activation of BC6OTHER signaling as well as BC6ENTC - seeking behavior.	False
Thus, BC6OTHER / BC6OTHER appears to mediate BC6OTHER activation of BC6ENTG signaling as well as BC6ENTC - seeking behavior.	False
 BC6ENTG regulates opiate activation of BC6OTHER signaling and relapse of BC6ENTC - seeking behavior.	False
 BC6OTHER regulates opiate activation of BC6ENTG signaling and relapse of BC6ENTC - seeking behavior.	False
The BC6ENTG inhibitor Compound C prevented the action of BC6ENTC and BC6OTHER but not BC6OTHER .	False
CONCLUSIONS AND IMPLICATIONS: Activation of BC6ENTG is associated with inhibition of apical BC6ENTC - sensitive BC6OTHER channels ( BC6OTHER ), which has important implications for the clinical use of BC6OTHER .	False
CONCLUSIONS AND IMPLICATIONS: Activation of BC6OTHER is associated with inhibition of apical BC6ENTC - sensitive BC6OTHER channels ( BC6ENTG ), which has important implications for the clinical use of BC6OTHER .	False
CONCLUSIONS AND IMPLICATIONS: Activation of BC6ENTG is associated with inhibition of apical CHEM - sensitive BC6ENTC channels ( BC6OTHER ), which has important implications for the clinical use of BC6OTHER .	False
CONCLUSIONS AND IMPLICATIONS: Activation of BC6OTHER is associated with inhibition of apical CHEM - sensitive BC6ENTC channels ( BC6ENTG ), which has important implications for the clinical use of BC6OTHER .	False
CONCLUSIONS AND IMPLICATIONS: Activation of BC6ENTG is associated with inhibition of apical CHEM - sensitive BC6OTHER channels ( BC6OTHER ), which has important implications for the clinical use of BC6ENTC .	False
CONCLUSIONS AND IMPLICATIONS: Activation of BC6OTHER is associated with inhibition of apical BC6ENTG ( BC6OTHER ), which has important implications for the clinical use of BC6ENTC .	False
CONCLUSIONS AND IMPLICATIONS: Activation of BC6OTHER is associated with inhibition of apical CHEM - sensitive BC6OTHER channels ( BC6ENTG ), which has important implications for the clinical use of BC6ENTC .	False
Additional pharmacological effects evoked by BC6ENTC and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6ENTG activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where CHEM BC6OTHER +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6ENTC and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6ENTG in cell systems where CHEM BC6OTHER +ATPase is an important component.	CPR:3
Additional pharmacological effects evoked by BC6ENTC and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where BC6ENTG is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6ENTC on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6ENTG activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where CHEM BC6OTHER +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6ENTC on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6ENTG in cell systems where CHEM BC6OTHER +ATPase is an important component.	CPR:3
Additional pharmacological effects evoked by BC6OTHER and BC6ENTC on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where BC6ENTG is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6ENTC ), with potential secondary effects on apical BC6OTHER conductance, BC6ENTG activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where CHEM BC6OTHER +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6ENTC ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6ENTG in cell systems where CHEM BC6OTHER +ATPase is an important component.	CPR:3
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6ENTC ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where BC6ENTG is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6ENTC conductance, BC6ENTG activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where CHEM BC6OTHER +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6ENTC conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6ENTG in cell systems where CHEM BC6OTHER +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6ENTC conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where BC6ENTG is an important component.	False
BACKGROUND AND PURPOSE: BC6ENTG ( BC6OTHER ) is activated by BC6OTHER , BC6OTHER , and the BC6OTHER mimetic, BC6OTHER ( BC6ENTC ).	CPR:3
BACKGROUND AND PURPOSE: BC6OTHER ( BC6ENTG ) is activated by BC6OTHER , BC6OTHER , and the BC6OTHER mimetic, BC6OTHER ( BC6ENTC ).	CPR:3
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6ENTG activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where BC6ENTC + BC6OTHER +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6ENTG in cell systems where BC6ENTC + BC6OTHER +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6ENTG activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6OTHER in cell systems where CHEM BC6ENTC +ATPase is an important component.	False
Additional pharmacological effects evoked by BC6OTHER and BC6OTHER on I( BC6OTHER ), with potential secondary effects on apical BC6OTHER conductance, BC6OTHER activity and monolayer resistance, have important consequences for their use as pharmacological activators of BC6ENTG in cell systems where CHEM BC6ENTC +ATPase is an important component.	False
The BC6ENTG inhibitor Compound C prevented the action of BC6OTHER and BC6ENTC but not BC6OTHER .	False
BACKGROUND AND PURPOSE: BC6ENTC - activated protein kinase ( BC6ENTG ) is activated by BC6OTHER , BC6OTHER , and the BC6OTHER mimetic, BC6OTHER ( BC6OTHER ).	False
We have completed an extensive study of the pharmacological effects of these drugs on BC6ENTG activation, BC6ENTC concentration, transepithelial BC6OTHER - sensitive (I( BC6OTHER )) and BC6OTHER - sensitive basolateral (I( BC6OTHER )) short circuit current in H441 lung epithelial cells.	False
We have completed an extensive study of the pharmacological effects of these drugs on BC6ENTG activation, BC6OTHER concentration, transepithelial BC6ENTC - sensitive (I( BC6OTHER )) and BC6OTHER - sensitive basolateral (I( BC6OTHER )) short circuit current in H441 lung epithelial cells.	False
We have completed an extensive study of the pharmacological effects of these drugs on BC6ENTG activation, BC6OTHER concentration, transepithelial BC6OTHER - sensitive (I( BC6ENTC )) and BC6OTHER - sensitive basolateral (I( BC6OTHER )) short circuit current in H441 lung epithelial cells.	False
We have completed an extensive study of the pharmacological effects of these drugs on BC6ENTG activation, BC6OTHER concentration, transepithelial BC6OTHER - sensitive (I( BC6OTHER )) and BC6ENTC - sensitive basolateral (I( BC6OTHER )) short circuit current in H441 lung epithelial cells.	False
We have completed an extensive study of the pharmacological effects of these drugs on BC6ENTG activation, BC6OTHER concentration, transepithelial BC6OTHER - sensitive (I( BC6OTHER )) and BC6OTHER - sensitive basolateral (I( BC6ENTC )) short circuit current in H441 lung epithelial cells.	False
BC6ENTG activity was measured as the amount of radiolabelled BC6ENTC transferred to the SAMS peptide.	False
BACKGROUND AND PURPOSE: BC6ENTG ( BC6OTHER ) is activated by BC6OTHER , BC6OTHER , and the BC6ENTC mimetic, BC6OTHER ( BC6OTHER ).	False
BACKGROUND AND PURPOSE: BC6OTHER ( BC6ENTG ) is activated by BC6OTHER , BC6OTHER , and the BC6ENTC mimetic, BC6OTHER ( BC6OTHER ).	False
BACKGROUND AND PURPOSE: BC6ENTG ( BC6OTHER ) is activated by BC6ENTC , BC6OTHER , and the BC6OTHER mimetic, BC6OTHER ( BC6OTHER ).	CPR:3
BACKGROUND AND PURPOSE: BC6OTHER ( BC6ENTG ) is activated by BC6ENTC , BC6OTHER , and the BC6OTHER mimetic, BC6OTHER ( BC6OTHER ).	CPR:3
BACKGROUND AND PURPOSE: BC6ENTG ( BC6OTHER ) is activated by BC6OTHER , BC6ENTC , and the BC6OTHER mimetic, BC6OTHER ( BC6OTHER ).	CPR:3
BACKGROUND AND PURPOSE: BC6OTHER ( BC6ENTG ) is activated by BC6OTHER , BC6ENTC , and the BC6OTHER mimetic, BC6OTHER ( BC6OTHER ).	CPR:3
KEY RESULTS: BC6ENTC , BC6OTHER and BC6OTHER increased BC6ENTG activity and decreased I( BC6OTHER ).	CPR:3
KEY RESULTS: BC6OTHER , BC6ENTC and BC6OTHER increased BC6ENTG activity and decreased I( BC6OTHER ).	CPR:3
KEY RESULTS: BC6OTHER , BC6OTHER and BC6ENTC increased BC6ENTG activity and decreased I( BC6OTHER ).	CPR:3
KEY RESULTS: BC6OTHER , BC6OTHER and BC6OTHER increased BC6ENTG activity and decreased I( BC6ENTC ).	False
Pharmacological activators of BC6ENTG have different effects on BC6ENTC transport processes across human lung epithelial cells.	False
The BC6ENTG inhibitor Compound C prevented the action of BC6OTHER and BC6OTHER but not BC6ENTC .	CPR:3
BACKGROUND AND PURPOSE: BC6ENTG ( BC6OTHER ) is activated by BC6OTHER , BC6OTHER , and the BC6OTHER mimetic, BC6ENTC ( BC6OTHER ).	CPR:3
BACKGROUND AND PURPOSE: BC6OTHER ( BC6ENTG ) is activated by BC6OTHER , BC6OTHER , and the BC6OTHER mimetic, BC6ENTC ( BC6OTHER ).	CPR:3
BC6OTHER has no significant effect on BC6ENTG - hypoglycemia - induced BC6OTHER and BC6ENTC levels and, therefore, no effect on stress - induced elevation of CHEM levels.	False
BC6OTHER has no significant effect on BC6OTHER - hypoglycemia - induced BC6ENTG and BC6ENTC levels and, therefore, no effect on stress - induced elevation of CHEM levels.	False
In seven normal subjects, basal BC6ENTG plasma levels were significantly suppressed 3 h after BC6ENTC administration (16 mg, orally) from 5 + / - 1 to 2 + / - 0 pmol / L (P less than 0.0001).	CPR:4
After the combined pituitary stimulation test (100 micrograms BC6ENTG , 100 micrograms BC6ENTC , 100 micrograms BC6OTHER , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6ENTC , 100 micrograms BC6ENTG , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6ENTC , 100 micrograms BC6OTHER , and 200 micrograms BC6ENTG ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6ENTC , 100 micrograms BC6OTHER , and 200 micrograms BC6OTHER ), the BC6ENTG peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6ENTC , 100 micrograms BC6OTHER , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6ENTG from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6ENTG , 100 micrograms BC6OTHER , 100 micrograms BC6ENTC , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6ENTG , 100 micrograms BC6ENTC , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6ENTC , and 200 micrograms BC6ENTG ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6ENTC , and 200 micrograms BC6OTHER ), the BC6ENTG peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6ENTC , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6ENTG from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6ENTG , 100 micrograms BC6OTHER , 100 micrograms BC6OTHER , and 200 micrograms BC6ENTC ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6ENTG , 100 micrograms BC6OTHER , and 200 micrograms BC6ENTC ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6ENTG , and 200 micrograms BC6ENTC ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6OTHER , and 200 micrograms BC6ENTC ), the BC6ENTG peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6OTHER , and 200 micrograms BC6ENTC ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6OTHER from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6ENTG from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	False
After the combined pituitary stimulation test (100 micrograms BC6ENTG , 100 micrograms BC6OTHER , 100 micrograms BC6OTHER , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6ENTC from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	CPR:4
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6ENTG , 100 micrograms BC6OTHER , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6ENTC from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	CPR:4
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6ENTG , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6ENTC from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	CPR:4
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6OTHER , and 200 micrograms BC6ENTG ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6ENTC from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	CPR:4
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6OTHER , and 200 micrograms BC6OTHER ), the BC6ENTG peak (maximum increase at 30 min) was significantly blunted by BC6ENTC from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6OTHER from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	CPR:4
After the combined pituitary stimulation test (100 micrograms BC6OTHER , 100 micrograms BC6OTHER , 100 micrograms BC6OTHER , and 200 micrograms BC6OTHER ), the BC6OTHER peak (maximum increase at 30 min) was significantly blunted by BC6ENTC from 9 + / - 1 to 4 + / - 1 pmol / L (P less than 0.001) and the area under the curve of BC6ENTG from 0 - 120 min was reduced from 35 + / - 5 to 23 + / - 4 pmol / L.2 h (P less than 0.05).	CPR:4
BC6ENTC , an opiate agonist of high specificity for mu - receptors, was recently reported to suppress BC6ENTG and BC6OTHER levels in normal subjects, but not in patients with proven BC6OTHER - dependent Cushing's disease.	CPR:4
BC6ENTC , an opiate agonist of high specificity for mu - receptors, was recently reported to suppress BC6OTHER and BC6OTHER levels in normal subjects, but not in patients with proven BC6ENTG - dependent Cushing's disease.	False
BC6OTHER , an opiate agonist of high specificity for mu - receptors, was recently reported to suppress BC6ENTG and BC6ENTC levels in normal subjects, but not in patients with proven BC6OTHER - dependent Cushing's disease.	False
BC6OTHER , an opiate agonist of high specificity for mu - receptors, was recently reported to suppress BC6OTHER and BC6ENTC levels in normal subjects, but not in patients with proven BC6ENTG - dependent Cushing's disease.	False
In the BC6ENTG - hypoglycemia test (0.15 IU / kg BW), neither the BC6OTHER peak nor the area under the curve of BC6OTHER was affected by BC6ENTC .	False
In the BC6OTHER - hypoglycemia test (0.15 IU / kg BW), neither the BC6ENTG peak nor the area under the curve of BC6OTHER was affected by BC6ENTC .	False
In the BC6OTHER - hypoglycemia test (0.15 IU / kg BW), neither the BC6OTHER peak nor the area under the curve of BC6ENTG was affected by BC6ENTC .	False
In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal BC6ENTG and BC6ENTC levels nor BC6OTHER - stimulated levels were influenced by BC6OTHER .	False
In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal BC6OTHER and BC6ENTC levels nor BC6ENTG - stimulated levels were influenced by BC6OTHER .	False
In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal BC6ENTG and BC6OTHER levels nor BC6OTHER - stimulated levels were influenced by BC6ENTC .	False
In six patients with Cushing's disease and one patient with secondary adrenal insufficiency due to hypothalamic failure, neither basal BC6OTHER and BC6OTHER levels nor BC6ENTG - stimulated levels were influenced by BC6ENTC .	False
In four cultured human corticotropic adenomas, BC6ENTC was not able to reduce basal and BC6ENTG - induced BC6OTHER secretion.	False
In four cultured human corticotropic adenomas, BC6ENTC was not able to reduce basal and BC6OTHER - induced BC6ENTG secretion.	False
In summary, BC6ENTC is able to reduce basal and BC6ENTG - induced BC6OTHER and BC6OTHER levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	CPR:4
In summary, BC6ENTC is able to reduce basal and BC6OTHER - induced BC6ENTG and BC6OTHER levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	CPR:4
In summary, BC6OTHER is able to reduce basal and BC6ENTG - induced BC6OTHER and BC6ENTC levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	False
In summary, BC6OTHER is able to reduce basal and BC6OTHER - induced BC6ENTG and BC6ENTC levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.	False
BC6ENTC has no significant effect on BC6ENTG - hypoglycemia - induced BC6OTHER and BC6OTHER levels and, therefore, no effect on stress - induced elevation of CHEM levels.	False
BC6ENTC has no significant effect on BC6OTHER - hypoglycemia - induced BC6ENTG and BC6OTHER levels and, therefore, no effect on stress - induced elevation of CHEM levels.	False
The activities of BC6ENTC dismutase, BC6ENTG and BC6OTHER peroxidase were found significantly higher in combined treated than untreated rats.	False
The activities of BC6ENTC dismutase, BC6OTHER and BC6ENTG were found significantly higher in combined treated than untreated rats.	False
The activities of BC6ENTG , BC6OTHER and BC6ENTC peroxidase were found significantly higher in combined treated than untreated rats.	False
The activities of BC6OTHER dismutase, BC6ENTG and BC6ENTC peroxidase were found significantly higher in combined treated than untreated rats.	False
We showed previously that BC6ENTG antagonizes BC6OTHER - mediated transformation through activation of BC6OTHER / c - Jun BC6ENTC - terminal kinase - 1, whereas both BC6OTHER and BC6OTHER induce mitogenic signals.	False
We showed previously that BC6OTHER antagonizes BC6ENTG - mediated transformation through activation of BC6OTHER / c - Jun BC6ENTC - terminal kinase - 1, whereas both BC6OTHER and BC6OTHER induce mitogenic signals.	False
We showed previously that BC6OTHER antagonizes BC6OTHER - mediated transformation through activation of BC6ENTG / c - Jun BC6ENTC - terminal kinase - 1, whereas both BC6OTHER and BC6OTHER induce mitogenic signals.	False
We showed previously that BC6OTHER antagonizes BC6OTHER - mediated transformation through activation of BC6OTHER / c - Jun BC6ENTC - terminal kinase - 1, whereas both BC6ENTG and BC6OTHER induce mitogenic signals.	False
We showed previously that BC6OTHER antagonizes BC6OTHER - mediated transformation through activation of BC6OTHER / c - Jun BC6ENTC - terminal kinase - 1, whereas both BC6OTHER and BC6ENTG induce mitogenic signals.	False
 BC6ENTG - activated c - Jun BC6ENTC - terminal kinase - 1 is critical for BC6OTHER - induced BC6OTHER activity independent of BC6OTHER .	False
 BC6OTHER - activated c - Jun BC6ENTC - terminal kinase - 1 is critical for BC6ENTG - induced BC6OTHER activity independent of BC6OTHER .	False
 BC6OTHER - activated c - Jun BC6ENTC - terminal kinase - 1 is critical for BC6OTHER - induced BC6ENTG activity independent of BC6OTHER .	False
 BC6OTHER - activated c - Jun BC6ENTC - terminal kinase - 1 is critical for BC6OTHER - induced BC6OTHER activity independent of BC6ENTG .	False
Other dams received 1.8ng / kg / day of a mixture of BC6ENTG ( BC6OTHER ) agonists ( BC6OTHER s, BC6OTHER and BC6ENTC ) without or with 0.5M (0.5M BC6OTHER ).	CPR:5
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6OTHER receptor ( BC6ENTG ) agonists ( BC6OTHER s, BC6OTHER and BC6ENTC ) without or with 0.5M (0.5M BC6OTHER ).	False
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6OTHER receptor ( BC6OTHER ) agonists ( BC6OTHER s, BC6OTHER and BC6ENTC ) without or with 0.5M (0.5M BC6ENTG ).	False
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6ENTC receptor ( BC6ENTG ) agonists ( BC6OTHER s, BC6OTHER and BC6OTHER ) without or with 0.5M (0.5M BC6OTHER ).	False
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6ENTC receptor ( BC6OTHER ) agonists ( BC6OTHER s, BC6OTHER and BC6OTHER ) without or with 0.5M (0.5M BC6ENTG ).	False
Other dams received 1.8ng / kg / day of a mixture of BC6ENTG ( BC6OTHER ) agonists ( BC6ENTC s, BC6OTHER and BC6OTHER ) without or with 0.5M (0.5M BC6OTHER ).	CPR:5
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6OTHER receptor ( BC6ENTG ) agonists ( BC6ENTC s, BC6OTHER and BC6OTHER ) without or with 0.5M (0.5M BC6OTHER ).	False
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6OTHER receptor ( BC6OTHER ) agonists ( BC6ENTC s, BC6OTHER and BC6OTHER ) without or with 0.5M (0.5M BC6ENTG ).	False
Other dams received 1.8ng / kg / day of a mixture of BC6ENTG ( BC6OTHER ) agonists ( BC6OTHER s, BC6ENTC and BC6OTHER ) without or with 0.5M (0.5M BC6OTHER ).	CPR:5
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6OTHER receptor ( BC6ENTG ) agonists ( BC6OTHER s, BC6ENTC and BC6OTHER ) without or with 0.5M (0.5M BC6OTHER ).	False
Other dams received 1.8ng / kg / day of a mixture of CHEM BC6OTHER receptor ( BC6OTHER ) agonists ( BC6OTHER s, BC6ENTC and BC6OTHER ) without or with 0.5M (0.5M BC6ENTG ).	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6ENTC on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
BC6ENTG ( BC6OTHER ) is a BC6OTHER enzyme that catalyses the reversible hydration reaction of BC6ENTC and plays a major role in the acid - base balance.	CPR:9
BC6OTHER ( BC6ENTG ) is a BC6OTHER enzyme that catalyses the reversible hydration reaction of BC6ENTC and plays a major role in the acid - base balance.	CPR:9
BC6ENTG ( BC6OTHER ) is a BC6ENTC enzyme that catalyses the reversible hydration reaction of BC6OTHER and plays a major role in the acid - base balance.	False
BC6OTHER ( BC6ENTG ) is a BC6ENTC enzyme that catalyses the reversible hydration reaction of BC6OTHER and plays a major role in the acid - base balance.	False
We studied the in vitro effects of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6ENTG , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6ENTG and vascular smooth muscle BC6OTHER isolated from rabbits.	False
We studied the in vitro effects of BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER and BC6OTHER on purified BC6OTHER and vascular smooth muscle BC6ENTG isolated from rabbits.	False
Of the new compounds, BC6OTHER (1) - BC6OTHER CHEM (4) (analogue 12) displayed the highest affinity toward BC6ENTG , in the picomolar range (Ki(μ) = 3.72 pM).	False
Of the new compounds, BC6OTHER (1) - BC6OTHER CHEM (4) (analogue 12) displayed the highest affinity toward BC6ENTG , in the picomolar range (Ki(μ) = 3.72 pM).	False
Design, Synthesis, and Pharmacological Characterization of Novel BC6ENTC Analogues as Extremely Potent BC6ENTG Agonists.	CPR:5
Of the new compounds, BC6ENTC (1) - BC6OTHER CHEM (4) (analogue 12) displayed the highest affinity toward BC6ENTG , in the picomolar range (Ki(μ) = 3.72 pM).	False
Of the new compounds, BC6OTHER (1) - BC6ENTC CHEM (4) (analogue 12) displayed the highest affinity toward BC6ENTG , in the picomolar range (Ki(μ) = 3.72 pM).	False
This suggests that the observed interaction of BC6OTHER with BC6ENTC is mainly caused by intestinal BC6ENTG inhibition, whereas the interaction with BC6OTHER is more due to hepatic BC6OTHER inhibition.	False
This suggests that the observed interaction of BC6OTHER with BC6ENTC is mainly caused by intestinal BC6OTHER inhibition, whereas the interaction with BC6OTHER is more due to hepatic BC6ENTG inhibition.	False
This suggests that the observed interaction of BC6OTHER with BC6OTHER is mainly caused by intestinal BC6ENTG inhibition, whereas the interaction with BC6ENTC is more due to hepatic BC6OTHER inhibition.	False
This suggests that the observed interaction of BC6OTHER with BC6OTHER is mainly caused by intestinal BC6OTHER inhibition, whereas the interaction with BC6ENTC is more due to hepatic BC6ENTG inhibition.	False
 BC6ENTC effects on BC6ENTG activity studied by its simultaneous and time - separated administration with BC6OTHER and BC6OTHER .	False
 BC6OTHER effects on BC6ENTG activity studied by its simultaneous and time - separated administration with BC6ENTC and BC6OTHER .	False
 BC6OTHER effects on BC6ENTG activity studied by its simultaneous and time - separated administration with BC6OTHER and BC6ENTC .	False
PURPOSE: To characterise further the previously observed BC6OTHER ( BC6OTHER ) interaction of the dual BC6ENTG antagonist BC6ENTC .	CPR:6
PURPOSE: To characterise further the previously observed BC6ENTG ( BC6OTHER ) interaction of the dual BC6OTHER antagonist BC6ENTC .	False
PURPOSE: To characterise further the previously observed BC6OTHER ( BC6ENTG ) interaction of the dual BC6OTHER antagonist BC6ENTC .	False
This suggests that the observed interaction of BC6ENTC with BC6OTHER is mainly caused by intestinal BC6ENTG inhibition, whereas the interaction with BC6OTHER is more due to hepatic BC6OTHER inhibition.	False
This suggests that the observed interaction of BC6ENTC with BC6OTHER is mainly caused by intestinal BC6OTHER inhibition, whereas the interaction with BC6OTHER is more due to hepatic BC6ENTG inhibition.	False
BC6ENTG knockout mice had low basal spontaneous locomotor activity, which was increased by BC6OTHER , whereas BC6OTHER had no effect in BC6ENTC transporter knockout mice.	False
CONCLUSIONS: Acute or chronic inactivation of the BC6ENTC transporter decreases spontaneous locomotor activity in novel and familiar environments unless coupled with BC6ENTG blockade.	False
CONCLUSIONS: Acute or chronic inactivation of the BC6ENTG decreases spontaneous locomotor activity in novel and familiar environments unless coupled with BC6ENTC transporter blockade.	False
Because BC6ENTC is an important regulator of spontaneous locomotor activity, we speculated that BC6ENTG blockade contributes to the effects of some antidepressants on spontaneous locomotor activity.	False
METHODS: Antidepressant drugs ( BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER ) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and BC6ENTG knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	False
METHODS: Antidepressant drugs ( BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER , BC6OTHER ) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and BC6ENTG knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	False
METHODS: Antidepressant drugs ( BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER , BC6OTHER ) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and BC6ENTG knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	False
METHODS: Antidepressant drugs ( BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC , BC6OTHER ) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and BC6ENTG knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	False
METHODS: Antidepressant drugs ( BC6OTHER , BC6OTHER , BC6OTHER , BC6OTHER , BC6ENTC ) were administered acutely (intraperitoneal) or chronically (via osmotic minipump) to control and BC6ENTG knockout mice, and spontaneous locomotor activity in novel or familiar environments was recorded.	False
The exception was BC6ENTC , a dual BC6ENTG / BC6OTHER transporter blocker, which tended to increase spontaneous locomotor activity.	CPR:4
The exception was BC6ENTC , a dual BC6OTHER transporter / BC6ENTG blocker, which tended to increase spontaneous locomotor activity.	CPR:4
The exception was BC6OTHER , a dual BC6ENTC transporter / BC6ENTG blocker, which tended to increase spontaneous locomotor activity.	False
The exception was BC6OTHER , a dual BC6ENTG / BC6ENTC transporter blocker, which tended to increase spontaneous locomotor activity.	False
Coadministration of BC6ENTC and the BC6ENTG blocker BC6OTHER also increased spontaneous locomotor activity.	False
Coadministration of BC6OTHER and the BC6ENTG blocker BC6ENTC also increased spontaneous locomotor activity.	CPR:4
BC6ENTC transporter knockout mice had low basal spontaneous locomotor activity, which was increased by BC6OTHER , whereas BC6OTHER had no effect in BC6ENTG knockout mice.	False
BC6ENTG knockout mice had low basal spontaneous locomotor activity, which was increased by BC6ENTC , whereas BC6OTHER had no effect in BC6OTHER knockout mice.	False
BC6OTHER transporter knockout mice had low basal spontaneous locomotor activity, which was increased by BC6ENTC , whereas BC6OTHER had no effect in BC6ENTG knockout mice.	False
BC6ENTG knockout mice had low basal spontaneous locomotor activity, which was increased by BC6OTHER , whereas BC6ENTC had no effect in BC6OTHER knockout mice.	False
BC6OTHER transporter knockout mice had low basal spontaneous locomotor activity, which was increased by BC6OTHER , whereas BC6ENTC had no effect in BC6ENTG knockout mice.	False
Moreover, BC6ENTC repressed BC6OTHER - induced phosphorylation of BC6ENTG , BC6OTHER and vascular permeability.	CPR:4
Moreover, BC6ENTC repressed BC6OTHER - induced phosphorylation of BC6OTHER , BC6ENTG and vascular permeability.	CPR:4
Moreover, BC6OTHER repressed BC6ENTC - induced phosphorylation of BC6ENTG , BC6OTHER and vascular permeability.	CPR:3
Moreover, BC6OTHER repressed BC6ENTC - induced phosphorylation of BC6OTHER , BC6ENTG and vascular permeability.	CPR:3
These results suggested that BC6ENTC could inhibit BC6OTHER - induced vascular permeability by downregulating the phosphorylation of BC6ENTG , and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.	CPR:4
These results suggested that BC6OTHER could inhibit BC6ENTC - induced vascular permeability by downregulating the phosphorylation of BC6ENTG , and that it might have a therapeutic potential for the diseases associated with the development of both oxidant and vascular permeability.	CPR:3
 BC6ENTC inhibits BC6OTHER - induced vascular permeability through suppressing the phosphorylation of BC6ENTG .	CPR:4
 BC6OTHER inhibits BC6ENTC - induced vascular permeability through suppressing the phosphorylation of BC6ENTG .	CPR:3
We found that BC6ENTC can suppress the BC6OTHER - stimulated BC6ENTG remodeling and BC6OTHER uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell CHEM - MB - 231.	CPR:4
We found that BC6ENTC can suppress the BC6OTHER - stimulated BC6OTHER remodeling and BC6ENTG uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell CHEM - MB - 231.	CPR:4
We found that BC6OTHER can suppress the BC6ENTC - stimulated BC6ENTG remodeling and BC6OTHER uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell CHEM - MB - 231.	CPR:3
We found that BC6OTHER can suppress the BC6ENTC - stimulated BC6OTHER remodeling and BC6ENTG uptake of HUVECs, as well as transendothelial cell migration of the human breast carcinoma cell CHEM - MB - 231.	CPR:3
The mechanism revealed that BC6ENTC inhibited BC6OTHER - induced phosphorylation of BC6ENTG ( BC6OTHER ) associating with the suppression of stabilization of BC6OTHER and BC6OTHER .	CPR:4
The mechanism revealed that BC6ENTC inhibited BC6OTHER - induced phosphorylation of BC6OTHER ( BC6ENTG ) associating with the suppression of stabilization of BC6OTHER and BC6OTHER .	CPR:4
The mechanism revealed that BC6ENTC inhibited BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) associating with the suppression of stabilization of BC6ENTG and BC6OTHER .	CPR:4
The mechanism revealed that BC6ENTC inhibited BC6OTHER - induced phosphorylation of BC6OTHER ( BC6OTHER ) associating with the suppression of stabilization of BC6OTHER and BC6ENTG .	CPR:4
The mechanism revealed that BC6OTHER inhibited BC6ENTC - induced phosphorylation of BC6ENTG ( BC6OTHER ) associating with the suppression of stabilization of BC6OTHER and BC6OTHER .	CPR:3
The mechanism revealed that BC6OTHER inhibited BC6ENTC - induced phosphorylation of BC6OTHER ( BC6ENTG ) associating with the suppression of stabilization of BC6OTHER and BC6OTHER .	CPR:3
The mechanism revealed that BC6OTHER inhibited BC6ENTC - induced phosphorylation of BC6OTHER ( BC6OTHER ) associating with the suppression of stabilization of BC6ENTG and BC6OTHER .	False
The mechanism revealed that BC6OTHER inhibited BC6ENTC - induced phosphorylation of BC6OTHER ( BC6OTHER ) associating with the suppression of stabilization of BC6OTHER and BC6ENTG .	False
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6ENTG inhibitors (MKIs) BC6ENTC , BC6OTHER , and BC6OTHER , which target multiple BC6OTHER as well as BC6OTHER .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6OTHER inhibitors (MKIs) BC6ENTC , BC6OTHER , and BC6OTHER , which target multiple BC6ENTG as well as BC6OTHER .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6OTHER inhibitors (MKIs) BC6ENTC , BC6OTHER , and BC6OTHER , which target multiple BC6OTHER as well as BC6ENTG .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6ENTG inhibitors (MKIs) BC6OTHER , BC6ENTC , and BC6OTHER , which target multiple BC6OTHER as well as BC6OTHER .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6OTHER inhibitors (MKIs) BC6OTHER , BC6ENTC , and BC6OTHER , which target multiple BC6ENTG as well as BC6OTHER .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6OTHER inhibitors (MKIs) BC6OTHER , BC6ENTC , and BC6OTHER , which target multiple BC6OTHER as well as BC6ENTG .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6ENTG inhibitors (MKIs) BC6OTHER , BC6OTHER , and BC6ENTC , which target multiple BC6OTHER as well as BC6OTHER .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6OTHER inhibitors (MKIs) BC6OTHER , BC6OTHER , and BC6ENTC , which target multiple BC6ENTG as well as BC6OTHER .	CPR:4
Significant advances in the treatment of clear - cell RCC have been derived from agents that target these pathways, including the multiple - BC6OTHER inhibitors (MKIs) BC6OTHER , BC6OTHER , and BC6ENTC , which target multiple BC6OTHER as well as BC6ENTG .	CPR:4
BC6ENTC has the added advantage of inhibiting multiple different BC6ENTG isoforms, which enables it to target BC6OTHER / BC6OTHER signaling and may also enhance its inhibition of BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC has the added advantage of inhibiting multiple different BC6OTHER isoforms, which enables it to target BC6ENTG / BC6OTHER signaling and may also enhance its inhibition of BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC has the added advantage of inhibiting multiple different BC6OTHER isoforms, which enables it to target BC6OTHER / BC6ENTG signaling and may also enhance its inhibition of BC6OTHER and BC6OTHER .	CPR:4
BC6ENTC has the added advantage of inhibiting multiple different BC6OTHER isoforms, which enables it to target BC6OTHER / BC6OTHER signaling and may also enhance its inhibition of BC6ENTG and BC6OTHER .	CPR:4
BC6ENTC has the added advantage of inhibiting multiple different BC6OTHER isoforms, which enables it to target BC6OTHER / BC6OTHER signaling and may also enhance its inhibition of BC6OTHER and BC6ENTG .	CPR:4
BC6ENTG ( BC6OTHER ), an extracellular matrix protein, has a functional BC6OTHER - BC6OTHER - BC6ENTC (RGD) domain for binding to BC6OTHER .	False
BC6OTHER ( BC6ENTG ), an extracellular matrix protein, has a functional BC6OTHER - BC6OTHER - BC6ENTC (RGD) domain for binding to BC6OTHER .	False
BC6OTHER ( BC6OTHER ), an extracellular matrix protein, has a functional BC6ENTG BC6ENTC (RGD) domain for binding to BC6OTHER .	False
BC6OTHER ( BC6OTHER ), an extracellular matrix protein, has a functional BC6OTHER - BC6OTHER - BC6ENTC (RGD) domain for binding to BC6ENTG .	False
BC6ENTG increased the mRNA and protein expression of BC6OTHER ( BC6OTHER ), a subfamily of BC6ENTC - binding cassette transporter in a concentration - and time - dependent manner.	False
BC6OTHER increased the mRNA and protein expression of BC6ENTG ( BC6OTHER ), a subfamily of BC6ENTC - binding cassette transporter in a concentration - and time - dependent manner.	False
BC6OTHER increased the mRNA and protein expression of BC6OTHER ( BC6ENTG ), a subfamily of BC6ENTC - binding cassette transporter in a concentration - and time - dependent manner.	False
BC6ENTC ( BC6OTHER ), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and BC6ENTG increased the drug pumping - out activity.	False
BC6OTHER ( BC6ENTC ), a chemotherapeutic agent with autofluorescence, was used to evaluate the pump activity, and BC6ENTG increased the drug pumping - out activity.	False
BC6ENTG inhibited BC6ENTC - induced cell death, which was antagonized by BC6OTHER monoclonal antibody.	False
BC6OTHER inhibited BC6ENTC - induced cell death, which was antagonized by BC6ENTG monoclonal antibody.	False
Long - term treatment with BC6ENTC further enhanced the expression of BC6ENTG .	False
Knockdown of endogenous BC6ENTG potentiated the BC6ENTC - induced apoptosis of PC - 3 cells.	False
Furthermore, knockdown of BC6ENTG enhanced cell death caused by other drugs, including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , which are also BC6OTHER substrates.	False
Furthermore, knockdown of BC6OTHER enhanced cell death caused by other drugs, including BC6ENTC , BC6OTHER , BC6OTHER , and BC6OTHER , which are also BC6ENTG substrates.	CPR:9
Furthermore, knockdown of BC6ENTG enhanced cell death caused by other drugs, including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , which are also BC6OTHER substrates.	False
Furthermore, knockdown of BC6OTHER enhanced cell death caused by other drugs, including BC6OTHER , BC6ENTC , BC6OTHER , and BC6OTHER , which are also BC6ENTG substrates.	CPR:9
Furthermore, knockdown of BC6ENTG enhanced cell death caused by other drugs, including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , which are also BC6OTHER substrates.	False
Furthermore, knockdown of BC6OTHER enhanced cell death caused by other drugs, including BC6OTHER , BC6OTHER , BC6ENTC , and BC6OTHER , which are also BC6ENTG substrates.	CPR:9
Furthermore, knockdown of BC6ENTG enhanced cell death caused by other drugs, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , which are also BC6OTHER substrates.	False
Furthermore, knockdown of BC6OTHER enhanced cell death caused by other drugs, including BC6OTHER , BC6OTHER , BC6OTHER , and BC6ENTC , which are also BC6ENTG substrates.	CPR:9
The animal studies also showed that BC6ENTG knockdown enhanced the cytotoxic action of BC6ENTC .	False
BC6ENTG ( BC6OTHER ), an extracellular matrix protein, has a functional BC6ENTC - BC6OTHER - BC6OTHER (RGD) domain for binding to BC6OTHER .	False
BC6OTHER ( BC6ENTG ), an extracellular matrix protein, has a functional BC6ENTC - BC6OTHER - BC6OTHER (RGD) domain for binding to BC6OTHER .	False
BC6OTHER ( BC6OTHER ), an extracellular matrix protein, has a functional BC6ENTC - BC6OTHER - BC6OTHER (RGD) domain for binding to BC6ENTG .	False
BC6ENTG ( BC6OTHER ), an extracellular matrix protein, has a functional BC6OTHER - BC6ENTC - BC6OTHER (RGD) domain for binding to BC6OTHER .	False
BC6OTHER ( BC6ENTG ), an extracellular matrix protein, has a functional BC6OTHER - BC6ENTC - BC6OTHER (RGD) domain for binding to BC6OTHER .	False
BC6OTHER ( BC6OTHER ), an extracellular matrix protein, has a functional BC6OTHER - BC6ENTC - BC6OTHER (RGD) domain for binding to BC6ENTG .	False
Rats treated with BC6ENTG plus BC6OTHER displayed abnormal estrous cycles with increasing BC6ENTC biosynthesis.	False
Rats treated with BC6OTHER plus BC6ENTG displayed abnormal estrous cycles with increasing BC6ENTC biosynthesis.	False
Identification of BC6ENTC - terminal receptor activity - modifying protein residues important for BC6OTHER , BC6ENTG , and BC6OTHER function.	False
Identification of BC6ENTC - terminal receptor activity - modifying protein residues important for BC6OTHER , BC6OTHER , and BC6ENTG function.	False
Identification of BC6ENTC - terminal receptor activity - modifying protein residues important for BC6ENTG , BC6OTHER , and BC6OTHER function.	False
Seven days after crush injury, transcript concentrations of all BC6ENTG and of BC6ENTC X receptor alpha were significantly higher than in non - lesioned nerves.	False
Protein levels of BC6ENTC receptor alpha, BC6ENTG and BC6OTHER were upregulated 4, 7 and 14 days after injury.	False
Protein levels of BC6ENTC receptor alpha, BC6OTHER and BC6ENTG were upregulated 4, 7 and 14 days after injury.	False
Protein levels of BC6ENTG , BC6ENTC receptor beta and BC6OTHER were upregulated 4, 7 and 14 days after injury.	False
Protein levels of BC6OTHER , BC6ENTC receptor beta and BC6ENTG were upregulated 4, 7 and 14 days after injury.	False
Protein levels of BC6ENTG , BC6OTHER and BC6ENTC X receptor alpha were upregulated 4, 7 and 14 days after injury.	False
Protein levels of BC6OTHER , BC6ENTG and BC6ENTC X receptor alpha were upregulated 4, 7 and 14 days after injury.	False
In degenerating nerves a significant increase of BC6ENTC receptor alpha was detected 7 and 14 days, and of BC6ENTG 14 and 21 days after complete transection.	False
In degenerating nerves a significant increase of BC6ENTG was detected 7 and 14 days, and of BC6ENTC receptor beta 14 and 21 days after complete transection.	False
Regulation of BC6ENTC receptors alpha, beta and BC6ENTG after sciatic nerve injury.	False
Regulation of BC6ENTG and BC6ENTC X receptor alpha after sciatic nerve injury.	False
In addition, we observed that BC6ENTC receptor alpha and BC6ENTG appeared in the cell nuclei of macrophages during the lesion - induced inflammatory reaction, and that BC6OTHER X receptor alpha - staining co - localized with some regenerating axons.	False
In addition, we observed that BC6ENTC receptor alpha and BC6OTHER X receptor alpha appeared in the cell nuclei of macrophages during the lesion - induced inflammatory reaction, and that BC6ENTG - staining co - localized with some regenerating axons.	False
In addition, we observed that BC6ENTG and BC6ENTC X receptor alpha appeared in the cell nuclei of macrophages during the lesion - induced inflammatory reaction, and that BC6OTHER X receptor alpha - staining co - localized with some regenerating axons.	False
In addition, we observed that BC6OTHER and BC6ENTC X receptor alpha appeared in the cell nuclei of macrophages during the lesion - induced inflammatory reaction, and that BC6ENTG - staining co - localized with some regenerating axons.	False
In addition, we observed that BC6ENTG and BC6OTHER X receptor alpha appeared in the cell nuclei of macrophages during the lesion - induced inflammatory reaction, and that BC6ENTC X receptor alpha - staining co - localized with some regenerating axons.	False
In addition, we observed that BC6OTHER and BC6ENTG appeared in the cell nuclei of macrophages during the lesion - induced inflammatory reaction, and that BC6ENTC X receptor alpha - staining co - localized with some regenerating axons.	False
Experiments with Schwann cell primary cultures revealed an effect of BC6ENTC on the expression of the BC6ENTG BC6OTHER , suggesting that one function of BC6OTHER consists in the regulation of neuroglial interactions after peripheral nerve injury.	False
Experiments with Schwann cell primary cultures revealed an effect of BC6ENTC on the expression of the BC6OTHER BC6ENTG , suggesting that one function of BC6OTHER consists in the regulation of neuroglial interactions after peripheral nerve injury.	False
Experiments with Schwann cell primary cultures revealed an effect of BC6OTHER on the expression of the BC6ENTG BC6OTHER , suggesting that one function of BC6ENTC consists in the regulation of neuroglial interactions after peripheral nerve injury.	False
Experiments with Schwann cell primary cultures revealed an effect of BC6OTHER on the expression of the BC6OTHER BC6ENTG , suggesting that one function of BC6ENTC consists in the regulation of neuroglial interactions after peripheral nerve injury.	False
Since the effect of BC6ENTC is mediated via BC6ENTG and BC6OTHER X receptors, we investigated mRNA and protein expression of these receptors during injury - induced degeneration and regeneration.	False
Since the effect of BC6ENTC is mediated via BC6OTHER receptors and BC6ENTG , we investigated mRNA and protein expression of these receptors during injury - induced degeneration and regeneration.	False
Since the effect of BC6OTHER is mediated via BC6ENTC receptors and BC6ENTG , we investigated mRNA and protein expression of these receptors during injury - induced degeneration and regeneration.	False
Since the effect of BC6OTHER is mediated via BC6ENTG and BC6ENTC X receptors, we investigated mRNA and protein expression of these receptors during injury - induced degeneration and regeneration.	False
Seven days after crush injury, transcript concentrations of all BC6ENTC receptors and of BC6ENTG were significantly higher than in non - lesioned nerves.	False
To investigate the role of BC6OTHER in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6ENTG , BC6ENTC (AZ) and the BC6OTHER - specific orthosteric agonist BC6OTHER ( BC6OTHER ).	False
To investigate the role of BC6OTHER in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6OTHER , BC6ENTC (AZ) and the BC6ENTG - specific orthosteric agonist BC6OTHER ( BC6OTHER ).	False
To investigate the role of BC6ENTG in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6OTHER , BC6ENTC (AZ) and the BC6OTHER - specific orthosteric agonist BC6OTHER ( BC6OTHER ).	False
To investigate the role of BC6OTHER in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6ENTG , BC6OTHER (AZ) and the BC6OTHER - specific orthosteric agonist BC6ENTC ( BC6OTHER ).	False
To investigate the role of BC6OTHER in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6OTHER , BC6OTHER (AZ) and the BC6ENTG - specific orthosteric agonist BC6ENTC ( BC6OTHER ).	CPR:5
To investigate the role of BC6ENTG in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6OTHER , BC6OTHER (AZ) and the BC6OTHER - specific orthosteric agonist BC6ENTC ( BC6OTHER ).	False
To investigate the role of BC6OTHER in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6ENTG , BC6OTHER (AZ) and the BC6OTHER - specific orthosteric agonist BC6OTHER ( BC6ENTC ).	False
To investigate the role of BC6OTHER in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6OTHER , BC6OTHER (AZ) and the BC6ENTG - specific orthosteric agonist BC6OTHER ( BC6ENTC ).	CPR:5
To investigate the role of BC6ENTG in modulating the synaptic responses of CHEM ganglion cells, we used a recently identified positive allosteric modulator of BC6OTHER , BC6OTHER (AZ) and the BC6OTHER - specific orthosteric agonist BC6OTHER ( BC6ENTC ).	False
The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous BC6ENTC being stronger during bright light stimulation and with BC6ENTG receptors mainly being localized away from BC6OTHER release sites, immuno - labeled with BC6OTHER .	False
The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous BC6ENTC being stronger during bright light stimulation and with BC6OTHER receptors mainly being localized away from BC6OTHER release sites, immuno - labeled with BC6ENTG .	False
The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous BC6OTHER being stronger during bright light stimulation and with BC6ENTG receptors mainly being localized away from BC6ENTC release sites, immuno - labeled with BC6OTHER .	False
The effects of the allosteric modulator were stronger for bright stimuli than for dim stimuli, consistent with receptor stimulation by endogenous BC6OTHER being stronger during bright light stimulation and with BC6OTHER receptors mainly being localized away from BC6ENTC release sites, immuno - labeled with BC6ENTG .	False
The differential sensitivity of ganglion cell light responses to BC6ENTC and AZ supports multiple sites where BC6ENTG modulates the light responses of ganglion cells.	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6ENTC BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6ENTC transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTC - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6ENTC transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	False
Here, we describe a new photolabile BC6ENTC derivative based on protection of BC6OTHER with the BC6OTHER ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6ENTC derivative based on protection of BC6OTHER with the BC6OTHER ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6ENTC derivative based on protection of BC6OTHER with the BC6OTHER ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6ENTC with the BC6OTHER ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6ENTC with the BC6OTHER ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6ENTC with the BC6OTHER ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6OTHER with the BC6ENTC ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6OTHER with the BC6ENTC ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6OTHER with the BC6ENTC ( BC6OTHER ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6ENTC , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6OTHER with the BC6OTHER ( BC6ENTC ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6ENTG , BC6OTHER , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6OTHER with the BC6OTHER ( BC6ENTC ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6ENTG , and BC6OTHER .	CPR:9
Here, we describe a new photolabile BC6OTHER derivative based on protection of BC6OTHER with the BC6OTHER ( BC6ENTC ) caging group, which we use for pre - steady - state kinetic analysis of CHEM transport by BC6OTHER , BC6OTHER , and BC6ENTG .	CPR:9
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	False
BC6ENTC - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6ENTC and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	CPR:9
Photolytic release of free BC6ENTC results in the generation of significant transient current components in HEK293 cells expressing the BC6ENTG , BC6OTHER , and BC6OTHER proteins.	False
Photolytic release of free BC6ENTC results in the generation of significant transient current components in HEK293 cells expressing the BC6OTHER , BC6ENTG , and BC6OTHER proteins.	False
Photolytic release of free BC6ENTC results in the generation of significant transient current components in HEK293 cells expressing the BC6OTHER , BC6OTHER , and BC6ENTG proteins.	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	CPR:9
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6ENTC , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	CPR:9
Pre - steady - state currents in BC6ENTG induced by photolysis of a new caged BC6ENTC derivative.	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6ENTG [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6ENTG , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6ENTG BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6ENTC transporters of the BC6OTHER [ BC6OTHER , BC6OTHER BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the BC6ENTG of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6ENTG [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6ENTG , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6ENTG ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6ENTG ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6ENTG families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [ BC6ENTG ( BC6OTHER ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6ENTG ), BC6OTHER , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6ENTG , and BC6OTHER ].	False
BC6OTHER - Dependent transmembrane transport of small neutral BC6OTHER , such as BC6OTHER and BC6OTHER , is mediated, among others, by the neutral BC6OTHER transporters of the BC6OTHER [ BC6OTHER , BC6ENTC BC6OTHER BC6OTHER transporter 1 ( BC6OTHER ), and BC6OTHER ] and BC6OTHER families [CHEM - coupled neutral BC6OTHER transporter 1 ( BC6OTHER ), BC6OTHER , and BC6ENTG ].	False
